{"PubmedArticle":[{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"31266021","DateCompleted":{"Year":"2020","Month":"08","Day":"24"},"DateRevised":{"Year":"2020","Month":"08","Day":"24"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1660-2862","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"19","Issue":"1","PubDate":{"Year":"2019"}},"Title":"Neuro-degenerative diseases","ISOAbbreviation":"Neurodegener Dis"},"ArticleTitle":"Associations of Neprilysin Activity in CSF with Biomarkers for Alzheimer's Disease.","Pagination":{"MedlinePgn":"43-50"},"ELocationID":"10.1159\/000500811","Abstract":{"AbstractText":["Neprilysin (NEP) cleaves amyloid-\u03b2 1-42 (A\u03b242) in the brain. Hence, we aimed to elucidate the effect of NEP on A\u03b242 in cerebrospinal fluid (CSF) and on in vivo brain amyloid load using amyloid positron emission tomography (PET) with [11C]PiB (Pittsburgh compound B). In addition, associations with the biomarkers for neuronal injury, CSF-tau and FDG-PET, were investigated.","Associations were calculated using global and voxel-based (SPM8) linear regression analyses in the same cohort of 23 highly characterized Alzheimer's disease patients.","CSF-NEP was significantly inversely associated with CSF-A\u03b242 and positively with the extent of neuronal injury as measured by CSF-tau and FDG-PET.","Our results on CSF-NEP are compatible with the assumption that local degradation, amongst other mechanisms of amyloid clearance, plays a role in the development of Alzheimer's pathology. In addition, CSF-NEP is associated with the extent and the rate of neurodegeneration."],"CopyrightInformation":"\u00a9 2019 S. Karger AG, Basel."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Grimmer","ForeName":"Timo","Initials":"T","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany, t.grimmer@lrz.tum.de."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Goldhardt","ForeName":"Oliver","Initials":"O","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Yakushev","ForeName":"Igor","Initials":"I","AffiliationInfo":{"Affiliation":"Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Ortner","ForeName":"Marion","Initials":"M","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Sorg","ForeName":"Christian","Initials":"C","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Diehl-Schmid","ForeName":"Janine","Initials":"J","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"F\u00f6rstl","ForeName":"Hans","Initials":"H","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Perneczky","ForeName":"Robert","Initials":"R","AffiliationInfo":[{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."},{"Affiliation":"Neuroepidemiology and Ageing Research Unit, School of Public Health, Faculty of Medicine, The Imperial College of Science, Technology and Medicine, London, United Kingdom."},{"Affiliation":"Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen, Munich, Germany."}]},{"@attributes":{"ValidYN":"Y"},"LastName":"Miners","ForeName":"Scott","Initials":"S","AffiliationInfo":{"Affiliation":"Dementia Research Group, School of Clinical Sciences, University of Bristol, Southmead Hospital, Bristol, United Kingdom."}}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Research Support, Non-U.S. Gov't"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2019","Month":"07","Day":"02"}},"MedlineJournalInfo":{"Country":"Switzerland","MedlineTA":"Neurodegener Dis","NlmUniqueID":"101189034","ISSNLinking":"1660-2854"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole"},{"RegistryNumber":"0","NameOfSubstance":"Amyloid beta-Peptides"},{"RegistryNumber":"0","NameOfSubstance":"Aniline Compounds"},{"RegistryNumber":"0","NameOfSubstance":"Apolipoprotein E4"},{"RegistryNumber":"0","NameOfSubstance":"Biomarkers"},{"RegistryNumber":"0","NameOfSubstance":"Carbon Radioisotopes"},{"RegistryNumber":"0","NameOfSubstance":"Carbon-11"},{"RegistryNumber":"0","NameOfSubstance":"Fluorine Radioisotopes"},{"RegistryNumber":"0","NameOfSubstance":"MAPT protein, human"},{"RegistryNumber":"0","NameOfSubstance":"Peptide Fragments"},{"RegistryNumber":"0","NameOfSubstance":"Radiopharmaceuticals"},{"RegistryNumber":"0","NameOfSubstance":"Thiazoles"},{"RegistryNumber":"0","NameOfSubstance":"amyloid beta-protein (1-42)"},{"RegistryNumber":"0","NameOfSubstance":"amyloid beta-protein (40-42)"},{"RegistryNumber":"0","NameOfSubstance":"tau Proteins"},{"RegistryNumber":"0Z5B2CJX4D","NameOfSubstance":"Fluorodeoxyglucose F18"},{"RegistryNumber":"EC 3.4.24.11","NameOfSubstance":"Neprilysin"},{"RegistryNumber":"GZ5I74KB8G","NameOfSubstance":"Fluorine-18"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Aged, 80 and over"},{"DescriptorName":"Alzheimer Disease","QualifierName":["cerebrospinal fluid","diagnostic imaging","pathology"]},{"DescriptorName":"Amyloid beta-Peptides","QualifierName":["analysis","metabolism"]},{"DescriptorName":"Aniline Compounds"},{"DescriptorName":"Apolipoprotein E4","QualifierName":"genetics"},{"DescriptorName":"Biomarkers"},{"DescriptorName":"Brain","QualifierName":"diagnostic imaging"},{"DescriptorName":"Brain Chemistry"},{"DescriptorName":"Carbon Radioisotopes"},{"DescriptorName":"Female"},{"DescriptorName":"Fluorine Radioisotopes"},{"DescriptorName":"Fluorodeoxyglucose F18"},{"DescriptorName":"Humans"},{"DescriptorName":"Male"},{"DescriptorName":"Mental Status and Dementia Tests"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Neprilysin","QualifierName":["cerebrospinal fluid","metabolism"]},{"DescriptorName":"Neuroimaging"},{"DescriptorName":"Peptide Fragments","QualifierName":"metabolism"},{"DescriptorName":"Positron-Emission Tomography"},{"DescriptorName":"Radiopharmaceuticals"},{"DescriptorName":"Thiazoles"},{"DescriptorName":"tau Proteins","QualifierName":"cerebrospinal fluid"}]},"KeywordList":{"@attributes":{"Owner":"NOTNLM"},"Keyword":["Alzheimer\u2019s disease","Amyloid clearance","CSF-A\u03b242","CSF-tau","Cerebrospinal fluid","FDG-PET","Neprilysin","Neuronal injury","Pittsburgh compound B","Positron emission tomography"]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2019","Month":"05","Day":"02"},{"@attributes":{"PubStatus":"accepted"},"Year":"2019","Month":"05","Day":"06"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2019","Month":"7","Day":"3","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2020","Month":"8","Day":"25","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"entrez"},"Year":"2019","Month":"7","Day":"3","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["31266021","000500811","10.1159\/000500811"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","IndexingMethod":"Curated","Owner":"NLM"},"PMID":"31111516","DateCompleted":{"Year":"2020","Month":"03","Day":"13"},"DateRevised":{"Year":"2020","Month":"03","Day":"13"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1099-1166","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"34","Issue":"10","PubDate":{"Year":"2019","Month":"10"}},"Title":"International journal of geriatric psychiatry","ISOAbbreviation":"Int J Geriatr Psychiatry"},"ArticleTitle":"Online information and support for carers of people with young-onset dementia: A multi-site randomised controlled pilot study.","Pagination":{"MedlinePgn":"1455-1464"},"ELocationID":"10.1002\/gps.5154","Abstract":{"AbstractText":["The European RHAPSODY project sought to develop and test an online information and support programme for caregivers of individuals diagnosed with young onset dementia. The objectives were to assess user acceptability and satisfaction with the programme and to test outcome measures for a larger effectiveness study.","A pilot randomised controlled trial in England, France, and Germany was conducted with 61 caregivers for adults with young onset Alzheimer's disease or frontotemporal degeneration. Evaluations at baseline, week 6, and week 12 assessed user acceptability and satisfaction. Use of the programme was measured from online back-end data. Qualitative feedback on user experiences was collected via semi-structured interviews. Measures of caregiver well-being (self-efficacy, stress, burden, frequency of patient symptoms, and caregiver reactions) were explored for use in a subsequent trial.","Participants logged in online on average once a week over a 6-week period, consulting approximately 31% of programme content. Seventy percent of participants described the programme as useful and easy to use. Eighty-five percent expressed intent to use the resource in the future. Reductions in reported levels of stress and caregivers' negative reactions to memory symptoms were observed following use of the programme.","Results indicated that the RHAPSODY programme was acceptable and useful to caregivers. The programme may be complementary to existing services in responding to the specific needs of families affected by young onset dementia. Distribution of the programme is underway in England, France, Germany, and Portugal."],"CopyrightInformation":"\u00a9 2019 John Wiley & Sons, Ltd."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Metcalfe","ForeName":"Anna","Initials":"A","Identifier":"0000-0002-5727-8914","AffiliationInfo":{"Affiliation":"H\u00f4pital de la Piti\u00e9-Salp\u00eatri\u00e8re, Sorbonne University, Assistance Publique - H\u00f4pitaux de Paris AP-HP, Paris, France."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Jones","ForeName":"Bridget","Initials":"B","Identifier":"0000-0001-9709-1794","AffiliationInfo":{"Affiliation":"Surrey Health Economics Centre, Department of Clinical and Experimental Medicine, University of Surrey, Guildford, UK."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Mayer","ForeName":"Johannes","Initials":"J","AffiliationInfo":{"Affiliation":"Department of Psychiatry, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Gage","ForeName":"Heather","Initials":"H","Identifier":"0000-0002-2049-9406","AffiliationInfo":{"Affiliation":"Surrey Health Economics Centre, Department of Clinical and Experimental Medicine, University of Surrey, Guildford, UK."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Oyebode","ForeName":"Jan","Initials":"J","Identifier":"0000-0002-0263-8740","AffiliationInfo":{"Affiliation":"Centre for Applied Dementia Studies, University of Bradford, Bradford, UK."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Boucault","ForeName":"Sarah","Initials":"S","AffiliationInfo":{"Affiliation":"H\u00f4pital de la Piti\u00e9-Salp\u00eatri\u00e8re, Sorbonne University, Assistance Publique - H\u00f4pitaux de Paris AP-HP, Paris, France."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Aloui","ForeName":"Sabrina","Initials":"S","AffiliationInfo":{"Affiliation":"H\u00f4pital de la Piti\u00e9-Salp\u00eatri\u00e8re, Sorbonne University, Assistance Publique - H\u00f4pitaux de Paris AP-HP, Paris, France."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Schwertel","ForeName":"Uta","Initials":"U","Identifier":"0000-0001-5804-5867","AffiliationInfo":{"Affiliation":"IMC, Information Multimedia Communication AG, Saarbr\u00fccken, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"B\u00f6hm","ForeName":"Markus","Initials":"M","AffiliationInfo":{"Affiliation":"Department of Psychiatry, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Tezenas du Montcel","ForeName":"Sophie","Initials":"S","Identifier":"0000-0002-2866-4330","AffiliationInfo":{"Affiliation":"Sorbonne Universit\u00e9s, INSERM, Institut Pierre Louis d'Epid\u00e9miologie et de Sant\u00e9 Publique, Assistance Publique-H\u00f4pitaux de Paris AP-HP, H\u00f4pitaux Universitaires Piti\u00e9-Salp\u00eatri\u00e8re-Charles Foix, Paris, France."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Lebbah","ForeName":"Said","Initials":"S","Identifier":"0000-0002-4657-3352","AffiliationInfo":{"Affiliation":"H\u00f4pital de la Piti\u00e9-Salp\u00eatri\u00e8re, Sorbonne University, Assistance Publique - H\u00f4pitaux de Paris AP-HP, Paris, France."}},{"@attributes":{"ValidYN":"Y"},"LastName":"De Mendon\u00e7a","ForeName":"Alexandre","Initials":"A","Identifier":"0000-0002-0488-1453","AffiliationInfo":{"Affiliation":"Instituto de Medicina Molecular, Universidade de Lisboa, Lisbon, Portugal."}},{"@attributes":{"ValidYN":"Y"},"LastName":"De Vugt","ForeName":"Marjolein","Initials":"M","Identifier":"0000-0002-2113-4134","AffiliationInfo":{"Affiliation":"School for Mental Health and Neuroscience, Maastricht University, Maastricht, Netherlands."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Graff","ForeName":"Caroline","Initials":"C","Identifier":"0000-0002-9949-2951","AffiliationInfo":[{"Affiliation":"Karolinska Institutet, Department NVS, Center for Alzheimer Research, Division of Neurogeriatrics, Bioclinicum J10:20, Solna, Sweden."},{"Affiliation":"Karolinska University Hospital, Theme Aging, Unit for Hereditary Dementias, Solna, Sweden."}]},{"@attributes":{"ValidYN":"Y"},"LastName":"Jansen","ForeName":"Sabine","Initials":"S","AffiliationInfo":{"Affiliation":"Deutsche Alzheimer Gesellschaft, Berlin, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Hergueta","ForeName":"Thierry","Initials":"T","AffiliationInfo":[{"Affiliation":"H\u00f4pital de la Piti\u00e9-Salp\u00eatri\u00e8re, Sorbonne University, Assistance Publique - H\u00f4pitaux de Paris AP-HP, Paris, France."},{"Affiliation":"Laboratoire de Psychopathologie et Processus de Sant\u00e9, Institut de Psychologie Universit\u00e9 Paris Descartes-Sorbonne Paris Cit\u00e9, Paris, France."}]},{"@attributes":{"ValidYN":"Y"},"LastName":"Dubois","ForeName":"Bruno","Initials":"B","AffiliationInfo":{"Affiliation":"H\u00f4pital de la Piti\u00e9-Salp\u00eatri\u00e8re, Sorbonne University, Assistance Publique - H\u00f4pitaux de Paris AP-HP, Paris, France."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A","AffiliationInfo":{"Affiliation":"Department of Psychiatry, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany."}}]},"Language":"eng","DataBankList":{"@attributes":{"CompleteYN":"Y"},"DataBank":{"DataBankName":"DRKS","AccessionNumberList":{"AccessionNumber":"DRKS00009891"}}},"PublicationTypeList":{"PublicationType":["Journal Article","Multicenter Study","Randomized Controlled Trial","Research Support, Non-U.S. Gov't"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2019","Month":"07","Day":"26"}},"MedlineJournalInfo":{"Country":"England","MedlineTA":"Int J Geriatr Psychiatry","NlmUniqueID":"8710629","ISSNLinking":"0885-6230"},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Adult"},{"DescriptorName":"Age of Onset"},{"DescriptorName":"Aged"},{"DescriptorName":"Alzheimer Disease","QualifierName":"nursing"},{"DescriptorName":"Caregivers","QualifierName":["education","psychology"]},{"DescriptorName":"Compassion Fatigue","QualifierName":"prevention & control"},{"DescriptorName":"Dementia","QualifierName":"nursing"},{"DescriptorName":"England"},{"DescriptorName":"Female"},{"DescriptorName":"France"},{"DescriptorName":"Germany"},{"DescriptorName":"Health Status"},{"DescriptorName":"Humans"},{"DescriptorName":"Internet-Based Intervention"},{"DescriptorName":"Male"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Patient Satisfaction"},{"DescriptorName":"Pilot Projects"},{"DescriptorName":"Self Efficacy"},{"DescriptorName":"Social Support"}]},"KeywordList":{"@attributes":{"Owner":"NOTNLM"},"Keyword":["Alzheimer's disease","caregiver support","family caregiver","frontotemporal degeneration","online intervention","psycho-education","randomised controlled trial","technology acceptance","thematic analysis","young onset dementia"]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2019","Month":"01","Day":"22"},{"@attributes":{"PubStatus":"accepted"},"Year":"2019","Month":"05","Day":"04"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2019","Month":"5","Day":"22","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2020","Month":"3","Day":"14","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"entrez"},"Year":"2019","Month":"5","Day":"22","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["31111516","10.1002\/gps.5154"]},"ReferenceList":{"Title":"REFERENCES","Reference":[{"Citation":"Harvey RJ, Skelton-Robinson M, Rossor MN. The prevalence and causes of dementia in people under the age of 65 years. J Neurol Neurosurg Psychiatry. 2003;74(9):1206-1209."},{"Citation":"Mercy L, Hodges JR, Dawson K, Barker RA, Brayne C. Incidence of early-onset dementias in Cambridgeshire, United Kingdom. Neurol. 2008;71(19):1496-1499. https:\/\/doi.org\/10.1212\/01.wnl.0000334277.16896.fa"},{"Citation":"Vieira RT, Caixeta L, Machado S, et al. Epidemiology of early-onset dementia: a review of the literature. CP & EMH. 2013;9(1):88-95. https:\/\/doi.org\/10.2174\/1745017901309010088"},{"Citation":"Sansoni J, Duncan C, Grootemaat P, Samsa P, Capell J, Westera A. Younger onset dementia: a literature review. Am J Alzheimers Dis Other Dement. 2016;31(8):693-705. https:\/\/doi.org\/10.1177\/1533317515619481"},{"Citation":"Svanberg E, Spector A, Stott J. The impact of young onset dementia on the family: a literature review. Int Psychogeriatr. 2011;23(3):356-371. https:\/\/doi.org\/10.1017\/S1041610210001353"},{"Citation":"Harris PB. Intimacy, sexuality, and early-stage dementia: the changing marital relationship. Alzheimer's Care Today 2009; April-June 10: 63-77."},{"Citation":"Millenaar J, van Vliet D, Bakker C, et al. The experiences and needs of children living with a parent with young onset dementia: results from the NeedYD study. Int Psychogeriatr. 2013;26(12):2001-2010. https:\/\/doi.org\/10.1017\/S1041610213001890"},{"Citation":"Ducharme F, Kergoat M, Antoine P, Pasquier F, Coulombe R. The unique experience of spouses in early-onset dementia. Am J Alzheimers Dis Other Dement. 2013;28(6):634-641. https:\/\/doi.org\/10.1177\/1533317513494443"},{"Citation":"Van Vliet D, de Vugt ME, Bakker C, Koopmans RTCM, Verhey FRJ. Impact of early onset dementia on caregivers: a review. Int J Geriatr Psychiatry. 2010;5(11):1091-1100."},{"Citation":"Rosness TA, Haugen PK, Gausdal M, Gj\u00f8ra L, Engedal K. Carers of patients with early-onset dementia, their burden and needs: a pilot study using a new questionnaire-Care-EOD. Int J Geriatr Psychiatry. 2012;27:1095-1097. https:\/\/doi.org\/10.1002\/gps.2818"},{"Citation":"Freyne A, Kidd N, Coen R, Lawlor BA. Burden in carers of dementia patients: higher levels in carers of younger sufferers. Int J Geriatr Psychiatry. 1999;14(9):784-788."},{"Citation":"Mendez MF. The accurate diagnosis of early-onset dementia. Int J Psychiatry Med. 2006;36(4):401-412. https:\/\/doi.org\/10.2190\/Q6J4-R143-P630-KW41"},{"Citation":"Bakker C, de Vugt ME, Vernooij-Dassen M, van Vliet D, Verhey FRJ, Koopmans RTCM. Needs in early onset dementia: a qualitative case from the NeedYD study. Am J Alzheimers Dis Other Dement. 2010;25(8):634-640. https:\/\/doi.org\/10.1177\/1533317510385811"},{"Citation":"Hooghiemstra AM, Eggermont LHP, Scheltens P, et al. Study protocol: EXERcise and Cognition In Sedentary adults with Early-ONset dementia (EXERCISE-ON). BMC Neurol. 2012;12(1):75."},{"Citation":"Kurz A, Bakker C, B\u00f6hm M, et al. RHAPSODY-Internet-based support for caregivers of people with young onset dementia: program design and methods of a pilot study. Int Psychogeriatr. 2016;28(12):2091-2099. https:\/\/doi.org\/10.1017\/S1041610216001186"},{"Citation":"Jones B, Gage H, Bakker C, et al. Availability of information on young onset dementia for patients and carers in six European countries. Patient Educ Couns. 2018;101(1):159-165."},{"Citation":"Parker D, Mills S, Abbey J. Effectiveness of interventions that assist caregivers to support people with dementia living in the community: a systematic review. Int J Evid Based Healthc. 2008;6(2):137-172."},{"Citation":"Livingston G, Johnston K, Katona C, Paton J, Lyketsos CG, Old Age Task Force of the World Federation of Biological Psychiatry. Systematic review of psychological approaches to the management of neuropsychiatric symptoms of dementia. Am J Psychiatry. 2005;162(11):1996-2021."},{"Citation":"Brodaty H, Green A, Koschera A. Meta-analysis of psychosocial interventions for caregivers of people with dementia. J Am Geriatr Soc. 2003;51(5):657-664."},{"Citation":"Godwin KM, Mills WL, Anderson JA, Kunik ME. Technology-driven interventions for caregivers of persons with dementia: a systematic review. Am J Alzheimers Dis Other Dement. 2013;28(3):216-222."},{"Citation":"Serafini JD, Damianakis T, Marziali E. Clinical practice standard and ethical issues applied to virtual group intervention for spousal caregivers of people with Alzheimer's. Soc Work Health Care. 2007;44(3):225-243."},{"Citation":"Boots LMM, de Vugt ME, van Knippenberg RJM, Kempen GIJM, Verhey FRJ. A systematic review of internet-based supportive intervention for caregivers of patients with dementia. Int J Geriatr Psychiatry. 2014;29(4):331-344."},{"Citation":"Lewis ML, Hobday JV, Hepburn KW. Internet-based program for dementia caregivers. Am J Alzheimers Dis Other Dement. 2010;25(8):674-679."},{"Citation":"Blom MM, Zarit SH, Groot Zwaaftink RBM, Cuijpers P, Pot AM. Effectiveness of an internet intervention for family caregivers of people with dementia: results of a randomized controlled trial. PLoS ONE. 2015;10(2):e0116622. https:\/\/doi.org\/10.1371\/journal.pone.0116622"},{"Citation":"Kajiyama B, Thompson LW, Eto-Iwase T, et al. Exploring the effectiveness of an internet-based program for reducing caregiver distress using the iCare stress management e-training program. Aging Ment Health. 2013;17(5):544-554."},{"Citation":"Beauchamp N, Irvine AB, Seeley J, Johnson B. Worksite-based Internet multimedia program for family caregivers of persons with dementia. Gerontologist. 2005;45(6):793-801."},{"Citation":"Finkel S, Czaja SJ, Martinovich Z, Harris C, Pezzuto D, Schulz R. E-Care: A telecommunications technology intervention for family caregivers of dementia patients. Am J Geriatr Psychiatry. 2007;15(5):443-448."},{"Citation":"Schulz R, O'Brien A, Czaja S, et al. Dementia caregiver intervention research: in search of clinical significance. Gerontologist. 2002;42(5):589-602."},{"Citation":"Cristancho-Lacroix V, Wrobel J, Cantegreil-Kallen I, Dub T, Rouquette A, Rigaud A. A web-based psychoeducational program for informal carers of patients with Alzheimer's disease: a pilot randomized controlled trial. J Med Internet Res. 2015; May;17(5):e117. https:\/\/doi.org\/10.2196\/jmir.3717"},{"Citation":"Hattink B, Meiland F, van der Roest H, et al. Web-based STAR e-learning course increases empathy and understanding in dementia caregivers: results from a randomized controlled trial in the Netherlands and the United Kingdom. J Med Internet Res. 2015;17(10):e241. https:\/\/doi.org\/10.2196\/jmir.4025"},{"Citation":"Belle SH, Burgio L, Burns R, et al. for the Resources for Enhancing Alzheimer's Caregiver Health (REACH) II Investigators. Enhancing the quality of life of dementia caregivers from different ethnic or racial groups: a randomized, controlled trial. Ann Intern Med. 2006;145(10):727-738."},{"Citation":"Burgio LD, Collins IB, Schmid B, Wharton T, McCallum D, DeCoster J. Translating the REACH caregiver intervention for use by area Agency on Aging Personnel: the REACH OUT Program. Gerontologist. 2009;49(1):103-116."},{"Citation":"Millenaar JK, Bakker C, Koopmans RTCM, Verhey FRJ, Kurz A, de Vugt M. The care needs and experiences with the use of services of people with young-onset dementia and their caregivers: a systematic review. Int J Geriatr Psychiatry. 2016;31(12):1261-1276. https:\/\/doi.org\/10.1002\/gps.4502"},{"Citation":"Millenaar JK, de Vugt ME, Bakker C, et al. The impact of young onset dementia on informal caregivers compared to late onset dementia: results from the NeedYD study. Am J Geriatr Psychiatry. 2015;24:467-474."},{"Citation":"McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):263-269."},{"Citation":"Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;13:2456-2477."},{"Citation":"Venkatesh V, Bala H. Technology Acceptance Model 3 and a research agenda on interventions. Decis Sci. 2008;39:2."},{"Citation":"Steffen AM, McKibbin C, Zeiss AM, Gallagher-Thompson D, Bandura A. The Revised Scale for Caregiving Self-Efficacy: reliability and validity studies. J Gerontol. 2002; Series B;57(1):74-86. https:\/\/doi.org\/10.1093\/geronb\/57.1.P74"},{"Citation":"Cohen S, Williamson G. Perceived stress in a probability sample of the United States. In: Spacapan S, Oskamp S, eds. The social psychology of health: Claremont Symposium on applied social psychology. Newbury Park, CA: Sage; 1988."},{"Citation":"Graessel E, Chiu T, Oliver R. Development and Validation of the Burden Scale for Family Caregivers (BSFC). Toronto: Ontario Comprehensive Rehabilitation and Mental Health Services; 2003."},{"Citation":"Teri L, Truax P, Logsdon R, Uomoto J, Zarit S, Vitaliano PP. Assessment of behavioral problems in dementia: the revised memory and behavior problems checklist. Psychol Aging. 1992;7(4):622-631."},{"Citation":"EuroQuol-Group. EQ-5D-5 L. Rotterdam: EuroQuol Group; 2009."},{"Citation":"Lancaster GA, Dodd S, Williamson PR. Design and analysis of pilot studies: recommendations for good practice. J Eval Clin Pract. 2004;10(2):307-312."},{"Citation":"Teare MD, Dimairo M, Shephard N, Hayman A, Whitehead A, Walters SJ. Sample size requirements to estimate key design parameters from external pilot randomised controlled trials: a simulation study. Trials. 2014;15:264. https:\/\/doi.org\/10.1186\/1745-6215-15-264"}]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"29143217","DateCompleted":{"Year":"2019","Month":"09","Day":"30"},"DateRevised":{"Year":"2019","Month":"09","Day":"30"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1435-1463","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"125","Issue":"2","PubDate":{"Year":"2018","Month":"02"}},"Title":"Journal of neural transmission (Vienna, Austria : 1996)","ISOAbbreviation":"J Neural Transm (Vienna)"},"ArticleTitle":"Fluid biomarker agreement and interrelation in dementia due to Alzheimer's disease.","Pagination":{"MedlinePgn":"193-201"},"ELocationID":"10.1007\/s00702-017-1810-z","Abstract":{"AbstractText":"The cerebrospinal fluid (CSF) levels of \u03b2-amyloid 42, total tau, and phosphorylated tau 181 are supposed to be all continuously abnormal in dementia due to Alzheimer's disease (AD), being the most advanced disease stage. The aim of the present study, which included a monocentric and a multicentric sample (N\u00a0=\u00a0119 and 178, respectively), was to investigate the degree of CSF biomarker agreement and interrelation in AD dementia. Based on previously published cut-off values, biomarker values were categorized as positive or negative for AD (dichotomization strategy) and as either positive, negative, or borderline (trichotomization strategy). The statistical analyses relied on distance correlation analysis and kappa (k) statistics. Poor agreement (k\u00a0<\u00a00.4) and low interrelations between the studied biomarkers were detected in all cases with the exception of the interrelation between the markers total tau and phosphorylated tau 181, especially in the monocentric sample. Interestingly, lower interrelation and agreement degrees were observed in carriers of the Apolipoprotein E \u03b54 allele compared to non-carriers. The clinical phenotype currently referred to as \"AD dementia\" is characterized by an inhomogeneous CSF biomarker profile, possibly mirroring the complex genesis of AD-typical dementia symptoms and pointing to the necessity of shedding more light on the hypothesis of biomarker stability over time in symptomatic AD."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Alexopoulos","ForeName":"Panagiotis","Initials":"P","Identifier":"0000-0002-9047-6365","AffiliationInfo":[{"Affiliation":"Department of Psychiatry, University of Patras, 26500, Rion Patras, Greece. panos.alexopoulos@upatras.gr."},{"Affiliation":"Department of Psychiatry and Psychotherapy, Technical University of Munich, Ismaninger Str. 22, 81675, Munich, Germany. panos.alexopoulos@upatras.gr."}]},{"@attributes":{"ValidYN":"Y"},"LastName":"Roesler","ForeName":"Jennifer","Initials":"J","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Technical University of Munich, Ismaninger Str. 22, 81675, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Werle","ForeName":"Lukas","Initials":"L","AffiliationInfo":[{"Affiliation":"Department of Psychiatry and Psychotherapy, Technical University of Munich, Ismaninger Str. 22, 81675, Munich, Germany."},{"Affiliation":"Max Planck Institute of Psychiatry, Munich, Germany."}]},{"@attributes":{"ValidYN":"Y"},"LastName":"Thierjung","ForeName":"Nathalie","Initials":"N","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Technical University of Munich, Ismaninger Str. 22, 81675, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Lentzari","ForeName":"Iliana","Initials":"I","AffiliationInfo":{"Affiliation":"Department of Psychiatry, University of Patras, 26500, Rion Patras, Greece."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Ortner","ForeName":"Marion","Initials":"M","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Technical University of Munich, Ismaninger Str. 22, 81675, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Grimmer","ForeName":"Timo","Initials":"T","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Technical University of Munich, Ismaninger Str. 22, 81675, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Laskaris","ForeName":"Nikolaos","Initials":"N","AffiliationInfo":{"Affiliation":"Department of Informatics, Aristotle University of Thessaloniki, 54124, Thessaloniki, Greece."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Politis","ForeName":"Antonios","Initials":"A","AffiliationInfo":[{"Affiliation":"First Department of Psychiatry, Eginition Hospital, National and Kapodistrian University of Athens, Vassilissis Sofias Ave 72-74, 11528, Athens, Greece."},{"Affiliation":"Division of Geriatric Psychiatry and Neuropsychiatry, Department of Psychiatry, John's Hopkins Medical School, Baltimore, USA."}]},{"@attributes":{"ValidYN":"Y"},"LastName":"Gourzis","ForeName":"Philippos","Initials":"P","AffiliationInfo":{"Affiliation":"Department of Psychiatry, University of Patras, 26500, Rion Patras, Greece."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Technical University of Munich, Ismaninger Str. 22, 81675, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Perneczky","ForeName":"Robert","Initials":"R","AffiliationInfo":[{"Affiliation":"Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen, Nussbaumstra\u00dfe 7, 80336, Munich, Germany."},{"Affiliation":"Neuroepidemiology and Ageing Research Unit, School of Public Health, Faculty of Medicine, The Imperial College of Science, Technology and Medicine, London, UK."},{"Affiliation":"West London Mental Health NHS Trust, London, UK."},{"Affiliation":"German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany."}]},{"@attributes":{"ValidYN":"Y"},"CollectiveName":"Alzheimer\u2019s Disease Neuroimaging Initiative"}]},"Language":"eng","GrantList":{"@attributes":{"CompleteYN":"Y"},"Grant":{"GrantID":"U01 AG024904","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"}},"PublicationTypeList":{"PublicationType":["Journal Article","Research Support, N.I.H., Extramural","Research Support, Non-U.S. Gov't","Research Support, U.S. Gov't, Non-P.H.S."]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2017","Month":"11","Day":"15"}},"MedlineJournalInfo":{"Country":"Austria","MedlineTA":"J Neural Transm (Vienna)","NlmUniqueID":"9702341","ISSNLinking":"0300-9564"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"Amyloid beta-Peptides"},{"RegistryNumber":"0","NameOfSubstance":"Biomarkers"},{"RegistryNumber":"0","NameOfSubstance":"tau Proteins"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Aged, 80 and over"},{"DescriptorName":"Alzheimer Disease","QualifierName":["cerebrospinal fluid","complications","diagnosis"]},{"DescriptorName":"Amyloid beta-Peptides","QualifierName":"cerebrospinal fluid"},{"DescriptorName":"Biomarkers","QualifierName":"cerebrospinal fluid"},{"DescriptorName":"Dementia","QualifierName":["cerebrospinal fluid","diagnosis","etiology"]},{"DescriptorName":"Female"},{"DescriptorName":"Humans"},{"DescriptorName":"Male"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"tau Proteins","QualifierName":"cerebrospinal fluid"}]},"KeywordList":{"@attributes":{"Owner":"NOTNLM"},"Keyword":["Phosphorylated tau 181","Total tau","\u03b2-Amyloid 1-42"]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2017","Month":"08","Day":"05"},{"@attributes":{"PubStatus":"accepted"},"Year":"2017","Month":"11","Day":"07"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2017","Month":"11","Day":"17","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2019","Month":"10","Day":"1","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"entrez"},"Year":"2017","Month":"11","Day":"17","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["29143217","10.1007\/s00702-017-1810-z","10.1007\/s00702-017-1810-z"]},"ReferenceList":{"Reference":[{"Citation":"Neuron. 2017 Sep 27;96(1):115-129.e5","ArticleIdList":{"ArticleId":"28957663"}},{"Citation":"Lancet. 1991 May 11;337(8750):1158-9","ArticleIdList":{"ArticleId":"1674030"}},{"Citation":"Alzheimers Dement. 2015 Feb;11(2):195-206.e1","ArticleIdList":{"ArticleId":"25150733"}},{"Citation":"Lancet Neurol. 2013 Apr;12(4):357-67","ArticleIdList":{"ArticleId":"23477989"}},{"Citation":"Curr Alzheimer Res. 2012 Feb;9(2):241-7","ArticleIdList":{"ArticleId":"22044023"}},{"Citation":"Alzheimers Res Ther. 2014 Jun 26;6(3):38","ArticleIdList":{"ArticleId":"25478015"}},{"Citation":"Eur Arch Psychiatry Clin Neurosci. 2016 Oct;266(7):587-97","ArticleIdList":{"ArticleId":"26253588"}},{"Citation":"Ann Neurol. 2009 Apr;65(4):403-13","ArticleIdList":{"ArticleId":"19296504"}},{"Citation":"J Neurochem. 1993 Nov;61(5):1828-34","ArticleIdList":{"ArticleId":"8228996"}},{"Citation":"Brain. 2015 Sep;138(Pt 9):2716-31","ArticleIdList":{"ArticleId":"26133663"}},{"Citation":"Neurology. 1999 May 12;52(8):1555-62","ArticleIdList":{"ArticleId":"10331678"}},{"Citation":"J Alzheimers Dis. 2017;56(2):601-617","ArticleIdList":{"ArticleId":"28035917"}},{"Citation":"Mol Neurodegener. 2009 Mar 11;4:13","ArticleIdList":{"ArticleId":"19284597"}},{"Citation":"Lancet Neurol. 2014 Jun;13(6):614-29","ArticleIdList":{"ArticleId":"24849862"}},{"Citation":"Alzheimers Dement. 2014 Nov;10 (6):808-17","ArticleIdList":{"ArticleId":"25150736"}},{"Citation":"Neurology. 2010 Jul 20;75(3):230-8","ArticleIdList":{"ArticleId":"20592257"}},{"Citation":"Alzheimers Dement. 2017 Apr;13(4):e1-e85","ArticleIdList":{"ArticleId":"28342697"}},{"Citation":"Neurology. 2012 Jan 3;78(1):47-54","ArticleIdList":{"ArticleId":"22170879"}},{"Citation":"Ann Neurol. 2006 Mar;59(3):512-9","ArticleIdList":{"ArticleId":"16372280"}},{"Citation":"Brain. 2016 Sep;139(Pt 9):2540-53","ArticleIdList":{"ArticleId":"27401520"}},{"Citation":"Amyloid. 2000 Dec;7(4):245-58","ArticleIdList":{"ArticleId":"11132093"}},{"Citation":"Alzheimers Dement. 2011 May;7(3):263-9","ArticleIdList":{"ArticleId":"21514250"}},{"Citation":"Neurology. 2009 Oct 13;73(15):1193-9","ArticleIdList":{"ArticleId":"19822868"}},{"Citation":"Dement Geriatr Cogn Disord. 2006;21(3):131-8","ArticleIdList":{"ArticleId":"16391474"}},{"Citation":"Ann Transl Med. 2016 Mar;4(6):107","ArticleIdList":{"ArticleId":"27127760"}},{"Citation":"Neuroimage. 2017 May 15;152:60-77","ArticleIdList":{"ArticleId":"28257929"}},{"Citation":"Nature. 2017 Jul 12;547(7662):153-155","ArticleIdList":{"ArticleId":"28703214"}},{"Citation":"Ann Neurol. 2013 Sep;74(3):478-89","ArticleIdList":{"ArticleId":"23798485"}},{"Citation":"Neurology. 2011 Jan 4;76(1):69-79","ArticleIdList":{"ArticleId":"21123754"}},{"Citation":"Ann Neurol. 2013 Dec;74(6):826-36","ArticleIdList":{"ArticleId":"23536396"}},{"Citation":"Alzheimers Dement. 2014 Nov;10 (6):684-9","ArticleIdList":{"ArticleId":"24857233"}},{"Citation":"J Mol Neurosci. 2012 May;47(1):1-14","ArticleIdList":{"ArticleId":"22058061"}},{"Citation":"J Alzheimers Dis. 2013;36(2):401-8","ArticleIdList":{"ArticleId":"23609762"}},{"Citation":"Alzheimers Dement. 2010 May;6(3):265-73","ArticleIdList":{"ArticleId":"20451875"}},{"Citation":"Neurochem Int. 2017 Sep;108:355-360","ArticleIdList":{"ArticleId":"28527630"}},{"Citation":"Clin Chem. 1997 Sep;43(9):1657-9","ArticleIdList":{"ArticleId":"9299950"}},{"Citation":"J Alzheimers Dis. 2015 ;45(4):1077-88","ArticleIdList":{"ArticleId":"25649653"}},{"Citation":"Dement Geriatr Cogn Dis Extra. 2016 Oct 7;6(3):465-476","ArticleIdList":{"ArticleId":"27843444"}},{"Citation":"Acta Neurol Belg. 2015 Dec;115(4):547-55","ArticleIdList":{"ArticleId":"25576445"}},{"Citation":"Alzheimers Dement. 2017 Mar;13(3):274-284","ArticleIdList":{"ArticleId":"28341065"}},{"Citation":"Alzheimers Res Ther. 2015 Jun 01;7(1):30","ArticleIdList":{"ArticleId":"26034513"}},{"Citation":"Alzheimers Dement. 2015 May;11(5):511-22","ArticleIdList":{"ArticleId":"25150730"}},{"Citation":"J Neural Transm (Vienna). 2013 Oct;120(10):1475-7","ArticleIdList":{"ArticleId":"23933662"}},{"Citation":"Alzheimers Res Ther. 2017 Aug 9;9(1):60","ArticleIdList":{"ArticleId":"28793924"}},{"Citation":"Lancet Neurol. 2013 Feb;12(2):207-16","ArticleIdList":{"ArticleId":"23332364"}},{"Citation":"Alzheimers Dement. 2013 Sep;9(5):580-6","ArticleIdList":{"ArticleId":"23232272"}},{"Citation":"Neurology. 1984 Jul;34(7):939-44","ArticleIdList":{"ArticleId":"6610841"}},{"Citation":"Alzheimers Dement. 2017 Jun;13(6):654-662","ArticleIdList":{"ArticleId":"27870939"}},{"Citation":"Alzheimers Dement. 2017 Mar;13(3):285-295","ArticleIdList":{"ArticleId":"28341066"}},{"Citation":"CNS Drugs. 2016 Sep;30(9):773-89","ArticleIdList":{"ArticleId":"27328687"}}]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"29130870","DateCompleted":{"Year":"2018","Month":"07","Day":"16"},"DateRevised":{"Year":"2018","Month":"07","Day":"19"},"Article":{"@attributes":{"PubModel":"Print"},"Journal":{"ISSN":"1741-203X","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"29","Issue":"12","PubDate":{"Year":"2017","Month":"12"}},"Title":"International psychogeriatrics","ISOAbbreviation":"Int Psychogeriatr"},"ArticleTitle":"Modern technology to support carers of care recipients with dementia or functional mental illness: promising progress, but a long road ahead.","Pagination":{"MedlinePgn":"1933-1935"},"ELocationID":"10.1017\/S1041610217002150","Abstract":{"AbstractText":"There is no doubt that family carers who look after a family member with dementia or with a functional mental illness fulfill an important role, not only for their loved one, but also for the health and aged care systems of the countries they live in. Due to increasing life expectancy, but also improved healthcare the number of family carers supporting older care recipients with functional mental illness or dementia is on the rise. While the carer role often can offer rewarding experiences caregivers are at increased risk of stress, depression, sleep problems, and often experience poor health outcomes with increased morbidity and mortality (Oyebode, 2003). Next to the stressors directly associated with the carer role, they often do not have the time to engage in healthy behavior to protect their physical, mental, and cognitive health (Loi et al., 2014). There is a wealth of literature providing evidence about effective strategies to support carers and the recent Lancet Commission on Dementia prevention, intervention, and care highlighted the importance of exploring how the use of technological innovations could support carers better (Livingston et al., 2017). The use of modern technology in this context can mean a variety of approaches, such as internet-based programs to provide education and skill-building, virtual support to assist with monitoring and managing challenging behavior, online support groups, and the use of assistive or therapeutic technology to improve safety, enable positive activities, and support communication between carer and care recipient, to name just a few (D'Onofrio et al., 2017; Ienca et al., 2017; Livingston et al., 2017). More specifically, telehealth approaches via videoconferences have the potential to better support carers who live in rural or remote regions (O'Connell et al., 2014) or who cannot attend face-to-face support programs for other reasons such as inability to leave the care recipient alone at home, being a multiple carer or having a disability themselves to give just some examples."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Lautenschlager","ForeName":"Nicola T","Initials":"NT","AffiliationInfo":{"Affiliation":"Academic Unit for Psychiatry of Old Age,Department of Psychiatry,The University of Melbourne,Melbourne,Australia."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Diehl-Schmid","ForeName":"Janine","Initials":"J","AffiliationInfo":{"Affiliation":"Department of Psychiatry,Technische Universit\u00e4t M\u00fcnchen,Munich,Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Loi","ForeName":"Samantha M","Initials":"SM","Identifier":"0000-0002-4953-4500","AffiliationInfo":{"Affiliation":"Academic Unit for Psychiatry of Old Age,Department of Psychiatry,The University of Melbourne,Melbourne,Australia."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Mayer","ForeName":"Johannes","Initials":"J","AffiliationInfo":{"Affiliation":"Department of Psychiatry,Technische Universit\u00e4t M\u00fcnchen,Munich,Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Tensil","ForeName":"Maria","Initials":"M","AffiliationInfo":{"Affiliation":"Department of Psychiatry,Technische Universit\u00e4t M\u00fcnchen,Munich,Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander F","Initials":"AF","AffiliationInfo":{"Affiliation":"Department of Psychiatry,Technische Universit\u00e4t M\u00fcnchen,Munich,Germany."}}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Editorial","Research Support, Non-U.S. Gov't"]}},"MedlineJournalInfo":{"Country":"England","MedlineTA":"Int Psychogeriatr","NlmUniqueID":"9007918","ISSNLinking":"1041-6102"},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Caregivers","QualifierName":["education","psychology"]},{"DescriptorName":"Communication"},{"DescriptorName":"Dementia","QualifierName":"nursing"},{"DescriptorName":"Depression","QualifierName":"psychology"},{"DescriptorName":"Family","QualifierName":"psychology"},{"DescriptorName":"Humans"},{"DescriptorName":"Internet"},{"DescriptorName":"Quality of Life"},{"DescriptorName":"Self-Help Groups"},{"DescriptorName":"Social Support"},{"DescriptorName":"Telemedicine"},{"DescriptorName":"Videoconferencing"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"entrez"},"Year":"2017","Month":"11","Day":"14","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2017","Month":"11","Day":"14","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2018","Month":"7","Day":"17","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["29130870","S1041610217002150","10.1017\/S1041610217002150"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"29017593","DateCompleted":{"Year":"2018","Month":"06","Day":"19"},"DateRevised":{"Year":"2018","Month":"11","Day":"13"},"Article":{"@attributes":{"PubModel":"Electronic"},"Journal":{"ISSN":"1758-9193","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"9","Issue":"1","PubDate":{"Year":"2017","Month":"Oct","Day":"10"}},"Title":"Alzheimer's research & therapy","ISOAbbreviation":"Alzheimers Res Ther"},"ArticleTitle":"Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.","Pagination":{"MedlinePgn":"84"},"ELocationID":"10.1186\/s13195-017-0301-7","Abstract":{"AbstractText":["The progression of mild cognitive impairment (MCI) to Alzheimer's disease (AD) dementia can be predicted by cognitive, neuroimaging, and cerebrospinal fluid (CSF) markers. Since most biomarkers reveal complementary information, a combination of biomarkers may increase the predictive power. We investigated which combination of the Mini-Mental State Examination (MMSE), Clinical Dementia Rating (CDR)-sum-of-boxes, the word list delayed free recall from the Consortium to Establish a Registry of Dementia (CERAD) test battery, hippocampal volume (HCV), amyloid-beta (A\u03b242), amyloid-beta (A\u03b240) levels, the ratio of A\u03b242\/A\u03b240, phosphorylated tau, and total tau (t-Tau) levels in the CSF best predicted a short-term conversion from MCI to AD dementia.","We used 115 complete datasets from MCI patients of the \"Dementia Competence Network\", a German multicenter cohort study with annual follow-up up to 3\u00a0years. MCI was broadly defined to include amnestic and nonamnestic syndromes. Variables known to predict progression in MCI patients were selected a priori. Nine individual predictors were compared by receiver operating characteristic (ROC) curve analysis. ROC curves of the five best two-, three-, and four-parameter combinations were analyzed for significant superiority by a bootstrapping wrapper around a support vector machine with linear kernel. The incremental value of combinations was tested for statistical significance by comparing the specificities of the different classifiers at a given sensitivity of 85%.","Out of 115 subjects, 28 (24.3%) with MCI progressed to AD dementia within a mean follow-up period of 25.5\u00a0months. At baseline, MCI-AD patients were no different from stable MCI in age and gender distribution, but had lower educational attainment. All single biomarkers were significantly different between the two groups at baseline. ROC curves of the individual predictors gave areas under the curve (AUC) between 0.66 and 0.77, and all single predictors were statistically superior to A\u03b240. The AUC of the two-parameter combinations ranged from 0.77 to 0.81. The three-parameter combinations ranged from AUC 0.80-0.83, and the four-parameter combination from AUC 0.81-0.82. None of the predictor combinations was significantly superior to the two best single predictors (HCV and t-Tau). When maximizing the AUC differences by fixing sensitivity at 85%, the two- to four-parameter combinations were superior to HCV alone.","A combination of two biomarkers of neurodegeneration (e.g., HCV and t-Tau) is not superior over the single parameters in identifying patients with MCI who are most likely to progress to AD dementia, although there is a gradual increase in the statistical measures across increasing biomarker combinations. This may have implications for clinical diagnosis and for selecting subjects for participation in clinical trials."]},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Fr\u00f6lich","ForeName":"Lutz","Initials":"L","AffiliationInfo":{"Affiliation":"Department of Geriatric Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Zentralinstitut f\u00fcr Seelische Gesundheit, Quadrat J5, D-68159, Mannheim, Germany. lutz.froelich@zi-mannheim.de."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Peters","ForeName":"Oliver","Initials":"O","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Campus Benjamin Franklin, Charit\u00e9, Berlin, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Lewczuk","ForeName":"Piotr","Initials":"P","AffiliationInfo":[{"Affiliation":"Department of Psychiatry and Psychotherapy, Friedrich-Alexander-University of Erlangen-Nuremberg, Nuremberg, Germany."},{"Affiliation":"Department of Neurodegeneration Diagnostics, Medical University of Bialystok, Bialystok, Poland."}]},{"@attributes":{"ValidYN":"Y"},"LastName":"Gruber","ForeName":"Oliver","Initials":"O","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, University Medical Center G\u00f6ttingen, and German Center for Neurodegenerative Diseases (DZNE), Research Site G\u00f6ttingen, G\u00f6ttingen, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Teipel","ForeName":"Stefan J","Initials":"SJ","AffiliationInfo":[{"Affiliation":"German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany."},{"Affiliation":"Department of Psychosomatic Medicine, University Medicine Rostock, Rostock, Germany."},{"Affiliation":"Department of Psychiatry and Psychotherapy, Ludwig-Maximilian-University of Munich, Munich, Germany."}]},{"@attributes":{"ValidYN":"Y"},"LastName":"Gertz","ForeName":"Hermann J","Initials":"HJ","AffiliationInfo":{"Affiliation":"Department of Psychiatry, University of Leipzig, Leipzig, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Jahn","ForeName":"Holger","Initials":"H","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, University Medical Center Hamburg, Hamburg, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Jessen","ForeName":"Frank","Initials":"F","AffiliationInfo":[{"Affiliation":"Department of Psychiatry and Psychotherapy, University of Bonn, Bonn, Germany."},{"Affiliation":"German Center for Neurodegenerative Diseases (DZNE), Cologne\/Bonn, Germany."},{"Affiliation":"Department of Psychiatry and Psychotherapy, Medical Faculty University of Cologne, Cologne, Germany."}]},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Technical University of Munich, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Luckhaus","ForeName":"Christian","Initials":"C","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, University of D\u00fcsseldorf, D\u00fcsseldorf, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"H\u00fcll","ForeName":"Michael","Initials":"M","AffiliationInfo":{"Affiliation":"Center for Psychiatry, Clinic for Geriatric Psychiatry and Psychotherapy Emmendingen and Department of Psychiatry and Psychotherapy, University of Freiburg, Freiburg, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Pantel","ForeName":"Johannes","Initials":"J","AffiliationInfo":{"Affiliation":"Institute of General Medicine University of Frankfurt, Frankfurt am Main, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Reischies","ForeName":"Friedel M","Initials":"FM","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Campus Benjamin Franklin, Charit\u00e9, Berlin, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Schr\u00f6der","ForeName":"Johannes","Initials":"J","AffiliationInfo":{"Affiliation":"Section for Geriatric Psychiatry Research, Department for Psychiatry, University of Heidelberg, Heidelberg, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Wagner","ForeName":"Michael","Initials":"M","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, University of Bonn, Bonn, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Rienhoff","ForeName":"Otto","Initials":"O","AffiliationInfo":{"Affiliation":"Department of Medical Informatics, University of G\u00f6ttingen, G\u00f6ttingen, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Wolf","ForeName":"Stefanie","Initials":"S","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, University Medical Center G\u00f6ttingen, and German Center for Neurodegenerative Diseases (DZNE), Research Site G\u00f6ttingen, G\u00f6ttingen, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Bauer","ForeName":"Chris","Initials":"C","AffiliationInfo":{"Affiliation":"MicroDiscovery GmbH, Berlin, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Schuchhardt","ForeName":"Johannes","Initials":"J","AffiliationInfo":{"Affiliation":"MicroDiscovery GmbH, Berlin, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Heuser","ForeName":"Isabella","Initials":"I","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Campus Benjamin Franklin, Charit\u00e9, Berlin, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"R\u00fcther","ForeName":"Eckart","Initials":"E","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, University Medical Center G\u00f6ttingen, and German Center for Neurodegenerative Diseases (DZNE), Research Site G\u00f6ttingen, G\u00f6ttingen, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Henn","ForeName":"Fritz","Initials":"F","AffiliationInfo":{"Affiliation":"Department of Geriatric Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Zentralinstitut f\u00fcr Seelische Gesundheit, Quadrat J5, D-68159, Mannheim, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Maier","ForeName":"Wolfgang","Initials":"W","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, University of Bonn, Bonn, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Wiltfang","ForeName":"Jens","Initials":"J","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, University Medical Center G\u00f6ttingen, and German Center for Neurodegenerative Diseases (DZNE), Research Site G\u00f6ttingen, G\u00f6ttingen, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Kornhuber","ForeName":"Johannes","Initials":"J","AffiliationInfo":[{"Affiliation":"Department of Psychiatry and Psychotherapy, Friedrich-Alexander-University of Erlangen-Nuremberg, Nuremberg, Germany."},{"Affiliation":"Department of Neurodegeneration Diagnostics, Medical University of Bialystok, Bialystok, Poland."}]}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Multicenter Study"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2017","Month":"10","Day":"10"}},"MedlineJournalInfo":{"Country":"England","MedlineTA":"Alzheimers Res Ther","NlmUniqueID":"101511643"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"Amyloid beta-Peptides"},{"RegistryNumber":"0","NameOfSubstance":"Biomarkers"},{"RegistryNumber":"0","NameOfSubstance":"MAPT protein, human"},{"RegistryNumber":"0","NameOfSubstance":"Peptide Fragments"},{"RegistryNumber":"0","NameOfSubstance":"amyloid beta-protein (1-40)"},{"RegistryNumber":"0","NameOfSubstance":"amyloid beta-protein (1-42)"},{"RegistryNumber":"0","NameOfSubstance":"tau Proteins"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Alzheimer Disease","QualifierName":["diagnosis","pathology","physiopathology"]},{"DescriptorName":"Amyloid beta-Peptides","QualifierName":"cerebrospinal fluid"},{"DescriptorName":"Biomarkers","QualifierName":"cerebrospinal fluid"},{"DescriptorName":"Cognitive Dysfunction","QualifierName":["diagnosis","pathology","physiopathology"]},{"DescriptorName":"Disease Progression"},{"DescriptorName":"Educational Status"},{"DescriptorName":"Female"},{"DescriptorName":"Follow-Up Studies"},{"DescriptorName":"Hippocampus","QualifierName":["diagnostic imaging","pathology"]},{"DescriptorName":"Humans"},{"DescriptorName":"Male"},{"DescriptorName":"Neuropsychological Tests"},{"DescriptorName":"Organ Size"},{"DescriptorName":"Peptide Fragments","QualifierName":"cerebrospinal fluid"},{"DescriptorName":"Phosphorylation"},{"DescriptorName":"Prognosis"},{"DescriptorName":"Sensitivity and Specificity"},{"DescriptorName":"Support Vector Machine"},{"DescriptorName":"tau Proteins","QualifierName":"cerebrospinal fluid"}]},"KeywordList":{"@attributes":{"Owner":"NOTNLM"},"Keyword":["Alzheimer\u2019s dementia","Amyloid-beta 42","Biomarkers","Hippocampal volume","Mild cognitive impairment","Phospho-tau","Prediction","Tau"]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2016","Month":"09","Day":"07"},{"@attributes":{"PubStatus":"accepted"},"Year":"2017","Month":"08","Day":"30"},{"@attributes":{"PubStatus":"entrez"},"Year":"2017","Month":"10","Day":"12","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2017","Month":"10","Day":"12","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2018","Month":"6","Day":"21","Hour":"6","Minute":"0"}]},"PublicationStatus":"epublish","ArticleIdList":{"ArticleId":["29017593","10.1186\/s13195-017-0301-7","10.1186\/s13195-017-0301-7","PMC5634868"]},"ReferenceList":{"Reference":[{"Citation":"Dement Geriatr Cogn Disord. 1998;9 Suppl 2:20-6","ArticleIdList":{"ArticleId":"9718231"}},{"Citation":"Med Image Comput Comput Assist Interv. 2012;15(Pt 1):132-40","ArticleIdList":{"ArticleId":"23285544"}},{"Citation":"Neuroimage. 2002 Oct;17(2):825-41","ArticleIdList":{"ArticleId":"12377157"}},{"Citation":"Neurobiol Aging. 2007 Jul;28(7):1070-4","ArticleIdList":{"ArticleId":"16782233"}},{"Citation":"Neurology. 2007 Mar 13;68(11):828-36","ArticleIdList":{"ArticleId":"17353470"}},{"Citation":"Neurocase. 2005 Feb;11(1):14-25","ArticleIdList":{"ArticleId":"15804920"}},{"Citation":"Radiology. 1983 Sep;148(3):839-43","ArticleIdList":{"ArticleId":"6878708"}},{"Citation":"Front Aging Neurosci. 2013 Oct 11;5:55","ArticleIdList":{"ArticleId":"24130528"}},{"Citation":"Neurobiol Aging. 2014 Jan;35(1):143-51","ArticleIdList":{"ArticleId":"23954175"}},{"Citation":"AJNR Am J Neuroradiol. 2010 Feb;31(2):347-54","ArticleIdList":{"ArticleId":"20075088"}},{"Citation":"Neuroimage Clin. 2015 May 21;8:583-93","ArticleIdList":{"ArticleId":"26199870"}},{"Citation":"Med Clin North Am. 2013 May;97(3):399-424","ArticleIdList":{"ArticleId":"23642578"}},{"Citation":"Neuroimage. 2004;23 Suppl 1:S208-19","ArticleIdList":{"ArticleId":"15501092"}},{"Citation":"Ann Neurol. 2009 Apr;65(4):403-13","ArticleIdList":{"ArticleId":"19296504"}},{"Citation":"Arch Gen Psychiatry. 2012 Jan;69(1):98-106","ArticleIdList":{"ArticleId":"22213792"}},{"Citation":"Neuroimage Clin. 2013 Nov 28;4:164-73","ArticleIdList":{"ArticleId":"24371799"}},{"Citation":"Neurobiol Aging. 1998 Mar-Apr;19(2):109-16","ArticleIdList":{"ArticleId":"9558143"}},{"Citation":"Neuroimage Clin. 2013 May 19;2:735-45","ArticleIdList":{"ArticleId":"24179825"}},{"Citation":"Neurology. 1999 May 12;52(8):1555-62","ArticleIdList":{"ArticleId":"10331678"}},{"Citation":"J Alzheimers Dis. 2010;20(3):881-91","ArticleIdList":{"ArticleId":"20413876"}},{"Citation":"Clin Chem. 2010 Feb;56(2):248-53","ArticleIdList":{"ArticleId":"19833838"}},{"Citation":"World J Biol Psychiatry. 2008;9(3):172-82","ArticleIdList":{"ArticleId":"17886169"}},{"Citation":"Ann Neurol. 2005 Jun;57(6):896-903","ArticleIdList":{"ArticleId":"15929035"}},{"Citation":"Neurology. 2005 Jul 12;65(1):102-6","ArticleIdList":{"ArticleId":"16009893"}},{"Citation":"J Alzheimers Dis. 2009;16(2):351-62","ArticleIdList":{"ArticleId":"19221425"}},{"Citation":"J Neurol Neurosurg Psychiatry. 2008 Dec;79(12):1386-91","ArticleIdList":{"ArticleId":"19010949"}},{"Citation":"Psychol Med. 2010 Jan;40(1):135-45","ArticleIdList":{"ArticleId":"19863841"}},{"Citation":"Med Clin North Am. 2013 May;97(3):369-76","ArticleIdList":{"ArticleId":"23642576"}},{"Citation":"Neurology. 2011 Oct 25;77(17 ):1619-28","ArticleIdList":{"ArticleId":"21998317"}},{"Citation":"Lancet Neurol. 2010 Jan;9(1):119-28","ArticleIdList":{"ArticleId":"20083042"}},{"Citation":"Neurobiol Aging. 2011 Dec;32(12 ):2322.e19-27","ArticleIdList":{"ArticleId":"20594615"}},{"Citation":"Neurology. 2009 Jul 28;73(4):294-301","ArticleIdList":{"ArticleId":"19636049"}},{"Citation":"Neurology. 1993 Nov;43(11):2412-4","ArticleIdList":{"ArticleId":"8232972"}},{"Citation":"Neurology. 2010 Jul 20;75(3):230-8","ArticleIdList":{"ArticleId":"20592257"}},{"Citation":"Cancer. 1950 Jan;3(1):32-5","ArticleIdList":{"ArticleId":"15405679"}},{"Citation":"Dement Geriatr Cogn Disord. 2009;27(5):404-17","ArticleIdList":{"ArticleId":"19339779"}},{"Citation":"Arch Gen Psychiatry. 2011 Sep;68(9):961-9","ArticleIdList":{"ArticleId":"21893661"}},{"Citation":"J Neural Transm (Vienna). 2006 Aug;113(8):1075-80","ArticleIdList":{"ArticleId":"16835693"}},{"Citation":"J Neurosci. 2010 Feb 10;30(6):2088-101","ArticleIdList":{"ArticleId":"20147537"}},{"Citation":"Alzheimers Dement. 2016 Feb;12 (2):154-163","ArticleIdList":{"ArticleId":"26368321"}},{"Citation":"Lancet Neurol. 2006 Mar;5(3):228-34","ArticleIdList":{"ArticleId":"16488378"}},{"Citation":"J Alzheimers Dis. 2015 ;43(1):183-91","ArticleIdList":{"ArticleId":"25079805"}},{"Citation":"Neuroscience. 2000;95(3):721-5","ArticleIdList":{"ArticleId":"10670438"}},{"Citation":"J Psychiatr Res. 1975 Nov;12(3):189-98","ArticleIdList":{"ArticleId":"1202204"}},{"Citation":"J Neurol Neurosurg Psychiatry. 2002 Apr;72(4):491-7","ArticleIdList":{"ArticleId":"11909909"}},{"Citation":"Nat Rev Neurol. 2010 Feb;6(2):67-77","ArticleIdList":{"ArticleId":"20139996"}},{"Citation":"Br J Psychiatry. 1979 Apr;134:382-9","ArticleIdList":{"ArticleId":"444788"}},{"Citation":"Neuroimage. 2011 Apr 1;55(3):856-67","ArticleIdList":{"ArticleId":"21236349"}},{"Citation":"Neurobiol Aging. 2012 Jul;33(7):1203-14","ArticleIdList":{"ArticleId":"21159408"}},{"Citation":"Alzheimers Dement. 2015 Jun;11(6):e1-120","ArticleIdList":{"ArticleId":"26073027"}},{"Citation":"Psychopharmacol Bull. 1988;24(4):641-52","ArticleIdList":{"ArticleId":"3249766"}},{"Citation":"J Proteome Res. 2006 Apr;5(4):1010-6","ArticleIdList":{"ArticleId":"16602710"}},{"Citation":"BMC Bioinformatics. 2011 Mar 17;12:77","ArticleIdList":{"ArticleId":"21414208"}},{"Citation":"J Neurol Neurosurg Psychiatry. 2006 Nov;77(11):1219-22","ArticleIdList":{"ArticleId":"16891386"}},{"Citation":"Clin Chem. 2001 Oct;47(10):1776-81","ArticleIdList":{"ArticleId":"11568086"}},{"Citation":"Arch Neurol. 2005 May;62(5):770-3","ArticleIdList":{"ArticleId":"15883264"}},{"Citation":"Neuroepidemiology. 2008;30(4):254-65","ArticleIdList":{"ArticleId":"18515975"}},{"Citation":"Neurobiol Aging. 2006 Aug;27(8):1051-9","ArticleIdList":{"ArticleId":"16169126"}},{"Citation":"Neuroimage. 2004 Oct;23(2):724-38","ArticleIdList":{"ArticleId":"15488422"}},{"Citation":"Psychiatry Res. 2007 Jul 15;155(2):167-71","ArticleIdList":{"ArticleId":"17531450"}},{"Citation":"Clin Chem. 2003 Jan;49(1):7-18","ArticleIdList":{"ArticleId":"12507954"}},{"Citation":"J Alzheimers Dis. 2012;29(2):319-27","ArticleIdList":{"ArticleId":"22233766"}},{"Citation":"Alzheimers Dement. 2011 Jul;7(4):386-395.e6","ArticleIdList":{"ArticleId":"21784349"}},{"Citation":"Nat Rev Neurol. 2016 Feb;12(2):117-24","ArticleIdList":{"ArticleId":"26782335"}},{"Citation":"J Intern Med. 2004 Sep;256(3):240-6","ArticleIdList":{"ArticleId":"15324367"}},{"Citation":"JAMA. 2009 Jul 22;302(4):385-93","ArticleIdList":{"ArticleId":"19622817"}},{"Citation":"Int Psychogeriatr. 2014 Apr;26(4):543-54","ArticleIdList":{"ArticleId":"24252258"}},{"Citation":"Alzheimers Res Ther. 2015 Jun 01;7(1):30","ArticleIdList":{"ArticleId":"26034513"}},{"Citation":"Neurobiol Aging. 2012 Oct;33(10 ):2272-81","ArticleIdList":{"ArticleId":"22264648"}},{"Citation":"Neurology. 2013 Mar 19;80(12 ):1124-32","ArticleIdList":{"ArticleId":"23446677"}},{"Citation":"Neurology. 2013 Mar 12;80(11):1048-56","ArticleIdList":{"ArticleId":"23390179"}},{"Citation":"Neurosci Lett. 2006 Nov 27;409(1):1-4","ArticleIdList":{"ArticleId":"17045397"}},{"Citation":"Neuroimage. 2009 Feb 15;44(4):1415-22","ArticleIdList":{"ArticleId":"19027862"}},{"Citation":"Neurology. 2012 Feb 7;78(6):379-86","ArticleIdList":{"ArticleId":"22238414"}},{"Citation":"Lancet Neurol. 2013 Feb;12(2):207-16","ArticleIdList":{"ArticleId":"23332364"}},{"Citation":"Neuroimage. 2011 Jun 1;56(3):907-22","ArticleIdList":{"ArticleId":"21352927"}},{"Citation":"Neurology. 1984 Jul;34(7):939-44","ArticleIdList":{"ArticleId":"6610841"}},{"Citation":"J Neurochem. 2007 May;101(4):1053-9","ArticleIdList":{"ArticleId":"17254013"}}]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","IndexingMethod":"Curated","Owner":"NLM"},"PMID":"28643900","DateCompleted":{"Year":"2019","Month":"01","Day":"24"},"DateRevised":{"Year":"2019","Month":"01","Day":"24"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1099-1166","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"33","Issue":"2","PubDate":{"Year":"2018","Month":"02"}},"Title":"International journal of geriatric psychiatry","ISOAbbreviation":"Int J Geriatr Psychiatry"},"ArticleTitle":"Exploring perspectives of young onset dementia caregivers with high versus low unmet needs.","Pagination":{"MedlinePgn":"340-347"},"ELocationID":"10.1002\/gps.4749","Abstract":{"AbstractText":["This study is part of the Research to Assess Policies and Strategies for Dementia in the Young project. Information about specific needs in young onset dementia (YOD) will provide the basis for the development of an e-health intervention to assist caregivers in coping with YOD in several European countries.","The aim was to investigate the issues caregivers of people with YOD face.","A qualitative content analysis method was used to analyse interviews with YOD caregivers. Quantitative data of the Needs in Young Onset Dementia study were used to select caregivers based on a ranking of unmet needs, to capture differences and similarities between caregivers that experienced high levels of unmet needs versus those with low levels of unmet needs. Needs were assessed with the Camberwell Assessment of Needs in the Elderly.","Findings revealed the following themes: (i) acceptance; (ii) perception of the relationship; (iii) role adaptation; (iv) Availability of appropriate services; (v) social support; and (vi) awareness in the person with dementia and acceptance of help. Several factors seemed more apparent in the caregivers who experienced few unmet needs opposed to the caregivers who experienced more unmet needs.","The current study provides an in-depth perspective on the caregiver's experiences and emphasizes specific themes that could be addressed in future interventions. This might contribute to a caring situation in which the caregiver experiences less unmet needs. Copyright \u00a9 2017 John Wiley & Sons, Ltd."],"CopyrightInformation":"Copyright \u00a9 2017 John Wiley & Sons, Ltd."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Millenaar","ForeName":"Joany K","Initials":"JK","Identifier":"0000-0002-8523-9277","AffiliationInfo":{"Affiliation":"School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University Medical Center, Maastricht, The Netherlands."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Bakker","ForeName":"Christian","Initials":"C","AffiliationInfo":[{"Affiliation":"Florence, Mariahoeve Center for Specialized Care in Young-Onset Dementia, Den Haag, The Netherlands."},{"Affiliation":"Department of Primary and Community Care: Center for Family Medicine, Geriatric Care and Public Health, Radboudumc Alzheimer Centre Nijmegen, Radboud University, Nijmegen, The Netherlands."}]},{"@attributes":{"ValidYN":"Y"},"LastName":"van Vliet","ForeName":"Deliane","Initials":"D","AffiliationInfo":{"Affiliation":"Department of Primary and Community Care: Center for Family Medicine, Geriatric Care and Public Health, Radboudumc Alzheimer Centre Nijmegen, Radboud University, Nijmegen, The Netherlands."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Koopmans","ForeName":"Raymond T C M","Initials":"RTCM","AffiliationInfo":[{"Affiliation":"Department of Primary and Community Care: Center for Family Medicine, Geriatric Care and Public Health, Radboudumc Alzheimer Centre Nijmegen, Radboud University, Nijmegen, The Netherlands."},{"Affiliation":"Joachim en Anna Center for Specialized Geriatric Care, Nijmegen, The Netherlands."}]},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Verhey","ForeName":"Frans R J","Initials":"FRJ","AffiliationInfo":{"Affiliation":"School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University Medical Center, Maastricht, The Netherlands."}},{"@attributes":{"ValidYN":"Y"},"LastName":"de Vugt","ForeName":"Marjolein E","Initials":"ME","AffiliationInfo":{"Affiliation":"School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University Medical Center, Maastricht, The Netherlands."}}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Research Support, Non-U.S. Gov't"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2017","Month":"06","Day":"23"}},"MedlineJournalInfo":{"Country":"England","MedlineTA":"Int J Geriatr Psychiatry","NlmUniqueID":"8710629","ISSNLinking":"0885-6230"},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Adaptation, Psychological"},{"DescriptorName":"Age of Onset"},{"DescriptorName":"Aged"},{"DescriptorName":"Caregivers","QualifierName":"psychology"},{"DescriptorName":"Dementia","QualifierName":"nursing"},{"DescriptorName":"Europe"},{"DescriptorName":"Female"},{"DescriptorName":"Health Services Needs and Demand"},{"DescriptorName":"Humans"},{"DescriptorName":"Interpersonal Relations"},{"DescriptorName":"Male"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Qualitative Research"},{"DescriptorName":"Social Support"}]},"KeywordList":{"@attributes":{"Owner":"NOTNLM"},"Keyword":["care needs","caregivers","service use","young onset dementia"]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2016","Month":"10","Day":"11"},{"@attributes":{"PubStatus":"accepted"},"Year":"2017","Month":"05","Day":"18"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2017","Month":"6","Day":"24","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2019","Month":"1","Day":"25","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"entrez"},"Year":"2017","Month":"6","Day":"24","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["28643900","10.1002\/gps.4749"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"28602012","DateCompleted":{"Year":"2018","Month":"10","Day":"26"},"DateRevised":{"Year":"2018","Month":"11","Day":"13"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1433-8491","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"268","Issue":"5","PubDate":{"Year":"2018","Month":"Aug"}},"Title":"European archives of psychiatry and clinical neuroscience","ISOAbbreviation":"Eur Arch Psychiatry Clin Neurosci"},"ArticleTitle":"Plasma levels of soluble amyloid precursor protein \u03b2 in symptomatic Alzheimer's disease.","Pagination":{"MedlinePgn":"519-524"},"ELocationID":"10.1007\/s00406-017-0815-9","Abstract":{"AbstractText":"The established biomarkers of Alzheimer's disease (AD) require invasive endeavours or presuppose sophisticated technical equipment. Consequently, new biomarkers are needed. Here, we report that plasma levels of soluble amyloid precursor protein \u03b2 (sAPP\u03b2), a protein of the initial phase of the amyloid cascade, were significantly lower in patients with symptomatic AD (21 with mild cognitive impairment due to AD and 44 with AD dementia) with AD-typical cerebral hypometabolic pattern compared with 27 cognitively healthy elderly individuals without preclinical AD. These findings yield further evidence for the potential of sAPP\u03b2 in plasma as an AD biomarker candidate."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Alexopoulos","ForeName":"Panagiotis","Initials":"P","AffiliationInfo":[{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany. panos.alexopoulos@upatras.gr."},{"Affiliation":"Department of Psychiatry, University Hospital of Rion, University of Patras, 26500, Patras, Greece. panos.alexopoulos@upatras.gr."}]},{"@attributes":{"ValidYN":"Y"},"LastName":"Gleixner","ForeName":"Lena-Sophie","Initials":"LS","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Werle","ForeName":"Lukas","Initials":"L","AffiliationInfo":[{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany."},{"Affiliation":"Max Planck Institute of Psychiatry, Munich, Germany."}]},{"@attributes":{"ValidYN":"Y"},"LastName":"Buhl","ForeName":"Felix","Initials":"F","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Thierjung","ForeName":"Nathalie","Initials":"N","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Giourou","ForeName":"Evangelia","Initials":"E","AffiliationInfo":{"Affiliation":"Department of Psychiatry, University Hospital of Rion, University of Patras, 26500, Patras, Greece."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Kagerbauer","ForeName":"Simone M","Initials":"SM","AffiliationInfo":{"Affiliation":"Department of Anaesthesiology, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Gourzis","ForeName":"Philippos","Initials":"P","AffiliationInfo":{"Affiliation":"Department of Psychiatry, University Hospital of Rion, University of Patras, 26500, Patras, Greece."}},{"@attributes":{"ValidYN":"Y"},"LastName":"K\u00fcbler","ForeName":"Hubert","Initials":"H","AffiliationInfo":{"Affiliation":"Department of Urology, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Grimmer","ForeName":"Timo","Initials":"T","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Yakushev","ForeName":"Igor","Initials":"I","AffiliationInfo":{"Affiliation":"Department of Nuclear Medicine, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Martin","ForeName":"Jan","Initials":"J","AffiliationInfo":{"Affiliation":"Department of Anaesthesiology, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Perneczky","ForeName":"Robert","Initials":"R","AffiliationInfo":[{"Affiliation":"Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen, Munich, Germany."},{"Affiliation":"Neuroepidemiology and Ageing Research Unit, Faculty of Medicine, School of Public Health, The Imperial College of Science, Technology and Medicine, London, UK."},{"Affiliation":"West London Mental Health NHS Trust, London, UK."},{"Affiliation":"German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany."}]}]},"Language":"eng","PublicationTypeList":{"PublicationType":"Journal Article"},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2017","Month":"06","Day":"10"}},"MedlineJournalInfo":{"Country":"Germany","MedlineTA":"Eur Arch Psychiatry Clin Neurosci","NlmUniqueID":"9103030","ISSNLinking":"0940-1334"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"Amyloid beta-Protein Precursor"},{"RegistryNumber":"0","NameOfSubstance":"Biomarkers"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Alzheimer Disease","QualifierName":["blood","diagnosis"]},{"DescriptorName":"Amyloid beta-Protein Precursor","QualifierName":"blood"},{"DescriptorName":"Biomarkers","QualifierName":"blood"},{"DescriptorName":"Cognitive Dysfunction","QualifierName":["blood","diagnosis"]},{"DescriptorName":"Female"},{"DescriptorName":"Humans"},{"DescriptorName":"Male"},{"DescriptorName":"Middle Aged"}]},"KeywordList":{"@attributes":{"Owner":"NOTNLM"},"Keyword":["Biomarker-underpinned diagnoses","Dementia due to Alzheimer\u2019s disease","FDG-PET","Mild cognitive impairment","Soluble amyloid precursor protein \u03b2 (sAPP\u03b2)","Upstream biomarkers"]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2016","Month":"11","Day":"07"},{"@attributes":{"PubStatus":"accepted"},"Year":"2017","Month":"06","Day":"06"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2017","Month":"6","Day":"12","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2018","Month":"10","Day":"27","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"entrez"},"Year":"2017","Month":"6","Day":"12","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["28602012","10.1007\/s00406-017-0815-9","10.1007\/s00406-017-0815-9"]},"ReferenceList":{"Reference":[{"Citation":"Lancet. 1991 May 11;337(8750):1158-9","ArticleIdList":{"ArticleId":"1674030"}},{"Citation":"Cochrane Database Syst Rev. 2014 Jul 23;(7):CD010386","ArticleIdList":{"ArticleId":"25052054"}},{"Citation":"Alzheimers Dement. 2014 Nov;10(6):684-9","ArticleIdList":{"ArticleId":"24857233"}},{"Citation":"Alzheimers Dement. 2009 Jan;5(1):18-29","ArticleIdList":{"ArticleId":"19118806"}},{"Citation":"Psychopathology. 2015;48(6):359-67","ArticleIdList":{"ArticleId":"26610315"}},{"Citation":"Eur Arch Psychiatry Clin Neurosci. 2016 Oct;266(7):587-97","ArticleIdList":{"ArticleId":"26253588"}},{"Citation":"Eur Arch Psychiatry Clin Neurosci. 2010 Oct;260(7):561-2","ArticleIdList":{"ArticleId":"20155362"}},{"Citation":"Clin Biochem. 2008 Aug;41(12):986-96","ArticleIdList":{"ArticleId":"18489907"}},{"Citation":"Brain. 2015 Sep;138(Pt 9):2716-31","ArticleIdList":{"ArticleId":"26133663"}},{"Citation":"Neurology. 1999 May 12;52(8):1555-62","ArticleIdList":{"ArticleId":"10331678"}},{"Citation":"Lancet Neurol. 2014 Jun;13(6):614-29","ArticleIdList":{"ArticleId":"24849862"}},{"Citation":"Lancet Neurol. 2016 Jun;15(7):673-684","ArticleIdList":{"ArticleId":"27068280"}},{"Citation":"J Biol Chem. 2012 Nov 23;287(48):40817-25","ArticleIdList":{"ArticleId":"23033480"}},{"Citation":"Trends Mol Med. 2014 Jan;20(1):8-15","ArticleIdList":{"ArticleId":"24524150"}},{"Citation":"Cochrane Database Syst Rev. 2015 Jan 28;1:CD010632","ArticleIdList":{"ArticleId":"25629415"}},{"Citation":"Transl Psychiatry. 2013 Feb 19;3:e227","ArticleIdList":{"ArticleId":"23423136"}},{"Citation":"Alzheimers Dement. 2017 Apr;13(4):e1-e85","ArticleIdList":{"ArticleId":"28342697"}},{"Citation":"Alzheimers Dement. 2011 May;7(3):263-9","ArticleIdList":{"ArticleId":"21514250"}},{"Citation":"Neurology. 2009 Oct 13;73(15):1193-9","ArticleIdList":{"ArticleId":"19822868"}},{"Citation":"Am J Med Genet B Neuropsychiatr Genet. 2003 Apr 1;118B(1):99-102","ArticleIdList":{"ArticleId":"12627474"}},{"Citation":"J Neurochem. 2012 Jan;120 Suppl 1:99-108","ArticleIdList":{"ArticleId":"22150401"}},{"Citation":"Dement Geriatr Cogn Disord. 2006;22(1):27-34","ArticleIdList":{"ArticleId":"16679762"}},{"Citation":"Alzheimers Dement. 2006 Jan;2(1):2-11","ArticleIdList":{"ArticleId":"19595851"}},{"Citation":"J Neurosci Res. 2011 Jun;89(6):822-32","ArticleIdList":{"ArticleId":"21433051"}},{"Citation":"Psychiatry Res. 2010 Feb 28;181(2):85-9","ArticleIdList":{"ArticleId":"20074912"}},{"Citation":"J Alzheimers Dis. 2013;36(2):401-8","ArticleIdList":{"ArticleId":"23609762"}},{"Citation":"Curr Neurovasc Res. 2013 Nov;10(4):297-303","ArticleIdList":{"ArticleId":"23937201"}},{"Citation":"Alzheimers Dement. 2011 May;7(3):270-9","ArticleIdList":{"ArticleId":"21514249"}},{"Citation":"Ann Neurol. 2013 Aug;74(2):199-208","ArticleIdList":{"ArticleId":"23686697"}},{"Citation":"Alzheimers Dement. 2017 Mar;13(3):274-284","ArticleIdList":{"ArticleId":"28341065"}},{"Citation":"Acta Neuropathol. 2015 Oct;130(4):487-99","ArticleIdList":{"ArticleId":"26363791"}},{"Citation":"Neurobiol Aging. 2013 Jun;34(6):1680-6","ArticleIdList":{"ArticleId":"23298733"}},{"Citation":"Int J Immunopathol Pharmacol. 2011 Apr-Jun;24(2):529-34","ArticleIdList":{"ArticleId":"21658330"}},{"Citation":"Alzheimers Dement. 2017 Mar;13(3):285-295","ArticleIdList":{"ArticleId":"28341066"}},{"Citation":"JAMA. 2011 Jun 15;305(23):2458-9","ArticleIdList":{"ArticleId":"21673298"}}]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"27931251","DateCompleted":{"Year":"2017","Month":"10","Day":"13"},"DateRevised":{"Year":"2018","Month":"11","Day":"13"},"Article":{"@attributes":{"PubModel":"Electronic"},"Journal":{"ISSN":"1758-9193","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"8","Issue":"1","PubDate":{"Year":"2016","Month":"12","Day":"09"}},"Title":"Alzheimer's research & therapy","ISOAbbreviation":"Alzheimers Res Ther"},"ArticleTitle":"Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer's disease.","Pagination":{"MedlinePgn":"51"},"Abstract":{"AbstractText":["According to new diagnostic guidelines for Alzheimer's disease (AD), biomarkers enable estimation of the individual likelihood of underlying AD pathophysiology and the associated risk of progression to AD dementia for patients with mild cognitive impairment (MCI). Nonetheless, how conflicting biomarker constellations affect the progression risk is still elusive. The present study explored the impact of different cerebrospinal fluid (CSF) biomarker constellations on the progression risk of MCI patients.","A multicentre cohort of 469 patients with MCI and available CSF biomarker results and clinical follow-up data was considered. Biomarker values were categorized as positive for AD, negative or borderline. Progression risk differences between patients with different constellations of total Tau (t-Tau), phosphorylated Tau at threonine 181 (p-Tau) and amyloid-beta 1-42 (A\u03b2) were studied. Group comparison analyses and Cox regression models were employed.","Patients with all biomarkers positive for AD (N\u2009=\u2009145) had the highest hazard for progression to dementia due to AD, whilst patients with no positive biomarkers (N\u2009=\u2009111) had the lowest. The risk of patients with only abnormal p-Tau and\/or t-Tau (N\u2009=\u200949) or with positive A\u03b2 in combination with positive t-Tau or p-Tau (N\u2009=\u2009119) is significantly lower than that of patients with all biomarkers positive.","The risk of progression to dementia due to AD differs between patients with different CSF biomarker constellations."]},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Alexopoulos","ForeName":"Panagiotis","Initials":"P","AffiliationInfo":[{"Affiliation":"Department of Psychiatry, University Hospital of Rion, University of Patras, 26504, Rio, Patras, Greece. panos.alexopoulos@upatras.gr."},{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, Ismaninger Stra\u00dfe 22, 81675, M\u00fcnchen, Germany. panos.alexopoulos@upatras.gr."},{"Affiliation":"Department of Psychiatry, University Hospital of Patras, University of Patras, 26504, Rion, Patras, Greece. panos.alexopoulos@upatras.gr."}]},{"@attributes":{"ValidYN":"Y"},"LastName":"Werle","ForeName":"Lukas","Initials":"L","AffiliationInfo":{"Affiliation":"Max Planck Institute of Psychiatry, Kraepelinstr. 2-10, 80804, M\u00fcnchen, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Roesler","ForeName":"Jennifer","Initials":"J","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, Ismaninger Stra\u00dfe 22, 81675, M\u00fcnchen, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Thierjung","ForeName":"Nathalie","Initials":"N","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, Ismaninger Stra\u00dfe 22, 81675, M\u00fcnchen, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Gleixner","ForeName":"Lena Sophie","Initials":"LS","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, Ismaninger Stra\u00dfe 22, 81675, M\u00fcnchen, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Yakushev","ForeName":"Igor","Initials":"I","AffiliationInfo":{"Affiliation":"Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, Ismaninger Stra\u00dfe 22, 81675, M\u00fcnchen, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Laskaris","ForeName":"Nikolaos","Initials":"N","AffiliationInfo":{"Affiliation":"Department of Informatics, Aristotle University of Thessaloniki, 54124, Thessaloniki, Greece."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Wagenpfeil","ForeName":"Stefan","Initials":"S","AffiliationInfo":{"Affiliation":"Institute of Medical Biometrics, Epidemiology, and Medical Informatics (IMBEI), University of the Saarland, 66421, Homburg\/Saar, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Gourzis","ForeName":"Philippos","Initials":"P","AffiliationInfo":{"Affiliation":"Department of Psychiatry, University Hospital of Rion, University of Patras, 26504, Rio, Patras, Greece."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, Ismaninger Stra\u00dfe 22, 81675, M\u00fcnchen, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Perneczky","ForeName":"Robert","Initials":"R","AffiliationInfo":[{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, Ismaninger Stra\u00dfe 22, 81675, M\u00fcnchen, Germany."},{"Affiliation":"Neuroepidemiology and Ageing Research Unit, School of Public Health, Faculty of Medicine, The Imperial College of Science, Technology and Medicine, London, W6 8RP, UK."},{"Affiliation":"Department of Psychiatry and Psychotherapy, Ludwig-Maximilans-Universit\u00e4t M\u00fcnchen, Nu\u00dfbaumstra\u00dfe 7, M\u00fcnchen, 80336, Germany."}]},{"@attributes":{"ValidYN":"Y"},"CollectiveName":"Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI)"}]},"Language":"eng","GrantList":{"@attributes":{"CompleteYN":"Y"},"Grant":[{"GrantID":"U01 AG024904","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"Agency":"CIHR","Country":"Canada"}]},"PublicationTypeList":{"PublicationType":["Journal Article","Multicenter Study","Research Support, N.I.H., Extramural","Research Support, U.S. Gov't, Non-P.H.S.","Research Support, Non-U.S. Gov't"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2016","Month":"12","Day":"09"}},"MedlineJournalInfo":{"Country":"England","MedlineTA":"Alzheimers Res Ther","NlmUniqueID":"101511643"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"Amyloid beta-Peptides"},{"RegistryNumber":"0","NameOfSubstance":"Apolipoproteins E"},{"RegistryNumber":"0","NameOfSubstance":"Biomarkers"},{"RegistryNumber":"0","NameOfSubstance":"Peptide Fragments"},{"RegistryNumber":"0","NameOfSubstance":"amyloid beta-protein (1-42)"},{"RegistryNumber":"0","NameOfSubstance":"tau Proteins"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Aged, 80 and over"},{"DescriptorName":"Alzheimer Disease","QualifierName":["cerebrospinal fluid","complications","genetics"]},{"DescriptorName":"Amyloid beta-Peptides","QualifierName":"cerebrospinal fluid"},{"DescriptorName":"Apolipoproteins E","QualifierName":"genetics"},{"DescriptorName":"Biomarkers","QualifierName":"cerebrospinal fluid"},{"DescriptorName":"Cognitive Dysfunction","QualifierName":["cerebrospinal fluid","etiology"]},{"DescriptorName":"Cohort Studies"},{"DescriptorName":"Disease Progression"},{"DescriptorName":"Female"},{"DescriptorName":"Humans"},{"DescriptorName":"Male"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Peptide Fragments","QualifierName":"cerebrospinal fluid"},{"DescriptorName":"Proportional Hazards Models"},{"DescriptorName":"tau Proteins","QualifierName":"cerebrospinal fluid"}]},"KeywordList":{"@attributes":{"Owner":"NOTNLM"},"Keyword":["Alzheimer\u2019s disease","Cerebrospinal fluid","Mild cognitive impairment","Prognosis"]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2015","Month":"12","Day":"08"},{"@attributes":{"PubStatus":"accepted"},"Year":"2016","Month":"10","Day":"28"},{"@attributes":{"PubStatus":"entrez"},"Year":"2016","Month":"12","Day":"10","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2016","Month":"12","Day":"10","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2017","Month":"10","Day":"14","Hour":"6","Minute":"0"}]},"PublicationStatus":"epublish","ArticleIdList":{"ArticleId":["27931251","10.1186\/s13195-016-0220-z","10.1186\/s13195-016-0220-z","PMC5146856"]},"ReferenceList":{"Reference":[{"Citation":"PLoS One. 2014 Jun 24;9(6):e100784","ArticleIdList":{"ArticleId":"24959687"}},{"Citation":"J Neurol. 2014 Jan;261(1):144-51","ArticleIdList":{"ArticleId":"24162039"}},{"Citation":"Lancet Neurol. 2013 Apr;12(4):357-67","ArticleIdList":{"ArticleId":"23477989"}},{"Citation":"Curr Alzheimer Res. 2012 Feb;9(2):241-7","ArticleIdList":{"ArticleId":"22044023"}},{"Citation":"Eur J Nucl Med Mol Imaging. 2016 Mar;43(3):499-508","ArticleIdList":{"ArticleId":"26341365"}},{"Citation":"J Am Geriatr Soc. 2008 Jan;56(1):51-8","ArticleIdList":{"ArticleId":"18028343"}},{"Citation":"Eur Arch Psychiatry Clin Neurosci. 2016 Oct;266(7):587-97","ArticleIdList":{"ArticleId":"26253588"}},{"Citation":"Alzheimers Dement. 2013 Nov;9(6):677-86","ArticleIdList":{"ArticleId":"23375562"}},{"Citation":"Ann Neurol. 2009 Apr;65(4):403-13","ArticleIdList":{"ArticleId":"19296504"}},{"Citation":"Nature. 1999 Oct 21;401(6755):788-91","ArticleIdList":{"ArticleId":"10548103"}},{"Citation":"Eur Arch Psychiatry Clin Neurosci. 2013 Jun;263(4):325-33","ArticleIdList":{"ArticleId":"22932720"}},{"Citation":"Alzheimers Res Ther. 2015 Nov 05;7(1):68","ArticleIdList":{"ArticleId":"26537709"}},{"Citation":"Dement Geriatr Cogn Disord. 2010;29(6):491-7","ArticleIdList":{"ArticleId":"20523047"}},{"Citation":"Lancet Neurol. 2014 Jun;13(6):614-29","ArticleIdList":{"ArticleId":"24849862"}},{"Citation":"Neurology. 2011 Oct 25;77(17 ):1619-28","ArticleIdList":{"ArticleId":"21998317"}},{"Citation":"Brain. 2015 May;138(Pt 5):1327-38","ArticleIdList":{"ArticleId":"25693589"}},{"Citation":"Lancet. 2016 Jul 30;388(10043):505-17","ArticleIdList":{"ArticleId":"26921134"}},{"Citation":"Neurology. 2009 Jul 28;73(4):294-301","ArticleIdList":{"ArticleId":"19636049"}},{"Citation":"Neurology. 2010 Jul 20;75(3):230-8","ArticleIdList":{"ArticleId":"20592257"}},{"Citation":"Arch Gerontol Geriatr. 2007;44 Suppl 1:233-41","ArticleIdList":{"ArticleId":"17317458"}},{"Citation":"Lancet Neurol. 2016 Jan;15(1):56-64","ArticleIdList":{"ArticleId":"26597325"}},{"Citation":"Neurology. 2012 Jan 3;78(1):47-54","ArticleIdList":{"ArticleId":"22170879"}},{"Citation":"Arch Gen Psychiatry. 2011 Sep;68(9):961-9","ArticleIdList":{"ArticleId":"21893661"}},{"Citation":"J Neuropathol Exp Neurol. 2012 Apr;71(4):266-73","ArticleIdList":{"ArticleId":"22437338"}},{"Citation":"Alzheimers Dement. 2011 May;7(3):263-9","ArticleIdList":{"ArticleId":"21514250"}},{"Citation":"Alzheimers Dement. 2015 May;11(5):523-32","ArticleIdList":{"ArticleId":"25156643"}},{"Citation":"Neurology. 2009 Oct 13;73(15):1193-9","ArticleIdList":{"ArticleId":"19822868"}},{"Citation":"Neurology. 2009 Oct 27;73(17):1353-8","ArticleIdList":{"ArticleId":"19858456"}},{"Citation":"Int J Geriatr Psychiatry. 2007 Dec;22(12):1217-22","ArticleIdList":{"ArticleId":"17562522"}},{"Citation":"Dement Geriatr Cogn Disord. 2006;22(1):27-34","ArticleIdList":{"ArticleId":"16679762"}},{"Citation":"Ann Neurol. 2012 Jun;71(6):765-75","ArticleIdList":{"ArticleId":"22488240"}},{"Citation":"Brain. 2014 Sep;137(Pt 9):2564-77","ArticleIdList":{"ArticleId":"25012224"}},{"Citation":"Neurology. 2011 Jan 4;76(1):69-79","ArticleIdList":{"ArticleId":"21123754"}},{"Citation":"J Alzheimers Dis. 2014;40(4):857-61","ArticleIdList":{"ArticleId":"24577469"}},{"Citation":"Alzheimers Dement. 2014 Nov;10 (6):684-9","ArticleIdList":{"ArticleId":"24857233"}},{"Citation":"Fortschr Neurol Psychiatr. 2009 Apr;77(4):212-7","ArticleIdList":{"ArticleId":"19347792"}},{"Citation":"Alzheimers Dement. 2014 Oct;10(5 Suppl):S390-S394.e2","ArticleIdList":{"ArticleId":"24269268"}},{"Citation":"Alzheimers Dement. 2014 Nov;10(6):713-723.e2","ArticleIdList":{"ArticleId":"24721526"}},{"Citation":"Alzheimers Dement. 2010 May;6(3):265-73","ArticleIdList":{"ArticleId":"20451875"}},{"Citation":"J Alzheimers Dis. 2015 ;45(4):1077-88","ArticleIdList":{"ArticleId":"25649653"}},{"Citation":"Biomark Med. 2012 Aug;6(4):419-30","ArticleIdList":{"ArticleId":"22917144"}},{"Citation":"Biol Psychiatry. 1999 Sep 15;46(6):750-5","ArticleIdList":{"ArticleId":"10494442"}},{"Citation":"Alzheimers Dement. 2011 May;7(3):270-9","ArticleIdList":{"ArticleId":"21514249"}},{"Citation":"Neuron. 2013 Dec 18;80(6):1347-58","ArticleIdList":{"ArticleId":"24360540"}},{"Citation":"Neurol Sci. 2008 Dec;29(6):417-23","ArticleIdList":{"ArticleId":"19011737"}},{"Citation":"Ann Neurol. 2013 Aug;74(2):199-208","ArticleIdList":{"ArticleId":"23686697"}},{"Citation":"JAMA. 2009 Jul 22;302(4):385-93","ArticleIdList":{"ArticleId":"19622817"}},{"Citation":"Neurology. 2012 Oct 23;79(17 ):1809-16","ArticleIdList":{"ArticleId":"23019259"}},{"Citation":"Alzheimers Dement. 2010 May;6(3):230-8","ArticleIdList":{"ArticleId":"20451871"}},{"Citation":"Alzheimers Res Ther. 2015 Jun 01;7(1):30","ArticleIdList":{"ArticleId":"26034513"}},{"Citation":"Alzheimers Dement. 2015 Oct;11(10):1191-201","ArticleIdList":{"ArticleId":"25646957"}},{"Citation":"Int J Geriatr Psychiatry. 2010 Apr;25(4):403-10","ArticleIdList":{"ArticleId":"19650161"}},{"Citation":"Neurology. 2013 Mar 19;80(12 ):1124-32","ArticleIdList":{"ArticleId":"23446677"}},{"Citation":"Neurology. 2013 Mar 12;80(11):1048-56","ArticleIdList":{"ArticleId":"23390179"}},{"Citation":"Dement Geriatr Cogn Disord. 2014;37(3-4):196-206","ArticleIdList":{"ArticleId":"24157938"}},{"Citation":"Lancet Neurol. 2013 Feb;12(2):207-16","ArticleIdList":{"ArticleId":"23332364"}},{"Citation":"J Am Geriatr Soc. 2006 Jun;54(6):1008-10","ArticleIdList":{"ArticleId":"16776804"}},{"Citation":"JAMA. 2011 Jun 15;305(23):2458-9","ArticleIdList":{"ArticleId":"21673298"}}]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","IndexingMethod":"Curated","Owner":"NLM"},"PMID":"27271788","DateCompleted":{"Year":"2018","Month":"02","Day":"21"},"DateRevised":{"Year":"2018","Month":"12","Day":"02"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1099-1166","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"31","Issue":"12","PubDate":{"Year":"2016","Month":"12"}},"Title":"International journal of geriatric psychiatry","ISOAbbreviation":"Int J Geriatr Psychiatry"},"ArticleTitle":"The care needs and experiences with the use of services of people with young-onset dementia and their caregivers: a systematic review.","Pagination":{"MedlinePgn":"1261-1276"},"ELocationID":"10.1002\/gps.4502","Abstract":{"AbstractText":["In this review, the care needs and experiences with the use of available services of individuals with young-onset dementia (YOD) and their caregivers were investigated. This knowledge is an important prerequisite for the development of appropriate interventions and personalized care to address their specific needs and problems.","A systematic literature search was performed in PubMed, Psycinfo and Cinahl. A quality checklist for observational and qualitative studies was used to appraise the methodological quality of the studies.","Twenty-seven studies were included, and a synthesis of the literature revealed six themes. The first theme concerned problems in the diagnostic period. Early recognition and referral was reported as an essential area that required improvement in order to obtain appropriate help in time. The second theme discussed the need for information about YOD and the availability of care throughout the caregiving trajectory. The third theme described barriers in access to care that hindered caregivers in finding the right services. The fourth theme showed the availability of appropriate services and specific unmet needs. The fifth theme illustrated that behavioural and personality changes pose a significant challenge for caregivers and other family members. The last theme showed the profound impact of YOD on caregivers.","The literature indicates that people with YOD and their caregivers face a wide range of difficulties during the disease process. The reviewed studies provide an important foundation for knowledge and awareness about the specific care needs and experiences of people with YOD and their caregivers. Copyright \u00a9 2016 John Wiley & Sons, Ltd."],"CopyrightInformation":"Copyright \u00a9 2016 John Wiley & Sons, Ltd."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Millenaar","ForeName":"Joany K","Initials":"JK","AffiliationInfo":{"Affiliation":"School for Mental Health and Neuroscience, Alzheimer Centre Limburg, Maastricht University Medical Centre, Maastricht, The Netherlands."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Bakker","ForeName":"Christian","Initials":"C","AffiliationInfo":[{"Affiliation":"Florence, Mariahoeve, Centre for Specialized Care in Young-Onset Dementia, The Hague, The Netherlands."},{"Affiliation":"Department of Primary and Community Care: Centre for Family Medicine, Geriatric Care and Public Health, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands."}]},{"@attributes":{"ValidYN":"Y"},"LastName":"Koopmans","ForeName":"Raymond T C M","Initials":"RT","AffiliationInfo":[{"Affiliation":"Department of Primary and Community Care: Centre for Family Medicine, Geriatric Care and Public Health, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands."},{"Affiliation":"Alzheimer Centre Nijmegen, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands."},{"Affiliation":"Joachim en Anna, Centre for Specialized Geriatric Care, Nijmegen, The Netherlands."}]},{"@attributes":{"ValidYN":"Y"},"LastName":"Verhey","ForeName":"Frans R J","Initials":"FR","AffiliationInfo":{"Affiliation":"School for Mental Health and Neuroscience, Alzheimer Centre Limburg, Maastricht University Medical Centre, Maastricht, The Netherlands."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"de Vugt","ForeName":"Marjolein E","Initials":"ME","AffiliationInfo":{"Affiliation":"School for Mental Health and Neuroscience, Alzheimer Centre Limburg, Maastricht University Medical Centre, Maastricht, The Netherlands. m.devugt@maastrichtuniversity.nl."}}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Review","Systematic Review"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2016","Month":"06","Day":"06"}},"MedlineJournalInfo":{"Country":"England","MedlineTA":"Int J Geriatr Psychiatry","NlmUniqueID":"8710629","ISSNLinking":"0885-6230"},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Age of Onset"},{"DescriptorName":"Caregivers","QualifierName":"psychology"},{"DescriptorName":"Dementia","QualifierName":["diagnosis","therapy"]},{"DescriptorName":"Health Services Accessibility","QualifierName":"standards"},{"DescriptorName":"Health Services Needs and Demand"},{"DescriptorName":"Humans"},{"DescriptorName":"Needs Assessment"},{"DescriptorName":"Qualitative Research"}]},"KeywordList":{"@attributes":{"Owner":"NOTNLM"},"Keyword":["care needs","caregivers","service use","young-onset dementia"]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2015","Month":"12","Day":"04"},{"@attributes":{"PubStatus":"revised"},"Year":"2016","Month":"04","Day":"07"},{"@attributes":{"PubStatus":"accepted"},"Year":"2016","Month":"04","Day":"19"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2016","Month":"10","Day":"30","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2018","Month":"2","Day":"22","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"entrez"},"Year":"2016","Month":"6","Day":"9","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["27271788","10.1002\/gps.4502"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"27572272","DateCompleted":{"Year":"2018","Month":"01","Day":"29"},"DateRevised":{"Year":"2018","Month":"01","Day":"30"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1741-203X","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"28","Issue":"12","PubDate":{"Year":"2016","Month":"12"}},"Title":"International psychogeriatrics","ISOAbbreviation":"Int Psychogeriatr"},"ArticleTitle":"RHAPSODY - Internet-based support for caregivers of people with young onset dementia: program design and methods of a pilot study.","Pagination":{"MedlinePgn":"2091-2099"},"Abstract":{"AbstractText":["Young Onset Dementia (YOD), defined by first symptoms of cognitive or behavioral decline occurring before the age of 65 years, is relatively rare compared to dementia of later onset, but it is associated with diagnostic difficulty and heavy burden on affected individuals and their informal carers. Existing health and social care structures rarely meet the needs of YOD patients. Internet-based interventions are a novel format of delivering health-related education, counseling, and support to this vulnerable yet underserved group.","The RHAPSODY (Research to Assess Policies and Strategies for Dementia in the Young) project is a European initiative to improve care for people with YOD by providing an internet-based information and skill-building program for family carers. The e-learning program focuses on managing problem behaviors, dealing with role change, obtaining support, and looking after oneself. It will be evaluated in a pilot study in three countries using a randomized unblinded design with a wait-list control group. Participants will be informal carers of people with dementia in Alzheimer's disease or behavioral-variant Frontotemporal degeneration with an onset before the age of 65 years. The primary outcome will be caregiving self-efficacy after 6 weeks of program use. As secondary outcomes, caregivers' stress and burden, carer health-related quality of life, caring-related knowledge, patient problem behaviors, and user satisfaction will be assessed. Program utilization will be monitored and a health-economic evaluation will also be performed.","The RHAPSODY project will add to the evidence on the potential and limitations of a conveniently accessible, user-friendly, and comprehensive internet-based intervention as an alternative for traditional forms of counseling and support in healthcare, aiming to optimize care and support for people with YOD and their informal caregivers."]},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy,Klinikum rechts der Isar,Technische Universit\u00e4t M\u00fcnchen,Munich,Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Bakker","ForeName":"Christian","Initials":"C","AffiliationInfo":{"Affiliation":"School for Mental Health and Neuroscience,Alzheimer Center Limburg,Maastricht University Medical Center,Maastricht,the Netherlands."}},{"@attributes":{"ValidYN":"Y"},"LastName":"B\u00f6hm","ForeName":"Markus","Initials":"M","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy,Klinikum rechts der Isar,Technische Universit\u00e4t M\u00fcnchen,Munich,Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Diehl-Schmid","ForeName":"Janine","Initials":"J","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy,Klinikum rechts der Isar,Technische Universit\u00e4t M\u00fcnchen,Munich,Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Dubois","ForeName":"Bruno","Initials":"B","AffiliationInfo":{"Affiliation":"Universit\u00e9 Pierre et Marie Curie,H\u00f4pital Piti\u00e9 Salp\u00eatri\u00e8re,Paris,France."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Ferreira","ForeName":"Catarina","Initials":"C","AffiliationInfo":{"Affiliation":"Institute of Molecular Medicine and Faculty of Medicine,University of Lisbon,Portugal."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Gage","ForeName":"Heather","Initials":"H","AffiliationInfo":{"Affiliation":"School of Economics,University of Surrey,Guildford,Surrey,UK."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Graff","ForeName":"Caroline","Initials":"C","AffiliationInfo":{"Affiliation":"Department of Neurobiology,Care Sciences and Society,Karolinska Institutet,Huddinge,Sweden."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Hergueta","ForeName":"Thierry","Initials":"T","AffiliationInfo":{"Affiliation":"Universit\u00e9 Pierre et Marie Curie,H\u00f4pital Piti\u00e9 Salp\u00eatri\u00e8re,Paris,France."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Jansen","ForeName":"Sabine","Initials":"S","AffiliationInfo":{"Affiliation":"Deutsche Alzheimer Gesellschaft,Selbsthilfe Demenz,Berlin,Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Jones","ForeName":"Bridget","Initials":"B","AffiliationInfo":{"Affiliation":"School of Economics,University of Surrey,Guildford,Surrey,UK."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Komar","ForeName":"Alexander","Initials":"A","AffiliationInfo":{"Affiliation":"Information Multimedia Communication GmbH (IM-C),Saarbr\u00fccken,Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"de Mendon\u00e7a","ForeName":"Alexandre","Initials":"A","AffiliationInfo":{"Affiliation":"Institute of Molecular Medicine and Faculty of Medicine,University of Lisbon,Portugal."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Metcalfe","ForeName":"Anna","Initials":"A","AffiliationInfo":{"Affiliation":"Universit\u00e9 Pierre et Marie Curie,H\u00f4pital Piti\u00e9 Salp\u00eatri\u00e8re,Paris,France."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Milecka","ForeName":"Katrina","Initials":"K","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy,Klinikum rechts der Isar,Technische Universit\u00e4t M\u00fcnchen,Munich,Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Millenaar","ForeName":"Joany","Initials":"J","AffiliationInfo":{"Affiliation":"School for Mental Health and Neuroscience,Alzheimer Center Limburg,Maastricht University Medical Center,Maastricht,the Netherlands."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Orrung Wallin","ForeName":"Anneli","Initials":"A","AffiliationInfo":{"Affiliation":"Department of Neurobiology,Care Sciences and Society,Karolinska Institutet,Huddinge,Sweden."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Oyebode","ForeName":"Jan","Initials":"J","AffiliationInfo":{"Affiliation":"School of Economics,University of Surrey,Guildford,Surrey,UK."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Schneider-Schelte","ForeName":"Helga","Initials":"H","AffiliationInfo":{"Affiliation":"Deutsche Alzheimer Gesellschaft,Selbsthilfe Demenz,Berlin,Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Saxl","ForeName":"Susanna","Initials":"S","AffiliationInfo":{"Affiliation":"Deutsche Alzheimer Gesellschaft,Selbsthilfe Demenz,Berlin,Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"de Vugt","ForeName":"Marjolein","Initials":"M","AffiliationInfo":{"Affiliation":"School for Mental Health and Neuroscience,Alzheimer Center Limburg,Maastricht University Medical Center,Maastricht,the Netherlands."}}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Randomized Controlled Trial","Research Support, Non-U.S. Gov't"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2016","Month":"08","Day":"30"}},"MedlineJournalInfo":{"Country":"England","MedlineTA":"Int Psychogeriatr","NlmUniqueID":"9007918","ISSNLinking":"1041-6102"},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Alzheimer Disease","QualifierName":["psychology","therapy"]},{"DescriptorName":"Caregivers","QualifierName":["education","psychology"]},{"DescriptorName":"Compassion Fatigue","QualifierName":"prevention & control"},{"DescriptorName":"Female"},{"DescriptorName":"Frontotemporal Dementia","QualifierName":["psychology","therapy"]},{"DescriptorName":"Humans"},{"DescriptorName":"International Cooperation"},{"DescriptorName":"Internet"},{"DescriptorName":"Male"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Professional Competence"},{"DescriptorName":"Quality of Life"},{"DescriptorName":"Research Design"},{"DescriptorName":"Self Efficacy"},{"DescriptorName":"Social Support"}]},"KeywordList":{"@attributes":{"Owner":"NOTNLM"},"Keyword":["caregiver","dementia","e-learning","early","education","guide","onset","young"]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"pubmed"},"Year":"2016","Month":"8","Day":"31","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2018","Month":"1","Day":"30","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"entrez"},"Year":"2016","Month":"8","Day":"31","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["27572272","S1041610216001186","10.1017\/S1041610216001186"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"26956520","DateCompleted":{"Year":"2016","Month":"11","Day":"07"},"DateRevised":{"Year":"2020","Month":"03","Day":"06"},"Article":{"@attributes":{"PubModel":"Electronic"},"Journal":{"ISSN":"1756-0500","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"9","PubDate":{"Year":"2016","Month":"Mar","Day":"08"}},"Title":"BMC research notes","ISOAbbreviation":"BMC Res Notes"},"ArticleTitle":"Which medical and social decision topics are important after early diagnosis of Alzheimer's Disease from the perspectives of people with Alzheimer's Disease, spouses and professionals?","Pagination":{"MedlinePgn":"149"},"ELocationID":"10.1186\/s13104-016-1960-3","Abstract":{"AbstractText":["The relevance of early decision making will rise with increasing availability of early detection of Alzheimer's disease (AD) using brain imaging or biomarkers.","Five people with mild AD, six relatives and 13 healthcare professionals with experience in the management of AD were interviewed in a qualitative study regarding medical and social decision topics that emerge after early diagnosis of Alzheimer's disease. Medical treatment, assistance in everyday life and legal issues emerged as the main decision topics after an early diagnosis of AD. People with AD mostly got in contact with the health and social care system through the initiative of their spouses. They were usually aware of their illness and most received antidementia drugs and\/or behavioural interventions. Following diagnosis people with AD received support by their spouses. Healthcare professionals were aware of the risk of excessive demand on relatives due to supporting their family member with AD. In the opinion of healthcare professionals legal issues should be arranged in time before patients lose their decisional capacity. In addition, people with AD and spouses reported various coping strategies, in particular \"carry on as normal\" after diagnosis but mostly are reluctant to actively plan for future stages of the disease.","Due to the common desire to \"carry on as usual\" after a diagnosis of AD, many people with AD and spouses may miss the opportunity to discuss and decide on important medical and social topics. A structured approach e.g. a decision aid might support people with AD and spouses in their decision making process and thereby preserve persons' with AD autonomy before they lose the capacity in decision-making."]},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Bronner","ForeName":"Katharina","Initials":"K","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany. Katharina.Bronner@mri.tum.de."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Perneczky","ForeName":"Robert","Initials":"R","AffiliationInfo":[{"Affiliation":"Department of Psychiatry and Psychotherapy, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany. r.perneczky@imperial.ac.uk."},{"Affiliation":"Neuroepidemiology and Ageing Research Unit, School of Public Health, Faculty of Medicine, The Imperial College of Science, Technology and Medicine, London, UK. r.perneczky@imperial.ac.uk."},{"Affiliation":"West London Cognitive Disorders Treatment and Research Unit, West London Mental Health Trust, London, UK. r.perneczky@imperial.ac.uk."}]},{"@attributes":{"ValidYN":"Y"},"LastName":"McCabe","ForeName":"Rose","Initials":"R","AffiliationInfo":{"Affiliation":"University of Exeter Medical School, Exeter, UK. R.McCabe@exeter.ac.uk."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany. a.kurz@tum.de."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Hamann","ForeName":"Johannes","Initials":"J","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany. j.hamann@tum.de."}}]},"Language":"eng","GrantList":{"@attributes":{"CompleteYN":"Y"},"Grant":{"GrantID":"PB-PG-1111-26063","Acronym":"DH_","Agency":"Department of Health","Country":"United Kingdom"}},"PublicationTypeList":{"PublicationType":["Journal Article","Research Support, Non-U.S. Gov't"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2016","Month":"03","Day":"08"}},"MedlineJournalInfo":{"Country":"England","MedlineTA":"BMC Res Notes","NlmUniqueID":"101462768","ISSNLinking":"1756-0500"},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Adaptation, Psychological"},{"DescriptorName":"Aged"},{"DescriptorName":"Alzheimer Disease","QualifierName":["diagnosis","physiopathology","psychology"]},{"DescriptorName":"Awareness"},{"DescriptorName":"Decision Making","QualifierName":"ethics"},{"DescriptorName":"Early Diagnosis"},{"DescriptorName":"Emotions"},{"DescriptorName":"Female"},{"DescriptorName":"Health Personnel","QualifierName":"psychology"},{"DescriptorName":"Humans"},{"DescriptorName":"Male"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Qualitative Research"},{"DescriptorName":"Spouses","QualifierName":"psychology"},{"DescriptorName":"Time Factors"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2016","Month":"02","Day":"11"},{"@attributes":{"PubStatus":"accepted"},"Year":"2016","Month":"02","Day":"25"},{"@attributes":{"PubStatus":"entrez"},"Year":"2016","Month":"3","Day":"10","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2016","Month":"3","Day":"10","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2016","Month":"11","Day":"8","Hour":"6","Minute":"0"}]},"PublicationStatus":"epublish","ArticleIdList":{"ArticleId":["26956520","10.1186\/s13104-016-1960-3","10.1186\/s13104-016-1960-3","PMC4782346"]},"ReferenceList":{"Reference":[{"Citation":"Dementia (London). 2016 Sep;15(5):1141-57","ArticleIdList":{"ArticleId":"25370075"}},{"Citation":"Aging Ment Health. 2002 May;6(2):139-48","ArticleIdList":{"ArticleId":"12028882"}},{"Citation":"Aging Ment Health. 2012;16(3):378-90","ArticleIdList":{"ArticleId":"22250961"}},{"Citation":"J Geriatr Psychiatry Neurol. 2004 Jun;17(2):55-60","ArticleIdList":{"ArticleId":"15157344"}},{"Citation":"Alzheimer Dis Assoc Disord. 2008 Jul-Sep;22(3):293-8","ArticleIdList":{"ArticleId":"18580595"}},{"Citation":"J Gerontol Nurs. 2009 Mar;35(3):8-15","ArticleIdList":{"ArticleId":"19326824"}},{"Citation":"Alzheimer Dis Assoc Disord. 2008 Jan-Mar;22(1):94-7","ArticleIdList":{"ArticleId":"18317253"}},{"Citation":"Neurology. 1989 Sep;39(9):1159-65","ArticleIdList":{"ArticleId":"2771064"}},{"Citation":"Am J Alzheimers Dis Other Demen. 2003 Nov-Dec;18(6):359-65","ArticleIdList":{"ArticleId":"14682085"}},{"Citation":"Aging Ment Health. 2005 Jul;9(4):337-47","ArticleIdList":{"ArticleId":"16019290"}},{"Citation":"Curr Alzheimer Res. 2009 Aug;6(4):368-74","ArticleIdList":{"ArticleId":"19689236"}},{"Citation":"Aging Ment Health. 2007 May;11(3):281-90","ArticleIdList":{"ArticleId":"17558579"}},{"Citation":"Alzheimers Dement. 2011 May;7(3):263-9","ArticleIdList":{"ArticleId":"21514250"}},{"Citation":"Neurology. 2008 Nov 4;71(19):1474-80","ArticleIdList":{"ArticleId":"18981368"}},{"Citation":"Qual Health Res. 2006 Apr;16(4):484-502","ArticleIdList":{"ArticleId":"16513992"}},{"Citation":"Eur J Neurol. 2007 Jan;14(1):e1-26","ArticleIdList":{"ArticleId":"17222085"}},{"Citation":"J Psychiatr Res. 1975 Nov;12(3):189-98","ArticleIdList":{"ArticleId":"1202204"}},{"Citation":"Br J Gen Pract. 2010 Sep;60(578):e360-5","ArticleIdList":{"ArticleId":"20849686"}},{"Citation":"J Am Geriatr Soc. 2011 Nov;59(11):2045-52","ArticleIdList":{"ArticleId":"22092150"}},{"Citation":"Alzheimers Dement. 2011 May;7(3):e51-9","ArticleIdList":{"ArticleId":"21546322"}},{"Citation":"PLoS One. 2014;9(1):e84905","ArticleIdList":{"ArticleId":"24465450"}},{"Citation":"Z Gerontol Geriatr. 2007 Apr;40(2):71-80","ArticleIdList":{"ArticleId":"17450406"}},{"Citation":"Can Geriatr J. 2012 Sep;15(3):85-94","ArticleIdList":{"ArticleId":"23259021"}}]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"26836175","DateCompleted":{"Year":"2016","Month":"12","Day":"13"},"DateRevised":{"Year":"2016","Month":"12","Day":"30"},"Article":{"@attributes":{"PubModel":"Print"},"Journal":{"ISSN":"1875-8908","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"51","Issue":"1","PubDate":{"Year":"2016"}},"Title":"Journal of Alzheimer's disease : JAD","ISOAbbreviation":"J Alzheimers Dis"},"ArticleTitle":"Increased Intrinsic Activity of Medial-Temporal Lobe Subregions is Associated with Decreased Cortical Thickness of Medial-Parietal Areas in Patients with Alzheimer's Disease Dementia.","Pagination":{"MedlinePgn":"313-26"},"ELocationID":"10.3233\/JAD-150823","Abstract":{"AbstractText":"In Alzheimer's disease (AD), disrupted connectivity between medial-parietal cortices and medial-temporal lobes (MTL) is linked with increased MTL local functional connectivity, and parietal atrophy is associated with increased MTL memory activation. We hypothesized that intrinsic activity in MTL subregions is increased and associated with medial-parietal degeneration and impaired memory in AD. To test this hypothesis, resting-state-functional and structural-MRI was assessed in 22 healthy controls, 22 mild cognitive impairment patients, and 21 AD-dementia patients. Intrinsic activity was measured by power-spectrum density of blood-oxygenation-level-dependent signal, medial-parietal degeneration by cortical thinning. In AD-dementia patients, intrinsic activity was increased for several right MTL subregions. Raised intrinsic activity in dentate gyrus and cornu ammonis 1 was associated with cortical thinning in posterior cingulate cortices, and at-trend with impaired delayed recall. Critically, increased intrinsic activity in the right entorhinal cortex was associated with ipsilateral posterior cingulate degeneration. Our results provide evidence that in AD, intrinsic activity in MTL subregions is increased and associated with medial-parietal atrophy. Results fit a model in which medial-parietal degeneration contributes to MTL dysconnectivity from medial-parietal cortices, potentially underpinning disinhibition-like changes in MTL activity. "},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Pasquini","ForeName":"Lorenzo","Initials":"L","AffiliationInfo":[{"Affiliation":"Department of Neuroradiology, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."},{"Affiliation":"TUM-Neuroimaging Center, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."}]},{"@attributes":{"ValidYN":"Y"},"LastName":"Scherr","ForeName":"Martin","Initials":"M","AffiliationInfo":[{"Affiliation":"Department of Neuroradiology, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."},{"Affiliation":"Department of Psychiatry, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."},{"Affiliation":"TUM-Neuroimaging Center, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."},{"Affiliation":"Department of Neurology, Christian Doppler Klinik, Paracelsus Medical University Salzburg, Salzburg, Austria."}]},{"@attributes":{"ValidYN":"Y"},"LastName":"Tahmasian","ForeName":"Masoud","Initials":"M","AffiliationInfo":[{"Affiliation":"Department of Neuroradiology, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."},{"Affiliation":"Department of Nuclear Medicine of Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."},{"Affiliation":"TUM-Neuroimaging Center, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."}]},{"@attributes":{"ValidYN":"Y"},"LastName":"Myers","ForeName":"Nicholas E","Initials":"NE","AffiliationInfo":[{"Affiliation":"TUM-Neuroimaging Center, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."},{"Affiliation":"Department of Experimental Psychology, Oxford University, Oxford, UK."}]},{"@attributes":{"ValidYN":"Y"},"LastName":"Ortner","ForeName":"Marion","Initials":"M","AffiliationInfo":{"Affiliation":"Department of Psychiatry, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A","AffiliationInfo":{"Affiliation":"Department of Psychiatry, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"F\u00f6rstl","ForeName":"Hans","Initials":"H","AffiliationInfo":{"Affiliation":"Department of Psychiatry, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Zimmer","ForeName":"Claus","Initials":"C","AffiliationInfo":{"Affiliation":"Department of Neuroradiology, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Grimmer","ForeName":"Timo","Initials":"T","AffiliationInfo":{"Affiliation":"Department of Psychiatry, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Akhrif","ForeName":"Atae","Initials":"A","AffiliationInfo":{"Affiliation":"Department of Child and Adolescent Psychiatry and Psychotherapy, University of W\u00fcrzburg, W\u00fcrzburg, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Wohlschl\u00e4ger","ForeName":"Afra M","Initials":"AM","AffiliationInfo":[{"Affiliation":"Department of Neuroradiology, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."},{"Affiliation":"TUM-Neuroimaging Center, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."}]},{"@attributes":{"ValidYN":"Y"},"LastName":"Riedl","ForeName":"Valentin","Initials":"V","AffiliationInfo":[{"Affiliation":"Department of Neuroradiology, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."},{"Affiliation":"Department of Nuclear Medicine of Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."},{"Affiliation":"TUM-Neuroimaging Center, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."}]},{"@attributes":{"ValidYN":"Y"},"LastName":"Sorg","ForeName":"Christian","Initials":"C","AffiliationInfo":[{"Affiliation":"Department of Neuroradiology, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."},{"Affiliation":"Department of Psychiatry, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."},{"Affiliation":"TUM-Neuroimaging Center, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."}]}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Research Support, Non-U.S. Gov't"]}},"MedlineJournalInfo":{"Country":"Netherlands","MedlineTA":"J Alzheimers Dis","NlmUniqueID":"9814863","ISSNLinking":"1387-2877"},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Aged, 80 and over"},{"DescriptorName":"Alzheimer Disease","QualifierName":["complications","diagnostic imaging","pathology"]},{"DescriptorName":"Cognitive Dysfunction","QualifierName":"pathology"},{"DescriptorName":"Female"},{"DescriptorName":"Humans"},{"DescriptorName":"Image Processing, Computer-Assisted"},{"DescriptorName":"Magnetic Resonance Imaging"},{"DescriptorName":"Male"},{"DescriptorName":"Memory Disorders","QualifierName":["etiology","pathology"]},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Nerve Net","QualifierName":["diagnostic imaging","pathology"]},{"DescriptorName":"Parietal Lobe","QualifierName":["diagnostic imaging","pathology"]},{"DescriptorName":"Temporal Lobe","QualifierName":["diagnostic imaging","pathology"]}]},"KeywordList":{"@attributes":{"Owner":"NOTNLM"},"Keyword":["Alzheimer\u2019s disease","atrophy","functional magnetic resonance imaging","hippocampus","medial-parietal cortex","medial-temporal lobe","neurodegeneration","neuroimaging","physiopathology","resting-state activity"]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"entrez"},"Year":"2016","Month":"2","Day":"3","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2016","Month":"2","Day":"3","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2016","Month":"12","Day":"15","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["26836175","JAD150823","10.3233\/JAD-150823"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","IndexingMethod":"Curated","Owner":"NLM"},"PMID":"26610315","DateCompleted":{"Year":"2016","Month":"07","Day":"06"},"DateRevised":{"Year":"2018","Month":"12","Day":"02"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1423-033X","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"48","Issue":"6","PubDate":{"Year":"2015"}},"Title":"Psychopathology","ISOAbbreviation":"Psychopathology"},"ArticleTitle":"The New Conceptualization of Alzheimer's Disease under the Microscope of Influential Definitions of Disease.","Pagination":{"MedlinePgn":"359-67"},"ELocationID":"10.1159\/000441327","Abstract":{"AbstractText":["According to its new conceptualization, Alzheimer's disease (AD) has preclinical and symptomatic phases, and biomarker abnormality justifies the diagnosis of the disease.","The conceptual validity of AD is assessed on the basis of the disease definitions of T. Szasz, R.E. Kendell and J.G. Scadding, C. Boorse, K.W.M. Fulford and J.C. Wakefield, as well as of the DSM-5 classification system.","The new AD conceptualization could fit the Szaszian disease definition, provided that AD biomarkers reflected the pathological hallmarks of a singular disease, but it seems that they do not. Moreover, preclinical AD does not yield a biological disadvantage, being a central criterion for justifying the presence of a disease according to the disease definition of Scadding and Kendell. In addition, it remains unclear whether abnormality of biomarkers in elderly people embodies a statistical deviation from normal ageing and a pathological characteristic. Furthermore, not all stages of AD are related to experiences of failure of intentional doing, which is the criterion of the disease definition of Fulford, whilst the Wakefieldian harmful dysfunction and the DSM-5 mental disorder criteria are fulfilled only in the symptomatic phases of the disease course.","Our analytical endeavours unveiled weak sides and the fuzzy boundaries of the new conceptualization of AD. Future refinements of the criteria should address them so that the validity of the AD concept is increased."],"CopyrightInformation":"\u00a9 2015 S. Karger AG, Basel."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Alexopoulos","ForeName":"Panagiotis","Initials":"P","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technische Universitx00E4;t Mx00FC;nchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Review"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2015","Month":"11","Day":"27"}},"MedlineJournalInfo":{"Country":"Switzerland","MedlineTA":"Psychopathology","NlmUniqueID":"8401537","ISSNLinking":"0254-4962"},"ChemicalList":{"Chemical":{"RegistryNumber":"0","NameOfSubstance":"Biomarkers"}},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Alzheimer Disease","QualifierName":["classification","diagnosis"]},{"DescriptorName":"Biomarkers","QualifierName":"analysis"},{"DescriptorName":"Cognitive Dysfunction","QualifierName":"diagnosis"},{"DescriptorName":"Dementia","QualifierName":["classification","diagnosis"]},{"DescriptorName":"Disease Progression"},{"DescriptorName":"Early Diagnosis"},{"DescriptorName":"Humans"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2015","Month":"05","Day":"04"},{"@attributes":{"PubStatus":"accepted"},"Year":"2015","Month":"09","Day":"25"},{"@attributes":{"PubStatus":"entrez"},"Year":"2015","Month":"11","Day":"27","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2015","Month":"11","Day":"27","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2016","Month":"7","Day":"7","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["26610315","000441327","10.1159\/000441327"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"26585056","DateCompleted":{"Year":"2016","Month":"06","Day":"14"},"DateRevised":{"Year":"2019","Month":"12","Day":"18"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1535-5667","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"57","Issue":"2","PubDate":{"Year":"2016","Month":"Feb"}},"Title":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","ISOAbbreviation":"J Nucl Med"},"ArticleTitle":"Visual Versus Fully Automated Analyses of 18F-FDG and Amyloid PET for Prediction of Dementia Due to Alzheimer Disease in Mild Cognitive Impairment.","Pagination":{"MedlinePgn":"204-7"},"ELocationID":"10.2967\/jnumed.115.163717","Abstract":{"AbstractText":["Biomarkers of Alzheimer disease (AD) can be imaged in vivo and can be used for diagnostic and prognostic purposes in people with cognitive decline and dementia. Indicators of amyloid deposition such as (11)C-Pittsburgh compound B ((11)C-PiB) PET are primarily used to identify or rule out brain diseases that are associated with amyloid pathology but have also been deployed to forecast the clinical course. Indicators of neuronal metabolism including (18)F-FDG PET demonstrate the localization and severity of neuronal dysfunction and are valuable for differential diagnosis and for predicting the progression from mild cognitive impairment (MCI) to dementia. It is a matter of debate whether to analyze these images visually or using automated techniques. Therefore, we compared the usefulness of both imaging methods and both analyzing strategies to predict dementia due to AD.","In MCI participants, a baseline examination, including clinical and imaging assessments, and a clinical follow-up examination after a planned interval of 24 mo were performed.","Of 28 MCI patients, 9 developed dementia due to AD, 2 developed frontotemporal dementia, and 1 developed moderate dementia of unknown etiology. The positive and negative predictive values and the accuracy of visual and fully automated analyses of (11)C-PiB for the prediction of progression to dementia due to AD were 0.50, 1.00, and 0.68, respectively, for the visual and 0.53, 1.00, and 0.71, respectively, for the automated analyses. Positive predictive value, negative predictive value, and accuracy of fully automated analyses of (18)F-FDG PET were 0.37, 0.78, and 0.50, respectively. Results of visual analyses were highly variable between raters but were superior to automated analyses.","Both (18)F-FDG and (11)C-PiB imaging appear to be of limited use for predicting the progression from MCI to dementia due to AD in short-term follow-up, irrespective of the strategy of analysis. On the other hand, amyloid PET is extremely useful to rule out underlying AD. The findings of the present study favor a fully automated method of analysis for (11)C-PiB assessments and a visual analysis by experts for (18)F-FDG assessments."],"CopyrightInformation":"\u00a9 2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Grimmer","ForeName":"Timo","Initials":"T","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum Rechts der Isar der Technischen Universit\u00e4t M\u00fcnchen, Munich, Germany t.grimmer@lrz.tum.de."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Wutz","ForeName":"Carolin","Initials":"C","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum Rechts der Isar der Technischen Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Alexopoulos","ForeName":"Panagiotis","Initials":"P","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum Rechts der Isar der Technischen Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Drzezga","ForeName":"Alexander","Initials":"A","AffiliationInfo":{"Affiliation":"Department of Nuclear Medicine, University Hospital of Cologne, Cologne, Germany; and."}},{"@attributes":{"ValidYN":"Y"},"LastName":"F\u00f6rster","ForeName":"Stefan","Initials":"S","AffiliationInfo":{"Affiliation":"Department of Nuclear Medicine, Klinikum Rechts der Isar der Technischen Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"F\u00f6rstl","ForeName":"Hans","Initials":"H","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum Rechts der Isar der Technischen Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Goldhardt","ForeName":"Oliver","Initials":"O","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum Rechts der Isar der Technischen Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Ortner","ForeName":"Marion","Initials":"M","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum Rechts der Isar der Technischen Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Sorg","ForeName":"Christian","Initials":"C","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum Rechts der Isar der Technischen Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum Rechts der Isar der Technischen Universit\u00e4t M\u00fcnchen, Munich, Germany."}}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Comparative Study","Journal Article"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2015","Month":"11","Day":"19"}},"MedlineJournalInfo":{"Country":"United States","MedlineTA":"J Nucl Med","NlmUniqueID":"0217410","ISSNLinking":"0161-5505"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole"},{"RegistryNumber":"0","NameOfSubstance":"Amyloid beta-Peptides"},{"RegistryNumber":"0","NameOfSubstance":"Benzothiazoles"},{"RegistryNumber":"0","NameOfSubstance":"Radiopharmaceuticals"},{"RegistryNumber":"0Z5B2CJX4D","NameOfSubstance":"Fluorodeoxyglucose F18"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Alzheimer Disease","QualifierName":"diagnostic imaging"},{"DescriptorName":"Amyloid beta-Peptides","QualifierName":"metabolism"},{"DescriptorName":"Benzothiazoles"},{"DescriptorName":"Cognitive Dysfunction","QualifierName":"diagnostic imaging"},{"DescriptorName":"Dementia","QualifierName":"diagnostic imaging"},{"DescriptorName":"Disease Progression"},{"DescriptorName":"Female"},{"DescriptorName":"Fluorodeoxyglucose F18"},{"DescriptorName":"Follow-Up Studies"},{"DescriptorName":"Humans"},{"DescriptorName":"Image Processing, Computer-Assisted"},{"DescriptorName":"Male"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Observer Variation"},{"DescriptorName":"Positron-Emission Tomography","QualifierName":"methods"},{"DescriptorName":"Predictive Value of Tests"},{"DescriptorName":"Radiopharmaceuticals"}]},"KeywordList":{"@attributes":{"Owner":"NOTNLM"},"Keyword":["AD","Alzheimer\u2019s disease","FDG","MCI","PET","PiB","Pittsburgh compound B","fluoro-deoxy-d-glucose","mild cognitive impairment","positron emission tomography"]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2015","Month":"07","Day":"13"},{"@attributes":{"PubStatus":"accepted"},"Year":"2015","Month":"11","Day":"03"},{"@attributes":{"PubStatus":"entrez"},"Year":"2015","Month":"11","Day":"21","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2015","Month":"11","Day":"21","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2016","Month":"6","Day":"15","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["26585056","jnumed.115.163717","10.2967\/jnumed.115.163717"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"26484902","DateCompleted":{"Year":"2016","Month":"09","Day":"12"},"DateRevised":{"Year":"2016","Month":"11","Day":"26"},"Article":{"@attributes":{"PubModel":"Print"},"Journal":{"ISSN":"1875-8908","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"49","Issue":"2","PubDate":{"Year":"2016"}},"Title":"Journal of Alzheimer's disease : JAD","ISOAbbreviation":"J Alzheimers Dis"},"ArticleTitle":"The Latent Dementia Phenotype \u03b4 is Associated with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Predicts Conversion to Dementia in Subjects with Mild Cognitive Impairment.","Pagination":{"MedlinePgn":"547-60"},"ELocationID":"10.3233\/JAD-150257","Abstract":{"AbstractText":["The recently proposed latent variable \u03b4 is a new tool for dementia case finding. It is built in a structural equation modeling framework of cognitive and functional data and constitutes a novel endophenotype for Alzheimer's disease (AD) research and clinical trials.","To investigate the association of \u03b4 with AD biomarkers and to compare the prediction of \u03b4 with established scales for conversion to dementia in patients with mild cognitive impairment (MCI).","Using data from a multicenter memory clinic study, we examined the external associations of the latent variable \u03b4 and compared \u03b4 with well-established cognitive and functional scales and cognitive-functional composite scores. For that purpose, logistic regressions with cerebrospinal fluid (CSF) biomarkers and conversion to dementia as dependent variables were performed with the investigated scores. The models were tested for significant differences.","In patients with MCI, \u03b4 based on a broad range of cognitive scales (including the ADAS-cog, the MMSE, and the CERAD neuropsychological battery) predicted an abnormal CSF A\u03b242\/tau ratio indicative of AD (n\u200a=\u200a340, AUC\u200a=\u200a0.78, p\u200a< \u200a0.001), and predicted incident dementia within 1-3 years of follow-up (n\u200a=\u200a525, AUC\u200a=\u200a0.84, p\u200a< \u200a0.001). These associations were generally stronger than for any other scale or cognitive-functional composite examined. Homologs of \u03b4 based on reduced test batteries yielded somewhat lower effects.","These findings support the interpretation of \u03b4 as a construct capturing the disease-related \"essence\" of cognitive and functional impairments in patients with MCI and dementia, and suggest that \u03b4 might become an analytical tool for dementia research."]},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Koppara","ForeName":"Alexander","Initials":"A","AffiliationInfo":[{"Affiliation":"Department of Psychiatry, University of Bonn, Germany."},{"Affiliation":"German Center for Neurodegenerative Diseases, Bonn, Germany."}]},{"@attributes":{"ValidYN":"Y"},"LastName":"Wolfsgruber","ForeName":"Steffen","Initials":"S","AffiliationInfo":[{"Affiliation":"Department of Psychiatry, University of Bonn, Germany."},{"Affiliation":"German Center for Neurodegenerative Diseases, Bonn, Germany."}]},{"@attributes":{"ValidYN":"Y"},"LastName":"Kleineidam","ForeName":"Luca","Initials":"L","AffiliationInfo":[{"Affiliation":"Department of Psychiatry, University of Bonn, Germany."},{"Affiliation":"German Center for Neurodegenerative Diseases, Bonn, Germany."}]},{"@attributes":{"ValidYN":"Y"},"LastName":"Schmidtke","ForeName":"Klaus","Initials":"K","AffiliationInfo":{"Affiliation":"Center for Geriatric Medicine, Ortenau Klinikum, Offenburg-Gengenbach, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Fr\u00f6lich","ForeName":"Lutz","Initials":"L","AffiliationInfo":{"Affiliation":"Department of Gerontopsychiatry, Central Institute of Mental Health, Mannheim, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A","AffiliationInfo":{"Affiliation":"Department of Psychiatry, Technical University of Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Schulz","ForeName":"Stefanie","Initials":"S","AffiliationInfo":{"Affiliation":"Department of Neurology, University of Aachen, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Hampel","ForeName":"Harald","Initials":"H","AffiliationInfo":{"Affiliation":"Department of Neurology, Universit\u00e9 Pierre et Marie Curie (Sorbonne), and AXA Research Fund & UPMC Chair, Paris, France."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Heuser","ForeName":"Isabella","Initials":"I","AffiliationInfo":{"Affiliation":"Department of Psychiatry, Charit\u00e9 Berlin, Campus Benjamin Franklin, Berlin, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Peters","ForeName":"Oliver","Initials":"O","AffiliationInfo":{"Affiliation":"Department of Psychiatry, Charit\u00e9 Berlin, Campus Benjamin Franklin, Berlin, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Reischies","ForeName":"Friedel M","Initials":"FM","AffiliationInfo":{"Affiliation":"Department of Psychiatry, Charit\u00e9 Berlin, Campus Benjamin Franklin, Berlin, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Jahn","ForeName":"Holger","Initials":"H","AffiliationInfo":{"Affiliation":"Department of Psychiatry, University of Hamburg, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Luckhaus","ForeName":"Christian","Initials":"C","AffiliationInfo":{"Affiliation":"Department of Psychiatry, University of D\u00fcsseldorf, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"H\u00fcll","ForeName":"Michael","Initials":"M","AffiliationInfo":{"Affiliation":"Center for Psychiatry, Clinic for Geronto- and Neuropsychiatry Emmendingen and Dep. of Psychiatry, University of Freiburg, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Gertz","ForeName":"Hermann-Josef","Initials":"HJ","AffiliationInfo":{"Affiliation":"Department of Psychiatry, University of Leipzig, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Schr\u00f6der","ForeName":"Johannes","Initials":"J","AffiliationInfo":{"Affiliation":"Section for Geriatric Psychiatry\/Institute of Gerontology, University of Heidelberg, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Pantel","ForeName":"Johannes","Initials":"J","AffiliationInfo":{"Affiliation":"Institute of General Medicine University of Frankfurt, Frankfurt am Main, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Rienhoff","ForeName":"Otto","Initials":"O","AffiliationInfo":{"Affiliation":"Department of Medical Informatics, University of G\u00f6ttingen, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"R\u00fcther","ForeName":"Eckart","Initials":"E","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, University of G\u00f6ttingen, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Henn","ForeName":"Fritz","Initials":"F","AffiliationInfo":{"Affiliation":"Ichan School of Medicine at Mt. Sinai, New York, USA."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Wiltfang","ForeName":"Jens","Initials":"J","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, University of G\u00f6ttingen, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Maier","ForeName":"Wolfgang","Initials":"W","AffiliationInfo":[{"Affiliation":"Department of Psychiatry, University of Bonn, Germany."},{"Affiliation":"German Center for Neurodegenerative Diseases, Bonn, Germany."}]},{"@attributes":{"ValidYN":"Y"},"LastName":"Jessen","ForeName":"Frank","Initials":"F","AffiliationInfo":[{"Affiliation":"Department of Psychiatry, University of Bonn, Germany."},{"Affiliation":"German Center for Neurodegenerative Diseases, Bonn, Germany."},{"Affiliation":"Department of Psychiatry, Medical Faculty University of Cologne, Germany."}]},{"@attributes":{"ValidYN":"Y"},"LastName":"Kornhuber","ForeName":"Johannes","Initials":"J","AffiliationInfo":{"Affiliation":"Department of Psychiatry, Friedrich-Alexander-University Erlangen, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Wagner","ForeName":"Michael","Initials":"M","AffiliationInfo":[{"Affiliation":"Department of Psychiatry, University of Bonn, Germany."},{"Affiliation":"German Center for Neurodegenerative Diseases, Bonn, Germany."}]}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Research Support, Non-U.S. Gov't"]}},"MedlineJournalInfo":{"Country":"Netherlands","MedlineTA":"J Alzheimers Dis","NlmUniqueID":"9814863","ISSNLinking":"1387-2877"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"Amyloid beta-Peptides"},{"RegistryNumber":"0","NameOfSubstance":"Biomarkers"},{"RegistryNumber":"0","NameOfSubstance":"Peptide Fragments"},{"RegistryNumber":"0","NameOfSubstance":"amyloid beta-protein (1-42)"},{"RegistryNumber":"0","NameOfSubstance":"tau Proteins"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Activities of Daily Living"},{"DescriptorName":"Aged"},{"DescriptorName":"Alzheimer Disease","QualifierName":["cerebrospinal fluid","psychology"]},{"DescriptorName":"Amyloid beta-Peptides","QualifierName":"cerebrospinal fluid"},{"DescriptorName":"Biomarkers","QualifierName":"cerebrospinal fluid"},{"DescriptorName":"Cognitive Dysfunction","QualifierName":["cerebrospinal fluid","psychology"]},{"DescriptorName":"Dementia","QualifierName":["cerebrospinal fluid","diagnosis"]},{"DescriptorName":"Disease Progression"},{"DescriptorName":"Female"},{"DescriptorName":"Humans"},{"DescriptorName":"Logistic Models"},{"DescriptorName":"Longitudinal Studies"},{"DescriptorName":"Male"},{"DescriptorName":"Mental Status Schedule"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Neuropsychological Tests"},{"DescriptorName":"Peptide Fragments","QualifierName":"cerebrospinal fluid"},{"DescriptorName":"Phenotype"},{"DescriptorName":"Predictive Value of Tests"},{"DescriptorName":"Retrospective Studies"},{"DescriptorName":"tau Proteins","QualifierName":"cerebrospinal fluid"}]},"KeywordList":{"@attributes":{"Owner":"NOTNLM"},"Keyword":["CSF AD biomarker signature","delta model","incident dementia","mild cognitive impairment"]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"entrez"},"Year":"2015","Month":"10","Day":"21","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2015","Month":"10","Day":"21","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2016","Month":"9","Day":"13","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["26484902","JAD150257","10.3233\/JAD-150257"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"26424328","DateCompleted":{"Year":"2016","Month":"08","Day":"18"},"DateRevised":{"Year":"2016","Month":"10","Day":"20"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1741-203X","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"27","Issue":"12","PubDate":{"Year":"2015","Month":"Dec"}},"Title":"International psychogeriatrics","ISOAbbreviation":"Int Psychogeriatr"},"ArticleTitle":"Trends of patient referral to a memory clinic and towards earlier diagnosis from 1985-2009.","Pagination":{"MedlinePgn":"1939-44"},"ELocationID":"10.1017\/S104161021500157X","Abstract":{"AbstractText":["It may be assumed that increased public awareness of dementia due to Alzheimer's disease (AD) together with the availability of efficacious treatment will result in diagnostic evaluation at earlier stages of cognitive decline and diagnosis of dementia due to AD at earlier stages.","All persons that were examined at a university based memory clinic, in Germany, between 1985 and 2009 were included.","In the 3,951 persons identified, linear regression analysis revealed a positive association between Mini Mental State Examination (MMSE) score and year of initial examination (yearIE) (\u03b2 = 0.266; p < 0.001). In the 1,821 patients diagnosed with dementia due to AD, a positive association between MMSE score and yearIE (\u03b2 = 0.230; p < 0.001) was revealed. MMSE scores were higher (\u03b2 = 0.195; p < 0.001) after the introduction of cholinesterase inhibitors in Germany in 1997.","Diagnostic evaluation of individuals occurred at progressively earlier stages of cognitive decline. Dementia due to AD was diagnosed at progressively earlier stages, and this trend was associated with the availability of efficacious treatment. This is the first study on changes in patient referral and diagnosis based on a continuous 25 years period."]},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Grimmer","ForeName":"Timo","Initials":"T","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy,Klinikum rechts der Isar der Technischen Universit\u00e4t M\u00fcnchen,Ismaninger Str. 22,81675 Munich,Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Beringer","ForeName":"Stephanie","Initials":"S","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy,Klinikum rechts der Isar der Technischen Universit\u00e4t M\u00fcnchen,Ismaninger Str. 22,81675 Munich,Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Kehl","ForeName":"Victoria","Initials":"V","AffiliationInfo":{"Affiliation":"Institute for Medical Statistics and Epidemiology,Klinikum rechts der Isar der Technischen Universit\u00e4t M\u00fcnchen,Ismaninger Str. 22,81675 Munich,Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Alexopoulos","ForeName":"Panagiotis","Initials":"P","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy,Klinikum rechts der Isar der Technischen Universit\u00e4t M\u00fcnchen,Ismaninger Str. 22,81675 Munich,Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Busche","ForeName":"Aurel","Initials":"A","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy,Klinikum rechts der Isar der Technischen Universit\u00e4t M\u00fcnchen,Ismaninger Str. 22,81675 Munich,Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"F\u00f6rstl","ForeName":"Hans","Initials":"H","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy,Klinikum rechts der Isar der Technischen Universit\u00e4t M\u00fcnchen,Ismaninger Str. 22,81675 Munich,Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Goldhardt","ForeName":"Oliver","Initials":"O","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy,Klinikum rechts der Isar der Technischen Universit\u00e4t M\u00fcnchen,Ismaninger Str. 22,81675 Munich,Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Natale","ForeName":"Bianca","Initials":"B","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy,Klinikum rechts der Isar der Technischen Universit\u00e4t M\u00fcnchen,Ismaninger Str. 22,81675 Munich,Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Ortner","ForeName":"Marion","Initials":"M","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy,Klinikum rechts der Isar der Technischen Universit\u00e4t M\u00fcnchen,Ismaninger Str. 22,81675 Munich,Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Peters","ForeName":"Henning","Initials":"H","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy,Klinikum rechts der Isar der Technischen Universit\u00e4t M\u00fcnchen,Ismaninger Str. 22,81675 Munich,Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Riedl","ForeName":"Lina","Initials":"L","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy,Klinikum rechts der Isar der Technischen Universit\u00e4t M\u00fcnchen,Ismaninger Str. 22,81675 Munich,Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Ro\u00dfmeier","ForeName":"Carola","Initials":"C","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy,Klinikum rechts der Isar der Technischen Universit\u00e4t M\u00fcnchen,Ismaninger Str. 22,81675 Munich,Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Valentin","ForeName":"Wiebke","Initials":"W","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy,Klinikum rechts der Isar der Technischen Universit\u00e4t M\u00fcnchen,Ismaninger Str. 22,81675 Munich,Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Diehl-Schmid","ForeName":"Janine","Initials":"J","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy,Klinikum rechts der Isar der Technischen Universit\u00e4t M\u00fcnchen,Ismaninger Str. 22,81675 Munich,Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy,Klinikum rechts der Isar der Technischen Universit\u00e4t M\u00fcnchen,Ismaninger Str. 22,81675 Munich,Germany."}}]},"Language":"eng","PublicationTypeList":{"PublicationType":"Journal Article"},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2015","Month":"10","Day":"02"}},"MedlineJournalInfo":{"Country":"England","MedlineTA":"Int Psychogeriatr","NlmUniqueID":"9007918","ISSNLinking":"1041-6102"},"ChemicalList":{"Chemical":{"RegistryNumber":"0","NameOfSubstance":"Cholinesterase Inhibitors"}},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Adult"},{"DescriptorName":"Aged"},{"DescriptorName":"Aged, 80 and over"},{"DescriptorName":"Alzheimer Disease","QualifierName":["complications","drug therapy"]},{"DescriptorName":"Cholinesterase Inhibitors","QualifierName":"therapeutic use"},{"DescriptorName":"Cognition Disorders","QualifierName":"diagnosis"},{"DescriptorName":"Early Diagnosis"},{"DescriptorName":"Female"},{"DescriptorName":"Forecasting"},{"DescriptorName":"Germany"},{"DescriptorName":"Humans"},{"DescriptorName":"Linear Models"},{"DescriptorName":"Male"},{"DescriptorName":"Memory Disorders","QualifierName":"diagnosis"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Neuropsychological Tests"},{"DescriptorName":"Psychiatric Status Rating Scales"},{"DescriptorName":"Referral and Consultation","QualifierName":"trends"},{"DescriptorName":"Young Adult"}]},"KeywordList":{"@attributes":{"Owner":"NOTNLM"},"Keyword":["Alzheimer\u2019s disease (AD)","dementia","early diagnosis","mini-mental state examination (MMSE)","trends of patient referral"]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"entrez"},"Year":"2015","Month":"10","Day":"2","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2015","Month":"10","Day":"2","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2016","Month":"8","Day":"19","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["26424328","S104161021500157X","10.1017\/S104161021500157X"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"26383147","DateCompleted":{"Year":"2016","Month":"04","Day":"05"},"DateRevised":{"Year":"2016","Month":"11","Day":"26"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1535-5667","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"56","Issue":"12","PubDate":{"Year":"2015","Month":"Dec"}},"Title":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","ISOAbbreviation":"J Nucl Med"},"ArticleTitle":"Metabolic Topology of Neurodegenerative Disorders: Influence of Cognitive and Motor Deficits.","Pagination":{"MedlinePgn":"1916-21"},"ELocationID":"10.2967\/jnumed.115.156067","Abstract":{"AbstractText":["Parkinson disease with and without dementia (PDD and PD, respectively), dementia with Lewy bodies (DLB), and Alzheimer dementia (AD) traditionally have been viewed as distinct clinical and pathologic entities. However, intriguing overlaps in biochemical, clinical, and imaging findings question the concept of distinct entities and suggest a continuous spectrum in which individual patients express PD-typical patterns and AD-typical patterns to a variable degree.","Following this concept, we built a topological map based on regional patterns of the cerebral metabolic rate of glucose as measured with (18)F-FDG PET to rank and localize single subjects' disease status according to PD-typical (PD vs. controls) and AD-typical (AD vs. controls) pattern expression in patients clinically characterized as PD, PDD, DLB, amnestic mild cognitive impairment, and AD.","The topology generally confirmed an indivisible spectrum of disease manifestation according to 2 separable expression patterns. The expression values derived from the first pattern were highly correlated with individual cognitive, but not motor, disability. The opposite was found for the corresponding expression values of the second pattern.","The metabolic imaging analysis supports the notion that there is a continuous spectrum of neurodegeneration between AD and PD. Furthermore, PDD and DLB may in fact represent 1 overlapping disease entity, characterized by the presence of mixed neuropathology and only different by the time course."],"CopyrightInformation":"\u00a9 2015 by the Society of Nuclear Medicine and Molecular Imaging, Inc."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Granert","ForeName":"Oliver","Initials":"O","AffiliationInfo":{"Affiliation":"Department of Neurology, Kiel University, Kiel, Germany o.granert@neurologie.uni-kiel.de."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Drzezga","ForeName":"Alexander E","Initials":"AE","AffiliationInfo":{"Affiliation":"Department of Nuclear Medicine, University of Cologne, Cologne, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Boecker","ForeName":"Henning","Initials":"H","AffiliationInfo":{"Affiliation":"Department of Radiology, Bonn University, Bonn, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Perneczky","ForeName":"Robert","Initials":"R","AffiliationInfo":{"Affiliation":"Neuroepidemiology and Ageing Research Unit, Imperial College of Science, Technology and Medicine, London, United Kingdom Cognitive Impairment and Dementia Services, West London Mental Health NHS Trust, London, United Kingdom Department of Psychiatry, TU Munich, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A","AffiliationInfo":{"Affiliation":"Department of Psychiatry, TU Munich, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"G\u00f6tz","ForeName":"Julia","Initials":"J","AffiliationInfo":{"Affiliation":"Department of Neurology, Kiel University, Kiel, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"van Eimeren","ForeName":"Thilo","Initials":"T","AffiliationInfo":{"Affiliation":"Department of Neurology, Kiel University, Kiel, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"H\u00e4ussermann","ForeName":"Peter","Initials":"P","AffiliationInfo":{"Affiliation":"Department of Psychiatry, Kiel University, Kiel, Germany; and LVR Clinic Cologne, Academic Teaching Hospital, University of Cologne, Cologne, Germany."}}]},"Language":"eng","PublicationTypeList":{"PublicationType":"Journal Article"},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2015","Month":"09","Day":"17"}},"MedlineJournalInfo":{"Country":"United States","MedlineTA":"J Nucl Med","NlmUniqueID":"0217410","ISSNLinking":"0161-5505"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"Radiopharmaceuticals"},{"RegistryNumber":"0Z5B2CJX4D","NameOfSubstance":"Fluorodeoxyglucose F18"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Alzheimer Disease","QualifierName":["diagnostic imaging","metabolism","psychology"]},{"DescriptorName":"Brain Mapping"},{"DescriptorName":"Cognition"},{"DescriptorName":"Cognitive Dysfunction","QualifierName":["diagnostic imaging","metabolism","psychology"]},{"DescriptorName":"Female"},{"DescriptorName":"Fluorodeoxyglucose F18"},{"DescriptorName":"Humans"},{"DescriptorName":"Image Processing, Computer-Assisted"},{"DescriptorName":"Lewy Body Disease","QualifierName":["diagnostic imaging","metabolism","psychology"]},{"DescriptorName":"Male"},{"DescriptorName":"Movement Disorders","QualifierName":["diagnostic imaging","metabolism","psychology"]},{"DescriptorName":"Neurodegenerative Diseases","QualifierName":["diagnostic imaging","metabolism","psychology"]},{"DescriptorName":"Parkinson Disease","QualifierName":["diagnostic imaging","metabolism","psychology"]},{"DescriptorName":"Parkinson Disease, Postencephalitic","QualifierName":["diagnostic imaging","metabolism","psychology"]},{"DescriptorName":"Radionuclide Imaging"},{"DescriptorName":"Radiopharmaceuticals"}]},"KeywordList":{"@attributes":{"Owner":"NOTNLM"},"Keyword":["Alzheimer","FDG PET","Parkinson","dementia","motor deficits"]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2015","Month":"02","Day":"20"},{"@attributes":{"PubStatus":"accepted"},"Year":"2015","Month":"08","Day":"10"},{"@attributes":{"PubStatus":"entrez"},"Year":"2015","Month":"9","Day":"19","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2015","Month":"9","Day":"19","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2016","Month":"4","Day":"6","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["26383147","jnumed.115.156067","10.2967\/jnumed.115.156067"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"26253588","DateCompleted":{"Year":"2017","Month":"02","Day":"13"},"DateRevised":{"Year":"2018","Month":"11","Day":"13"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1433-8491","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"266","Issue":"7","PubDate":{"Year":"2016","Month":"Oct"}},"Title":"European archives of psychiatry and clinical neuroscience","ISOAbbreviation":"Eur Arch Psychiatry Clin Neurosci"},"ArticleTitle":"Mapping CSF biomarker profiles onto NIA-AA guidelines for Alzheimer's disease.","Pagination":{"MedlinePgn":"587-97"},"ELocationID":"10.1007\/s00406-015-0628-7","Abstract":{"AbstractText":"The National Institute on Aging-Alzheimer's Association (NIA-AA) guidelines for Alzheimer's disease (AD) propose the categorization of individuals according to their biomarker constellation. Though the NIA-AA criteria for preclinical AD and AD dementia have already been applied in conjunction with imaging AD biomarkers, the application of the criteria using comprehensive cerebrospinal fluid (CSF) biomarker information has not been thoroughly studied yet. The study included a monocentric cohort with healthy (N\u00a0=\u00a041) and disease (N\u00a0=\u00a022) controls and patients with AD dementia (N\u00a0=\u00a0119), and a multicentric sample with healthy controls (N\u00a0=\u00a0116) and patients with AD dementia (N\u00a0=\u00a0102). The CSF biomarkers \u03b2-amyloid 1-42, total tau, and phosphorylated tau at threonine 181 were measured with commercially available assays. Biomarker values were trichotomized into positive for AD, negative, or borderline. In controls the presence of normal CSF profiles varied between 13.6 and 25.4\u00a0% across the studied groups, while up to 8.6\u00a0% of them had abnormal CSF biomarkers. In 40.3-52.9\u00a0% of patients with AD dementia, a typical CSF profile for AD was detected. Approximately 40\u00a0% of the potential biomarker constellations are not considered in the NIA-AA guidelines, and more than 40\u00a0% of participants could not be classified into the NIA-AA categories with distinct biomarker constellations. Here, a refined scheme covering all potential biomarker constellations is proposed. These results enrich the discussion on the NIA-AA guidelines and point to a discordance between clinical symptomatology and CSF biomarkers even in patients with full-blown AD dementia, who are supposed to have a clearly positive for AD neurochemical profile. "},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Alexopoulos","ForeName":"Panagiotis","Initials":"P","AffiliationInfo":[{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany. panos.alexopoulos@lrz.tum.de."},{"Affiliation":"Department of Psychiatry, University Hospital of Rion, University of Patras, 26500, Rion, Patras, Greece. panos.alexopoulos@lrz.tum.de."}]},{"@attributes":{"ValidYN":"Y"},"LastName":"Roesler","ForeName":"Jennifer","Initials":"J","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Thierjung","ForeName":"Nathalie","Initials":"N","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Werle","ForeName":"Lukas","Initials":"L","AffiliationInfo":[{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."},{"Affiliation":"Max Planck Institute of Psychiatry, 80804, Munich, Germany."}]},{"@attributes":{"ValidYN":"Y"},"LastName":"Buck","ForeName":"Dorothea","Initials":"D","AffiliationInfo":{"Affiliation":"Department of Neurology, Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Yakushev","ForeName":"Igor","Initials":"I","AffiliationInfo":{"Affiliation":"Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Gleixner","ForeName":"Lena","Initials":"L","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Kagerbauer","ForeName":"Simone","Initials":"S","AffiliationInfo":{"Affiliation":"Department of Anaesthesiology, Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Ortner","ForeName":"Marion","Initials":"M","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Grimmer","ForeName":"Timo","Initials":"T","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"K\u00fcbler","ForeName":"Hubert","Initials":"H","AffiliationInfo":{"Affiliation":"Department of Urology, Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Martin","ForeName":"Jan","Initials":"J","AffiliationInfo":{"Affiliation":"Department of Anaesthesiology, Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Laskaris","ForeName":"Nikolaos","Initials":"N","AffiliationInfo":{"Affiliation":"Department of Informatics, Aristotle University of Thessaloniki, Thessalon\u00edki, Greece."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Perneczky","ForeName":"Robert","Initials":"R","AffiliationInfo":[{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."},{"Affiliation":"Neuroepidemiology and Ageing Research Unit, Faculty of Medicine, School of Public Health, The Imperial College of Science, Technology and Medicine, London, UK."},{"Affiliation":"West London Cognitive Disorders Treatment and Research Unit, West London Mental Health Trust, London, UK."}]}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Multicenter Study"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2015","Month":"08","Day":"08"}},"MedlineJournalInfo":{"Country":"Germany","MedlineTA":"Eur Arch Psychiatry Clin Neurosci","NlmUniqueID":"9103030","ISSNLinking":"0940-1334"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"Amyloid beta-Peptides"},{"RegistryNumber":"0","NameOfSubstance":"Biomarkers"},{"RegistryNumber":"0","NameOfSubstance":"Peptide Fragments"},{"RegistryNumber":"0","NameOfSubstance":"amyloid beta-protein (1-42)"},{"RegistryNumber":"0","NameOfSubstance":"tau Proteins"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Aged, 80 and over"},{"DescriptorName":"Alzheimer Disease","QualifierName":["cerebrospinal fluid","classification"]},{"DescriptorName":"Amyloid beta-Peptides","QualifierName":"cerebrospinal fluid"},{"DescriptorName":"Biomarkers","QualifierName":"cerebrospinal fluid"},{"DescriptorName":"Female"},{"DescriptorName":"Humans"},{"DescriptorName":"Male"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"National Institute on Aging (U.S.)","QualifierName":"standards"},{"DescriptorName":"Peptide Fragments","QualifierName":"cerebrospinal fluid"},{"DescriptorName":"Societies, Medical","QualifierName":"standards"},{"DescriptorName":"United States"},{"DescriptorName":"tau Proteins","QualifierName":"cerebrospinal fluid"}]},"KeywordList":{"@attributes":{"Owner":"NOTNLM"},"Keyword":["Biomarkers","Cognitive aging","Dementia","Diagnostic criteria"]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2015","Month":"03","Day":"25"},{"@attributes":{"PubStatus":"accepted"},"Year":"2015","Month":"07","Day":"26"},{"@attributes":{"PubStatus":"entrez"},"Year":"2015","Month":"8","Day":"9","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2015","Month":"8","Day":"9","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2017","Month":"2","Day":"14","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["26253588","10.1007\/s00406-015-0628-7","10.1007\/s00406-015-0628-7"]},"ReferenceList":{"Reference":[{"Citation":"Alzheimers Dement. 2012 Jul;8(4):304-11","ArticleIdList":{"ArticleId":"22055653"}},{"Citation":"Lancet Neurol. 2013 Oct;12(10):957-65","ArticleIdList":{"ArticleId":"24012374"}},{"Citation":"Ann Neurol. 2009 Apr;65(4):403-13","ArticleIdList":{"ArticleId":"19296504"}},{"Citation":"Eur Arch Psychiatry Clin Neurosci. 2010 Oct;260(7):561-2","ArticleIdList":{"ArticleId":"20155362"}},{"Citation":"Lancet Neurol. 2014 Oct;13(10 ):997-1005","ArticleIdList":{"ArticleId":"25201514"}},{"Citation":"Nature. 1999 Oct 21;401(6755):788-91","ArticleIdList":{"ArticleId":"10548103"}},{"Citation":"J Neurochem. 1993 Nov;61(5):1828-34","ArticleIdList":{"ArticleId":"8228996"}},{"Citation":"Eur Arch Psychiatry Clin Neurosci. 2013 Jun;263(4):325-33","ArticleIdList":{"ArticleId":"22932720"}},{"Citation":"Neurology. 1999 May 12;52(8):1555-62","ArticleIdList":{"ArticleId":"10331678"}},{"Citation":"Alzheimers Res Ther. 2014 Nov 21;6(9):82","ArticleIdList":{"ArticleId":"25419243"}},{"Citation":"Lancet. 2011 Mar 19;377(9770):1019-31","ArticleIdList":{"ArticleId":"21371747"}},{"Citation":"Neurology. 2013 Jun 4;80(23 ):2130-7","ArticleIdList":{"ArticleId":"23645596"}},{"Citation":"Trends Mol Med. 2014 Jan;20(1):8-15","ArticleIdList":{"ArticleId":"24524150"}},{"Citation":"Brain. 2015 May;138(Pt 5):1327-38","ArticleIdList":{"ArticleId":"25693589"}},{"Citation":"J Intern Med. 2014 Mar;275(3):229-50","ArticleIdList":{"ArticleId":"24605807"}},{"Citation":"Transl Psychiatry. 2013 Feb 19;3:e227","ArticleIdList":{"ArticleId":"23423136"}},{"Citation":"Neurology. 2010 Jul 20;75(3):230-8","ArticleIdList":{"ArticleId":"20592257"}},{"Citation":"IEEE Trans Biomed Eng. 2013 Jan;60(1):164-8","ArticleIdList":{"ArticleId":"22893371"}},{"Citation":"Amyloid. 2000 Dec;7(4):245-58","ArticleIdList":{"ArticleId":"11132093"}},{"Citation":"J Neuropathol Exp Neurol. 2012 Apr;71(4):266-73","ArticleIdList":{"ArticleId":"22437338"}},{"Citation":"Alzheimers Dement. 2011 May;7(3):263-9","ArticleIdList":{"ArticleId":"21514250"}},{"Citation":"Neurology. 2009 Oct 13;73(15):1193-9","ArticleIdList":{"ArticleId":"19822868"}},{"Citation":"Contemp Clin Trials. 2013 Nov;36(2):616-23","ArticleIdList":{"ArticleId":"23816492"}},{"Citation":"Ann Neurol. 2012 Jun;71(6):765-75","ArticleIdList":{"ArticleId":"22488240"}},{"Citation":"Neurology. 2011 Jan 4;76(1):69-79","ArticleIdList":{"ArticleId":"21123754"}},{"Citation":"Alzheimers Dement. 2014 Nov;10 (6):684-9","ArticleIdList":{"ArticleId":"24857233"}},{"Citation":"N Engl J Med. 2014 Jan 23;370(4):322-33","ArticleIdList":{"ArticleId":"24450891"}},{"Citation":"J Alzheimers Dis. 2013;36(2):401-8","ArticleIdList":{"ArticleId":"23609762"}},{"Citation":"Neurology. 2010 Jan 19;74(3):201-9","ArticleIdList":{"ArticleId":"20042704"}},{"Citation":"Arch Neurol. 2009 Mar;66(3):382-9","ArticleIdList":{"ArticleId":"19273758"}},{"Citation":"JAMA. 2009 Jul 22;302(4):385-93","ArticleIdList":{"ArticleId":"19622817"}},{"Citation":"Nervenarzt. 2011 Mar;82(3):325-30, 332-35","ArticleIdList":{"ArticleId":"20938631"}},{"Citation":"Acta Neuropathol. 2013 Sep;126(3):365-84","ArticleIdList":{"ArticleId":"23900711"}},{"Citation":"Alzheimers Dement. 2011 May;7(3):280-92","ArticleIdList":{"ArticleId":"21514248"}},{"Citation":"Lancet Neurol. 2013 Feb;12(2):207-16","ArticleIdList":{"ArticleId":"23332364"}},{"Citation":"Alzheimers Dement. 2013 Sep;9(5):580-6","ArticleIdList":{"ArticleId":"23232272"}},{"Citation":"Neurology. 1984 Jul;34(7):939-44","ArticleIdList":{"ArticleId":"6610841"}},{"Citation":"JAMA. 2011 Jun 15;305(23):2458-9","ArticleIdList":{"ArticleId":"21673298"}}]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"25936935","DateCompleted":{"Year":"2016","Month":"09","Day":"08"},"DateRevised":{"Year":"2018","Month":"11","Day":"13"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1552-5279","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"11","Issue":"12","PubDate":{"Year":"2015","Month":"Dec"}},"Title":"Alzheimer's & dementia : the journal of the Alzheimer's Association","ISOAbbreviation":"Alzheimers Dement"},"ArticleTitle":"The role of TREM2 R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease.","Pagination":{"MedlinePgn":"1407-1416"},"ELocationID":["S1552-5260(15)00122-3","10.1016\/j.jalz.2014.12.009"],"Abstract":{"AbstractText":"A rare variant in TREM2 (p.R47H, rs75932628) was recently reported to increase the risk of Alzheimer's disease (AD) and, subsequently, other neurodegenerative diseases, i.e. frontotemporal lobar degeneration (FTLD), amyotrophic lateral sclerosis (ALS), and Parkinson's disease (PD). Here we comprehensively assessed TREM2 rs75932628 for association with these diseases in a total of 19,940 previously untyped subjects of European descent. These data were combined with those from 28 published data sets by meta-analysis. Furthermore, we tested whether rs75932628 shows association with amyloid beta (A\u03b242) and total-tau protein levels in the cerebrospinal fluid (CSF) of 828 individuals with AD or mild cognitive impairment. Our data show that rs75932628 is highly significantly associated with the risk of AD across 24,086 AD cases and 148,993 controls of European descent (odds ratio or OR = 2.71, P = 4.67 \u00d7 10(-25)). No consistent evidence for association was found between this marker and the risk of FTLD (OR = 2.24, P = .0113 across 2673 cases\/9283 controls), PD (OR = 1.36, P = .0767 across 8311 cases\/79,938 controls) and ALS (OR = 1.41, P = .198 across 5544 cases\/7072 controls). Furthermore, carriers of the rs75932628 risk allele showed significantly increased levels of CSF-total-tau (P = .0110) but not A\u03b242 suggesting that TREM2's role in AD may involve tau dysfunction.","CopyrightInformation":"Copyright \u00a9 2015 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Lill","ForeName":"Christina M","Initials":"CM","AffiliationInfo":{"Affiliation":"Platform for Genome Analytics, Institutes of Neurogenetics & Integrative and Experimental Genomics, University of L\u00fcbeck, L\u00fcbeck, Germany; Department of Vertebrate Genomics, Max Planck Institute for Molecular Genetics, Berlin, Germany. Electronic address: christina.lill@gmx.de."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Rengmark","ForeName":"Aina","Initials":"A","AffiliationInfo":{"Affiliation":"Department of Neurology, Oslo University Hospital, Oslo, Norway."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Pihlstr\u00f8m","ForeName":"Lasse","Initials":"L","AffiliationInfo":{"Affiliation":"Department of Neurology, Oslo University Hospital, Oslo, Norway."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Fogh","ForeName":"Isabella","Initials":"I","AffiliationInfo":{"Affiliation":"Department of Clinical Neuroscience, Institute of Psychiatry, King's College London, London, UK."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Shatunov","ForeName":"Aleksey","Initials":"A","AffiliationInfo":{"Affiliation":"Department of Clinical Neuroscience, Institute of Psychiatry, King's College London, London, UK."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Sleiman","ForeName":"Patrick M","Initials":"PM","AffiliationInfo":{"Affiliation":"Center for Applied Genomics, Abramson Research Center, The Children's Hospital of Philadelphia, Philadelphia, PA, USA; Division of Human Genetics, Abramson Research Center, The Children's Hospital of Philadelphia, Philadelphia, PA, USA; Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Wang","ForeName":"Li-San","Initials":"LS","AffiliationInfo":{"Affiliation":"Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Liu","ForeName":"Tian","Initials":"T","AffiliationInfo":{"Affiliation":"Max Planck Institute for Human Development, Berlin, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Lassen","ForeName":"Christina F","Initials":"CF","AffiliationInfo":{"Affiliation":"Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Meissner","ForeName":"Esther","Initials":"E","AffiliationInfo":{"Affiliation":"Department of Vertebrate Genomics, Max Planck Institute for Molecular Genetics, Berlin, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Alexopoulos","ForeName":"Panos","Initials":"P","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Calvo","ForeName":"Andrea","Initials":"A","AffiliationInfo":{"Affiliation":"Rita Levi Montalcini Department of Neuroscience, ALS Center, University of Torino, Torino, Italy."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Chio","ForeName":"Adriano","Initials":"A","AffiliationInfo":{"Affiliation":"Rita Levi Montalcini Department of Neuroscience, ALS Center, University of Torino, Torino, Italy; Neuroscience Institute of Turin, Turin, Italy."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Dizdar","ForeName":"Nil","Initials":"N","AffiliationInfo":{"Affiliation":"Department of Neurology, Link\u00f6ping University, Link\u00f6ping, Sweden."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Faltraco","ForeName":"Frank","Initials":"F","AffiliationInfo":{"Affiliation":"Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, Goethe University of Frankfurt, Frankfurt, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Forsgren","ForeName":"Lars","Initials":"L","AffiliationInfo":{"Affiliation":"Department of Pharmacology and Clinical Neuroscience, Ume\u00e5 University, Ume\u00e5, Sweden."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Kirchheiner","ForeName":"Julia","Initials":"J","AffiliationInfo":{"Affiliation":"Department of Neurology, University of Ulm, Ulm, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Larsen","ForeName":"Jan P","Initials":"JP","AffiliationInfo":{"Affiliation":"The Norwegian Centre for Movement Disorders, Stavanger University Hospital, Stavanger, Norway."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Liebsch","ForeName":"Maria","Initials":"M","AffiliationInfo":{"Affiliation":"Department of Vertebrate Genomics, Max Planck Institute for Molecular Genetics, Berlin, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Linder","ForeName":"Jan","Initials":"J","AffiliationInfo":{"Affiliation":"Department of Pharmacology and Clinical Neuroscience, Ume\u00e5 University, Ume\u00e5, Sweden."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Morrison","ForeName":"Karen E","Initials":"KE","AffiliationInfo":{"Affiliation":"School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK; Neurosciences Division, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Nissbrandt","ForeName":"Hans","Initials":"H","AffiliationInfo":{"Affiliation":"Department of Pharmacology, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Otto","ForeName":"Markus","Initials":"M","AffiliationInfo":{"Affiliation":"Department of Neurology, University of Ulm, Ulm, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Pahnke","ForeName":"Jens","Initials":"J","AffiliationInfo":{"Affiliation":"Department of Neuro-\/Pathology, University of Oslo and Oslo University Hospital, Oslo, Norway; L\u00fcbeck Institute of Experimental Dermatology, University of L\u00fcbeck, L\u00fcbeck, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Partch","ForeName":"Amanda","Initials":"A","AffiliationInfo":{"Affiliation":"Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Restagno","ForeName":"Gabriella","Initials":"G","AffiliationInfo":{"Affiliation":"Department of Clinical Pathology, Molecular Genetics Unit, Azienda Ospedaliera Citt\u00e0 della Salute e della Scienza, Torino, Italy."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Rujescu","ForeName":"Dan","Initials":"D","AffiliationInfo":{"Affiliation":"Department of Psychiatry, University of Halle-Wittenberg, Halle, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Schnack","ForeName":"Cathrin","Initials":"C","AffiliationInfo":{"Affiliation":"Department of Neurology, University of Ulm, Ulm, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Shaw","ForeName":"Christopher E","Initials":"CE","AffiliationInfo":{"Affiliation":"Department of Clinical Neuroscience, Institute of Psychiatry, King's College London, London, UK."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Shaw","ForeName":"Pamela J","Initials":"PJ","AffiliationInfo":{"Affiliation":"Department of Neuroscience, Sheffield Institute for Translational Neuroscience (SITraN), Faculty of Medicine, Dentistry and Health, University of Sheffield, Sheffield, UK."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Tumani","ForeName":"Hayrettin","Initials":"H","AffiliationInfo":{"Affiliation":"Department of Neurology, University of Ulm, Ulm, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Tysnes","ForeName":"Ole-Bj\u00f8rn","Initials":"OB","AffiliationInfo":{"Affiliation":"Department of Neurology, Haukeland University Hospital, Bergen, Norway; Department of Clinical Medicine, University of Bergen, Bergen, Norway."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Valladares","ForeName":"Otto","Initials":"O","AffiliationInfo":{"Affiliation":"Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Silani","ForeName":"Vincenzo","Initials":"V","AffiliationInfo":{"Affiliation":"Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milano, Italy; Department of Pathophysiology and Tranplantation, \"Dino Ferrari\" Center, Universit\u00e0 degli Studi di Milano, Milano, Italy."}},{"@attributes":{"ValidYN":"Y"},"LastName":"van den Berg","ForeName":"Leonard H","Initials":"LH","AffiliationInfo":{"Affiliation":"Department of Neurology, Neuromuscular Diseases Brain Center Rudolf Magnus, Netherlands ALS Center, University Medical Center Utrecht, Utrecht, The Netherlands."}},{"@attributes":{"ValidYN":"Y"},"LastName":"van Rheenen","ForeName":"Wouter","Initials":"W","AffiliationInfo":{"Affiliation":"Department of Neurology, Neuromuscular Diseases Brain Center Rudolf Magnus, Netherlands ALS Center, University Medical Center Utrecht, Utrecht, The Netherlands."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Veldink","ForeName":"Jan H","Initials":"JH","AffiliationInfo":{"Affiliation":"Department of Neurology, Neuromuscular Diseases Brain Center Rudolf Magnus, Netherlands ALS Center, University Medical Center Utrecht, Utrecht, The Netherlands."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Lindenberger","ForeName":"Ulman","Initials":"U","AffiliationInfo":{"Affiliation":"Max Planck Institute for Human Development, Berlin, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Steinhagen-Thiessen","ForeName":"Elisabeth","Initials":"E","AffiliationInfo":{"Affiliation":"Interdisciplinary Metabolic Center, Lipids Clinic, Charit\u00e9 University Medicine, Berlin, Germany."}},{"@attributes":{"ValidYN":"Y"},"CollectiveName":"SLAGEN Consortium"},{"@attributes":{"ValidYN":"Y"},"LastName":"Teipel","ForeName":"Stefan","Initials":"S","AffiliationInfo":{"Affiliation":"German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany; Department of Psychosomatic Medicine, University of Rostock, Rostock, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Perneczky","ForeName":"Robert","Initials":"R","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany; Neuroepidemiology and Ageing Research Unit, School of Public Health, Faculty of Medicine, The Imperial College of Science, Technology, and Medicine, London, UK; West London Cognitive Disorders Treatment and Research Unit, West London Mental Health Trust, London, UK."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Hakonarson","ForeName":"Hakon","Initials":"H","AffiliationInfo":{"Affiliation":"Center for Applied Genomics, Abramson Research Center, The Children's Hospital of Philadelphia, Philadelphia, PA, USA; Division of Human Genetics, Abramson Research Center, The Children's Hospital of Philadelphia, Philadelphia, PA, USA; Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Hampel","ForeName":"Harald","Initials":"H","AffiliationInfo":{"Affiliation":"AXA Research Fund & UPMC Chair, Paris, France; D\u00e9partement de Neurologie, Sorbonne Universit\u00e9s, Universit\u00e9 Pierre et Marie Curie, Institut de la M\u00e9moire et de la Maladie d'Alzheimer & Institut du Cerveau et de la Moelle \u00e9pini\u00e8re (ICM), H\u00f4pital de la Piti\u00e9-Salp\u00e9tri\u00e8re, Paris, France."}},{"@attributes":{"ValidYN":"Y"},"LastName":"von Arnim","ForeName":"Christine A F","Initials":"CAF","AffiliationInfo":{"Affiliation":"Department of Neurology, University of Ulm, Ulm, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Olsen","ForeName":"J\u00f8rgen H","Initials":"JH","AffiliationInfo":{"Affiliation":"Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Van Deerlin","ForeName":"Vivianna M","Initials":"VM","AffiliationInfo":{"Affiliation":"Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Al-Chalabi","ForeName":"Ammar","Initials":"A","AffiliationInfo":{"Affiliation":"Department of Clinical Neuroscience, Institute of Psychiatry, King's College London, London, UK."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Toft","ForeName":"Mathias","Initials":"M","AffiliationInfo":{"Affiliation":"Department of Neurology, Oslo University Hospital, Oslo, Norway."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Ritz","ForeName":"Beate","Initials":"B","AffiliationInfo":{"Affiliation":"Department of Epidemiology and Environmental Sciences, School of Public Health, University of California, Los Angeles, CA, USA."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Bertram","ForeName":"Lars","Initials":"L","AffiliationInfo":{"Affiliation":"Platform for Genome Analytics, Institutes of Neurogenetics & Integrative and Experimental Genomics, University of L\u00fcbeck, L\u00fcbeck, Germany; Department of Vertebrate Genomics, Max Planck Institute for Molecular Genetics, Berlin, Germany; Neuroepidemiology and Ageing Research Unit, School of Public Health, Faculty of Medicine, The Imperial College of Science, Technology, and Medicine, London, UK."}}]},"Language":"eng","GrantList":{"@attributes":{"CompleteYN":"Y"},"Grant":[{"GrantID":"089701","Agency":"Wellcome Trust","Country":"United Kingdom"},{"GrantID":"MC_G1000733","Agency":"Medical Research Council","Country":"United Kingdom"},{"GrantID":"MR\/L501529\/1","Agency":"Medical Research Council","Country":"United Kingdom"},{"GrantID":"P01 AG017586","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"MR\/L021803\/1","Agency":"Medical Research Council","Country":"United Kingdom"},{"GrantID":"G0500289","Agency":"Medical Research Council","Country":"United Kingdom"},{"GrantID":"P30 ES013508","Acronym":"ES","Agency":"NIEHS NIH HHS","Country":"United States"},{"GrantID":"G0900688","Agency":"Medical Research Council","Country":"United Kingdom"},{"GrantID":"R01ES013717","Acronym":"ES","Agency":"NIEHS NIH HHS","Country":"United States"},{"GrantID":"R01 ES013717","Acronym":"ES","Agency":"NIEHS NIH HHS","Country":"United States"}]},"PublicationTypeList":{"PublicationType":["Journal Article","Meta-Analysis","Research Support, N.I.H., Extramural","Research Support, Non-U.S. Gov't"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2015","Month":"04","Day":"30"}},"MedlineJournalInfo":{"Country":"United States","MedlineTA":"Alzheimers Dement","NlmUniqueID":"101231978","ISSNLinking":"1552-5260"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"Membrane Glycoproteins"},{"RegistryNumber":"0","NameOfSubstance":"Receptors, Immunologic"},{"RegistryNumber":"0","NameOfSubstance":"TREM2 protein, human"},{"RegistryNumber":"0","NameOfSubstance":"tau Proteins"}]},"CitationSubset":"IM","CommentsCorrectionsList":{"CommentsCorrections":{"@attributes":{"RefType":"CommentIn"},"RefSource":"Nat Rev Neurol. 2015 Jun;11(6):307","PMID":"25986503"}},"MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Alleles"},{"DescriptorName":"Alzheimer Disease","QualifierName":"genetics"},{"DescriptorName":"Amyotrophic Lateral Sclerosis","QualifierName":"genetics"},{"DescriptorName":"Case-Control Studies"},{"DescriptorName":"European Continental Ancestry Group"},{"DescriptorName":"Female"},{"DescriptorName":"Frontotemporal Lobar Degeneration","QualifierName":"genetics"},{"DescriptorName":"Genetic Predisposition to Disease"},{"DescriptorName":"Genotype"},{"DescriptorName":"Humans"},{"DescriptorName":"Male"},{"DescriptorName":"Membrane Glycoproteins","QualifierName":"genetics"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Neurodegenerative Diseases","QualifierName":"genetics"},{"DescriptorName":"Parkinson Disease","QualifierName":"genetics"},{"DescriptorName":"Quantitative Trait Loci"},{"DescriptorName":"Receptors, Immunologic","QualifierName":"genetics"},{"DescriptorName":"Risk Factors"},{"DescriptorName":"tau Proteins","QualifierName":"cerebrospinal fluid"}]},"KeywordList":{"@attributes":{"Owner":"NOTNLM"},"Keyword":["Alzheimer disease","Amyotrophic lateral sclerosis","Frontotemporal lobar degeneration","GWAS","Genetic association","Imputation","Meta-analysis","Neurodegenerative disease","Parkinson disease","R47H","Rare variant","TREM2","rs75932628"]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2014","Month":"06","Day":"11"},{"@attributes":{"PubStatus":"revised"},"Year":"2014","Month":"10","Day":"22"},{"@attributes":{"PubStatus":"accepted"},"Year":"2014","Month":"12","Day":"02"},{"@attributes":{"PubStatus":"entrez"},"Year":"2015","Month":"5","Day":"5","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2015","Month":"5","Day":"6","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2016","Month":"9","Day":"9","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["25936935","S1552-5260(15)00122-3","10.1016\/j.jalz.2014.12.009","PMC4627856","NIHMS692224"]},"ReferenceList":{"Reference":[{"Citation":"J Neurol Sci. 1999 Oct 31;169(1-2):2-12","ArticleIdList":{"ArticleId":"10540001"}},{"Citation":"Am J Hum Genet. 2002 Sep;71(3):656-62","ArticleIdList":{"ArticleId":"12080485"}},{"Citation":"Neurology. 1984 Jul;34(7):939-44","ArticleIdList":{"ArticleId":"6610841"}},{"Citation":"J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181-4","ArticleIdList":{"ArticleId":"1564476"}},{"Citation":"Arch Neurol. 1999 Jan;56(1):33-9","ArticleIdList":{"ArticleId":"9923759"}},{"Citation":"Arch Neurol. 1999 Mar;56(3):303-8","ArticleIdList":{"ArticleId":"10190820"}},{"Citation":"Stat Med. 2006 Oct 30;25(20):3443-57","ArticleIdList":{"ArticleId":"16345038"}},{"Citation":"Nat Genet. 2007 Jan;39(1):17-23","ArticleIdList":{"ArticleId":"17192785"}},{"Citation":"BMJ. 2008;337:a2494","ArticleIdList":{"ArticleId":"19074944"}},{"Citation":"Nat Genet. 2010 Mar;42(3):234-9","ArticleIdList":{"ArticleId":"20154673"}},{"Citation":"Eur J Hum Genet. 2010 Jul;18(7):746-50","ArticleIdList":{"ArticleId":"20179745"}},{"Citation":"Arch Gen Psychiatry. 2011 Feb;68(2):207-13","ArticleIdList":{"ArticleId":"21300948"}},{"Citation":"PLoS One. 2011;6(3):e18362","ArticleIdList":{"ArticleId":"21479240"}},{"Citation":"Semin Neurol. 2011 Nov;31(5):531-41","ArticleIdList":{"ArticleId":"22266890"}},{"Citation":"PLoS Genet. 2012;8(3):e1002548","ArticleIdList":{"ArticleId":"22438815"}},{"Citation":"J Neuroinflammation. 2012;9:47","ArticleIdList":{"ArticleId":"22397366"}},{"Citation":"N Engl J Med. 2013 Jan 10;368(2):107-16","ArticleIdList":{"ArticleId":"23150908"}},{"Citation":"N Engl J Med. 2013 Jan 10;368(2):117-27","ArticleIdList":{"ArticleId":"23150934"}},{"Citation":"JAMA Neurol. 2013 Jan;70(1):78-84","ArticleIdList":{"ArticleId":"23318515"}},{"Citation":"Neurobiol Aging. 2013 Jun;34(6):1711.e15-7","ArticleIdList":{"ArticleId":"23391427"}},{"Citation":"Eur J Epidemiol. 2013 Feb;28(2):131-8","ArticleIdList":{"ArticleId":"23371043"}},{"Citation":"J Alzheimers Dis. 2013;35(1):45-9","ArticleIdList":{"ArticleId":"23380991"}},{"Citation":"Neuron. 2013 Apr 24;78(2):256-68","ArticleIdList":{"ArticleId":"23562540"}},{"Citation":"Neurobiol Aging. 2013 Aug;34(8):2077.e11-8","ArticleIdList":{"ArticleId":"23582655"}},{"Citation":"Mol Neurodegener. 2013;8:19","ArticleIdList":{"ArticleId":"23800361"}},{"Citation":"Neurobiol Aging. 2013 Dec;34(12):2889.e11-3","ArticleIdList":{"ArticleId":"23855982"}},{"Citation":"Science. 2013 Oct 4;342(6154):1235587","ArticleIdList":{"ArticleId":"24092746"}},{"Citation":"N Engl J Med. 2013 Oct 17;369(16):1568-9","ArticleIdList":{"ArticleId":"24131183"}},{"Citation":"N Engl J Med. 2013 Oct 17;369(16):1564-5","ArticleIdList":{"ArticleId":"24131184"}},{"Citation":"N Engl J Med. 2013 Oct 17;369(16):1565","ArticleIdList":{"ArticleId":"24131185"}},{"Citation":"N Engl J Med. 2013 Oct 17;369(16):1567-8","ArticleIdList":{"ArticleId":"24131187"}},{"Citation":"Neurobiol Aging. 2014 Feb;35(2):444.e1-4","ArticleIdList":{"ArticleId":"24041969"}},{"Citation":"Nat Genet. 2013 Dec;45(12):1452-8","ArticleIdList":{"ArticleId":"24162737"}},{"Citation":"Neurobiol Aging. 2014 Mar;35(3):726.e11-9","ArticleIdList":{"ArticleId":"24119542"}},{"Citation":"Neurobiol Aging. 2014 Apr;35(4):934.e7-10","ArticleIdList":{"ArticleId":"24139279"}},{"Citation":"Neurobiol Aging. 2014 Apr;35(4):937.e1-3","ArticleIdList":{"ArticleId":"24184202"}},{"Citation":"Hum Mol Genet. 2014 Apr 15;23(8):2220-31","ArticleIdList":{"ArticleId":"24256812"}},{"Citation":"JAMA Neurol. 2014 Apr;71(4):449-53","ArticleIdList":{"ArticleId":"24535663"}},{"Citation":"Alzheimers Dement. 2014 May;10(3):349-59","ArticleIdList":{"ArticleId":"23712001"}},{"Citation":"Int J Epidemiol. 2014 Jun;43(3):703-12","ArticleIdList":{"ArticleId":"23505255"}},{"Citation":"J Alzheimers Dis. 2014;41(4):1031-8","ArticleIdList":{"ArticleId":"24762945"}},{"Citation":"Nat Genet. 2014 Sep;46(9):989-93","ArticleIdList":{"ArticleId":"25064009"}},{"Citation":"Neurology. 2014 Oct 7;83(15):1353-8","ArticleIdList":{"ArticleId":"25186855"}},{"Citation":"Alzheimers Dement. 2014 Nov;10(6):602-608.e4","ArticleIdList":{"ArticleId":"25160042"}}]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"25919662","DateCompleted":{"Year":"2015","Month":"12","Day":"29"},"DateRevised":{"Year":"2020","Month":"03","Day":"11"},"Article":{"@attributes":{"PubModel":"Electronic-eCollection"},"Journal":{"ISSN":"1932-6203","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"10","Issue":"4","PubDate":{"Year":"2014"}},"Title":"PloS one","ISOAbbreviation":"PLoS One"},"ArticleTitle":"Gaussian Mixture Models and Model Selection for [18F] Fluorodeoxyglucose Positron Emission Tomography Classification in Alzheimer's Disease.","Pagination":{"MedlinePgn":"e0122731"},"ELocationID":"10.1371\/journal.pone.0122731","Abstract":{"AbstractText":"We present a method to discover discriminative brain metabolism patterns in [18F] fluorodeoxyglucose positron emission tomography (PET) scans, facilitating the clinical diagnosis of Alzheimer's disease. In the work, the term \"pattern\" stands for a certain brain region that characterizes a target group of patients and can be used for a classification as well as interpretation purposes. Thus, it can be understood as a so-called \"region of interest (ROI)\". In the literature, an ROI is often found by a given brain atlas that defines a number of brain regions, which corresponds to an anatomical approach. The present work introduces a semi-data-driven approach that is based on learning the characteristics of the given data, given some prior anatomical knowledge. A Gaussian Mixture Model (GMM) and model selection are combined to return a clustering of voxels that may serve for the definition of ROIs. Experiments on both an in-house dataset and data of the Alzheimer's Disease Neuroimaging Initiative (ADNI) suggest that the proposed approach arrives at a better diagnosis than a merely anatomical approach or conventional statistical hypothesis testing. "},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Li","ForeName":"Rui","Initials":"R","AffiliationInfo":{"Affiliation":"Institut f\u00fcr Informatik\/I12, Technische Universit\u00e4t M\u00fcnchen, Garching bei M\u00fcnchen, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Perneczky","ForeName":"Robert","Initials":"R","AffiliationInfo":{"Affiliation":"Klinik und Poliklinik f\u00fcr Psychiatrie und Psychotherapie, Technische Universit\u00e4t M\u00fcnchen, M\u00fcnchen, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Yakushev","ForeName":"Igor","Initials":"I","AffiliationInfo":{"Affiliation":"Nuklearmedizinische Klinik, Technische Universit\u00e4t M\u00fcnchen, M\u00fcnchen, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"F\u00f6rster","ForeName":"Stefan","Initials":"S","AffiliationInfo":{"Affiliation":"Nuklearmedizinische Klinik, Technische Universit\u00e4t M\u00fcnchen, M\u00fcnchen, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A","AffiliationInfo":{"Affiliation":"Klinik und Poliklinik f\u00fcr Psychiatrie und Psychotherapie, Technische Universit\u00e4t M\u00fcnchen, M\u00fcnchen, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Drzezga","ForeName":"Alexander","Initials":"A","AffiliationInfo":{"Affiliation":"Klinik und Poliklinik f\u00fcr Nuklearmedizin, Universit\u00e4t zu K\u00f6ln, K\u00f6ln, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Kramer","ForeName":"Stefan","Initials":"S","AffiliationInfo":{"Affiliation":"Institut f\u00fcr Informatik, Johannes Gutenberg-Universit\u00e4t Mainz, Mainz, Germany."}},{"@attributes":{"ValidYN":"Y"},"CollectiveName":"Alzheimer\u2019s Disease Neuroimaging Initiative"}]},"Language":"eng","GrantList":{"@attributes":{"CompleteYN":"Y"},"Grant":[{"GrantID":"MR\/M024903\/1","Acronym":"MRC_","Agency":"Medical Research Council","Country":"United Kingdom"},{"GrantID":"P30 AG062421","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"P50 AG005134","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"U01 AG024904","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"}]},"PublicationTypeList":{"PublicationType":["Journal Article","Research Support, Non-U.S. Gov't"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2015","Month":"04","Day":"28"}},"MedlineJournalInfo":{"Country":"United States","MedlineTA":"PLoS One","NlmUniqueID":"101285081","ISSNLinking":"1932-6203"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"Radiopharmaceuticals"},{"RegistryNumber":"0Z5B2CJX4D","NameOfSubstance":"Fluorodeoxyglucose F18"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Aged, 80 and over"},{"DescriptorName":"Alzheimer Disease","QualifierName":["diagnostic imaging","pathology"]},{"DescriptorName":"Brain","QualifierName":["diagnostic imaging","pathology"]},{"DescriptorName":"Female"},{"DescriptorName":"Fluorodeoxyglucose F18","QualifierName":"pharmacokinetics"},{"DescriptorName":"Humans"},{"DescriptorName":"Male"},{"DescriptorName":"Models, Theoretical"},{"DescriptorName":"Normal Distribution"},{"DescriptorName":"Positron-Emission Tomography","QualifierName":"methods"},{"DescriptorName":"Radiopharmaceuticals","QualifierName":"pharmacokinetics"},{"DescriptorName":"Sensitivity and Specificity"}]},"InvestigatorList":{"Investigator":[{"@attributes":{"ValidYN":"Y"},"LastName":"Weiner","ForeName":"Michael W","Initials":"MW"},{"@attributes":{"ValidYN":"Y"},"LastName":"Aisen","ForeName":"Paul","Initials":"P"},{"@attributes":{"ValidYN":"Y"},"LastName":"Weiner","ForeName":"Michael","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Aisen","ForeName":"Paul","Initials":"P"},{"@attributes":{"ValidYN":"Y"},"LastName":"Jack","ForeName":"Clifford R","Initials":"CR","Suffix":"Jr"},{"@attributes":{"ValidYN":"Y"},"LastName":"Jagust","ForeName":"William","Initials":"W"},{"@attributes":{"ValidYN":"Y"},"LastName":"Saykin","ForeName":"Andrew J","Initials":"AJ"},{"@attributes":{"ValidYN":"Y"},"LastName":"Khachaturian","ForeName":"Zaven","Initials":"Z"},{"@attributes":{"ValidYN":"Y"},"LastName":"Sorensen","ForeName":"Greg","Initials":"G"},{"@attributes":{"ValidYN":"Y"},"LastName":"Carrillo","ForeName":"Maria","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kuller","ForeName":"Lew","Initials":"L"},{"@attributes":{"ValidYN":"Y"},"LastName":"Raichle","ForeName":"Marc","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Paul","ForeName":"Steven","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"Davies","ForeName":"Peter","Initials":"P"},{"@attributes":{"ValidYN":"Y"},"LastName":"Fillit","ForeName":"Howard","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Hefti","ForeName":"Franz","Initials":"F"},{"@attributes":{"ValidYN":"Y"},"LastName":"Holtzman","ForeName":"Davie","Initials":"D"},{"@attributes":{"ValidYN":"Y"},"LastName":"Mesulam","ForeName":"Louis M  Marcel","Initials":"LM"},{"@attributes":{"ValidYN":"Y"},"LastName":"Potter","ForeName":"William","Initials":"W"},{"@attributes":{"ValidYN":"Y"},"LastName":"Schwartz","ForeName":"Adam","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Green","ForeName":"Robert C","Initials":"RC"},{"@attributes":{"ValidYN":"Y"},"LastName":"Montine","ForeName":"Tom","Initials":"T"},{"@attributes":{"ValidYN":"Y"},"LastName":"Petersen","ForeName":"Ronald","Initials":"R"},{"@attributes":{"ValidYN":"Y"},"LastName":"Aisen","ForeName":"Paul","Initials":"P"},{"@attributes":{"ValidYN":"Y"},"LastName":"Thomas","ForeName":"Ronald G","Initials":"RG"},{"@attributes":{"ValidYN":"Y"},"LastName":"Sather","ForeName":"Tamie","Initials":"T"},{"@attributes":{"ValidYN":"Y"},"LastName":"Jiminez","ForeName":"Gus","Initials":"G"},{"@attributes":{"ValidYN":"Y"},"LastName":"Balasubramanian","ForeName":"Archana B","Initials":"AB"},{"@attributes":{"ValidYN":"Y"},"LastName":"Mason","ForeName":"Jennifer","Initials":"J"},{"@attributes":{"ValidYN":"Y"},"LastName":"Beckett","ForeName":"Laurel","Initials":"L"},{"@attributes":{"ValidYN":"Y"},"LastName":"Harvey","ForeName":"Danielle","Initials":"D"},{"@attributes":{"ValidYN":"Y"},"LastName":"Donohue","ForeName":"Michael","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Jack","ForeName":"Clifford R","Initials":"CR","Suffix":"Jr"},{"@attributes":{"ValidYN":"Y"},"LastName":"Bernstein","ForeName":"Matthew","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Fox","ForeName":"Rochester Nick","Initials":"RN"},{"@attributes":{"ValidYN":"Y"},"LastName":"Thompson","ForeName":"Paul","Initials":"P"},{"@attributes":{"ValidYN":"Y"},"LastName":"Schuff","ForeName":"Norbert","Initials":"N"},{"@attributes":{"ValidYN":"Y"},"LastName":"DeCArli","ForeName":"Charles","Initials":"C"},{"@attributes":{"ValidYN":"Y"},"LastName":"Borowski","ForeName":"Bret","Initials":"B"},{"@attributes":{"ValidYN":"Y"},"LastName":"Gunter","ForeName":"Jeff","Initials":"J"},{"@attributes":{"ValidYN":"Y"},"LastName":"Senjem","ForeName":"Matt","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Jones","ForeName":"David","Initials":"D"},{"@attributes":{"ValidYN":"Y"},"LastName":"Jagust","ForeName":"William","Initials":"W"},{"@attributes":{"ValidYN":"Y"},"LastName":"Toga","ForeName":"Arthur W","Initials":"AW"},{"@attributes":{"ValidYN":"Y"},"LastName":"Koeppe","ForeName":"Robert A","Initials":"RA"},{"@attributes":{"ValidYN":"Y"},"LastName":"Foster","ForeName":"Norm","Initials":"N"},{"@attributes":{"ValidYN":"Y"},"LastName":"Reiman","ForeName":"Eric M","Initials":"EM"},{"@attributes":{"ValidYN":"Y"},"LastName":"Chen","ForeName":"Kewei","Initials":"K"},{"@attributes":{"ValidYN":"Y"},"LastName":"Mathis","ForeName":"Chet","Initials":"C"},{"@attributes":{"ValidYN":"Y"},"LastName":"Crawford","ForeName":"Karen","Initials":"K"},{"@attributes":{"ValidYN":"Y"},"LastName":"Cairns","ForeName":"Nigel J","Initials":"NJ"},{"@attributes":{"ValidYN":"Y"},"LastName":"Shaw","ForeName":"Leslie M","Initials":"LM"},{"@attributes":{"ValidYN":"Y"},"LastName":"Lee","ForeName":"Virginia","Initials":"V"},{"@attributes":{"ValidYN":"Y"},"LastName":"Korecka","ForeName":"Magdalena","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Figurski","ForeName":"Michal","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Neu","ForeName":"Scott","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"Saykin","ForeName":"Andrew J","Initials":"AJ"},{"@attributes":{"ValidYN":"Y"},"LastName":"Foroud","ForeName":"Tatiana M","Initials":"TM"},{"@attributes":{"ValidYN":"Y"},"LastName":"Potkin","ForeName":"Steven","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"Faber","ForeName":"Kelley","Initials":"K"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kim","ForeName":"Sungeun","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"Weiner","ForeName":"Michael W","Initials":"MW"},{"@attributes":{"ValidYN":"Y"},"LastName":"Khachaturian","ForeName":"Zaven","Initials":"Z"},{"@attributes":{"ValidYN":"Y"},"LastName":"Thal","ForeName":"Leon","Initials":"L"},{"@attributes":{"ValidYN":"Y"},"LastName":"Weiner","ForeName":"Michael W","Initials":"MW"},{"@attributes":{"ValidYN":"Y"},"LastName":"Snyder","ForeName":"Peter J","Initials":"PJ"},{"@attributes":{"ValidYN":"Y"},"LastName":"Potter","ForeName":"William","Initials":"W"},{"@attributes":{"ValidYN":"Y"},"LastName":"Paul","ForeName":"Steven","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"Albert","ForeName":"Marylyn","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Frank","ForeName":"Richard","Initials":"R"},{"@attributes":{"ValidYN":"Y"},"LastName":"Khachaturian","ForeName":"Zaven","Initials":"Z"},{"@attributes":{"ValidYN":"Y"},"LastName":"Hsiao","ForeName":"John","Initials":"J"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kaye","ForeName":"Jeffrey","Initials":"J"},{"@attributes":{"ValidYN":"Y"},"LastName":"Quinn","ForeName":"Joseph","Initials":"J"},{"@attributes":{"ValidYN":"Y"},"LastName":"Silbert","ForeName":"Lisa","Initials":"L"},{"@attributes":{"ValidYN":"Y"},"LastName":"Lind","ForeName":"Betty","Initials":"B"},{"@attributes":{"ValidYN":"Y"},"LastName":"Carter","ForeName":"Raina","Initials":"R"},{"@attributes":{"ValidYN":"Y"},"LastName":"Dolen","ForeName":"Sara","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"Schneider","ForeName":"Lon S","Initials":"LS"},{"@attributes":{"ValidYN":"Y"},"LastName":"Pawluczyk","ForeName":"Sonia","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"Beccera","ForeName":"Mauricio","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Cerbone","ForeName":"Brittany","Initials":"B"},{"@attributes":{"ValidYN":"Y"},"LastName":"Spann","ForeName":"Bryan M","Initials":"BM"},{"@attributes":{"ValidYN":"Y"},"LastName":"Brewer","ForeName":"James","Initials":"J"},{"@attributes":{"ValidYN":"Y"},"LastName":"Vanderswag","ForeName":"Helen","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Fleisher","ForeName":"Adam","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Heidebrink","ForeName":"Judith L","Initials":"JL"},{"@attributes":{"ValidYN":"Y"},"LastName":"Lord","ForeName":"Joanne L","Initials":"JL"},{"@attributes":{"ValidYN":"Y"},"LastName":"Petersen","ForeName":"Ronald","Initials":"R"},{"@attributes":{"ValidYN":"Y"},"LastName":"Mason","ForeName":"Sara S","Initials":"SS"},{"@attributes":{"ValidYN":"Y"},"LastName":"Albers","ForeName":"Colleen S","Initials":"CS"},{"@attributes":{"ValidYN":"Y"},"LastName":"Knopman","ForeName":"David","Initials":"D"},{"@attributes":{"ValidYN":"Y"},"LastName":"Johnson","ForeName":"Kris","Initials":"K"},{"@attributes":{"ValidYN":"Y"},"LastName":"Doody","ForeName":"Rachelle S","Initials":"RS"},{"@attributes":{"ValidYN":"Y"},"LastName":"Villanueva-Meyer","ForeName":"Javier","Initials":"J"},{"@attributes":{"ValidYN":"Y"},"LastName":"Chowdhury","ForeName":"Munir","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Rountree","ForeName":"Susan","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"Dang","ForeName":"Mimi","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Stern","ForeName":"Yaakov","Initials":"Y"},{"@attributes":{"ValidYN":"Y"},"LastName":"Honig","ForeName":"Lawrence S","Initials":"LS"},{"@attributes":{"ValidYN":"Y"},"LastName":"Bell","ForeName":"Karen L","Initials":"KL"},{"@attributes":{"ValidYN":"Y"},"LastName":"Morris","ForeName":"John C","Initials":"JC"},{"@attributes":{"ValidYN":"Y"},"LastName":"Carroll","ForeName":"Maria","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Creech","ForeName":"Mary L","Initials":"ML"},{"@attributes":{"ValidYN":"Y"},"LastName":"Franklin","ForeName":"Erin","Initials":"E"},{"@attributes":{"ValidYN":"Y"},"LastName":"Mintun","ForeName":"Mark A","Initials":"MA"},{"@attributes":{"ValidYN":"Y"},"LastName":"Schneider","ForeName":"Stacy","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"Oliver","ForeName":"Angela","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Marson","ForeName":"Daniel","Initials":"D"},{"@attributes":{"ValidYN":"Y"},"LastName":"Griffith","ForeName":"Randall","Initials":"R"},{"@attributes":{"ValidYN":"Y"},"LastName":"Clark","ForeName":"David","Initials":"D"},{"@attributes":{"ValidYN":"Y"},"LastName":"Geldmacher","ForeName":"David","Initials":"D"},{"@attributes":{"ValidYN":"Y"},"LastName":"Brockington","ForeName":"John","Initials":"J"},{"@attributes":{"ValidYN":"Y"},"LastName":"Roberson","ForeName":"Erik","Initials":"E"},{"@attributes":{"ValidYN":"Y"},"LastName":"Love","ForeName":"Marissa Natelson","Initials":"MN"},{"@attributes":{"ValidYN":"Y"},"LastName":"Grossman","ForeName":"Hillel","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Mitsis","ForeName":"Effie","Initials":"E"},{"@attributes":{"ValidYN":"Y"},"LastName":"Shah","ForeName":"Raj C","Initials":"RC"},{"@attributes":{"ValidYN":"Y"},"LastName":"deToledo-Morrell","ForeName":"Leyla","Initials":"L"},{"@attributes":{"ValidYN":"Y"},"LastName":"Duara","ForeName":"Ranjan","Initials":"R"},{"@attributes":{"ValidYN":"Y"},"LastName":"Varon","ForeName":"Daniel","Initials":"D"},{"@attributes":{"ValidYN":"Y"},"LastName":"Greig","ForeName":"Maria T","Initials":"MT"},{"@attributes":{"ValidYN":"Y"},"LastName":"Roberts","ForeName":"Peggy","Initials":"P"},{"@attributes":{"ValidYN":"Y"},"LastName":"Albert","ForeName":"Marilyn","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Onyike","ForeName":"Chiadi","Initials":"C"},{"@attributes":{"ValidYN":"Y"},"LastName":"D'Agostino","ForeName":"Daniel","Initials":"D","Suffix":"2nd"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kielb","ForeName":"Stephanie","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"Galvin","ForeName":"James E","Initials":"JE"},{"@attributes":{"ValidYN":"Y"},"LastName":"Michel","ForeName":"Christina A","Initials":"CA"},{"@attributes":{"ValidYN":"Y"},"LastName":"Pogorelec","ForeName":"Dana M","Initials":"DM"},{"@attributes":{"ValidYN":"Y"},"LastName":"Rusinek","ForeName":"Henry","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"de Leon","ForeName":"Mony J","Initials":"MJ"},{"@attributes":{"ValidYN":"Y"},"LastName":"Glodzik","ForeName":"Lidia","Initials":"L"},{"@attributes":{"ValidYN":"Y"},"LastName":"De Santi","ForeName":"Susan","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"Doraiswamy","ForeName":"P  Murali","Initials":"P"},{"@attributes":{"ValidYN":"Y"},"LastName":"Petrella","ForeName":"Jeffrey R","Initials":"JR"},{"@attributes":{"ValidYN":"Y"},"LastName":"Borges-Neto","ForeName":"Salvador","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"Wong","ForeName":"Terence Z","Initials":"TZ"},{"@attributes":{"ValidYN":"Y"},"LastName":"Coleman","ForeName":"Edward","Initials":"E"},{"@attributes":{"ValidYN":"Y"},"LastName":"Arnold","ForeName":"Steven E","Initials":"SE"},{"@attributes":{"ValidYN":"Y"},"LastName":"Karlawish","ForeName":"Jason H","Initials":"JH"},{"@attributes":{"ValidYN":"Y"},"LastName":"Wolk","ForeName":"David","Initials":"D"},{"@attributes":{"ValidYN":"Y"},"LastName":"Clark","ForeName":"Christopher M","Initials":"CM"},{"@attributes":{"ValidYN":"Y"},"LastName":"Smith","ForeName":"Charles D","Initials":"CD"},{"@attributes":{"ValidYN":"Y"},"LastName":"Jicha","ForeName":"Greg","Initials":"G"},{"@attributes":{"ValidYN":"Y"},"LastName":"Hardy","ForeName":"Peter","Initials":"P"},{"@attributes":{"ValidYN":"Y"},"LastName":"Sinha","ForeName":"Partha","Initials":"P"},{"@attributes":{"ValidYN":"Y"},"LastName":"Oates","ForeName":"Elizabeth","Initials":"E"},{"@attributes":{"ValidYN":"Y"},"LastName":"Conrad","ForeName":"Gary","Initials":"G"},{"@attributes":{"ValidYN":"Y"},"LastName":"Lopez","ForeName":"Oscar L","Initials":"OL"},{"@attributes":{"ValidYN":"Y"},"LastName":"Oakley","ForeName":"MaryAnn","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Simpson","ForeName":"Donna M","Initials":"DM"},{"@attributes":{"ValidYN":"Y"},"LastName":"Porsteinsson","ForeName":"Anton P","Initials":"AP"},{"@attributes":{"ValidYN":"Y"},"LastName":"Goldstein","ForeName":"Bonnie S","Initials":"BS"},{"@attributes":{"ValidYN":"Y"},"LastName":"Martin","ForeName":"Kim","Initials":"K"},{"@attributes":{"ValidYN":"Y"},"LastName":"Makino","ForeName":"Kelly M","Initials":"KM"},{"@attributes":{"ValidYN":"Y"},"LastName":"Ismail","ForeName":"M  Saleem","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Mulnard","ForeName":"Ruth A","Initials":"RA"},{"@attributes":{"ValidYN":"Y"},"LastName":"Mc-Adams-Ortiz","ForeName":"Catherine","Initials":"C"},{"@attributes":{"ValidYN":"Y"},"LastName":"Womack","ForeName":"Kyle","Initials":"K"},{"@attributes":{"ValidYN":"Y"},"LastName":"Mathews","ForeName":"Dana","Initials":"D"},{"@attributes":{"ValidYN":"Y"},"LastName":"Quiceno","ForeName":"Mary","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Levey","ForeName":"Allan I","Initials":"AI"},{"@attributes":{"ValidYN":"Y"},"LastName":"Lah","ForeName":"James J","Initials":"JJ"},{"@attributes":{"ValidYN":"Y"},"LastName":"Cellar","ForeName":"Janet S","Initials":"JS"},{"@attributes":{"ValidYN":"Y"},"LastName":"Burns","ForeName":"Jeffrey M","Initials":"JM"},{"@attributes":{"ValidYN":"Y"},"LastName":"Swerdlow","ForeName":"Russell H","Initials":"RH"},{"@attributes":{"ValidYN":"Y"},"LastName":"Brooks","ForeName":"William M","Initials":"WM"},{"@attributes":{"ValidYN":"Y"},"LastName":"Apostolova","ForeName":"Liana","Initials":"L"},{"@attributes":{"ValidYN":"Y"},"LastName":"Tingus","ForeName":"Kathleen","Initials":"K"},{"@attributes":{"ValidYN":"Y"},"LastName":"Woo","ForeName":"Ellen","Initials":"E"},{"@attributes":{"ValidYN":"Y"},"LastName":"Silverman","ForeName":"Daniel H S","Initials":"DH"},{"@attributes":{"ValidYN":"Y"},"LastName":"Lu","ForeName":"Po H","Initials":"PH"},{"@attributes":{"ValidYN":"Y"},"LastName":"Bartzokis","ForeName":"George","Initials":"G"},{"@attributes":{"ValidYN":"Y"},"LastName":"Graff-Radford","ForeName":"Neill R","Initials":"NR"},{"@attributes":{"ValidYN":"Y"},"LastName":"Parfitt","ForeName":"Francine","Initials":"F"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kendall","ForeName":"Tracy","Initials":"T"},{"@attributes":{"ValidYN":"Y"},"LastName":"Johnson","ForeName":"Heather","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Farlow","ForeName":"Martin R","Initials":"MR"},{"@attributes":{"ValidYN":"Y"},"LastName":"Hake","ForeName":"Ann Marie","Initials":"AM"},{"@attributes":{"ValidYN":"Y"},"LastName":"Matthews","ForeName":"Brandy R","Initials":"BR"},{"@attributes":{"ValidYN":"Y"},"LastName":"Brosch","ForeName":"Jared R","Initials":"JR"},{"@attributes":{"ValidYN":"Y"},"LastName":"Hunt","ForeName":"Cynthia","Initials":"C"},{"@attributes":{"ValidYN":"Y"},"LastName":"van Dyck","ForeName":"Christopher H","Initials":"CH"},{"@attributes":{"ValidYN":"Y"},"LastName":"Carson","ForeName":"Richard E","Initials":"RE"},{"@attributes":{"ValidYN":"Y"},"LastName":"MacAvoy","ForeName":"Martha G","Initials":"MG"},{"@attributes":{"ValidYN":"Y"},"LastName":"Varma","ForeName":"Pradeep","Initials":"P"},{"@attributes":{"ValidYN":"Y"},"LastName":"Chertkow","ForeName":"Howard","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Bergman","ForeName":"Howard","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Hosein","ForeName":"Chris","Initials":"C"},{"@attributes":{"ValidYN":"Y"},"LastName":"Black","ForeName":"Sandra","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"Stefanovic","ForeName":"Bojana","Initials":"B"},{"@attributes":{"ValidYN":"Y"},"LastName":"Caldwell","ForeName":"Curtis","Initials":"C"},{"@attributes":{"ValidYN":"Y"},"LastName":"Hsiung","ForeName":"Robin","Initials":"R"},{"@attributes":{"ValidYN":"Y"},"LastName":"Feldman","ForeName":"Howard","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Mudge","ForeName":"Benita","Initials":"B"},{"@attributes":{"ValidYN":"Y"},"LastName":"Assaly","ForeName":"Michele","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Finger","ForeName":"Elizabeth","Initials":"E"},{"@attributes":{"ValidYN":"Y"},"LastName":"Pasternack","ForeName":"Stephen","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"Rachisky","ForeName":"Irina","Initials":"I"},{"@attributes":{"ValidYN":"Y"},"LastName":"Trost","ForeName":"Dick","Initials":"D"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kertesz","ForeName":"Andrew","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Center","ForeName":"Lou Ruvo","Initials":"LR"},{"@attributes":{"ValidYN":"Y"},"LastName":"Bernick","ForeName":"Charles","Initials":"C"},{"@attributes":{"ValidYN":"Y"},"LastName":"Munic","ForeName":"Donna","Initials":"D"},{"@attributes":{"ValidYN":"Y"},"LastName":"Mesulam","ForeName":"Marek-Marsel","Initials":"MM"},{"@attributes":{"ValidYN":"Y"},"LastName":"Lipowski","ForeName":"Kristine","Initials":"K"},{"@attributes":{"ValidYN":"Y"},"LastName":"Weintraub","ForeName":"Sandra","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"Bonakdarpour","ForeName":"Borna","Initials":"B"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kerwin","ForeName":"Diana","Initials":"D"},{"@attributes":{"ValidYN":"Y"},"LastName":"Wu","ForeName":"Chuang-Kuo","Initials":"CK"},{"@attributes":{"ValidYN":"Y"},"LastName":"Johnson","ForeName":"Nancy","Initials":"N"},{"@attributes":{"ValidYN":"Y"},"LastName":"Sadowsky","ForeName":"Carl","Initials":"C"},{"@attributes":{"ValidYN":"Y"},"LastName":"Villena","ForeName":"Teresa","Initials":"T"},{"@attributes":{"ValidYN":"Y"},"LastName":"Turner","ForeName":"Raymond Scott","Initials":"RS"},{"@attributes":{"ValidYN":"Y"},"LastName":"Johnson","ForeName":"Kathleen","Initials":"K"},{"@attributes":{"ValidYN":"Y"},"LastName":"Reynolds","ForeName":"Brigid","Initials":"B"},{"@attributes":{"ValidYN":"Y"},"LastName":"Sperling","ForeName":"Reisa A","Initials":"RA"},{"@attributes":{"ValidYN":"Y"},"LastName":"Johnson","ForeName":"Keith A","Initials":"KA"},{"@attributes":{"ValidYN":"Y"},"LastName":"Marshall","ForeName":"Gad","Initials":"G"},{"@attributes":{"ValidYN":"Y"},"LastName":"Yesavage","ForeName":"Jerome","Initials":"J"},{"@attributes":{"ValidYN":"Y"},"LastName":"Taylor","ForeName":"Joy L","Initials":"JL"},{"@attributes":{"ValidYN":"Y"},"LastName":"Lane","ForeName":"Barton","Initials":"B"},{"@attributes":{"ValidYN":"Y"},"LastName":"Rosen","ForeName":"Allyson","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Tinklenberg","ForeName":"Jared","Initials":"J"},{"@attributes":{"ValidYN":"Y"},"LastName":"Sabbagh","ForeName":"Marwan N","Initials":"MN"},{"@attributes":{"ValidYN":"Y"},"LastName":"Belden","ForeName":"Christine M","Initials":"CM"},{"@attributes":{"ValidYN":"Y"},"LastName":"Jacobson","ForeName":"Sandra A","Initials":"SA"},{"@attributes":{"ValidYN":"Y"},"LastName":"Sirrel","ForeName":"Sherye A","Initials":"SA"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kowall","ForeName":"Neil","Initials":"N"},{"@attributes":{"ValidYN":"Y"},"LastName":"Killiany","ForeName":"Ronald","Initials":"R"},{"@attributes":{"ValidYN":"Y"},"LastName":"Budson","ForeName":"Andrew E","Initials":"AE"},{"@attributes":{"ValidYN":"Y"},"LastName":"Norbash","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Johnson","ForeName":"Patricia Lynn","Initials":"PL"},{"@attributes":{"ValidYN":"Y"},"LastName":"Obisesan","ForeName":"Thomas O","Initials":"TO"},{"@attributes":{"ValidYN":"Y"},"LastName":"Allard","ForeName":"Joanne","Initials":"J"},{"@attributes":{"ValidYN":"Y"},"LastName":"Lerner","ForeName":"Alan","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Ogrocki","ForeName":"Paula","Initials":"P"},{"@attributes":{"ValidYN":"Y"},"LastName":"Tatsuoka","ForeName":"Curtis","Initials":"C"},{"@attributes":{"ValidYN":"Y"},"LastName":"Fatica","ForeName":"Parianne","Initials":"P"},{"@attributes":{"ValidYN":"Y"},"LastName":"Fletcher","ForeName":"Evan","Initials":"E"},{"@attributes":{"ValidYN":"Y"},"LastName":"Maillard","ForeName":"Pauline","Initials":"P"},{"@attributes":{"ValidYN":"Y"},"LastName":"Olichney","ForeName":"John","Initials":"J"},{"@attributes":{"ValidYN":"Y"},"LastName":"DeCarli","ForeName":"Charles","Initials":"C"},{"@attributes":{"ValidYN":"Y"},"LastName":"Carmichael","ForeName":"Owen","Initials":"O"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kittur","ForeName":"Smita","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"Borrie","ForeName":"Michael","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Bartha","ForeName":"Rob","Initials":"R"},{"@attributes":{"ValidYN":"Y"},"LastName":"Johnson","ForeName":"Sterling","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"Asthana","ForeName":"Sanjay","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"Carlsson","ForeName":"Cynthia M","Initials":"CM"},{"@attributes":{"ValidYN":"Y"},"LastName":"Potkin","ForeName":"Steven G","Initials":"SG"},{"@attributes":{"ValidYN":"Y"},"LastName":"Preda","ForeName":"Adrian","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Nguyen","ForeName":"Dana","Initials":"D"},{"@attributes":{"ValidYN":"Y"},"LastName":"Tariot","ForeName":"Pierre","Initials":"P"},{"@attributes":{"ValidYN":"Y"},"LastName":"Burke","ForeName":"Anna","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Trncic","ForeName":"Nadira","Initials":"N"},{"@attributes":{"ValidYN":"Y"},"LastName":"Fleisher","ForeName":"Adam","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Reeder","ForeName":"Stephanie","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"Bates","ForeName":"Vernice","Initials":"V"},{"@attributes":{"ValidYN":"Y"},"LastName":"Capote","ForeName":"Horacio","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Rainka","ForeName":"Michelle","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Scharre","ForeName":"Douglas W","Initials":"DW"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kataki","ForeName":"Maria","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Adeli","ForeName":"Anahita","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Zimmerman","ForeName":"Earl A","Initials":"EA"},{"@attributes":{"ValidYN":"Y"},"LastName":"Celmins","ForeName":"Dzintra","Initials":"D"},{"@attributes":{"ValidYN":"Y"},"LastName":"Brown","ForeName":"Alice D","Initials":"AD"},{"@attributes":{"ValidYN":"Y"},"LastName":"Pearlson","ForeName":"Godfrey D","Initials":"GD"},{"@attributes":{"ValidYN":"Y"},"LastName":"Blank","ForeName":"Karen","Initials":"K"},{"@attributes":{"ValidYN":"Y"},"LastName":"Anderson","ForeName":"Karen","Initials":"K"},{"@attributes":{"ValidYN":"Y"},"LastName":"Gordineer","ForeName":"Leslie","Initials":"L"},{"@attributes":{"ValidYN":"Y"},"LastName":"Flashman","ForeName":"Laura A","Initials":"LA"},{"@attributes":{"ValidYN":"Y"},"LastName":"Seltzer","ForeName":"Marc","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Hynes","ForeName":"Mary L","Initials":"ML"},{"@attributes":{"ValidYN":"Y"},"LastName":"Santulli","ForeName":"Robert B","Initials":"RB"},{"@attributes":{"ValidYN":"Y"},"LastName":"Sink","ForeName":"Kaycee M","Initials":"KM"},{"@attributes":{"ValidYN":"Y"},"LastName":"Williamson","ForeName":"Jeff D","Initials":"JD"},{"@attributes":{"ValidYN":"Y"},"LastName":"Garg","ForeName":"Pradeep","Initials":"P"},{"@attributes":{"ValidYN":"Y"},"LastName":"Watkins","ForeName":"Franklin","Initials":"F"},{"@attributes":{"ValidYN":"Y"},"LastName":"Ott","ForeName":"Brian R","Initials":"BR"},{"@attributes":{"ValidYN":"Y"},"LastName":"Querfurth","ForeName":"Henry","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Tremont","ForeName":"Geoffrey","Initials":"G"},{"@attributes":{"ValidYN":"Y"},"LastName":"Salloway","ForeName":"Stephen","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"Malloy","ForeName":"Paul","Initials":"P"},{"@attributes":{"ValidYN":"Y"},"LastName":"Correia","ForeName":"Stephen","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"Rosen","ForeName":"Howard J","Initials":"HJ"},{"@attributes":{"ValidYN":"Y"},"LastName":"Miller","ForeName":"Bruce L","Initials":"BL"},{"@attributes":{"ValidYN":"Y"},"LastName":"Perry","ForeName":"David","Initials":"D"},{"@attributes":{"ValidYN":"Y"},"LastName":"Mintzer","ForeName":"Jacobo","Initials":"J"},{"@attributes":{"ValidYN":"Y"},"LastName":"Spicer","ForeName":"Kenneth","Initials":"K"},{"@attributes":{"ValidYN":"Y"},"LastName":"Bachman","ForeName":"David","Initials":"D"},{"@attributes":{"ValidYN":"Y"},"LastName":"Pasternak","ForeName":"Stephen","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"Rachinsky","ForeName":"Irina","Initials":"I"},{"@attributes":{"ValidYN":"Y"},"LastName":"Rogers","ForeName":"John","Initials":"J"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kertesz","ForeName":"Andrew","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Drost","ForeName":"Dick","Initials":"D"},{"@attributes":{"ValidYN":"Y"},"LastName":"Hernando","ForeName":"Raymundo","Initials":"R"},{"@attributes":{"ValidYN":"Y"},"LastName":"Sarrael","ForeName":"Antero","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Schultz","ForeName":"Susan K","Initials":"SK"},{"@attributes":{"ValidYN":"Y"},"LastName":"Ponto","ForeName":"Laura L  Boles","Initials":"LL"},{"@attributes":{"ValidYN":"Y"},"LastName":"Shim","ForeName":"Hyungsub","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Smith","ForeName":"Karen Ekstam","Initials":"KE"},{"@attributes":{"ValidYN":"Y"},"LastName":"Relkin","ForeName":"Norman","Initials":"N"},{"@attributes":{"ValidYN":"Y"},"LastName":"Chaing","ForeName":"Gloria","Initials":"G"},{"@attributes":{"ValidYN":"Y"},"LastName":"Lin","ForeName":"Michael","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Ravdin","ForeName":"Lisa","Initials":"L"},{"@attributes":{"ValidYN":"Y"},"LastName":"Smith","ForeName":"Amanda","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Raj","ForeName":"Balebail Ashok","Initials":"BA"},{"@attributes":{"ValidYN":"Y"},"LastName":"Fargher","ForeName":"Kristin","Initials":"K"},{"@attributes":{"ValidYN":"Y"},"LastName":"Weiner","ForeName":"Michael W","Initials":"MW"},{"@attributes":{"ValidYN":"Y"},"LastName":"Aisen","ForeName":"Paul","Initials":"P"},{"@attributes":{"ValidYN":"Y"},"LastName":"Weiner","ForeName":"Michael","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Aisen","ForeName":"Paul","Initials":"P"},{"@attributes":{"ValidYN":"Y"},"LastName":"Green","ForeName":"Rochester Robert C","Initials":"RR"},{"@attributes":{"ValidYN":"Y"},"LastName":"Harvey","ForeName":"Danielle","Initials":"D"},{"@attributes":{"ValidYN":"Y"},"LastName":"Jack","ForeName":"Clifford R","Initials":"CR","Suffix":"Jr"},{"@attributes":{"ValidYN":"Y"},"LastName":"Jagust","ForeName":"Rochester William","Initials":"RW"},{"@attributes":{"ValidYN":"Y"},"LastName":"Saykin","ForeName":"Andrew J","Initials":"AJ"},{"@attributes":{"ValidYN":"Y"},"LastName":"Shaw","ForeName":"Leslie M","Initials":"LM"},{"@attributes":{"ValidYN":"Y"},"LastName":"Trojanowki","ForeName":"John Q","Initials":"JQ"},{"@attributes":{"ValidYN":"Y"},"LastName":"Neylan","ForeName":"Thomas","Initials":"T"},{"@attributes":{"ValidYN":"Y"},"LastName":"Grafman","ForeName":"Jordan","Initials":"J"},{"@attributes":{"ValidYN":"Y"},"LastName":"Green","ForeName":"Robert C","Initials":"RC"},{"@attributes":{"ValidYN":"Y"},"LastName":"Montine","ForeName":"Tom","Initials":"T"},{"@attributes":{"ValidYN":"Y"},"LastName":"Weiner","ForeName":"Michael","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Petersen","ForeName":"Ronald","Initials":"R"},{"@attributes":{"ValidYN":"Y"},"LastName":"Aisen","ForeName":"Paul","Initials":"P"},{"@attributes":{"ValidYN":"Y"},"LastName":"Thomas","ForeName":"Ronald G","Initials":"RG"},{"@attributes":{"ValidYN":"Y"},"LastName":"Sather","ForeName":"Tamie","Initials":"T"},{"@attributes":{"ValidYN":"Y"},"LastName":"Morrison","ForeName":"Rosemary","Initials":"R"},{"@attributes":{"ValidYN":"Y"},"LastName":"Jiminez","ForeName":"Gus","Initials":"G"},{"@attributes":{"ValidYN":"Y"},"LastName":"Neylan","ForeName":"Thomas","Initials":"T"},{"@attributes":{"ValidYN":"Y"},"LastName":"Harvey","ForeName":"Danielle","Initials":"D"},{"@attributes":{"ValidYN":"Y"},"LastName":"Donohue","ForeName":"Michael","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Jack","ForeName":"Clifford R","Initials":"CR","Suffix":"Jr"},{"@attributes":{"ValidYN":"Y"},"LastName":"Bernstein","ForeName":"Matthew","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Borowski","ForeName":"Bret","Initials":"B"},{"@attributes":{"ValidYN":"Y"},"LastName":"Gunter","ForeName":"Jeff","Initials":"J"},{"@attributes":{"ValidYN":"Y"},"LastName":"Senjem","ForeName":"Matt","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Jagust","ForeName":"William","Initials":"W"},{"@attributes":{"ValidYN":"Y"},"LastName":"Koeppe","ForeName":"Robert A","Initials":"RA"},{"@attributes":{"ValidYN":"Y"},"LastName":"Reiman","ForeName":"Eric M","Initials":"EM"},{"@attributes":{"ValidYN":"Y"},"LastName":"Chen","ForeName":"Kewei","Initials":"K"},{"@attributes":{"ValidYN":"Y"},"LastName":"Landau","ForeName":"Susan","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"Crawford","ForeName":"Karen","Initials":"K"},{"@attributes":{"ValidYN":"Y"},"LastName":"Cairns","ForeName":"Nigel J","Initials":"NJ"},{"@attributes":{"ValidYN":"Y"},"LastName":"Householder","ForeName":"Erin","Initials":"E"},{"@attributes":{"ValidYN":"Y"},"LastName":"Shaw","ForeName":"Leslie M","Initials":"LM"},{"@attributes":{"ValidYN":"Y"},"LastName":"Trojanowki","ForeName":"John Q","Initials":"JQ"},{"@attributes":{"ValidYN":"Y"},"LastName":"Lee","ForeName":"Virginia","Initials":"V"},{"@attributes":{"ValidYN":"Y"},"LastName":"Korecka","ForeName":"Magdalena","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Figurski","ForeName":"Michal","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Neu","ForeName":"Scott","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"Saykin","ForeName":"Andrew J","Initials":"AJ"},{"@attributes":{"ValidYN":"Y"},"LastName":"Foroud","ForeName":"Tatiana M","Initials":"TM"},{"@attributes":{"ValidYN":"Y"},"LastName":"Potkin","ForeName":"Steven","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"Faber","ForeName":"Kelley","Initials":"K"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kim","ForeName":"Sungeun","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"Weiner","ForeName":"Michael W","Initials":"MW"},{"@attributes":{"ValidYN":"Y"},"LastName":"Schneider","ForeName":"Lon S","Initials":"LS"},{"@attributes":{"ValidYN":"Y"},"LastName":"Pawluczyk","ForeName":"Sonia","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"Brewer","ForeName":"James","Initials":"J"},{"@attributes":{"ValidYN":"Y"},"LastName":"Vanderswag","ForeName":"Helen","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Stern","ForeName":"Yaakov","Initials":"Y"},{"@attributes":{"ValidYN":"Y"},"LastName":"Honig","ForeName":"Lawrence S","Initials":"LS"},{"@attributes":{"ValidYN":"Y"},"LastName":"Bell","ForeName":"Karen L","Initials":"KL"},{"@attributes":{"ValidYN":"Y"},"LastName":"Fleischman","ForeName":"Debra","Initials":"D"},{"@attributes":{"ValidYN":"Y"},"LastName":"Arfanakis","ForeName":"Konstantinos","Initials":"K"},{"@attributes":{"ValidYN":"Y"},"LastName":"Shah","ForeName":"Raj C","Initials":"RC"},{"@attributes":{"ValidYN":"Y"},"LastName":"Duara","ForeName":"Ranjan","Initials":"R"},{"@attributes":{"ValidYN":"Y"},"LastName":"Varon","ForeName":"Daniel","Initials":"D"},{"@attributes":{"ValidYN":"Y"},"LastName":"Greig","ForeName":"Maria T","Initials":"MT"},{"@attributes":{"ValidYN":"Y"},"LastName":"Doraiswamy","ForeName":"P  Murali","Initials":"P"},{"@attributes":{"ValidYN":"Y"},"LastName":"Petrella","ForeName":"Jeffrey R","Initials":"JR"},{"@attributes":{"ValidYN":"Y"},"LastName":"James","ForeName":"Olga","Initials":"O"},{"@attributes":{"ValidYN":"Y"},"LastName":"Porsteinsson","ForeName":"Anton P","Initials":"AP"},{"@attributes":{"ValidYN":"Y"},"LastName":"Goldstein","ForeName":"Bonnie","Initials":"B"},{"@attributes":{"ValidYN":"Y"},"LastName":"Martin","ForeName":"Kimberly S","Initials":"KS"},{"@attributes":{"ValidYN":"Y"},"LastName":"Mulnard","ForeName":"Ruth A","Initials":"RA"},{"@attributes":{"ValidYN":"Y"},"LastName":"McAdams-Ortiz","ForeName":"Catherine","Initials":"C"},{"@attributes":{"ValidYN":"Y"},"LastName":"Mintzer","ForeName":"Jacobo","Initials":"J"},{"@attributes":{"ValidYN":"Y"},"LastName":"Massoglia","ForeName":"Dino","Initials":"D"},{"@attributes":{"ValidYN":"Y"},"LastName":"Brawman-Mintzer","ForeName":"Olga","Initials":"O"},{"@attributes":{"ValidYN":"Y"},"LastName":"Sadowsky","ForeName":"Carl","Initials":"C"},{"@attributes":{"ValidYN":"Y"},"LastName":"Martinez","ForeName":"Walter","Initials":"W"},{"@attributes":{"ValidYN":"Y"},"LastName":"Villena","ForeName":"Teresa","Initials":"T"},{"@attributes":{"ValidYN":"Y"},"LastName":"Jagust","ForeName":"William","Initials":"W"},{"@attributes":{"ValidYN":"Y"},"LastName":"Landau","ForeName":"Susan","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"Rosen","ForeName":"Howard","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Perry","ForeName":"David","Initials":"D"},{"@attributes":{"ValidYN":"Y"},"LastName":"Turner","ForeName":"Raymond Scott","Initials":"RS"},{"@attributes":{"ValidYN":"Y"},"LastName":"Behan","ForeName":"Kelly","Initials":"K"},{"@attributes":{"ValidYN":"Y"},"LastName":"Reynolds","ForeName":"Brigid","Initials":"B"},{"@attributes":{"ValidYN":"Y"},"LastName":"Sperling","ForeName":"Reisa A","Initials":"RA"},{"@attributes":{"ValidYN":"Y"},"LastName":"Johnson","ForeName":"Keith A","Initials":"KA"},{"@attributes":{"ValidYN":"Y"},"LastName":"Marshall","ForeName":"Gad","Initials":"G"},{"@attributes":{"ValidYN":"Y"},"LastName":"Sabbagh","ForeName":"Marwan N","Initials":"MN"},{"@attributes":{"ValidYN":"Y"},"LastName":"Jacobson","ForeName":"Sandra A","Initials":"SA"},{"@attributes":{"ValidYN":"Y"},"LastName":"Sirrel","ForeName":"Sherye A","Initials":"SA"},{"@attributes":{"ValidYN":"Y"},"LastName":"Obisesan","ForeName":"Thomas O","Initials":"TO"},{"@attributes":{"ValidYN":"Y"},"LastName":"Allard","ForeName":"Joanne","Initials":"J"},{"@attributes":{"ValidYN":"Y"},"LastName":"Johnson","ForeName":"Sterling C","Initials":"SC"},{"@attributes":{"ValidYN":"Y"},"LastName":"Fruehling","ForeName":"J  Jay","Initials":"J"},{"@attributes":{"ValidYN":"Y"},"LastName":"Harding","ForeName":"M A  Sandra","Initials":"MA"},{"@attributes":{"ValidYN":"Y"},"LastName":"Peskind","ForeName":"Elaine R","Initials":"ER"},{"@attributes":{"ValidYN":"Y"},"LastName":"Petrie","ForeName":"Eric C","Initials":"EC"},{"@attributes":{"ValidYN":"Y"},"LastName":"Li","ForeName":"Gail","Initials":"G"},{"@attributes":{"ValidYN":"Y"},"LastName":"Yesavage","ForeName":"Jerome A","Initials":"JA"},{"@attributes":{"ValidYN":"Y"},"LastName":"Taylor","ForeName":"Joy L","Initials":"JL"},{"@attributes":{"ValidYN":"Y"},"LastName":"Chao","ForeName":"Steven","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"Relkin","ForeName":"Norman","Initials":"N"},{"@attributes":{"ValidYN":"Y"},"LastName":"Chaing","ForeName":"Gloria","Initials":"G"},{"@attributes":{"ValidYN":"Y"},"LastName":"Ravdin","ForeName":"Lisa","Initials":"L"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2014","Month":"09","Day":"25"},{"@attributes":{"PubStatus":"accepted"},"Year":"2015","Month":"02","Day":"12"},{"@attributes":{"PubStatus":"entrez"},"Year":"2015","Month":"4","Day":"29","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2015","Month":"4","Day":"29","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2015","Month":"12","Day":"30","Hour":"6","Minute":"0"}]},"PublicationStatus":"epublish","ArticleIdList":{"ArticleId":["25919662","10.1371\/journal.pone.0122731","PONE-D-14-42500","PMC4412726"]},"ReferenceList":{"Reference":[{"Citation":"Radiother Oncol. 2013 Jan;106(1):124-9","ArticleIdList":{"ArticleId":"23127772"}},{"Citation":"Bioinformatics. 2010 Feb 1;26(3):440-3","ArticleIdList":{"ArticleId":"19880370"}},{"Citation":"Neuroimage. 2011 May 15;56(2):766-81","ArticleIdList":{"ArticleId":"20542124"}},{"Citation":"Multivariate Behav Res. 2013 Jan;48(1):28-56","ArticleIdList":{"ArticleId":"26789208"}},{"Citation":"Radiology. 2009 Apr;251(1):195-205","ArticleIdList":{"ArticleId":"19201945"}},{"Citation":"Behav Neurol. 2009;21(1):101-15","ArticleIdList":{"ArticleId":"19847049"}},{"Citation":"Neurosci Lett. 2009 Aug 28;460(2):108-11","ArticleIdList":{"ArticleId":"19454303"}},{"Citation":"J Neurosci. 2010 Feb 10;30(6):2088-101","ArticleIdList":{"ArticleId":"20147537"}},{"Citation":"Lancet Neurol. 2007 Aug;6(8):734-46","ArticleIdList":{"ArticleId":"17616482"}},{"Citation":"Neuroimage. 2011 Apr 1;55(3):856-67","ArticleIdList":{"ArticleId":"21236349"}},{"Citation":"Eur J Nucl Med Mol Imaging. 2014 Aug;41(8):1501-10","ArticleIdList":{"ArticleId":"24806110"}},{"Citation":"J Cereb Blood Flow Metab. 2005 Nov;25(11):1528-47","ArticleIdList":{"ArticleId":"15944649"}},{"Citation":"J Neurol. 2007 Dec;254(12):1666-75","ArticleIdList":{"ArticleId":"17994313"}},{"Citation":"Phys Med Biol. 2012 Aug 7;57(15):5035-55","ArticleIdList":{"ArticleId":"22805318"}},{"Citation":"Neuroimage. 2002 Jan;15(1):273-89","ArticleIdList":{"ArticleId":"11771995"}},{"Citation":"Psychiatry Res. 2008 Nov 30;164(2):143-53","ArticleIdList":{"ArticleId":"18930634"}},{"Citation":"Neuroimage. 2012 Mar;60(1):59-70","ArticleIdList":{"ArticleId":"22166797"}},{"Citation":"Neuroimage. 2013 Jan 15;65:167-75","ArticleIdList":{"ArticleId":"23041336"}},{"Citation":"Neuroimage. 2012 Apr 2;60(2):1106-16","ArticleIdList":{"ArticleId":"22270352"}},{"Citation":"Eur J Nucl Med Mol Imaging. 2008 Dec;35(12 ):2191-202","ArticleIdList":{"ArticleId":"18648805"}}]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"25833732","DateCompleted":{"Year":"2015","Month":"08","Day":"05"},"DateRevised":{"Year":"2018","Month":"12","Day":"02"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1423-0348","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"84","Issue":"3","PubDate":{"Year":"2015"}},"Title":"Psychotherapy and psychosomatics","ISOAbbreviation":"Psychother Psychosom"},"ArticleTitle":"Latent change score modeling as a method for analyzing the antidepressant effect of a psychosocial intervention in Alzheimer's disease.","Pagination":{"MedlinePgn":"159-66"},"ELocationID":"10.1159\/000376583","Abstract":{"AbstractText":["Developing and evaluating interventions for patients with age-associated disorders is a rising field in psychotherapy research. Its methodological challenges include the high between-subject variability and the wealth of influencing factors associated with longer lifetime. Latent change score modeling (LCSM), a technique based on structural equation modeling, may be well suited to analyzing longitudinal data sets obtained in clinical trials. Here, we used LCSM to evaluate the antidepressant effect of a combined cognitive behavioral\/cognitive rehabilitation (CB\/CR) intervention in Alzheimer's disease (AD).","LCSM was applied to predict the change in depressive symptoms from baseline as an outcome of the CORDIAL study, a randomized controlled trial involving 201 patients with mild AD. The participants underwent either the CORDIAL CB\/CR program or standard treatment. Using LCSM, the model best predicting changes in Geriatric Depression Scale scores was determined based on this data set.","The best fit was achieved by a model predicting a decline in depressive symptoms between before and after testing. Assignment to the intervention group as well as female gender revealed significant effects in model fit indices, which remained stable at 6- and 12-month follow-up examinations. The pre-post effect was pronounced for patients with clinically relevant depressive symptoms at baseline.","LCSM confirmed the antidepressant effect of the CORDIAL therapy program, which was limited to women. The effect was pronounced in patients with clinically relevant depressive symptoms at baseline. Methodologically, LCSM appears well suited to analyzing longitudinal data from clinical trials in aged populations, by accounting for the high between-subject variability and providing information on the differential indication of the probed intervention."]},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Werheid","ForeName":"Katja","Initials":"K","AffiliationInfo":{"Affiliation":"Clinical Gerontopsychology, Humboldt Universit\u00e4t zu Berlin, Berlin, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"K\u00f6hncke","ForeName":"Ylva","Initials":"Y"},{"@attributes":{"ValidYN":"Y"},"LastName":"Ziegler","ForeName":"Matthias","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Randomized Controlled Trial"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2015","Month":"03","Day":"28"}},"MedlineJournalInfo":{"Country":"Switzerland","MedlineTA":"Psychother Psychosom","NlmUniqueID":"0024046","ISSNLinking":"0033-3190"},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Aged, 80 and over"},{"DescriptorName":"Alzheimer Disease","QualifierName":["psychology","therapy"]},{"DescriptorName":"Cognitive Behavioral Therapy"},{"DescriptorName":"Data Interpretation, Statistical"},{"DescriptorName":"Depression","QualifierName":"therapy"},{"DescriptorName":"Female"},{"DescriptorName":"Humans"},{"DescriptorName":"Male"},{"DescriptorName":"Models, Psychological"},{"DescriptorName":"Models, Statistical"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2013","Month":"08","Day":"21"},{"@attributes":{"PubStatus":"accepted"},"Year":"2015","Month":"01","Day":"29"},{"@attributes":{"PubStatus":"entrez"},"Year":"2015","Month":"4","Day":"3","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2015","Month":"4","Day":"4","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2015","Month":"8","Day":"6","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["25833732","000376583","10.1159\/000376583"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"25791052","DateCompleted":{"Year":"2015","Month":"06","Day":"09"},"DateRevised":{"Year":"2016","Month":"12","Day":"30"},"Article":{"@attributes":{"PubModel":"Print"},"Journal":{"ISSN":"0040-5930","JournalIssue":{"@attributes":{"CitedMedium":"Print"},"Volume":"72","Issue":"4","PubDate":{"Year":"2015","Month":"Apr"}},"Title":"Therapeutische Umschau. Revue therapeutique","ISOAbbreviation":"Ther Umsch"},"ArticleTitle":"[New therapeutic approaches].","Pagination":{"MedlinePgn":"279-85"},"ELocationID":"10.1024\/0040-5930\/a000676","Abstract":{"AbstractText":"The most prevalent causes of dementia are progressive and irreversible neurodegenerative diseases of the brain. Alzheimer's disease ranks first and is follwed by Parkinson and Lewy body disease as well as the Frontotemporal lobar degenerations. These neurodegenerative processes are characterised by the production, aggregation and deposition of pathological proteins. These are \u03b2 amyloid and tau in Alzheimer's disease; \u03b1 synuclein in der Parkinson's- and Lewy body disease, and tau, TDP-43 as well as FUS in the Frontotemporal lobar degenerations. Aggregation into oligomers and fibrils and subsequent sedimentation of these proteins lead to nerve cell dysfunction, synaptic failure and ultimately to the demise of neurons. The deficits and imbalance of neurotransmitter systems which represent an important target of the current pharmacological treatment of dementia are consequences of nerve cell loss. Many of the novel treatment approaches that are being tested in clinical trials are aimed at preventing, slowing or ameliorating the production, aggregation and deposition of pathological proteins. Key strategies are inhibition of secretases which generate \u03b2 amyloid, active and passive immunisation against \u03b2 amyloid, restriction \u03b2 amyloid and tau aggregation as well as stimulation of \u03b2 amyloid clearance. In addition clinical trials are ongoing on symptomatic treatments including the simultaneous stimulation of multiple neurotransmitter systems, compensation of brain insulin resistance, and neuroprotection through certain nutrients. In addition to novel drug treatments non-pharmacological interventions are also being developed. "},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A","AffiliationInfo":{"Affiliation":"Klinik und Poliklinik f\u00fcr Psychiatrie und Psychotherapie, Klinikum rechts der Isar; Technische Universit\u00e4t M\u00fcnchen."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Grimmer","ForeName":"Timo","Initials":"T","AffiliationInfo":{"Affiliation":"Klinik und Poliklinik f\u00fcr Psychiatrie und Psychotherapie, Klinikum rechts der Isar; Technische Universit\u00e4t M\u00fcnchen."}}]},"Language":"ger","PublicationTypeList":{"PublicationType":["Journal Article","Review"]},"VernacularTitle":"Neue Therapieans\u00e4tze."},"MedlineJournalInfo":{"Country":"Switzerland","MedlineTA":"Ther Umsch","NlmUniqueID":"0407224","ISSNLinking":"0040-5930"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"Amyloid beta-Peptides"},{"RegistryNumber":"0","NameOfSubstance":"Nerve Tissue Proteins"},{"RegistryNumber":"0","NameOfSubstance":"Neurotransmitter Agents"},{"RegistryNumber":"EC 3.4.-","NameOfSubstance":"Amyloid Precursor Protein Secretases"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Alzheimer Disease","QualifierName":["drug therapy","etiology","physiopathology"]},{"DescriptorName":"Amyloid Precursor Protein Secretases","QualifierName":"antagonists & inhibitors"},{"DescriptorName":"Amyloid beta-Peptides","QualifierName":["antagonists & inhibitors","immunology","metabolism"]},{"DescriptorName":"Brain","QualifierName":["drug effects","physiopathology"]},{"DescriptorName":"Humans"},{"DescriptorName":"Immunization, Passive"},{"DescriptorName":"Nerve Tissue Proteins","QualifierName":["drug effects","immunology"]},{"DescriptorName":"Neurotransmitter Agents","QualifierName":"metabolism"},{"DescriptorName":"TDP-43 Proteinopathies","QualifierName":["drug therapy","etiology","physiopathology"]},{"DescriptorName":"Vaccination"}]},"OtherAbstract":{"@attributes":{"Type":"Publisher","Language":"ger"},"AbstractText":"Die h\u00e4ufigsten Ursachen der Demenz sind fortschreitende und irreversible neurodegenerative Krankheiten des Gehirns. An erster Stelle steht die Alzheimer-Krankheit, gefolgt von Parkinson- und Lewy-K\u00f6rper-Krankheit und den Frontotemporalen lob\u00e4ren Degenerationen. Die neurodegenerativen Prozesse sind durch die Entstehung, Zusammenballung und Ablagerung von pathologischen Proteinen gekennzeichnet. Diese sind \u03b2-Amyloid und Tau bei der Alzheimer-Krankheit; \u03b1-Synuklein bei der Parkinson- und Lewy-K\u00f6rper-Krankheit sowie Tau, TDP-43 und FUS bei den Frontotemporalen Degenerationen. Die Aggregation zu Oligomeren und Fibrillen sowie die nachfolgende Sedimentierung dieser Proteine f\u00fchren zur Funktionsst\u00f6rung von Nervenzellen, zum Versagen von synaptischen Verbindungen und schlie\u00dflich zum Zelluntergang. Die Defizite und Imbalancen von Neurotransmittersystemen, die einen wichtigen Ansatzpunkt der derzeitigen pharmakologischen Therapie der Demenz darstellen, sind Folgen des Nervenzelluntergangs. Viele der neuen, in Entwicklung befindlichen Therapieans\u00e4tze sind darauf gerichtet, die Entstehung, Zusammenballung und Ablagerung pathologischer Proteine zu verhindern, zu verlangsamen oder abzumildern. Wichtige Strategien sind Hemmung der Sekretasen, die \u03b2-Amyloid generieren, aktive und passive Immunisierung gegen \u03b2-Amyloid, Hemmung der Aggregation von \u03b2-Amyloid und Tau sowie Stimulierung des aktiven Transports von \u03b2-Amyloid aus dem Gehirn. In klinischer Pr\u00fcfung befinden sich auch neue symptomatische Therapieformen einschlie\u00dflich der simultanen Stimulation mehrerer Neurotransmittersysteme, des Ausgleichs der zerebralen Insulinresistenz und der Neuroprotektion mittels spezieller Nahrungsbestandteile. Neben den pharmakologischen Behandlungsformen werden auch nicht-medikament\u00f6se Interventionen weiterentwickelt."}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"entrez"},"Year":"2015","Month":"3","Day":"21","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2015","Month":"3","Day":"21","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2015","Month":"6","Day":"10","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["25791052","5557532L460R76H7","10.1024\/0040-5930\/a000676"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"25716354","DateCompleted":{"Year":"2015","Month":"05","Day":"22"},"DateRevised":{"Year":"2016","Month":"11","Day":"25"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1526-632X","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"84","Issue":"12","PubDate":{"Year":"2015","Month":"Mar","Day":"24"}},"Title":"Neurology","ISOAbbreviation":"Neurology"},"ArticleTitle":"Subjective cognitive decline is related to CSF biomarkers of AD in patients with MCI.","Pagination":{"MedlinePgn":"1261-8"},"ELocationID":"10.1212\/WNL.0000000000001399","Abstract":{"AbstractText":["To test whether, in individuals with mild cognitive impairment (MCI), different measures of subjective cognitive decline (SCD) in the memory domain predict abnormal CSF biomarkers of Alzheimer disease (AD).","We analyzed the multicenter baseline (cross-sectional) data of 245 patients with MCI. SCD was measured quantitatively with the Subjective Memory Decline Scale (SMDS) and qualitatively by assessing particular concerns associated with self-experienced worsening of memory. Logistic regression models were used to examine associations between SCD and abnormal CSF biomarkers, taking into account objective memory impairment, depressive symptoms, and education as covariates.","Abnormal CSF \u03b2-amyloid 1-42 (A\u03b242) and more depressive symptoms were associated with higher SMDS scores and with the report of memory concerns. Risk of abnormal CSF A\u03b242 increased by an estimated 57% for a 1-SD increase in SMDS scores and was doubled in patients who had SMDS scores >4 or who reported memory concerns, respectively. In addition, both SCD measures predicted risk of having a biomarker signature indicative of prodromal AD defined as presence of low CSF A\u03b242 together with either high CSF tau or CSF phosphorylated tau 181 levels.","In MCI, specific aspects of SCD severity and quality are related to CSF biomarkers indicative of AD. This extends findings in pre-MCI samples and calls for an improved operational assessment of SCD in MCI. This might be useful for sample enrichment strategies for increased likelihood of AD pathology."],"CopyrightInformation":"\u00a9 2015 American Academy of Neurology."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Wolfsgruber","ForeName":"Steffen","Initials":"S","AffiliationInfo":{"Affiliation":"From the Department of Psychiatry (S.W., F.J., A. Koppara, L.K., W.M., M.W.), University of Bonn; German Center for Neurodegenerative Diseases (S.W., F.J. A. Koppara, L.K., W.M., M.W.), Bonn; Center for Geriatric Medicine (K.S.), Ortenau Klinikum, Offenburg-Gengenbach; Department of Gerontopsychiatry (L.F.), Central Institute of Mental Health, Mannheim; Department of Psychiatry (A. Kurz), Technical University of Munich; Department of Neurology (S.S.), University of Aachen; Department of Psychiatry and Psychotherapy (S.S., E.R., J.W.), University of G\u00f6ttingen, Germany; AXA Research Fund & UPMC Chair Sorbonne Universit\u00e9s (H.H.), Universit\u00e9 Pierre et Marie Curie, Paris; Institut de la M\u00e9moire et de la Maladie d'Alzheimer (H.H.), D\u00e9partement de Neurologie, H\u00f4pital de la Piti\u00e9-Salp\u00e9tri\u00e8re, Paris; INSERM U1127 (H.H.), Institut du Cerveau et de la Moelle \u00e9pini\u00e8re, Paris, France; Department of Psychiatry (I.H., O.P., F.M.R.), Charit\u00e9 Berlin, Campus Benjamin Franklin, Berlin; Department of Psychiatry (H.J.), University of Hamburg; Department of Psychiatry (C.L.), University of D\u00fcsseldorf; Center for Geriatric Medicine and Gerontology (M.H.), University of Freiburg; Department of Psychiatry (H.-J.G.), University of Leipzig; Department of Psychiatry (J.S.), University of Heidelberg; Department of General Medicine (J.P.), University of Frankfurt, Frankfurt am Main; Department of Medical Informatics (O.R.), University of G\u00f6ttingen, Germany; Brookhaven National Laboratory (F.H.), Upton, New York; and Department of Psychiatry (J.K.), Friedrich-Alexander University Erlangen, Germany. F.J. is currently with the Department of Psychiatry, University of Cologne. steffen.wolfsgruber@ukb.uni-bonn.de."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Jessen","ForeName":"Frank","Initials":"F","AffiliationInfo":{"Affiliation":"From the Department of Psychiatry (S.W., F.J., A. Koppara, L.K., W.M., M.W.), University of Bonn; German Center for Neurodegenerative Diseases (S.W., F.J. A. Koppara, L.K., W.M., M.W.), Bonn; Center for Geriatric Medicine (K.S.), Ortenau Klinikum, Offenburg-Gengenbach; Department of Gerontopsychiatry (L.F.), Central Institute of Mental Health, Mannheim; Department of Psychiatry (A. Kurz), Technical University of Munich; Department of Neurology (S.S.), University of Aachen; Department of Psychiatry and Psychotherapy (S.S., E.R., J.W.), University of G\u00f6ttingen, Germany; AXA Research Fund & UPMC Chair Sorbonne Universit\u00e9s (H.H.), Universit\u00e9 Pierre et Marie Curie, Paris; Institut de la M\u00e9moire et de la Maladie d'Alzheimer (H.H.), D\u00e9partement de Neurologie, H\u00f4pital de la Piti\u00e9-Salp\u00e9tri\u00e8re, Paris; INSERM U1127 (H.H.), Institut du Cerveau et de la Moelle \u00e9pini\u00e8re, Paris, France; Department of Psychiatry (I.H., O.P., F.M.R.), Charit\u00e9 Berlin, Campus Benjamin Franklin, Berlin; Department of Psychiatry (H.J.), University of Hamburg; Department of Psychiatry (C.L.), University of D\u00fcsseldorf; Center for Geriatric Medicine and Gerontology (M.H.), University of Freiburg; Department of Psychiatry (H.-J.G.), University of Leipzig; Department of Psychiatry (J.S.), University of Heidelberg; Department of General Medicine (J.P.), University of Frankfurt, Frankfurt am Main; Department of Medical Informatics (O.R.), University of G\u00f6ttingen, Germany; Brookhaven National Laboratory (F.H.), Upton, New York; and Department of Psychiatry (J.K.), Friedrich-Alexander University Erlangen, Germany. F.J. is currently with the Department of Psychiatry, University of Cologne."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Koppara","ForeName":"Alexander","Initials":"A","AffiliationInfo":{"Affiliation":"From the Department of Psychiatry (S.W., F.J., A. Koppara, L.K., W.M., M.W.), University of Bonn; German Center for Neurodegenerative Diseases (S.W., F.J. A. Koppara, L.K., W.M., M.W.), Bonn; Center for Geriatric Medicine (K.S.), Ortenau Klinikum, Offenburg-Gengenbach; Department of Gerontopsychiatry (L.F.), Central Institute of Mental Health, Mannheim; Department of Psychiatry (A. Kurz), Technical University of Munich; Department of Neurology (S.S.), University of Aachen; Department of Psychiatry and Psychotherapy (S.S., E.R., J.W.), University of G\u00f6ttingen, Germany; AXA Research Fund & UPMC Chair Sorbonne Universit\u00e9s (H.H.), Universit\u00e9 Pierre et Marie Curie, Paris; Institut de la M\u00e9moire et de la Maladie d'Alzheimer (H.H.), D\u00e9partement de Neurologie, H\u00f4pital de la Piti\u00e9-Salp\u00e9tri\u00e8re, Paris; INSERM U1127 (H.H.), Institut du Cerveau et de la Moelle \u00e9pini\u00e8re, Paris, France; Department of Psychiatry (I.H., O.P., F.M.R.), Charit\u00e9 Berlin, Campus Benjamin Franklin, Berlin; Department of Psychiatry (H.J.), University of Hamburg; Department of Psychiatry (C.L.), University of D\u00fcsseldorf; Center for Geriatric Medicine and Gerontology (M.H.), University of Freiburg; Department of Psychiatry (H.-J.G.), University of Leipzig; Department of Psychiatry (J.S.), University of Heidelberg; Department of General Medicine (J.P.), University of Frankfurt, Frankfurt am Main; Department of Medical Informatics (O.R.), University of G\u00f6ttingen, Germany; Brookhaven National Laboratory (F.H.), Upton, New York; and Department of Psychiatry (J.K.), Friedrich-Alexander University Erlangen, Germany. F.J. is currently with the Department of Psychiatry, University of Cologne."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Kleineidam","ForeName":"Luca","Initials":"L","AffiliationInfo":{"Affiliation":"From the Department of Psychiatry (S.W., F.J., A. Koppara, L.K., W.M., M.W.), University of Bonn; German Center for Neurodegenerative Diseases (S.W., F.J. A. Koppara, L.K., W.M., M.W.), Bonn; Center for Geriatric Medicine (K.S.), Ortenau Klinikum, Offenburg-Gengenbach; Department of Gerontopsychiatry (L.F.), Central Institute of Mental Health, Mannheim; Department of Psychiatry (A. Kurz), Technical University of Munich; Department of Neurology (S.S.), University of Aachen; Department of Psychiatry and Psychotherapy (S.S., E.R., J.W.), University of G\u00f6ttingen, Germany; AXA Research Fund & UPMC Chair Sorbonne Universit\u00e9s (H.H.), Universit\u00e9 Pierre et Marie Curie, Paris; Institut de la M\u00e9moire et de la Maladie d'Alzheimer (H.H.), D\u00e9partement de Neurologie, H\u00f4pital de la Piti\u00e9-Salp\u00e9tri\u00e8re, Paris; INSERM U1127 (H.H.), Institut du Cerveau et de la Moelle \u00e9pini\u00e8re, Paris, France; Department of Psychiatry (I.H., O.P., F.M.R.), Charit\u00e9 Berlin, Campus Benjamin Franklin, Berlin; Department of Psychiatry (H.J.), University of Hamburg; Department of Psychiatry (C.L.), University of D\u00fcsseldorf; Center for Geriatric Medicine and Gerontology (M.H.), University of Freiburg; Department of Psychiatry (H.-J.G.), University of Leipzig; Department of Psychiatry (J.S.), University of Heidelberg; Department of General Medicine (J.P.), University of Frankfurt, Frankfurt am Main; Department of Medical Informatics (O.R.), University of G\u00f6ttingen, Germany; Brookhaven National Laboratory (F.H.), Upton, New York; and Department of Psychiatry (J.K.), Friedrich-Alexander University Erlangen, Germany. F.J. is currently with the Department of Psychiatry, University of Cologne."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Schmidtke","ForeName":"Klaus","Initials":"K","AffiliationInfo":{"Affiliation":"From the Department of Psychiatry (S.W., F.J., A. Koppara, L.K., W.M., M.W.), University of Bonn; German Center for Neurodegenerative Diseases (S.W., F.J. A. Koppara, L.K., W.M., M.W.), Bonn; Center for Geriatric Medicine (K.S.), Ortenau Klinikum, Offenburg-Gengenbach; Department of Gerontopsychiatry (L.F.), Central Institute of Mental Health, Mannheim; Department of Psychiatry (A. Kurz), Technical University of Munich; Department of Neurology (S.S.), University of Aachen; Department of Psychiatry and Psychotherapy (S.S., E.R., J.W.), University of G\u00f6ttingen, Germany; AXA Research Fund & UPMC Chair Sorbonne Universit\u00e9s (H.H.), Universit\u00e9 Pierre et Marie Curie, Paris; Institut de la M\u00e9moire et de la Maladie d'Alzheimer (H.H.), D\u00e9partement de Neurologie, H\u00f4pital de la Piti\u00e9-Salp\u00e9tri\u00e8re, Paris; INSERM U1127 (H.H.), Institut du Cerveau et de la Moelle \u00e9pini\u00e8re, Paris, France; Department of Psychiatry (I.H., O.P., F.M.R.), Charit\u00e9 Berlin, Campus Benjamin Franklin, Berlin; Department of Psychiatry (H.J.), University of Hamburg; Department of Psychiatry (C.L.), University of D\u00fcsseldorf; Center for Geriatric Medicine and Gerontology (M.H.), University of Freiburg; Department of Psychiatry (H.-J.G.), University of Leipzig; Department of Psychiatry (J.S.), University of Heidelberg; Department of General Medicine (J.P.), University of Frankfurt, Frankfurt am Main; Department of Medical Informatics (O.R.), University of G\u00f6ttingen, Germany; Brookhaven National Laboratory (F.H.), Upton, New York; and Department of Psychiatry (J.K.), Friedrich-Alexander University Erlangen, Germany. F.J. is currently with the Department of Psychiatry, University of Cologne."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Fr\u00f6lich","ForeName":"Lutz","Initials":"L","AffiliationInfo":{"Affiliation":"From the Department of Psychiatry (S.W., F.J., A. Koppara, L.K., W.M., M.W.), University of Bonn; German Center for Neurodegenerative Diseases (S.W., F.J. A. Koppara, L.K., W.M., M.W.), Bonn; Center for Geriatric Medicine (K.S.), Ortenau Klinikum, Offenburg-Gengenbach; Department of Gerontopsychiatry (L.F.), Central Institute of Mental Health, Mannheim; Department of Psychiatry (A. Kurz), Technical University of Munich; Department of Neurology (S.S.), University of Aachen; Department of Psychiatry and Psychotherapy (S.S., E.R., J.W.), University of G\u00f6ttingen, Germany; AXA Research Fund & UPMC Chair Sorbonne Universit\u00e9s (H.H.), Universit\u00e9 Pierre et Marie Curie, Paris; Institut de la M\u00e9moire et de la Maladie d'Alzheimer (H.H.), D\u00e9partement de Neurologie, H\u00f4pital de la Piti\u00e9-Salp\u00e9tri\u00e8re, Paris; INSERM U1127 (H.H.), Institut du Cerveau et de la Moelle \u00e9pini\u00e8re, Paris, France; Department of Psychiatry (I.H., O.P., F.M.R.), Charit\u00e9 Berlin, Campus Benjamin Franklin, Berlin; Department of Psychiatry (H.J.), University of Hamburg; Department of Psychiatry (C.L.), University of D\u00fcsseldorf; Center for Geriatric Medicine and Gerontology (M.H.), University of Freiburg; Department of Psychiatry (H.-J.G.), University of Leipzig; Department of Psychiatry (J.S.), University of Heidelberg; Department of General Medicine (J.P.), University of Frankfurt, Frankfurt am Main; Department of Medical Informatics (O.R.), University of G\u00f6ttingen, Germany; Brookhaven National Laboratory (F.H.), Upton, New York; and Department of Psychiatry (J.K.), Friedrich-Alexander University Erlangen, Germany. F.J. is currently with the Department of Psychiatry, University of Cologne."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A","AffiliationInfo":{"Affiliation":"From the Department of Psychiatry (S.W., F.J., A. Koppara, L.K., W.M., M.W.), University of Bonn; German Center for Neurodegenerative Diseases (S.W., F.J. A. Koppara, L.K., W.M., M.W.), Bonn; Center for Geriatric Medicine (K.S.), Ortenau Klinikum, Offenburg-Gengenbach; Department of Gerontopsychiatry (L.F.), Central Institute of Mental Health, Mannheim; Department of Psychiatry (A. Kurz), Technical University of Munich; Department of Neurology (S.S.), University of Aachen; Department of Psychiatry and Psychotherapy (S.S., E.R., J.W.), University of G\u00f6ttingen, Germany; AXA Research Fund & UPMC Chair Sorbonne Universit\u00e9s (H.H.), Universit\u00e9 Pierre et Marie Curie, Paris; Institut de la M\u00e9moire et de la Maladie d'Alzheimer (H.H.), D\u00e9partement de Neurologie, H\u00f4pital de la Piti\u00e9-Salp\u00e9tri\u00e8re, Paris; INSERM U1127 (H.H.), Institut du Cerveau et de la Moelle \u00e9pini\u00e8re, Paris, France; Department of Psychiatry (I.H., O.P., F.M.R.), Charit\u00e9 Berlin, Campus Benjamin Franklin, Berlin; Department of Psychiatry (H.J.), University of Hamburg; Department of Psychiatry (C.L.), University of D\u00fcsseldorf; Center for Geriatric Medicine and Gerontology (M.H.), University of Freiburg; Department of Psychiatry (H.-J.G.), University of Leipzig; Department of Psychiatry (J.S.), University of Heidelberg; Department of General Medicine (J.P.), University of Frankfurt, Frankfurt am Main; Department of Medical Informatics (O.R.), University of G\u00f6ttingen, Germany; Brookhaven National Laboratory (F.H.), Upton, New York; and Department of Psychiatry (J.K.), Friedrich-Alexander University Erlangen, Germany. F.J. is currently with the Department of Psychiatry, University of Cologne."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Schulz","ForeName":"Stefanie","Initials":"S","AffiliationInfo":{"Affiliation":"From the Department of Psychiatry (S.W., F.J., A. Koppara, L.K., W.M., M.W.), University of Bonn; German Center for Neurodegenerative Diseases (S.W., F.J. A. Koppara, L.K., W.M., M.W.), Bonn; Center for Geriatric Medicine (K.S.), Ortenau Klinikum, Offenburg-Gengenbach; Department of Gerontopsychiatry (L.F.), Central Institute of Mental Health, Mannheim; Department of Psychiatry (A. Kurz), Technical University of Munich; Department of Neurology (S.S.), University of Aachen; Department of Psychiatry and Psychotherapy (S.S., E.R., J.W.), University of G\u00f6ttingen, Germany; AXA Research Fund & UPMC Chair Sorbonne Universit\u00e9s (H.H.), Universit\u00e9 Pierre et Marie Curie, Paris; Institut de la M\u00e9moire et de la Maladie d'Alzheimer (H.H.), D\u00e9partement de Neurologie, H\u00f4pital de la Piti\u00e9-Salp\u00e9tri\u00e8re, Paris; INSERM U1127 (H.H.), Institut du Cerveau et de la Moelle \u00e9pini\u00e8re, Paris, France; Department of Psychiatry (I.H., O.P., F.M.R.), Charit\u00e9 Berlin, Campus Benjamin Franklin, Berlin; Department of Psychiatry (H.J.), University of Hamburg; Department of Psychiatry (C.L.), University of D\u00fcsseldorf; Center for Geriatric Medicine and Gerontology (M.H.), University of Freiburg; Department of Psychiatry (H.-J.G.), University of Leipzig; Department of Psychiatry (J.S.), University of Heidelberg; Department of General Medicine (J.P.), University of Frankfurt, Frankfurt am Main; Department of Medical Informatics (O.R.), University of G\u00f6ttingen, Germany; Brookhaven National Laboratory (F.H.), Upton, New York; and Department of Psychiatry (J.K.), Friedrich-Alexander University Erlangen, Germany. F.J. is currently with the Department of Psychiatry, University of Cologne."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Hampel","ForeName":"Harald","Initials":"H","AffiliationInfo":{"Affiliation":"From the Department of Psychiatry (S.W., F.J., A. Koppara, L.K., W.M., M.W.), University of Bonn; German Center for Neurodegenerative Diseases (S.W., F.J. A. Koppara, L.K., W.M., M.W.), Bonn; Center for Geriatric Medicine (K.S.), Ortenau Klinikum, Offenburg-Gengenbach; Department of Gerontopsychiatry (L.F.), Central Institute of Mental Health, Mannheim; Department of Psychiatry (A. Kurz), Technical University of Munich; Department of Neurology (S.S.), University of Aachen; Department of Psychiatry and Psychotherapy (S.S., E.R., J.W.), University of G\u00f6ttingen, Germany; AXA Research Fund & UPMC Chair Sorbonne Universit\u00e9s (H.H.), Universit\u00e9 Pierre et Marie Curie, Paris; Institut de la M\u00e9moire et de la Maladie d'Alzheimer (H.H.), D\u00e9partement de Neurologie, H\u00f4pital de la Piti\u00e9-Salp\u00e9tri\u00e8re, Paris; INSERM U1127 (H.H.), Institut du Cerveau et de la Moelle \u00e9pini\u00e8re, Paris, France; Department of Psychiatry (I.H., O.P., F.M.R.), Charit\u00e9 Berlin, Campus Benjamin Franklin, Berlin; Department of Psychiatry (H.J.), University of Hamburg; Department of Psychiatry (C.L.), University of D\u00fcsseldorf; Center for Geriatric Medicine and Gerontology (M.H.), University of Freiburg; Department of Psychiatry (H.-J.G.), University of Leipzig; Department of Psychiatry (J.S.), University of Heidelberg; Department of General Medicine (J.P.), University of Frankfurt, Frankfurt am Main; Department of Medical Informatics (O.R.), University of G\u00f6ttingen, Germany; Brookhaven National Laboratory (F.H.), Upton, New York; and Department of Psychiatry (J.K.), Friedrich-Alexander University Erlangen, Germany. F.J. is currently with the Department of Psychiatry, University of Cologne."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Heuser","ForeName":"Isabella","Initials":"I","AffiliationInfo":{"Affiliation":"From the Department of Psychiatry (S.W., F.J., A. Koppara, L.K., W.M., M.W.), University of Bonn; German Center for Neurodegenerative Diseases (S.W., F.J. A. Koppara, L.K., W.M., M.W.), Bonn; Center for Geriatric Medicine (K.S.), Ortenau Klinikum, Offenburg-Gengenbach; Department of Gerontopsychiatry (L.F.), Central Institute of Mental Health, Mannheim; Department of Psychiatry (A. Kurz), Technical University of Munich; Department of Neurology (S.S.), University of Aachen; Department of Psychiatry and Psychotherapy (S.S., E.R., J.W.), University of G\u00f6ttingen, Germany; AXA Research Fund & UPMC Chair Sorbonne Universit\u00e9s (H.H.), Universit\u00e9 Pierre et Marie Curie, Paris; Institut de la M\u00e9moire et de la Maladie d'Alzheimer (H.H.), D\u00e9partement de Neurologie, H\u00f4pital de la Piti\u00e9-Salp\u00e9tri\u00e8re, Paris; INSERM U1127 (H.H.), Institut du Cerveau et de la Moelle \u00e9pini\u00e8re, Paris, France; Department of Psychiatry (I.H., O.P., F.M.R.), Charit\u00e9 Berlin, Campus Benjamin Franklin, Berlin; Department of Psychiatry (H.J.), University of Hamburg; Department of Psychiatry (C.L.), University of D\u00fcsseldorf; Center for Geriatric Medicine and Gerontology (M.H.), University of Freiburg; Department of Psychiatry (H.-J.G.), University of Leipzig; Department of Psychiatry (J.S.), University of Heidelberg; Department of General Medicine (J.P.), University of Frankfurt, Frankfurt am Main; Department of Medical Informatics (O.R.), University of G\u00f6ttingen, Germany; Brookhaven National Laboratory (F.H.), Upton, New York; and Department of Psychiatry (J.K.), Friedrich-Alexander University Erlangen, Germany. F.J. is currently with the Department of Psychiatry, University of Cologne."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Peters","ForeName":"Oliver","Initials":"O","AffiliationInfo":{"Affiliation":"From the Department of Psychiatry (S.W., F.J., A. Koppara, L.K., W.M., M.W.), University of Bonn; German Center for Neurodegenerative Diseases (S.W., F.J. A. Koppara, L.K., W.M., M.W.), Bonn; Center for Geriatric Medicine (K.S.), Ortenau Klinikum, Offenburg-Gengenbach; Department of Gerontopsychiatry (L.F.), Central Institute of Mental Health, Mannheim; Department of Psychiatry (A. Kurz), Technical University of Munich; Department of Neurology (S.S.), University of Aachen; Department of Psychiatry and Psychotherapy (S.S., E.R., J.W.), University of G\u00f6ttingen, Germany; AXA Research Fund & UPMC Chair Sorbonne Universit\u00e9s (H.H.), Universit\u00e9 Pierre et Marie Curie, Paris; Institut de la M\u00e9moire et de la Maladie d'Alzheimer (H.H.), D\u00e9partement de Neurologie, H\u00f4pital de la Piti\u00e9-Salp\u00e9tri\u00e8re, Paris; INSERM U1127 (H.H.), Institut du Cerveau et de la Moelle \u00e9pini\u00e8re, Paris, France; Department of Psychiatry (I.H., O.P., F.M.R.), Charit\u00e9 Berlin, Campus Benjamin Franklin, Berlin; Department of Psychiatry (H.J.), University of Hamburg; Department of Psychiatry (C.L.), University of D\u00fcsseldorf; Center for Geriatric Medicine and Gerontology (M.H.), University of Freiburg; Department of Psychiatry (H.-J.G.), University of Leipzig; Department of Psychiatry (J.S.), University of Heidelberg; Department of General Medicine (J.P.), University of Frankfurt, Frankfurt am Main; Department of Medical Informatics (O.R.), University of G\u00f6ttingen, Germany; Brookhaven National Laboratory (F.H.), Upton, New York; and Department of Psychiatry (J.K.), Friedrich-Alexander University Erlangen, Germany. F.J. is currently with the Department of Psychiatry, University of Cologne."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Reischies","ForeName":"Friedel M","Initials":"FM","AffiliationInfo":{"Affiliation":"From the Department of Psychiatry (S.W., F.J., A. Koppara, L.K., W.M., M.W.), University of Bonn; German Center for Neurodegenerative Diseases (S.W., F.J. A. Koppara, L.K., W.M., M.W.), Bonn; Center for Geriatric Medicine (K.S.), Ortenau Klinikum, Offenburg-Gengenbach; Department of Gerontopsychiatry (L.F.), Central Institute of Mental Health, Mannheim; Department of Psychiatry (A. Kurz), Technical University of Munich; Department of Neurology (S.S.), University of Aachen; Department of Psychiatry and Psychotherapy (S.S., E.R., J.W.), University of G\u00f6ttingen, Germany; AXA Research Fund & UPMC Chair Sorbonne Universit\u00e9s (H.H.), Universit\u00e9 Pierre et Marie Curie, Paris; Institut de la M\u00e9moire et de la Maladie d'Alzheimer (H.H.), D\u00e9partement de Neurologie, H\u00f4pital de la Piti\u00e9-Salp\u00e9tri\u00e8re, Paris; INSERM U1127 (H.H.), Institut du Cerveau et de la Moelle \u00e9pini\u00e8re, Paris, France; Department of Psychiatry (I.H., O.P., F.M.R.), Charit\u00e9 Berlin, Campus Benjamin Franklin, Berlin; Department of Psychiatry (H.J.), University of Hamburg; Department of Psychiatry (C.L.), University of D\u00fcsseldorf; Center for Geriatric Medicine and Gerontology (M.H.), University of Freiburg; Department of Psychiatry (H.-J.G.), University of Leipzig; Department of Psychiatry (J.S.), University of Heidelberg; Department of General Medicine (J.P.), University of Frankfurt, Frankfurt am Main; Department of Medical Informatics (O.R.), University of G\u00f6ttingen, Germany; Brookhaven National Laboratory (F.H.), Upton, New York; and Department of Psychiatry (J.K.), Friedrich-Alexander University Erlangen, Germany. F.J. is currently with the Department of Psychiatry, University of Cologne."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Jahn","ForeName":"Holger","Initials":"H","AffiliationInfo":{"Affiliation":"From the Department of Psychiatry (S.W., F.J., A. Koppara, L.K., W.M., M.W.), University of Bonn; German Center for Neurodegenerative Diseases (S.W., F.J. A. Koppara, L.K., W.M., M.W.), Bonn; Center for Geriatric Medicine (K.S.), Ortenau Klinikum, Offenburg-Gengenbach; Department of Gerontopsychiatry (L.F.), Central Institute of Mental Health, Mannheim; Department of Psychiatry (A. Kurz), Technical University of Munich; Department of Neurology (S.S.), University of Aachen; Department of Psychiatry and Psychotherapy (S.S., E.R., J.W.), University of G\u00f6ttingen, Germany; AXA Research Fund & UPMC Chair Sorbonne Universit\u00e9s (H.H.), Universit\u00e9 Pierre et Marie Curie, Paris; Institut de la M\u00e9moire et de la Maladie d'Alzheimer (H.H.), D\u00e9partement de Neurologie, H\u00f4pital de la Piti\u00e9-Salp\u00e9tri\u00e8re, Paris; INSERM U1127 (H.H.), Institut du Cerveau et de la Moelle \u00e9pini\u00e8re, Paris, France; Department of Psychiatry (I.H., O.P., F.M.R.), Charit\u00e9 Berlin, Campus Benjamin Franklin, Berlin; Department of Psychiatry (H.J.), University of Hamburg; Department of Psychiatry (C.L.), University of D\u00fcsseldorf; Center for Geriatric Medicine and Gerontology (M.H.), University of Freiburg; Department of Psychiatry (H.-J.G.), University of Leipzig; Department of Psychiatry (J.S.), University of Heidelberg; Department of General Medicine (J.P.), University of Frankfurt, Frankfurt am Main; Department of Medical Informatics (O.R.), University of G\u00f6ttingen, Germany; Brookhaven National Laboratory (F.H.), Upton, New York; and Department of Psychiatry (J.K.), Friedrich-Alexander University Erlangen, Germany. F.J. is currently with the Department of Psychiatry, University of Cologne."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Luckhaus","ForeName":"Christian","Initials":"C","AffiliationInfo":{"Affiliation":"From the Department of Psychiatry (S.W., F.J., A. Koppara, L.K., W.M., M.W.), University of Bonn; German Center for Neurodegenerative Diseases (S.W., F.J. A. Koppara, L.K., W.M., M.W.), Bonn; Center for Geriatric Medicine (K.S.), Ortenau Klinikum, Offenburg-Gengenbach; Department of Gerontopsychiatry (L.F.), Central Institute of Mental Health, Mannheim; Department of Psychiatry (A. Kurz), Technical University of Munich; Department of Neurology (S.S.), University of Aachen; Department of Psychiatry and Psychotherapy (S.S., E.R., J.W.), University of G\u00f6ttingen, Germany; AXA Research Fund & UPMC Chair Sorbonne Universit\u00e9s (H.H.), Universit\u00e9 Pierre et Marie Curie, Paris; Institut de la M\u00e9moire et de la Maladie d'Alzheimer (H.H.), D\u00e9partement de Neurologie, H\u00f4pital de la Piti\u00e9-Salp\u00e9tri\u00e8re, Paris; INSERM U1127 (H.H.), Institut du Cerveau et de la Moelle \u00e9pini\u00e8re, Paris, France; Department of Psychiatry (I.H., O.P., F.M.R.), Charit\u00e9 Berlin, Campus Benjamin Franklin, Berlin; Department of Psychiatry (H.J.), University of Hamburg; Department of Psychiatry (C.L.), University of D\u00fcsseldorf; Center for Geriatric Medicine and Gerontology (M.H.), University of Freiburg; Department of Psychiatry (H.-J.G.), University of Leipzig; Department of Psychiatry (J.S.), University of Heidelberg; Department of General Medicine (J.P.), University of Frankfurt, Frankfurt am Main; Department of Medical Informatics (O.R.), University of G\u00f6ttingen, Germany; Brookhaven National Laboratory (F.H.), Upton, New York; and Department of Psychiatry (J.K.), Friedrich-Alexander University Erlangen, Germany. F.J. is currently with the Department of Psychiatry, University of Cologne."}},{"@attributes":{"ValidYN":"Y"},"LastName":"H\u00fcll","ForeName":"Michael","Initials":"M","AffiliationInfo":{"Affiliation":"From the Department of Psychiatry (S.W., F.J., A. Koppara, L.K., W.M., M.W.), University of Bonn; German Center for Neurodegenerative Diseases (S.W., F.J. A. Koppara, L.K., W.M., M.W.), Bonn; Center for Geriatric Medicine (K.S.), Ortenau Klinikum, Offenburg-Gengenbach; Department of Gerontopsychiatry (L.F.), Central Institute of Mental Health, Mannheim; Department of Psychiatry (A. Kurz), Technical University of Munich; Department of Neurology (S.S.), University of Aachen; Department of Psychiatry and Psychotherapy (S.S., E.R., J.W.), University of G\u00f6ttingen, Germany; AXA Research Fund & UPMC Chair Sorbonne Universit\u00e9s (H.H.), Universit\u00e9 Pierre et Marie Curie, Paris; Institut de la M\u00e9moire et de la Maladie d'Alzheimer (H.H.), D\u00e9partement de Neurologie, H\u00f4pital de la Piti\u00e9-Salp\u00e9tri\u00e8re, Paris; INSERM U1127 (H.H.), Institut du Cerveau et de la Moelle \u00e9pini\u00e8re, Paris, France; Department of Psychiatry (I.H., O.P., F.M.R.), Charit\u00e9 Berlin, Campus Benjamin Franklin, Berlin; Department of Psychiatry (H.J.), University of Hamburg; Department of Psychiatry (C.L.), University of D\u00fcsseldorf; Center for Geriatric Medicine and Gerontology (M.H.), University of Freiburg; Department of Psychiatry (H.-J.G.), University of Leipzig; Department of Psychiatry (J.S.), University of Heidelberg; Department of General Medicine (J.P.), University of Frankfurt, Frankfurt am Main; Department of Medical Informatics (O.R.), University of G\u00f6ttingen, Germany; Brookhaven National Laboratory (F.H.), Upton, New York; and Department of Psychiatry (J.K.), Friedrich-Alexander University Erlangen, Germany. F.J. is currently with the Department of Psychiatry, University of Cologne."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Gertz","ForeName":"Hermann-Josef","Initials":"HJ","AffiliationInfo":{"Affiliation":"From the Department of Psychiatry (S.W., F.J., A. Koppara, L.K., W.M., M.W.), University of Bonn; German Center for Neurodegenerative Diseases (S.W., F.J. A. Koppara, L.K., W.M., M.W.), Bonn; Center for Geriatric Medicine (K.S.), Ortenau Klinikum, Offenburg-Gengenbach; Department of Gerontopsychiatry (L.F.), Central Institute of Mental Health, Mannheim; Department of Psychiatry (A. Kurz), Technical University of Munich; Department of Neurology (S.S.), University of Aachen; Department of Psychiatry and Psychotherapy (S.S., E.R., J.W.), University of G\u00f6ttingen, Germany; AXA Research Fund & UPMC Chair Sorbonne Universit\u00e9s (H.H.), Universit\u00e9 Pierre et Marie Curie, Paris; Institut de la M\u00e9moire et de la Maladie d'Alzheimer (H.H.), D\u00e9partement de Neurologie, H\u00f4pital de la Piti\u00e9-Salp\u00e9tri\u00e8re, Paris; INSERM U1127 (H.H.), Institut du Cerveau et de la Moelle \u00e9pini\u00e8re, Paris, France; Department of Psychiatry (I.H., O.P., F.M.R.), Charit\u00e9 Berlin, Campus Benjamin Franklin, Berlin; Department of Psychiatry (H.J.), University of Hamburg; Department of Psychiatry (C.L.), University of D\u00fcsseldorf; Center for Geriatric Medicine and Gerontology (M.H.), University of Freiburg; Department of Psychiatry (H.-J.G.), University of Leipzig; Department of Psychiatry (J.S.), University of Heidelberg; Department of General Medicine (J.P.), University of Frankfurt, Frankfurt am Main; Department of Medical Informatics (O.R.), University of G\u00f6ttingen, Germany; Brookhaven National Laboratory (F.H.), Upton, New York; and Department of Psychiatry (J.K.), Friedrich-Alexander University Erlangen, Germany. F.J. is currently with the Department of Psychiatry, University of Cologne."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Schr\u00f6der","ForeName":"Johannes","Initials":"J","AffiliationInfo":{"Affiliation":"From the Department of Psychiatry (S.W., F.J., A. Koppara, L.K., W.M., M.W.), University of Bonn; German Center for Neurodegenerative Diseases (S.W., F.J. A. Koppara, L.K., W.M., M.W.), Bonn; Center for Geriatric Medicine (K.S.), Ortenau Klinikum, Offenburg-Gengenbach; Department of Gerontopsychiatry (L.F.), Central Institute of Mental Health, Mannheim; Department of Psychiatry (A. Kurz), Technical University of Munich; Department of Neurology (S.S.), University of Aachen; Department of Psychiatry and Psychotherapy (S.S., E.R., J.W.), University of G\u00f6ttingen, Germany; AXA Research Fund & UPMC Chair Sorbonne Universit\u00e9s (H.H.), Universit\u00e9 Pierre et Marie Curie, Paris; Institut de la M\u00e9moire et de la Maladie d'Alzheimer (H.H.), D\u00e9partement de Neurologie, H\u00f4pital de la Piti\u00e9-Salp\u00e9tri\u00e8re, Paris; INSERM U1127 (H.H.), Institut du Cerveau et de la Moelle \u00e9pini\u00e8re, Paris, France; Department of Psychiatry (I.H., O.P., F.M.R.), Charit\u00e9 Berlin, Campus Benjamin Franklin, Berlin; Department of Psychiatry (H.J.), University of Hamburg; Department of Psychiatry (C.L.), University of D\u00fcsseldorf; Center for Geriatric Medicine and Gerontology (M.H.), University of Freiburg; Department of Psychiatry (H.-J.G.), University of Leipzig; Department of Psychiatry (J.S.), University of Heidelberg; Department of General Medicine (J.P.), University of Frankfurt, Frankfurt am Main; Department of Medical Informatics (O.R.), University of G\u00f6ttingen, Germany; Brookhaven National Laboratory (F.H.), Upton, New York; and Department of Psychiatry (J.K.), Friedrich-Alexander University Erlangen, Germany. F.J. is currently with the Department of Psychiatry, University of Cologne."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Pantel","ForeName":"Johannes","Initials":"J","AffiliationInfo":{"Affiliation":"From the Department of Psychiatry (S.W., F.J., A. Koppara, L.K., W.M., M.W.), University of Bonn; German Center for Neurodegenerative Diseases (S.W., F.J. A. Koppara, L.K., W.M., M.W.), Bonn; Center for Geriatric Medicine (K.S.), Ortenau Klinikum, Offenburg-Gengenbach; Department of Gerontopsychiatry (L.F.), Central Institute of Mental Health, Mannheim; Department of Psychiatry (A. Kurz), Technical University of Munich; Department of Neurology (S.S.), University of Aachen; Department of Psychiatry and Psychotherapy (S.S., E.R., J.W.), University of G\u00f6ttingen, Germany; AXA Research Fund & UPMC Chair Sorbonne Universit\u00e9s (H.H.), Universit\u00e9 Pierre et Marie Curie, Paris; Institut de la M\u00e9moire et de la Maladie d'Alzheimer (H.H.), D\u00e9partement de Neurologie, H\u00f4pital de la Piti\u00e9-Salp\u00e9tri\u00e8re, Paris; INSERM U1127 (H.H.), Institut du Cerveau et de la Moelle \u00e9pini\u00e8re, Paris, France; Department of Psychiatry (I.H., O.P., F.M.R.), Charit\u00e9 Berlin, Campus Benjamin Franklin, Berlin; Department of Psychiatry (H.J.), University of Hamburg; Department of Psychiatry (C.L.), University of D\u00fcsseldorf; Center for Geriatric Medicine and Gerontology (M.H.), University of Freiburg; Department of Psychiatry (H.-J.G.), University of Leipzig; Department of Psychiatry (J.S.), University of Heidelberg; Department of General Medicine (J.P.), University of Frankfurt, Frankfurt am Main; Department of Medical Informatics (O.R.), University of G\u00f6ttingen, Germany; Brookhaven National Laboratory (F.H.), Upton, New York; and Department of Psychiatry (J.K.), Friedrich-Alexander University Erlangen, Germany. F.J. is currently with the Department of Psychiatry, University of Cologne."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Rienhoff","ForeName":"Otto","Initials":"O","AffiliationInfo":{"Affiliation":"From the Department of Psychiatry (S.W., F.J., A. Koppara, L.K., W.M., M.W.), University of Bonn; German Center for Neurodegenerative Diseases (S.W., F.J. A. Koppara, L.K., W.M., M.W.), Bonn; Center for Geriatric Medicine (K.S.), Ortenau Klinikum, Offenburg-Gengenbach; Department of Gerontopsychiatry (L.F.), Central Institute of Mental Health, Mannheim; Department of Psychiatry (A. Kurz), Technical University of Munich; Department of Neurology (S.S.), University of Aachen; Department of Psychiatry and Psychotherapy (S.S., E.R., J.W.), University of G\u00f6ttingen, Germany; AXA Research Fund & UPMC Chair Sorbonne Universit\u00e9s (H.H.), Universit\u00e9 Pierre et Marie Curie, Paris; Institut de la M\u00e9moire et de la Maladie d'Alzheimer (H.H.), D\u00e9partement de Neurologie, H\u00f4pital de la Piti\u00e9-Salp\u00e9tri\u00e8re, Paris; INSERM U1127 (H.H.), Institut du Cerveau et de la Moelle \u00e9pini\u00e8re, Paris, France; Department of Psychiatry (I.H., O.P., F.M.R.), Charit\u00e9 Berlin, Campus Benjamin Franklin, Berlin; Department of Psychiatry (H.J.), University of Hamburg; Department of Psychiatry (C.L.), University of D\u00fcsseldorf; Center for Geriatric Medicine and Gerontology (M.H.), University of Freiburg; Department of Psychiatry (H.-J.G.), University of Leipzig; Department of Psychiatry (J.S.), University of Heidelberg; Department of General Medicine (J.P.), University of Frankfurt, Frankfurt am Main; Department of Medical Informatics (O.R.), University of G\u00f6ttingen, Germany; Brookhaven National Laboratory (F.H.), Upton, New York; and Department of Psychiatry (J.K.), Friedrich-Alexander University Erlangen, Germany. F.J. is currently with the Department of Psychiatry, University of Cologne."}},{"@attributes":{"ValidYN":"Y"},"LastName":"R\u00fcther","ForeName":"Eckart","Initials":"E","AffiliationInfo":{"Affiliation":"From the Department of Psychiatry (S.W., F.J., A. Koppara, L.K., W.M., M.W.), University of Bonn; German Center for Neurodegenerative Diseases (S.W., F.J. A. Koppara, L.K., W.M., M.W.), Bonn; Center for Geriatric Medicine (K.S.), Ortenau Klinikum, Offenburg-Gengenbach; Department of Gerontopsychiatry (L.F.), Central Institute of Mental Health, Mannheim; Department of Psychiatry (A. Kurz), Technical University of Munich; Department of Neurology (S.S.), University of Aachen; Department of Psychiatry and Psychotherapy (S.S., E.R., J.W.), University of G\u00f6ttingen, Germany; AXA Research Fund & UPMC Chair Sorbonne Universit\u00e9s (H.H.), Universit\u00e9 Pierre et Marie Curie, Paris; Institut de la M\u00e9moire et de la Maladie d'Alzheimer (H.H.), D\u00e9partement de Neurologie, H\u00f4pital de la Piti\u00e9-Salp\u00e9tri\u00e8re, Paris; INSERM U1127 (H.H.), Institut du Cerveau et de la Moelle \u00e9pini\u00e8re, Paris, France; Department of Psychiatry (I.H., O.P., F.M.R.), Charit\u00e9 Berlin, Campus Benjamin Franklin, Berlin; Department of Psychiatry (H.J.), University of Hamburg; Department of Psychiatry (C.L.), University of D\u00fcsseldorf; Center for Geriatric Medicine and Gerontology (M.H.), University of Freiburg; Department of Psychiatry (H.-J.G.), University of Leipzig; Department of Psychiatry (J.S.), University of Heidelberg; Department of General Medicine (J.P.), University of Frankfurt, Frankfurt am Main; Department of Medical Informatics (O.R.), University of G\u00f6ttingen, Germany; Brookhaven National Laboratory (F.H.), Upton, New York; and Department of Psychiatry (J.K.), Friedrich-Alexander University Erlangen, Germany. F.J. is currently with the Department of Psychiatry, University of Cologne."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Henn","ForeName":"Fritz","Initials":"F","AffiliationInfo":{"Affiliation":"From the Department of Psychiatry (S.W., F.J., A. Koppara, L.K., W.M., M.W.), University of Bonn; German Center for Neurodegenerative Diseases (S.W., F.J. A. Koppara, L.K., W.M., M.W.), Bonn; Center for Geriatric Medicine (K.S.), Ortenau Klinikum, Offenburg-Gengenbach; Department of Gerontopsychiatry (L.F.), Central Institute of Mental Health, Mannheim; Department of Psychiatry (A. Kurz), Technical University of Munich; Department of Neurology (S.S.), University of Aachen; Department of Psychiatry and Psychotherapy (S.S., E.R., J.W.), University of G\u00f6ttingen, Germany; AXA Research Fund & UPMC Chair Sorbonne Universit\u00e9s (H.H.), Universit\u00e9 Pierre et Marie Curie, Paris; Institut de la M\u00e9moire et de la Maladie d'Alzheimer (H.H.), D\u00e9partement de Neurologie, H\u00f4pital de la Piti\u00e9-Salp\u00e9tri\u00e8re, Paris; INSERM U1127 (H.H.), Institut du Cerveau et de la Moelle \u00e9pini\u00e8re, Paris, France; Department of Psychiatry (I.H., O.P., F.M.R.), Charit\u00e9 Berlin, Campus Benjamin Franklin, Berlin; Department of Psychiatry (H.J.), University of Hamburg; Department of Psychiatry (C.L.), University of D\u00fcsseldorf; Center for Geriatric Medicine and Gerontology (M.H.), University of Freiburg; Department of Psychiatry (H.-J.G.), University of Leipzig; Department of Psychiatry (J.S.), University of Heidelberg; Department of General Medicine (J.P.), University of Frankfurt, Frankfurt am Main; Department of Medical Informatics (O.R.), University of G\u00f6ttingen, Germany; Brookhaven National Laboratory (F.H.), Upton, New York; and Department of Psychiatry (J.K.), Friedrich-Alexander University Erlangen, Germany. F.J. is currently with the Department of Psychiatry, University of Cologne."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Wiltfang","ForeName":"Jens","Initials":"J","AffiliationInfo":{"Affiliation":"From the Department of Psychiatry (S.W., F.J., A. Koppara, L.K., W.M., M.W.), University of Bonn; German Center for Neurodegenerative Diseases (S.W., F.J. A. Koppara, L.K., W.M., M.W.), Bonn; Center for Geriatric Medicine (K.S.), Ortenau Klinikum, Offenburg-Gengenbach; Department of Gerontopsychiatry (L.F.), Central Institute of Mental Health, Mannheim; Department of Psychiatry (A. Kurz), Technical University of Munich; Department of Neurology (S.S.), University of Aachen; Department of Psychiatry and Psychotherapy (S.S., E.R., J.W.), University of G\u00f6ttingen, Germany; AXA Research Fund & UPMC Chair Sorbonne Universit\u00e9s (H.H.), Universit\u00e9 Pierre et Marie Curie, Paris; Institut de la M\u00e9moire et de la Maladie d'Alzheimer (H.H.), D\u00e9partement de Neurologie, H\u00f4pital de la Piti\u00e9-Salp\u00e9tri\u00e8re, Paris; INSERM U1127 (H.H.), Institut du Cerveau et de la Moelle \u00e9pini\u00e8re, Paris, France; Department of Psychiatry (I.H., O.P., F.M.R.), Charit\u00e9 Berlin, Campus Benjamin Franklin, Berlin; Department of Psychiatry (H.J.), University of Hamburg; Department of Psychiatry (C.L.), University of D\u00fcsseldorf; Center for Geriatric Medicine and Gerontology (M.H.), University of Freiburg; Department of Psychiatry (H.-J.G.), University of Leipzig; Department of Psychiatry (J.S.), University of Heidelberg; Department of General Medicine (J.P.), University of Frankfurt, Frankfurt am Main; Department of Medical Informatics (O.R.), University of G\u00f6ttingen, Germany; Brookhaven National Laboratory (F.H.), Upton, New York; and Department of Psychiatry (J.K.), Friedrich-Alexander University Erlangen, Germany. F.J. is currently with the Department of Psychiatry, University of Cologne."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Maier","ForeName":"Wolfgang","Initials":"W","AffiliationInfo":{"Affiliation":"From the Department of Psychiatry (S.W., F.J., A. Koppara, L.K., W.M., M.W.), University of Bonn; German Center for Neurodegenerative Diseases (S.W., F.J. A. Koppara, L.K., W.M., M.W.), Bonn; Center for Geriatric Medicine (K.S.), Ortenau Klinikum, Offenburg-Gengenbach; Department of Gerontopsychiatry (L.F.), Central Institute of Mental Health, Mannheim; Department of Psychiatry (A. Kurz), Technical University of Munich; Department of Neurology (S.S.), University of Aachen; Department of Psychiatry and Psychotherapy (S.S., E.R., J.W.), University of G\u00f6ttingen, Germany; AXA Research Fund & UPMC Chair Sorbonne Universit\u00e9s (H.H.), Universit\u00e9 Pierre et Marie Curie, Paris; Institut de la M\u00e9moire et de la Maladie d'Alzheimer (H.H.), D\u00e9partement de Neurologie, H\u00f4pital de la Piti\u00e9-Salp\u00e9tri\u00e8re, Paris; INSERM U1127 (H.H.), Institut du Cerveau et de la Moelle \u00e9pini\u00e8re, Paris, France; Department of Psychiatry (I.H., O.P., F.M.R.), Charit\u00e9 Berlin, Campus Benjamin Franklin, Berlin; Department of Psychiatry (H.J.), University of Hamburg; Department of Psychiatry (C.L.), University of D\u00fcsseldorf; Center for Geriatric Medicine and Gerontology (M.H.), University of Freiburg; Department of Psychiatry (H.-J.G.), University of Leipzig; Department of Psychiatry (J.S.), University of Heidelberg; Department of General Medicine (J.P.), University of Frankfurt, Frankfurt am Main; Department of Medical Informatics (O.R.), University of G\u00f6ttingen, Germany; Brookhaven National Laboratory (F.H.), Upton, New York; and Department of Psychiatry (J.K.), Friedrich-Alexander University Erlangen, Germany. F.J. is currently with the Department of Psychiatry, University of Cologne."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Kornhuber","ForeName":"Johannes","Initials":"J","AffiliationInfo":{"Affiliation":"From the Department of Psychiatry (S.W., F.J., A. Koppara, L.K., W.M., M.W.), University of Bonn; German Center for Neurodegenerative Diseases (S.W., F.J. A. Koppara, L.K., W.M., M.W.), Bonn; Center for Geriatric Medicine (K.S.), Ortenau Klinikum, Offenburg-Gengenbach; Department of Gerontopsychiatry (L.F.), Central Institute of Mental Health, Mannheim; Department of Psychiatry (A. Kurz), Technical University of Munich; Department of Neurology (S.S.), University of Aachen; Department of Psychiatry and Psychotherapy (S.S., E.R., J.W.), University of G\u00f6ttingen, Germany; AXA Research Fund & UPMC Chair Sorbonne Universit\u00e9s (H.H.), Universit\u00e9 Pierre et Marie Curie, Paris; Institut de la M\u00e9moire et de la Maladie d'Alzheimer (H.H.), D\u00e9partement de Neurologie, H\u00f4pital de la Piti\u00e9-Salp\u00e9tri\u00e8re, Paris; INSERM U1127 (H.H.), Institut du Cerveau et de la Moelle \u00e9pini\u00e8re, Paris, France; Department of Psychiatry (I.H., O.P., F.M.R.), Charit\u00e9 Berlin, Campus Benjamin Franklin, Berlin; Department of Psychiatry (H.J.), University of Hamburg; Department of Psychiatry (C.L.), University of D\u00fcsseldorf; Center for Geriatric Medicine and Gerontology (M.H.), University of Freiburg; Department of Psychiatry (H.-J.G.), University of Leipzig; Department of Psychiatry (J.S.), University of Heidelberg; Department of General Medicine (J.P.), University of Frankfurt, Frankfurt am Main; Department of Medical Informatics (O.R.), University of G\u00f6ttingen, Germany; Brookhaven National Laboratory (F.H.), Upton, New York; and Department of Psychiatry (J.K.), Friedrich-Alexander University Erlangen, Germany. F.J. is currently with the Department of Psychiatry, University of Cologne."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Wagner","ForeName":"Michael","Initials":"M","AffiliationInfo":{"Affiliation":"From the Department of Psychiatry (S.W., F.J., A. Koppara, L.K., W.M., M.W.), University of Bonn; German Center for Neurodegenerative Diseases (S.W., F.J. A. Koppara, L.K., W.M., M.W.), Bonn; Center for Geriatric Medicine (K.S.), Ortenau Klinikum, Offenburg-Gengenbach; Department of Gerontopsychiatry (L.F.), Central Institute of Mental Health, Mannheim; Department of Psychiatry (A. Kurz), Technical University of Munich; Department of Neurology (S.S.), University of Aachen; Department of Psychiatry and Psychotherapy (S.S., E.R., J.W.), University of G\u00f6ttingen, Germany; AXA Research Fund & UPMC Chair Sorbonne Universit\u00e9s (H.H.), Universit\u00e9 Pierre et Marie Curie, Paris; Institut de la M\u00e9moire et de la Maladie d'Alzheimer (H.H.), D\u00e9partement de Neurologie, H\u00f4pital de la Piti\u00e9-Salp\u00e9tri\u00e8re, Paris; INSERM U1127 (H.H.), Institut du Cerveau et de la Moelle \u00e9pini\u00e8re, Paris, France; Department of Psychiatry (I.H., O.P., F.M.R.), Charit\u00e9 Berlin, Campus Benjamin Franklin, Berlin; Department of Psychiatry (H.J.), University of Hamburg; Department of Psychiatry (C.L.), University of D\u00fcsseldorf; Center for Geriatric Medicine and Gerontology (M.H.), University of Freiburg; Department of Psychiatry (H.-J.G.), University of Leipzig; Department of Psychiatry (J.S.), University of Heidelberg; Department of General Medicine (J.P.), University of Frankfurt, Frankfurt am Main; Department of Medical Informatics (O.R.), University of G\u00f6ttingen, Germany; Brookhaven National Laboratory (F.H.), Upton, New York; and Department of Psychiatry (J.K.), Friedrich-Alexander University Erlangen, Germany. F.J. is currently with the Department of Psychiatry, University of Cologne."}}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Multicenter Study","Observational Study","Research Support, Non-U.S. Gov't"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2015","Month":"02","Day":"25"}},"MedlineJournalInfo":{"Country":"United States","MedlineTA":"Neurology","NlmUniqueID":"0401060","ISSNLinking":"0028-3878"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"Amyloid beta-Peptides"},{"RegistryNumber":"0","NameOfSubstance":"Biomarkers"},{"RegistryNumber":"0","NameOfSubstance":"Peptide Fragments"},{"RegistryNumber":"0","NameOfSubstance":"amyloid beta-protein (1-42)"},{"RegistryNumber":"0","NameOfSubstance":"tau Proteins"}]},"CitationSubset":["AIM","IM"],"MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Aged, 80 and over"},{"DescriptorName":"Alzheimer Disease","QualifierName":["cerebrospinal fluid","physiopathology","psychology"]},{"DescriptorName":"Amyloid beta-Peptides","QualifierName":"cerebrospinal fluid"},{"DescriptorName":"Biomarkers","QualifierName":"cerebrospinal fluid"},{"DescriptorName":"Cognitive Dysfunction","QualifierName":["cerebrospinal fluid","physiopathology","psychology"]},{"DescriptorName":"Female"},{"DescriptorName":"Humans"},{"DescriptorName":"Male"},{"DescriptorName":"Memory Disorders","QualifierName":["cerebrospinal fluid","physiopathology","psychology"]},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Peptide Fragments","QualifierName":"cerebrospinal fluid"},{"DescriptorName":"Prodromal Symptoms"},{"DescriptorName":"tau Proteins","QualifierName":"cerebrospinal fluid"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"entrez"},"Year":"2015","Month":"2","Day":"27","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2015","Month":"2","Day":"27","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2015","Month":"5","Day":"23","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["25716354","WNL.0000000000001399","10.1212\/WNL.0000000000001399"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"25604855","DateCompleted":{"Year":"2016","Month":"06","Day":"15"},"DateRevised":{"Year":"2018","Month":"11","Day":"13"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1476-5438","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"23","Issue":"10","PubDate":{"Year":"2015","Month":"Oct"}},"Title":"European journal of human genetics : EJHG","ISOAbbreviation":"Eur J Hum Genet"},"ArticleTitle":"Rare variants in \u03b2-Amyloid precursor protein (APP) and Parkinson's disease.","Pagination":{"MedlinePgn":"1328-33"},"ELocationID":"10.1038\/ejhg.2014.300","Abstract":{"AbstractText":"Many individuals with Parkinson's disease (PD) develop cognitive deficits, and a phenotypic and molecular overlap between neurodegenerative diseases exists. We investigated the contribution of rare variants in seven genes of known relevance to dementias (\u03b2-amyloid precursor protein (APP), PSEN1\/2, MAPT (microtubule-associated protein tau), fused in sarcoma (FUS), granulin (GRN) and TAR DNA-binding protein 43 (TDP-43)) to PD and PD plus dementia (PD+D) in a discovery sample of 376 individuals with PD and followed by the genotyping of 25 out of the 27 identified variants with a minor allele frequency <5% in 975 individuals with PD, 93 cases with Lewy body disease on neuropathological examination, 613 individuals with Alzheimer's disease (AD), 182 cases with frontotemporal dementia and 1014 general population controls. Variants identified in APP were functionally followed up by A\u03b2 mass spectrometry in transiently transfected HEK293 cells. PD+D cases harbored more rare variants across all the seven genes than PD individuals without dementia, and rare variants in APP were more common in PD cases overall than in either the AD cases or controls. When additional controls from publically available databases were added, one rare variant in APP (c.1795G>A(p.(E599K))) was significantly associated with the PD phenotype but was not found in either the PD cases or controls of an independent replication sample. One of the identified rare variants (c.2125G>A (p.(G709S))) shifted the A\u03b2 spectrum from A\u03b240 to A\u03b239 and A\u03b237. Although the precise mechanism remains to be elucidated, our data suggest a possible role for APP in modifying the PD phenotype as well as a general contribution of genetic factors to the development of dementia in individuals with PD. "},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Schulte","ForeName":"Eva C","Initials":"EC","AffiliationInfo":[{"Affiliation":"Klinik und Poliklinik f\u00fcr Neurologie, Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."},{"Affiliation":"Institut f\u00fcr Humangenetik, Helmholtz Zentrum M\u00fcnchen, Munich, Germany."}]},{"@attributes":{"ValidYN":"Y"},"LastName":"Fukumori","ForeName":"Akio","Initials":"A","AffiliationInfo":[{"Affiliation":"Department of Biochemistry, Adolf-Butenandt-Institut, Ludwig-Maximilians Universit\u00e4t M\u00fcnchen, Munich, Germany."},{"Affiliation":"German Center for Neurodegenerative Diseases (DZNE), Munich, Germany."}]},{"@attributes":{"ValidYN":"Y"},"LastName":"Mollenhauer","ForeName":"Brit","Initials":"B","AffiliationInfo":[{"Affiliation":"Paracelsus Elena Klinik, Kassel, Germany."},{"Affiliation":"Neurochirurgische Klinik, Georg August Universit\u00e4t G\u00f6ttingen, G\u00f6ttingen, Germany."}]},{"@attributes":{"ValidYN":"Y"},"LastName":"Hor","ForeName":"Hyun","Initials":"H","AffiliationInfo":{"Affiliation":"Genomics and Disease Group, Centre for Genomic Regulation (CRG), Pompeu Fabra University (UPF) and Centro de Investigaci\u00f3n Biom\u00e9dica en Red en Epidemiolog\u00eda y Salud P\u00fablica, Barcelona, Spain."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Arzberger","ForeName":"Thomas","Initials":"T","AffiliationInfo":{"Affiliation":"Institut f\u00fcr Neuropathologie, Ludwig-Maximillians Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Perneczky","ForeName":"Robert","Initials":"R","AffiliationInfo":[{"Affiliation":"Psychiatrische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."},{"Affiliation":"Neuroepidemiology and Ageing Research Unit, School of Public Health, Faculty of Medicine, The Imperial College of Science, Technology and Medicine, London, UK."}]},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A","AffiliationInfo":{"Affiliation":"Psychiatrische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Diehl-Schmid","ForeName":"Janine","Initials":"J","AffiliationInfo":{"Affiliation":"Psychiatrische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"H\u00fcll","ForeName":"Michael","Initials":"M","AffiliationInfo":{"Affiliation":"Psychiatrische Universit\u00e4tsklinik, Albert Ludwigs Universit\u00e4t, Freiburg, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Lichtner","ForeName":"Peter","Initials":"P","AffiliationInfo":[{"Affiliation":"Institut f\u00fcr Humangenetik, Helmholtz Zentrum M\u00fcnchen, Munich, Germany."},{"Affiliation":"Institut f\u00fcr Humangenetik, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."}]},{"@attributes":{"ValidYN":"Y"},"LastName":"Eckstein","ForeName":"Gertrud","Initials":"G","AffiliationInfo":{"Affiliation":"Institut f\u00fcr Humangenetik, Helmholtz Zentrum M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Zimprich","ForeName":"Alexander","Initials":"A","AffiliationInfo":{"Affiliation":"Department of Neurology, Medical University of Vienna, Vienna, Austria."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Haubenberger","ForeName":"Dietrich","Initials":"D","AffiliationInfo":{"Affiliation":"Department of Neurology, Medical University of Vienna, Vienna, Austria."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Pirker","ForeName":"Walter","Initials":"W","AffiliationInfo":{"Affiliation":"Department of Neurology, Medical University of Vienna, Vienna, Austria."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Br\u00fccke","ForeName":"Thomas","Initials":"T","AffiliationInfo":{"Affiliation":"Neurologische Klinik, Wilhelminenspital, Vienna, Austria."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Bereznai","ForeName":"Benjamin","Initials":"B","AffiliationInfo":{"Affiliation":"Institute of Genomic Medicine and Rare Disorders, Semmelweis University, Budapest, Hungary."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Molnar","ForeName":"Maria J","Initials":"MJ","AffiliationInfo":{"Affiliation":"Institute of Genomic Medicine and Rare Disorders, Semmelweis University, Budapest, Hungary."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Lorenzo-Betancor","ForeName":"Oswaldo","Initials":"O","AffiliationInfo":[{"Affiliation":"Neurogenetics Laboratory, Division of Neurosciences, Center for Applied Medical Research, University of Navarra, Pamplona, Spain."},{"Affiliation":"Department of Neurology, Clinica Universidad de Navarra, University of Navarra School of Medicine, Pamplona, Spain."},{"Affiliation":"CIBERNED, Centro de Investigacion Biomedica en Red en Enfermedades Neurodegenerativas, Instituto de Salud Carlos III, Spain."}]},{"@attributes":{"ValidYN":"Y"},"LastName":"Pastor","ForeName":"Pau","Initials":"P","Identifier":"http:\/\/orcid.org\/0000-0002-7493-8777","AffiliationInfo":[{"Affiliation":"Neurogenetics Laboratory, Division of Neurosciences, Center for Applied Medical Research, University of Navarra, Pamplona, Spain."},{"Affiliation":"Department of Neurology, Clinica Universidad de Navarra, University of Navarra School of Medicine, Pamplona, Spain."},{"Affiliation":"CIBERNED, Centro de Investigacion Biomedica en Red en Enfermedades Neurodegenerativas, Instituto de Salud Carlos III, Spain."}]},{"@attributes":{"ValidYN":"Y"},"LastName":"Peters","ForeName":"Annette","Initials":"A","AffiliationInfo":{"Affiliation":"Institut f\u00fcr Epidemiologie II, Helmholtz Zentrum M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Gieger","ForeName":"Christian","Initials":"C","AffiliationInfo":{"Affiliation":"Institut f\u00fcr Genetische Epidemiologie, Helmholtz Zentrum M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Estivill","ForeName":"Xavier","Initials":"X","AffiliationInfo":{"Affiliation":"Genomics and Disease Group, Centre for Genomic Regulation (CRG), Pompeu Fabra University (UPF) and Centro de Investigaci\u00f3n Biom\u00e9dica en Red en Epidemiolog\u00eda y Salud P\u00fablica, Barcelona, Spain."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Meitinger","ForeName":"Thomas","Initials":"T","AffiliationInfo":[{"Affiliation":"Institut f\u00fcr Humangenetik, Helmholtz Zentrum M\u00fcnchen, Munich, Germany."},{"Affiliation":"Institut f\u00fcr Humangenetik, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."},{"Affiliation":"Munich Cluster for Systems Neurology, SyNergy, Munich, Germany."}]},{"@attributes":{"ValidYN":"Y"},"LastName":"Kretzschmar","ForeName":"Hans A","Initials":"HA","AffiliationInfo":{"Affiliation":"Institut f\u00fcr Neuropathologie, Ludwig-Maximillians Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Trenkwalder","ForeName":"Claudia","Initials":"C","AffiliationInfo":[{"Affiliation":"Paracelsus Elena Klinik, Kassel, Germany."},{"Affiliation":"Neurochirurgische Klinik, Georg August Universit\u00e4t G\u00f6ttingen, G\u00f6ttingen, Germany."}]},{"@attributes":{"ValidYN":"Y"},"LastName":"Haass","ForeName":"Christian","Initials":"C","AffiliationInfo":[{"Affiliation":"Department of Biochemistry, Adolf-Butenandt-Institut, Ludwig-Maximilians Universit\u00e4t M\u00fcnchen, Munich, Germany."},{"Affiliation":"German Center for Neurodegenerative Diseases (DZNE), Munich, Germany."},{"Affiliation":"Munich Cluster for Systems Neurology, SyNergy, Munich, Germany."}]},{"@attributes":{"ValidYN":"Y"},"LastName":"Winkelmann","ForeName":"Juliane","Initials":"J","AffiliationInfo":[{"Affiliation":"Klinik und Poliklinik f\u00fcr Neurologie, Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."},{"Affiliation":"Institut f\u00fcr Humangenetik, Helmholtz Zentrum M\u00fcnchen, Munich, Germany."},{"Affiliation":"Institut f\u00fcr Humangenetik, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."},{"Affiliation":"Munich Cluster for Systems Neurology, SyNergy, Munich, Germany."}]}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Research Support, Non-U.S. Gov't"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2015","Month":"01","Day":"21"}},"MedlineJournalInfo":{"Country":"England","MedlineTA":"Eur J Hum Genet","NlmUniqueID":"9302235","ISSNLinking":"1018-4813"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"Amyloid beta-Protein Precursor"},{"RegistryNumber":"0","NameOfSubstance":"DNA-Binding Proteins"}]},"CitationSubset":"IM","CommentsCorrectionsList":{"CommentsCorrections":{"@attributes":{"RefType":"CommentIn"},"RefSource":"Eur J Hum Genet. 2016 Dec;24(12):1661-1662","PMID":"27329738"}},"MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Alzheimer Disease","QualifierName":"genetics"},{"DescriptorName":"Amyloid beta-Protein Precursor","QualifierName":"genetics"},{"DescriptorName":"Cell Line"},{"DescriptorName":"DNA-Binding Proteins","QualifierName":"genetics"},{"DescriptorName":"Dementia","QualifierName":"genetics"},{"DescriptorName":"Female"},{"DescriptorName":"Gene Frequency","QualifierName":"genetics"},{"DescriptorName":"Genetic Variation","QualifierName":"genetics"},{"DescriptorName":"Genotype"},{"DescriptorName":"HEK293 Cells"},{"DescriptorName":"Humans"},{"DescriptorName":"Male"},{"DescriptorName":"Neurodegenerative Diseases","QualifierName":"genetics"},{"DescriptorName":"Parkinson Disease","QualifierName":"genetics"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2014","Month":"08","Day":"08"},{"@attributes":{"PubStatus":"revised"},"Year":"2014","Month":"12","Day":"18"},{"@attributes":{"PubStatus":"accepted"},"Year":"2014","Month":"12","Day":"19"},{"@attributes":{"PubStatus":"entrez"},"Year":"2015","Month":"1","Day":"22","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2015","Month":"1","Day":"22","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2016","Month":"6","Day":"16","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["25604855","ejhg2014300","10.1038\/ejhg.2014.300","PMC4592093"]},"ReferenceList":{"Reference":[{"Citation":"Ann Neurol. 2000 Feb;47(2):242-5","ArticleIdList":{"ArticleId":"10665497"}},{"Citation":"Mov Disord. 2007 Sep 15;22(12):1689-707; quiz 1837","ArticleIdList":{"ArticleId":"17542011"}},{"Citation":"Mol Psychiatry. 2013 Feb;18(2):245-54","ArticleIdList":{"ArticleId":"22212595"}},{"Citation":"Cold Spring Harb Perspect Med. 2012 May;2(5):a006270","ArticleIdList":{"ArticleId":"22553493"}},{"Citation":"Nat Med. 2012 Feb;18(2):291-5","ArticleIdList":{"ArticleId":"22286308"}},{"Citation":"Lancet Neurol. 2011 Oct;10(10):898-908","ArticleIdList":{"ArticleId":"21885347"}},{"Citation":"PLoS Genet. 2011 Jul;7(7):e1002171","ArticleIdList":{"ArticleId":"21779176"}},{"Citation":"Cell. 2010 Sep 17;142(6):857-67","ArticleIdList":{"ArticleId":"20817278"}},{"Citation":"Brain. 2010 Jun;133(Pt 6):1755-62","ArticleIdList":{"ArticleId":"20371510"}},{"Citation":"J Neurol. 2008 Feb;255(2):255-64","ArticleIdList":{"ArticleId":"18204803"}},{"Citation":"Brain. 2009 Nov;132(Pt 11):2922-31","ArticleIdList":{"ArticleId":"19674978"}},{"Citation":"Nat Genet. 2009 Dec;41(12):1308-12","ArticleIdList":{"ArticleId":"19915575"}},{"Citation":"Arch Neurol. 2003 Mar;60(3):387-92","ArticleIdList":{"ArticleId":"12633150"}},{"Citation":"Lancet. 1987 Nov 21;2(8569):1219-20","ArticleIdList":{"ArticleId":"2890848"}},{"Citation":"Nature. 1991 Feb 21;349(6311):704-6","ArticleIdList":{"ArticleId":"1671712"}},{"Citation":"Nature. 1995 Jun 29;375(6534):754-60","ArticleIdList":{"ArticleId":"7596406"}},{"Citation":"Science. 1995 Aug 18;269(5226):973-7","ArticleIdList":{"ArticleId":"7638622"}},{"Citation":"Nature. 1995 Aug 31;376(6543):775-8","ArticleIdList":{"ArticleId":"7651536"}},{"Citation":"Nature. 1998 Jun 18;393(6686):702-5","ArticleIdList":{"ArticleId":"9641683"}},{"Citation":"Proc Natl Acad Sci U S A. 2006 Feb 7;103(6):1953-8","ArticleIdList":{"ArticleId":"16446437"}},{"Citation":"J Neuropathol Exp Neurol. 2006 Mar;65(3):278-88","ArticleIdList":{"ArticleId":"16651889"}},{"Citation":"Nature. 2006 Aug 24;442(7105):920-4","ArticleIdList":{"ArticleId":"16862115"}},{"Citation":"Science. 2006 Oct 6;314(5796):130-3","ArticleIdList":{"ArticleId":"17023659"}},{"Citation":"J Neurochem. 2013 May;125(4):610-9","ArticleIdList":{"ArticleId":"23253155"}}]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","IndexingMethod":"Curated","Owner":"NLM"},"PMID":"25231337","DateCompleted":{"Year":"2016","Month":"03","Day":"31"},"DateRevised":{"Year":"2018","Month":"12","Day":"02"},"Article":{"@attributes":{"PubModel":"Print"},"Journal":{"ISSN":"1873-4111","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"79","Issue":"2","PubDate":{"Year":"2014","Month":"Oct"}},"Title":"Maturitas","ISOAbbreviation":"Maturitas"},"ArticleTitle":"Non-pharmacological strategies to delay cognitive decline.","Pagination":{"MedlinePgn":"170-3"},"ELocationID":["10.1016\/j.maturitas.2014.07.012","S0378-5122(14)00241-2"],"Abstract":{"AbstractText":"Non-pharmacological preventive strategies to delay cognitive decline have become the focus of recent research. This review aims to discuss evidence supporting the use of physical and cognitive activity to reduce the risk of cognitive decline and dementia in later life. Both strategies are associated with better cognitive health in older adults. This positive effect seems stronger for middle-aged and older adults with normal cognition and less clear when cognitive impairment is present. Physical and cognitive activities have been linked to indirect and direct biological factors affecting brain health. Future research will need to explore details about type, intensity, duration and combination of interventions. An important aim is standardization between studies, as well as evidence of improved clinical outcomes and cost-effectiveness. Identifying strategies that succeed at sustaining improved lifestyle is necessary, and the use of modern technology could play a crucial role in this regard. In the meantime advice on physical and cognitive activities should be included when health advice is given to middle-aged and older adults. ","CopyrightInformation":"Copyright \u00a9 2014. Published by Elsevier Ireland Ltd."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Lautenschlager","ForeName":"Nicola T","Initials":"NT","AffiliationInfo":{"Affiliation":"The Academic Unit for Psychiatry of Old Age, St. Vincent's Health, Department of Psychiatry, University of Melbourne, Melbourne, Australia; School of Psychiatry and Clinical Neurosciences & WA Centre for Health and Ageing, University of Western Australia, Perth, Australia. Electronic address: nicolatl@unimelb.edu.au."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Anstey","ForeName":"Kaarin J","Initials":"KJ","AffiliationInfo":{"Affiliation":"Centre for Research on Ageing Health and Wellbeing, The Australian National University, Canberra, Australia."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander F","Initials":"AF","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."}}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Research Support, Non-U.S. Gov't","Review"]}},"MedlineJournalInfo":{"Country":"Ireland","MedlineTA":"Maturitas","NlmUniqueID":"7807333","ISSNLinking":"0378-5122"},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Cognition"},{"DescriptorName":"Cognition Disorders","QualifierName":"prevention & control"},{"DescriptorName":"Cognitive Aging","QualifierName":"psychology"},{"DescriptorName":"Cost-Benefit Analysis"},{"DescriptorName":"Dementia","QualifierName":"prevention & control"},{"DescriptorName":"Exercise","QualifierName":"psychology"},{"DescriptorName":"Humans"},{"DescriptorName":"Motor Activity"},{"DescriptorName":"Treatment Outcome"}]},"KeywordList":{"@attributes":{"Owner":"NOTNLM"},"Keyword":["Ageing","Alzheimer's disease","Cognitive decline","Dementia","Exercise","Non-pharmacological"]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"entrez"},"Year":"2014","Month":"9","Day":"19","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2014","Month":"9","Day":"19","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2016","Month":"4","Day":"1","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["25231337","S0378-5122(14)00241-2","10.1016\/j.maturitas.2014.07.012"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"25150733","DateCompleted":{"Year":"2015","Month":"11","Day":"23"},"DateRevised":{"Year":"2016","Month":"11","Day":"25"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1552-5279","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"11","Issue":"2","PubDate":{"Year":"2015","Month":"Feb"}},"Title":"Alzheimer's & dementia : the journal of the Alzheimer's Association","ISOAbbreviation":"Alzheimers Dement"},"ArticleTitle":"The use of biomarkers for the etiologic diagnosis of MCI in Europe: an EADC survey.","Pagination":{"MedlinePgn":"195-206.e1"},"ELocationID":["10.1016\/j.jalz.2014.06.006","S1552-5260(14)02465-0"],"Abstract":{"AbstractText":"We investigated the use of Alzheimer's disease (AD) biomarkers in European Alzheimer's Disease Consortium centers and assessed their perceived usefulness for the etiologic diagnosis of mild cognitive impairment (MCI). We surveyed availability, frequency of use, and confidence in diagnostic usefulness of markers of brain amyloidosis (amyloid positron emission tomography [PET], cerebrospinal fluid [CSF] A\u03b242) and neurodegeneration (medial temporal atrophy [MTA] on MR, fluorodeoxyglucose positron emission tomography [FDG-PET], CSF tau). The most frequently used biomarker is visually rated MTA (75% of the 37 responders reported using it \"always\/frequently\") followed by CSF markers (22%), FDG-PET (16%), and amyloid-PET (3%). Only 45% of responders perceive MTA as contributing to diagnostic confidence, where the contribution was rated as \"moderate\". Seventy-nine percent of responders felt \"very\/extremely\" comfortable delivering a diagnosis of MCI due to AD when both amyloid and neuronal injury biomarkers were abnormal (P\u00a0<\u00a0.02 versus any individual biomarker). Responders largely agreed that a combination of amyloidosis and neuronal injury biomarkers was a strongly indicative AD signature. ","CopyrightInformation":"Copyright \u00a9 2015 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Bocchetta","ForeName":"Martina","Initials":"M","AffiliationInfo":{"Affiliation":"LENITEM (Laboratory of Epidemiology, Neuroimaging and Telemedicine), IRCCS Istituto Centro S. Giovanni di Dio Fatebenefratelli, Brescia, Italy; Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Galluzzi","ForeName":"Samantha","Initials":"S","AffiliationInfo":{"Affiliation":"LENITEM (Laboratory of Epidemiology, Neuroimaging and Telemedicine), IRCCS Istituto Centro S. Giovanni di Dio Fatebenefratelli, Brescia, Italy."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Kehoe","ForeName":"Patrick Gavin","Initials":"PG","AffiliationInfo":{"Affiliation":"Dementia Research Group, School of Clinical Sciences, University of Bristol, Frenchay Hospital, Bristol, UK."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Aguera","ForeName":"Eduardo","Initials":"E","AffiliationInfo":{"Affiliation":"Servicio Neurologia, Hospital Universitario Reina Sof\u00eda C\u00f3rdoba, Spain."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Bernabei","ForeName":"Roberto","Initials":"R","AffiliationInfo":{"Affiliation":"Department of Gerontological, Geriatric and Psychiatric Sciences, Universit\u00e0 Cattolica del Sacro Cuore, Rome, Italy."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Bullock","ForeName":"Roger","Initials":"R","AffiliationInfo":{"Affiliation":"Victoria Centre, Swindon, UK."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Ceccaldi","ForeName":"Mathieu","Initials":"M","AffiliationInfo":{"Affiliation":"Service de Neurologie et Neuropsychologie, CHU Timone and INSERM U1106, Aix-Marseille Univ, Marseille, France."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Dartigues","ForeName":"Jean-Fran\u00e7ois","Initials":"JF","AffiliationInfo":{"Affiliation":"Bordeaux CMRR, France."}},{"@attributes":{"ValidYN":"Y"},"LastName":"de Mendon\u00e7a","ForeName":"Alexandre","Initials":"A","AffiliationInfo":{"Affiliation":"Laboratory of Neurosciences, Inst of Molecular Medicine, Lisbon, Portugal."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Didic","ForeName":"Mira","Initials":"M","AffiliationInfo":{"Affiliation":"Service de Neurologie et Neuropsychologie, CHU Timone and INSERM U1106, Aix-Marseille Univ, Marseille, France."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Eriksdotter","ForeName":"Maria","Initials":"M","AffiliationInfo":{"Affiliation":"Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden."}},{"@attributes":{"ValidYN":"Y"},"LastName":"F\u00e9lician","ForeName":"Olivier","Initials":"O","AffiliationInfo":{"Affiliation":"Service de Neurologie et Neuropsychologie, CHU Timone and INSERM U1106, Aix-Marseille Univ, Marseille, France."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Fr\u00f6lich","ForeName":"Lutz","Initials":"L","AffiliationInfo":{"Affiliation":"Department of Geriatric Psychiatry, Zentralinstitut f\u00fcr Seelische, Gesundheit Mannheim, University of Heidelberg, Mannheim, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Gertz","ForeName":"Hermann-Josef","Initials":"HJ","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, University Hospital Leipzig, Leipzig, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Hallikainen","ForeName":"Merja","Initials":"M","AffiliationInfo":{"Affiliation":"University of Eastern Finland, Univ Hospital, Kuopio, Finland."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Hasselbalch","ForeName":"Steen G","Initials":"SG","AffiliationInfo":{"Affiliation":"Memory Disorders Research Unit, Rigshospitalet, Copenhagen, Denmark."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Hausner","ForeName":"Lucrezia","Initials":"L","AffiliationInfo":{"Affiliation":"Department of Geriatric Psychiatry, Zentralinstitut f\u00fcr Seelische, Gesundheit Mannheim, University of Heidelberg, Mannheim, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Heuser","ForeName":"Isabell","Initials":"I","AffiliationInfo":{"Affiliation":"Klinik und Poliklinik f\u00fcr Psychiatrie und Psychotherapie, Universit\u00e4tsklinikum Bonn, Bonn, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Jessen","ForeName":"Frank","Initials":"F","AffiliationInfo":{"Affiliation":"Department of Psychiatry, University of Bonn, Bonn, Germany; German Center for Neurodegenerative Disease (DZNE), Bonn, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Jones","ForeName":"Roy W","Initials":"RW","AffiliationInfo":{"Affiliation":"RICE - The Research Institute for the Care of Older People, Royal United Hospital, Bath, UK."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A","AffiliationInfo":{"Affiliation":"Technische Universit\u00e4t Psychiatrische Klinik, Munchen, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Lawlor","ForeName":"Brian","Initials":"B","AffiliationInfo":{"Affiliation":"Mercer's Institue for Research on Ageing, St James' Hospital, Dublin, Ireland."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Lleo","ForeName":"Alberto","Initials":"A","AffiliationInfo":{"Affiliation":"Memory Unit, Neurology Service, Hospital Santa Creu i, Sant Pau, Barcelona, Spain."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Martinez-Lage","ForeName":"Pablo","Initials":"P","AffiliationInfo":{"Affiliation":"Fundacion CITA-Alzheimer Fundazioa, San Sebastian, Spain."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Mecocci","ForeName":"Patrizia","Initials":"P","AffiliationInfo":{"Affiliation":"Section of Gerontology and Geriatrics, University of Perugia, Perugia, Italy."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Mehrabian","ForeName":"Shima","Initials":"S","AffiliationInfo":{"Affiliation":"Department of Neurology, Univ Hospital Alexandrovska, Sofia, Bulgaria."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Monsch","ForeName":"Andreas","Initials":"A","AffiliationInfo":{"Affiliation":"Memory Clinic, University Center for Medicine of Aging Basel, Felix Platter Hospital, Basel, Switzerland."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Nobili","ForeName":"Flavio","Initials":"F","AffiliationInfo":{"Affiliation":"Clinical Neurology, Dept of Neuroscience (DINOGMI), University of Genoa, Genoa, Italy."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Nordberg","ForeName":"Agneta","Initials":"A","AffiliationInfo":{"Affiliation":"Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Rikkert","ForeName":"Marcel Olde","Initials":"MO","AffiliationInfo":{"Affiliation":"Department of Geriatric Medicine, Radboud University Medical Centre, Radboud Alzheimer Centre, Nijmegen, Netherlands."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Orgogozo","ForeName":"Jean-Marc","Initials":"JM","AffiliationInfo":{"Affiliation":"Bordeaux CMRR, France."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Pasquier","ForeName":"Florence","Initials":"F","AffiliationInfo":{"Affiliation":"CHU de Lille, Universit\u00e9 de Lille 2, Lille, France."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Peters","ForeName":"Oliver","Initials":"O","AffiliationInfo":{"Affiliation":"Department of Psychiatry, Charit\u00e9-Universit\u00e4tsmedizin Berlin, Berlin, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Salmon","ForeName":"Eric","Initials":"E","AffiliationInfo":{"Affiliation":"Universit\u00e9 de Li\u00e8ge, Cyclotron Research Centre, Liege, Belgium."}},{"@attributes":{"ValidYN":"Y"},"LastName":"S\u00e1nchez-Castellano","ForeName":"Carmen","Initials":"C","AffiliationInfo":{"Affiliation":"Servicio de Geriatr\u00eda, Hospital Universitario Ram\u00f3n y Cajal, Madrid, Spain."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Santana","ForeName":"Isabel","Initials":"I","AffiliationInfo":{"Affiliation":"Neurology Department, Coimbra University Hospital, Coimbra, Portugal."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Sarazin","ForeName":"Marie","Initials":"M","AffiliationInfo":{"Affiliation":"Neurologie de la M\u00e9moire et du Langage, Universit\u00e9 Paris Descartes, Sorbonne Paris Cit\u00e9, INSERM UMR S894, Centre Hospitalier Sainte Anne, Paris, France."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Traykov","ForeName":"Latchezar","Initials":"L","AffiliationInfo":{"Affiliation":"Department of Neurology, Univ Hospital Alexandrovska, Sofia, Bulgaria."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Tsolaki","ForeName":"Magda","Initials":"M","AffiliationInfo":{"Affiliation":"3rd Department of Neurology, Aristotle University of Thessaloniki, Thessaloniki, Greece."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Visser","ForeName":"Pieter Jelle","Initials":"PJ","AffiliationInfo":{"Affiliation":"Alzheimer Centre, Vrije Univ Medical Centre, Amsterdam, Netherlands; Alzheimer centre Maastricht University, Maastricht, Netherlands."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Wallin","ForeName":"\u00c5sa K","Initials":"\u00c5K","AffiliationInfo":{"Affiliation":"Clinical Memory Research Unit, Lund University, Memory Clinic Malm\u00f6, Sweden."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Wilcock","ForeName":"Gordon","Initials":"G","AffiliationInfo":{"Affiliation":"University of Oxford, Nuffield Dept of Medicine, John Radcliffe Hospital, Oxford, UK."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Wilkinson","ForeName":"David","Initials":"D","AffiliationInfo":{"Affiliation":"Memory Assessment and Research Centre MARC, Moorgreen Hospital, Southampton, UK."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Wolf","ForeName":"Henrike","Initials":"H","AffiliationInfo":{"Affiliation":"German Center for Neurodegenerative Disease (DZNE), Bonn, Germany; Department of Psychiatry Research, Zurich, Switzerland."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Yener","ForeName":"G\u00f6rsev","Initials":"G","AffiliationInfo":{"Affiliation":"Dokuz Eyl\u00fcl University, Izmir, Turkey."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Zekry","ForeName":"Dina","Initials":"D","AffiliationInfo":{"Affiliation":"Department of Internal Medicine and Geriatrics, University Hospitals and University of Geneva, Geneva, Switzerland."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Frisoni","ForeName":"Giovanni B","Initials":"GB","AffiliationInfo":{"Affiliation":"LENITEM (Laboratory of Epidemiology, Neuroimaging and Telemedicine), IRCCS Istituto Centro S. Giovanni di Dio Fatebenefratelli, Brescia, Italy; Memory Clinic and Laboratoire de Neuroimagerie du Vieillissement (LANVIE), University Hospitals and University of Geneva, Geneva, Switzerland. Electronic address: giovanni.frisoni@gmail.com."}}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Multicenter Study"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2014","Month":"08","Day":"20"}},"MedlineJournalInfo":{"Country":"United States","MedlineTA":"Alzheimers Dement","NlmUniqueID":"101231978","ISSNLinking":"1552-5260"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"Amyloid beta-Peptides"},{"RegistryNumber":"0","NameOfSubstance":"Biomarkers"},{"RegistryNumber":"0","NameOfSubstance":"MAPT protein, human"},{"RegistryNumber":"0","NameOfSubstance":"Peptide Fragments"},{"RegistryNumber":"0","NameOfSubstance":"Radiopharmaceuticals"},{"RegistryNumber":"0","NameOfSubstance":"amyloid beta-protein (1-42)"},{"RegistryNumber":"0","NameOfSubstance":"tau Proteins"},{"RegistryNumber":"0Z5B2CJX4D","NameOfSubstance":"Fluorodeoxyglucose F18"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Alzheimer Disease","QualifierName":["cerebrospinal fluid","complications","diagnosis","pathology"]},{"DescriptorName":"Amyloid beta-Peptides","QualifierName":"cerebrospinal fluid"},{"DescriptorName":"Atrophy"},{"DescriptorName":"Biomarkers","QualifierName":"cerebrospinal fluid"},{"DescriptorName":"Brain","QualifierName":["diagnostic imaging","pathology"]},{"DescriptorName":"Cognitive Dysfunction","QualifierName":["cerebrospinal fluid","diagnosis","etiology","pathology"]},{"DescriptorName":"Europe"},{"DescriptorName":"Fluorodeoxyglucose F18"},{"DescriptorName":"Internet"},{"DescriptorName":"Magnetic Resonance Imaging"},{"DescriptorName":"Peptide Fragments","QualifierName":"cerebrospinal fluid"},{"DescriptorName":"Positron-Emission Tomography"},{"DescriptorName":"Practice Patterns, Physicians'"},{"DescriptorName":"Radiopharmaceuticals"},{"DescriptorName":"Surveys and Questionnaires"},{"DescriptorName":"tau Proteins","QualifierName":"cerebrospinal fluid"}]},"KeywordList":{"@attributes":{"Owner":"NOTNLM"},"Keyword":["Alzheimer's disease","Biomarkers","Diagnosis","Mild cognitive impairment"]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2013","Month":"12","Day":"13"},{"@attributes":{"PubStatus":"revised"},"Year":"2014","Month":"04","Day":"27"},{"@attributes":{"PubStatus":"accepted"},"Year":"2014","Month":"06","Day":"11"},{"@attributes":{"PubStatus":"entrez"},"Year":"2014","Month":"8","Day":"25","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2014","Month":"8","Day":"26","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2015","Month":"12","Day":"15","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["25150733","S1552-5260(14)02465-0","10.1016\/j.jalz.2014.06.006"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","IndexingMethod":"Curated","Owner":"NLM"},"PMID":"25085661","DateCompleted":{"Year":"2014","Month":"12","Day":"05"},"DateRevised":{"Year":"2018","Month":"12","Day":"02"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1744-7666","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"15","Issue":"13","PubDate":{"Year":"2014","Month":"Sep"}},"Title":"Expert opinion on pharmacotherapy","ISOAbbreviation":"Expert Opin Pharmacother"},"ArticleTitle":"Efficacy of memantine hydrochloride once-daily in Alzheimer's disease.","Pagination":{"MedlinePgn":"1955-60"},"ELocationID":"10.1517\/14656566.2014.945907","Abstract":{"AbstractText":["In people with moderate-to-severe dementia in Alzheimer's disease (AD) memantine provides some clinical benefits. It is commonly administered twice daily at a maximum dose of 20 mg. To improve medication adherence, convenience of use and to enable a higher daily dose, a 28 mg, extended-release formulation of memantine has been developed.","We review the results of a Phase III randomized and controlled trial of memantine extended release as an add-on treatment and compared the findings with a similarly designed previous trial evaluating the immediate release (IR) form.","Memantine extended release produced minor benefits on cognitive ability, including verbal fluency, behavioral problems and global clinical assessment. There was no difference between the treatment groups on activities of daily living. The observed effects were not larger than those of the IR formulation tested in a similar setting. The lack of impact on activities of daily living suggests that the small improvements in cognition and behavior did not translate into clinically important changes. In conclusion, there is no convincing evidence that the novel once-daily formulation of memantine represents a significant progress in the clinical management of AD that would justify additional treatment costs."]},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A","AffiliationInfo":{"Affiliation":"Technische Universit\u00e4t M\u00fcnchen, Klinikum rechts der Isar, Department of Psychiatry and Psychotherapy , Ismaninger Strasse 22, D-81675 Munich , Germany alexander.kurz@lrz.tum.de."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Grimmer","ForeName":"Timo","Initials":"T"}]},"Language":"eng","PublicationTypeList":{"PublicationType":"Journal Article"},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2014","Month":"08","Day":"01"}},"MedlineJournalInfo":{"Country":"England","MedlineTA":"Expert Opin Pharmacother","NlmUniqueID":"100897346","ISSNLinking":"1465-6566"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"Excitatory Amino Acid Antagonists"},{"RegistryNumber":"0","NameOfSubstance":"Receptors, N-Methyl-D-Aspartate"},{"RegistryNumber":"W8O17SJF3T","NameOfSubstance":"Memantine"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Activities of Daily Living"},{"DescriptorName":"Alzheimer Disease","QualifierName":["drug therapy","psychology"]},{"DescriptorName":"Cognition Disorders","QualifierName":["drug therapy","psychology"]},{"DescriptorName":"Excitatory Amino Acid Antagonists","QualifierName":["administration & dosage","therapeutic use"]},{"DescriptorName":"Humans"},{"DescriptorName":"Medication Adherence"},{"DescriptorName":"Memantine","QualifierName":["administration & dosage","therapeutic use"]},{"DescriptorName":"Randomized Controlled Trials as Topic"},{"DescriptorName":"Receptors, N-Methyl-D-Aspartate","QualifierName":"antagonists & inhibitors"}]},"KeywordList":{"@attributes":{"Owner":"NOTNLM"},"Keyword":["Alzheimer\u2019s disease","Phase III","efficacy","extended release","memantine","randomized controlled trial"]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"entrez"},"Year":"2014","Month":"8","Day":"3","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2014","Month":"8","Day":"3","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2014","Month":"12","Day":"15","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["25085661","10.1517\/14656566.2014.945907"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","IndexingMethod":"Curated","Owner":"NLM"},"PMID":"25059437","DateCompleted":{"Year":"2016","Month":"03","Day":"31"},"DateRevised":{"Year":"2019","Month":"12","Day":"10"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1873-4111","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"79","Issue":"2","PubDate":{"Year":"2014","Month":"Oct"}},"Title":"Maturitas","ISOAbbreviation":"Maturitas"},"ArticleTitle":"What is frontotemporal dementia?","Pagination":{"MedlinePgn":"216-9"},"ELocationID":["10.1016\/j.maturitas.2014.07.001","S0378-5122(14)00228-X"],"Abstract":{"AbstractText":"Frontotemporal dementia (FTD) is the clinical manifestation of progressive nerve cell loss in the frontal and anterior temporal lobes. It represents the second most frequent form of early-onset dementia. The two major types of FTD are determined by the localisation of the underlying pathology. The behaviour variant is characterised by disinhibition, socially inappropriate manners, loss of empathy, blunting of affect and hyperorality. Key features of the language variant are either non-fluent effortful speech and grammatical errors or impaired word finding and loss of meaning of words and objects. Histopathological changes are characterised by the abnormal processing of proteins including microtubule associated protein Tau, transactive response DNA-binding protein, and tumour-associated protein fused in sarcoma. The familial forms of FTD are caused by mutations in 5 genes. The diagnosis of FTD rests on careful history and psychiatric, neuropsychological and neurological examination supported by laboratory assessments and brain imaging. The management requires an interdisciplinary approach involving the carer and using non-pharmacological approaches in the first line. Current antidementia drugs, including cholinesterase inhibitors and memantine, have no consistent positive effects in FTD. Behavioural symptoms may respond favourably to selective serotonergic antidepressants. Antipsychotic agents should be used with caution regarding motor, cardiovascular and mortality risks. ","CopyrightInformation":"Copyright \u00a9 2014. Published by Elsevier Ireland Ltd."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany. Electronic address: alexander.kurz@lrz.tum.de."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Carolin","Initials":"C","AffiliationInfo":{"Affiliation":"Department of Neurology, Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Ellis","ForeName":"Kathryn","Initials":"K","AffiliationInfo":{"Affiliation":"The Academic Unit for Psychiatry of Old Age, St. Vincent's Health, Department of Psychiatry, University of Melbourne, Australia."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Lautenschlager","ForeName":"Nicola T","Initials":"NT","AffiliationInfo":{"Affiliation":"The Academic Unit for Psychiatry of Old Age, St. Vincent's Health, Department of Psychiatry, University of Melbourne, Australia; School of Psychiatry and Clinical Neurosciences & WA Centre for Health and Ageing, University of Western Australia."}}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Review"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2014","Month":"07","Day":"03"}},"MedlineJournalInfo":{"Country":"Ireland","MedlineTA":"Maturitas","NlmUniqueID":"7807333","ISSNLinking":"0378-5122"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"Antidepressive Agents"},{"RegistryNumber":"0","NameOfSubstance":"DNA-Binding Proteins"},{"RegistryNumber":"0","NameOfSubstance":"FUS protein, human"},{"RegistryNumber":"0","NameOfSubstance":"MAPT protein, human"},{"RegistryNumber":"0","NameOfSubstance":"RNA-Binding Protein FUS"},{"RegistryNumber":"0","NameOfSubstance":"tau Proteins"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Antidepressive Agents","QualifierName":"therapeutic use"},{"DescriptorName":"Aphasia, Primary Progressive","QualifierName":["diagnosis","genetics","psychology","therapy"]},{"DescriptorName":"DNA-Binding Proteins","QualifierName":"genetics"},{"DescriptorName":"Empathy"},{"DescriptorName":"Frontal Lobe","QualifierName":"pathology"},{"DescriptorName":"Frontotemporal Dementia","QualifierName":["diagnosis","genetics","psychology","therapy"]},{"DescriptorName":"Humans"},{"DescriptorName":"Inhibition, Psychological"},{"DescriptorName":"Mutation"},{"DescriptorName":"RNA-Binding Protein FUS","QualifierName":"genetics"},{"DescriptorName":"Social Behavior"},{"DescriptorName":"Temporal Lobe","QualifierName":"pathology"},{"DescriptorName":"tau Proteins","QualifierName":"genetics"}]},"KeywordList":{"@attributes":{"Owner":"NOTNLM"},"Keyword":["Frontotemporal dementia","diagnosis","genetics","management","neuropathology"]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"entrez"},"Year":"2014","Month":"7","Day":"26","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2014","Month":"7","Day":"26","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2016","Month":"4","Day":"1","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["25059437","S0378-5122(14)00228-X","10.1016\/j.maturitas.2014.07.001"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"25043909","DateCompleted":{"Year":"2016","Month":"01","Day":"28"},"DateRevised":{"Year":"2015","Month":"05","Day":"13"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1552-5279","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"11","Issue":"5","PubDate":{"Year":"2015","Month":"May"}},"Title":"Alzheimer's & dementia : the journal of the Alzheimer's Association","ISOAbbreviation":"Alzheimers Dement"},"ArticleTitle":"Link between hippocampus' raised local and eased global intrinsic connectivity in AD.","Pagination":{"MedlinePgn":"475-84"},"ELocationID":["10.1016\/j.jalz.2014.02.007","S1552-5260(14)02415-7"],"Abstract":{"AbstractText":["The hippocampus (HP) is part of the default mode network (DMN), and both are key targets of Alzheimer's disease (AD). Because of widespread network degeneration, it has been suggested that increasing HP disconnection from the DMN may lead to progressive disinhibition of intra-HP synchronized activity.","To analyze HP local (i.e., within HP) and global (i.e., within DMN) intrinsic functional connectivity (local\/global intrinsic functional connectivity [iFC]), healthy controls and patients with mild cognitive impairment and AD dementia were assessed by spatial high and normal resolution resting-state functional magnetic resonance imaging.","Although patients' parietal local-iFC was reduced and positively correlated with reduced global-iFC within the DMN, HP local connectivity was progressively increased and negatively correlated with HP decreased global connectivity. Increased intra-HP connectivity was associated with impaired memory.","Our result demonstrates a link between increased local and reduced global hippocampal connectivity in AD. Increased intra-HP synchrony may contribute to distinct symptoms such as memory impairment or more speculatively epileptic seizure."],"CopyrightInformation":"Copyright \u00a9 2015 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Pasquini","ForeName":"Lorenzo","Initials":"L","AffiliationInfo":{"Affiliation":"Department of Neuroradiology, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany; TUM-Neuroimaging Center, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Scherr","ForeName":"Martin","Initials":"M","AffiliationInfo":{"Affiliation":"TUM-Neuroimaging Center, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany; Department of Neurology, Christian Doppler Klinik, Paracelsus Medical University Salzburg, Salzburg, Austria."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Tahmasian","ForeName":"Masoud","Initials":"M","AffiliationInfo":{"Affiliation":"Department of Neuroradiology, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany; TUM-Neuroimaging Center, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany; Department of Nuclear Medicine, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Meng","ForeName":"Chun","Initials":"C","AffiliationInfo":{"Affiliation":"Department of Neuroradiology, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Myers","ForeName":"Nicholas E","Initials":"NE","AffiliationInfo":{"Affiliation":"TUM-Neuroimaging Center, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany; Department of Experimental Psychology, Oxford University, Oxford, United Kingdom."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Ortner","ForeName":"Marion","Initials":"M","AffiliationInfo":{"Affiliation":"Department of Psychiatry, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"M\u00fchlau","ForeName":"Mark","Initials":"M","AffiliationInfo":{"Affiliation":"TUM-Neuroimaging Center, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany; Department of Neurology of Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A","AffiliationInfo":{"Affiliation":"Department of Psychiatry, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"F\u00f6rstl","ForeName":"Hans","Initials":"H","AffiliationInfo":{"Affiliation":"Department of Psychiatry, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Zimmer","ForeName":"Claus","Initials":"C","AffiliationInfo":{"Affiliation":"Department of Neuroradiology, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Grimmer","ForeName":"Timo","Initials":"T","AffiliationInfo":{"Affiliation":"Department of Psychiatry, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Wohlschl\u00e4ger","ForeName":"Afra M","Initials":"AM","AffiliationInfo":{"Affiliation":"Department of Neuroradiology, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany; TUM-Neuroimaging Center, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Riedl","ForeName":"Valentin","Initials":"V","AffiliationInfo":{"Affiliation":"Department of Neuroradiology, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany; TUM-Neuroimaging Center, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany; Department of Nuclear Medicine, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Sorg","ForeName":"Christian","Initials":"C","AffiliationInfo":{"Affiliation":"Department of Neuroradiology, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany; TUM-Neuroimaging Center, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany; Department of Psychiatry, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany. Electronic address: c.sorg@lrz.tum.de."}}]},"Language":"eng","GrantList":{"@attributes":{"CompleteYN":"Y"},"Grant":{"Agency":"Wellcome Trust","Country":"United Kingdom"}},"PublicationTypeList":{"PublicationType":["Journal Article","Research Support, Non-U.S. Gov't"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2014","Month":"07","Day":"17"}},"MedlineJournalInfo":{"Country":"United States","MedlineTA":"Alzheimers Dement","NlmUniqueID":"101231978","ISSNLinking":"1552-5260"},"ChemicalList":{"Chemical":{"RegistryNumber":"S88TT14065","NameOfSubstance":"Oxygen"}},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Aged, 80 and over"},{"DescriptorName":"Alzheimer Disease","QualifierName":"pathology"},{"DescriptorName":"Analysis of Variance"},{"DescriptorName":"Female"},{"DescriptorName":"Hippocampus","QualifierName":["blood supply","pathology"]},{"DescriptorName":"Humans"},{"DescriptorName":"Image Processing, Computer-Assisted"},{"DescriptorName":"Magnetic Resonance Imaging"},{"DescriptorName":"Male"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Nerve Net","QualifierName":["blood supply","pathology"]},{"DescriptorName":"Neural Pathways","QualifierName":["blood supply","pathology"]},{"DescriptorName":"Neurologic Examination"},{"DescriptorName":"Oxygen","QualifierName":"blood"},{"DescriptorName":"Psychiatric Status Rating Scales"}]},"KeywordList":{"@attributes":{"Owner":"NOTNLM"},"Keyword":["Alzheimer's disease","Default mode network","High-resolution resting-state fMRI","Hippocampus","Independent component analysis","Intrinsic functional connectivity","Mild cognitive impairment","Synchrony"]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2013","Month":"08","Day":"09"},{"@attributes":{"PubStatus":"revised"},"Year":"2013","Month":"12","Day":"18"},{"@attributes":{"PubStatus":"accepted"},"Year":"2014","Month":"02","Day":"20"},{"@attributes":{"PubStatus":"entrez"},"Year":"2014","Month":"7","Day":"22","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2014","Month":"7","Day":"22","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2016","Month":"1","Day":"29","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["25043909","S1552-5260(14)02415-7","10.1016\/j.jalz.2014.02.007"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"25019225","DateCompleted":{"Year":"2016","Month":"04","Day":"25"},"DateRevised":{"Year":"2018","Month":"11","Day":"13"},"Article":{"@attributes":{"PubModel":"Electronic-eCollection"},"Journal":{"ISSN":"1932-6203","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"9","Issue":"7","PubDate":{"Year":"2014"}},"Title":"PloS one","ISOAbbreviation":"PLoS One"},"ArticleTitle":"Memory concerns, memory performance and risk of dementia in patients with mild cognitive impairment.","Pagination":{"MedlinePgn":"e100812"},"ELocationID":"10.1371\/journal.pone.0100812","Abstract":{"AbstractText":["Concerns about worsening memory (\"memory concerns\"; MC) and impairment in memory performance are both predictors of Alzheimer's dementia (AD). The relationship of both in dementia prediction at the pre-dementia disease stage, however, is not well explored. Refined understanding of the contribution of both MC and memory performance in dementia prediction is crucial for defining at-risk populations. We examined the risk of incident AD by MC and memory performance in patients with mild cognitive impairment (MCI).","We analyzed data of 417 MCI patients from a longitudinal multicenter observational study. Patients were classified based on presence (n\u200a=\u200a305) vs. absence (n\u200a=\u200a112) of MC. Risk of incident AD was estimated with Cox Proportional-Hazards regression models.","Risk of incident AD was increased by MC (HR\u200a=\u200a2.55, 95%CI: 1.33-4.89), lower memory performance (HR\u200a=\u200a0.63, 95%CI: 0.56-0.71) and ApoE4-genotype (HR\u200a=\u200a1.89, 95%CI: 1.18-3.02). An interaction effect between MC and memory performance was observed. The predictive power of MC was greatest for patients with very mild memory impairment and decreased with increasing memory impairment.","Our data suggest that the power of MC as a predictor of future dementia at the MCI stage varies with the patients' level of cognitive impairment. While MC are predictive at early stage MCI, their predictive value at more advanced stages of MCI is reduced. This suggests that loss of insight related to AD may occur at the late stage of MCI."]},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Wolfsgruber","ForeName":"Steffen","Initials":"S","AffiliationInfo":{"Affiliation":"Department of Psychiatry, University of Bonn, Bonn, Germany; German Center for Neurodegenerative Diseases, Bonn, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Wagner","ForeName":"Michael","Initials":"M","AffiliationInfo":{"Affiliation":"Department of Psychiatry, University of Bonn, Bonn, Germany; German Center for Neurodegenerative Diseases, Bonn, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Schmidtke","ForeName":"Klaus","Initials":"K","AffiliationInfo":{"Affiliation":"Center for Geriatric Medicine, Ortenau Klinikum, Offenburg-Gengenbach, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Fr\u00f6lich","ForeName":"Lutz","Initials":"L","AffiliationInfo":{"Affiliation":"Department of Gerontopsychiatry, Central Institute of Mental Health, Mannheim, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A","AffiliationInfo":{"Affiliation":"Department of Psychiatry, Technical University of Munich, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Schulz","ForeName":"Stefanie","Initials":"S","AffiliationInfo":{"Affiliation":"Department of Neurology, University of Aachen, Aachen, Germany; Department of Psychiatry, University of G\u00f6ttingen, G\u00f6ttingen, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Hampel","ForeName":"Harald","Initials":"H","AffiliationInfo":{"Affiliation":"Department of Psychiatry, Ludwig Maximilian University, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Heuser","ForeName":"Isabella","Initials":"I","AffiliationInfo":{"Affiliation":"Department of Psychiatry, Charit\u00e9 Berlin, Campus Benjamin Franklin, Berlin, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Peters","ForeName":"Oliver","Initials":"O","AffiliationInfo":{"Affiliation":"Department of Psychiatry, Charit\u00e9 Berlin, Campus Benjamin Franklin, Berlin, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Reischies","ForeName":"Friedel M","Initials":"FM","AffiliationInfo":{"Affiliation":"Department of Psychiatry, Charit\u00e9 Berlin, Campus Benjamin Franklin, Berlin, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Jahn","ForeName":"Holger","Initials":"H","AffiliationInfo":{"Affiliation":"Department of Psychiatry, University of Hamburg, Hamburg, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Luckhaus","ForeName":"Christian","Initials":"C","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"H\u00fcll","ForeName":"Michael","Initials":"M","AffiliationInfo":{"Affiliation":"Center for Geriatric Medicine and Gerontology, University of Freiburg, Freiburg, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Gertz","ForeName":"Hermann-Josef","Initials":"HJ","AffiliationInfo":{"Affiliation":"Department of Psychiatry, University of Leipzig, Leipzig, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Schr\u00f6der","ForeName":"Johannes","Initials":"J","AffiliationInfo":{"Affiliation":"Department of Psychiatry, University of Heidelberg, Heidelberg, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Pantel","ForeName":"Johannes","Initials":"J","AffiliationInfo":{"Affiliation":"Institute of General Practice, University of Frankfurt, Frankfurt am Main, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Rienhoff","ForeName":"Otto","Initials":"O","AffiliationInfo":{"Affiliation":"Department of Medical Informatics, University of G\u00f6ttingen, G\u00f6ttingen, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"R\u00fcther","ForeName":"Eckart","Initials":"E","AffiliationInfo":{"Affiliation":"Department of Psychiatry, University of G\u00f6ttingen, G\u00f6ttingen, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Henn","ForeName":"Fritz","Initials":"F","AffiliationInfo":{"Affiliation":"Brookhaven National Laboratory, Upton, New York, United States of America."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Wiltfang","ForeName":"Jens","Initials":"J","AffiliationInfo":{"Affiliation":"Department of Psychiatry University of Essen, Essen, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Maier","ForeName":"Wolfgang","Initials":"W","AffiliationInfo":{"Affiliation":"Department of Psychiatry, University of Bonn, Bonn, Germany; German Center for Neurodegenerative Diseases, Bonn, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Kornhuber","ForeName":"Johannes","Initials":"J","AffiliationInfo":{"Affiliation":"Department of Psychiatry, Friedrich-Alexander-University Erlangen, Erlangen, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Jessen","ForeName":"Frank","Initials":"F","AffiliationInfo":{"Affiliation":"Department of Psychiatry, University of Bonn, Bonn, Germany; German Center for Neurodegenerative Diseases, Bonn, Germany."}}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Multicenter Study","Observational Study","Research Support, Non-U.S. Gov't"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2014","Month":"07","Day":"14"}},"MedlineJournalInfo":{"Country":"United States","MedlineTA":"PLoS One","NlmUniqueID":"101285081","ISSNLinking":"1932-6203"},"ChemicalList":{"Chemical":{"RegistryNumber":"0","NameOfSubstance":"Apolipoprotein E4"}},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Alzheimer Disease","QualifierName":["epidemiology","genetics"]},{"DescriptorName":"Apolipoprotein E4","QualifierName":"genetics"},{"DescriptorName":"Cognitive Dysfunction","QualifierName":"psychology"},{"DescriptorName":"Female"},{"DescriptorName":"Genotype"},{"DescriptorName":"Humans"},{"DescriptorName":"Longitudinal Studies"},{"DescriptorName":"Male"},{"DescriptorName":"Memory"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Proportional Hazards Models"},{"DescriptorName":"Risk"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2014","Month":"01","Day":"06"},{"@attributes":{"PubStatus":"accepted"},"Year":"2014","Month":"05","Day":"14"},{"@attributes":{"PubStatus":"entrez"},"Year":"2014","Month":"7","Day":"15","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2014","Month":"7","Day":"16","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2016","Month":"4","Day":"26","Hour":"6","Minute":"0"}]},"PublicationStatus":"epublish","ArticleIdList":{"ArticleId":["25019225","10.1371\/journal.pone.0100812","PONE-D-14-00375","PMC4096405"]},"ReferenceList":{"Reference":[{"Citation":"Alzheimers Dement. 2010 May;6(3):239-46","ArticleIdList":{"ArticleId":"20451872"}},{"Citation":"Neurology. 2006 Sep 12;67(5):834-42","ArticleIdList":{"ArticleId":"16966547"}},{"Citation":"Dement Geriatr Cogn Disord. 1998;9 Suppl 2:20-6","ArticleIdList":{"ArticleId":"9718231"}},{"Citation":"Dement Geriatr Cogn Disord. 2004;17(3):181-7","ArticleIdList":{"ArticleId":"14739542"}},{"Citation":"Dement Geriatr Cogn Dis Extra. 2013 Sep 11;3(1):291-300","ArticleIdList":{"ArticleId":"24174924"}},{"Citation":"Int J Geriatr Psychiatry. 2011 Jul;26(7):695-701","ArticleIdList":{"ArticleId":"21495076"}},{"Citation":"Alzheimers Dement. 2014 Jan;10(1):76-83","ArticleIdList":{"ArticleId":"23375567"}},{"Citation":"Neurology. 2012 Oct 9;79(15):1570-7","ArticleIdList":{"ArticleId":"22972644"}},{"Citation":"Neurology. 1989 Sep;39(9):1159-65","ArticleIdList":{"ArticleId":"2771064"}},{"Citation":"Am J Geriatr Psychiatry. 2014 Oct;22(10):1017-28","ArticleIdList":{"ArticleId":"23759289"}},{"Citation":"Arch Neurol. 1996 May;53(5):423-7","ArticleIdList":{"ArticleId":"8624217"}},{"Citation":"Arch Gen Psychiatry. 2010 Apr;67(4):414-22","ArticleIdList":{"ArticleId":"20368517"}},{"Citation":"Acta Neurol Scand. 2012 Jan;125(1):16-23","ArticleIdList":{"ArticleId":"21198445"}},{"Citation":"Int J Geriatr Psychiatry. 2005 Mar;20(3):238-46","ArticleIdList":{"ArticleId":"15717342"}},{"Citation":"Am J Psychiatry. 1999 Apr;156(4):531-7","ArticleIdList":{"ArticleId":"10200730"}},{"Citation":"Alzheimers Dement. 2010 Jan;6(1):11-24","ArticleIdList":{"ArticleId":"20129317"}},{"Citation":"J Am Geriatr Soc. 2012 Jun;60(6):1128-34","ArticleIdList":{"ArticleId":"22690986"}},{"Citation":"Lancet Neurol. 2009 Jul;8(7):619-27","ArticleIdList":{"ArticleId":"19523877"}},{"Citation":"Dement Geriatr Cogn Disord. 2005;19(5-6):349-56","ArticleIdList":{"ArticleId":"15802909"}},{"Citation":"J Alzheimers Dis. 2013;33(2):507-15","ArticleIdList":{"ArticleId":"23247007"}},{"Citation":"Dement Geriatr Cogn Disord. 2009;27(5):404-17","ArticleIdList":{"ArticleId":"19339779"}},{"Citation":"Dement Geriatr Cogn Disord. 2009;28(2):95-109","ArticleIdList":{"ArticleId":"19684399"}},{"Citation":"J Psychiatr Res. 1975 Nov;12(3):189-98","ArticleIdList":{"ArticleId":"1202204"}},{"Citation":"Dement Geriatr Cogn Disord. 2006;22(5-6):471-85","ArticleIdList":{"ArticleId":"17047326"}},{"Citation":"Br J Psychiatry. 1979 Apr;134:382-9","ArticleIdList":{"ArticleId":"444788"}},{"Citation":"Biol Psychiatry. 2008 Mar 15;63(6):609-18","ArticleIdList":{"ArticleId":"17720148"}},{"Citation":"J Intern Med. 2004 Sep;256(3):183-94","ArticleIdList":{"ArticleId":"15324362"}},{"Citation":"Int J Geriatr Psychiatry. 2008 Nov;23(11):1191-202","ArticleIdList":{"ArticleId":"18500688"}},{"Citation":"Int Psychogeriatr. 2013 Aug;25(8):1307-15","ArticleIdList":{"ArticleId":"23693133"}},{"Citation":"Neuropsychologia. 2012 Oct;50(12):2880-6","ArticleIdList":{"ArticleId":"22940426"}},{"Citation":"Ann Neurol. 2010 Mar;67(3):317-24","ArticleIdList":{"ArticleId":"20373343"}},{"Citation":"Neurology. 2012 Sep 25;79(13):1332-9","ArticleIdList":{"ArticleId":"22914828"}},{"Citation":"Arch Clin Neuropsychol. 2005 Mar;20(2):271-6","ArticleIdList":{"ArticleId":"15708735"}},{"Citation":"Alzheimers Dement. 2011 May;7(3):270-9","ArticleIdList":{"ArticleId":"21514249"}},{"Citation":"J Alzheimers Dis. 2010;22(3):993-1003","ArticleIdList":{"ArticleId":"20858977"}},{"Citation":"J Intern Med. 2004 Sep;256(3):240-6","ArticleIdList":{"ArticleId":"15324367"}},{"Citation":"Alzheimers Dement. 2007 Apr;3(2):92-7","ArticleIdList":{"ArticleId":"19595922"}},{"Citation":"Neurology. 2003 Dec 9;61(11):1479-85","ArticleIdList":{"ArticleId":"14663028"}},{"Citation":"Neurology. 1984 Jul;34(7):939-44","ArticleIdList":{"ArticleId":"6610841"}},{"Citation":"J Alzheimers Dis. 2013;34(3):769-80","ArticleIdList":{"ArticleId":"23271318"}},{"Citation":"PLoS One. 2011;6(2):e16852","ArticleIdList":{"ArticleId":"21364746"}}]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"24996404","DateCompleted":{"Year":"2016","Month":"08","Day":"18"},"DateRevised":{"Year":"2018","Month":"11","Day":"13"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1460-2199","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"25","Issue":"12","PubDate":{"Year":"2015","Month":"Dec"}},"Title":"Cerebral cortex (New York, N.Y. : 1991)","ISOAbbreviation":"Cereb Cortex"},"ArticleTitle":"Disrupted Intrinsic Networks Link Amyloid-\u03b2 Pathology and Impaired Cognition in Prodromal Alzheimer's Disease.","Pagination":{"MedlinePgn":"4678-88"},"ELocationID":"10.1093\/cercor\/bhu151","Abstract":{"AbstractText":"Amyloid-\u03b2 pathology (A\u03b2) and impaired cognition characterize Alzheimer's disease (AD); however, neural mechanisms that link A\u03b2-pathology with impaired cognition are incompletely understood. Large-scale intrinsic connectivity networks (ICNs) are potential candidates for this link: A\u03b2-pathology affects specific networks in early AD, these networks show disrupted connectivity, and they process specific cognitive functions impaired in AD, like memory or attention. We hypothesized that, in AD, regional changes of ICNs, which persist across rest- and cognitive task-states, might link A\u03b2-pathology with impaired cognition via impaired intrinsic connectivity. Pittsburgh compound B (PiB)-positron emission tomography reflecting in vivo A\u03b2-pathology, resting-state fMRI, task-fMRI, and cognitive testing were used in patients with prodromal AD and healthy controls. In patients, default mode network's (DMN) functional connectivity (FC) was reduced in the medial parietal cortex during rest relative to healthy controls, relatively increased in the same region during an attention-demanding task, and associated with patients' cognitive impairment. Local PiB-uptake correlated negatively with DMN connectivity. Importantly, corresponding results were found for the right lateral parietal region of an attentional network. Finally, structural equation modeling confirmed a direct influence of DMN resting-state FC on the association between A\u03b2-pathology and cognitive impairment. Data provide evidence that disrupted intrinsic network connectivity links A\u03b2-pathology with cognitive impairment in early AD. ","CopyrightInformation":"\u00a9 The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Koch","ForeName":"Kathrin","Initials":"K","AffiliationInfo":{"Affiliation":"Department of Neuroradiology TUM-Neuroimaging Center of Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen (TUM), 81675 Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Myers","ForeName":"Nicholas E","Initials":"NE","AffiliationInfo":{"Affiliation":"Department of Neuroradiology TUM-Neuroimaging Center of Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen (TUM), 81675 Munich, Germany Department of Experimental Psychology, Oxford University, Oxford OX1 3UD, UK."}},{"@attributes":{"ValidYN":"Y"},"LastName":"G\u00f6ttler","ForeName":"Jens","Initials":"J","AffiliationInfo":{"Affiliation":"Department of Neuroradiology TUM-Neuroimaging Center of Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen (TUM), 81675 Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Pasquini","ForeName":"Lorenzo","Initials":"L","AffiliationInfo":{"Affiliation":"Department of Neuroradiology TUM-Neuroimaging Center of Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen (TUM), 81675 Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Grimmer","ForeName":"Timo","Initials":"T","AffiliationInfo":{"Affiliation":"Department of Psychiatry."}},{"@attributes":{"ValidYN":"Y"},"LastName":"F\u00f6rster","ForeName":"Stefan","Initials":"S","AffiliationInfo":{"Affiliation":"Department of Nuclear Medicine TUM-Neuroimaging Center of Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen (TUM), 81675 Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Manoliu","ForeName":"Andrei","Initials":"A","AffiliationInfo":{"Affiliation":"Department of Neuroradiology Department of Psychiatry TUM-Neuroimaging Center of Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen (TUM), 81675 Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Neitzel","ForeName":"Julia","Initials":"J","AffiliationInfo":{"Affiliation":"Department of Neuroradiology TUM-Neuroimaging Center of Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen (TUM), 81675 Munich, Germany Graduate School of Systemic Neurosciences (GSN), Ludwig-Maximilians-Universit\u00e4t, Biocenter, 82152 Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A","AffiliationInfo":{"Affiliation":"Department of Psychiatry."}},{"@attributes":{"ValidYN":"Y"},"LastName":"F\u00f6rstl","ForeName":"Hans","Initials":"H","AffiliationInfo":{"Affiliation":"Department of Psychiatry."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Riedl","ForeName":"Valentin","Initials":"V","AffiliationInfo":{"Affiliation":"Department of Neuroradiology Department of Nuclear Medicine TUM-Neuroimaging Center of Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen (TUM), 81675 Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Wohlschl\u00e4ger","ForeName":"Afra M","Initials":"AM","AffiliationInfo":{"Affiliation":"Department of Neuroradiology Department of Neurology TUM-Neuroimaging Center of Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen (TUM), 81675 Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Drzezga","ForeName":"Alexander","Initials":"A","AffiliationInfo":{"Affiliation":"Klinik und Poliklinik f\u00fcr Nuklearmedizin,50937 Cologne, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Sorg","ForeName":"Christian","Initials":"C","AffiliationInfo":{"Affiliation":"Department of Neuroradiology Department of Psychiatry Department of Nuclear Medicine TUM-Neuroimaging Center of Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen (TUM), 81675 Munich, Germany."}}]},"Language":"eng","GrantList":{"@attributes":{"CompleteYN":"Y"},"Grant":{"Agency":"Wellcome Trust","Country":"United Kingdom"}},"PublicationTypeList":{"PublicationType":["Journal Article","Research Support, Non-U.S. Gov't"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2014","Month":"07","Day":"04"}},"MedlineJournalInfo":{"Country":"United States","MedlineTA":"Cereb Cortex","NlmUniqueID":"9110718","ISSNLinking":"1047-3211"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole"},{"RegistryNumber":"0","NameOfSubstance":"Amyloid beta-Peptides"},{"RegistryNumber":"0","NameOfSubstance":"Aniline Compounds"},{"RegistryNumber":"0","NameOfSubstance":"Thiazoles"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Aged, 80 and over"},{"DescriptorName":"Alzheimer Disease","QualifierName":["metabolism","psychology"]},{"DescriptorName":"Amyloid beta-Peptides","QualifierName":"metabolism"},{"DescriptorName":"Aniline Compounds"},{"DescriptorName":"Attention","QualifierName":"physiology"},{"DescriptorName":"Brain Mapping"},{"DescriptorName":"Cognition","QualifierName":"physiology"},{"DescriptorName":"Cognitive Dysfunction","QualifierName":["metabolism","psychology"]},{"DescriptorName":"Female"},{"DescriptorName":"Humans"},{"DescriptorName":"Magnetic Resonance Imaging"},{"DescriptorName":"Male"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Neuropsychological Tests"},{"DescriptorName":"Positron-Emission Tomography"},{"DescriptorName":"Thiazoles"}]},"KeywordList":{"@attributes":{"Owner":"NOTNLM"},"Keyword":["PiB-PET","amyloid plaques","impaired cognition","intrinsic connectivity networks","prodromal Alzheimer's disease","resting-state fMRI","task-fMRI"]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"entrez"},"Year":"2014","Month":"7","Day":"6","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2014","Month":"7","Day":"6","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2016","Month":"8","Day":"19","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["24996404","bhu151","10.1093\/cercor\/bhu151","PMC4635914"]},"ReferenceList":{"Reference":[{"Citation":"Neuron. 2009 Jul 30;63(2):178-88","ArticleIdList":{"ArticleId":"19640477"}},{"Citation":"J Alzheimers Dis. 2013;35(3):599-609","ArticleIdList":{"ArticleId":"23478309"}},{"Citation":"J Neurosci. 2006 Oct 4;26(40):10222-31","ArticleIdList":{"ArticleId":"17021177"}},{"Citation":"J Cogn Neurosci. 2011 Dec;23(12):4022-37","ArticleIdList":{"ArticleId":"21671731"}},{"Citation":"Neuron. 2004 Jun 10;42(5):865-75","ArticleIdList":{"ArticleId":"15182724"}},{"Citation":"Brain Connect. 2011;1(1):3-12","ArticleIdList":{"ArticleId":"22432951"}},{"Citation":"Trends Cogn Sci. 2013 Oct;17(10):502-9","ArticleIdList":{"ArticleId":"24018144"}},{"Citation":"Lancet. 2005 Dec 17;366(9503):2112-7","ArticleIdList":{"ArticleId":"16360788"}},{"Citation":"Lancet. 2006 Apr 15;367(9518):1262-70","ArticleIdList":{"ArticleId":"16631882"}},{"Citation":"Neurology. 1989 Sep;39(9):1159-65","ArticleIdList":{"ArticleId":"2771064"}},{"Citation":"Brain. 1999 Jun;122 ( Pt 6):1093-106","ArticleIdList":{"ArticleId":"10356062"}},{"Citation":"Brain. 2006 Nov;129(Pt 11):2856-66","ArticleIdList":{"ArticleId":"16854944"}},{"Citation":"Brain. 1997 Mar;120 ( Pt 3):515-33","ArticleIdList":{"ArticleId":"9126062"}},{"Citation":"Nat Rev Neurosci. 2002 Mar;3(3):201-15","ArticleIdList":{"ArticleId":"11994752"}},{"Citation":"Eur Neurol. 1993;33(6):403-8","ArticleIdList":{"ArticleId":"8307060"}},{"Citation":"Nat Rev Neurosci. 2007 Sep;8(9):700-11","ArticleIdList":{"ArticleId":"17704812"}},{"Citation":"Radiology. 2007 Oct;245(1):224-35","ArticleIdList":{"ArticleId":"17885190"}},{"Citation":"Neuroimage. 2012 Jan 2;59(1):431-8","ArticleIdList":{"ArticleId":"21810475"}},{"Citation":"Neuroimage. 2012 Feb 1;59(3):2142-54","ArticleIdList":{"ArticleId":"22019881"}},{"Citation":"Neurology. 1993 Nov;43(11):2412-4","ArticleIdList":{"ArticleId":"8232972"}},{"Citation":"Ann Neurol. 2004 Jul;56(1):27-35","ArticleIdList":{"ArticleId":"15236399"}},{"Citation":"Proc Natl Acad Sci U S A. 2006 Sep 12;103(37):13848-53","ArticleIdList":{"ArticleId":"16945915"}},{"Citation":"Neuromolecular Med. 2010 Mar;12(1):27-43","ArticleIdList":{"ArticleId":"20069392"}},{"Citation":"Science. 2002 Oct 25;298(5594):789-91","ArticleIdList":{"ArticleId":"12399581"}},{"Citation":"Hum Brain Mapp. 2001 May;13(1):43-53","ArticleIdList":{"ArticleId":"11284046"}},{"Citation":"Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18760-5","ArticleIdList":{"ArticleId":"18003904"}},{"Citation":"Neurosci Lett. 2009 Feb 6;450(3):336-9","ArticleIdList":{"ArticleId":"19010392"}},{"Citation":"J Neurosci. 2009 Oct 7;29(40):12686-94","ArticleIdList":{"ArticleId":"19812343"}},{"Citation":"Lancet Neurol. 2006 Mar;5(3):228-34","ArticleIdList":{"ArticleId":"16488378"}},{"Citation":"Hum Brain Mapp. 2012 May;33(5):1076-88","ArticleIdList":{"ArticleId":"21538702"}},{"Citation":"Front Syst Neurosci. 2011 Feb 04;5:2","ArticleIdList":{"ArticleId":"21442040"}},{"Citation":"Brain. 2011 Jun;134(Pt 6):1635-46","ArticleIdList":{"ArticleId":"21490054"}},{"Citation":"Brain. 2014 Jul;137(Pt 7):2052-64","ArticleIdList":{"ArticleId":"24771519"}},{"Citation":"Biol Psychiatry. 2015 Apr 15;77(8):693-703","ArticleIdList":{"ArticleId":"24529280"}},{"Citation":"Lancet Neurol. 2007 Aug;6(8):734-46","ArticleIdList":{"ArticleId":"17616482"}},{"Citation":"Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4637-42","ArticleIdList":{"ArticleId":"15070770"}},{"Citation":"Science. 2011 Jan 7;331(6013):83-7","ArticleIdList":{"ArticleId":"21212356"}},{"Citation":"Neurology. 2011 Jul 5;77(1):39-47","ArticleIdList":{"ArticleId":"21700583"}},{"Citation":"Neurobiol Aging. 2009 Dec;30(12):1902-9","ArticleIdList":{"ArticleId":"18346821"}},{"Citation":"J Alzheimers Dis. 2012;31 Suppl 3:S1-3","ArticleIdList":{"ArticleId":"22903126"}},{"Citation":"Neuroimage. 2011 Jul 1;57(1):206-13","ArticleIdList":{"ArticleId":"21514392"}},{"Citation":"Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):13040-5","ArticleIdList":{"ArticleId":"19620724"}},{"Citation":"Science. 2008 Sep 19;321(5896):1686-9","ArticleIdList":{"ArticleId":"18802001"}},{"Citation":"Curr Alzheimer Res. 2009 Dec;6(6):541-53","ArticleIdList":{"ArticleId":"19747154"}},{"Citation":"Hum Brain Mapp. 2008 Jul;29(7):828-38","ArticleIdList":{"ArticleId":"18438867"}},{"Citation":"J Nucl Med. 2008 Mar;49(3):390-8","ArticleIdList":{"ArticleId":"18287270"}},{"Citation":"Proc Natl Acad Sci U S A. 2009 Oct 13;106(41):17558-63","ArticleIdList":{"ArticleId":"19805061"}},{"Citation":"Nat Neurosci. 2010 Jul;13(7):812-8","ArticleIdList":{"ArticleId":"20581818"}},{"Citation":"Brain. 2005 Jun;128(Pt 6):1418-27","ArticleIdList":{"ArticleId":"15705612"}},{"Citation":"Neurobiol Aging. 2012 Aug;33(8):1564-78","ArticleIdList":{"ArticleId":"21813210"}},{"Citation":"Alzheimers Dement. 2011 May;7(3):270-9","ArticleIdList":{"ArticleId":"21514249"}},{"Citation":"Trends Cogn Sci. 2008 Mar;12(3):99-105","ArticleIdList":{"ArticleId":"18262825"}},{"Citation":"J Alzheimers Dis. 2011;25(2):309-21","ArticleIdList":{"ArticleId":"21422523"}},{"Citation":"Biol Psychiatry. 2010 Mar 15;67(6):584-7","ArticleIdList":{"ArticleId":"19833321"}},{"Citation":"Ann N Y Acad Sci. 2008 Mar;1124:1-38","ArticleIdList":{"ArticleId":"18400922"}},{"Citation":"Hum Brain Mapp. 2005 Dec;26(4):231-9","ArticleIdList":{"ArticleId":"15954139"}},{"Citation":"J Pers Soc Psychol. 1986 Dec;51(6):1173-82","ArticleIdList":{"ArticleId":"3806354"}},{"Citation":"Acta Neurol Scand. 2005 Mar;111(3):172-9","ArticleIdList":{"ArticleId":"15691286"}},{"Citation":"Proc Natl Acad Sci U S A. 2008 Apr 22;105(16):6173-8","ArticleIdList":{"ArticleId":"18427123"}},{"Citation":"Cereb Cortex. 2011 Oct;21(10):2399-407","ArticleIdList":{"ArticleId":"21383234"}},{"Citation":"J Neurosci. 2009 Feb 11;29(6):1860-73","ArticleIdList":{"ArticleId":"19211893"}}]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"24943344","DateCompleted":{"Year":"2014","Month":"08","Day":"11"},"DateRevised":{"Year":"2019","Month":"12","Day":"20"},"Article":{"@attributes":{"PubModel":"Print"},"Journal":{"ISSN":"1474-4465","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"13","Issue":"7","PubDate":{"Year":"2014","Month":"Jul"}},"Title":"The Lancet. Neurology","ISOAbbreviation":"Lancet Neurol"},"ArticleTitle":"Frontotemporal dementia and its subtypes: a genome-wide association study.","Pagination":{"MedlinePgn":"686-99"},"ELocationID":["10.1016\/S1474-4422(14)70065-1","S1474-4422(14)70065-1"],"Abstract":{"AbstractText":["Frontotemporal dementia (FTD) is a complex disorder characterised by a broad range of clinical manifestations, differential pathological signatures, and genetic variability. Mutations in three genes-MAPT, GRN, and C9orf72--have been associated with FTD. We sought to identify novel genetic risk loci associated with the disorder.","We did a two-stage genome-wide association study on clinical FTD, analysing samples from 3526 patients with FTD and 9402 healthy controls. To reduce genetic heterogeneity, all participants were of European ancestry. In the discovery phase (samples from 2154 patients with FTD and 4308 controls), we did separate association analyses for each FTD subtype (behavioural variant FTD, semantic dementia, progressive non-fluent aphasia, and FTD overlapping with motor neuron disease [FTD-MND]), followed by a meta-analysis of the entire dataset. We carried forward replication of the novel suggestive loci in an independent sample series (samples from 1372 patients and 5094 controls) and then did joint phase and brain expression and methylation quantitative trait loci analyses for the associated (p<5\u2008\u00d7\u200810(-8)) single-nucleotide polymorphisms.","We identified novel associations exceeding the genome-wide significance threshold (p<5\u2008\u00d7\u200810(-8)). Combined (joint) analyses of discovery and replication phases showed genome-wide significant association at 6p21.3, HLA locus (immune system), for rs9268877 (p=1\u00b705\u2008\u00d7\u200810(-8); odds ratio=1\u00b7204 [95% CI 1\u00b711-1\u00b730]), rs9268856 (p=5\u00b751\u2008\u00d7\u200810(-9); 0\u00b7809 [0\u00b776-0\u00b786]) and rs1980493 (p value=1\u00b757\u2008\u00d7\u200810(-8), 0\u00b7775 [0\u00b769-0\u00b786]) in the entire cohort. We also identified a potential novel locus at 11q14, encompassing RAB38\/CTSC (the transcripts of which are related to lysosomal biology), for the behavioural FTD subtype for which joint analyses showed suggestive association for rs302668 (p=2\u00b744\u2008\u00d7\u200810(-7); 0\u00b7814 [0\u00b771-0\u00b792]). Analysis of expression and methylation quantitative trait loci data suggested that these loci might affect expression and methylation in cis.","Our findings suggest that immune system processes (link to 6p21.3) and possibly lysosomal and autophagy pathways (link to 11q14) are potentially involved in FTD. Our findings need to be replicated to better define the association of the newly identified loci with disease and to shed light on the pathomechanisms contributing to FTD.","The National Institute of Neurological Disorders and Stroke and National Institute on Aging, the Wellcome\/MRC Centre on Parkinson's disease, Alzheimer's Research UK, and Texas Tech University Health Sciences Center."],"CopyrightInformation":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Ferrari","ForeName":"Raffaele","Initials":"R","AffiliationInfo":{"Affiliation":"Laboratory of Neurogenetics, Department of Internal Medicine, Texas Tech University Health Science Center, Lubbock, Texas, USA; Reta Lila Weston Research Laboratories, Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Hernandez","ForeName":"Dena G","Initials":"DG","AffiliationInfo":{"Affiliation":"Reta Lila Weston Research Laboratories, Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK; Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Nalls","ForeName":"Michael A","Initials":"MA","AffiliationInfo":{"Affiliation":"Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Rohrer","ForeName":"Jonathan D","Initials":"JD","AffiliationInfo":{"Affiliation":"Reta Lila Weston Research Laboratories, Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK; Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Ramasamy","ForeName":"Adaikalavan","Initials":"A","AffiliationInfo":{"Affiliation":"Reta Lila Weston Research Laboratories, Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK; Department of Medical and Molecular Genetics, King's College London, Guy's Hospital, London, UK."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Kwok","ForeName":"John B J","Initials":"JB","AffiliationInfo":{"Affiliation":"Neuroscience Research Australia, Sydney, NSW, Australia; University of New South Wales, Sydney, NSW, Australia."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Dobson-Stone","ForeName":"Carol","Initials":"C","AffiliationInfo":{"Affiliation":"Neuroscience Research Australia, Sydney, NSW, Australia; University of New South Wales, Sydney, NSW, Australia."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Brooks","ForeName":"William S","Initials":"WS","AffiliationInfo":{"Affiliation":"Neuroscience Research Australia, Sydney, NSW, Australia; University of New South Wales, Sydney, NSW, Australia."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Schofield","ForeName":"Peter R","Initials":"PR","AffiliationInfo":{"Affiliation":"Neuroscience Research Australia, Sydney, NSW, Australia; University of New South Wales, Sydney, NSW, Australia."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Halliday","ForeName":"Glenda M","Initials":"GM","AffiliationInfo":{"Affiliation":"Neuroscience Research Australia, Sydney, NSW, Australia; University of New South Wales, Sydney, NSW, Australia."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Hodges","ForeName":"John R","Initials":"JR","AffiliationInfo":{"Affiliation":"Neuroscience Research Australia, Sydney, NSW, Australia; University of New South Wales, Sydney, NSW, Australia."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Piguet","ForeName":"Olivier","Initials":"O","AffiliationInfo":{"Affiliation":"Neuroscience Research Australia, Sydney, NSW, Australia; University of New South Wales, Sydney, NSW, Australia."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Bartley","ForeName":"Lauren","Initials":"L","AffiliationInfo":{"Affiliation":"Neuroscience Research Australia, Sydney, NSW, Australia."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Thompson","ForeName":"Elizabeth","Initials":"E","AffiliationInfo":{"Affiliation":"South Australian Clinical Genetics Service, SA Pathology at Women's and Children's Hospital, North Adelaide, SA, Australia; Department of Paediatrics, University of Adelaide, Adelaide, SA, Australia."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Haan","ForeName":"Eric","Initials":"E","AffiliationInfo":{"Affiliation":"South Australian Clinical Genetics Service, SA Pathology at Women's and Children's Hospital, North Adelaide, SA, Australia; Department of Paediatrics, University of Adelaide, Adelaide, SA, Australia."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Hern\u00e1ndez","ForeName":"Isabel","Initials":"I","AffiliationInfo":{"Affiliation":"Memory Clinic of Fundaci\u00f3 ACE, Institut Catal\u00e0 de Neuroci\u00e8ncies Aplicades, Barcelona, Spain."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Ruiz","ForeName":"Agust\u00edn","Initials":"A","AffiliationInfo":{"Affiliation":"Memory Clinic of Fundaci\u00f3 ACE, Institut Catal\u00e0 de Neuroci\u00e8ncies Aplicades, Barcelona, Spain."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Boada","ForeName":"Merc\u00e8","Initials":"M","AffiliationInfo":{"Affiliation":"Memory Clinic of Fundaci\u00f3 ACE, Institut Catal\u00e0 de Neuroci\u00e8ncies Aplicades, Barcelona, Spain; Hospital Universitari Vall d'Hebron-Institut de Recerca, Universitat Autonoma de Barcelona (VHIR-UAB), Barcelona, Spain."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Borroni","ForeName":"Barbara","Initials":"B","AffiliationInfo":{"Affiliation":"Neurology Clinic, University of Brescia, Brescia, Italy."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Padovani","ForeName":"Alessandro","Initials":"A","AffiliationInfo":{"Affiliation":"Neurology Clinic, University of Brescia, Brescia, Italy."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Cruchaga","ForeName":"Carlos","Initials":"C","AffiliationInfo":{"Affiliation":"Department of Psychiatry, Washington University School of Medicine, St Louis, Missouri, USA; Hope Center, Washington University School of Medicine, St Louis, Missouri, USA."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Cairns","ForeName":"Nigel J","Initials":"NJ","AffiliationInfo":{"Affiliation":"Hope Center, Washington University School of Medicine, St Louis, Missouri, USA; Department of Pathology and Immunology, Washington University, St Louis, Missouri, USA."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Benussi","ForeName":"Luisa","Initials":"L","AffiliationInfo":{"Affiliation":"NeuroBioGen Lab-Memory Clinic, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Binetti","ForeName":"Giuliano","Initials":"G","AffiliationInfo":{"Affiliation":"NeuroBioGen Lab-Memory Clinic, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Ghidoni","ForeName":"Roberta","Initials":"R","AffiliationInfo":{"Affiliation":"Proteomics Unit, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Forloni","ForeName":"Gianluigi","Initials":"G","AffiliationInfo":{"Affiliation":"Biology of Neurodegenerative Disorders, IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Galimberti","ForeName":"Daniela","Initials":"D","AffiliationInfo":{"Affiliation":"University of Milan, Milan, Italy; Fondazione C\u00e0 Granda, IRCCS Ospedale Maggiore Policlinico, Milan, Italy."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Fenoglio","ForeName":"Chiara","Initials":"C","AffiliationInfo":{"Affiliation":"University of Milan, Milan, Italy; Fondazione C\u00e0 Granda, IRCCS Ospedale Maggiore Policlinico, Milan, Italy."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Serpente","ForeName":"Maria","Initials":"M","AffiliationInfo":{"Affiliation":"University of Milan, Milan, Italy; Fondazione C\u00e0 Granda, IRCCS Ospedale Maggiore Policlinico, Milan, Italy."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Scarpini","ForeName":"Elio","Initials":"E","AffiliationInfo":{"Affiliation":"University of Milan, Milan, Italy; Fondazione C\u00e0 Granda, IRCCS Ospedale Maggiore Policlinico, Milan, Italy."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Clarim\u00f3n","ForeName":"Jordi","Initials":"J","AffiliationInfo":{"Affiliation":"Memory Unit, Neurology Department and Sant Pau Biomedical Research Institute, Hospital de la Santa Creu i Sant Pau, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain; Center for Networker Biomedical Research in Neurodegenerative Diseases (CIBERNED), Madrid, Spain."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Lle\u00f3","ForeName":"Alberto","Initials":"A","AffiliationInfo":{"Affiliation":"Memory Unit, Neurology Department and Sant Pau Biomedical Research Institute, Hospital de la Santa Creu i Sant Pau, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain; Center for Networker Biomedical Research in Neurodegenerative Diseases (CIBERNED), Madrid, Spain."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Blesa","ForeName":"Rafael","Initials":"R","AffiliationInfo":{"Affiliation":"Memory Unit, Neurology Department and Sant Pau Biomedical Research Institute, Hospital de la Santa Creu i Sant Pau, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain; Center for Networker Biomedical Research in Neurodegenerative Diseases (CIBERNED), Madrid, Spain."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Wald\u00f6","ForeName":"Maria Landqvist","Initials":"ML","AffiliationInfo":{"Affiliation":"Unit of Geriatric Psychiatry, Department of Clinical Sciences, Lund University, Sweden."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Nilsson","ForeName":"Karin","Initials":"K","AffiliationInfo":{"Affiliation":"Unit of Geriatric Psychiatry, Department of Clinical Sciences, Lund University, Sweden."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Nilsson","ForeName":"Christer","Initials":"C","AffiliationInfo":{"Affiliation":"Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Sweden."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Mackenzie","ForeName":"Ian R A","Initials":"IR","AffiliationInfo":{"Affiliation":"Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Hsiung","ForeName":"Ging-Yuek R","Initials":"GY","AffiliationInfo":{"Affiliation":"Division of Neurology, University of British Columbia, Vancouver, Canada."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Mann","ForeName":"David M A","Initials":"DM","AffiliationInfo":{"Affiliation":"Institute of Brain, Behaviour and Mental Health, University of Manchester, Salford Royal Hospital, Stott Lane, Salford, UK."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Grafman","ForeName":"Jordan","Initials":"J","AffiliationInfo":{"Affiliation":"Rehabilitation Institute of Chicago, Departments of Physical Medicine and Rehabilitation, Psychiatry, and Cognitive Neurology and Alzheimer's Disease Center, IL, USA; Feinberg School of Medicine, Northwestern University, IL, USA; Department of Psychology, Weinberg College of Arts and Sciences, Northwestern University, IL, USA."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Morris","ForeName":"Christopher M","Initials":"CM","AffiliationInfo":{"Affiliation":"Rehabilitation Institute of Chicago, Departments of Physical Medicine and Rehabilitation, Psychiatry, and Cognitive Neurology and Alzheimer's Disease Center, IL, USA; Feinberg School of Medicine, Northwestern University, IL, USA; Newcastle Brain Tissue Resource, Institute for Ageing and Health, Newcastle University, Newcastle upon Tyne, UK; Newcastle University, Institute for Ageing and Health, Campus for Ageing and Vitality, Newcastle upon Tyne, UK; Institute of Neuroscience, Newcastle University Medical School, Newcastle upon Tyne, UK."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Attems","ForeName":"Johannes","Initials":"J","AffiliationInfo":{"Affiliation":"Rehabilitation Institute of Chicago, Departments of Physical Medicine and Rehabilitation, Psychiatry, and Cognitive Neurology and Alzheimer's Disease Center, IL, USA; Feinberg School of Medicine, Northwestern University, IL, USA; Newcastle Brain Tissue Resource, Institute for Ageing and Health, Newcastle University, Newcastle upon Tyne, UK; Newcastle University, Institute for Ageing and Health, Campus for Ageing and Vitality, Newcastle upon Tyne, UK."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Griffiths","ForeName":"Timothy D","Initials":"TD","AffiliationInfo":{"Affiliation":"Rehabilitation Institute of Chicago, Departments of Physical Medicine and Rehabilitation, Psychiatry, and Cognitive Neurology and Alzheimer's Disease Center, IL, USA; Feinberg School of Medicine, Northwestern University, IL, USA; Newcastle Brain Tissue Resource, Institute for Ageing and Health, Newcastle University, Newcastle upon Tyne, UK; Institute of Neuroscience, Newcastle University Medical School, Newcastle upon Tyne, UK."}},{"@attributes":{"ValidYN":"Y"},"LastName":"McKeith","ForeName":"Ian G","Initials":"IG","AffiliationInfo":{"Affiliation":"Biomedical Research Building, Campus for Ageing and Vitality, Newcastle University, Newcastle upon Tyne, UK."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Thomas","ForeName":"Alan J","Initials":"AJ","AffiliationInfo":{"Affiliation":"Newcastle University, Institute for Ageing and Health, Campus for Ageing and Vitality, Newcastle upon Tyne, UK."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Pietrini","ForeName":"P","Initials":"P","AffiliationInfo":{"Affiliation":"Clinical Psychology Branch, Pisa University Hospital, Pisa, Italy; Laboratory of Clinical Biochemistry and Molecular Biology, University of Pisa, Pisa, Italy."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Huey","ForeName":"Edward D","Initials":"ED","AffiliationInfo":{"Affiliation":"Taub Institute, Departments of Psychiatry and Neurology, Columbia University, New York, NY, USA 10032."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Wassermann","ForeName":"Eric M","Initials":"EM","AffiliationInfo":{"Affiliation":"Behavioral Neurology Unit, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Baborie","ForeName":"Atik","Initials":"A","AffiliationInfo":{"Affiliation":"Neuropathology Department, Walton Centre FT, Liverpool, UK."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Jaros","ForeName":"Evelyn","Initials":"E","AffiliationInfo":{"Affiliation":"Newcastle University, Institute for Ageing and Health, Campus for Ageing and Vitality, Newcastle upon Tyne, UK; Neuropathology\/Cellular Pathology, Royal Victoria Infirmary, Newcastle upon Tyne, UK."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Tierney","ForeName":"Michael C","Initials":"MC","AffiliationInfo":{"Affiliation":"Behavioral Neurology Unit, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Pastor","ForeName":"Pau","Initials":"P","AffiliationInfo":{"Affiliation":"Center for Networker Biomedical Research in Neurodegenerative Diseases (CIBERNED), Madrid, Spain; Neurogenetics Laboratory, Division of Neurosciences, Center for Applied Medical Research, Universidad de Navarra, Pamplona, Spain; Department of Neurology, Cl\u00ednica Universidad de Navarra, University of Navarra School of Medicine, Pamplona, Spain."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Razquin","ForeName":"Cristina","Initials":"C","AffiliationInfo":{"Affiliation":"Neurogenetics Laboratory, Division of Neurosciences, Center for Applied Medical Research, Universidad de Navarra, Pamplona, Spain."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Ortega-Cubero","ForeName":"Sara","Initials":"S","AffiliationInfo":{"Affiliation":"Center for Networker Biomedical Research in Neurodegenerative Diseases (CIBERNED), Madrid, Spain; Neurogenetics Laboratory, Division of Neurosciences, Center for Applied Medical Research, Universidad de Navarra, Pamplona, Spain."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Alonso","ForeName":"Elena","Initials":"E","AffiliationInfo":{"Affiliation":"Neurogenetics Laboratory, Division of Neurosciences, Center for Applied Medical Research, Universidad de Navarra, Pamplona, Spain."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Perneczky","ForeName":"Robert","Initials":"R","AffiliationInfo":{"Affiliation":"Neuroepidemiology and Ageing Research Unit, School of Public Health, Faculty of Medicine, The Imperial College of Science, Technology and Medicine, London, UK; West London Cognitive Disorders Treatment and Research Unit, West London Mental Health Trust, London TW8 8 DS, UK; Department of Psychiatry and Psychotherapy, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Diehl-Schmid","ForeName":"Janine","Initials":"J","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Alexopoulos","ForeName":"Panagiotis","Initials":"P","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Rainero","ForeName":"Innocenzo","Initials":"I","AffiliationInfo":{"Affiliation":"Neurology I, Department of Neuroscience, University of Torino, Italy; AO Citt\u00e0 della Salute e della Scienza di Torino, Italy."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Rubino","ForeName":"Elisa","Initials":"E","AffiliationInfo":{"Affiliation":"Neurology I, Department of Neuroscience, University of Torino, Italy; AO Citt\u00e0 della Salute e della Scienza di Torino, Italy."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Pinessi","ForeName":"Lorenzo","Initials":"L","AffiliationInfo":{"Affiliation":"Neurology I, Department of Neuroscience, University of Torino, Italy; AO Citt\u00e0 della Salute e della Scienza di Torino, Italy."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Rogaeva","ForeName":"Ekaterina","Initials":"E","AffiliationInfo":{"Affiliation":"Tanz Centre for Research in Neurodegenerative Diseases and Department of Medicine, University of Toronto, Toronto, Ontario, Canada."}},{"@attributes":{"ValidYN":"Y"},"LastName":"St George-Hyslop","ForeName":"Peter","Initials":"P","AffiliationInfo":{"Affiliation":"Tanz Centre for Research in Neurodegenerative Diseases and Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Cambridge Institute for Medical Research and the Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Rossi","ForeName":"Giacomina","Initials":"G","AffiliationInfo":{"Affiliation":"Division of Neurology V and Neuropathology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Tagliavini","ForeName":"Fabrizio","Initials":"F","AffiliationInfo":{"Affiliation":"Division of Neurology V and Neuropathology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Giaccone","ForeName":"Giorgio","Initials":"G","AffiliationInfo":{"Affiliation":"Division of Neurology V and Neuropathology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Rowe","ForeName":"James B","Initials":"JB","AffiliationInfo":{"Affiliation":"Cambridge University Department of Clinical Neurosciences, Cambridge CB2 0SZ, UK; MRC Cognition and Brain Sciences Unit, Cambridge, UK; Behavioural and Clinical Neuroscience Institute, Cambridge, UK."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Schlachetzki","ForeName":"Johannes C M","Initials":"JC","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, University of Freiburg Medical School, Germany; Department of Molecular Neurology, University Hospital Erlangen, Erlangen, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Uphill","ForeName":"James","Initials":"J","AffiliationInfo":{"Affiliation":"MRC Prion Unit, Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Collinge","ForeName":"John","Initials":"J","AffiliationInfo":{"Affiliation":"MRC Prion Unit, Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Mead","ForeName":"Simon","Initials":"S","AffiliationInfo":{"Affiliation":"MRC Prion Unit, Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Danek","ForeName":"Adrian","Initials":"A","AffiliationInfo":{"Affiliation":"Neurologische Klinik und Poliklinik, Ludwig-Maximilians-Universit\u00e4t, Munich, Germany; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Van Deerlin","ForeName":"Vivianna M","Initials":"VM","AffiliationInfo":{"Affiliation":"University of Pennsylvania Perelman School of Medicine, Department of Neurology and Penn Frontotemporal Degeneration Center, Philadelphia, PA, USA."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Grossman","ForeName":"Murray","Initials":"M","AffiliationInfo":{"Affiliation":"University of Pennsylvania Perelman School of Medicine, Department of Neurology and Penn Frontotemporal Degeneration Center, Philadelphia, PA, USA."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Trojanowski","ForeName":"John Q","Initials":"JQ","AffiliationInfo":{"Affiliation":"University of Pennsylvania Perelman School of Medicine, Department of Neurology and Penn Frontotemporal Degeneration Center, Philadelphia, PA, USA."}},{"@attributes":{"ValidYN":"Y"},"LastName":"van der Zee","ForeName":"Julie","Initials":"J","AffiliationInfo":{"Affiliation":"Neurodegenerative Brain Diseases group, Department of Molecular Genetics, VIB, Antwerp, Belgium; Laboratory of Neurogenetics, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Deschamps","ForeName":"William","Initials":"W","AffiliationInfo":{"Affiliation":"Neurodegenerative Brain Diseases group, Department of Molecular Genetics, VIB, Antwerp, Belgium; Laboratory of Neurogenetics, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Van Langenhove","ForeName":"Tim","Initials":"T","AffiliationInfo":{"Affiliation":"Neurodegenerative Brain Diseases group, Department of Molecular Genetics, VIB, Antwerp, Belgium; Laboratory of Neurogenetics, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Cruts","ForeName":"Marc","Initials":"M","AffiliationInfo":{"Affiliation":"Neurodegenerative Brain Diseases group, Department of Molecular Genetics, VIB, Antwerp, Belgium; Laboratory of Neurogenetics, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Van Broeckhoven","ForeName":"Christine","Initials":"C","AffiliationInfo":{"Affiliation":"Neurodegenerative Brain Diseases group, Department of Molecular Genetics, VIB, Antwerp, Belgium; Laboratory of Neurogenetics, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Cappa","ForeName":"Stefano F","Initials":"SF","AffiliationInfo":{"Affiliation":"Neurorehabilitation Unit, Deptartment Of Clinical Neuroscience, Vita-Salute University and San Raffaele Scientific Institute, Milan, Italy."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Le Ber","ForeName":"Isabelle","Initials":"I","AffiliationInfo":{"Affiliation":"Inserm, UMR_S975, CRICM, F-75013; UPMC Univ Paris 06, UMR_S975, F-75013; and CNRS UMR 7225, F-75013, Paris, France; AP-HP, H\u00f4pital de la Salp\u00eatri\u00e8re, D\u00e9partement de Neurologie-Centre de R\u00e9f\u00e9rences des D\u00e9mences Rares, F-75013, Paris, France."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Hannequin","ForeName":"Didier","Initials":"D","AffiliationInfo":{"Affiliation":"Service de Neurologie, Inserm U1079, CNR-MAJ, Rouen University Hospital, France."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Golfier","ForeName":"V\u00e9ronique","Initials":"V","AffiliationInfo":{"Affiliation":"Service de neurologie, CH Saint Brieuc, France."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Vercelletto","ForeName":"Martine","Initials":"M","AffiliationInfo":{"Affiliation":"Service de Neurologie, CHU Nantes, France."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Brice","ForeName":"Alexis","Initials":"A","AffiliationInfo":{"Affiliation":"Inserm, UMR_S975, CRICM, F-75013; UPMC Univ Paris 06, UMR_S975, F-75013; and CNRS UMR 7225, F-75013, Paris, France; AP-HP, H\u00f4pital de la Salp\u00eatri\u00e8re, D\u00e9partement de Neurologie-Centre de R\u00e9f\u00e9rences des D\u00e9mences Rares, F-75013, Paris, France."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Nacmias","ForeName":"Benedetta","Initials":"B","AffiliationInfo":{"Affiliation":"Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA) University of Florence, Florence, Italy."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Sorbi","ForeName":"Sandro","Initials":"S","AffiliationInfo":{"Affiliation":"Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA) University of Florence, Florence, Italy."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Bagnoli","ForeName":"Silvia","Initials":"S","AffiliationInfo":{"Affiliation":"Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA) University of Florence, Florence, Italy."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Piaceri","ForeName":"Irene","Initials":"I","AffiliationInfo":{"Affiliation":"Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA) University of Florence, Florence, Italy."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Nielsen","ForeName":"J\u00f8rgen E","Initials":"JE","AffiliationInfo":{"Affiliation":"Danish Dementia Research Centre, Neurogenetics Clinic, Department of Neurology, Rigshospitalet, Copenhagen University Hospital, Denmark; Department of Cellular and Molecular Medicine, Section of Neurogenetics, The Panum Institute, University of Copenhagen, Denmark."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Hjermind","ForeName":"Lena E","Initials":"LE","AffiliationInfo":{"Affiliation":"Danish Dementia Research Centre, Neurogenetics Clinic, Department of Neurology, Rigshospitalet, Copenhagen University Hospital, Denmark; Department of Cellular and Molecular Medicine, Section of Neurogenetics, The Panum Institute, University of Copenhagen, Denmark."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Riemenschneider","ForeName":"Matthias","Initials":"M","AffiliationInfo":{"Affiliation":"Saarland University Hospital, Department for Psychiatry and Psychotherapy, Homburg\/Saar, Germany; Saarland University, Laboratory for Neurogenetics, Kirrberger, Homburg\/Saar, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Mayhaus","ForeName":"Manuel","Initials":"M","AffiliationInfo":{"Affiliation":"Saarland University, Laboratory for Neurogenetics, Kirrberger, Homburg\/Saar, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Ibach","ForeName":"Bernd","Initials":"B","AffiliationInfo":{"Affiliation":"University Regensburg, Department of Psychiatry, Psychotherapy and Psychosomatics, Universit\u00e4tsstr 84, Regensburg, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Gasparoni","ForeName":"Gilles","Initials":"G","AffiliationInfo":{"Affiliation":"Saarland University, Laboratory for Neurogenetics, Kirrberger, Homburg\/Saar, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Pichler","ForeName":"Sabrina","Initials":"S","AffiliationInfo":{"Affiliation":"Saarland University, Laboratory for Neurogenetics, Kirrberger, Homburg\/Saar, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Gu","ForeName":"Wei","Initials":"W","AffiliationInfo":{"Affiliation":"Saarland University, Laboratory for Neurogenetics, Kirrberger, Homburg\/Saar, Germany; Luxembourg Centre For Systems Biomedicine (LCSB), University of Luxembourg, Luxembourg."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Rossor","ForeName":"Martin N","Initials":"MN","AffiliationInfo":{"Affiliation":"Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Fox","ForeName":"Nick C","Initials":"NC","AffiliationInfo":{"Affiliation":"Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Warren","ForeName":"Jason D","Initials":"JD","AffiliationInfo":{"Affiliation":"Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Spillantini","ForeName":"Maria Grazia","Initials":"MG","AffiliationInfo":{"Affiliation":"University of Cambridge, Department of Clinical Neurosciences, John Van Geest Brain Repair Centre, Cambridge, UK."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Morris","ForeName":"Huw R","Initials":"HR","AffiliationInfo":{"Affiliation":"MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, School of Medicine, Cardiff, UK."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Rizzu","ForeName":"Patrizia","Initials":"P","AffiliationInfo":{"Affiliation":"German Center of Neurodegenerative Diseases-T\u00fcbingen, T\u00fcbingen, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Heutink","ForeName":"Peter","Initials":"P","AffiliationInfo":{"Affiliation":"German Center of Neurodegenerative Diseases-T\u00fcbingen, T\u00fcbingen, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Snowden","ForeName":"Julie S","Initials":"JS","AffiliationInfo":{"Affiliation":"Institute of Brain, Behaviour and Mental Health, Faculty of Medical and Human Sciences, University of Manchester, Manchester, UK."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Rollinson","ForeName":"Sara","Initials":"S","AffiliationInfo":{"Affiliation":"Institute of Brain, Behaviour and Mental Health, Faculty of Medical and Human Sciences, University of Manchester, Manchester, UK."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Richardson","ForeName":"Anna","Initials":"A","AffiliationInfo":{"Affiliation":"Salford Royal Foundation Trust, Faculty of Medical and Human Sciences, University of Manchester, UK."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Gerhard","ForeName":"Alexander","Initials":"A","AffiliationInfo":{"Affiliation":"Institute of Brain, Behaviour and Mental Health, The University of Manchester, Withington, Manchester, UK."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Bruni","ForeName":"Amalia C","Initials":"AC","AffiliationInfo":{"Affiliation":"Regional Neurogenetic Centre, ASPCZ, Lamezia Terme, Italy."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Maletta","ForeName":"Raffaele","Initials":"R","AffiliationInfo":{"Affiliation":"Regional Neurogenetic Centre, ASPCZ, Lamezia Terme, Italy."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Frangipane","ForeName":"Francesca","Initials":"F","AffiliationInfo":{"Affiliation":"Regional Neurogenetic Centre, ASPCZ, Lamezia Terme, Italy."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Cupidi","ForeName":"Chiara","Initials":"C","AffiliationInfo":{"Affiliation":"Regional Neurogenetic Centre, ASPCZ, Lamezia Terme, Italy."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Bernardi","ForeName":"Livia","Initials":"L","AffiliationInfo":{"Affiliation":"Regional Neurogenetic Centre, ASPCZ, Lamezia Terme, Italy."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Anfossi","ForeName":"Maria","Initials":"M","AffiliationInfo":{"Affiliation":"Regional Neurogenetic Centre, ASPCZ, Lamezia Terme, Italy."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Gallo","ForeName":"Maura","Initials":"M","AffiliationInfo":{"Affiliation":"Regional Neurogenetic Centre, ASPCZ, Lamezia Terme, Italy."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Conidi","ForeName":"Maria Elena","Initials":"ME","AffiliationInfo":{"Affiliation":"Regional Neurogenetic Centre, ASPCZ, Lamezia Terme, Italy."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Smirne","ForeName":"Nicoletta","Initials":"N","AffiliationInfo":{"Affiliation":"Regional Neurogenetic Centre, ASPCZ, Lamezia Terme, Italy."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Rademakers","ForeName":"Rosa","Initials":"R","AffiliationInfo":{"Affiliation":"Department of Neuroscience, Mayo Clinic Jacksonville, Jacksonville, FL, USA."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Baker","ForeName":"Matt","Initials":"M","AffiliationInfo":{"Affiliation":"Department of Neuroscience, Mayo Clinic Jacksonville, Jacksonville, FL, USA."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Dickson","ForeName":"Dennis W","Initials":"DW","AffiliationInfo":{"Affiliation":"Department of Neuroscience, Mayo Clinic Jacksonville, Jacksonville, FL, USA."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Graff-Radford","ForeName":"Neill R","Initials":"NR","AffiliationInfo":{"Affiliation":"Department of Neurology, Mayo Clinic Jacksonville, Jacksonville, FL, USA."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Petersen","ForeName":"Ronald C","Initials":"RC","AffiliationInfo":{"Affiliation":"Department of Neurology, Mayo Clinic Rochester, Rochester, MN, USA."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Knopman","ForeName":"David","Initials":"D","AffiliationInfo":{"Affiliation":"Department of Neurology, Mayo Clinic Rochester, Rochester, MN, USA."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Josephs","ForeName":"Keith A","Initials":"KA","AffiliationInfo":{"Affiliation":"Department of Neurology, Mayo Clinic Rochester, Rochester, MN, USA."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Boeve","ForeName":"Bradley F","Initials":"BF","AffiliationInfo":{"Affiliation":"Department of Neurology, Mayo Clinic Rochester, Rochester, MN, USA."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Parisi","ForeName":"Joseph E","Initials":"JE","AffiliationInfo":{"Affiliation":"Department of Pathology, Mayo Clinic Rochester, Rochester, MN, USA."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Seeley","ForeName":"William W","Initials":"WW","AffiliationInfo":{"Affiliation":"Department of Neurology, University of California, San Francisco, CA, USA."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Miller","ForeName":"Bruce L","Initials":"BL","AffiliationInfo":{"Affiliation":"Department of Neurology, University of California, San Francisco, CA, USA."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Karydas","ForeName":"Anna M","Initials":"AM","AffiliationInfo":{"Affiliation":"Department of Neurology, University of California, San Francisco, CA, USA."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Rosen","ForeName":"Howard","Initials":"H","AffiliationInfo":{"Affiliation":"Department of Neurology, University of California, San Francisco, CA, USA."}},{"@attributes":{"ValidYN":"Y"},"LastName":"van Swieten","ForeName":"John C","Initials":"JC","AffiliationInfo":{"Affiliation":"Department of Neurology, Erasmus Medical Centre, Rotterdam, The Netherlands; Department of Medical Genetics, VU University Medical Centre, Amsterdam, The Netherlands."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Dopper","ForeName":"Elise G P","Initials":"EG","AffiliationInfo":{"Affiliation":"Department of Neurology, Erasmus Medical Centre, Rotterdam, The Netherlands."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Seelaar","ForeName":"Harro","Initials":"H","AffiliationInfo":{"Affiliation":"Department of Neurology, Erasmus Medical Centre, Rotterdam, The Netherlands."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Pijnenburg","ForeName":"Yolande A L","Initials":"YA","AffiliationInfo":{"Affiliation":"Alzheimer Centre and Department of Neurology, VU University Medical Centre, Amsterdam, The Netherlands."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Scheltens","ForeName":"Philip","Initials":"P","AffiliationInfo":{"Affiliation":"Alzheimer Centre and Department of Neurology, VU University Medical Centre, Amsterdam, The Netherlands."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Logroscino","ForeName":"Giancarlo","Initials":"G","AffiliationInfo":{"Affiliation":"Department of Basic Medical Sciences, Neurosciences and Sense Organs of the Aldo Moro, University of Bari, Italy."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Capozzo","ForeName":"Rosa","Initials":"R","AffiliationInfo":{"Affiliation":"Department of Basic Medical Sciences, Neurosciences and Sense Organs of the Aldo Moro, University of Bari, Italy."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Novelli","ForeName":"Valeria","Initials":"V","AffiliationInfo":{"Affiliation":"Department of Molecular Cardiology, IRCCS Fondazione S Maugeri, Pavia, Italy."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Puca","ForeName":"Annibale A","Initials":"AA","AffiliationInfo":{"Affiliation":"Cardiovascular Research Unit, IRCCS Multimedica, Milan, Italy; Department of Medicine and Surgery, University of Salerno, Baronissi (SA), Italy."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Franceschi","ForeName":"Massimo","Initials":"M","AffiliationInfo":{"Affiliation":"Neurology Department, IRCCS Multimedica, Milan, Italy."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Postiglione","ForeName":"Alfredo","Initials":"A","AffiliationInfo":{"Affiliation":"Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Milan","ForeName":"Graziella","Initials":"G","AffiliationInfo":{"Affiliation":"Geriatric Center Frullone-ASL Napoli 1 Centro, Naples, Italy."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Sorrentino","ForeName":"Paolo","Initials":"P","AffiliationInfo":{"Affiliation":"Geriatric Center Frullone-ASL Napoli 1 Centro, Naples, Italy."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Kristiansen","ForeName":"Mark","Initials":"M","AffiliationInfo":{"Affiliation":"UCL Genomics, Institute of Child Health (ICH), UCL, London, UK."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Chiang","ForeName":"Huei-Hsin","Initials":"HH","AffiliationInfo":{"Affiliation":"Karolinska Institutet, Department NVS, KI-Alzheimer Disease Research Center, Stockholm, Sweden; Department of Geriatric Medicine, Genetics Unit, Karolinska Universtiy Hospital, Stockholm."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Graff","ForeName":"Caroline","Initials":"C","AffiliationInfo":{"Affiliation":"Karolinska Institutet, Department NVS, KI-Alzheimer Disease Research Center, Stockholm, Sweden; Department of Geriatric Medicine, Genetics Unit, Karolinska Universtiy Hospital, Stockholm."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Pasquier","ForeName":"Florence","Initials":"F","AffiliationInfo":{"Affiliation":"Universit\u00e9 Lille Nord de France, Lille, France."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Rollin","ForeName":"Adeline","Initials":"A","AffiliationInfo":{"Affiliation":"Universit\u00e9 Lille Nord de France, Lille, France."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Deramecourt","ForeName":"Vincent","Initials":"V","AffiliationInfo":{"Affiliation":"Universit\u00e9 Lille Nord de France, Lille, France."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Lebert","ForeName":"Florence","Initials":"F","AffiliationInfo":{"Affiliation":"Universit\u00e9 Lille Nord de France, Lille, France."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Kapogiannis","ForeName":"Dimitrios","Initials":"D","AffiliationInfo":{"Affiliation":"Laboratory of Neurosciences, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Ferrucci","ForeName":"Luigi","Initials":"L","AffiliationInfo":{"Affiliation":"Clinical Research Branch, National Institute on Aging, Baltimore, MD, USA."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Pickering-Brown","ForeName":"Stuart","Initials":"S","AffiliationInfo":{"Affiliation":"Institute of Brain, Behaviour and Mental Health, Faculty of Medical and Human Sciences, University of Manchester, Manchester, UK."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Singleton","ForeName":"Andrew B","Initials":"AB","AffiliationInfo":{"Affiliation":"Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Hardy","ForeName":"John","Initials":"J","AffiliationInfo":{"Affiliation":"Reta Lila Weston Research Laboratories, Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK. Electronic address: j.hardy@ucl.ac.uk."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Momeni","ForeName":"Parastoo","Initials":"P","AffiliationInfo":{"Affiliation":"Laboratory of Neurogenetics, Department of Internal Medicine, Texas Tech University Health Science Center, Lubbock, Texas, USA."}}]},"Language":"eng","GrantList":{"@attributes":{"CompleteYN":"Y"},"Grant":[{"GrantID":"R01 NS076837","Acronym":"NS","Agency":"NINDS NIH HHS","Country":"United States"},{"GrantID":"R01 NS044266","Acronym":"NS","Agency":"NINDS NIH HHS","Country":"United States"},{"GrantID":"P01 AG032953","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"G0901254","Agency":"Medical Research Council","Country":"United Kingdom"},{"GrantID":"ZIA AG000932","Agency":"Intramural NIH HHS","Country":"United States"},{"GrantID":"MR\/L016451\/1","Agency":"Medical Research Council","Country":"United Kingdom"},{"GrantID":"MC_U123192748","Agency":"Medical Research Council","Country":"United Kingdom"},{"GrantID":"P50 AG05681","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"P30 AG010124","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"P50 AG023501","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"089701","Agency":"Wellcome Trust","Country":"United Kingdom"},{"GrantID":"P50 NS72187","Acronym":"NS","Agency":"NINDS NIH HHS","Country":"United States"},{"GrantID":"ZIA AG000932-04","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"P50 AG016574","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"P01 AG017586","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"AG017586","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"MC_U123160651","Agency":"Medical Research Council","Country":"United Kingdom"},{"GrantID":"P50AG023501","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"G1100643","Agency":"Medical Research Council","Country":"United Kingdom"},{"GrantID":"R01 NS076471","Acronym":"NS","Agency":"NINDS NIH HHS","Country":"United States"},{"GrantID":"P50NS072187","Acronym":"NS","Agency":"NINDS NIH HHS","Country":"United States"},{"GrantID":"P01 AG003991","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"P50 AG005681","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"P01 AG026276","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"MC_U105597119","Agency":"Medical Research Council","Country":"United Kingdom"},{"GrantID":"G0400074","Agency":"Medical Research Council","Country":"United Kingdom"},{"GrantID":"P01 AG03991","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"G0900652","Agency":"Medical Research Council","Country":"United Kingdom"},{"GrantID":"089703","Agency":"Wellcome Trust","Country":"United Kingdom"},{"GrantID":"P50AG016574","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"G0802462","Agency":"Medical Research Council","Country":"United Kingdom"},{"GrantID":"AG010124","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"P01 AG019724","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"G0301152","Agency":"Medical Research Council","Country":"United Kingdom"},{"GrantID":"G0502157","Agency":"Medical Research Council","Country":"United Kingdom"},{"Agency":"Canadian Institutes of Health Research","Country":"Canada"},{"GrantID":"R01 AG032306","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"G0701441","Agency":"Medical Research Council","Country":"United Kingdom"},{"GrantID":"G1100540","Agency":"Medical Research Council","Country":"United Kingdom"},{"GrantID":"P50 NS072187","Acronym":"NS","Agency":"NINDS NIH HHS","Country":"United States"},{"GrantID":"AG019724","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"MR\/J009482\/1","Agency":"Medical Research Council","Country":"United Kingdom"},{"GrantID":"P30-NS069329-01","Acronym":"NS","Agency":"NINDS NIH HHS","Country":"United States"},{"GrantID":"R01 AG041797","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"AG032953","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"091681","Agency":"Wellcome Trust","Country":"United Kingdom"},{"GrantID":"R01 NS065782","Acronym":"NS","Agency":"NINDS NIH HHS","Country":"United States"},{"GrantID":"AG032306","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"R01 AG037491","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"MR\/K006584\/1","Agency":"Medical Research Council","Country":"United Kingdom"},{"GrantID":"088324","Agency":"Wellcome Trust","Country":"United Kingdom"},{"GrantID":"P01 AG003949","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"AG023501","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"R01 AG026251","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"P30 NS069329","Acronym":"NS","Agency":"NINDS NIH HHS","Country":"United States"},{"GrantID":"100140","Agency":"Wellcome Trust","Country":"United Kingdom"},{"GrantID":"081864","Agency":"Wellcome Trust","Country":"United Kingdom"},{"GrantID":"U01 AG006786","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"P01AG019724","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"NS044266","Acronym":"NS","Agency":"NINDS NIH HHS","Country":"United States"},{"GrantID":"G0700943","Agency":"Medical Research Council","Country":"United Kingdom"},{"GrantID":"R01 NS080882","Acronym":"NS","Agency":"NINDS NIH HHS","Country":"United States"}]},"PublicationTypeList":{"PublicationType":["Journal Article","Multicenter Study","Research Support, N.I.H., Extramural","Research Support, N.I.H., Intramural","Research Support, Non-U.S. Gov't","Research Support, U.S. Gov't, Non-P.H.S."]}},"MedlineJournalInfo":{"Country":"England","MedlineTA":"Lancet Neurol","NlmUniqueID":"101139309","ISSNLinking":"1474-4422"},"CitationSubset":"IM","CommentsCorrectionsList":{"CommentsCorrections":{"@attributes":{"RefType":"CommentIn"},"RefSource":"Lancet Neurol. 2014 Jul;13(7):643-4","PMID":"24943334"}},"MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Adult"},{"DescriptorName":"Aged"},{"DescriptorName":"Aged, 80 and over"},{"DescriptorName":"Female"},{"DescriptorName":"Frontotemporal Dementia","QualifierName":["classification","diagnosis","genetics"]},{"DescriptorName":"Genome-Wide Association Study","QualifierName":"methods"},{"DescriptorName":"Genotype"},{"DescriptorName":"Humans"},{"DescriptorName":"Male"},{"DescriptorName":"Middle Aged"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"entrez"},"Year":"2014","Month":"6","Day":"20","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2014","Month":"6","Day":"20","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2014","Month":"8","Day":"12","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["24943344","S1474-4422(14)70065-1","10.1016\/S1474-4422(14)70065-1","PMC4112126","NIHMS599470"]},"ReferenceList":{"Reference":[{"Citation":"Exp Neurol. 2014 Dec;262 Pt B:75-83","ArticleIdList":{"ArticleId":"24246281"}},{"Citation":"Neurogenetics. 2006 May;7(2):67-80","ArticleIdList":{"ArticleId":"16572319"}},{"Citation":"Nat Genet. 2006 Aug;38(8):904-9","ArticleIdList":{"ArticleId":"16862161"}},{"Citation":"Nature. 2006 Aug 24;442(7105):920-4","ArticleIdList":{"ArticleId":"16862115"}},{"Citation":"Nature. 2006 Aug 24;442(7105):916-9","ArticleIdList":{"ArticleId":"16862116"}},{"Citation":"N Engl J Med. 2007 Aug 30;357(9):851-62","ArticleIdList":{"ArticleId":"17660530"}},{"Citation":"J Pathol. 2007 Dec;213(4):369-75","ArticleIdList":{"ArticleId":"17990279"}},{"Citation":"Cell Tissue Bank. 2008 Sep;9(3):229-45","ArticleIdList":{"ArticleId":"18347928"}},{"Citation":"Neurology. 2008 Oct 7;71(15):1191-7","ArticleIdList":{"ArticleId":"18838666"}},{"Citation":"Hum Mol Genet. 2009 Feb 15;18(4):767-78","ArticleIdList":{"ArticleId":"19010793"}},{"Citation":"Amyotroph Lateral Scler. 2009 Jun;10(3):131-46","ArticleIdList":{"ArticleId":"19462523"}},{"Citation":"Annu Rev Genomics Hum Genet. 2009;10:387-406","ArticleIdList":{"ArticleId":"19715440"}},{"Citation":"Nat Genet. 2009 Oct;41(10):1083-7","ArticleIdList":{"ArticleId":"19734901"}},{"Citation":"Nucleic Acids Res. 2010 Jan;38(3):e17","ArticleIdList":{"ArticleId":"19923232"}},{"Citation":"Nat Genet. 2010 Mar;42(3):234-9","ArticleIdList":{"ArticleId":"20154673"}},{"Citation":"CNS Drugs. 2010 May;24(5):375-98","ArticleIdList":{"ArticleId":"20369906"}},{"Citation":"JAMA. 2010 May 12;303(18):1832-40","ArticleIdList":{"ArticleId":"20460622"}},{"Citation":"PLoS Genet. 2010 May;6(5):e1000952","ArticleIdList":{"ArticleId":"20485568"}},{"Citation":"PLoS One. 2010;5(5):e10693","ArticleIdList":{"ArticleId":"20502693"}},{"Citation":"Nat Genet. 2010 Sep;42(9):781-5","ArticleIdList":{"ArticleId":"20711177"}},{"Citation":"Nature. 2010 Sep 2;467(7311):52-8","ArticleIdList":{"ArticleId":"20811451"}},{"Citation":"Genet Epidemiol. 2010 Dec;34(8):816-34","ArticleIdList":{"ArticleId":"21058334"}},{"Citation":"Neuron. 2010 Nov 18;68(4):654-67","ArticleIdList":{"ArticleId":"21092856"}},{"Citation":"Lancet. 2011 Feb 19;377(9766):641-9","ArticleIdList":{"ArticleId":"21292315"}},{"Citation":"Neurology. 2011 Mar 15;76(11):1006-14","ArticleIdList":{"ArticleId":"21325651"}},{"Citation":"Nature. 1998 Jun 18;393(6686):702-5","ArticleIdList":{"ArticleId":"9641683"}},{"Citation":"Acta Neuropathol. 2011 Jul;122(1):111-3","ArticleIdList":{"ArticleId":"21644037"}},{"Citation":"Nat Genet. 2011 Jul;43(7):699-705","ArticleIdList":{"ArticleId":"21685912"}},{"Citation":"Neurology. 1998 Dec;51(6):1546-54","ArticleIdList":{"ArticleId":"9855500"}},{"Citation":"Traffic. 2011 Apr;12(4):407-20","ArticleIdList":{"ArticleId":"21255211"}},{"Citation":"Cancer Res. 2000 Jul 1;60(13):3584-91","ArticleIdList":{"ArticleId":"10910072"}},{"Citation":"Biostatistics. 2003 Apr;4(2):249-64","ArticleIdList":{"ArticleId":"12925520"}},{"Citation":"PLoS Genet. 2011 Jun;7(6):e1002142","ArticleIdList":{"ArticleId":"21738488"}},{"Citation":"Trends Mol Med. 2011 Sep;17(9):485-93","ArticleIdList":{"ArticleId":"21723784"}},{"Citation":"Brain. 2011 Sep;134(Pt 9):2456-77","ArticleIdList":{"ArticleId":"21810890"}},{"Citation":"J Neurochem. 2011 Oct;119(2):275-82","ArticleIdList":{"ArticleId":"21848658"}},{"Citation":"Neuron. 2011 Oct 20;72(2):245-56","ArticleIdList":{"ArticleId":"21944778"}},{"Citation":"Neuron. 2011 Oct 20;72(2):257-68","ArticleIdList":{"ArticleId":"21944779"}},{"Citation":"Nature. 2011 Oct 27;478(7370):483-9","ArticleIdList":{"ArticleId":"22031440"}},{"Citation":"Curr Opin Neurol. 2011 Dec;24(6):542-9","ArticleIdList":{"ArticleId":"21986680"}},{"Citation":"Bioinformatics. 2012 May 15;28(10):1353-8","ArticleIdList":{"ArticleId":"22492648"}},{"Citation":"J Biol Chem. 2012 Jun 1;287(23):19550-63","ArticleIdList":{"ArticleId":"22511774"}},{"Citation":"Acta Neuropathol. 2012 Sep;124(3):373-82","ArticleIdList":{"ArticleId":"22878865"}},{"Citation":"Nature. 2012 Sep 20;489(7416):391-9","ArticleIdList":{"ArticleId":"22996553"}},{"Citation":"Nature. 2012 Nov 1;491(7422):56-65","ArticleIdList":{"ArticleId":"23128226"}},{"Citation":"Hum Mol Genet. 2013 Feb 15;22(4):685-95","ArticleIdList":{"ArticleId":"23136129"}},{"Citation":"Hum Mutat. 2013 Feb;34(2):363-73","ArticleIdList":{"ArticleId":"23111906"}},{"Citation":"PLoS One. 2013;8(3):e58352","ArticleIdList":{"ArticleId":"23472185"}},{"Citation":"Nucleic Acids Res. 2013 Apr;41(7):e88","ArticleIdList":{"ArticleId":"23435227"}},{"Citation":"Int Rev Psychiatry. 2013 Apr;25(2):221-9","ArticleIdList":{"ArticleId":"23611351"}},{"Citation":"J Mol Med (Berl). 2013 Jun;91(6):673-81","ArticleIdList":{"ArticleId":"23546523"}},{"Citation":"PLoS One. 2013;8(7):e68095","ArticleIdList":{"ArticleId":"23874508"}},{"Citation":"Neuron. 2013 Aug 7;79(3):416-38","ArticleIdList":{"ArticleId":"23931993"}},{"Citation":"Nat Genet. 2013 Dec;45(12):1452-8","ArticleIdList":{"ArticleId":"24162737"}}]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"24857233","DateCompleted":{"Year":"2015","Month":"07","Day":"30"},"DateRevised":{"Year":"2016","Month":"11","Day":"25"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1552-5279","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"10","Issue":"6","PubDate":{"Year":"2014","Month":"Nov"}},"Title":"Alzheimer's & dementia : the journal of the Alzheimer's Association","ISOAbbreviation":"Alzheimers Dement"},"ArticleTitle":"Limited agreement between biomarkers of neuronal injury at different stages of Alzheimer's disease.","Pagination":{"MedlinePgn":"684-9"},"ELocationID":["10.1016\/j.jalz.2014.03.006","S1552-5260(14)00112-5"],"Abstract":{"AbstractText":"New diagnostic criteria for Alzheimer's disease (AD) treat different biomarkers of neuronal injury as equivalent. Here, we quantified the degree of agreement between hippocampal volume on structural magnetic resonance imaging, regional glucose metabolism on positron emission tomography, and levels of phosphorylated tau in cerebrospinal fluid (CSF) in 585 subjects from all phases of the AD Neuroimaging Initiative. The overall chance-corrected agreement was poor (Cohen \u03ba, 0.24-0.34), in accord with a high rate of conflicting findings (26%-41%). Neither diagnosis nor APOE \u03b54 status significantly influenced the distribution of agreement between the biomarkers. The degree of agreement tended to be higher in individuals with abnormal versus normal CSF \u03b2-amyloid (A\u03b21-42) levels. Prospective diagnostic criteria for AD should address the relative importance of markers of neuronal injury and elaborate a way of dealing with conflicting biomarker findings. ","CopyrightInformation":"Copyright \u00a9 2014 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Alexopoulos","ForeName":"Panagiotis","Initials":"P","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany; Department of Psychiatry, University of Patras, Rion Patras, Greece."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Kriett","ForeName":"Laura","Initials":"L","AffiliationInfo":{"Affiliation":"Department of Nuclear Medicine, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Haller","ForeName":"Bernhard","Initials":"B","AffiliationInfo":{"Affiliation":"Institute of Medical Statistics and Epidemiology, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Klupp","ForeName":"Elisabeth","Initials":"E","AffiliationInfo":{"Affiliation":"Department of Nuclear Medicine, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Gray","ForeName":"Katherine","Initials":"K","AffiliationInfo":{"Affiliation":"Biomedical Image Analysis Group, Department of Computing, Imperial College London, UK."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Grimmer","ForeName":"Timo","Initials":"T","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Laskaris","ForeName":"Nikolaos","Initials":"N","AffiliationInfo":{"Affiliation":"Department of Informatics, Aristotle University of Thessaloniki, Thessaloniki, Greece."}},{"@attributes":{"ValidYN":"Y"},"LastName":"F\u00f6rster","ForeName":"Stefan","Initials":"S","AffiliationInfo":{"Affiliation":"Department of Nuclear Medicine, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Perneczky","ForeName":"Robert","Initials":"R","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany; Neuroepidemiology and Ageing Research Unit, School of Public Health, The Imperial College of Science, Technology and Medicine, London, UK; West London Cognitive Disorders Treatment and Research Unit, West London Mental Health Trust, London, UK."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Drzezga","ForeName":"Alexander","Initials":"A","AffiliationInfo":{"Affiliation":"Department of Nuclear Medicine, University of Cologne, Cologne, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Fellgiebel","ForeName":"Andreas","Initials":"A","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, University Medical Center of Mainz, Mainz, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Yakushev","ForeName":"Igor","Initials":"I","AffiliationInfo":{"Affiliation":"Department of Nuclear Medicine, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany. Electronic address: igor.yakushev@lrz.tum.de."}},{"@attributes":{"ValidYN":"Y"},"CollectiveName":"Alzheimer's Disease Neuroimaging Initiative"}]},"Language":"eng","GrantList":{"@attributes":{"CompleteYN":"Y"},"Grant":[{"GrantID":"U01 AG024904","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"Agency":"Canadian Institutes of Health Research","Country":"Canada"}]},"PublicationTypeList":{"PublicationType":["Journal Article","Research Support, N.I.H., Extramural","Research Support, Non-U.S. Gov't","Research Support, U.S. Gov't, Non-P.H.S."]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2014","Month":"05","Day":"22"}},"MedlineJournalInfo":{"Country":"United States","MedlineTA":"Alzheimers Dement","NlmUniqueID":"101231978","ISSNLinking":"1552-5260"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"Apolipoproteins E"},{"RegistryNumber":"0","NameOfSubstance":"Biomarkers"},{"RegistryNumber":"0","NameOfSubstance":"tau Proteins"},{"RegistryNumber":"0Z5B2CJX4D","NameOfSubstance":"Fluorodeoxyglucose F18"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Alzheimer Disease","QualifierName":["complications","pathology"]},{"DescriptorName":"Apolipoproteins E","QualifierName":"genetics"},{"DescriptorName":"Atrophy","QualifierName":"etiology"},{"DescriptorName":"Biomarkers","QualifierName":"cerebrospinal fluid"},{"DescriptorName":"Chi-Square Distribution"},{"DescriptorName":"Cognitive Dysfunction","QualifierName":["diagnosis","etiology"]},{"DescriptorName":"Female"},{"DescriptorName":"Fluorodeoxyglucose F18"},{"DescriptorName":"Hippocampus","QualifierName":["diagnostic imaging","pathology"]},{"DescriptorName":"Humans"},{"DescriptorName":"Male"},{"DescriptorName":"Mental Status Schedule"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Positron-Emission Tomography"},{"DescriptorName":"tau Proteins","QualifierName":"cerebrospinal fluid"}]},"KeywordList":{"@attributes":{"Owner":"NOTNLM"},"Keyword":["Agreement","Dementia","Diagnostic criteria","FDG-PET","Hippocampal atrophy","Tau"]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2013","Month":"11","Day":"21"},{"@attributes":{"PubStatus":"revised"},"Year":"2014","Month":"02","Day":"13"},{"@attributes":{"PubStatus":"accepted"},"Year":"2014","Month":"03","Day":"16"},{"@attributes":{"PubStatus":"entrez"},"Year":"2014","Month":"5","Day":"27","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2014","Month":"5","Day":"27","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2015","Month":"8","Day":"1","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["24857233","S1552-5260(14)00112-5","10.1016\/j.jalz.2014.03.006"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"24771519","DateCompleted":{"Year":"2014","Month":"08","Day":"25"},"DateRevised":{"Year":"2018","Month":"11","Day":"13"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1460-2156","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"137","Issue":"Pt 7","PubDate":{"Year":"2014","Month":"Jul"}},"Title":"Brain : a journal of neurology","ISOAbbreviation":"Brain"},"ArticleTitle":"Within-patient correspondence of amyloid-\u03b2 and intrinsic network connectivity in Alzheimer's disease.","Pagination":{"MedlinePgn":"2052-64"},"ELocationID":"10.1093\/brain\/awu103","Abstract":{"AbstractText":"There is striking overlap between the spatial distribution of amyloid-\u03b2 pathology in patients with Alzheimer's disease and the spatial distribution of high intrinsic functional connectivity in healthy persons. This overlap suggests a mechanistic link between amyloid-\u03b2 and intrinsic connectivity, and indeed there is evidence in patients for the detrimental effects of amyloid-\u03b2 plaque accumulation on intrinsic connectivity in areas of high connectivity in heteromodal hubs, and particularly in the default mode network. However, the observed spatial extent of amyloid-\u03b2 exceeds these tightly circumscribed areas, suggesting that previous studies may have underestimated the negative impact of amyloid-\u03b2 on intrinsic connectivity. We hypothesized that the known positive baseline correlation between patterns of amyloid-\u03b2 and intrinsic connectivity may mask the larger extent of the negative effects of amyloid-\u03b2 on connectivity. Crucially, a test of this hypothesis requires the within-patient comparison of intrinsic connectivity and amyloid-\u03b2 distributions. Here we compared spatial patterns of amyloid-\u03b2-plaques (measured by Pittsburgh compound B positron emission tomography) and intrinsic functional connectivity (measured by resting-state functional magnetic resonance imaging) in patients with prodromal Alzheimer's disease via spatial correlations in intrinsic networks covering fronto-parietal heteromodal cortices. At the global network level, we found that amyloid-\u03b2 and intrinsic connectivity patterns were positively correlated in the default mode and several fronto-parietal attention networks, confirming that amyloid-\u03b2 aggregates in areas of high intrinsic connectivity on a within-network basis. Further, we saw an internetwork gradient of the magnitude of correlation that depended on network plaque-load. After accounting for this globally positive correlation, local amyloid-\u03b2-plaque concentration in regions of high connectivity co-varied negatively with intrinsic connectivity, indicating that amyloid-\u03b2 pathology adversely reduces connectivity anywhere in an affected network as a function of local amyloid-\u03b2-plaque concentration. The local negative association between amyloid-\u03b2 and intrinsic connectivity was much more pronounced than conventional group comparisons of intrinsic connectivity would suggest. Our findings indicate that the negative impact of amyloid-\u03b2 on intrinsic connectivity in heteromodal networks is underestimated by conventional analyses. Moreover, our results provide first within-patient evidence for correspondent patterns of amyloid-\u03b2 and intrinsic connectivity, with the distribution of amyloid-\u03b2 pathology following functional connectivity gradients within and across intrinsic networks. ","CopyrightInformation":"\u00a9 The Author (2014). Published by Oxford University Press on behalf of the Guarantors of Brain."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Myers","ForeName":"Nicholas","Initials":"N","AffiliationInfo":{"Affiliation":"1 Department of Neuroradiology, Technische Universit\u00e4t M\u00fcnchen, Ismaningerstr. 22, 81675 Munich, Germany2 TUM-Neuroimaging Centre, Technische Universit\u00e4t M\u00fcnchen, Ismaningerstr. 22, 81675 Munich, Germany3 Department of Experimental Psychology, Oxford University, 9 South Parks Road, Oxford OX1 3UD, UK nicholas.myers@psy.ox.ac.uk."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Pasquini","ForeName":"Lorenzo","Initials":"L","AffiliationInfo":{"Affiliation":"1 Department of Neuroradiology, Technische Universit\u00e4t M\u00fcnchen, Ismaningerstr. 22, 81675 Munich, Germany2 TUM-Neuroimaging Centre, Technische Universit\u00e4t M\u00fcnchen, Ismaningerstr. 22, 81675 Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"G\u00f6ttler","ForeName":"Jens","Initials":"J","AffiliationInfo":{"Affiliation":"1 Department of Neuroradiology, Technische Universit\u00e4t M\u00fcnchen, Ismaningerstr. 22, 81675 Munich, Germany2 TUM-Neuroimaging Centre, Technische Universit\u00e4t M\u00fcnchen, Ismaningerstr. 22, 81675 Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Grimmer","ForeName":"Timo","Initials":"T","AffiliationInfo":{"Affiliation":"4 Department of Psychiatry, Technische Universit\u00e4t M\u00fcnchen, Ismaningerstr. 22, 81675 Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Koch","ForeName":"Kathrin","Initials":"K","AffiliationInfo":{"Affiliation":"1 Department of Neuroradiology, Technische Universit\u00e4t M\u00fcnchen, Ismaningerstr. 22, 81675 Munich, Germany2 TUM-Neuroimaging Centre, Technische Universit\u00e4t M\u00fcnchen, Ismaningerstr. 22, 81675 Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Ortner","ForeName":"Marion","Initials":"M","AffiliationInfo":{"Affiliation":"4 Department of Psychiatry, Technische Universit\u00e4t M\u00fcnchen, Ismaningerstr. 22, 81675 Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Neitzel","ForeName":"Julia","Initials":"J","AffiliationInfo":{"Affiliation":"1 Department of Neuroradiology, Technische Universit\u00e4t M\u00fcnchen, Ismaningerstr. 22, 81675 Munich, Germany2 TUM-Neuroimaging Centre, Technische Universit\u00e4t M\u00fcnchen, Ismaningerstr. 22, 81675 Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"M\u00fchlau","ForeName":"Mark","Initials":"M","AffiliationInfo":{"Affiliation":"2 TUM-Neuroimaging Centre, Technische Universit\u00e4t M\u00fcnchen, Ismaningerstr. 22, 81675 Munich, Germany5 Department of Neurology of Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, Ismaningerstr. 22, 81675 Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"F\u00f6rster","ForeName":"Stefan","Initials":"S","AffiliationInfo":{"Affiliation":"2 TUM-Neuroimaging Centre, Technische Universit\u00e4t M\u00fcnchen, Ismaningerstr. 22, 81675 Munich, Germany6 Department of Nuclear Medicine, Technische Universit\u00e4t M\u00fcnchen, Ismaningerstr. 22, 81675 Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A","AffiliationInfo":{"Affiliation":"4 Department of Psychiatry, Technische Universit\u00e4t M\u00fcnchen, Ismaningerstr. 22, 81675 Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"F\u00f6rstl","ForeName":"Hans","Initials":"H","AffiliationInfo":{"Affiliation":"4 Department of Psychiatry, Technische Universit\u00e4t M\u00fcnchen, Ismaningerstr. 22, 81675 Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Zimmer","ForeName":"Claus","Initials":"C","AffiliationInfo":{"Affiliation":"1 Department of Neuroradiology, Technische Universit\u00e4t M\u00fcnchen, Ismaningerstr. 22, 81675 Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Wohlschl\u00e4ger","ForeName":"Afra M","Initials":"AM","AffiliationInfo":{"Affiliation":"1 Department of Neuroradiology, Technische Universit\u00e4t M\u00fcnchen, Ismaningerstr. 22, 81675 Munich, Germany2 TUM-Neuroimaging Centre, Technische Universit\u00e4t M\u00fcnchen, Ismaningerstr. 22, 81675 Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Riedl","ForeName":"Valentin","Initials":"V","AffiliationInfo":{"Affiliation":"1 Department of Neuroradiology, Technische Universit\u00e4t M\u00fcnchen, Ismaningerstr. 22, 81675 Munich, Germany2 TUM-Neuroimaging Centre, Technische Universit\u00e4t M\u00fcnchen, Ismaningerstr. 22, 81675 Munich, Germany6 Department of Nuclear Medicine, Technische Universit\u00e4t M\u00fcnchen, Ismaningerstr. 22, 81675 Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Drzezga","ForeName":"Alexander","Initials":"A","AffiliationInfo":{"Affiliation":"6 Department of Nuclear Medicine, Technische Universit\u00e4t M\u00fcnchen, Ismaningerstr. 22, 81675 Munich, Germany7 Department of Nuclear Medicine, University of Cologne, Kerpener Stra\u00dfe 62, 50937 K\u00f6ln, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Sorg","ForeName":"Christian","Initials":"C","AffiliationInfo":{"Affiliation":"1 Department of Neuroradiology, Technische Universit\u00e4t M\u00fcnchen, Ismaningerstr. 22, 81675 Munich, Germany2 TUM-Neuroimaging Centre, Technische Universit\u00e4t M\u00fcnchen, Ismaningerstr. 22, 81675 Munich, Germany4 Department of Psychiatry, Technische Universit\u00e4t M\u00fcnchen, Ismaningerstr. 22, 81675 Munich, Germany."}}]},"Language":"eng","GrantList":{"@attributes":{"CompleteYN":"Y"},"Grant":{"Agency":"Wellcome Trust","Country":"United Kingdom"}},"PublicationTypeList":{"PublicationType":["Journal Article","Research Support, Non-U.S. Gov't"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2014","Month":"04","Day":"26"}},"MedlineJournalInfo":{"Country":"England","MedlineTA":"Brain","NlmUniqueID":"0372537","ISSNLinking":"0006-8950"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole"},{"RegistryNumber":"0","NameOfSubstance":"Amyloid beta-Peptides"},{"RegistryNumber":"0","NameOfSubstance":"Aniline Compounds"},{"RegistryNumber":"0","NameOfSubstance":"Thiazoles"}]},"CitationSubset":["AIM","IM"],"MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Aged, 80 and over"},{"DescriptorName":"Alzheimer Disease","QualifierName":["metabolism","pathology"]},{"DescriptorName":"Amyloid beta-Peptides","QualifierName":"metabolism"},{"DescriptorName":"Analysis of Variance"},{"DescriptorName":"Aniline Compounds"},{"DescriptorName":"Brain","QualifierName":["diagnostic imaging","pathology"]},{"DescriptorName":"Brain Mapping"},{"DescriptorName":"Female"},{"DescriptorName":"Humans"},{"DescriptorName":"Magnetic Resonance Imaging"},{"DescriptorName":"Male"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Neural Pathways","QualifierName":["diagnostic imaging","pathology"]},{"DescriptorName":"Neuropsychological Tests"},{"DescriptorName":"Plaque, Amyloid","QualifierName":["metabolism","pathology"]},{"DescriptorName":"Positron-Emission Tomography"},{"DescriptorName":"Thiazoles"}]},"KeywordList":{"@attributes":{"Owner":"NOTNLM"},"Keyword":["Alzheimer\u2019s disease","PiB-PET","amyloid-\u03b2 plaques","intrinsic connectivity","resting-state functional MRI"]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"entrez"},"Year":"2014","Month":"4","Day":"29","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2014","Month":"4","Day":"29","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2014","Month":"8","Day":"26","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["24771519","awu103","10.1093\/brain\/awu103","PMC4065018"]},"ReferenceList":{"Reference":[{"Citation":"Neuron. 2009 Jul 30;63(2):178-88","ArticleIdList":{"ArticleId":"19640477"}},{"Citation":"Biol Psychiatry. 2013 Sep 1;74(5):340-7","ArticleIdList":{"ArticleId":"23290495"}},{"Citation":"Lancet. 2006 Apr 15;367(9518):1262-70","ArticleIdList":{"ArticleId":"16631882"}},{"Citation":"J Neurosci. 2012 Jun 27;32(26):8890-9","ArticleIdList":{"ArticleId":"22745490"}},{"Citation":"Proc Natl Acad Sci U S A. 2011 Oct 4;108(40):16783-8","ArticleIdList":{"ArticleId":"21930901"}},{"Citation":"J Neurosci. 2005 Aug 24;25(34):7709-17","ArticleIdList":{"ArticleId":"16120771"}},{"Citation":"Neurology. 1989 Sep;39(9):1159-65","ArticleIdList":{"ArticleId":"2771064"}},{"Citation":"Biol Psychiatry. 2012 May 1;71(9):798-804","ArticleIdList":{"ArticleId":"22079258"}},{"Citation":"Neuroimage. 2012 Jan 2;59(1):431-8","ArticleIdList":{"ArticleId":"21810475"}},{"Citation":"Neuroimage. 2012 Feb 1;59(3):2142-54","ArticleIdList":{"ArticleId":"22019881"}},{"Citation":"Lancet Neurol. 2010 Jan;9(1):119-28","ArticleIdList":{"ArticleId":"20083042"}},{"Citation":"Neuron. 2012 Mar 22;73(6):1216-27","ArticleIdList":{"ArticleId":"22445348"}},{"Citation":"Neuron. 2012 Mar 22;73(6):1204-15","ArticleIdList":{"ArticleId":"22445347"}},{"Citation":"Neurology. 1993 Nov;43(11):2412-4","ArticleIdList":{"ArticleId":"8232972"}},{"Citation":"Nat Neurosci. 2011 Jun;14(6):750-6","ArticleIdList":{"ArticleId":"21532579"}},{"Citation":"Science. 2002 Oct 25;298(5594):789-91","ArticleIdList":{"ArticleId":"12399581"}},{"Citation":"Hum Brain Mapp. 2001 May;13(1):43-53","ArticleIdList":{"ArticleId":"11284046"}},{"Citation":"Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18760-5","ArticleIdList":{"ArticleId":"18003904"}},{"Citation":"Acta Neuropathol. 1991;82(4):239-59","ArticleIdList":{"ArticleId":"1759558"}},{"Citation":"J Neurosci. 2009 Oct 7;29(40):12686-94","ArticleIdList":{"ArticleId":"19812343"}},{"Citation":"Trends Cogn Sci. 2011 Nov;15(11):520-6","ArticleIdList":{"ArticleId":"21983147"}},{"Citation":"Neuroimage. 2003 Jun;19(2 Pt 1):253-60","ArticleIdList":{"ArticleId":"12814576"}},{"Citation":"Cell. 2012 Mar 16;148(6):1204-22","ArticleIdList":{"ArticleId":"22424230"}},{"Citation":"Hum Brain Mapp. 2012 May;33(5):1076-88","ArticleIdList":{"ArticleId":"21538702"}},{"Citation":"Front Syst Neurosci. 2011 Feb 04;5:2","ArticleIdList":{"ArticleId":"21442040"}},{"Citation":"Brain. 2011 Jun;134(Pt 6):1635-46","ArticleIdList":{"ArticleId":"21490054"}},{"Citation":"Schizophr Bull. 2013 Mar;39(2):387-95","ArticleIdList":{"ArticleId":"22241165"}},{"Citation":"Lancet Neurol. 2007 Aug;6(8):734-46","ArticleIdList":{"ArticleId":"17616482"}},{"Citation":"Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4637-42","ArticleIdList":{"ArticleId":"15070770"}},{"Citation":"J Neurosci. 2012 Mar 28;32(13):4334-40","ArticleIdList":{"ArticleId":"22457485"}},{"Citation":"PLoS Comput Biol. 2012;8(8):e1002582","ArticleIdList":{"ArticleId":"22915996"}},{"Citation":"Nat Neurosci. 2012 Jun;15(6):884-90","ArticleIdList":{"ArticleId":"22561454"}},{"Citation":"Science. 2008 Sep 19;321(5896):1686-9","ArticleIdList":{"ArticleId":"18802001"}},{"Citation":"Curr Alzheimer Res. 2009 Dec;6(6):541-53","ArticleIdList":{"ArticleId":"19747154"}},{"Citation":"J Nucl Med. 2008 Mar;49(3):390-8","ArticleIdList":{"ArticleId":"18287270"}},{"Citation":"J Neurosci. 2008 Apr 30;28(18):4756-66","ArticleIdList":{"ArticleId":"18448652"}},{"Citation":"Neurobiol Aging. 2012 Aug;33(8):1564-78","ArticleIdList":{"ArticleId":"21813210"}},{"Citation":"Brain. 2013 Jul;136(Pt 7):2239-52","ArticleIdList":{"ArticleId":"23801740"}},{"Citation":"Neuron. 2009 Apr 16;62(1):42-52","ArticleIdList":{"ArticleId":"19376066"}},{"Citation":"Hum Brain Mapp. 2011 Dec;32(12):2075-95","ArticleIdList":{"ArticleId":"21162045"}},{"Citation":"Neuroimage. 2005 Jul 1;26(3):839-51","ArticleIdList":{"ArticleId":"15955494"}},{"Citation":"Brain. 2013 Mar;136(Pt 3):844-58","ArticleIdList":{"ArticleId":"23358601"}},{"Citation":"J Alzheimers Dis. 2011;25(2):309-21","ArticleIdList":{"ArticleId":"21422523"}},{"Citation":"Proc Natl Acad Sci U S A. 2009 Apr 28;106(17):7209-14","ArticleIdList":{"ArticleId":"19357304"}},{"Citation":"Biol Psychiatry. 2010 Mar 15;67(6):584-7","ArticleIdList":{"ArticleId":"19833321"}},{"Citation":"Proc Natl Acad Sci U S A. 2010 Oct 12;107(41):17763-7","ArticleIdList":{"ArticleId":"20837517"}},{"Citation":"Proc Natl Acad Sci U S A. 2013 Jul 9;110(28):11606-11","ArticleIdList":{"ArticleId":"23798398"}},{"Citation":"N Engl J Med. 2012 Aug 30;367(9):795-804","ArticleIdList":{"ArticleId":"22784036"}},{"Citation":"Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3863-8","ArticleIdList":{"ArticleId":"16537458"}},{"Citation":"Cereb Cortex. 2011 Oct;21(10):2399-407","ArticleIdList":{"ArticleId":"21383234"}},{"Citation":"Brain Res Bull. 2012 May 1;88(1):3-12","ArticleIdList":{"ArticleId":"22142973"}},{"Citation":"J Neurosci. 2009 Feb 11;29(6):1860-73","ArticleIdList":{"ArticleId":"19211893"}}]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"24689864","DateCompleted":{"Year":"2015","Month":"02","Day":"09"},"DateRevised":{"Year":"2018","Month":"11","Day":"13"},"Article":{"@attributes":{"PubModel":"Print"},"Journal":{"ISSN":"2158-0022","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"4","Issue":"5","PubDate":{"Year":"2014","Month":"Jun"}},"Title":"Brain connectivity","ISOAbbreviation":"Brain Connect"},"ArticleTitle":"Intrinsic brain activity of cognitively normal older persons resembles more that of patients both with and at risk for Alzheimer's disease than that of healthy younger persons.","Pagination":{"MedlinePgn":"323-36"},"ELocationID":"10.1089\/brain.2013.0213","Abstract":{"AbstractText":"In Alzheimer's disease (AD), recent findings suggest that amyloid-\u03b2 (A\u03b2)-pathology might start 20-30 years before first cognitive symptoms arise. To account for age as most relevant risk factor for sporadic AD, it has been hypothesized that lifespan intrinsic (i.e., ongoing) activity of hetero-modal brain areas with highest levels of functional connectivity triggers A\u03b2-pathology. This model induces the simple question whether in older persons without any cognitive symptoms intrinsic activity of hetero-modal areas is more similar to that of symptomatic patients with AD or to that of younger healthy persons. We hypothesize that due to advanced age and therefore potential impact of pre-clinical AD, intrinsic activity of older persons resembles more that of patients than that of younger controls. We tested this hypothesis in younger (ca. 25 years) and older healthy persons (ca. 70 years) and patients with mild cognitive impairment and AD-dementia (ca. 70 years) by the use of resting-state functional magnetic resonance imaging, distinct measures of intrinsic brain activity, and different hierarchical clustering approaches. Independently of applied methods and involved areas, healthy older persons' intrinsic brain activity was consistently more alike that of patients than that of younger controls. Our result provides evidence for larger similarity in intrinsic brain activity between healthy older persons and patients with or at-risk for AD than between older and younger ones, suggesting a significant proportion of pre-clinical AD cases in the group of cognitively normal older people. The observed link of aging and AD with intrinsic brain activity supports the view that lifespan intrinsic activity may contribute critically to the pathogenesis of AD."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Pasquini","ForeName":"Lorenzo","Initials":"L","AffiliationInfo":{"Affiliation":"1 Department of Neuroradiology, Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen , Munich, Germany ."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Tonch","ForeName":"Annika","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Plant","ForeName":"Claudia","Initials":"C"},{"@attributes":{"ValidYN":"Y"},"LastName":"Zherdin","ForeName":"Andrew","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Ortner","ForeName":"Marion","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"F\u00f6rstl","ForeName":"Hans","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Zimmer","ForeName":"Claus","Initials":"C"},{"@attributes":{"ValidYN":"Y"},"LastName":"Grimmer","ForeName":"Timo","Initials":"T"},{"@attributes":{"ValidYN":"Y"},"LastName":"Wohlsch\u00e4ger","ForeName":"Afra","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Riedl","ForeName":"Valentin","Initials":"V"},{"@attributes":{"ValidYN":"Y"},"LastName":"Sorg","ForeName":"Christian","Initials":"C"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Research Support, Non-U.S. Gov't"]}},"MedlineJournalInfo":{"Country":"United States","MedlineTA":"Brain Connect","NlmUniqueID":"101550313","ISSNLinking":"2158-0014"},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Adolescent"},{"DescriptorName":"Adult"},{"DescriptorName":"Age Factors"},{"DescriptorName":"Aged"},{"DescriptorName":"Aged, 80 and over"},{"DescriptorName":"Alzheimer Disease","QualifierName":"physiopathology"},{"DescriptorName":"Brain","QualifierName":"physiopathology"},{"DescriptorName":"Brain Mapping","QualifierName":"methods"},{"DescriptorName":"Case-Control Studies"},{"DescriptorName":"Cognitive Dysfunction","QualifierName":"physiopathology"},{"DescriptorName":"Female"},{"DescriptorName":"Health Status"},{"DescriptorName":"Humans"},{"DescriptorName":"Magnetic Resonance Imaging","QualifierName":"methods"},{"DescriptorName":"Male"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Rest"},{"DescriptorName":"Young Adult"}]},"KeywordList":{"@attributes":{"Owner":"NOTNLM"},"Keyword":["Alzheimer's disease","aging","functional connectivity","hierarchical clustering","intrinsic brain activity","mild cognitive impairment","resting-state functional MRI"]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"entrez"},"Year":"2014","Month":"4","Day":"3","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2014","Month":"4","Day":"3","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2015","Month":"2","Day":"11","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["24689864","10.1089\/brain.2013.0213","PMC4064725"]},"ReferenceList":{"Reference":[{"Citation":"Neuron. 2009 Jul 30;63(2):178-88","ArticleIdList":{"ArticleId":"19640477"}},{"Citation":"Biochim Biophys Acta. 2012 Mar;1822(3):431-41","ArticleIdList":{"ArticleId":"21807094"}},{"Citation":"Arch Neurol. 2003 Aug;60(8):1119-22","ArticleIdList":{"ArticleId":"12925369"}},{"Citation":"Biol Psychiatry. 2013 Sep 1;74(5):340-7","ArticleIdList":{"ArticleId":"23290495"}},{"Citation":"Lancet. 2006 Apr 15;367(9518):1262-70","ArticleIdList":{"ArticleId":"16631882"}},{"Citation":"Ann Neurol. 2013 Jun;73(6):762-73","ArticleIdList":{"ArticleId":"23447373"}},{"Citation":"J Neurosci. 2005 Aug 24;25(34):7709-17","ArticleIdList":{"ArticleId":"16120771"}},{"Citation":"Neurology. 1989 Sep;39(9):1159-65","ArticleIdList":{"ArticleId":"2771064"}},{"Citation":"Ann N Y Acad Sci. 2008 Mar;1124:127-44","ArticleIdList":{"ArticleId":"18400928"}},{"Citation":"Neuroimage. 2012 Jan 2;59(1):431-8","ArticleIdList":{"ArticleId":"21810475"}},{"Citation":"Neuroimage. 2012 Feb 1;59(3):2142-54","ArticleIdList":{"ArticleId":"22019881"}},{"Citation":"J Neurosci Methods. 2010 Feb 15;186(2):179-85","ArticleIdList":{"ArticleId":"19941896"}},{"Citation":"Science. 2002 Oct 25;298(5594):789-91","ArticleIdList":{"ArticleId":"12399581"}},{"Citation":"Neurobiol Aging. 2012 Apr;33(4):833.e27-37","ArticleIdList":{"ArticleId":"22015314"}},{"Citation":"Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18760-5","ArticleIdList":{"ArticleId":"18003904"}},{"Citation":"Acta Neuropathol. 1991;82(4):239-59","ArticleIdList":{"ArticleId":"1759558"}},{"Citation":"Hippocampus. 2003;13(5):572-86","ArticleIdList":{"ArticleId":"12921348"}},{"Citation":"Nat Rev Neurosci. 2003 Nov;4(11):863-72","ArticleIdList":{"ArticleId":"14595398"}},{"Citation":"Trends Cogn Sci. 2011 Nov;15(11):520-6","ArticleIdList":{"ArticleId":"21983147"}},{"Citation":"Behav Neurol. 2009;21(1):63-75","ArticleIdList":{"ArticleId":"19847046"}},{"Citation":"Front Syst Neurosci. 2011 Feb 04;5:2","ArticleIdList":{"ArticleId":"21442040"}},{"Citation":"Brain. 2011 Jun;134(Pt 6):1635-46","ArticleIdList":{"ArticleId":"21490054"}},{"Citation":"Psychopharmacol Bull. 1988;24(4):641-52","ArticleIdList":{"ArticleId":"3249766"}},{"Citation":"J Neurosci. 2010 Dec 15;30(50):16755-62","ArticleIdList":{"ArticleId":"21159946"}},{"Citation":"Lancet. 2006 Jul 29;368(9533):387-403","ArticleIdList":{"ArticleId":"16876668"}},{"Citation":"Aging Dis. 2012 Apr;3(2):181-93","ArticleIdList":{"ArticleId":"22724079"}},{"Citation":"Aging Dis. 2011 Jan 1;2(1):30-48","ArticleIdList":{"ArticleId":"21461180"}},{"Citation":"Science. 2008 Sep 19;321(5896):1686-9","ArticleIdList":{"ArticleId":"18802001"}},{"Citation":"Curr Alzheimer Res. 2009 Dec;6(6):541-53","ArticleIdList":{"ArticleId":"19747154"}},{"Citation":"Lancet Neurol. 2012 Dec;11(12):1018-20","ArticleIdList":{"ArticleId":"23137951"}},{"Citation":"Nat Neurosci. 2010 Jul;13(7):812-8","ArticleIdList":{"ArticleId":"20581818"}},{"Citation":"Hum Brain Mapp. 2010 Aug;31(8):1207-16","ArticleIdList":{"ArticleId":"20063361"}},{"Citation":"Neuron. 2009 Apr 16;62(1):42-52","ArticleIdList":{"ArticleId":"19376066"}},{"Citation":"J Cogn Neurosci. 2000;12 Suppl 2:24-34","ArticleIdList":{"ArticleId":"11506645"}},{"Citation":"Biol Psychiatry. 2010 Mar 15;67(6):584-7","ArticleIdList":{"ArticleId":"19833321"}},{"Citation":"Ann N Y Acad Sci. 2008 Mar;1124:1-38","ArticleIdList":{"ArticleId":"18400922"}},{"Citation":"Neuroimage. 2009 Mar;45(1 Suppl):S163-72","ArticleIdList":{"ArticleId":"19059344"}},{"Citation":"Proc Natl Acad Sci U S A. 2010 Apr 20;107(16):7550-5","ArticleIdList":{"ArticleId":"20363957"}},{"Citation":"Proc Natl Acad Sci U S A. 2010 Oct 12;107(41):17763-7","ArticleIdList":{"ArticleId":"20837517"}},{"Citation":"Proc Natl Acad Sci U S A. 2012 May 29;109(22):8740-5","ArticleIdList":{"ArticleId":"22592800"}},{"Citation":"Lancet Neurol. 2013 Feb;12(2):207-16","ArticleIdList":{"ArticleId":"23332364"}},{"Citation":"N Engl J Med. 2012 Aug 30;367(9):795-804","ArticleIdList":{"ArticleId":"22784036"}},{"Citation":"Neurology. 1984 Jul;34(7):939-44","ArticleIdList":{"ArticleId":"6610841"}},{"Citation":"J Neurosci. 2009 Feb 11;29(6):1860-73","ArticleIdList":{"ArticleId":"19211893"}}]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"24613195","DateCompleted":{"Year":"2016","Month":"01","Day":"01"},"DateRevised":{"Year":"2019","Month":"12","Day":"18"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1873-2402","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"77","Issue":"8","PubDate":{"Year":"2015","Month":"Apr","Day":"15"}},"Title":"Biological psychiatry","ISOAbbreviation":"Biol Psychiatry"},"ArticleTitle":"Small vessel disease, but neither amyloid load nor metabolic deficit, is dependent on age at onset in Alzheimer's disease.","Pagination":{"MedlinePgn":"704-10"},"ELocationID":["10.1016\/j.biopsych.2014.01.019","S0006-3223(14)00058-4"],"Abstract":{"AbstractText":["There is controversy concerning whether Alzheimer's disease (AD) with early onset is distinct from AD with late onset with regard to amyloid pathology and neuronal metabolic deficit. We hypothesized that compared with patients with early-onset AD, patients with late-onset AD have more comorbid small vessel disease (SVD) contributing to clinical severity, whereas there are no differences in amyloid pathology and neuronal metabolic deficit.","The study included two groups of patients with probable AD dementia with evidence of the AD pathophysiologic process: 24 patients with age at onset <60 years old and 36 patients with age at onset >70 years old. Amyloid deposition was assessed using carbon-11-labeled Pittsburgh compound B positron emission tomography, comorbid SVD was assessed using magnetic resonance imaging, and neuronal metabolic deficit was assessed using fluorodeoxyglucose positron emission tomography. Group differences of global and regional distribution of pathology were explored using region of interest and voxel-based analyses, respectively, carefully controlling for the influence of dementia severity, apolipoprotein E genotype, and in particular SVD. The pattern of cognitive impairment was determined using z scores of the subtests of the Consortium to Establish a Registry for Alzheimer's Disease Neuropsychological Assessment Battery.","Patients with late-onset AD showed a significantly greater amount of SVD. No statistically significant differences in global or regional amyloid deposition or neuronal metabolic deficit between the two groups were revealed. However, when not controlling for SVD, subtle differences in fluorodeoxyglucose uptake between early-onset AD and late-onset AD groups were detectable. There were no significant differences regarding cognitive functioning.","Age at onset does not influence amyloid deposition or neuronal metabolic deficit in AD. The greater extent of SVD in late-onset AD influences the association between neuronal metabolic deficit and clinical symptoms."],"CopyrightInformation":"Copyright \u00a9 2015 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Ortner","ForeName":"Marion","Initials":"M","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar der Technischen Universit\u00e4t M\u00fcnchen, Munich, Germany. Electronic address: marion.ortner@lrz.tum.de."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar der Technischen Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Alexopoulos","ForeName":"Panagiotis","Initials":"P","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar der Technischen Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Auer","ForeName":"Florian","Initials":"F","AffiliationInfo":{"Affiliation":"Department Diagnostic and Interventional Neuroradiology, Klinikum rechts der Isar der Technischen Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Diehl-Schmid","ForeName":"Janine","Initials":"J","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar der Technischen Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Drzezga","ForeName":"Alexander","Initials":"A","AffiliationInfo":{"Affiliation":"Department of Nuclear Medicine, University K\u00f6ln, Cologne, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"F\u00f6rster","ForeName":"Stefan","Initials":"S","AffiliationInfo":{"Affiliation":"Department Nuclear Medicine, Klinikum rechts der Isar der Technischen Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"F\u00f6rstl","ForeName":"Hans","Initials":"H","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar der Technischen Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Perneczky","ForeName":"Robert","Initials":"R","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar der Technischen Universit\u00e4t M\u00fcnchen, Munich, Germany; Neuroepidemiology and Ageing Research Unit, School of Public Health, Faculty of Medicine, The Imperial College of Science, Technology, and Medicine, London; West London Cognitive Disorders Treatment and Research Unit, West London Mental Health Trust, London, United Kingdom."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Sorg","ForeName":"Christian","Initials":"C","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar der Technischen Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Yousefi","ForeName":"Behrooz H","Initials":"BH","AffiliationInfo":{"Affiliation":"Pharmaceutical Radiochemistry, Faculties of Chemistry and Medicine, Technische Universit\u00e4t M\u00fcnchen, Garching, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Grimmer","ForeName":"Timo","Initials":"T","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar der Technischen Universit\u00e4t M\u00fcnchen, Munich, Germany."}}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Research Support, Non-U.S. Gov't"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2014","Month":"01","Day":"31"}},"MedlineJournalInfo":{"Country":"United States","MedlineTA":"Biol Psychiatry","NlmUniqueID":"0213264","ISSNLinking":"0006-3223"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole"},{"RegistryNumber":"0","NameOfSubstance":"Amyloid"},{"RegistryNumber":"0","NameOfSubstance":"Apolipoproteins E"},{"RegistryNumber":"0","NameOfSubstance":"Benzothiazoles"},{"RegistryNumber":"0Z5B2CJX4D","NameOfSubstance":"Fluorodeoxyglucose F18"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Age of Onset"},{"DescriptorName":"Aged"},{"DescriptorName":"Aged, 80 and over"},{"DescriptorName":"Alzheimer Disease","QualifierName":["complications","diagnostic imaging","genetics","metabolism"]},{"DescriptorName":"Amyloid","QualifierName":"metabolism"},{"DescriptorName":"Apolipoproteins E","QualifierName":"genetics"},{"DescriptorName":"Benzothiazoles","QualifierName":"pharmacokinetics"},{"DescriptorName":"Brain","QualifierName":["diagnostic imaging","pathology"]},{"DescriptorName":"Female"},{"DescriptorName":"Fluorodeoxyglucose F18","QualifierName":"pharmacokinetics"},{"DescriptorName":"Humans"},{"DescriptorName":"Male"},{"DescriptorName":"Metabolic Diseases","QualifierName":["diagnostic imaging","etiology"]},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Radionuclide Imaging"},{"DescriptorName":"Vascular Diseases","QualifierName":["diagnostic imaging","etiology"]}]},"KeywordList":{"@attributes":{"Owner":"NOTNLM"},"Keyword":["AD","Age at onset","Alzheimer\u2019s disease","Amyloid load","Metabolic deficit","Small vessel disease"]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2013","Month":"10","Day":"02"},{"@attributes":{"PubStatus":"revised"},"Year":"2013","Month":"12","Day":"30"},{"@attributes":{"PubStatus":"accepted"},"Year":"2014","Month":"01","Day":"17"},{"@attributes":{"PubStatus":"entrez"},"Year":"2014","Month":"3","Day":"12","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2014","Month":"3","Day":"13","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2016","Month":"1","Day":"2","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["24613195","S0006-3223(14)00058-4","10.1016\/j.biopsych.2014.01.019"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"24596678","DateCompleted":{"Year":"2016","Month":"02","Day":"22"},"DateRevised":{"Year":"2019","Month":"12","Day":"18"},"Article":{"@attributes":{"PubModel":"Electronic-eCollection"},"Journal":{"ISSN":"2213-1582","JournalIssue":{"@attributes":{"CitedMedium":"Print"},"Volume":"4","PubDate":{"Year":"2014"}},"Title":"NeuroImage. Clinical","ISOAbbreviation":"Neuroimage Clin"},"ArticleTitle":"LRP-1 polymorphism is associated with global and regional amyloid load in Alzheimer's Disease in humans in-vivo.","Pagination":{"MedlinePgn":"411-6"},"ELocationID":"10.1016\/j.nicl.2014.01.016","Abstract":{"AbstractText":["Impaired amyloid clearance has been proposed to contribute to \u03b2-amyloid deposition in sporadic late-onset Alzheimer's disease (AD). Low density lipoprotein receptor-related protein 1 (LRP-1) is involved in the active outward transport of \u03b2-amyloid across the blood-brain barrier (BBB). The C667T polymorphism (rs1799986) of the LRP-1 gene has been inconsistently associated with AD in genetic studies. We aimed to elucidate the association of this polymorphism with in-vivo brain amyloid load of AD patients using amyloid PET with [(11)C]PiB.","72 patients with very mild to moderate AD were examined with amyloid PET and C667T polymorphism was obtained using TaqMan PCR assays. The association of C667T polymorphism with global and regional amyloid load was calculated using linear regression and voxel based analysis, respectively. The effect of the previously identified modulator of amyloid uptake, the apolipoprotein E genotype, on this association was also determined.","The regression analysis between amyloid load and C667T polymorphism was statistically significant (p\u00a0=\u00a00.046, \u03b2\u00a0=\u00a00.236). In an additional analysis ApoE genotype and gender were identified to explain further variability of amyloid load. Voxel based analysis revealed a significant (p\u00a0<\u00a00.05) association between C667T polymorphism and amyloid uptake in the temporo-parietal cortex bilaterally. ApoE did not interact significantly with the LRP-1 polymorphism.","In conclusion, C667T polymorphism of LRP-1 is moderately but significantly associated with global and regional amyloid deposition in AD. The relationship appears to be independent of the ApoE genotype. This finding is compatible with the hypothesis that impaired amyloid clearance contributes to amyloid deposition in late-onset sporadic AD."]},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Grimmer","ForeName":"Timo","Initials":"T","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar der Technischen Universit\u00e4t M\u00fcnchen, Ismaninger Str. 22, 81675 Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Goldhardt","ForeName":"Oliver","Initials":"O","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar der Technischen Universit\u00e4t M\u00fcnchen, Ismaninger Str. 22, 81675 Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Guo","ForeName":"Liang-Hao","Initials":"LH","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar der Technischen Universit\u00e4t M\u00fcnchen, Ismaninger Str. 22, 81675 Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Yousefi","ForeName":"Behrooz H","Initials":"BH","AffiliationInfo":{"Affiliation":"Department of Nuclear Medicine, Klinikum rechts der Isar der Technischen Universit\u00e4t M\u00fcnchen, Ismaninger Str. 22, 81675 Munich, Germany ; Pharmaceutical Radiochemistry, Faculties of Chemistry and Medicine, Technische Universit\u00e4t M\u00fcnchen, Walther-Mei\u00dfner-Str. 3, 85748 Garching, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"F\u00f6rster","ForeName":"Stefan","Initials":"S","AffiliationInfo":{"Affiliation":"Department of Nuclear Medicine, Klinikum rechts der Isar der Technischen Universit\u00e4t M\u00fcnchen, Ismaninger Str. 22, 81675 Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Drzezga","ForeName":"Alexander","Initials":"A","AffiliationInfo":{"Affiliation":"Department of Nuclear Medicine, University Hospital of Cologne, Kerpener Stra\u00dfe 62, 50937 Cologne, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Sorg","ForeName":"Christian","Initials":"C","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar der Technischen Universit\u00e4t M\u00fcnchen, Ismaninger Str. 22, 81675 Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Alexopoulos","ForeName":"Panagiotis","Initials":"P","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar der Technischen Universit\u00e4t M\u00fcnchen, Ismaninger Str. 22, 81675 Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"F\u00f6rstl","ForeName":"Hans","Initials":"H","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar der Technischen Universit\u00e4t M\u00fcnchen, Ismaninger Str. 22, 81675 Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar der Technischen Universit\u00e4t M\u00fcnchen, Ismaninger Str. 22, 81675 Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Perneczky","ForeName":"Robert","Initials":"R","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar der Technischen Universit\u00e4t M\u00fcnchen, Ismaninger Str. 22, 81675 Munich, Germany ; Neuroepidemiology and Ageing Research Unit, School of Public Health, Faculty of Medicine, The Imperial College of Science, Technology and Medicine, London, UK."}}]},"Language":"eng","PublicationTypeList":{"PublicationType":"Journal Article"},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2014","Month":"02","Day":"05"}},"MedlineJournalInfo":{"Country":"Netherlands","MedlineTA":"Neuroimage Clin","NlmUniqueID":"101597070","ISSNLinking":"2213-1582"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole"},{"RegistryNumber":"0","NameOfSubstance":"Amyloidogenic Proteins"},{"RegistryNumber":"0","NameOfSubstance":"Benzothiazoles"},{"RegistryNumber":"0","NameOfSubstance":"LRP1 protein, human"},{"RegistryNumber":"0","NameOfSubstance":"Low Density Lipoprotein Receptor-Related Protein-1"},{"RegistryNumber":"0","NameOfSubstance":"Radiopharmaceuticals"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Aged, 80 and over"},{"DescriptorName":"Alzheimer Disease","QualifierName":["diagnostic imaging","physiopathology"]},{"DescriptorName":"Amyloidogenic Proteins","QualifierName":"metabolism"},{"DescriptorName":"Benzothiazoles","QualifierName":"pharmacokinetics"},{"DescriptorName":"Brain","QualifierName":["diagnostic imaging","physiopathology"]},{"DescriptorName":"Female"},{"DescriptorName":"Genetic Predisposition to Disease","QualifierName":"genetics"},{"DescriptorName":"Humans"},{"DescriptorName":"Low Density Lipoprotein Receptor-Related Protein-1","QualifierName":"genetics"},{"DescriptorName":"Male"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Polymorphism, Single Nucleotide","QualifierName":"genetics"},{"DescriptorName":"Positron-Emission Tomography","QualifierName":"methods"},{"DescriptorName":"Radiopharmaceuticals","QualifierName":"pharmacokinetics"},{"DescriptorName":"Reproducibility of Results"},{"DescriptorName":"Sensitivity and Specificity"},{"DescriptorName":"Tissue Distribution"}]},"KeywordList":{"@attributes":{"Owner":"NOTNLM"},"Keyword":["Alzheimer's disease (AD)","Apolipoprotein E (ApoE)","C667T polymorphism","Low density lipoprotein receptor related protein 1 (LRP-1)","Pittsburgh compound B ([11C]PiB)","Positron emission tomography (PET)"]},"GeneralNote":"Original DateCompleted: 20140305"},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2013","Month":"12","Day":"16"},{"@attributes":{"PubStatus":"revised"},"Year":"2014","Month":"01","Day":"14"},{"@attributes":{"PubStatus":"accepted"},"Year":"2014","Month":"01","Day":"30"},{"@attributes":{"PubStatus":"entrez"},"Year":"2014","Month":"3","Day":"6","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2014","Month":"3","Day":"7","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2014","Month":"3","Day":"7","Hour":"6","Minute":"1"}]},"PublicationStatus":"epublish","ArticleIdList":{"ArticleId":["24596678","10.1016\/j.nicl.2014.01.016","S2213-1582(14)00017-5","PMC3939495"]},"ReferenceList":{"Reference":[{"Citation":"Curr Alzheimer Res. 2008 Feb;5(1):15-25","ArticleIdList":{"ArticleId":"18288927"}},{"Citation":"J Clin Invest. 2001 Sep;108(6):779-84","ArticleIdList":{"ArticleId":"11560943"}},{"Citation":"Nat Med. 2000 Feb;6(2):143-50","ArticleIdList":{"ArticleId":"10655101"}},{"Citation":"J Clin Invest. 2000 Nov;106(9):1159-66","ArticleIdList":{"ArticleId":"11067868"}},{"Citation":"Clin Genet. 2000 Oct;58(4):319-23","ArticleIdList":{"ArticleId":"11076057"}},{"Citation":"J Nucl Med. 2000 Nov;41(11):1920-8","ArticleIdList":{"ArticleId":"11079505"}},{"Citation":"Alzheimer Dis Assoc Disord. 2008 Jan-Mar;22(1):61-5","ArticleIdList":{"ArticleId":"18317248"}},{"Citation":"Brain Pathol. 2008 Apr;18(2):240-52","ArticleIdList":{"ArticleId":"18363935"}},{"Citation":"J Clin Invest. 2008 Dec;118(12):4002-13","ArticleIdList":{"ArticleId":"19033669"}},{"Citation":"J Biol Chem. 2008 Dec 12;283(50):34554-62","ArticleIdList":{"ArticleId":"18940800"}},{"Citation":"PLoS One. 2009;4(2):e4627","ArticleIdList":{"ArticleId":"19247480"}},{"Citation":"CNS Neurol Disord Drug Targets. 2009 Mar;8(1):16-30","ArticleIdList":{"ArticleId":"19275634"}},{"Citation":"Neurology. 2009 Apr 28;72(17):1487-94","ArticleIdList":{"ArticleId":"19339712"}},{"Citation":"Biol Psychiatry. 2009 Jun 1;65(11):927-34","ArticleIdList":{"ArticleId":"19268916"}},{"Citation":"Acta Neuropathol. 2009 Jul;118(1):5-36","ArticleIdList":{"ArticleId":"19381658"}},{"Citation":"ScientificWorldJournal. 2009;9:557-63","ArticleIdList":{"ArticleId":"19578713"}},{"Citation":"Neurobiol Aging. 2009 Dec;30(12):1902-9","ArticleIdList":{"ArticleId":"18346821"}},{"Citation":"Neurology. 2010 Jun 15;74(24):1954-60","ArticleIdList":{"ArticleId":"20548041"}},{"Citation":"J Clin Invest. 2000 Dec;106(12):1489-99","ArticleIdList":{"ArticleId":"11120756"}},{"Citation":"Eur Arch Psychiatry Clin Neurosci. 2012 Sep;262(6):529-34","ArticleIdList":{"ArticleId":"22286501"}},{"Citation":"Neurology. 2002 Jun 25;58(12):1791-800","ArticleIdList":{"ArticleId":"12084879"}},{"Citation":"Science. 2002 Jul 19;297(5580):353-6","ArticleIdList":{"ArticleId":"12130773"}},{"Citation":"J Neurochem. 2003 Mar;84(6):1442-51","ArticleIdList":{"ArticleId":"12614344"}},{"Citation":"Am J Med Genet B Neuropsychiatr Genet. 2003 Aug 15;121B(1):128-30","ArticleIdList":{"ArticleId":"12898587"}},{"Citation":"Neurosci Res. 2004 Sep;50(1):85-101","ArticleIdList":{"ArticleId":"15288502"}},{"Citation":"J Psychiatr Res. 1975 Nov;12(3):189-98","ArticleIdList":{"ArticleId":"1202204"}},{"Citation":"Neurology. 1984 Jul;34(7):939-44","ArticleIdList":{"ArticleId":"6610841"}},{"Citation":"Am J Physiol. 1984 Jun;246(6 Pt 2):F835-44","ArticleIdList":{"ArticleId":"6742132"}},{"Citation":"Neurology. 1989 Sep;39(9):1159-65","ArticleIdList":{"ArticleId":"2771064"}},{"Citation":"Acta Neuropathol. 1991;82(4):239-59","ArticleIdList":{"ArticleId":"1759558"}},{"Citation":"Acta Neuropathol. 1992;83(3):233-9","ArticleIdList":{"ArticleId":"1373020"}},{"Citation":"J Biol Chem. 1992 May 5;267(13):9035-40","ArticleIdList":{"ArticleId":"1374383"}},{"Citation":"Neuroscience. 1994 Mar;59(2):229-43","ArticleIdList":{"ArticleId":"8008189"}},{"Citation":"Genomics. 1994 Nov 1;24(1):78-89","ArticleIdList":{"ArticleId":"7534747"}},{"Citation":"J Nucl Med. 1995 Jul;36(7):1238-48","ArticleIdList":{"ArticleId":"7790950"}},{"Citation":"Neurology. 1997 Jul;49(1):56-61","ArticleIdList":{"ArticleId":"9222170"}},{"Citation":"Clin Chem. 1997 Sep;43(9):1657-9","ArticleIdList":{"ArticleId":"9299950"}},{"Citation":"Neurosci Lett. 1998 Mar 13;244(2):65-8","ArticleIdList":{"ArticleId":"9572586"}},{"Citation":"Am J Pathol. 1998 Sep;153(3):725-33","ArticleIdList":{"ArticleId":"9736023"}},{"Citation":"Neurosci Lett. 1999 Jan 4;259(1):29-32","ArticleIdList":{"ArticleId":"10027548"}},{"Citation":"Neurosci Lett. 2005 Jul 15;382(3):221-6","ArticleIdList":{"ArticleId":"15925094"}},{"Citation":"Yi Chuan. 2006 Apr;28(4):393-8","ArticleIdList":{"ArticleId":"16606588"}},{"Citation":"J Neural Transm (Vienna). 2006 Sep;113(9):1253-62","ArticleIdList":{"ArticleId":"16362633"}},{"Citation":"Neuroimage. 2006 Oct 15;33(1):94-102","ArticleIdList":{"ArticleId":"16905334"}},{"Citation":"Curr Alzheimer Res. 2007 Apr;4(2):191-7","ArticleIdList":{"ArticleId":"17430246"}},{"Citation":"Neurology. 2007 Aug 28;69(9):871-7","ArticleIdList":{"ArticleId":"17724289"}},{"Citation":"PLoS One. 2010;5(7):e11884","ArticleIdList":{"ArticleId":"20686698"}},{"Citation":"Biol Psychiatry. 2010 Nov 15;68(10):879-84","ArticleIdList":{"ArticleId":"20598287"}},{"Citation":"J Neurochem. 2010 Dec;115(5):1077-89","ArticleIdList":{"ArticleId":"20854368"}},{"Citation":"Science. 2010 Dec 24;330(6012):1774","ArticleIdList":{"ArticleId":"21148344"}},{"Citation":"Ann Neurol. 2011 Jan;69(1):181-92","ArticleIdList":{"ArticleId":"21280088"}},{"Citation":"Alzheimers Dement. 2011 May;7(3):263-9","ArticleIdList":{"ArticleId":"21514250"}},{"Citation":"Sci Transl Med. 2011 Jun 29;3(89):89ra57","ArticleIdList":{"ArticleId":"21715678"}},{"Citation":"Neurobiol Aging. 2011 Dec;32(12):2323.e1-11","ArticleIdList":{"ArticleId":"20630619"}},{"Citation":"J Alzheimers Dis. 2012;31(1):151-65","ArticleIdList":{"ArticleId":"22504320"}},{"Citation":"Neurobiol Aging. 2012 Dec;33(12):2766-73","ArticleIdList":{"ArticleId":"22410648"}},{"Citation":"Neuropathol Appl Neurobiol. 2008 Apr;34(2):131-44","ArticleIdList":{"ArticleId":"18208483"}}]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"24524150","DateCompleted":{"Year":"2014","Month":"08","Day":"08"},"DateRevised":{"Year":"2019","Month":"11","Day":"12"},"Article":{"@attributes":{"PubModel":"Print"},"Journal":{"ISSN":"1471-499X","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"20","Issue":"1","PubDate":{"Year":"2014","Month":"Jan"}},"Title":"Trends in molecular medicine","ISOAbbreviation":"Trends Mol Med"},"ArticleTitle":"Soluble amyloid precursor proteins and secretases as Alzheimer's disease biomarkers.","Pagination":{"MedlinePgn":"8-15"},"Abstract":{"AbstractText":"Recently revised diagnostic guidelines for Alzheimer's disease (AD) emphasise the use of biomarkers, heralding a paradigm shift towards a more biological definition of the disorder. Currently available biomarkers offer added diagnostic accuracy in certain situations, but their performance in terms of early diagnostic sensitivity and specificity does not fully live up to the desired standards. One feasible approach to improve the diagnostic and prognostic performance of AD biomarkers is to measure upstream events of amyloid precursor protein (APP) processing, which are at the core of the initial phase of AD pathogenesis. Here we review evidence on the APP processing enzymes and their cleavage products and discuss possible applications and limitations in their use as AD biomarkers."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Perneczky","ForeName":"Robert","Initials":"R"},{"@attributes":{"ValidYN":"Y"},"LastName":"Alexopoulos","ForeName":"Panagiotis","Initials":"P"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Review"]}},"MedlineJournalInfo":{"Country":"England","MedlineTA":"Trends Mol Med","NlmUniqueID":"100966035","ISSNLinking":"1471-4914"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"Amyloid beta-Protein Precursor"},{"RegistryNumber":"0","NameOfSubstance":"Biomarkers"},{"RegistryNumber":"EC 3.4.-","NameOfSubstance":"Amyloid Precursor Protein Secretases"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Alzheimer Disease","QualifierName":["blood","cerebrospinal fluid","diagnosis","metabolism"]},{"DescriptorName":"Amyloid Precursor Protein Secretases","QualifierName":["blood","cerebrospinal fluid","metabolism"]},{"DescriptorName":"Amyloid beta-Protein Precursor","QualifierName":["blood","cerebrospinal fluid","metabolism"]},{"DescriptorName":"Animals"},{"DescriptorName":"Biomarkers","QualifierName":["blood","cerebrospinal fluid"]},{"DescriptorName":"Humans"},{"DescriptorName":"Proteolysis"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"entrez"},"Year":"2014","Month":"2","Day":"14","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2014","Month":"2","Day":"14","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2014","Month":"8","Day":"13","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["24524150","S1471-4914(13)00178-0","10.1016\/j.molmed.2013.10.001"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","IndexingMethod":"Curated","Owner":"NLM"},"PMID":"23904354","DateCompleted":{"Year":"2014","Month":"04","Day":"14"},"DateRevised":{"Year":"2018","Month":"12","Day":"02"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"0891-9887","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"26","Issue":"4","PubDate":{"Year":"2013","Month":"Dec"}},"Title":"Journal of geriatric psychiatry and neurology","ISOAbbreviation":"J Geriatr Psychiatry Neurol"},"ArticleTitle":"Caregiver burden and needs in frontotemporal dementia.","Pagination":{"MedlinePgn":"221-9"},"ELocationID":"10.1177\/0891988713498467","Abstract":{"AbstractText":["It is well known that burden among caregivers of patients with frontotemporal dementia (FTD) is high. However, little is known about the specific problems, the factors that contribute to caregiver burden, and the needs of the FTD caregivers-particularly those needs that are accessible by external support strategies.","We developed a standardized questionnaire that addressed burdens, problems, and the actual needs of FTD caregivers. A total of 94 caregivers were interviewed.","It appears that changes in the patients' behavior and in the interpersonal relations between caregivers and patients are associated with caregiver depression. The most important needs and requests of the caregivers included information and psychosocial support through educated staff, financial support as well as the education of medical staff about the disease.","Support strategies should focus on information and psychosocial support. Given the low prevalence of FTD, internet- and telephone-based strategies appear suitable."]},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Diehl-Schmid","ForeName":"Janine","Initials":"J","AffiliationInfo":{"Affiliation":"Department of Psychiatry, Technische Universit\u00e4t M\u00fcnchen, M\u00fcnchen, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Schmidt","ForeName":"Eva-Maria","Initials":"EM"},{"@attributes":{"ValidYN":"Y"},"LastName":"Nunnemann","ForeName":"Sabine","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"Riedl","ForeName":"Lina","Initials":"L"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"F\u00f6rstl","ForeName":"Hans","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Wagenpfeil","ForeName":"Stefan","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"Cramer","ForeName":"Barbara","Initials":"B"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Research Support, Non-U.S. Gov't"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2013","Month":"07","Day":"31"}},"MedlineJournalInfo":{"Country":"United States","MedlineTA":"J Geriatr Psychiatry Neurol","NlmUniqueID":"8805645","ISSNLinking":"0891-9887"},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Activities of Daily Living"},{"DescriptorName":"Adaptation, Psychological"},{"DescriptorName":"Adult"},{"DescriptorName":"Aged"},{"DescriptorName":"Aged, 80 and over"},{"DescriptorName":"Caregivers","QualifierName":"psychology"},{"DescriptorName":"Cost of Illness"},{"DescriptorName":"Depression","QualifierName":"psychology"},{"DescriptorName":"Female"},{"DescriptorName":"Frontotemporal Dementia","QualifierName":["diagnosis","psychology"]},{"DescriptorName":"Health Services Needs and Demand"},{"DescriptorName":"Humans"},{"DescriptorName":"Interpersonal Relations"},{"DescriptorName":"Male"},{"DescriptorName":"Mental Disorders"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Psychiatric Status Rating Scales"},{"DescriptorName":"Quality of Life"},{"DescriptorName":"Social Support"},{"DescriptorName":"Socioeconomic Factors"},{"DescriptorName":"Surveys and Questionnaires"}]},"KeywordList":{"@attributes":{"Owner":"NOTNLM"},"Keyword":["caregiver burden","caregiver support","frontotemporal dementia"]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"entrez"},"Year":"2013","Month":"8","Day":"2","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2013","Month":"8","Day":"2","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2014","Month":"4","Day":"15","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["23904354","0891988713498467","10.1177\/0891988713498467"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","IndexingMethod":"Curated","Owner":"NLM"},"PMID":"23812170","DateCompleted":{"Year":"2014","Month":"01","Day":"16"},"DateRevised":{"Year":"2019","Month":"03","Day":"18"},"Article":{"@attributes":{"PubModel":"Print"},"Journal":{"ISSN":"1543-3641","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"26","Issue":"2","PubDate":{"Year":"2013","Month":"Jun"}},"Title":"Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology","ISOAbbreviation":"Cogn Behav Neurol"},"ArticleTitle":"Guilty by suspicion? Criminal behavior in frontotemporal lobar degeneration.","Pagination":{"MedlinePgn":"73-7"},"ELocationID":"10.1097\/WNN.0b013e31829cff11","Abstract":{"AbstractText":["Our aim was to compare the frequency of criminal conduct in patients with behavioral variant frontotemporal dementia (bvFTD), semantic dementia (SD), and Alzheimer disease.","A few small-scale studies of antisocial and criminal behavior in patients with frontotemporal lobar degeneration have focused on the clinical subtype bvFTD. It is not yet known whether antisocial behavior affects patients with other clinical subtypes of frontotemporal lobar degeneration, like SD, and patients with other dementing disorders, like Alzheimer disease.","We used a standardized caregiver interview to assess criminal behavior in 83 outpatients: 32 with bvFTD, 18 with SD, and 33 with Alzheimer disease.","We found criminal behavior (theft, willful damage to property, housebreaking, assault, or indecent behavior) in 54% of the patients with bvFTD and 56% of those with SD, but only 12% of those with Alzheimer disease.","Just over half of our patients with bvFTD or SD had committed crimes. When middle-aged or older patients commit minor crimes, frontotemporal lobar degeneration should be considered as a possible cause. If an affected person faces criminal charges, the court might take incapability or diminished responsibility into account in reaching a verdict."]},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Diehl-Schmid","ForeName":"Janine","Initials":"J","AffiliationInfo":{"Affiliation":"Department of Psychiatry, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany. janine.schmid@lrz.tum.de"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Perneczky","ForeName":"Robert","Initials":"R"},{"@attributes":{"ValidYN":"Y"},"LastName":"Koch","ForeName":"Julia","Initials":"J"},{"@attributes":{"ValidYN":"Y"},"LastName":"Nedopil","ForeName":"Norbert","Initials":"N"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"}]},"Language":"eng","PublicationTypeList":{"PublicationType":"Journal Article"}},"MedlineJournalInfo":{"Country":"United States","MedlineTA":"Cogn Behav Neurol","NlmUniqueID":"101167278","ISSNLinking":"1543-3633"},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Age Distribution"},{"DescriptorName":"Aged"},{"DescriptorName":"Antisocial Personality Disorder","QualifierName":"epidemiology"},{"DescriptorName":"Causality"},{"DescriptorName":"Comorbidity"},{"DescriptorName":"Crime","QualifierName":"statistics & numerical data"},{"DescriptorName":"Female"},{"DescriptorName":"Frontotemporal Dementia","QualifierName":"epidemiology"},{"DescriptorName":"Frontotemporal Lobar Degeneration","QualifierName":"epidemiology"},{"DescriptorName":"Humans"},{"DescriptorName":"Male"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Sex Distribution"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"entrez"},"Year":"2013","Month":"7","Day":"2","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2013","Month":"7","Day":"3","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2014","Month":"1","Day":"17","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["23812170","10.1097\/WNN.0b013e31829cff11","00146965-201306000-00006"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"23668966","DateCompleted":{"Year":"2014","Month":"03","Day":"17"},"DateRevised":{"Year":"2018","Month":"09","Day":"05"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1095-9572","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"81","PubDate":{"Year":"2013","Month":"Nov","Day":"01"}},"Title":"NeuroImage","ISOAbbreviation":"Neuroimage"},"ArticleTitle":"Selectively and progressively disrupted structural connectivity of functional brain networks in Alzheimer's disease - revealed by a novel framework to analyze edge distributions of networks detecting disruptions with strong statistical evidence.","Pagination":{"MedlinePgn":"96-109"},"ELocationID":["S1053-8119(13)00503-X","10.1016\/j.neuroimage.2013.05.011"],"Abstract":{"AbstractText":"Alzheimer's disease (AD) disrupts selectively and progressively (increasing with severity) functional connectivity of intrinsic brain networks (IBNs), most prominent in the default mode network. Given that IBNs' functional connectivity depends on structural connectivity, we hypothesize for our study selective and progressive changes of IBN based structural connectivity in AD. To achieve strong statistical evidence, we introduce a novel statistical method based on the edge frequency distributions of structural connectivity networks. Such non-Gaussian distributions are compared in a multiple testing scheme, combining a flexible nonparametric test statistic with permutation based strong control of the family wise error rate. We assessed 26 healthy elderly, 23 patients with AD-dementia, and 28 patients with mild cognitive impairment (MCI) by resting-state functional MRI, diffusion tensor imaging, and clinical-neuropsychological testing including annual follow-up assessment. After 3years, 50% of the patients with MCI converted to AD. Tractography of diffusion tensor data identifies structural connectivity networks between regions of IBNs, which are detected by an independent component analysis of resting state fMRI data. We find that IBNs' structural connectivity is selectively and progressively disrupted with primary changes in the default mode network. Correspondent results are found for IBNs' functional connectivity. In addition, structural connectivity across the nodes of all IBNs separated individual MCI patients converting to AD from non-converters. Conclusively, our study provides a new approach to analyze connectivity networks by their non-Gaussian edge frequency distributions and achieves strong statistical evidence by application of the family wise error rate. Data analysis provides selective and progressive disruptions of IBN's structural connectivity in AD and demonstrates the increased power of our method compared to recent studies. ","CopyrightInformation":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Hahn","ForeName":"Klaus","Initials":"K","AffiliationInfo":{"Affiliation":"Institute of Computational Biology, Helmholtz Zentrum M\u00fcnchen, German Research Center for Environmental Health, Ingolstaedter Landstrasse 1, 85764 Neuherberg, Germany. Electronic address: hahn@helmholtz-muenchen.de."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Myers","ForeName":"Nicholas","Initials":"N","AffiliationInfo":{"Affiliation":"Department of Psychiatry, Technische Universit\u00e4t M\u00fcnchen, Ismaningerstrasse 22, 81675 Munich, Germany; Department of Neuroradiology, Technische Universit\u00e4t M\u00fcnchen, Ismaningerstrasse 22, 81675 Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Prigarin","ForeName":"Sergei","Initials":"S","AffiliationInfo":{"Affiliation":"Institute of Computational Mathematics and Mathematical Geophysics, Siberian Branch of Russian Academy of Sciences, pr. Lavrentieva 6, Novosibirsk 630090, Russia."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Rodenacker","ForeName":"Karsten","Initials":"K","AffiliationInfo":{"Affiliation":"Institute of Computational Biology, Helmholtz Zentrum M\u00fcnchen, German Research Center for Environmental Health, Ingolstaedter Landstrasse 1, 85764 Neuherberg, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A","AffiliationInfo":{"Affiliation":"Department of Psychiatry, Technische Universit\u00e4t M\u00fcnchen, Ismaningerstrasse 22, 81675 Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"F\u00f6rstl","ForeName":"Hans","Initials":"H","AffiliationInfo":{"Affiliation":"Department of Psychiatry, Technische Universit\u00e4t M\u00fcnchen, Ismaningerstrasse 22, 81675 Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Zimmer","ForeName":"Claus","Initials":"C","AffiliationInfo":{"Affiliation":"Department of Neuroradiology, Technische Universit\u00e4t M\u00fcnchen, Ismaningerstrasse 22, 81675 Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Wohlschl\u00e4ger","ForeName":"Afra M","Initials":"AM","AffiliationInfo":{"Affiliation":"Department of Neuroradiology, Technische Universit\u00e4t M\u00fcnchen, Ismaningerstrasse 22, 81675 Munich, Germany; Department of Neurology of Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, Ismaningerstrasse 22, 81675 Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Sorg","ForeName":"Christian","Initials":"C","AffiliationInfo":{"Affiliation":"Department of Psychiatry, Technische Universit\u00e4t M\u00fcnchen, Ismaningerstrasse 22, 81675 Munich, Germany; Department of Neuroradiology, Technische Universit\u00e4t M\u00fcnchen, Ismaningerstrasse 22, 81675 Munich, Germany."}}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Research Support, Non-U.S. Gov't"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2013","Month":"05","Day":"11"}},"MedlineJournalInfo":{"Country":"United States","MedlineTA":"Neuroimage","NlmUniqueID":"9215515","ISSNLinking":"1053-8119"},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Alzheimer Disease","QualifierName":["pathology","physiopathology"]},{"DescriptorName":"Brain","QualifierName":["pathology","physiopathology"]},{"DescriptorName":"Cognitive Dysfunction","QualifierName":["pathology","physiopathology"]},{"DescriptorName":"Diffusion Tensor Imaging"},{"DescriptorName":"Female"},{"DescriptorName":"Humans"},{"DescriptorName":"Image Interpretation, Computer-Assisted","QualifierName":"methods"},{"DescriptorName":"Magnetic Resonance Imaging"},{"DescriptorName":"Male"},{"DescriptorName":"Nerve Net","QualifierName":["pathology","physiopathology"]},{"DescriptorName":"Statistics, Nonparametric"}]},"KeywordList":{"@attributes":{"Owner":"NOTNLM"},"Keyword":["Edge frequency distributions","Intrinsic functional brain networks","Multimodal fMRI\/DTI analysis of Alzheimer's disease","Nonparametric Brunner statistic","Structural connectivity networks"]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2013","Month":"01","Day":"03"},{"@attributes":{"PubStatus":"revised"},"Year":"2013","Month":"04","Day":"03"},{"@attributes":{"PubStatus":"accepted"},"Year":"2013","Month":"05","Day":"01"},{"@attributes":{"PubStatus":"entrez"},"Year":"2013","Month":"5","Day":"15","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2013","Month":"5","Day":"15","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2014","Month":"3","Day":"19","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["23668966","S1053-8119(13)00503-X","10.1016\/j.neuroimage.2013.05.011"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"23609762","DateCompleted":{"Year":"2014","Month":"01","Day":"27"},"DateRevised":{"Year":"2018","Month":"12","Day":"03"},"Article":{"@attributes":{"PubModel":"Print"},"Journal":{"ISSN":"1875-8908","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"36","Issue":"2","PubDate":{"Year":"2013"}},"Title":"Journal of Alzheimer's disease : JAD","ISOAbbreviation":"J Alzheimers Dis"},"ArticleTitle":"Amyloid cascade and tau pathology cerebrospinal fluid markers in mild cognitive impairment with regards to Alzheimer's disease cerebral metabolic signature.","Pagination":{"MedlinePgn":"401-8"},"ELocationID":"10.3233\/JAD-122329","Abstract":{"AbstractText":["Biomarker relationships in early stages of Alzheimer's disease (AD) are elusive. Cerebrospinal fluid (CSF) levels of amyloid-\u03b2 1-42 (A\u03b242) and total tau (tTau) as well as 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) contribute to help unravel AD pathology. Furthermore, peptides related to amyloid-\u03b2 protein precursor (A\u03b2PP) processing [e.g., soluble A\u03b2PP\u03b1 and \u03b2 (sA\u03b2PP\u03b1 and sA\u03b2PP\u03b2, respectively); sortilin-related receptor with A-type repeats (SORL1, also called LR11 or SORLA)] are factors crucially implicated in the formation of pathological hallmarks of AD.","To unveil differences in CSF concentrations of A\u03b242, sA\u03b2PP\u03b1, sA\u03b2PP\u03b2, tTau, and SORL1 between patients with mild cognitive impairment (MCI) who were categorized according to expert interpretation of FDG scans.","PET results were classified as suggesting high likelihood for AD (MCI-AD high), intermediate likelihood for AD (MCI-AD intermediate), or little likelihood for AD (MCI-AD unlikely). An AD dementia group was also included. Differences between the groups were tested by Kruskal- Wallis test, Mann-Whitney test, or \u03c72. Provided statistically significant differences were detected, multiple linear regression models were employed.","A\u03b242 levels in patients with MCI-AD high (n = 15) were lower compared to MCI-AD intermediate (n = 18) and MCI-AD unlikely patients (n = 25) (p = 0.002), while they did not differ from patients with AD dementia (n = 17). The regression model revealed a significant impact of the metabolic pattern on A\u03b242 concentrations. SORL1, tTau, sA\u03b2PP\u03b1, and sA\u03b2PP\u03b2 concentrations did not differ between the groups.","These findings point to linkages between plaque pathology and glucose cerebral hypometabolism."]},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Alexopoulos","ForeName":"Panagiotis","Initials":"P","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar der Technischen Universit\u00e4t M\u00fcnchen, Munich, Germany. panos.alexopoulos@lrz.tum.de"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Guo","ForeName":"Liang-Hao","Initials":"LH"},{"@attributes":{"ValidYN":"Y"},"LastName":"Jiang","ForeName":"Meizi","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Bujo","ForeName":"Hideaki","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Grimmer","ForeName":"Timo","Initials":"T"},{"@attributes":{"ValidYN":"Y"},"LastName":"F\u00f6rster","ForeName":"Stefan","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"Drzezga","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Perneczky","ForeName":"Robert","Initials":"R"}]},"Language":"eng","PublicationTypeList":{"PublicationType":"Journal Article"}},"MedlineJournalInfo":{"Country":"Netherlands","MedlineTA":"J Alzheimers Dis","NlmUniqueID":"9814863","ISSNLinking":"1387-2877"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"Adaptor Proteins, Vesicular Transport"},{"RegistryNumber":"0","NameOfSubstance":"Amyloid beta-Peptides"},{"RegistryNumber":"0","NameOfSubstance":"Amyloid beta-Protein Precursor"},{"RegistryNumber":"0","NameOfSubstance":"Apolipoprotein E4"},{"RegistryNumber":"0","NameOfSubstance":"Peptide Fragments"},{"RegistryNumber":"0","NameOfSubstance":"amyloid beta-protein (1-42)"},{"RegistryNumber":"0","NameOfSubstance":"tau Proteins"},{"RegistryNumber":"0Z5B2CJX4D","NameOfSubstance":"Fluorodeoxyglucose F18"},{"RegistryNumber":"Z020Y8WIJ4","NameOfSubstance":"sortilin"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Adaptor Proteins, Vesicular Transport","QualifierName":"cerebrospinal fluid"},{"DescriptorName":"Adult"},{"DescriptorName":"Aged"},{"DescriptorName":"Aged, 80 and over"},{"DescriptorName":"Alzheimer Disease","QualifierName":"cerebrospinal fluid"},{"DescriptorName":"Amyloid beta-Peptides","QualifierName":"cerebrospinal fluid"},{"DescriptorName":"Amyloid beta-Protein Precursor","QualifierName":"cerebrospinal fluid"},{"DescriptorName":"Apolipoprotein E4","QualifierName":"genetics"},{"DescriptorName":"Cognitive Dysfunction","QualifierName":["cerebrospinal fluid","diagnostic imaging","genetics"]},{"DescriptorName":"Female"},{"DescriptorName":"Fluorodeoxyglucose F18"},{"DescriptorName":"Humans"},{"DescriptorName":"Male"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Neuropsychological Tests"},{"DescriptorName":"Peptide Fragments","QualifierName":"cerebrospinal fluid"},{"DescriptorName":"Positron-Emission Tomography"},{"DescriptorName":"Psychiatric Status Rating Scales"},{"DescriptorName":"Statistics, Nonparametric"},{"DescriptorName":"tau Proteins","QualifierName":"cerebrospinal fluid"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"entrez"},"Year":"2013","Month":"4","Day":"24","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2013","Month":"4","Day":"24","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2014","Month":"1","Day":"28","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["23609762","JQ91N20858121171","10.3233\/JAD-122329"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"23451025","DateCompleted":{"Year":"2013","Month":"09","Day":"03"},"DateRevised":{"Year":"2018","Month":"11","Day":"13"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1932-6203","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"8","Issue":"2","PubDate":{"Year":"2013"}},"Title":"PloS one","ISOAbbreviation":"PLoS One"},"ArticleTitle":"Reference cluster normalization improves detection of frontotemporal lobar degeneration by means of FDG-PET.","Pagination":{"MedlinePgn":"e55415"},"ELocationID":"10.1371\/journal.pone.0055415","Abstract":{"AbstractText":"Positron emission tomography with [18F] fluorodeoxyglucose (FDG-PET) plays a well-established role in assisting early detection of frontotemporal lobar degeneration (FTLD). Here, we examined the impact of intensity normalization to different reference areas on accuracy of FDG-PET to discriminate between patients with mild FTLD and healthy elderly subjects. FDG-PET was conducted at two centers using different acquisition protocols: 41 FTLD patients and 42 controls were studied at center 1, 11 FTLD patients and 13 controls were studied at center 2. All PET images were intensity normalized to the cerebellum, primary sensorimotor cortex (SMC), cerebral global mean (CGM), and a reference cluster with most preserved FDG uptake in the aforementioned patients group of center 1. Metabolic deficits in the patient group at center 1 appeared 1.5, 3.6, and 4.6 times greater in spatial extent, when tracer uptake was normalized to the reference cluster rather than to the cerebellum, SMC, and CGM, respectively. Logistic regression analyses based on normalized values from FTLD-typical regions showed that at center 1, cerebellar, SMC, CGM, and cluster normalizations differentiated patients from controls with accuracies of 86%, 76%, 75% and 90%, respectively. A similar order of effects was found at center 2. Cluster normalization leads to a significant increase of statistical power in detecting early FTLD-associated metabolic deficits. The established FTLD-specific cluster can be used to improve detection of FTLD on a single case basis at independent centers - a decisive step towards early diagnosis and prediction of FTLD syndromes enabling specific therapies in the future."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Dukart","ForeName":"Juergen","Initials":"J","AffiliationInfo":{"Affiliation":"LREN, D\u00e9partement des Neurosciences Cliniques, CHUV, Universit\u00e9 de Lausanne, Lausanne, Switzerland. dukart@cbs.mpg.de"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Perneczky","ForeName":"Robert","Initials":"R"},{"@attributes":{"ValidYN":"Y"},"LastName":"F\u00f6rster","ForeName":"Stefan","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"Barthel","ForeName":"Henryk","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Diehl-Schmid","ForeName":"Janine","Initials":"J"},{"@attributes":{"ValidYN":"Y"},"LastName":"Draganski","ForeName":"Bogdan","Initials":"B"},{"@attributes":{"ValidYN":"Y"},"LastName":"Obrig","ForeName":"Hellmuth","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Santarnecchi","ForeName":"Emiliano","Initials":"E"},{"@attributes":{"ValidYN":"Y"},"LastName":"Drzezga","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Fellgiebel","ForeName":"Andreas","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Frackowiak","ForeName":"Richard","Initials":"R"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"M\u00fcller","ForeName":"Karsten","Initials":"K"},{"@attributes":{"ValidYN":"Y"},"LastName":"Sabri","ForeName":"Osama","Initials":"O"},{"@attributes":{"ValidYN":"Y"},"LastName":"Schroeter","ForeName":"Matthias L","Initials":"ML"},{"@attributes":{"ValidYN":"Y"},"LastName":"Yakushev","ForeName":"Igor","Initials":"I"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Research Support, Non-U.S. Gov't"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2013","Month":"02","Day":"25"}},"MedlineJournalInfo":{"Country":"United States","MedlineTA":"PLoS One","NlmUniqueID":"101285081","ISSNLinking":"1932-6203"},"ChemicalList":{"Chemical":{"RegistryNumber":"0Z5B2CJX4D","NameOfSubstance":"Fluorodeoxyglucose F18"}},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Adult"},{"DescriptorName":"Female"},{"DescriptorName":"Fluorodeoxyglucose F18"},{"DescriptorName":"Frontotemporal Lobar Degeneration","QualifierName":"diagnosis"},{"DescriptorName":"Humans"},{"DescriptorName":"Male"},{"DescriptorName":"Positron-Emission Tomography","QualifierName":"methods"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2012","Month":"09","Day":"05"},{"@attributes":{"PubStatus":"accepted"},"Year":"2012","Month":"12","Day":"22"},{"@attributes":{"PubStatus":"entrez"},"Year":"2013","Month":"3","Day":"2","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2013","Month":"3","Day":"2","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2013","Month":"9","Day":"4","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["23451025","10.1371\/journal.pone.0055415","PONE-D-12-27196","PMC3581522"]},"ReferenceList":{"Reference":[{"Citation":"Brain. 2007 Oct;130(Pt 10):2616-35","ArticleIdList":{"ArticleId":"17704526"}},{"Citation":"J Nucl Med. 1998 Feb;39(2):293-8","ArticleIdList":{"ArticleId":"9476938"}},{"Citation":"Eur J Nucl Med Mol Imaging. 2007 Oct;34(10):1658-69","ArticleIdList":{"ArticleId":"17520250"}},{"Citation":"Eur Arch Psychiatry Clin Neurosci. 2011 Sep;261(6):433-46","ArticleIdList":{"ArticleId":"21207049"}},{"Citation":"Acta Neurol Scand. 2012 May;125(5):303-10","ArticleIdList":{"ArticleId":"21692755"}},{"Citation":"J Comput Assist Tomogr. 1995 Jul-Aug;19(4):541-7","ArticleIdList":{"ArticleId":"7622680"}},{"Citation":"Neurobiol Aging. 2004 Sep;25(8):1051-6","ArticleIdList":{"ArticleId":"15212830"}},{"Citation":"Neuroimage. 1998 Oct;8(3):302-6","ArticleIdList":{"ArticleId":"9758743"}},{"Citation":"Neuroimage. 2009 Jul 15;46(4):981-8","ArticleIdList":{"ArticleId":"19303935"}},{"Citation":"Neuroimage. 2007 Jul 1;36(3):497-510","ArticleIdList":{"ArticleId":"17478101"}},{"Citation":"J Nucl Med. 2005 Feb;46(2):233-9","ArticleIdList":{"ArticleId":"15695781"}},{"Citation":"Brain. 2009 Sep;132(Pt 9):2566-78","ArticleIdList":{"ArticleId":"19416953"}},{"Citation":"Am J Pathol. 2006 Oct;169(4):1343-52","ArticleIdList":{"ArticleId":"17003490"}},{"Citation":"Neuroimage. 2010 Jan 15;49(2):1490-5","ArticleIdList":{"ArticleId":"19770055"}},{"Citation":"Neurobiol Aging. 2008 Mar;29(3):418-26","ArticleIdList":{"ArticleId":"17140704"}},{"Citation":"Neuroimage. 2003 Jul;19(3):1233-9","ArticleIdList":{"ArticleId":"12880848"}},{"Citation":"Neuroimage. 2004 Jan;21(1):450-5","ArticleIdList":{"ArticleId":"14741682"}},{"Citation":"Neurology. 2004 Dec 28;63(12):2332-40","ArticleIdList":{"ArticleId":"15623696"}},{"Citation":"J Neurol Neurosurg Psychiatry. 2011 May;82(5):476-86","ArticleIdList":{"ArticleId":"20971753"}},{"Citation":"Science. 2006 Oct 6;314(5796):130-3","ArticleIdList":{"ArticleId":"17023659"}},{"Citation":"J Nucl Med. 2004 Apr;45(4):594-607","ArticleIdList":{"ArticleId":"15073255"}},{"Citation":"AJR Am J Roentgenol. 1992 May;158(5):1155-9","ArticleIdList":{"ArticleId":"1566683"}},{"Citation":"J Neurol Sci. 2012 Feb 15;313(1-2):123-8","ArticleIdList":{"ArticleId":"21975016"}},{"Citation":"Neuroimage. 2012 Jun;61(2):457-63","ArticleIdList":{"ArticleId":"22094642"}},{"Citation":"Psychiatry Res. 2013 Jun 30;212(3):230-6","ArticleIdList":{"ArticleId":"23149027"}},{"Citation":"Neuroimage. 2002 Oct;17(2):532-42","ArticleIdList":{"ArticleId":"12377132"}},{"Citation":"Front Aging Neurosci. 2011 Jul 19;3:10","ArticleIdList":{"ArticleId":"21811457"}},{"Citation":"Lancet Neurol. 2011 Feb;10(2):162-72","ArticleIdList":{"ArticleId":"21147039"}},{"Citation":"Neurology. 1998 Dec;51(6):1546-54","ArticleIdList":{"ArticleId":"9855500"}},{"Citation":"Neuroimage. 2009 Jan 1;44(1):43-50","ArticleIdList":{"ArticleId":"18691659"}},{"Citation":"J Nucl Med. 2008 Mar;49(3):390-8","ArticleIdList":{"ArticleId":"18287270"}},{"Citation":"Neuroimage. 2009 Oct 1;47(4):1514-21","ArticleIdList":{"ArticleId":"19465133"}},{"Citation":"J Neurol Neurosurg Psychiatry. 2003 Sep;74(9):1206-9","ArticleIdList":{"ArticleId":"12933919"}},{"Citation":"Neurobiol Aging. 2007 Jan;28(1):42-50","ArticleIdList":{"ArticleId":"16448722"}},{"Citation":"Neuroimage. 2002 Jan;15(1):273-89","ArticleIdList":{"ArticleId":"11771995"}},{"Citation":"Eur J Nucl Med Mol Imaging. 2008 Mar;35(3):605-10","ArticleIdList":{"ArticleId":"17968544"}},{"Citation":"Psychiatry Res. 2008 Nov 30;164(2):143-53","ArticleIdList":{"ArticleId":"18930634"}},{"Citation":"J Nucl Med. 2011 Feb;52(2):173-9","ArticleIdList":{"ArticleId":"21233181"}},{"Citation":"Neuroimage. 2004 Oct;23(2):739-43","ArticleIdList":{"ArticleId":"15488423"}},{"Citation":"Q J Nucl Med Mol Imaging. 2012 Jun;56(3):299-308","ArticleIdList":{"ArticleId":"22695340"}},{"Citation":"Neuroimage. 2009 Oct 1;47(4):1196-206","ArticleIdList":{"ArticleId":"19463961"}},{"Citation":"Am J Geriatr Psychiatry. 2006 Feb;14(2):139-44","ArticleIdList":{"ArticleId":"16473978"}},{"Citation":"PLoS One. 2011;6(3):e18111","ArticleIdList":{"ArticleId":"21448435"}},{"Citation":"Ann Neurol. 2006 Sep;60(3):314-22","ArticleIdList":{"ArticleId":"16983685"}},{"Citation":"Lancet Neurol. 2010 Feb;9(2):149-58","ArticleIdList":{"ArticleId":"20061183"}},{"Citation":"Eur Neurol. 2001;45(1):19-27","ArticleIdList":{"ArticleId":"11150836"}}]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"23314060","DateCompleted":{"Year":"2014","Month":"07","Day":"08"},"DateRevised":{"Year":"2019","Month":"01","Day":"08"},"Article":{"@attributes":{"PubModel":"Print"},"Journal":{"ISSN":"1546-4156","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"27","Issue":"4","PubDate":{"MedlineDate":"2013 Oct-Dec"}},"Title":"Alzheimer disease and associated disorders","ISOAbbreviation":"Alzheimer Dis Assoc Disord"},"ArticleTitle":"Plasma proteomics for the identification of Alzheimer disease.","Pagination":{"MedlinePgn":"337-42"},"ELocationID":"10.1097\/WAD.0b013e31827b60d2","Abstract":{"AbstractText":"Less-invasive biomarkers for early Alzheimer disease (AD) are urgently needed. The present study aimed to establish a panel of plasma proteins that accurately distinguishes early AD from physiological aging and to compare the findings with previous reports. Fifty-eight healthy controls (CON) and 109 patients with AD dementia were randomly split into a training (40%) and a test (60%) sample. Significant proteins to differentiate between the CON and AD dementia groups were identified in a comprehensive panel of 107 plasma analytes in the training sample; the accuracy in differentiating these 2 groups was explored in the test sample. A set of 5 plasma proteins was identified, which differentiated between the CON group and the AD dementia group with a sensitivity of 89.36% and a specificity of 79.17%. A biological pathway analysis showed that 4 of 5 proteins belonged to a common network with amyloid precursor protein and tau. Apolipoprotein E was the only protein that was both significant in the present report and in a previous proteomic study. The study provides a piece of evidence in support of the feasibility of a blood-based biomarker approach in AD diagnostics; however, further research is required because of issues with replicability. "},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Guo","ForeName":"Liang-Hao","Initials":"LH","AffiliationInfo":{"Affiliation":"*Department of Psychiatry and Psychotherapy \u2020Institute for Medical Statistics and Epidemiology, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany \u2021Neuroepidemiology and Ageing Research Unit, School of Public Health, Faculty of Medicine, The Imperial College of Science, Technology, and Medicine, London, UK."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Alexopoulos","ForeName":"Panagiotis","Initials":"P"},{"@attributes":{"ValidYN":"Y"},"LastName":"Wagenpfeil","ForeName":"Stefan","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Perneczky","ForeName":"Robert","Initials":"R"},{"@attributes":{"ValidYN":"Y"},"CollectiveName":"Alzheimer\u2019s Disease Neuroimaging Initiative"}]},"Language":"eng","GrantList":{"@attributes":{"CompleteYN":"Y"},"Grant":[{"GrantID":"K01 AG030514","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"P30 AG010129","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"U01 AG024904","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"P30AG010129","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"}]},"PublicationTypeList":{"PublicationType":["Journal Article","Randomized Controlled Trial","Research Support, N.I.H., Extramural","Research Support, Non-U.S. Gov't"]}},"MedlineJournalInfo":{"Country":"United States","MedlineTA":"Alzheimer Dis Assoc Disord","NlmUniqueID":"8704771","ISSNLinking":"0893-0341"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"Apolipoproteins E"},{"RegistryNumber":"0","NameOfSubstance":"Biomarkers"},{"RegistryNumber":"0","NameOfSubstance":"Blood Proteins"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Aged, 80 and over"},{"DescriptorName":"Alzheimer Disease","QualifierName":["blood","diagnosis","genetics"]},{"DescriptorName":"Apolipoproteins E","QualifierName":["blood","genetics"]},{"DescriptorName":"Biomarkers","QualifierName":"blood"},{"DescriptorName":"Blood Proteins","QualifierName":["genetics","metabolism"]},{"DescriptorName":"Cohort Studies"},{"DescriptorName":"Female"},{"DescriptorName":"Follow-Up Studies"},{"DescriptorName":"Humans"},{"DescriptorName":"Male"},{"DescriptorName":"Proteomics","QualifierName":"methods"},{"DescriptorName":"Reproducibility of Results"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"entrez"},"Year":"2013","Month":"1","Day":"15","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2013","Month":"1","Day":"15","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2014","Month":"7","Day":"9","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["23314060","10.1097\/WAD.0b013e31827b60d2","PMC3626738","NIHMS424683"]},"ReferenceList":{"Reference":[{"Citation":"Neurosci Lett. 1999 Jan 4;259(1):33-6","ArticleIdList":{"ArticleId":"10027549"}},{"Citation":"Ann Clin Lab Sci. 1999 Jan-Mar;29(1):18-23","ArticleIdList":{"ArticleId":"10074964"}},{"Citation":"Neurology. 1999 May 12;52(8):1555-62","ArticleIdList":{"ArticleId":"10331678"}},{"Citation":"Clin Chem Lab Med. 2000 Aug;38(8):721-30","ArticleIdList":{"ArticleId":"11071064"}},{"Citation":"Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9440-5","ArticleIdList":{"ArticleId":"12883005"}},{"Citation":"J Neuroimmunol. 2004 Jan;146(1-2):39-45","ArticleIdList":{"ArticleId":"14698845"}},{"Citation":"Arch Neurol. 2004 May;61(5):668-72","ArticleIdList":{"ArticleId":"15148142"}},{"Citation":"Dement Geriatr Cogn Disord. 2004;17(4):350-4","ArticleIdList":{"ArticleId":"15178952"}},{"Citation":"Brain Res Mol Brain Res. 2004 Dec 20;132(2):155-67","ArticleIdList":{"ArticleId":"15582155"}},{"Citation":"CMAJ. 2005 Feb 1;172(3):367-79","ArticleIdList":{"ArticleId":"15684121"}},{"Citation":"Neurosci Lett. 2005 Nov 4;388(1):49-53","ArticleIdList":{"ArticleId":"16039064"}},{"Citation":"IUBMB Life. 2005 Nov;57(11):749-59","ArticleIdList":{"ArticleId":"16511968"}},{"Citation":"Mol Cell Proteomics. 2006 Oct;5(10):1720-6","ArticleIdList":{"ArticleId":"16546995"}},{"Citation":"Eur J Neurosci. 2006 May;23(10):2648-56","ArticleIdList":{"ArticleId":"16817867"}},{"Citation":"Nat Med. 2006 Sep;12(9):1005-15","ArticleIdList":{"ArticleId":"16960575"}},{"Citation":"Brain. 2006 Nov;129(Pt 11):3042-50","ArticleIdList":{"ArticleId":"17071923"}},{"Citation":"Arch Immunol Ther Exp (Warsz). 2007 Jan-Feb;55(1):41-7","ArticleIdList":{"ArticleId":"17221335"}},{"Citation":"Nat Med. 2007 Nov;13(11):1359-62","ArticleIdList":{"ArticleId":"17934472"}},{"Citation":"Neuroimage. 2008 Jan 15;39(2):619-33","ArticleIdList":{"ArticleId":"17962045"}},{"Citation":"J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Apr 15;866(1-2):77-88","ArticleIdList":{"ArticleId":"18033744"}},{"Citation":"Methods. 2008 Apr;44(4):289-98","ArticleIdList":{"ArticleId":"18374272"}},{"Citation":"J Neurol Sci. 2008 Sep 15;272(1-2):164-70","ArticleIdList":{"ArticleId":"18597785"}},{"Citation":"Biomarkers. 2008 Sep;13(6):618-36","ArticleIdList":{"ArticleId":"18830857"}},{"Citation":"Neurobiol Dis. 2009 Aug;35(2):157-64","ArticleIdList":{"ArticleId":"18938247"}},{"Citation":"J Neurol. 2008 Nov;255(11):1712-20","ArticleIdList":{"ArticleId":"19156487"}},{"Citation":"Acta Neuropathol. 2009 Jul;118(1):181-95","ArticleIdList":{"ArticleId":"19259691"}},{"Citation":"Acta Neuropathol. 2009 Jul;118(1):167-79","ArticleIdList":{"ArticleId":"19390859"}},{"Citation":"Neurobiol Aging. 2011 Mar;32(3):539-40","ArticleIdList":{"ArticleId":"19395124"}},{"Citation":"J Alzheimers Dis. 2009;18(2):413-7","ArticleIdList":{"ArticleId":"19661632"}},{"Citation":"Geriatr Gerontol Int. 2009 Sep;9(3):242-5","ArticleIdList":{"ArticleId":"19702933"}},{"Citation":"CNS Neurosci Ther. 2009 Winter;15(4):358-74","ArticleIdList":{"ArticleId":"19840034"}},{"Citation":"Ann N Y Acad Sci. 2009 Oct;1180:56-67","ArticleIdList":{"ArticleId":"19906261"}},{"Citation":"Neuron. 2009 Dec 10;64(5):632-44","ArticleIdList":{"ArticleId":"20005821"}},{"Citation":"Nat Rev Neurol. 2010 Feb;6(2):67-77","ArticleIdList":{"ArticleId":"20139996"}},{"Citation":"Nat Rev Neurol. 2010 Mar;6(3):131-44","ArticleIdList":{"ArticleId":"20157306"}},{"Citation":"Biomark Med. 2010 Feb;4(1):65-79","ArticleIdList":{"ArticleId":"20387303"}},{"Citation":"Eur Neurol. 2010;63(6):326-30","ArticleIdList":{"ArticleId":"20516693"}},{"Citation":"Arch Neurol. 2010 Sep;67(9):1077-81","ArticleIdList":{"ArticleId":"20837851"}},{"Citation":"Curr Opin HIV AIDS. 2010 Nov;5(6):517-23","ArticleIdList":{"ArticleId":"20978395"}},{"Citation":"Neurology. 2011 Jan 4;76(1):69-79","ArticleIdList":{"ArticleId":"21123754"}},{"Citation":"Proteomics Clin Appl. 2007 May;1(5):506-12","ArticleIdList":{"ArticleId":"21136702"}},{"Citation":"Pharmacogenomics. 2010 Dec;11(12):1733-41","ArticleIdList":{"ArticleId":"21142917"}},{"Citation":"Neurology. 2011 Mar 22;76(12):1091-8","ArticleIdList":{"ArticleId":"21422459"}},{"Citation":"Int J Neuropsychopharmacol. 2011 Oct;14(9):1147-55","ArticleIdList":{"ArticleId":"21466745"}},{"Citation":"PLoS One. 2011 Mar 24;6(3):e17481","ArticleIdList":{"ArticleId":"21479255"}},{"Citation":"J Biol Inorg Chem. 2011 Jun;16(5):809-16","ArticleIdList":{"ArticleId":"21523435"}},{"Citation":"Neurology. 2011 Jul 5;77(1):35-8","ArticleIdList":{"ArticleId":"21700579"}},{"Citation":"Mol Cell Proteomics. 2011 Oct;10(10):M111.008862","ArticleIdList":{"ArticleId":"21742799"}},{"Citation":"PLoS One. 2011;6(12):e28092","ArticleIdList":{"ArticleId":"22163278"}},{"Citation":"J Cereb Blood Flow Metab. 2012 May;32(5):780-91","ArticleIdList":{"ArticleId":"22167233"}},{"Citation":"PLoS One. 2011;6(12):e28527","ArticleIdList":{"ArticleId":"22205954"}},{"Citation":"Neurology. 2012 Feb 7;78(6):379-86","ArticleIdList":{"ArticleId":"22238414"}},{"Citation":"Adv Clin Chem. 2012;56:1-54","ArticleIdList":{"ArticleId":"22397027"}},{"Citation":"Scand J Infect Dis. 1989;21(4):381-7","ArticleIdList":{"ArticleId":"2587940"}},{"Citation":"Multimodal Brain Image Anal (2011). 2011 Sep;7012:27-34","ArticleIdList":{"ArticleId":"27054198"}},{"Citation":"Ann Neurol. 1988 Jul;24(1):17-22","ArticleIdList":{"ArticleId":"3415196"}},{"Citation":"Neurology. 1996 Aug;47(2):440-3","ArticleIdList":{"ArticleId":"8757017"}},{"Citation":"Neurosci Lett. 1997 Feb 14;223(1):29-32","ArticleIdList":{"ArticleId":"9058415"}},{"Citation":"Lancet. 1997 Sep 13;350(9080):784","ArticleIdList":{"ArticleId":"9298004"}}]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"23307487","DateCompleted":{"Year":"2015","Month":"02","Day":"12"},"DateRevised":{"Year":"2020","Month":"06","Day":"13"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1097-0193","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"35","Issue":"3","PubDate":{"Year":"2014","Month":"Mar"}},"Title":"Human brain mapping","ISOAbbreviation":"Hum Brain Mapp"},"ArticleTitle":"Predicting effective connectivity from resting-state networks in healthy elderly and patients with prodromal Alzheimer's disease.","Pagination":{"MedlinePgn":"954-63"},"ELocationID":"10.1002\/hbm.22226","Abstract":{"AbstractText":"Using functional neuroimaging techniques two aspects of functional integration in the human brain have been investigated, functional connectivity and effective connectivity. In this study we examined both connectivity types in parallel within an executive attention network during rest and while performing an attention task. We analyzed the predictive value of resting-state functional connectivity on task-induced effective connectivity in patients with prodromal Alzheimer's disease (AD) and healthy elderly. We found that in healthy elderly, functional connectivity was a significant predictor for effective connectivity, however, it was frequency-specific. Effective top-down connectivity emerging from prefrontal areas was related with higher frequencies of functional connectivity (e.g., 0.08-0.15 Hz), in contrast to effective bottom-up connectivity going to prefrontal areas, which was related to lower frequencies of functional connectivity (e.g., 0.001-0.03 Hz). In patients, the prediction of effective connectivity by functional connectivity was disturbed. We conclude that functional connectivity and effective connectivity are interrelated in healthy brains but this relationship is aberrant in very early AD.","CopyrightInformation":"Copyright \u00a9 2013 Wiley Periodicals, Inc."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Neufang","ForeName":"Susanne","Initials":"S","AffiliationInfo":{"Affiliation":"Department of Neuroradiology, Klinikum Rechts der Isar, Technical University Munich, Ismaningerstrasse 22, 81675 Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Akhrif","ForeName":"Atae","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Riedl","ForeName":"Valentin","Initials":"V"},{"@attributes":{"ValidYN":"Y"},"LastName":"F\u00f6rstl","ForeName":"Hans","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Zimmer","ForeName":"Claus","Initials":"C"},{"@attributes":{"ValidYN":"Y"},"LastName":"Sorg","ForeName":"Christian","Initials":"C"},{"@attributes":{"ValidYN":"Y"},"LastName":"Wohlschl\u00e4ger","ForeName":"Afra M","Initials":"AM"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Research Support, Non-U.S. Gov't"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2013","Month":"01","Day":"10"}},"MedlineJournalInfo":{"Country":"United States","MedlineTA":"Hum Brain Mapp","NlmUniqueID":"9419065","ISSNLinking":"1065-9471"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"Antigens, Viral"},{"RegistryNumber":"0","NameOfSubstance":"FMR antigen"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Aging","QualifierName":"physiology"},{"DescriptorName":"Alzheimer Disease","QualifierName":"physiopathology"},{"DescriptorName":"Antigens, Viral"},{"DescriptorName":"Attention","QualifierName":"physiology"},{"DescriptorName":"Cognitive Dysfunction","QualifierName":"physiopathology"},{"DescriptorName":"Connectome","QualifierName":["instrumentation","methods"]},{"DescriptorName":"Disease Progression"},{"DescriptorName":"Executive Function","QualifierName":"physiology"},{"DescriptorName":"Female"},{"DescriptorName":"Follow-Up Studies"},{"DescriptorName":"Humans"},{"DescriptorName":"Male"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Nerve Net","QualifierName":"physiopathology"},{"DescriptorName":"Prefrontal Cortex","QualifierName":"physiopathology"},{"DescriptorName":"Prodromal Symptoms"},{"DescriptorName":"Prognosis"},{"DescriptorName":"Psychomotor Performance","QualifierName":"physiology"},{"DescriptorName":"Rest","QualifierName":"physiology"}]},"KeywordList":{"@attributes":{"Owner":"NOTNLM"},"Keyword":["effective connectivity","executive attention network","prodromal Alzheimer's disease","resting-state functional connectivity"]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2012","Month":"01","Day":"31"},{"@attributes":{"PubStatus":"revised"},"Year":"2012","Month":"09","Day":"12"},{"@attributes":{"PubStatus":"accepted"},"Year":"2012","Month":"10","Day":"22"},{"@attributes":{"PubStatus":"entrez"},"Year":"2013","Month":"1","Day":"12","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2013","Month":"1","Day":"12","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2015","Month":"2","Day":"13","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["23307487","10.1002\/hbm.22226","PMC6869061"]},"ReferenceList":{"Reference":[{"Citation":"Neuroimage. 2005 Dec;28(4):956-66","ArticleIdList":{"ArticleId":"16043368"}},{"Citation":"Clin Neurophysiol. 2005 Mar;116(3):708-15","ArticleIdList":{"ArticleId":"15721085"}},{"Citation":"Schizophr Bull. 2009 May;35(3):509-27","ArticleIdList":{"ArticleId":"19155345"}},{"Citation":"Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18760-5","ArticleIdList":{"ArticleId":"18003904"}},{"Citation":"J Neurosci. 2010 Dec 15;30(50):17035-40","ArticleIdList":{"ArticleId":"21159973"}},{"Citation":"Neuroimage. 2012 Feb 1;59(3):2045-56","ArticleIdList":{"ArticleId":"22019883"}},{"Citation":"Neuroimage. 2008 Jan 1;39(1):279-89","ArticleIdList":{"ArticleId":"17919927"}},{"Citation":"Neurology. 1984 Jul;34(7):939-44","ArticleIdList":{"ArticleId":"6610841"}},{"Citation":"Neuroimage. 2004 Feb;21(2):647-58","ArticleIdList":{"ArticleId":"14980567"}},{"Citation":"Neuron. 2006 Sep 7;51(5):527-39","ArticleIdList":{"ArticleId":"16950152"}},{"Citation":"J Neurophysiol. 2009 Jun;101(6):3270-83","ArticleIdList":{"ArticleId":"19339462"}},{"Citation":"Neuroimage. 2006 Jun;31(2):496-504","ArticleIdList":{"ArticleId":"16473024"}},{"Citation":"Lancet. 2006 Apr 15;367(9518):1262-70","ArticleIdList":{"ArticleId":"16631882"}},{"Citation":"Eur Neuropsychopharmacol. 2010 Aug;20(8):519-34","ArticleIdList":{"ArticleId":"20471808"}},{"Citation":"Neurology. 1989 Sep;39(9):1159-65","ArticleIdList":{"ArticleId":"2771064"}},{"Citation":"Brain Struct Funct. 2009 Oct;213(6):525-33","ArticleIdList":{"ArticleId":"19565262"}},{"Citation":"Exp Brain Res. 2009 Jan;192(3):489-97","ArticleIdList":{"ArticleId":"19030851"}},{"Citation":"Am J Psychiatry. 2007 Mar;164(3):450-7","ArticleIdList":{"ArticleId":"17329470"}},{"Citation":"PLoS Biol. 2009 Jul;7(7):e1000157","ArticleIdList":{"ArticleId":"19621066"}},{"Citation":"Cereb Cortex. 2009 Jan;19(1):72-8","ArticleIdList":{"ArticleId":"18403396"}},{"Citation":"Brain. 2011 Jun;134(Pt 6):1635-46","ArticleIdList":{"ArticleId":"21490054"}},{"Citation":"Neuroimage. 2005 Jun;26(2):471-9","ArticleIdList":{"ArticleId":"15907304"}},{"Citation":"Philos Trans R Soc Lond B Biol Sci. 2005 May 29;360(1457):937-46","ArticleIdList":{"ArticleId":"16087438"}},{"Citation":"Biol Cybern. 2010 Jan;102(1):57-69","ArticleIdList":{"ArticleId":"19937337"}},{"Citation":"Neuroimage. 2011 Mar 1;55(1):24-31","ArticleIdList":{"ArticleId":"21073962"}},{"Citation":"Prog Brain Res. 2011;193:259-76","ArticleIdList":{"ArticleId":"21854968"}},{"Citation":"Hum Brain Mapp. 2009 Feb;30(2):452-61","ArticleIdList":{"ArticleId":"18064582"}},{"Citation":"Front Syst Neurosci. 2010 Aug 05;4:","ArticleIdList":{"ArticleId":"20844603"}},{"Citation":"Neuroimage. 2011 Jun 15;56(4):2109-28","ArticleIdList":{"ArticleId":"21396454"}},{"Citation":"J Neurosci. 2006 Jan 4;26(1):63-72","ArticleIdList":{"ArticleId":"16399673"}},{"Citation":"Wiley Interdiscip Rev Cogn Sci. 2010 May;1(3):446-459","ArticleIdList":{"ArticleId":"21209846"}},{"Citation":"J Neurophysiol. 2010 Jan;103(1):297-321","ArticleIdList":{"ArticleId":"19889849"}},{"Citation":"Cereb Cortex. 2010 Dec;20(12):2852-62","ArticleIdList":{"ArticleId":"20237243"}},{"Citation":"J Alzheimers Dis. 2011;25(2):309-21","ArticleIdList":{"ArticleId":"21422523"}},{"Citation":"Neuroimage. 2008 Nov 15;43(3):554-61","ArticleIdList":{"ArticleId":"18771736"}},{"Citation":"PLoS Comput Biol. 2008 Jun 27;4(6):e1000100","ArticleIdList":{"ArticleId":"18584043"}},{"Citation":"Neuroimage. 2001 Nov;14(5):1080-8","ArticleIdList":{"ArticleId":"11697939"}},{"Citation":"PLoS One. 2011;6(5):e20079","ArticleIdList":{"ArticleId":"21611155"}},{"Citation":"Brain. 1999 Mar;122 ( Pt 3):383-404","ArticleIdList":{"ArticleId":"10094249"}},{"Citation":"NMR Biomed. 1997 Jun-Aug;10(4-5):165-70","ArticleIdList":{"ArticleId":"9430343"}},{"Citation":"Neuron. 2009 Jul 30;63(2):178-88","ArticleIdList":{"ArticleId":"19640477"}},{"Citation":"Neurology. 2009 Dec 1;73(22):1899-905","ArticleIdList":{"ArticleId":"19846828"}},{"Citation":"Neuroimage. 2011 Mar 15;55(2):688-704","ArticleIdList":{"ArticleId":"21095229"}}]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"23232272","DateCompleted":{"Year":"2014","Month":"03","Day":"25"},"DateRevised":{"Year":"2016","Month":"12","Day":"09"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1552-5279","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"9","Issue":"5","PubDate":{"Year":"2013","Month":"Sep"}},"Title":"Alzheimer's & dementia : the journal of the Alzheimer's Association","ISOAbbreviation":"Alzheimers Dement"},"ArticleTitle":"Brain size and the compensation of Alzheimer's disease symptoms: a longitudinal cohort study.","Pagination":{"MedlinePgn":"580-6"},"ELocationID":["10.1016\/j.jalz.2012.10.002","S1552-5260(12)02464-8"],"Abstract":{"AbstractText":["Greater intracranial volume (ICV) has been associated with less severe Alzheimer's disease (AD) symptoms at a given level of cerebral pathology. In this study we examine whether ICV modulates the association between clinical disease progression on the one hand and brain atrophy or the apolipoprotein E genotype on the other.","Six hundred seventy-four subjects were studied from the AD Neuroimaging Initiative (ADNI). Subjects included 204 controls, 144 patients with AD dementia, and 326 with amnestic mild cognitive impairment (aMCI). Longitudinal analyses were conducted applying generalized estimating equations to examine the influence of ICV on clinical deterioration and atrophy progression. Follow-up data were available for up to 60 months after the baseline visit (mean 31.42 months, SD 13.12 months).","ICV was not directly associated with clinical worsening or atrophy progression. However, ICV attenuated the impact of atrophy and the apolipoprotein E \u03b54 allele on clinical disease progression in aMCI.","Greater ICV, that is, premorbid brain size, seems to protect against clinical deterioration in the face of AD-related brain atrophy in aMCI. The results support the theory of a compensatory role of brain reserve in contrast to a neuroprotective role. The protective effects of morphologic reserve seem to be limited to early clinical AD; once a certain threshold of neurodegenerative burden is passed, a larger premorbid brain no longer offers an advantage in this context."],"CopyrightInformation":"Copyright \u00a9 2013. Published by Elsevier Inc."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Guo","ForeName":"Liang-Hao","Initials":"LH","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Alexopoulos","ForeName":"Panagiotis","Initials":"P"},{"@attributes":{"ValidYN":"Y"},"LastName":"Wagenpfeil","ForeName":"Stefan","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Perneczky","ForeName":"Robert","Initials":"R"},{"@attributes":{"ValidYN":"Y"},"CollectiveName":"Alzheimer's Disease Neuroimaging Initiative"}]},"Language":"eng","GrantList":{"@attributes":{"CompleteYN":"Y"},"Grant":[{"GrantID":"P30 AG010129","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"U01 AG024904","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"Agency":"Canadian Institutes of Health Research","Country":"Canada"},{"GrantID":"K01 AG030514","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"}]},"PublicationTypeList":{"PublicationType":["Journal Article","Research Support, N.I.H., Extramural","Research Support, Non-U.S. Gov't"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2012","Month":"12","Day":"08"}},"MedlineJournalInfo":{"Country":"United States","MedlineTA":"Alzheimers Dement","NlmUniqueID":"101231978","ISSNLinking":"1552-5260"},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Aged, 80 and over"},{"DescriptorName":"Alzheimer Disease","QualifierName":"pathology"},{"DescriptorName":"Brain","QualifierName":"pathology"},{"DescriptorName":"Cognitive Reserve"},{"DescriptorName":"Cohort Studies"},{"DescriptorName":"Disease Progression"},{"DescriptorName":"Female"},{"DescriptorName":"Humans"},{"DescriptorName":"Longitudinal Studies"},{"DescriptorName":"Magnetic Resonance Imaging"},{"DescriptorName":"Male"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Organ Size"}]},"KeywordList":{"@attributes":{"Owner":"NOTNLM"},"Keyword":["Apolipoprotein E","Atrophy","Brain reserve","Cognitive reserve","Dementia","Head circumference","Intracranial volume","Magnetic resonance imaging","Mild cognitive impairment"]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2012","Month":"06","Day":"20"},{"@attributes":{"PubStatus":"revised"},"Year":"2012","Month":"08","Day":"23"},{"@attributes":{"PubStatus":"accepted"},"Year":"2012","Month":"10","Day":"01"},{"@attributes":{"PubStatus":"entrez"},"Year":"2012","Month":"12","Day":"13","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2012","Month":"12","Day":"13","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2014","Month":"3","Day":"26","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["23232272","S1552-5260(12)02464-8","10.1016\/j.jalz.2012.10.002"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"23127467","DateCompleted":{"Year":"2013","Month":"10","Day":"21"},"DateRevised":{"Year":"2015","Month":"11","Day":"19"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1552-5279","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"9","Issue":"4","PubDate":{"Year":"2013","Month":"Jul"}},"Title":"Alzheimer's & dementia : the journal of the Alzheimer's Association","ISOAbbreviation":"Alzheimers Dement"},"ArticleTitle":"\u03b2-Site amyloid precursor protein-cleaving enzyme 1 activity is related to cerebrospinal fluid concentrations of sortilin-related receptor with A-type repeats, soluble amyloid precursor protein, and tau.","Pagination":{"MedlinePgn":"386-91"},"ELocationID":["10.1016\/j.jalz.2012.01.015","S1552-5260(12)00056-8"],"Abstract":{"AbstractText":["\u03b2-Site amyloid precursor protein (APP)-cleaving enzyme 1 (BACE1) activity determines the rate of APP cleavage and is therefore the main driver of amyloid \u03b2 production, which is a pathological hallmark of Alzheimer's disease (AD).","The present study explored the correlation between BACE1 activity and cerebrospinal fluid (CSF) markers of APP metabolism and axonal degeneration in 63 patients with mild AD and 12 healthy control subjects.","In the AD group, positive correlations between BACE1 activity and soluble APP \u03b2, the APP sorting receptor sortilin-related receptor with A-type repeats (also known as SorLA or LR11), and tau were detected. BACE1 activity was not associated with amyloid \u03b21-42 or soluble APP \u03b1 concentrations in the AD group, and no associations between BACE1 activity and any of the protein concentrations were found in the control group.","Our results confirm the relevance of BACE1 and sortilin-related receptor with A-type repeats within the amyloid cascade and also provide a further piece of evidence for the link between amyloid and tau pathology in AD."],"CopyrightInformation":"Copyright \u00a9 2013 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Tsolakidou","ForeName":"Amalia","Initials":"A","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, M\u00fcnchen, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Alexopoulos","ForeName":"Panagiotis","Initials":"P"},{"@attributes":{"ValidYN":"Y"},"LastName":"Guo","ForeName":"Liang-Hao","Initials":"LH"},{"@attributes":{"ValidYN":"Y"},"LastName":"Grimmer","ForeName":"Timo","Initials":"T"},{"@attributes":{"ValidYN":"Y"},"LastName":"Westerteicher","ForeName":"Christine","Initials":"C"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kratzer","ForeName":"Martina","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Jiang","ForeName":"Meizi","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Bujo","ForeName":"Hideaki","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Roselli","ForeName":"Francesco","Initials":"F"},{"@attributes":{"ValidYN":"Y"},"LastName":"Leante","ForeName":"Maria Rosaria","Initials":"MR"},{"@attributes":{"ValidYN":"Y"},"LastName":"Livrea","ForeName":"Paolo","Initials":"P"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Perneczky","ForeName":"Robert","Initials":"R"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Research Support, Non-U.S. Gov't"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2012","Month":"11","Day":"03"}},"MedlineJournalInfo":{"Country":"United States","MedlineTA":"Alzheimers Dement","NlmUniqueID":"101231978","ISSNLinking":"1552-5260"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"Amyloid beta-Peptides"},{"RegistryNumber":"0","NameOfSubstance":"Amyloid beta-Protein Precursor"},{"RegistryNumber":"0","NameOfSubstance":"Biomarkers"},{"RegistryNumber":"0","NameOfSubstance":"LDL-Receptor Related Proteins"},{"RegistryNumber":"0","NameOfSubstance":"MAPT protein, human"},{"RegistryNumber":"0","NameOfSubstance":"Membrane Transport Proteins"},{"RegistryNumber":"0","NameOfSubstance":"Peptide Fragments"},{"RegistryNumber":"0","NameOfSubstance":"SORL1 protein, human"},{"RegistryNumber":"0","NameOfSubstance":"amyloid beta-protein (1-42)"},{"RegistryNumber":"0","NameOfSubstance":"tau Proteins"},{"RegistryNumber":"EC 3.4.-","NameOfSubstance":"Amyloid Precursor Protein Secretases"},{"RegistryNumber":"EC 3.4.23.-","NameOfSubstance":"Aspartic Acid Endopeptidases"},{"RegistryNumber":"EC 3.4.23.46","NameOfSubstance":"BACE1 protein, human"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Adult"},{"DescriptorName":"Aged"},{"DescriptorName":"Alzheimer Disease","QualifierName":"cerebrospinal fluid"},{"DescriptorName":"Amyloid Precursor Protein Secretases","QualifierName":"cerebrospinal fluid"},{"DescriptorName":"Amyloid beta-Peptides","QualifierName":"cerebrospinal fluid"},{"DescriptorName":"Amyloid beta-Protein Precursor","QualifierName":["cerebrospinal fluid","metabolism"]},{"DescriptorName":"Aspartic Acid Endopeptidases","QualifierName":"cerebrospinal fluid"},{"DescriptorName":"Biomarkers"},{"DescriptorName":"Female"},{"DescriptorName":"Humans"},{"DescriptorName":"LDL-Receptor Related Proteins","QualifierName":"cerebrospinal fluid"},{"DescriptorName":"Male"},{"DescriptorName":"Membrane Transport Proteins","QualifierName":"cerebrospinal fluid"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Peptide Fragments","QualifierName":"cerebrospinal fluid"},{"DescriptorName":"Psychometrics"},{"DescriptorName":"Retrograde Degeneration"},{"DescriptorName":"tau Proteins","QualifierName":"cerebrospinal fluid"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2011","Month":"08","Day":"03"},{"@attributes":{"PubStatus":"revised"},"Year":"2011","Month":"12","Day":"30"},{"@attributes":{"PubStatus":"accepted"},"Year":"2012","Month":"01","Day":"24"},{"@attributes":{"PubStatus":"entrez"},"Year":"2012","Month":"11","Day":"7","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2012","Month":"11","Day":"7","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2013","Month":"10","Day":"22","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["23127467","S1552-5260(12)00056-8","10.1016\/j.jalz.2012.01.015"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"23036071","DateCompleted":{"Year":"2013","Month":"08","Day":"21"},"DateRevised":{"Year":"2019","Month":"12","Day":"18"},"Article":{"@attributes":{"PubModel":"Print"},"Journal":{"ISSN":"1875-5828","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"10","Issue":"1","PubDate":{"Year":"2013","Month":"Jan"}},"Title":"Current Alzheimer research","ISOAbbreviation":"Curr Alzheimer Res"},"ArticleTitle":"The usefulness of amyloid imaging in predicting the clinical outcome after two years in subjects with mild cognitive impairment.","Pagination":{"MedlinePgn":"82-5"},"Abstract":{"AbstractText":["Mild cognitive impairment (MCI) is a syndrome heterogeneous with regards to etiology and prognosis. Amyloid imaging enables to visualize a hallmark pathology of Alzheimer's disease (AD). Therefore we aimed to assess the usefulness of [(11)C]PiB PET for predicting clinical outcome of MCI patients after an interval of 2 years.","In 28 MCI participants with a global CDR rating at baseline of 0.5 a baseline examination including clinical assessments and [(11)C]PiB PET imaging and a clinical follow-up examination after a planned interval of 24 months were performed. Predictive values and accuracy of amyloid-positive and negative scans for conversion to dementia of any type and to dementia due to AD were calculated and compared to neuropsychological tests and ApoE genotyping.","Of 17 MCI patients who were amyloid-positive at baseline converted 9 to dementia all of the AD type. 3 of the 11 amyloid-negative MCI subjects converted to dementia but none to dementia due to AD. PPV, NPV and accuracy (to dementia: 0.53, 0.73 and 0.61; to AD: 0.53, 1.00 and 0.70) was comparable to neuropsychological tests and superior to ApoE genotyping.","All MCI subjects who converted to dementia due to AD were amyloid-positive. However, only 50% of these MCI due to AD, intermediate likelihood, patients developed manifest dementia due to AD after 24 months limiting the usefulness of [(11)C]PiB PET for individual prediction of clinical outcome."]},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Grimmer","ForeName":"Timo","Initials":"T","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technische Universitat Munchen, Mohlstr. 26, 81675 Munchen, Germany. t.grimmer@lrz.tum.de"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Wutz","ForeName":"Carolin","Initials":"C"},{"@attributes":{"ValidYN":"Y"},"LastName":"Drzezga","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"F\u00f6rster","ForeName":"Stefan","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"F\u00f6rstl","ForeName":"Hans","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Ortner","ForeName":"Marion","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Perneczky","ForeName":"Robert","Initials":"R"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Research Support, Non-U.S. Gov't"]}},"MedlineJournalInfo":{"Country":"United Arab Emirates","MedlineTA":"Curr Alzheimer Res","NlmUniqueID":"101208441","ISSNLinking":"1567-2050"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole"},{"RegistryNumber":"0","NameOfSubstance":"Amyloid"},{"RegistryNumber":"0","NameOfSubstance":"Apolipoprotein E4"},{"RegistryNumber":"0","NameOfSubstance":"Benzothiazoles"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Alzheimer Disease"},{"DescriptorName":"Amyloid","QualifierName":["genetics","metabolism"]},{"DescriptorName":"Apolipoprotein E4","QualifierName":"genetics"},{"DescriptorName":"Benzothiazoles"},{"DescriptorName":"Cognitive Dysfunction","QualifierName":["diagnostic imaging","genetics","metabolism"]},{"DescriptorName":"Dementia"},{"DescriptorName":"Disease Progression"},{"DescriptorName":"Female"},{"DescriptorName":"Humans"},{"DescriptorName":"Longitudinal Studies"},{"DescriptorName":"Magnetic Resonance Imaging"},{"DescriptorName":"Male"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Neuropsychological Tests"},{"DescriptorName":"Outcome Assessment, Health Care"},{"DescriptorName":"Positron-Emission Tomography"},{"DescriptorName":"Predictive Value of Tests"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2012","Month":"02","Day":"13"},{"@attributes":{"PubStatus":"revised"},"Year":"2012","Month":"10","Day":"03"},{"@attributes":{"PubStatus":"accepted"},"Year":"2012","Month":"10","Day":"04"},{"@attributes":{"PubStatus":"entrez"},"Year":"2012","Month":"10","Day":"6","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2012","Month":"10","Day":"6","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2013","Month":"8","Day":"22","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["23036071","CAR-EPUB-20121003-1"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"22932720","DateCompleted":{"Year":"2014","Month":"01","Day":"08"},"DateRevised":{"Year":"2018","Month":"11","Day":"13"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1433-8491","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"263","Issue":"4","PubDate":{"Year":"2013","Month":"Jun"}},"Title":"European archives of psychiatry and clinical neuroscience","ISOAbbreviation":"Eur Arch Psychiatry Clin Neurosci"},"ArticleTitle":"The National Institute on Aging-Alzheimer's Association research criteria for mild cognitive impairment due to Alzheimer's disease: predicting the outcome.","Pagination":{"MedlinePgn":"325-33"},"ELocationID":"10.1007\/s00406-012-0349-0","Abstract":{"AbstractText":"The National Institute on Aging-Alzheimer's Association (NIA-AA) clinical research criteria for mild cognitive impairment (MCI) due to Alzheimer's disease (AD) incorporate the use of biomarkers to classify patients according to the likelihood of the presence of AD pathology. The aim of the study was to compare the risk of progression to AD dementia between the four NIA-AA MCI subgroups using data from the AD Neuroimaging Initiative. Patients with MCI were categorised according to the NIA-AA criteria into subgroups with high, intermediate, and low likelihood of the presence of AD pathology (MCI-high, MCI-intermediate, and MCI-unlikely, respectively) or into a group of patients that only met the MCI-core clinical criteria (MCI-core). Data of follow-up visits conducted 6-60 months after baseline were used to compare the relative risk of future AD dementia between the four subgroups employing a Cox regression model. The MCI-high subgroup (N = 22) had a 2.3 times higher risk of developing AD dementia compared with the MCI-core subgroup (N = 327; P = 0.002), while there was a trend for a higher risk in the MCI-high subgroup in contrast to the MCI-intermediate subgroup (N = 31, P = 0.08). No patients in the MCI-unlikely subgroup (N = 17) progressed to AD dementia. Patients with MCI-high have a higher risk for developing AD dementia. The new NIA-AA MCI criteria represent a valuable research instrument that could be incorporated into the diagnostic process of the MCI syndrome after optimisation and refinement."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Guo","ForeName":"Liang-Hao","Initials":"LH","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar der Technischen Universit\u00e4t M\u00fcnchen, Ismaninger Str. 22, 81675 Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Alexopoulos","ForeName":"Panagiotis","Initials":"P"},{"@attributes":{"ValidYN":"Y"},"LastName":"Eisele","ForeName":"Tamara","Initials":"T"},{"@attributes":{"ValidYN":"Y"},"LastName":"Wagenpfeil","ForeName":"Stefan","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Perneczky","ForeName":"Robert","Initials":"R"}]},"Language":"eng","GrantList":{"@attributes":{"CompleteYN":"Y"},"Grant":[{"GrantID":"K01 AG030514","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"P30AG010129","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"U01 AG024904","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"}]},"PublicationTypeList":{"PublicationType":["Journal Article","Research Support, N.I.H., Extramural","Research Support, Non-U.S. Gov't","Research Support, U.S. Gov't, P.H.S."]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2012","Month":"08","Day":"30"}},"MedlineJournalInfo":{"Country":"Germany","MedlineTA":"Eur Arch Psychiatry Clin Neurosci","NlmUniqueID":"9103030","ISSNLinking":"0940-1334"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"Apolipoproteins E"},{"RegistryNumber":"0","NameOfSubstance":"Biomarkers"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Aged, 80 and over"},{"DescriptorName":"Alzheimer Disease","QualifierName":["diagnostic imaging","pathology","psychology"]},{"DescriptorName":"Apolipoproteins E","QualifierName":"genetics"},{"DescriptorName":"Biomarkers"},{"DescriptorName":"Cognitive Dysfunction","QualifierName":["diagnostic imaging","pathology","psychology"]},{"DescriptorName":"Data Interpretation, Statistical"},{"DescriptorName":"Disease Progression"},{"DescriptorName":"Female"},{"DescriptorName":"Follow-Up Studies"},{"DescriptorName":"Forecasting"},{"DescriptorName":"Genotype"},{"DescriptorName":"Humans"},{"DescriptorName":"Image Processing, Computer-Assisted"},{"DescriptorName":"Magnetic Resonance Imaging"},{"DescriptorName":"Male"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"National Institute on Aging (U.S.)"},{"DescriptorName":"Neuropsychological Tests"},{"DescriptorName":"Positron-Emission Tomography"},{"DescriptorName":"Regression Analysis"},{"DescriptorName":"Survival Analysis"},{"DescriptorName":"United States"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2012","Month":"05","Day":"22"},{"@attributes":{"PubStatus":"accepted"},"Year":"2012","Month":"08","Day":"10"},{"@attributes":{"PubStatus":"entrez"},"Year":"2012","Month":"8","Day":"31","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2012","Month":"8","Day":"31","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2014","Month":"1","Day":"9","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["22932720","10.1007\/s00406-012-0349-0"]},"ReferenceList":{"Reference":[{"Citation":"J Mol Neurosci. 2011 Nov;45(3):384-9","ArticleIdList":{"ArticleId":"21720721"}},{"Citation":"Neurology. 2001 Jan 9;56(1):37-42","ArticleIdList":{"ArticleId":"11148233"}},{"Citation":"J Nucl Med. 2005 Dec;46(12 ):1959-72","ArticleIdList":{"ArticleId":"16330558"}},{"Citation":"Ann Neurol. 2009 Apr;65(4):403-13","ArticleIdList":{"ArticleId":"19296504"}},{"Citation":"Eur Arch Psychiatry Clin Neurosci. 2010 Oct;260(7):561-2","ArticleIdList":{"ArticleId":"20155362"}},{"Citation":"Neurology. 2003 Jul 8;61(1):46-54","ArticleIdList":{"ArticleId":"12847155"}},{"Citation":"Brain. 2009 May;132(Pt 5):1310-23","ArticleIdList":{"ArticleId":"19042931"}},{"Citation":"Brain. 2006 Nov;129(Pt 11):2856-66","ArticleIdList":{"ArticleId":"16854944"}},{"Citation":"Lancet. 2011 Mar 19;377(9770):1019-31","ArticleIdList":{"ArticleId":"21371747"}},{"Citation":"Neurology. 2011 Oct 25;77(17 ):1619-28","ArticleIdList":{"ArticleId":"21998317"}},{"Citation":"Ann Neurol. 1988 Jul;24(1):17-22","ArticleIdList":{"ArticleId":"3415196"}},{"Citation":"J Clin Psychiatry. 2011 Sep;72(9):1190-6","ArticleIdList":{"ArticleId":"21951985"}},{"Citation":"Neurology. 2010 Jul 20;75(3):230-8","ArticleIdList":{"ArticleId":"20592257"}},{"Citation":"Alzheimers Dement. 2010 May;6(3):221-9","ArticleIdList":{"ArticleId":"20451870"}},{"Citation":"Arch Neurol. 1999 Mar;56(3):303-8","ArticleIdList":{"ArticleId":"10190820"}},{"Citation":"Arch Gen Psychiatry. 2011 Sep;68(9):961-9","ArticleIdList":{"ArticleId":"21893661"}},{"Citation":"Brain. 2008 Mar;131(Pt 3):665-80","ArticleIdList":{"ArticleId":"18263627"}},{"Citation":"Neuroimage. 2006 Jul 1;31(3):968-80","ArticleIdList":{"ArticleId":"16530430"}},{"Citation":"Neurology. 2009 Oct 13;73(15):1193-9","ArticleIdList":{"ArticleId":"19822868"}},{"Citation":"J Nucl Med. 2005 Oct;46(10):1625-32","ArticleIdList":{"ArticleId":"16204712"}},{"Citation":"Arch Neurol. 2001 Dec;58(12):1985-92","ArticleIdList":{"ArticleId":"11735772"}},{"Citation":"Int J Geriatr Psychiatry. 2011 Oct;26(10 ):991-9","ArticleIdList":{"ArticleId":"21905095"}},{"Citation":"J Psychiatr Res. 1975 Nov;12(3):189-98","ArticleIdList":{"ArticleId":"1202204"}},{"Citation":"Neurology. 2011 Nov 8;77(19):1737-44","ArticleIdList":{"ArticleId":"22031532"}},{"Citation":"Neurology. 2011 Jan 4;76(1):69-79","ArticleIdList":{"ArticleId":"21123754"}},{"Citation":"Handb Clin Neurol. 2008;89:223-32","ArticleIdList":{"ArticleId":"18631747"}},{"Citation":"Eur Arch Psychiatry Clin Neurosci. 2010 Sep;260(6):441-2","ArticleIdList":{"ArticleId":"20845022"}},{"Citation":"Arch Neurol. 2011 Jun;68(6):761-7","ArticleIdList":{"ArticleId":"21670400"}},{"Citation":"Int Psychogeriatr. 2011 Oct;23(8):1191-6","ArticleIdList":{"ArticleId":"21813035"}},{"Citation":"Alzheimers Dement. 2010 May;6(3):265-73","ArticleIdList":{"ArticleId":"20451875"}},{"Citation":"Alzheimers Dement. 2011 May;7(3):270-9","ArticleIdList":{"ArticleId":"21514249"}},{"Citation":"Alzheimers Dement. 2011 Jul;7(4):386-395.e6","ArticleIdList":{"ArticleId":"21784349"}},{"Citation":"Arch Neurol. 2004 Jan;61(1):59-66","ArticleIdList":{"ArticleId":"14732621"}},{"Citation":"Neurology. 2010 Jan 19;74(3):201-9","ArticleIdList":{"ArticleId":"20042704"}},{"Citation":"J Magn Reson Imaging. 2008 Apr;27(4):685-91","ArticleIdList":{"ArticleId":"18302232"}},{"Citation":"Neurology. 2002 Nov 26;59(10):1594-9","ArticleIdList":{"ArticleId":"12451203"}},{"Citation":"Br J Psychiatry. 2003 May;182:449-54","ArticleIdList":{"ArticleId":"12724250"}},{"Citation":"Alzheimers Dement. 2012 Jan;8(1):65-73","ArticleIdList":{"ArticleId":"22047631"}},{"Citation":"J Am Geriatr Soc. 2006 Jun;54(6):1008-10","ArticleIdList":{"ArticleId":"16776804"}},{"Citation":"Neurology. 1984 Jul;34(7):939-44","ArticleIdList":{"ArticleId":"6610841"}},{"Citation":"Ann Neurol. 2011 Dec;70(6):871-80","ArticleIdList":{"ArticleId":"22190361"}},{"Citation":"Alzheimers Dement. 2012 Feb;8(1 Suppl):S1-68","ArticleIdList":{"ArticleId":"22047634"}}]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"22926714","DateCompleted":{"Year":"2013","Month":"05","Day":"07"},"DateRevised":{"Year":"2018","Month":"11","Day":"13"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1619-7089","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"39","Issue":"12","PubDate":{"Year":"2012","Month":"Dec"}},"Title":"European journal of nuclear medicine and molecular imaging","ISOAbbreviation":"Eur J Nucl Med Mol Imaging"},"ArticleTitle":"Quantitative longitudinal interrelationships between brain metabolism and amyloid deposition during a 2-year follow-up in patients with early Alzheimer's disease.","Pagination":{"MedlinePgn":"1927-36"},"ELocationID":"10.1007\/s00259-012-2230-9","Abstract":{"AbstractText":["Similar regional anatomical distributions were reported for fibrillary amyloid deposition [measured by (11)C-Pittsburgh compound B (PIB) positron emission tomography (PET)] and brain hypometabolism [measured by (18)F-fluorodeoxyglucose (FDG) PET] in numerous Alzheimer's disease (AD) studies. However, there is a lack of longitudinal studies evaluating the interrelationships of these two different pathological markers in the same AD population. Our most recent AD study suggested that the longitudinal pattern of hypometabolism anatomically follows the pattern of amyloid deposition with temporal delay, which indicates that neuronal dysfunction may spread within the anatomical pattern of amyloid pathology. Based on this finding we now hypothesize that in early AD patients quantitative longitudinal decline in hypometabolism may be related to the amount of baseline amyloid deposition during a follow-up period of 2 years.","Fifteen patients with mild probable AD underwent baseline (T1) and follow-up (T2) examination after 24 \u00b1 2.1 months with [(18)F]FDG PET, [(11)C]PIB PET, structural T1-weighted MRI and neuropsychological testing [Consortium to Establish a Registry for Alzheimer's Disease (CERAD) neuropsychological battery]. Longitudinal cognitive measures and quantitative PET measures of amyloid deposition and metabolism [standardized uptake value ratios (SUVRs)] were obtained using volume of interest (VOI)-based approaches in the frontal-lateral-retrosplenial (FLR) network and in predefined bihemispheric brain regions after partial volume effect (PVE) correction of PET data. Statistical group comparisons (SUVRs and cognitive measures) between patients and 15 well-matched elderly controls who had undergone identical imaging procedures once as well as Pearson's correlation analyses within patients were performed.","Group comparison revealed significant cognitive decline and increased mean PIB\/decreased FDG SUVRs in the FLR network as well as in several AD-typical regions in patients relative to controls. Concurrent with cognitive decline patients showed longitudinal increase in mean PIB\/decrease in mean FDG SUVRs over time in the FLR network and in several AD-typical brain regions. Correlation analyses of FLR network SUVRs in patients revealed significant positive correlations between PIB T1 and delta FDG (FDG T1-T2) SUVRs, between PIB T1 and PIB T2 SUVRs, between FDG T1 and PIB T2 SUVRs as well as between FDG T1 and FDG T2 SUVRs, while significant negative correlations were found between FDG T1 and delta PIB (PIB T1-T2) SUVRs as well as between FDG T2 and delta FDG (FDG T1-T2) SUVRs. These findings were confirmed in locoregional correlation analyses, revealing significant associations in the same directions for two left hemispheric regions and nine right hemispheric regions, showing the strongest association for bilateral precuneus.","Baseline amyloid deposition in patients with mild probable AD was associated with longitudinal metabolic decline. Additionally, mildly decreased\/relatively preserved baseline metabolism was associated with a longitudinal increase in amyloid deposition. The latter bidirectional associations were present in the whole AD-typical FLR network and in several highly interconnected hub regions (i.e. in the precuneus). Our longitudinal findings point to a bidirectional quantitative interrelationship of the two investigated AD pathologies, comprising an initial relative maintenance of neuronal activity in already amyloid-positive hub regions (neuronal compensation), followed by accelerated amyloid deposition, accompanied by functional neuronal decline (neuronal breakdown) along with cognitive decline."]},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"F\u00f6rster","ForeName":"Stefan","Initials":"S","AffiliationInfo":{"Affiliation":"Department of Nuclear Medicine, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany. stefan.foerster@lrz.tum.de"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Yousefi","ForeName":"Behrooz H","Initials":"BH"},{"@attributes":{"ValidYN":"Y"},"LastName":"Wester","ForeName":"Hans-J\u00fcrgen","Initials":"HJ"},{"@attributes":{"ValidYN":"Y"},"LastName":"Klupp","ForeName":"Elisabeth","Initials":"E"},{"@attributes":{"ValidYN":"Y"},"LastName":"Rominger","ForeName":"Axel","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"F\u00f6rstl","ForeName":"Hans","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Grimmer","ForeName":"Timo","Initials":"T"},{"@attributes":{"ValidYN":"Y"},"LastName":"Drzezga","ForeName":"Alexander","Initials":"A"}]},"Language":"eng","PublicationTypeList":{"PublicationType":"Journal Article"},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2012","Month":"08","Day":"28"}},"MedlineJournalInfo":{"Country":"Germany","MedlineTA":"Eur J Nucl Med Mol Imaging","NlmUniqueID":"101140988","ISSNLinking":"1619-7070"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole"},{"RegistryNumber":"0","NameOfSubstance":"Amyloid"},{"RegistryNumber":"0","NameOfSubstance":"Aniline Compounds"},{"RegistryNumber":"0","NameOfSubstance":"Radiopharmaceuticals"},{"RegistryNumber":"0","NameOfSubstance":"Thiazoles"},{"RegistryNumber":"0Z5B2CJX4D","NameOfSubstance":"Fluorodeoxyglucose F18"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Alzheimer Disease","QualifierName":["diagnostic imaging","metabolism"]},{"DescriptorName":"Amyloid","QualifierName":"metabolism"},{"DescriptorName":"Aniline Compounds"},{"DescriptorName":"Brain","QualifierName":["diagnostic imaging","metabolism"]},{"DescriptorName":"Case-Control Studies"},{"DescriptorName":"Female"},{"DescriptorName":"Fluorodeoxyglucose F18"},{"DescriptorName":"Follow-Up Studies"},{"DescriptorName":"Humans"},{"DescriptorName":"Longitudinal Studies"},{"DescriptorName":"Magnetic Resonance Imaging"},{"DescriptorName":"Male"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Positron-Emission Tomography"},{"DescriptorName":"Radiopharmaceuticals"},{"DescriptorName":"Thiazoles"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2011","Month":"11","Day":"15"},{"@attributes":{"PubStatus":"accepted"},"Year":"2012","Month":"08","Day":"09"},{"@attributes":{"PubStatus":"entrez"},"Year":"2012","Month":"8","Day":"29","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2012","Month":"8","Day":"29","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2013","Month":"5","Day":"8","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["22926714","10.1007\/s00259-012-2230-9"]},"ReferenceList":{"Reference":[{"Citation":"Neurosci Lett. 2009 Sep 22;462(2):147-51","ArticleIdList":{"ArticleId":"19596405"}},{"Citation":"Ann Neurol. 2011 Jan;69(1):181-92","ArticleIdList":{"ArticleId":"21280088"}},{"Citation":"Neurology. 2009 Oct 13;73(15):1186-92","ArticleIdList":{"ArticleId":"19726751"}},{"Citation":"Ann N Y Acad Sci. 2008 Dec;1147:180-95","ArticleIdList":{"ArticleId":"19076441"}},{"Citation":"Brain. 2010 Nov;133(11):3301-14","ArticleIdList":{"ArticleId":"20688814"}},{"Citation":"Neurology. 2009 Apr 28;72 (17 ):1487-94","ArticleIdList":{"ArticleId":"19339712"}},{"Citation":"J Neurosci. 2005 Aug 24;25(34):7709-17","ArticleIdList":{"ArticleId":"16120771"}},{"Citation":"Brain. 2006 Nov;129(Pt 11):2856-66","ArticleIdList":{"ArticleId":"16854944"}},{"Citation":"J Alzheimers Dis. 2011;25(4):695-706","ArticleIdList":{"ArticleId":"21498904"}},{"Citation":"Neurobiol Aging. 2012 Jan;33(1):198.e1-14","ArticleIdList":{"ArticleId":"20688420"}},{"Citation":"Biol Psychiatry. 2012 May 1;71(9):792-7","ArticleIdList":{"ArticleId":"21679929"}},{"Citation":"Neuroimage. 2006 Oct 15;33(1):94-102","ArticleIdList":{"ArticleId":"16905334"}},{"Citation":"Science. 2002 Oct 25;298(5594):789-91","ArticleIdList":{"ArticleId":"12399581"}},{"Citation":"Acta Neuropathol. 1991;82(4):239-59","ArticleIdList":{"ArticleId":"1759558"}},{"Citation":"Neuroimage. 2008 Jan 15;39(2):619-33","ArticleIdList":{"ArticleId":"17962045"}},{"Citation":"J Neurosci. 2009 Oct 7;29(40):12686-94","ArticleIdList":{"ArticleId":"19812343"}},{"Citation":"J Nucl Med. 2007 Apr;48(4):547-52","ArticleIdList":{"ArticleId":"17401090"}},{"Citation":"Neuroimage. 2006 Jul 1;31(3):968-80","ArticleIdList":{"ArticleId":"16530430"}},{"Citation":"Brain. 2011 Jun;134(Pt 6):1635-46","ArticleIdList":{"ArticleId":"21490054"}},{"Citation":"Biol Psychiatry. 2009 Jun 1;65(11):927-34","ArticleIdList":{"ArticleId":"19268916"}},{"Citation":"Am J Psychiatry. 2002 May;159(5):738-45","ArticleIdList":{"ArticleId":"11986126"}},{"Citation":"Neuron. 2005 Dec 22;48(6):913-22","ArticleIdList":{"ArticleId":"16364896"}},{"Citation":"Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4637-42","ArticleIdList":{"ArticleId":"15070770"}},{"Citation":"Neurobiol Aging. 1997 Jul-Aug;18(4 Suppl):S85-8","ArticleIdList":{"ArticleId":"9330992"}},{"Citation":"Neurobiol Aging. 2011 Jul;32(7):1207-18","ArticleIdList":{"ArticleId":"19660834"}},{"Citation":"J Alzheimers Dis. 2010;22(2):581-91","ArticleIdList":{"ArticleId":"20847402"}},{"Citation":"Ann Neurol. 2004 Mar;55(3):306-19","ArticleIdList":{"ArticleId":"14991808"}},{"Citation":"J Neurosci. 2009 Nov 25;29(47):14770-8","ArticleIdList":{"ArticleId":"19940172"}},{"Citation":"Neuron. 2003 Mar 27;37(6):925-37","ArticleIdList":{"ArticleId":"12670422"}},{"Citation":"Nat Neurosci. 2010 Feb;13(2):190-6","ArticleIdList":{"ArticleId":"20037574"}},{"Citation":"J Psychiatr Res. 2010 May;44(7):462-9","ArticleIdList":{"ArticleId":"19875130"}},{"Citation":"Ann N Y Acad Sci. 2008 Mar;1124:1-38","ArticleIdList":{"ArticleId":"18400922"}},{"Citation":"Brain. 2008 Jan;131(Pt 1):60-71","ArticleIdList":{"ArticleId":"18063588"}},{"Citation":"Brain. 2009 May;132(Pt 5):1355-65","ArticleIdList":{"ArticleId":"19339253"}},{"Citation":"Neurology. 2007 Feb 13;68(7):501-8","ArticleIdList":{"ArticleId":"17065593"}},{"Citation":"Brain. 2008 Dec;131(Pt 12):3286-98","ArticleIdList":{"ArticleId":"18927145"}},{"Citation":"Biol Psychiatry. 2010 Nov 15;68(10 ):879-84","ArticleIdList":{"ArticleId":"20598287"}},{"Citation":"Neurology. 1984 Jul;34(7):939-44","ArticleIdList":{"ArticleId":"6610841"}},{"Citation":"Neurology. 2004 Mar 23;62(6):925-31","ArticleIdList":{"ArticleId":"15037694"}},{"Citation":"Brain. 2011 Apr;134(Pt 4):1077-88","ArticleIdList":{"ArticleId":"21429865"}}]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"22717212","DateCompleted":{"Year":"2012","Month":"11","Day":"28"},"DateRevised":{"Year":"2018","Month":"12","Day":"01"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1741-203X","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"24","Issue":"9","PubDate":{"Year":"2012","Month":"Sep"}},"Title":"International psychogeriatrics","ISOAbbreviation":"Int Psychogeriatr"},"ArticleTitle":"Caregivers of patients with frontotemporal lobar degeneration: a review of burden, problems, needs, and interventions.","Pagination":{"MedlinePgn":"1368-86"},"ELocationID":"10.1017\/S104161021200035X","Abstract":{"AbstractText":["Frontotemporal lobar degeneration (FTLD) is a relatively rare disease compared to Alzheimer' disease (AD), but nevertheless causes higher burden and stress to caregivers. Only little is known about the problems and needs of the caregivers of patients with FTLD. Such information is crucial for the development of caregiver support interventions. The aim of the current study is to systematically review publications on (1) burden, problems, and needs of FTLD caregivers, and (2) the feasibility and efficacy of caregiver interventions in FTLD.","A systematic review was conducted. Medical, psychological, and social sciences databases were searched for publications on burden, problems, needs of FTLD caregivers, and support interventions.","Very little published data are available on burden, problems, and needs of FTLD caregivers. Burden among FTLD caregivers is higher than among AD caregivers and correlated with neuropsychiatric symptoms. Specific problems include delayed diagnosis, young age of patients, behavioral disturbances, lack of information and suitable care facilities, caregivers' depression, social isolation, and neglect of personal needs. Hardly any literature is available on the actual needs of FTLD caregivers. Regarding interventions for caregivers, no randomized controlled trials exist. Eight publications could be identified that provide narrative reports on structured caregiver support groups or respite care in combination with caregiver support intervention or advanced practice nursing.","More research and funding are needed to elucidate the complex construct of burden of FTLD caregivers to identify and quantify their problems and needs in order to develop helpful interventions and services."]},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Nunnemann","ForeName":"Sabine","Initials":"S","AffiliationInfo":{"Affiliation":"Department of Psychiatry, Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany. Sabine.Nunnemann@lrz.tum.de"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Leucht","ForeName":"Stefan","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"Diehl-Schmid","ForeName":"Janine","Initials":"J"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Research Support, Non-U.S. Gov't","Review","Systematic Review"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2012","Month":"04","Day":"16"}},"MedlineJournalInfo":{"Country":"England","MedlineTA":"Int Psychogeriatr","NlmUniqueID":"9007918","ISSNLinking":"1041-6102"},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Caregivers","QualifierName":["education","organization & administration","psychology"]},{"DescriptorName":"Cost of Illness"},{"DescriptorName":"Frontotemporal Dementia","QualifierName":["psychology","therapy"]},{"DescriptorName":"Health Services Needs and Demand"},{"DescriptorName":"Humans"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"entrez"},"Year":"2012","Month":"6","Day":"22","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2012","Month":"6","Day":"22","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2012","Month":"12","Day":"10","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["22717212","S104161021200035X","10.1017\/S104161021200035X"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"22687271","DateCompleted":{"Year":"2013","Month":"02","Day":"01"},"DateRevised":{"Year":"2016","Month":"10","Day":"20"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1741-203X","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"24","Issue":"10","PubDate":{"Year":"2012","Month":"Oct"}},"Title":"International psychogeriatrics","ISOAbbreviation":"Int Psychogeriatr"},"ArticleTitle":"Dealing with uncertainty: biomarkers for the early detection of Alzheimer's disease.","Pagination":{"MedlinePgn":"1533-5"},"ELocationID":"10.1017\/S1041610212001056","AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Perneczky","ForeName":"Robert","Initials":"R"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"}]},"Language":"eng","PublicationTypeList":{"PublicationType":"Editorial"},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2012","Month":"06","Day":"12"}},"MedlineJournalInfo":{"Country":"England","MedlineTA":"Int Psychogeriatr","NlmUniqueID":"9007918","ISSNLinking":"1041-6102"},"ChemicalList":{"Chemical":{"RegistryNumber":"0","NameOfSubstance":"Biomarkers"}},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Alzheimer Disease","QualifierName":["cerebrospinal fluid","diagnosis"]},{"DescriptorName":"Biomarkers","QualifierName":"cerebrospinal fluid"},{"DescriptorName":"Early Diagnosis"},{"DescriptorName":"Humans"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"entrez"},"Year":"2012","Month":"6","Day":"13","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2012","Month":"6","Day":"13","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2013","Month":"2","Day":"5","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["22687271","S1041610212001056","10.1017\/S1041610212001056"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"22410648","DateCompleted":{"Year":"2013","Month":"03","Day":"12"},"DateRevised":{"Year":"2016","Month":"11","Day":"25"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1558-1497","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"33","Issue":"12","PubDate":{"Year":"2012","Month":"Dec"}},"Title":"Neurobiology of aging","ISOAbbreviation":"Neurobiol Aging"},"ArticleTitle":"White matter hyperintensities predict amyloid increase in Alzheimer's disease.","Pagination":{"MedlinePgn":"2766-73"},"ELocationID":["10.1016\/j.neurobiolaging.2012.01.016","S0197-4580(12)00037-1"],"Abstract":{"AbstractText":"Impaired amyloid clearance probably contributes to increased amyloid deposition in sporadic Alzheimer's disease (AD). Diminished perivascular drainage due to cerebral small-vessel disease (CSVD) has been proposed as a cause of reduced amyloid clearance. White matter hyperintensities (WMHs) are considered to reflect CSVD and can be measured using fluid-attenuated inversion recovery (FLAIR) magnetic resonance imaging (MRI). Amyloid deposition can be determined in vivo using Pittsburgh compound B ([11C]PiB) positron emission tomography (PET). We aimed to elucidate the association between WMH and the progression of amyloid deposition in patients with AD. Twenty-two patients with probable AD underwent FLAIR-MRI and [11C]PiB-PET examinations at baseline (BL) and after a mean follow-up (FU) interval of 28 months. The relationship between BL-WMH and the progression of cerebral amyloid between BL and FU was examined using a regions-of-interest (ROI) approach. The region-specific variability of this relationship was analyzed using a voxel-based method. The longitudinal analysis revealed a statistically significant association between the amount of BL-WMH and the progression of amyloid load between BL and FU (p = 0.006, adjusted R2 = 0.375, standardized coefficient \u03b2 = 0.384). The association was particularly observed in parieto-occipital regions and tended to be closer in regions adjacent to the brain surface. According to our knowledge, this is the first in vivo study in human being supporting the hypothesis that impaired amyloid clearance along perivascular drainage pathways may contribute to \u03b2-amyloid deposition in sporadic AD. The extent of WMH might be a relevant factor to be assessed in antiamyloid drug trials.","CopyrightInformation":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Grimmer","ForeName":"Timo","Initials":"T","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar der Technischen Universit\u00e4t M\u00fcnchen, Ismaninger Str. 22, 81675 Munich, Germany. t.grimmer@lrz.tum.de"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Faust","ForeName":"Maximilian","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Auer","ForeName":"Florian","Initials":"F"},{"@attributes":{"ValidYN":"Y"},"LastName":"Alexopoulos","ForeName":"Panagiotis","Initials":"P"},{"@attributes":{"ValidYN":"Y"},"LastName":"F\u00f6rstl","ForeName":"Hans","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Henriksen","ForeName":"Gjermund","Initials":"G"},{"@attributes":{"ValidYN":"Y"},"LastName":"Perneczky","ForeName":"Robert","Initials":"R"},{"@attributes":{"ValidYN":"Y"},"LastName":"Sorg","ForeName":"Christian","Initials":"C"},{"@attributes":{"ValidYN":"Y"},"LastName":"Yousefi","ForeName":"Behrooz H","Initials":"BH"},{"@attributes":{"ValidYN":"Y"},"LastName":"Drzezga","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Research Support, Non-U.S. Gov't"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2012","Month":"03","Day":"10"}},"MedlineJournalInfo":{"Country":"United States","MedlineTA":"Neurobiol Aging","NlmUniqueID":"8100437","ISSNLinking":"0197-4580"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole"},{"RegistryNumber":"0","NameOfSubstance":"Amyloid"},{"RegistryNumber":"0","NameOfSubstance":"Aniline Compounds"},{"RegistryNumber":"0","NameOfSubstance":"Apolipoprotein E4"},{"RegistryNumber":"0","NameOfSubstance":"Thiazoles"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Alzheimer Disease","QualifierName":["diagnostic imaging","genetics","pathology"]},{"DescriptorName":"Amyloid","QualifierName":"metabolism"},{"DescriptorName":"Aniline Compounds"},{"DescriptorName":"Apolipoprotein E4","QualifierName":"genetics"},{"DescriptorName":"Brain","QualifierName":["diagnostic imaging","pathology"]},{"DescriptorName":"Brain Mapping"},{"DescriptorName":"Cross-Sectional Studies"},{"DescriptorName":"Female"},{"DescriptorName":"Follow-Up Studies"},{"DescriptorName":"Humans"},{"DescriptorName":"Magnetic Resonance Imaging"},{"DescriptorName":"Male"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Nerve Fibers, Myelinated","QualifierName":["diagnostic imaging","pathology"]},{"DescriptorName":"Neuropsychological Tests"},{"DescriptorName":"Positron-Emission Tomography"},{"DescriptorName":"Predictive Value of Tests"},{"DescriptorName":"Psychiatric Status Rating Scales"},{"DescriptorName":"Thiazoles"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2011","Month":"06","Day":"10"},{"@attributes":{"PubStatus":"revised"},"Year":"2012","Month":"01","Day":"12"},{"@attributes":{"PubStatus":"accepted"},"Year":"2012","Month":"01","Day":"27"},{"@attributes":{"PubStatus":"entrez"},"Year":"2012","Month":"3","Day":"14","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2012","Month":"3","Day":"14","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2013","Month":"3","Day":"13","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["22410648","S0197-4580(12)00037-1","10.1016\/j.neurobiolaging.2012.01.016"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"22405045","DateCompleted":{"Year":"2013","Month":"03","Day":"12"},"DateRevised":{"Year":"2018","Month":"11","Day":"13"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1558-1497","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"33","Issue":"12","PubDate":{"Year":"2012","Month":"Dec"}},"Title":"Neurobiology of aging","ISOAbbreviation":"Neurobiol Aging"},"ArticleTitle":"Prediction of Alzheimer's disease using individual structural connectivity networks.","Pagination":{"MedlinePgn":"2756-65"},"ELocationID":["10.1016\/j.neurobiolaging.2012.01.017","S0197-4580(12)00038-3"],"Abstract":{"AbstractText":"Alzheimer's disease (AD) progressively degrades the brain's gray and white matter. Changes in white matter reflect changes in the brain's structural connectivity pattern. Here, we established individual structural connectivity networks (ISCNs) to distinguish predementia and dementia AD from healthy aging in individual scans. Diffusion tractography was used to construct ISCNs with a fully automated procedure for 21 healthy control subjects (HC), 23 patients with mild cognitive impairment and conversion to AD dementia within 3 years (AD-MCI), and 17 patients with mild AD dementia. Three typical pattern classifiers were used for AD prediction. Patients with AD and AD-MCI were separated from HC with accuracies greater than 95% and 90%, respectively, irrespective of prediction approach and specific fiber properties. Most informative connections involved medial prefrontal, posterior parietal, and insular cortex. Patients with mild AD were separated from those with AD-MCI with an accuracy of approximately 85%. Our finding provides evidence that ISCNs are sensitive to the impact of earliest stages of AD. ISCNs may be useful as a white matter-based imaging biomarker to distinguish healthy aging from AD.","CopyrightInformation":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Shao","ForeName":"Junming","Initials":"J","AffiliationInfo":{"Affiliation":"Department of Neuroradiology of Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, Ismaningerstrasse 22, 81675 Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Myers","ForeName":"Nicholas","Initials":"N"},{"@attributes":{"ValidYN":"Y"},"LastName":"Yang","ForeName":"Qinli","Initials":"Q"},{"@attributes":{"ValidYN":"Y"},"LastName":"Feng","ForeName":"Jing","Initials":"J"},{"@attributes":{"ValidYN":"Y"},"LastName":"Plant","ForeName":"Claudia","Initials":"C"},{"@attributes":{"ValidYN":"Y"},"LastName":"B\u00f6hm","ForeName":"Christian","Initials":"C"},{"@attributes":{"ValidYN":"Y"},"LastName":"F\u00f6rstl","ForeName":"Hans","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Zimmer","ForeName":"Claus","Initials":"C"},{"@attributes":{"ValidYN":"Y"},"LastName":"Meng","ForeName":"Chun","Initials":"C"},{"@attributes":{"ValidYN":"Y"},"LastName":"Riedl","ForeName":"Valentin","Initials":"V"},{"@attributes":{"ValidYN":"Y"},"LastName":"Wohlschl\u00e4ger","ForeName":"Afra","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Sorg","ForeName":"Christian","Initials":"C"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Research Support, Non-U.S. Gov't"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2012","Month":"03","Day":"08"}},"MedlineJournalInfo":{"Country":"United States","MedlineTA":"Neurobiol Aging","NlmUniqueID":"8100437","ISSNLinking":"0197-4580"},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Aged, 80 and over"},{"DescriptorName":"Alzheimer Disease","QualifierName":"diagnosis"},{"DescriptorName":"Anisotropy"},{"DescriptorName":"Brain","QualifierName":"pathology"},{"DescriptorName":"Brain Mapping"},{"DescriptorName":"Cognitive Dysfunction","QualifierName":"diagnosis"},{"DescriptorName":"Diffusion Tensor Imaging"},{"DescriptorName":"Female"},{"DescriptorName":"Functional Laterality"},{"DescriptorName":"Humans"},{"DescriptorName":"Imaging, Three-Dimensional"},{"DescriptorName":"Male"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Nerve Fibers","QualifierName":"pathology"},{"DescriptorName":"Neural Pathways","QualifierName":"pathology"},{"DescriptorName":"Neuropsychological Tests"},{"DescriptorName":"Predictive Value of Tests"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2011","Month":"10","Day":"20"},{"@attributes":{"PubStatus":"revised"},"Year":"2012","Month":"01","Day":"10"},{"@attributes":{"PubStatus":"accepted"},"Year":"2012","Month":"01","Day":"27"},{"@attributes":{"PubStatus":"entrez"},"Year":"2012","Month":"3","Day":"13","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2012","Month":"3","Day":"13","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2013","Month":"3","Day":"13","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["22405045","S0197-4580(12)00038-3","10.1016\/j.neurobiolaging.2012.01.017","PMC3778749"]},"ReferenceList":{"Reference":[{"Citation":"J Neurol Neurosurg Psychiatry. 2000 Oct;69(4):528-30","ArticleIdList":{"ArticleId":"10990518"}},{"Citation":"Neurobiol Aging. 2011 Dec;32(12):2322.e5-18","ArticleIdList":{"ArticleId":"20619504"}},{"Citation":"Neurology. 2002 Jun 25;58(12):1791-800","ArticleIdList":{"ArticleId":"12084879"}},{"Citation":"Hum Brain Mapp. 2003 Apr;18(4):306-21","ArticleIdList":{"ArticleId":"12632468"}},{"Citation":"Neuropsychol Rev. 2003 Jun;13(2):79-92","ArticleIdList":{"ArticleId":"12887040"}},{"Citation":"Dement Geriatr Cogn Disord. 2004;18(1):101-8","ArticleIdList":{"ArticleId":"15087585"}},{"Citation":"Neurology. 1984 Jul;34(7):939-44","ArticleIdList":{"ArticleId":"6610841"}},{"Citation":"Ann Neurol. 1986 Mar;19(3):253-62","ArticleIdList":{"ArticleId":"3963770"}},{"Citation":"Prog Neuropsychopharmacol Biol Psychiatry. 1986;10(3-5):297-308","ArticleIdList":{"ArticleId":"3492011"}},{"Citation":"Neurology. 1989 Sep;39(9):1159-65","ArticleIdList":{"ArticleId":"2771064"}},{"Citation":"Acta Neuropathol. 1991;82(4):239-59","ArticleIdList":{"ArticleId":"1759558"}},{"Citation":"Neurology. 1993 Nov;43(11):2412-4","ArticleIdList":{"ArticleId":"8232972"}},{"Citation":"J Comput Assist Tomogr. 1998 Jan-Feb;22(1):153-65","ArticleIdList":{"ArticleId":"9448780"}},{"Citation":"Ann Neurol. 1999 Feb;45(2):265-9","ArticleIdList":{"ArticleId":"9989633"}},{"Citation":"Neurobiol Aging. 2005 Aug-Sep;26(8):1193-8","ArticleIdList":{"ArticleId":"15917103"}},{"Citation":"AJNR Am J Neuroradiol. 2005 Oct;26(9):2183-6","ArticleIdList":{"ArticleId":"16219820"}},{"Citation":"Neurobiol Aging. 2006 May;27(5):663-72","ArticleIdList":{"ArticleId":"16005548"}},{"Citation":"Lancet. 2006 Apr 15;367(9518):1262-70","ArticleIdList":{"ArticleId":"16631882"}},{"Citation":"Lancet. 2006 Jul 29;368(9533):387-403","ArticleIdList":{"ArticleId":"16876668"}},{"Citation":"Radiology. 2007 May;243(2):483-92","ArticleIdList":{"ArticleId":"17456872"}},{"Citation":"PLoS One. 2007;2(7):e597","ArticleIdList":{"ArticleId":"17611629"}},{"Citation":"Neuroimage. 2007 Oct 15;38(1):13-24","ArticleIdList":{"ArticleId":"17827035"}},{"Citation":"Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18760-5","ArticleIdList":{"ArticleId":"18003904"}},{"Citation":"Brain. 2008 Mar;131(Pt 3):681-9","ArticleIdList":{"ArticleId":"18202106"}},{"Citation":"Neurobiol Aging. 2008 Apr;29(4):514-23","ArticleIdList":{"ArticleId":"17174012"}},{"Citation":"PLoS Biol. 2008 Jul 1;6(7):e159","ArticleIdList":{"ArticleId":"18597554"}},{"Citation":"Hum Brain Mapp. 2009 Apr;30(4):1051-9","ArticleIdList":{"ArticleId":"18412132"}},{"Citation":"Annu Rev Neurosci. 2009;32:75-94","ArticleIdList":{"ArticleId":"19400718"}},{"Citation":"Hum Brain Mapp. 2009 Oct;30(10):3127-41","ArticleIdList":{"ArticleId":"19235882"}},{"Citation":"Curr Alzheimer Res. 2009 Dec;6(6):541-53","ArticleIdList":{"ArticleId":"19747154"}},{"Citation":"Neuroimage. 2010 Mar;50(1):162-74","ArticleIdList":{"ArticleId":"19961938"}},{"Citation":"Brain. 2010 Feb;133(Pt 2):529-39","ArticleIdList":{"ArticleId":"19914928"}},{"Citation":"Neuroimage. 2010 Apr 15;50(3):970-83","ArticleIdList":{"ArticleId":"20035887"}},{"Citation":"Neuromolecular Med. 2010 Mar;12(1):27-43","ArticleIdList":{"ArticleId":"20069392"}},{"Citation":"J Neurosci. 2010 Dec 15;30(50):16876-85","ArticleIdList":{"ArticleId":"21159959"}},{"Citation":"Neuroimage. 2011 May 15;56(2):766-81","ArticleIdList":{"ArticleId":"20542124"}},{"Citation":"Neurobiol Aging. 2011 Sep;32(9):1558-71","ArticleIdList":{"ArticleId":"19913331"}},{"Citation":"Trends Neurosci. 2011 Aug;34(8):430-42","ArticleIdList":{"ArticleId":"21696834"}},{"Citation":"J Neurol Neurosurg Psychiatry. 2002 Jun;72(6):742-6","ArticleIdList":{"ArticleId":"12023417"}}]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"22286501","DateCompleted":{"Year":"2013","Month":"01","Day":"14"},"DateRevised":{"Year":"2018","Month":"11","Day":"13"},"Article":{"@attributes":{"PubModel":"Print"},"Journal":{"ISSN":"1433-8491","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"262","Issue":"6","PubDate":{"Year":"2012","Month":"Sep"}},"Title":"European archives of psychiatry and clinical neuroscience","ISOAbbreviation":"Eur Arch Psychiatry Clin Neurosci"},"ArticleTitle":"SORL1 genetic variants and cerebrospinal fluid  biomarkers of Alzheimer\u2019s disease.","Pagination":{"MedlinePgn":"529-34"},"Abstract":{"AbstractText":"The neuronal sortilin-related receptor with A-type repeats (SORL1, also called LR11 or sorLA) is involved in amyloidogenesis, and the SORL1 gene is a major risk factor for Alzheimer\u2019s disease (AD). We investigated AD-related CSF biomarkers for associations with SORL1 genetic variants in 105 German patients with mild cognitive impairment (MCI) and AD. The homozygous CC-allele of single nucleotide polymorphism (SNP) 4 was associated with increased Tau concentrations in AD, and the minor alleles of SNP8, SNP9, and SNP10 and the haplotype CGT of these SNPs were associated with increased SORL1 concentrations in MCI. SNP22 and SNP23, and the haplotypes TCT of SNP19-21-23, and TTC of SNP22-23-24 were correlated with decreased Ab42 levels in AD. These results strengthen the functional role of SORL1 in AD."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Guo","ForeName":"Liang-Hao","Initials":"LH"},{"@attributes":{"ValidYN":"Y"},"LastName":"Westerteicher","ForeName":"Christine","Initials":"C"},{"@attributes":{"ValidYN":"Y"},"LastName":"Wang","ForeName":"Xin-Hui","Initials":"XH"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kratzer","ForeName":"Martina","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Tsolakidou","ForeName":"Amalia","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Jiang","ForeName":"Meizi","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Grimmer","ForeName":"Timo","Initials":"T"},{"@attributes":{"ValidYN":"Y"},"LastName":"Laws","ForeName":"Simon M","Initials":"SM"},{"@attributes":{"ValidYN":"Y"},"LastName":"Alexopoulos","ForeName":"Panagiotis","Initials":"P"},{"@attributes":{"ValidYN":"Y"},"LastName":"Bujo","ForeName":"Hideaki","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Perneczky","ForeName":"Robert","Initials":"R"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Research Support, Non-U.S. Gov't"]}},"MedlineJournalInfo":{"Country":"Germany","MedlineTA":"Eur Arch Psychiatry Clin Neurosci","NlmUniqueID":"9103030","ISSNLinking":"0940-1334"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"Amyloid beta-Peptides"},{"RegistryNumber":"0","NameOfSubstance":"Biomarkers"},{"RegistryNumber":"0","NameOfSubstance":"LDL-Receptor Related Proteins"},{"RegistryNumber":"0","NameOfSubstance":"Membrane Transport Proteins"},{"RegistryNumber":"0","NameOfSubstance":"Peptide Fragments"},{"RegistryNumber":"0","NameOfSubstance":"SORL1 protein, human"},{"RegistryNumber":"0","NameOfSubstance":"amyloid beta-protein (1-42)"},{"RegistryNumber":"0","NameOfSubstance":"tau Proteins"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Alzheimer Disease","QualifierName":["cerebrospinal fluid","genetics"]},{"DescriptorName":"Amyloid beta-Peptides","QualifierName":"cerebrospinal fluid"},{"DescriptorName":"Biomarkers","QualifierName":"cerebrospinal fluid"},{"DescriptorName":"Case-Control Studies"},{"DescriptorName":"Cognitive Dysfunction","QualifierName":["cerebrospinal fluid","genetics"]},{"DescriptorName":"Female"},{"DescriptorName":"Genetic Predisposition to Disease"},{"DescriptorName":"Humans"},{"DescriptorName":"LDL-Receptor Related Proteins","QualifierName":["cerebrospinal fluid","genetics"]},{"DescriptorName":"Male"},{"DescriptorName":"Membrane Transport Proteins","QualifierName":["cerebrospinal fluid","genetics"]},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Peptide Fragments","QualifierName":"cerebrospinal fluid"},{"DescriptorName":"Polymorphism, Single Nucleotide"},{"DescriptorName":"tau Proteins","QualifierName":"cerebrospinal fluid"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2011","Month":"07","Day":"30"},{"@attributes":{"PubStatus":"accepted"},"Year":"2012","Month":"01","Day":"17"},{"@attributes":{"PubStatus":"entrez"},"Year":"2012","Month":"1","Day":"31","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2012","Month":"1","Day":"31","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2013","Month":"1","Day":"15","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["22286501","10.1007\/s00406-012-0295-x"]},"ReferenceList":{"Reference":[{"Citation":"J Alzheimers Dis. 2010;21(3):833-42","ArticleIdList":{"ArticleId":"20634593"}},{"Citation":"Nat Rev Neurosci. 2008 Dec;9(12):899-909","ArticleIdList":{"ArticleId":"19002190"}},{"Citation":"Clin Chem. 2009 Oct;55(10):1801-8","ArticleIdList":{"ArticleId":"19661140"}},{"Citation":"Arch Neurol. 2009 Oct;66(10):1260-6","ArticleIdList":{"ArticleId":"19822782"}},{"Citation":"Mol Neurodegener. 2009 Nov 04;4:46","ArticleIdList":{"ArticleId":"19889229"}},{"Citation":"Neurology. 2006 Aug 22;67(4):710-2","ArticleIdList":{"ArticleId":"16924032"}},{"Citation":"BMJ. 1998 Apr 18;316(7139):1236-8","ArticleIdList":{"ArticleId":"9553006"}},{"Citation":"Neurogenetics. 2010 Feb;11(1):139-42","ArticleIdList":{"ArticleId":"19653016"}},{"Citation":"Nat Genet. 2007 Feb;39(2):168-77","ArticleIdList":{"ArticleId":"17220890"}},{"Citation":"Neurosci Lett. 2008 Jul 25;440(1):68-71","ArticleIdList":{"ArticleId":"18541377"}},{"Citation":"Neurosci Lett. 2011 Jan 7;487(2):169-73","ArticleIdList":{"ArticleId":"20951764"}},{"Citation":"Arch Neurol. 2009 Apr;66(4):448-57","ArticleIdList":{"ArticleId":"19364929"}},{"Citation":"Arch Neurol. 2007 Apr;64(4):501-6","ArticleIdList":{"ArticleId":"17420311"}},{"Citation":"Dement Geriatr Cogn Disord. 2010;30(1):28-32","ArticleIdList":{"ArticleId":"20689279"}},{"Citation":"Neurology. 2011 Jul 5;77(1):35-8","ArticleIdList":{"ArticleId":"21700579"}},{"Citation":"Mol Psychiatry. 2010 Jul;15(7):756-66","ArticleIdList":{"ArticleId":"19125160"}},{"Citation":"Eur Arch Psychiatry Clin Neurosci. 2009 Sep;259(6):362-7","ArticleIdList":{"ArticleId":"19255708"}},{"Citation":"Neuroreport. 2007 Nov 19;18(17):1761-4","ArticleIdList":{"ArticleId":"18090307"}},{"Citation":"Neurobiol Dis. 2008 Feb;29(2):293-6","ArticleIdList":{"ArticleId":"17949987"}},{"Citation":"Am J Epidemiol. 2009 Feb 15;169(4):505-14","ArticleIdList":{"ArticleId":"19126586"}},{"Citation":"Hum Mutat. 2008 May;29(5):769-70","ArticleIdList":{"ArticleId":"18407551"}},{"Citation":"Arch Neurol. 2011 Jan;68(1):99-106","ArticleIdList":{"ArticleId":"21220680"}},{"Citation":"Behav Res Methods. 2009 Nov;41(4):1149-60","ArticleIdList":{"ArticleId":"19897823"}},{"Citation":"Eur Arch Psychiatry Clin Neurosci. 2012 Feb;262(1):69-77","ArticleIdList":{"ArticleId":"21786091"}},{"Citation":"Arch Neurol. 2008 Dec;65(12):1640-8","ArticleIdList":{"ArticleId":"19064752"}},{"Citation":"J Neurosci. 2006 Feb 1;26(5):1596-603","ArticleIdList":{"ArticleId":"16452683"}},{"Citation":"Genome Res. 2006 Mar;16(3):331-9","ArticleIdList":{"ArticleId":"16467561"}}]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"22272179","DateCompleted":{"Year":"2012","Month":"05","Day":"16"},"DateRevised":{"Year":"2018","Month":"11","Day":"13"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1537-744X","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"2012","PubDate":{"Year":"2012"}},"Title":"TheScientificWorldJournal","ISOAbbreviation":"ScientificWorldJournal"},"ArticleTitle":"Cerebrospinal fluid BACE1 activity and brain amyloid load in Alzheimer's disease.","Pagination":{"MedlinePgn":"712048"},"ELocationID":"10.1100\/2012\/712048","Abstract":{"AbstractText":"The secretase BACE1 is fundamentally involved in the development of cerebral amyloid pathology in Alzheimer's disease (AD). It has not been studied so far to what extent BACE1 activity in cerebrospinal fluid (CSF) mirrors in vivo amyloid load in AD. We explored associations between CSF BACE1 activity and fibrillar amyloid pathology as measured by carbon-11-labelled Pittsburgh Compound B positron emission tomography ([\u00b9\u00b9C]PIB PET). [\u00b9\u00b9C]PIB and CSF studies were performed in 31 patients with AD. Voxel-based linear regression analysis revealed significant associations between CSF BACE1 activity and [\u00b9\u00b9C]PIB tracer uptake in the bilateral parahippocampal region, the thalamus, and the pons. Our study provides evidence for a brain region-specific correlation between CSF BACE1 activity and in-vivo fibrillar amyloid pathology in AD. Associations were found in areas close to the brain ventricles, which may have important implications for the use of BACE1 in CSF as a marker for AD pathology and for antiamyloid treatment monitoring."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Grimmer","ForeName":"Timo","Initials":"T","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, Ismaninger Street 22, 81675 M\u00fcnchen, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Alexopoulos","ForeName":"Panagiotis","Initials":"P"},{"@attributes":{"ValidYN":"Y"},"LastName":"Tsolakidou","ForeName":"Amalia","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Guo","ForeName":"Liang-Hao","Initials":"LH"},{"@attributes":{"ValidYN":"Y"},"LastName":"Henriksen","ForeName":"Gjermund","Initials":"G"},{"@attributes":{"ValidYN":"Y"},"LastName":"Yousefi","ForeName":"Behrooz H","Initials":"BH"},{"@attributes":{"ValidYN":"Y"},"LastName":"F\u00f6rstl","ForeName":"Hans","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Sorg","ForeName":"Christian","Initials":"C"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Drzezga","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Perneczky","ForeName":"Robert","Initials":"R"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Research Support, Non-U.S. Gov't"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2012","Month":"01","Day":"03"}},"MedlineJournalInfo":{"Country":"United States","MedlineTA":"ScientificWorldJournal","NlmUniqueID":"101131163","ISSNLinking":"1537-744X"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"Amyloid"},{"RegistryNumber":"0","NameOfSubstance":"Biomarkers"},{"RegistryNumber":"EC 3.4.-","NameOfSubstance":"Amyloid Precursor Protein Secretases"},{"RegistryNumber":"EC 3.4.23.-","NameOfSubstance":"Aspartic Acid Endopeptidases"},{"RegistryNumber":"EC 3.4.23.46","NameOfSubstance":"BACE1 protein, human"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Alzheimer Disease","QualifierName":["cerebrospinal fluid","enzymology","pathology"]},{"DescriptorName":"Amyloid","QualifierName":"analysis"},{"DescriptorName":"Amyloid Precursor Protein Secretases","QualifierName":"cerebrospinal fluid"},{"DescriptorName":"Aspartic Acid Endopeptidases","QualifierName":"cerebrospinal fluid"},{"DescriptorName":"Biomarkers","QualifierName":"cerebrospinal fluid"},{"DescriptorName":"Brain","QualifierName":"pathology"},{"DescriptorName":"Brain Chemistry"},{"DescriptorName":"Female"},{"DescriptorName":"Hippocampus","QualifierName":"chemistry"},{"DescriptorName":"Humans"},{"DescriptorName":"Male"},{"DescriptorName":"Neuroimaging"},{"DescriptorName":"Pons","QualifierName":"chemistry"},{"DescriptorName":"Positron-Emission Tomography"},{"DescriptorName":"Thalamus","QualifierName":"chemistry"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2011","Month":"10","Day":"17"},{"@attributes":{"PubStatus":"accepted"},"Year":"2011","Month":"11","Day":"02"},{"@attributes":{"PubStatus":"entrez"},"Year":"2012","Month":"1","Day":"25","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2012","Month":"1","Day":"25","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2012","Month":"5","Day":"17","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["22272179","10.1100\/2012\/712048","PMC3259508"]},"ReferenceList":{"Reference":[{"Citation":"Nat Neurosci. 2001 Mar;4(3):233-4","ArticleIdList":{"ArticleId":"11224536"}},{"Citation":"Exp Neurol. 2002 May;175(1):10-22","ArticleIdList":{"ArticleId":"12009756"}},{"Citation":"Science. 2002 Jul 19;297(5580):353-6","ArticleIdList":{"ArticleId":"12130773"}},{"Citation":"Arch Neurol. 2002 Sep;59(9):1381-9","ArticleIdList":{"ArticleId":"12223024"}},{"Citation":"Nat Med. 2003 Jan;9(1):3-4","ArticleIdList":{"ArticleId":"12514700"}},{"Citation":"J Mol Neurosci. 2004;23(1-2):105-14","ArticleIdList":{"ArticleId":"15126696"}},{"Citation":"Ann N Y Acad Sci. 2004 Jun;1019:24-8","ArticleIdList":{"ArticleId":"15246987"}},{"Citation":"J Biol Chem. 2004 Sep 17;279(38):39710-7","ArticleIdList":{"ArticleId":"15247262"}},{"Citation":"Ann Neurol. 1988 Jul;24(1):17-22","ArticleIdList":{"ArticleId":"3415196"}},{"Citation":"Lancet. 1991 May 11;337(8750):1158-9","ArticleIdList":{"ArticleId":"1674030"}},{"Citation":"Acta Neuropathol. 1992;83(3):233-9","ArticleIdList":{"ArticleId":"1373020"}},{"Citation":"Neurology. 1999 May 12;52(8):1555-62","ArticleIdList":{"ArticleId":"10331678"}},{"Citation":"J Biol Chem. 2004 Dec 10;279(50):52535-42","ArticleIdList":{"ArticleId":"15452128"}},{"Citation":"Dement Geriatr Cogn Disord. 2005;19(4):171-83","ArticleIdList":{"ArticleId":"15677864"}},{"Citation":"Nat Rev Neurol. 2010 Mar;6(3):131-44","ArticleIdList":{"ArticleId":"20157306"}},{"Citation":"Neurology. 2006 Aug 22;67(4):710-2","ArticleIdList":{"ArticleId":"16924032"}},{"Citation":"Brain. 2006 Nov;129(Pt 11):2856-66","ArticleIdList":{"ArticleId":"16854944"}},{"Citation":"Neurobiol Aging. 2007 Jan;28(1):75-84","ArticleIdList":{"ArticleId":"16387391"}},{"Citation":"Arch Gen Psychiatry. 2007 Jun;64(6):718-26","ArticleIdList":{"ArticleId":"17548753"}},{"Citation":"Neurodegener Dis. 2007;4(2-3):127-35","ArticleIdList":{"ArticleId":"17596707"}},{"Citation":"Brain. 2007 Oct;130(Pt 10):2607-15","ArticleIdList":{"ArticleId":"17698496"}},{"Citation":"J Neurosci. 2007 Sep 26;27(39):10365-71","ArticleIdList":{"ArticleId":"17898208"}},{"Citation":"Br J Neurosurg. 2007 Oct;21(5):510-20","ArticleIdList":{"ArticleId":"17922324"}},{"Citation":"J Nucl Med. 2008 Mar;49(3):390-8","ArticleIdList":{"ArticleId":"18287270"}},{"Citation":"J Neurochem. 2008 May;105(4):1428-37","ArticleIdList":{"ArticleId":"18221373"}},{"Citation":"Brain. 2008 May;131(Pt 5):1252-8","ArticleIdList":{"ArticleId":"18334538"}},{"Citation":"Brain. 2008 Jun;131(Pt 6):1630-45","ArticleIdList":{"ArticleId":"18339640"}},{"Citation":"Arch Neurol. 2008 Aug;65(8):1102-7","ArticleIdList":{"ArticleId":"18695061"}},{"Citation":"Neurobiol Aging. 2008 Oct;29(10):1456-65","ArticleIdList":{"ArticleId":"17499392"}},{"Citation":"Neurology. 2009 Apr 28;72(17):1487-94","ArticleIdList":{"ArticleId":"19339712"}},{"Citation":"Biol Psychiatry. 2009 Jun 1;65(11):927-34","ArticleIdList":{"ArticleId":"19268916"}},{"Citation":"J Nucl Med. 2009 Sep;50(9):1464-70","ArticleIdList":{"ArticleId":"19690025"}},{"Citation":"Curr Alzheimer Res. 2010 Feb;7(1):56-66","ArticleIdList":{"ArticleId":"20205671"}},{"Citation":"Am J Pathol. 2001 Jan;158(1):173-7","ArticleIdList":{"ArticleId":"11141490"}},{"Citation":"Science. 1999 Oct 22;286(5440):735-41","ArticleIdList":{"ArticleId":"10531052"}},{"Citation":"Ann Neurol. 2006 Mar;59(3):512-9","ArticleIdList":{"ArticleId":"16372280"}},{"Citation":"Dement Geriatr Cogn Disord. 2010;29(3):204-12","ArticleIdList":{"ArticleId":"20332638"}},{"Citation":"Neurobiol Aging. 2012 Jan;33(1):198.e1-14","ArticleIdList":{"ArticleId":"20688420"}},{"Citation":"Biol Psychiatry. 2010 Nov 15;68(10):879-84","ArticleIdList":{"ArticleId":"20598287"}},{"Citation":"Neurobiol Aging. 2010 Aug;31(8):1275-83","ArticleIdList":{"ArticleId":"20472326"}}]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"22136539","DateCompleted":{"Year":"2012","Month":"02","Day":"02"},"DateRevised":{"Year":"2013","Month":"11","Day":"21"},"Article":{"@attributes":{"PubModel":"Print"},"Journal":{"ISSN":"1532-5415","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"59","Issue":"9","PubDate":{"Year":"2011","Month":"Sep"}},"Title":"Journal of the American Geriatrics Society","ISOAbbreviation":"J Am Geriatr Soc"},"ArticleTitle":"Cognitive reserve, homocysteine, and cognition in the Bavarian School Sisters Study.","Pagination":{"MedlinePgn":"1754-6"},"ELocationID":"10.1111\/j.1532-5415.2011.03568.x","AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Perneczky","ForeName":"Robert","Initials":"R"},{"@attributes":{"ValidYN":"Y"},"LastName":"Alexopoulos","ForeName":"Panagiotis","Initials":"P"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Bickel","ForeName":"Horst","Initials":"H"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Letter","Research Support, Non-U.S. Gov't"]}},"MedlineJournalInfo":{"Country":"United States","MedlineTA":"J Am Geriatr Soc","NlmUniqueID":"7503062","ISSNLinking":"0002-8614"},"ChemicalList":{"Chemical":{"RegistryNumber":"0LVT1QZ0BA","NameOfSubstance":"Homocysteine"}},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Aged, 80 and over"},{"DescriptorName":"Alzheimer Disease","QualifierName":["blood","physiopathology"]},{"DescriptorName":"Cognition","QualifierName":"physiology"},{"DescriptorName":"Cognition Disorders","QualifierName":["blood","physiopathology"]},{"DescriptorName":"Educational Status"},{"DescriptorName":"Female"},{"DescriptorName":"Homocysteine","QualifierName":"blood"},{"DescriptorName":"Humans"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"entrez"},"Year":"2011","Month":"12","Day":"6","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2011","Month":"12","Day":"6","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2012","Month":"2","Day":"3","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["22136539","10.1111\/j.1532-5415.2011.03568.x"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"22122982","DateCompleted":{"Year":"2012","Month":"04","Day":"05"},"DateRevised":{"Year":"2011","Month":"12","Day":"13"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1421-9824","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"32","Issue":"3","PubDate":{"Year":"2011"}},"Title":"Dementia and geriatric cognitive disorders","ISOAbbreviation":"Dement Geriatr Cogn Disord"},"ArticleTitle":"Association of clusterin gene polymorphisms with late-onset Alzheimer's disease.","Pagination":{"MedlinePgn":"198-201"},"ELocationID":"10.1159\/000331276","Abstract":{"AbstractText":["Some studies have implicated the role of apolipoprotein J [clusterin (CLU), apoJ] in the pathogenesis of Alzheimer's disease (AD). In this study, we investigated the polymorphisms rs11136000 and rs9331888 within CLU in late-onset sporadic AD (LOAD) patients and nondemented subjects.","LOAD patients and control subjects were analyzed. Genotyping of rs11136000 and rs9331888 was performed using standard PCR following different restriction endonuclease digestion.","Although there were no significant differences in genotype frequencies of these two polymorphisms, the haplotype CG was associated with a statistically significantly increased LOAD risk.","The rs11136000 and rs9331888 polymorphisms of the CLU gene are associated with LOAD."],"CopyrightInformation":"Copyright \u00a9 2011 S. Karger AG, Basel."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Gu","ForeName":"Huiying","Initials":"H","AffiliationInfo":{"Affiliation":"Department of Neurology, Indiana University School of Medicine, Indianapolis, USA."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Wei","ForeName":"Xing","Initials":"X"},{"@attributes":{"ValidYN":"Y"},"LastName":"Chen","ForeName":"Shirley","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"M\u00fcller","ForeName":"Ulrich","Initials":"U"},{"@attributes":{"ValidYN":"Y"},"LastName":"Gasser","ForeName":"Thomas","Initials":"T"},{"@attributes":{"ValidYN":"Y"},"LastName":"Dodel","ForeName":"Richard C","Initials":"RC"},{"@attributes":{"ValidYN":"Y"},"LastName":"Farlow","ForeName":"Martin R","Initials":"MR"},{"@attributes":{"ValidYN":"Y"},"LastName":"Du","ForeName":"Yansheng","Initials":"Y"}]},"Language":"eng","PublicationTypeList":{"PublicationType":"Journal Article"},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2011","Month":"11","Day":"26"}},"MedlineJournalInfo":{"Country":"Switzerland","MedlineTA":"Dement Geriatr Cogn Disord","NlmUniqueID":"9705200","ISSNLinking":"1420-8008"},"ChemicalList":{"Chemical":{"RegistryNumber":"0","NameOfSubstance":"Clusterin"}},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Age Factors"},{"DescriptorName":"Age of Onset"},{"DescriptorName":"Aged"},{"DescriptorName":"Aged, 80 and over"},{"DescriptorName":"Alzheimer Disease","QualifierName":"genetics"},{"DescriptorName":"Clusterin","QualifierName":"genetics"},{"DescriptorName":"Female"},{"DescriptorName":"Gene Frequency"},{"DescriptorName":"Genetic Association Studies"},{"DescriptorName":"Genotype"},{"DescriptorName":"Haplotypes"},{"DescriptorName":"Humans"},{"DescriptorName":"Linkage Disequilibrium"},{"DescriptorName":"Male"},{"DescriptorName":"Polymorphism, Genetic","QualifierName":"genetics"},{"DescriptorName":"Real-Time Polymerase Chain Reaction"},{"DescriptorName":"Sex Factors"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"accepted"},"Year":"2011","Month":"07","Day":"28"},{"@attributes":{"PubStatus":"entrez"},"Year":"2011","Month":"11","Day":"30","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2011","Month":"11","Day":"30","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2012","Month":"4","Day":"6","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["22122982","000331276","10.1159\/000331276"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"22092150","DateCompleted":{"Year":"2012","Month":"01","Day":"12"},"DateRevised":{"Year":"2011","Month":"11","Day":"21"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1532-5415","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"59","Issue":"11","PubDate":{"Year":"2011","Month":"Nov"}},"Title":"Journal of the American Geriatrics Society","ISOAbbreviation":"J Am Geriatr Soc"},"ArticleTitle":"Patient participation in medical and social decisions in Alzheimer's disease.","Pagination":{"MedlinePgn":"2045-52"},"ELocationID":"10.1111\/j.1532-5415.2011.03661.x","Abstract":{"AbstractText":["To analyze the preferences of people with amnestic mild cognitive impairment (aMCI) and mild dementia in Alzheimer's disease (AD) regarding different aspects of healthcare-related decisions, to correlate these findings with different measures of decision-making capacity, and to explore the views of relatives and referring physicians.","Cross-sectional survey.","University-based memory clinic in Munich, Germany.","One hundred people with aMCI or mild AD, their relatives (N = 99), and their referring physicians (N = 93).","Participation preferences and decisional capacity and assessment of these measures according to relatives and physicians.","Patients had a preference for participation in healthcare-related decisions, especially in social ones. Overall, individuals wanted their relatives to play a secondary role in decision-making. Relatives and referring physicians performed poorly in predicting the individuals' participation preferences, and relatives wanted to attribute less decision-making power to patients than the patients did themselves. Patients refrained from participation if they had lower Mini-Mental State Examination scores or were unsure about their decisional capacity. There were deficits in decision-making capacity, which mostly related to understanding of the information presented. There was only weak correlation between the different measures (patient's, relative's, and physician's estimate, MacArthur Competence Assessment Tool for Treatment) of the patients' decisional capacity.","The combination of marked participation preferences and impairments in the decisional capacity of individuals with aMCI and early AD constitute an ethical and practical challenge. A thorough implementation of structured probes of the patients' decisional capacity combined with interventions that aid patients in their decision-making capability might help to overcome some of these challenges."],"CopyrightInformation":"\u00a9 2011, Copyright the Authors Journal compilation \u00a9 2011, The American Geriatrics Society."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Hamann","ForeName":"Johannes","Initials":"J","AffiliationInfo":{"Affiliation":"Department of Psychiatry, Technische Universit\u00e4t M\u00fcnchen, M\u00fcnchen, Germany. j.hamann@lrz.tum.de"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Bronner","ForeName":"Katharina","Initials":"K"},{"@attributes":{"ValidYN":"Y"},"LastName":"Margull","ForeName":"Julia","Initials":"J"},{"@attributes":{"ValidYN":"Y"},"LastName":"Mendel","ForeName":"Rosmarie","Initials":"R"},{"@attributes":{"ValidYN":"Y"},"LastName":"Diehl-Schmid","ForeName":"Janine","Initials":"J"},{"@attributes":{"ValidYN":"Y"},"LastName":"B\u00fchner","ForeName":"Markus","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Klein","ForeName":"Reinhold","Initials":"R"},{"@attributes":{"ValidYN":"Y"},"LastName":"Schneider","ForeName":"Antonius","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Perneczky","ForeName":"Robert","Initials":"R"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Comparative Study","Journal Article","Research Support, Non-U.S. Gov't"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2011","Month":"10","Day":"22"}},"MedlineJournalInfo":{"Country":"United States","MedlineTA":"J Am Geriatr Soc","NlmUniqueID":"7503062","ISSNLinking":"0002-8614"},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Advance Directive Adherence"},{"DescriptorName":"Aged"},{"DescriptorName":"Aged, 80 and over"},{"DescriptorName":"Alzheimer Disease","QualifierName":["diagnosis","epidemiology","psychology"]},{"DescriptorName":"Cross-Sectional Studies"},{"DescriptorName":"Decision Making","QualifierName":"ethics"},{"DescriptorName":"Family"},{"DescriptorName":"Female"},{"DescriptorName":"Follow-Up Studies"},{"DescriptorName":"Germany","QualifierName":"epidemiology"},{"DescriptorName":"Health Care Surveys"},{"DescriptorName":"Humans"},{"DescriptorName":"Legal Guardians","QualifierName":"psychology"},{"DescriptorName":"Male"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Morbidity","QualifierName":"trends"},{"DescriptorName":"Patient Compliance"},{"DescriptorName":"Physician-Patient Relations"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"entrez"},"Year":"2011","Month":"11","Day":"19","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2011","Month":"11","Day":"19","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2012","Month":"1","Day":"13","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["22092150","10.1111\/j.1532-5415.2011.03661.x"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"22079258","DateCompleted":{"Year":"2012","Month":"08","Day":"13"},"DateRevised":{"Year":"2016","Month":"11","Day":"25"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1873-2402","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"71","Issue":"9","PubDate":{"Year":"2012","Month":"May","Day":"01"}},"Title":"Biological psychiatry","ISOAbbreviation":"Biol Psychiatry"},"ArticleTitle":"Asymmetric loss of parietal activity causes spatial bias in prodromal and mild Alzheimer's disease.","Pagination":{"MedlinePgn":"798-804"},"ELocationID":"10.1016\/j.biopsych.2011.09.027","Abstract":{"AbstractText":["In Alzheimer's disease (AD), loss of effective neuronal activity is reflected by cortical glucose hypometabolism. Hypometabolism in the posterior parietal cortex (PPC) is among the first in vivo signs of AD; however, its functional impact on large-scale brain mechanisms and behavior is poorly understood. The lateral PPC contributes to spatial attention constituting a basic function of the human brain. We hypothesized 1) that lateral PPC hypometabolism is associated with impaired spatial attention in very early AD and 2) that impaired competition of effective neuronal activity across hemispheres might underlie this deficit in terms of brain mechanisms.","A model-based imaging approach was applied to assess patients with prodromal (n = 28) and mild (n = 7) AD. Quantitative attention parameters, derived from performance on simple psychophysical tasks and analyzed by Bundesen's computational theory of visual attention, were related to brain metabolism, measured by (18)F-fluorodeoxyglucose positron emission tomography.","Patients' left and right lateral PPC metabolism was reduced. Nine patients had significant spatial attentional bias on the left side and two patients on the right. Direction and degree of spatial bias was correlated with direction and degree of an interhemispheric metabolism bias in the inferior parietal lobe and temporoparietal junction.","Our data provide evidence that in very early AD, asymmetric hypometabolism of the lateral PPC causes spatial attentional bias. Results are broadly consistent with the model that asymmetrically impaired effective neuronal PPC activity in AD biases the competition of visual objects for cortical representation and access to awareness to one side."],"CopyrightInformation":"Copyright \u00a9 2012 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Sorg","ForeName":"Christian","Initials":"C","AffiliationInfo":{"Affiliation":"Department of Psychiatry, Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany. c.sorg@lrz.tum.de"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Myers","ForeName":"Nicholas","Initials":"N"},{"@attributes":{"ValidYN":"Y"},"LastName":"Redel","ForeName":"Petra","Initials":"P"},{"@attributes":{"ValidYN":"Y"},"LastName":"Bublak","ForeName":"Peter","Initials":"P"},{"@attributes":{"ValidYN":"Y"},"LastName":"Riedl","ForeName":"Valentin","Initials":"V"},{"@attributes":{"ValidYN":"Y"},"LastName":"Manoliu","ForeName":"Andrei","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Perneczky","ForeName":"Robert","Initials":"R"},{"@attributes":{"ValidYN":"Y"},"LastName":"Grimmer","ForeName":"Timo","Initials":"T"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"F\u00f6rstl","ForeName":"Hans","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Drzezga","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"M\u00fcller","ForeName":"Hermann J","Initials":"HJ"},{"@attributes":{"ValidYN":"Y"},"LastName":"Wohlschl\u00e4ger","ForeName":"Afra M","Initials":"AM"},{"@attributes":{"ValidYN":"Y"},"LastName":"Finke","ForeName":"Kathrin","Initials":"K"}]},"Language":"eng","GrantList":{"@attributes":{"CompleteYN":"Y"},"Grant":{"Agency":"Wellcome Trust","Country":"United Kingdom"}},"PublicationTypeList":{"PublicationType":["Journal Article","Research Support, Non-U.S. Gov't"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2011","Month":"11","Day":"12"}},"MedlineJournalInfo":{"Country":"United States","MedlineTA":"Biol Psychiatry","NlmUniqueID":"0213264","ISSNLinking":"0006-3223"},"ChemicalList":{"Chemical":{"RegistryNumber":"0Z5B2CJX4D","NameOfSubstance":"Fluorodeoxyglucose F18"}},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Alzheimer Disease","QualifierName":["diagnosis","diagnostic imaging","physiopathology"]},{"DescriptorName":"Attention","QualifierName":"physiology"},{"DescriptorName":"Early Diagnosis"},{"DescriptorName":"Female"},{"DescriptorName":"Fluorodeoxyglucose F18"},{"DescriptorName":"Functional Laterality","QualifierName":"physiology"},{"DescriptorName":"Functional Neuroimaging","QualifierName":["methods","psychology"]},{"DescriptorName":"Humans"},{"DescriptorName":"Male"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Parietal Lobe","QualifierName":["diagnostic imaging","physiopathology"]},{"DescriptorName":"Positron-Emission Tomography","QualifierName":["methods","psychology"]},{"DescriptorName":"Psychomotor Performance","QualifierName":"physiology"},{"DescriptorName":"Space Perception","QualifierName":"physiology"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2011","Month":"05","Day":"09"},{"@attributes":{"PubStatus":"revised"},"Year":"2011","Month":"09","Day":"19"},{"@attributes":{"PubStatus":"accepted"},"Year":"2011","Month":"09","Day":"20"},{"@attributes":{"PubStatus":"entrez"},"Year":"2011","Month":"11","Day":"15","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2011","Month":"11","Day":"15","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2012","Month":"8","Day":"14","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["22079258","S0006-3223(11)00947-4","10.1016\/j.biopsych.2011.09.027"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"22056939","DateCompleted":{"Year":"2012","Month":"03","Day":"15"},"DateRevised":{"Year":"2011","Month":"12","Day":"22"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1423-0208","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"37","Issue":"3-4","PubDate":{"Year":"2011"}},"Title":"Neuroepidemiology","ISOAbbreviation":"Neuroepidemiology"},"ArticleTitle":"Survival in a German population with frontotemporal lobar degeneration.","Pagination":{"MedlinePgn":"160-5"},"ELocationID":"10.1159\/000331485","Abstract":{"AbstractText":["The present study aimed at analysing survival of patients with behavioural-variant frontotemporal dementia (bvFTD), semantic dementia (SD) and progressive non-fluent aphasia (PNFA). Furthermore, the objective of the study was to identify prognostic factors associated with survival and to examine causes of death.","Interviews were performed with the proxies of 124 patients with frontotemporal lobar degeneration (FTLD).","Survival from the onset of first symptoms was significantly longer in SD than in bvFTD (10.5 years). Median survival in PNFA was 12.6 years. Age at onset, gender, education and severity of dementia at diagnosis did not significantly influence survival. We did not identify any phenocopy cases. The most frequent cause of death as reported by caregivers was respiratory system disorder.","This study adds to the growing literature on survival in patients with FTLD and provides insights into the causes of death."],"CopyrightInformation":"Copyright \u00a9 2011 S. Karger AG, Basel."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Nunnemann","ForeName":"Sabine","Initials":"S","AffiliationInfo":{"Affiliation":"Department of Psychiatry, Technische Universit\u00e4t M\u00fcnchen, M\u00fcnchen, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Last","ForeName":"Dirk","Initials":"D"},{"@attributes":{"ValidYN":"Y"},"LastName":"Schuster","ForeName":"Tibor","Initials":"T"},{"@attributes":{"ValidYN":"Y"},"LastName":"F\u00f6rstl","ForeName":"Hans","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Diehl-Schmid","ForeName":"Janine","Initials":"J"}]},"Language":"eng","PublicationTypeList":{"PublicationType":"Journal Article"},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2011","Month":"11","Day":"02"}},"MedlineJournalInfo":{"Country":"Switzerland","MedlineTA":"Neuroepidemiology","NlmUniqueID":"8218700","ISSNLinking":"0251-5350"},"CitationSubset":"IM","CommentsCorrectionsList":{"CommentsCorrections":{"@attributes":{"RefType":"CommentIn"},"RefSource":"Neuroepidemiology. 2011;37(3-4):166-7","PMID":"22056969"}},"MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Age of Onset"},{"DescriptorName":"Aged"},{"DescriptorName":"Cause of Death"},{"DescriptorName":"Female"},{"DescriptorName":"Frontotemporal Dementia","QualifierName":"mortality"},{"DescriptorName":"Frontotemporal Lobar Degeneration","QualifierName":"mortality"},{"DescriptorName":"Germany","QualifierName":"epidemiology"},{"DescriptorName":"Humans"},{"DescriptorName":"Male"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Primary Progressive Nonfluent Aphasia","QualifierName":"mortality"},{"DescriptorName":"Prognosis"},{"DescriptorName":"Prospective Studies"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2010","Month":"11","Day":"05"},{"@attributes":{"PubStatus":"accepted"},"Year":"2011","Month":"08","Day":"03"},{"@attributes":{"PubStatus":"entrez"},"Year":"2011","Month":"11","Day":"8","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2011","Month":"11","Day":"8","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2012","Month":"3","Day":"16","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["22056939","000331485","10.1159\/000331485"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"22055653","DateCompleted":{"Year":"2012","Month":"11","Day":"13"},"DateRevised":{"Year":"2016","Month":"11","Day":"25"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1552-5279","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"8","Issue":"4","PubDate":{"Year":"2012","Month":"Jul"}},"Title":"Alzheimer's & dementia : the journal of the Alzheimer's Association","ISOAbbreviation":"Alzheimers Dement"},"ArticleTitle":"Clinical and neurobiological correlates of soluble amyloid precursor proteins in the cerebrospinal fluid.","Pagination":{"MedlinePgn":"304-11"},"ELocationID":"10.1016\/j.jalz.2011.04.009","Abstract":{"AbstractText":["According to a widely accepted hypothesis, the amyloid precursor protein (APP) is processed by two competing pathways: the amyloidogenic \u03b2-secretase-mediated pathway or the nonamyloidogenic \u03b1-secretase-mediated pathway. APP is cleaved preferentially through the nonamyloidogenic pathway in normal brain, whereas the balance shifts to the amyloidogenic pathway in Alzheimer's disease (AD). The levels of the \u03b1-secretase-cleaved soluble APP (sAPP\u03b1) and \u03b2-secretase-cleaved soluble APP (sAPP\u03b2) in cerebrospinal fluid (CSF) are likely to reflect these competing mechanisms.","We investigated the levels and the relationship between sAPP\u03b1 and sAPP\u03b2 in the CSF of 64 patients with mild AD, 76 patients with mild cognitive impairment, and 12 cognitively healthy control subjects, as well as the effect of apolipoprotein E genotype and sex on soluble APP levels.","There was a significant positive correlation between sAPP\u03b1 and sAPP\u03b2 levels in all three groups. sAPP\u03b1 and sAPP\u03b2 concentrations were higher in patients with mild cognitive impairment compared with patients with AD. In the AD group, females exhibited higher sAPP\u03b1 and sAPP\u03b2 levels than males. No influence of the apolipoprotein E genotype on soluble APP concentrations was detected.","The positive correlation between sAPP\u03b1 and sAPP\u03b2 challenges the hypothesis that AD is caused by an imbalance of the \u03b1- and \u03b2-secretase APP proteolysis through competing mechanisms. Moreover, the differences in CSF levels of sAPP\u03b1 and sAPP\u03b2 between male and female patients with AD may reflect a \"sexual dimorphism\" in the activity of the two APP processing pathways in AD."],"CopyrightInformation":"Copyright \u00a9 2012 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Alexopoulos","ForeName":"Panagiotis","Initials":"P","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany. panos.alexopoulos@lrz.tu-muenchen.de"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Tsolakidou","ForeName":"Amalia","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Roselli","ForeName":"Francesco","Initials":"F"},{"@attributes":{"ValidYN":"Y"},"LastName":"Arnold","ForeName":"Anila","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Grimmer","ForeName":"Timo","Initials":"T"},{"@attributes":{"ValidYN":"Y"},"LastName":"Westerteicher","ForeName":"Christine","Initials":"C"},{"@attributes":{"ValidYN":"Y"},"LastName":"Leante","ForeName":"Maria Rosaria","Initials":"MR"},{"@attributes":{"ValidYN":"Y"},"LastName":"F\u00f6rstl","ForeName":"Hans","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Livrea","ForeName":"Paolo","Initials":"P"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Perneczky","ForeName":"Robert","Initials":"R"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Research Support, Non-U.S. Gov't"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2011","Month":"11","Day":"04"}},"MedlineJournalInfo":{"Country":"United States","MedlineTA":"Alzheimers Dement","NlmUniqueID":"101231978","ISSNLinking":"1552-5260"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"Apolipoproteins E"},{"RegistryNumber":"EC 3.4.-","NameOfSubstance":"Amyloid Precursor Protein Secretases"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Adult"},{"DescriptorName":"Aged"},{"DescriptorName":"Alzheimer Disease","QualifierName":["blood","cerebrospinal fluid","genetics"]},{"DescriptorName":"Amyloid Precursor Protein Secretases","QualifierName":["blood","cerebrospinal fluid"]},{"DescriptorName":"Apolipoproteins E","QualifierName":"genetics"},{"DescriptorName":"Chi-Square Distribution"},{"DescriptorName":"Cognitive Dysfunction","QualifierName":["blood","cerebrospinal fluid","genetics"]},{"DescriptorName":"Female"},{"DescriptorName":"Humans"},{"DescriptorName":"Male"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Neuropsychological Tests"},{"DescriptorName":"Psychiatric Status Rating Scales"},{"DescriptorName":"Sex Factors"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2010","Month":"09","Day":"16"},{"@attributes":{"PubStatus":"revised"},"Year":"2011","Month":"03","Day":"14"},{"@attributes":{"PubStatus":"accepted"},"Year":"2011","Month":"04","Day":"27"},{"@attributes":{"PubStatus":"entrez"},"Year":"2011","Month":"11","Day":"8","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2011","Month":"11","Day":"8","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2012","Month":"11","Day":"14","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["22055653","S1552-5260(11)01040-5","10.1016\/j.jalz.2011.04.009"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"22045485","DateCompleted":{"Year":"2012","Month":"06","Day":"15"},"DateRevised":{"Year":"2016","Month":"11","Day":"25"},"Article":{"@attributes":{"PubModel":"Print"},"Journal":{"ISSN":"1875-8908","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"28","Issue":"3","PubDate":{"Year":"2012"}},"Title":"Journal of Alzheimer's disease : JAD","ISOAbbreviation":"J Alzheimers Dis"},"ArticleTitle":"Interrelations between CSF soluble A\u03b2PP\u03b2, amyloid-\u03b2 1-42, SORL1, and tau levels in Alzheimer's disease.","Pagination":{"MedlinePgn":"543-52"},"ELocationID":"10.3233\/JAD-2011-110983","Abstract":{"AbstractText":"Recently, light has been shed on possible interrelations between the two most important pathological hallmarks of Alzheimer's disease (AD): the amyloid cascade and axonal degeneration. In this study, we investigated associations between s\u03b2APP\u03b2, a product of the cleavage of the amyloid-\u03b2 protein precursor (A\u03b2PP) by \u03b2-secretase, amyloid-\u03b2 1-42 (A\u03b242), soluble SORL1 (also called LR11 or SORLA), a receptor that is involved in A\u03b2PP processing, and the marker of axonal degeneration tau in the cerebrospinal fluid (CSF) of 76 patients with mild cognitive impairment (MCI), 61 patients with AD, and 17 patients with frontotemporal dementia, which neuropathologically is not related to the amyloid pathology. In the AD group, significant associations between sA\u03b2PP\u03b2, tau (p < 0.001), and soluble SORL1 (p < 0.001) were detected according to linear regression models. In patients with MCI, sA\u03b2PP\u03b2 correlated significantly with tau (p < 0.001) and soluble SORL1 (p = 0.003). In the FTD group, only SORL1 (p = 0.011) was associated with sA\u03b2PP\u03b2 and not tau. A\u03b242 was found to be significantly related to tau levels in CSF in the MCI group (p < 0.001) and they tended to be associated in the AD group (p = 0.05). Our results provide further evidence for a link between the two facets of AD pathology, which is likely to be mediated by the binding of A\u03b2 oligomers to specifically targeted neurons, resulting in stimulating tau hyperphosphorylation and neurodegeneration."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Alexopoulos","ForeName":"Panagiotis","Initials":"P","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Guo","ForeName":"Liang-Hao","Initials":"LH"},{"@attributes":{"ValidYN":"Y"},"LastName":"Tsolakidou","ForeName":"Amalia","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kratzer","ForeName":"Martina","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Grimmer","ForeName":"Timo","Initials":"T"},{"@attributes":{"ValidYN":"Y"},"LastName":"Westerteicher","ForeName":"Christine","Initials":"C"},{"@attributes":{"ValidYN":"Y"},"LastName":"Jiang","ForeName":"Meizi","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Bujo","ForeName":"Hideaki","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Diehl-Schmid","ForeName":"Janine","Initials":"J"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Perneczky","ForeName":"Robert","Initials":"R"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Research Support, Non-U.S. Gov't"]}},"MedlineJournalInfo":{"Country":"Netherlands","MedlineTA":"J Alzheimers Dis","NlmUniqueID":"9814863","ISSNLinking":"1387-2877"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"APP protein, human"},{"RegistryNumber":"0","NameOfSubstance":"Amyloid beta-Peptides"},{"RegistryNumber":"0","NameOfSubstance":"Amyloid beta-Protein Precursor"},{"RegistryNumber":"0","NameOfSubstance":"LDL-Receptor Related Proteins"},{"RegistryNumber":"0","NameOfSubstance":"Membrane Transport Proteins"},{"RegistryNumber":"0","NameOfSubstance":"Peptide Fragments"},{"RegistryNumber":"0","NameOfSubstance":"SORL1 protein, human"},{"RegistryNumber":"0","NameOfSubstance":"amyloid beta-protein (1-42)"},{"RegistryNumber":"0","NameOfSubstance":"tau Proteins"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Alzheimer Disease","QualifierName":["cerebrospinal fluid","complications"]},{"DescriptorName":"Amyloid beta-Peptides","QualifierName":"cerebrospinal fluid"},{"DescriptorName":"Amyloid beta-Protein Precursor","QualifierName":"cerebrospinal fluid"},{"DescriptorName":"Analysis of Variance"},{"DescriptorName":"Chi-Square Distribution"},{"DescriptorName":"Cognitive Dysfunction","QualifierName":["cerebrospinal fluid","etiology"]},{"DescriptorName":"Enzyme-Linked Immunosorbent Assay"},{"DescriptorName":"Female"},{"DescriptorName":"Frontotemporal Dementia","QualifierName":"cerebrospinal fluid"},{"DescriptorName":"Humans"},{"DescriptorName":"LDL-Receptor Related Proteins","QualifierName":"cerebrospinal fluid"},{"DescriptorName":"Male"},{"DescriptorName":"Membrane Transport Proteins","QualifierName":"cerebrospinal fluid"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Peptide Fragments","QualifierName":"cerebrospinal fluid"},{"DescriptorName":"tau Proteins","QualifierName":"cerebrospinal fluid"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"entrez"},"Year":"2011","Month":"11","Day":"3","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2011","Month":"11","Day":"3","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2012","Month":"6","Day":"16","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["22045485","N05T5556477N0U87","10.3233\/JAD-2011-110983"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"21997402","DateCompleted":{"Year":"2012","Month":"04","Day":"05"},"DateRevised":{"Year":"2018","Month":"11","Day":"13"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1421-9824","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"32","Issue":"3","PubDate":{"Year":"2011"}},"Title":"Dementia and geriatric cognitive disorders","ISOAbbreviation":"Dement Geriatr Cogn Disord"},"ArticleTitle":"Impact of SORL1 single nucleotide polymorphisms on Alzheimer's disease cerebrospinal fluid markers.","Pagination":{"MedlinePgn":"164-70"},"ELocationID":"10.1159\/000332017","Abstract":{"AbstractText":["Recently, genetic variants of the neuronal sortilin-related receptor with A-type repeats (SORL1, also called LR11 or sorLA) have emerged as risk factors for the development of Alzheimer's disease (AD).","In this study, SORL1 gene polymorphisms, which have been shown to be related to AD, were analyzed for associations with cerebrospinal fluid (CSF) amyloid beta1-42 (A\u03b2(1-42)), phosphorylated tau181, and total tau levels in a non-Hispanic Caucasian sample, which encompassed 100 cognitively healthy elderly individuals, 166 patients with mild cognitive impairment, and 87 patients with probable AD. The data were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (www.loni.ucla.edu\/ADNI). Moreover, the impact of gene-gene interactions between SORL1 single nucleotide polymorphisms (SNPs) and the apolipoprotein E (APOE) \u03b54 allele, the major genetic risk factor for sporadic AD, on A\u03b2(1-42) concentrations was investigated.","Significant associations between CSF A\u03b2(1-42) levels and the SORL1 SNPs 23 (rs3824968) and 24 (rs2282649) were detected in the AD group. The latter association became marginally statistically insignificant after Bonferroni correction for multiple comparisons. Carriers of the SORL1 SNP24 T allele and the SNP23 A allele both had lower CSF A\u03b2(1-42) concentrations than non-carriers of these alleles. The analysis of the impact of interactions between APOE \u03b54 allele and SORL1 SNPs on CSF A\u03b2(1-42) levels unraveled significant influences of APOE.","Our findings provide further support for the notion that SORL1 genetic variants are related to AD pathology, probably by regulating the amyloid cascade."],"CopyrightInformation":"Copyright \u00a9 2011 S. Karger AG, Basel."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Alexopoulos","ForeName":"Panagiotis","Initials":"P","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany. panos.alexopoulos @ lrz.tum.de"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Guo","ForeName":"Liang-Hao","Initials":"LH"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kratzer","ForeName":"Martina","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Westerteicher","ForeName":"Christine","Initials":"C"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Perneczky","ForeName":"Robert","Initials":"R"}]},"Language":"eng","GrantList":{"@attributes":{"CompleteYN":"Y"},"Grant":[{"GrantID":"K01 AG030514","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"P30 AG010129","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"U01 AG024904","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"U19 AG010483","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"}]},"PublicationTypeList":{"PublicationType":["Journal Article","Research Support, N.I.H., Extramural","Research Support, Non-U.S. Gov't"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2011","Month":"10","Day":"13"}},"MedlineJournalInfo":{"Country":"Switzerland","MedlineTA":"Dement Geriatr Cogn Disord","NlmUniqueID":"9705200","ISSNLinking":"1420-8008"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"Amyloid beta-Peptides"},{"RegistryNumber":"0","NameOfSubstance":"Apolipoproteins E"},{"RegistryNumber":"0","NameOfSubstance":"Biomarkers"},{"RegistryNumber":"0","NameOfSubstance":"LDL-Receptor Related Proteins"},{"RegistryNumber":"0","NameOfSubstance":"Membrane Transport Proteins"},{"RegistryNumber":"0","NameOfSubstance":"Peptide Fragments"},{"RegistryNumber":"0","NameOfSubstance":"SORL1 protein, human"},{"RegistryNumber":"0","NameOfSubstance":"amyloid beta-protein (1-42)"},{"RegistryNumber":"0","NameOfSubstance":"tau Proteins"},{"RegistryNumber":"9007-49-2","NameOfSubstance":"DNA"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Aged, 80 and over"},{"DescriptorName":"Alzheimer Disease","QualifierName":["cerebrospinal fluid","genetics"]},{"DescriptorName":"Amyloid beta-Peptides","QualifierName":"cerebrospinal fluid"},{"DescriptorName":"Apolipoproteins E","QualifierName":"genetics"},{"DescriptorName":"Biomarkers","QualifierName":"cerebrospinal fluid"},{"DescriptorName":"DNA","QualifierName":"genetics"},{"DescriptorName":"Data Interpretation, Statistical"},{"DescriptorName":"Databases, Factual"},{"DescriptorName":"Female"},{"DescriptorName":"Humans"},{"DescriptorName":"LDL-Receptor Related Proteins","QualifierName":"genetics"},{"DescriptorName":"Male"},{"DescriptorName":"Membrane Transport Proteins","QualifierName":"genetics"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Peptide Fragments","QualifierName":"cerebrospinal fluid"},{"DescriptorName":"Polymorphism, Single Nucleotide","QualifierName":"genetics"},{"DescriptorName":"Regression Analysis"},{"DescriptorName":"tau Proteins","QualifierName":"cerebrospinal fluid"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"accepted"},"Year":"2011","Month":"08","Day":"03"},{"@attributes":{"PubStatus":"entrez"},"Year":"2011","Month":"10","Day":"15","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2011","Month":"10","Day":"15","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2012","Month":"4","Day":"6","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["21997402","000332017","10.1159\/000332017","PMC3696367"]},"ReferenceList":{"Reference":[{"Citation":"Neurosci Lett. 2008 Jul 25;440(1):68-71","ArticleIdList":{"ArticleId":"18541377"}},{"Citation":"J Neural Transm (Vienna). 2011 Feb;118(2):249-57","ArticleIdList":{"ArticleId":"21190051"}},{"Citation":"Dement Geriatr Cogn Disord. 2008;26(2):161-4","ArticleIdList":{"ArticleId":"18685254"}},{"Citation":"Nat Rev Neurosci. 2008 Dec;9(12):899-909","ArticleIdList":{"ArticleId":"19002190"}},{"Citation":"Neurogenetics. 2009 Feb;10(1):13-7","ArticleIdList":{"ArticleId":"18813964"}},{"Citation":"PLoS One. 2009;4(4):e5088","ArticleIdList":{"ArticleId":"19352431"}},{"Citation":"Neurobiol Aging. 2009 Jul;30(7):1048-51","ArticleIdList":{"ArticleId":"18063222"}},{"Citation":"Neurosci Lett. 2009 Sep 18;461(2):177-80","ArticleIdList":{"ArticleId":"19539718"}},{"Citation":"J Alzheimers Dis. 2009;18(1):51-64","ArticleIdList":{"ArticleId":"19584446"}},{"Citation":"Neurobiol Aging. 2011 Aug;32(8):1443-51","ArticleIdList":{"ArticleId":"19889475"}},{"Citation":"Ann Neurol. 1999 Dec;46(6):860-6","ArticleIdList":{"ArticleId":"10589538"}},{"Citation":"Arterioscler Thromb Vasc Biol. 2001 Sep;21(9):1501-6","ArticleIdList":{"ArticleId":"11557679"}},{"Citation":"Lancet Neurol. 2003 Jan;2(1):15-21","ArticleIdList":{"ArticleId":"12849297"}},{"Citation":"J Neural Transm (Vienna). 2003 Oct;110(10):1149-60","ArticleIdList":{"ArticleId":"14523627"}},{"Citation":"Lancet. 1993 Sep 18;342(8873):697-9","ArticleIdList":{"ArticleId":"8103819"}},{"Citation":"Arch Neurol. 1999 Jun;56(6):673-80","ArticleIdList":{"ArticleId":"10369305"}},{"Citation":"J Am Geriatr Soc. 2006 Jun;54(6):1008-10","ArticleIdList":{"ArticleId":"16776804"}},{"Citation":"J Neuropathol Exp Neurol. 2006 Sep;65(9):866-72","ArticleIdList":{"ArticleId":"16957580"}},{"Citation":"Nat Genet. 2007 Jan;39(1):17-23","ArticleIdList":{"ArticleId":"17192785"}},{"Citation":"Nat Genet. 2007 Feb;39(2):168-77","ArticleIdList":{"ArticleId":"17220890"}},{"Citation":"Neurosci Lett. 2007 Sep 25;425(2):105-9","ArticleIdList":{"ArticleId":"17826910"}},{"Citation":"BMC Med Genet. 2007;8 Suppl 1:S15","ArticleIdList":{"ArticleId":"17903297"}},{"Citation":"Neuroreport. 2007 Nov 19;18(17):1761-4","ArticleIdList":{"ArticleId":"18090307"}},{"Citation":"Ann Neurol. 2007 Dec;62(6):640-7","ArticleIdList":{"ArticleId":"17721864"}},{"Citation":"Neurodegener Dis. 2008;5(2):60-4","ArticleIdList":{"ArticleId":"17975299"}},{"Citation":"Arch Neurol. 2008 Jan;65(1):45-53","ArticleIdList":{"ArticleId":"17998437"}},{"Citation":"Neurobiol Dis. 2008 Feb;29(2):293-6","ArticleIdList":{"ArticleId":"17949987"}},{"Citation":"Neurology. 2008 Mar 11;70(11):887-9","ArticleIdList":{"ArticleId":"17978276"}},{"Citation":"Hum Mutat. 2008 May;29(5):769-70","ArticleIdList":{"ArticleId":"18407551"}},{"Citation":"J Biol Chem. 2008 May 23;283(21):14826-34","ArticleIdList":{"ArticleId":"18362153"}},{"Citation":"Neuroscience. 2009 Nov 24;164(1):174-90","ArticleIdList":{"ArticleId":"19362127"}},{"Citation":"Arch Neurol. 2009 Oct;66(10):1260-6","ArticleIdList":{"ArticleId":"19822782"}},{"Citation":"Brain Res. 2009 Apr 6;1264:1-6","ArticleIdList":{"ArticleId":"19368828"}},{"Citation":"Neurogenetics. 2010 Feb;11(1):139-42","ArticleIdList":{"ArticleId":"19653016"}},{"Citation":"Int J Geriatr Psychiatry. 2010 May;25(5):542-3","ArticleIdList":{"ArticleId":"20391590"}},{"Citation":"Mol Psychiatry. 2010 Jul;15(7):756-66","ArticleIdList":{"ArticleId":"19125160"}},{"Citation":"Dement Geriatr Cogn Disord. 2010;30(1):28-32","ArticleIdList":{"ArticleId":"20689279"}},{"Citation":"Eur Arch Psychiatry Clin Neurosci. 2010 Sep;260(6):441-2","ArticleIdList":{"ArticleId":"20845022"}},{"Citation":"J Alzheimers Dis. 2010;21(3):833-42","ArticleIdList":{"ArticleId":"20634593"}},{"Citation":"Eur Arch Psychiatry Clin Neurosci. 2010 Oct;260(7):561-2","ArticleIdList":{"ArticleId":"20155362"}},{"Citation":"Neurology. 2011 Jan 4;76(1):69-79","ArticleIdList":{"ArticleId":"21123754"}},{"Citation":"Arch Neurol. 2011 Jan;68(1):99-106","ArticleIdList":{"ArticleId":"21220680"}},{"Citation":"Neurosci Lett. 2008 Aug 1;440(2):190-2","ArticleIdList":{"ArticleId":"18562096"}}]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"21986341","DateCompleted":{"Year":"2013","Month":"01","Day":"04"},"DateRevised":{"Year":"2018","Month":"12","Day":"01"},"Article":{"@attributes":{"PubModel":"Print"},"Journal":{"ISSN":"1546-4156","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"26","Issue":"3","PubDate":{"MedlineDate":"2012 Jul-Sep"}},"Title":"Alzheimer disease and associated disorders","ISOAbbreviation":"Alzheimer Dis Assoc Disord"},"ArticleTitle":"CORDIAL: cognitive rehabilitation and cognitive-behavioral treatment for early dementia in Alzheimer disease: a multicenter, randomized, controlled trial.","Pagination":{"MedlinePgn":"246-53"},"Abstract":{"AbstractText":"Cognitive rehabilitation (CR) is a promising treatment approach for older adults with dementia because it aims at supporting the management of day-to-day problems. There is insufficient evidence regarding whether CR provides clinically meaningful benefits. In this study, we evaluated the feasibility, acceptance, efficacy, and usefulness of a CR intervention in a multicenter, randomized, controlled trial on 201 patients with mild dementia in Alzheimer disease and their carers. The intervention comprised 12 individual weekly sessions and combined 4 established strategies adopted from neurorehabilitation and psychotherapy. Activities of daily living were chosen as the primary outcome. The results show that the feasibility, treatment adherence, and carer commitment were excellent. However, no effect of the intervention was demonstrable on everyday functioning. There were improvements favoring the intervention on quality of life and treatment satisfaction and a significant antidepressant effect in female participants. The lack of impact on everyday activities may be due to methodological limitations including insufficient personalization, short treatment duration, poor transfer into the real-life setting, and low sensitivity of assessment instruments. The findings of this study may be helpful for designing further studies that are needed to determine the potential of CR in older adults with dementia."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany. alexander.kurz@lrz.tum.de"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Th\u00f6ne-Otto","ForeName":"Angelika","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Cramer","ForeName":"Barbara","Initials":"B"},{"@attributes":{"ValidYN":"Y"},"LastName":"Egert","ForeName":"Silvia","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"Fr\u00f6lich","ForeName":"Lutz","Initials":"L"},{"@attributes":{"ValidYN":"Y"},"LastName":"Gertz","ForeName":"Hermann-Josef","Initials":"HJ"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kehl","ForeName":"Victoria","Initials":"V"},{"@attributes":{"ValidYN":"Y"},"LastName":"Wagenpfeil","ForeName":"Stefan","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"Werheid","ForeName":"Katja","Initials":"K"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Multicenter Study","Randomized Controlled Trial","Research Support, Non-U.S. Gov't"]}},"MedlineJournalInfo":{"Country":"United States","MedlineTA":"Alzheimer Dis Assoc Disord","NlmUniqueID":"8704771","ISSNLinking":"0893-0341"},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Activities of Daily Living"},{"DescriptorName":"Aged"},{"DescriptorName":"Alzheimer Disease","QualifierName":["complications","psychology","therapy"]},{"DescriptorName":"Cognitive Behavioral Therapy","QualifierName":"methods"},{"DescriptorName":"Dementia","QualifierName":["etiology","therapy"]},{"DescriptorName":"Female"},{"DescriptorName":"Humans"},{"DescriptorName":"Male"},{"DescriptorName":"Patient Satisfaction"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"entrez"},"Year":"2011","Month":"10","Day":"12","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2011","Month":"10","Day":"12","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2013","Month":"1","Day":"5","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["21986341","10.1097\/WAD.0b013e318231e46e"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"21977802","DateCompleted":{"Year":"2011","Month":"11","Day":"01"},"DateRevised":{"Year":"2011","Month":"10","Day":"07"},"Article":{"@attributes":{"PubModel":"Print"},"Journal":{"ISSN":"1438-3276","JournalIssue":{"@attributes":{"CitedMedium":"Print"},"Volume":"153","Issue":"38","PubDate":{"Year":"2011","Month":"Sep","Day":"22"}},"Title":"MMW Fortschritte der Medizin","ISOAbbreviation":"MMW Fortschr Med"},"ArticleTitle":"[Early diagnosis and treatment of dementia].","Pagination":{"MedlinePgn":"86-9; quiz 90"},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Frob\u00f6se","ForeName":"Teresa","Initials":"T","AffiliationInfo":{"Affiliation":"Klinik f\u00fcr Psychiatrie und Psychotherapie, Zentrum f\u00fcr kognitive St\u00f6rungen, Klinikum rechts der Isar,TU M\u00fcnchen t.froboese@lrz.tu-muenchen.de"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"}]},"Language":"ger","PublicationTypeList":{"PublicationType":["Journal Article","Review"]},"VernacularTitle":"Alzheimer, Lewy-K\u00f6rper-Krankheit oder Durchblutungsst\u00f6rung? Demenz: So wichtig ist die fr\u00fche Diagnose."},"MedlineJournalInfo":{"Country":"Germany","MedlineTA":"MMW Fortschr Med","NlmUniqueID":"100893959","ISSNLinking":"1438-3276"},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Alzheimer Disease","QualifierName":["classification","diagnosis","etiology","therapy"]},{"DescriptorName":"Combined Modality Therapy"},{"DescriptorName":"Dementia","QualifierName":["classification","diagnosis","etiology","therapy"]},{"DescriptorName":"Dementia, Multi-Infarct","QualifierName":["classification","diagnosis","etiology","therapy"]},{"DescriptorName":"Humans"},{"DescriptorName":"Lewy Body Disease","QualifierName":["classification","diagnosis","etiology","therapy"]},{"DescriptorName":"Mental Disorders","QualifierName":["classification","diagnosis","etiology","therapy"]},{"DescriptorName":"Neuropsychological Tests"},{"DescriptorName":"Risk Factors"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"entrez"},"Year":"2011","Month":"10","Day":"8","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2011","Month":"10","Day":"8","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2011","Month":"11","Day":"2","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":"21977802"}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"21958648","DateCompleted":{"Year":"2012","Month":"03","Day":"05"},"DateRevised":{"Year":"2016","Month":"11","Day":"25"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1873-3514","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"49","Issue":"13","PubDate":{"Year":"2011","Month":"Nov"}},"Title":"Neuropsychologia","ISOAbbreviation":"Neuropsychologia"},"ArticleTitle":"Relationship between occupation attributes and brain metabolism in frontotemporal dementia.","Pagination":{"MedlinePgn":"3699-703"},"ELocationID":"10.1016\/j.neuropsychologia.2011.09.025","Abstract":{"AbstractText":"Occupation has been associated with cognitive reserve in healthy aging and Alzheimer's disease. Here we assess the relationship between cerebral metabolic deficits in behavioral variant frontotemporal dementia (bvFTD) and occupation characteristics. Using factor analysis, we derived verbal, physical and visuospatial occupation scores from the US Department of Labor, Occupational Information Network and related these scores to regional cerebral metabolic rate of glucose utilization in 31 patients diagnosed with behavioral variant bvFTD, controlling for cognitive status (CERAD neuropsychological assessment battery), gender and education. Regression analyses showed a marked inverse association between glucose metabolism and (a) verbal occupation scores in left prefrontal cortex and, (b) physical occupation characteristics in right supplementary motor area. We concluded that, consistent with the cognitive reserve hypothesis, lifelong occupation characteristics are related to focal cerebral metabolic deficits in bvFTD. Specific occupation demands spanning decades may strengthen cognitive resistance to pathology.","CopyrightInformation":"Copyright \u00c2\u00a9 2011 Elsevier Ltd. All rights reserved."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Spreng","ForeName":"R Nathan","Initials":"RN","AffiliationInfo":{"Affiliation":"Department of Psychology, Harvard University, Cambridge, MA 02138, USA. nathan.spreng@gmail.com"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Drzezga","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Diehl-Schmid","ForeName":"Janine","Initials":"J"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Levine","ForeName":"Brian","Initials":"B"},{"@attributes":{"ValidYN":"Y"},"LastName":"Perneczky","ForeName":"Robert","Initials":"R"}]},"Language":"eng","GrantList":{"@attributes":{"CompleteYN":"Y"},"Grant":[{"GrantID":"HD42385-01","Acronym":"HD","Agency":"NICHD NIH HHS","Country":"United States"},{"GrantID":"MOP-108540","Agency":"Canadian Institutes of Health Research","Country":"Canada"}]},"PublicationTypeList":{"PublicationType":["Journal Article","Research Support, N.I.H., Extramural","Research Support, Non-U.S. Gov't"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2011","Month":"09","Day":"21"}},"MedlineJournalInfo":{"Country":"England","MedlineTA":"Neuropsychologia","NlmUniqueID":"0020713","ISSNLinking":"0028-3932"},"ChemicalList":{"Chemical":{"RegistryNumber":"0Z5B2CJX4D","NameOfSubstance":"Fluorodeoxyglucose F18"}},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Brain","QualifierName":["diagnostic imaging","metabolism"]},{"DescriptorName":"Brain Mapping"},{"DescriptorName":"Cognition Disorders","QualifierName":"etiology"},{"DescriptorName":"Factor Analysis, Statistical"},{"DescriptorName":"Female"},{"DescriptorName":"Fluorodeoxyglucose F18"},{"DescriptorName":"Frontotemporal Dementia","QualifierName":["complications","pathology","psychology"]},{"DescriptorName":"Humans"},{"DescriptorName":"Male"},{"DescriptorName":"Mental Status Schedule"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Motor Activity"},{"DescriptorName":"Neuropsychological Tests"},{"DescriptorName":"Occupations"},{"DescriptorName":"Photic Stimulation"},{"DescriptorName":"Positron-Emission Tomography"},{"DescriptorName":"Regression Analysis"},{"DescriptorName":"Space Perception"},{"DescriptorName":"Verbal Behavior"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2011","Month":"02","Day":"15"},{"@attributes":{"PubStatus":"revised"},"Year":"2011","Month":"07","Day":"28"},{"@attributes":{"PubStatus":"accepted"},"Year":"2011","Month":"09","Day":"15"},{"@attributes":{"PubStatus":"entrez"},"Year":"2011","Month":"10","Day":"1","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2011","Month":"10","Day":"1","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2012","Month":"3","Day":"6","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["21958648","S0028-3932(11)00432-5","10.1016\/j.neuropsychologia.2011.09.025"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"21786091","DateCompleted":{"Year":"2012","Month":"05","Day":"31"},"DateRevised":{"Year":"2018","Month":"11","Day":"13"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1433-8491","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"262","Issue":"1","PubDate":{"Year":"2012","Month":"Feb"}},"Title":"European archives of psychiatry and clinical neuroscience","ISOAbbreviation":"Eur Arch Psychiatry Clin Neurosci"},"ArticleTitle":"Perfusion abnormalities in mild cognitive impairment and mild dementia in Alzheimer's disease measured by pulsed arterial spin labeling MRI.","Pagination":{"MedlinePgn":"69-77"},"ELocationID":"10.1007\/s00406-011-0226-2","Abstract":{"AbstractText":"Alzheimer's disease (AD) and mild cognitive impairment (MCI), the transitional clinical stage between cognition in normal aging and dementia, have been linked to abnormalities in brain perfusion. Pulsed arterial spin labeling (PASL) is a magnetic resonance imaging (MRI) technique for evaluating brain perfusion. The present study aimed to determine regional perfusion abnormalities in 19 patients with mild dementia in AD and 24 patients with MCI as compared to 24 cognitively healthy elderly controls using PASL. In line with nuclear imaging methods, lower perfusion in patients with MCI and AD was found mainly in the parietal lobe, but also in angular and middle temporal areas as well as in the left middle occipital lobe and precuneus. Our data imply that PASL may be a valuable instrument for investigating perfusion changes in the transition from normal aging to dementia and indicate that it might become an alternative to nuclear imaging techniques in AD diagnostics."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Alexopoulos","ForeName":"Panagiotis","Initials":"P","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar der TU M\u00fcnchen, Ismaninger Str. 22, 81675, M\u00fcnchen, Germany. panos.alexopoulos@lrz.tu-muenchen.de"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Sorg","ForeName":"Christian","Initials":"C"},{"@attributes":{"ValidYN":"Y"},"LastName":"F\u00f6rschler","ForeName":"Annette","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Grimmer","ForeName":"Timo","Initials":"T"},{"@attributes":{"ValidYN":"Y"},"LastName":"Skokou","ForeName":"Maria","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Wohlschl\u00e4ger","ForeName":"Afra","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Perneczky","ForeName":"Robert","Initials":"R"},{"@attributes":{"ValidYN":"Y"},"LastName":"Zimmer","ForeName":"Claus","Initials":"C"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Preibisch","ForeName":"Christine","Initials":"C"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Research Support, Non-U.S. Gov't"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2011","Month":"07","Day":"24"}},"MedlineJournalInfo":{"Country":"Germany","MedlineTA":"Eur Arch Psychiatry Clin Neurosci","NlmUniqueID":"9103030","ISSNLinking":"0940-1334"},"ChemicalList":{"Chemical":{"RegistryNumber":"0","NameOfSubstance":"Spin Labels"}},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Aged, 80 and over"},{"DescriptorName":"Alzheimer Disease","QualifierName":["complications","physiopathology"]},{"DescriptorName":"Analysis of Variance"},{"DescriptorName":"Brain Mapping"},{"DescriptorName":"Cerebrovascular Circulation"},{"DescriptorName":"Cognitive Dysfunction","QualifierName":["diagnosis","physiopathology"]},{"DescriptorName":"Dementia","QualifierName":"complications"},{"DescriptorName":"Female"},{"DescriptorName":"Humans"},{"DescriptorName":"Male"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Neuropsychological Tests"},{"DescriptorName":"Perfusion Imaging","QualifierName":"methods"},{"DescriptorName":"Psychiatric Status Rating Scales"},{"DescriptorName":"Spin Labels"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2011","Month":"04","Day":"08"},{"@attributes":{"PubStatus":"accepted"},"Year":"2011","Month":"07","Day":"09"},{"@attributes":{"PubStatus":"entrez"},"Year":"2011","Month":"7","Day":"26","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2011","Month":"7","Day":"26","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2012","Month":"6","Day":"1","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["21786091","10.1007\/s00406-011-0226-2"]},"ReferenceList":{"Reference":[{"Citation":"Proc Natl Acad Sci U S A. 2001 Sep 11;98 (19):10966-71","ArticleIdList":{"ArticleId":"11526211"}},{"Citation":"J Neurosci Methods. 2008 Jul 30;172(2):277-82","ArticleIdList":{"ArticleId":"18582948"}},{"Citation":"J Neurosci. 2006 Oct 4;26(40):10222-31","ArticleIdList":{"ArticleId":"17021177"}},{"Citation":"Br Med Bull. 1984 Apr;40(2):187-90","ArticleIdList":{"ArticleId":"6744006"}},{"Citation":"Stat Methods Med Res. 2003 Oct;12(5):401-18","ArticleIdList":{"ArticleId":"14599003"}},{"Citation":"J Alzheimers Dis. 2010;20(3):871-80","ArticleIdList":{"ArticleId":"20413865"}},{"Citation":"Eur Arch Psychiatry Clin Neurosci. 2010 Oct;260(7):561-2","ArticleIdList":{"ArticleId":"20155362"}},{"Citation":"Neurology. 1999 Apr 22;52(7):1397-403","ArticleIdList":{"ArticleId":"10227624"}},{"Citation":"Neuroimage. 2008 Oct 1;42(4):1267-74","ArticleIdList":{"ArticleId":"18602481"}},{"Citation":"Mil Med. 1980 Aug;145(8):521-4","ArticleIdList":{"ArticleId":"6774283"}},{"Citation":"Dement Geriatr Cogn Disord. 2004;17 (3):207-14","ArticleIdList":{"ArticleId":"14739546"}},{"Citation":"Am J Alzheimers Dis Other Demen. 2009 Apr-May;24(2):95-121","ArticleIdList":{"ArticleId":"19116299"}},{"Citation":"Curr Neurol Neurosci Rep. 2006 Nov;6(6):496-503","ArticleIdList":{"ArticleId":"17074285"}},{"Citation":"Neuropsychologia. 2008;46(6):1624-35","ArticleIdList":{"ArticleId":"18206188"}},{"Citation":"Alzheimers Dement. 2011 Mar;7(2):185-96","ArticleIdList":{"ArticleId":"21074500"}},{"Citation":"Am J Geriatr Psychiatry. 2004 Nov-Dec;12 (6):554-70","ArticleIdList":{"ArticleId":"15545324"}},{"Citation":"Nervenarzt. 2010 May;81(5):602-6","ArticleIdList":{"ArticleId":"20221742"}},{"Citation":"Br J Radiol. 2007 Dec;80 Spec No 2:S160-7","ArticleIdList":{"ArticleId":"18445746"}},{"Citation":"Dement Geriatr Cogn Disord. 2006;22(5-6):385-91","ArticleIdList":{"ArticleId":"16960447"}},{"Citation":"Nat Rev Neurosci. 2003 Nov;4(11):863-72","ArticleIdList":{"ArticleId":"14595398"}},{"Citation":"Neuroimage. 2004;23 Suppl 1:S220-33","ArticleIdList":{"ArticleId":"15501093"}},{"Citation":"J Magn Reson Imaging. 2006 Dec;24(6):1229-35","ArticleIdList":{"ArticleId":"17094105"}},{"Citation":"Magn Reson Med. 1998 May;39(5):702-8","ArticleIdList":{"ArticleId":"9581600"}},{"Citation":"Radiology. 2009 Mar;250(3):856-66","ArticleIdList":{"ArticleId":"19164119"}},{"Citation":"J Psychiatr Res. 1975 Nov;12(3):189-98","ArticleIdList":{"ArticleId":"1202204"}},{"Citation":"Proc Natl Acad Sci U S A. 1994 Jan 4;91(1):33-7","ArticleIdList":{"ArticleId":"8278387"}},{"Citation":"Dement Geriatr Cogn Disord. 2006;22(1):27-34","ArticleIdList":{"ArticleId":"16679762"}},{"Citation":"Magn Reson Med. 2005 Jan;53(1):15-21","ArticleIdList":{"ArticleId":"15690497"}},{"Citation":"PLoS One. 2009;4(4):e5088","ArticleIdList":{"ArticleId":"19352431"}},{"Citation":"Stat Methods Med Res. 2003 Oct;12(5):419-46","ArticleIdList":{"ArticleId":"14599004"}},{"Citation":"Hum Brain Mapp. 1999;7(4):254-66","ArticleIdList":{"ArticleId":"10408769"}},{"Citation":"Arch Neurol. 2002 Sep;59(9):1381-9","ArticleIdList":{"ArticleId":"12223024"}},{"Citation":"Magn Reson Med. 1999 Jun;41(6):1246-54","ArticleIdList":{"ArticleId":"10371458"}},{"Citation":"Eur Arch Psychiatry Clin Neurosci. 2010 Sep;260(6):441-2","ArticleIdList":{"ArticleId":"20845022"}},{"Citation":"Science. 1984 Sep 14;225(4667):1168-70","ArticleIdList":{"ArticleId":"6474172"}},{"Citation":"AJNR Am J Neuroradiol. 2004 Aug;25(7):1199-204","ArticleIdList":{"ArticleId":"15313710"}},{"Citation":"Trends Mol Med. 2008 Feb;14(2):45-53","ArticleIdList":{"ArticleId":"18218341"}},{"Citation":"Neuroimage. 2002 Jan;15(1):273-89","ArticleIdList":{"ArticleId":"11771995"}},{"Citation":"Eur J Nucl Med Mol Imaging. 2003 Aug;30(8):1104-13","ArticleIdList":{"ArticleId":"12764551"}},{"Citation":"Neurology. 2005 Jun 14;64(11):1860-7","ArticleIdList":{"ArticleId":"15955934"}},{"Citation":"J Cereb Blood Flow Metab. 1988 Dec;8(6):783-9","ArticleIdList":{"ArticleId":"3192645"}},{"Citation":"Magn Reson Med. 1998 Sep;40(3):383-96","ArticleIdList":{"ArticleId":"9727941"}},{"Citation":"Brain Res. 2010 Feb 22;1315:119-27","ArticleIdList":{"ArticleId":"20026320"}},{"Citation":"J Intern Med. 2004 Sep;256(3):240-6","ArticleIdList":{"ArticleId":"15324367"}},{"Citation":"J Neurol Neurosurg Psychiatry. 2007 Mar;78(3):240-7","ArticleIdList":{"ArticleId":"17056633"}},{"Citation":"AJNR Am J Neuroradiol. 2009 Jun;30(6):1134-41","ArticleIdList":{"ArticleId":"19357387"}},{"Citation":"Radiology. 2005 Mar;234(3):851-9","ArticleIdList":{"ArticleId":"15734937"}},{"Citation":"Brain. 2002 Aug;125(Pt 8):1772-81","ArticleIdList":{"ArticleId":"12135968"}},{"Citation":"Exp Gerontol. 2010 Jan;45(1):23-9","ArticleIdList":{"ArticleId":"19698775"}},{"Citation":"Proc Biol Sci. 2001 Sep 7;268(1478):1775-81","ArticleIdList":{"ArticleId":"11522195"}},{"Citation":"Neurology. 1984 Jul;34(7):939-44","ArticleIdList":{"ArticleId":"6610841"}},{"Citation":"Neurobiol Aging. 1991 Jul-Aug;12(4):295-312","ArticleIdList":{"ArticleId":"1961359"}}]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"21740614","DateCompleted":{"Year":"2014","Month":"04","Day":"14"},"DateRevised":{"Year":"2018","Month":"12","Day":"02"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1741-203X","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"23","Issue":"9","PubDate":{"Year":"2011","Month":"Nov"}},"Title":"International psychogeriatrics","ISOAbbreviation":"Int Psychogeriatr"},"ArticleTitle":"The clinical significance of cognition-focused interventions for cognitively impaired older adults: a systematic review of randomized controlled trials.","Pagination":{"MedlinePgn":"1364-75"},"ELocationID":"10.1017\/S1041610211001001","Abstract":{"AbstractText":["Cognitive stimulation, training or rehabilitation can achieve modest, skill-specific gains in cognitively healthy older adults. With regard to the limited efficacy of currently available anti-dementia drugs it is crucial to investigate whether such treatments also provide clinically meaningful benefits to cognitively impaired older individuals.","We conducted a systematic review of randomized controlled trials evaluating cognition-focused interventions in participants with mild cognitive impairment or dementia. Meta-analytic strategies were used to calculate effect sizes.","Cognition-focused interventions confer small and inconsistent effects on trained cognitive skills which, according to some studies, translate into gains on general cognitive ability. Instruments measuring such effects such as the Mini-Mental State Examination (MMSE) or the Alzheimer's Disease Assessment Scale, cognitive part (ADAS-Cog) show standardized mean differences of 0.20 and 0.30, respectively, which are comparable with those of current antidementia drug treatments. However, convincing evidence of clinical significance was only obtained from single trials in terms of delay of cognitive decline, improvement in activities of daily living, or enhanced attainment of personally relevant goals.","The potential of cognition-focused interventions has probably been obscured by the methodological inconsistencies and limitations of the clinical studies conducted thus far. Further randomized controlled trials on the efficacy of these treatment modalities are required using optimized and consistent methods. Emphasis should be placed on tailoring interventions to individual needs and resources while maintaining a high level of standardization, on implementing newly acquired skills and strategies in the everyday context, on appropriate treatment duration, and on including person-centered outcomes."]},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander F","Initials":"AF","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany. alexander.kurz@lrz.tum.de"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Leucht","ForeName":"Stefan","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"Lautenschlager","ForeName":"Nicola T","Initials":"NT"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Review","Systematic Review"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2011","Month":"07","Day":"11"}},"MedlineJournalInfo":{"Country":"England","MedlineTA":"Int Psychogeriatr","NlmUniqueID":"9007918","ISSNLinking":"1041-6102"},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Cognition"},{"DescriptorName":"Cognitive Behavioral Therapy"},{"DescriptorName":"Cognitive Dysfunction","QualifierName":"therapy"},{"DescriptorName":"Dementia","QualifierName":"therapy"},{"DescriptorName":"Humans"},{"DescriptorName":"Randomized Controlled Trials as Topic"},{"DescriptorName":"Treatment Outcome"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"entrez"},"Year":"2011","Month":"7","Day":"12","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2011","Month":"7","Day":"12","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2014","Month":"4","Day":"15","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["21740614","S1041610211001001","10.1017\/S1041610211001001"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"21705868","DateCompleted":{"Year":"2012","Month":"09","Day":"13"},"DateRevised":{"Year":"2018","Month":"12","Day":"01"},"Article":{"@attributes":{"PubModel":"Print"},"Journal":{"ISSN":"1546-4156","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"26","Issue":"2","PubDate":{"MedlineDate":"2012 Apr-Jun"}},"Title":"Alzheimer disease and associated disorders","ISOAbbreviation":"Alzheimer Dis Assoc Disord"},"ArticleTitle":"Health care utilization in frontotemporal lobar degeneration.","Pagination":{"MedlinePgn":"166-70"},"ELocationID":"10.1097\/WAD.0b013e3182263edc","Abstract":{"AbstractText":"The aim of this study was to find out how patients with frontotemporal lobar degeneration are cared for, to which extent family caregivers utilize professional support, and which medical treatment patients receive. Using a standardized interview, information was obtained from the caregivers of 124 patients with frontotemporal lobar degeneration on patient survival, sociodemographic characteristics, living arrangements, health care situation including formal and informal support, and pharmacological and nonpharmacological treatment. At the time of the interview, 72 patients were still alive, whereas 52 patients had already died before the interview. Fifty-seven percent of the patients lived at home. At the time of the interview\/before death, respectively, 43% of the patients had been institutionalized into a nursing home on average 6.4 years after the onset of first symptoms. The mortality risk for patients who were admitted to a nursing home was 5 times higher than for those who were cared for at home. Fifty-one percent of the patients were treated with antidepressants, 23% with antipsychotics, and 34% with cholinesterase inhibitors or memantine. Forty percent of the patients received nonpharmacological treatment."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Diehl-Schmid","ForeName":"Janine","Initials":"J","AffiliationInfo":{"Affiliation":"Department of Psychiatry, TU M\u00fcnchen, Ismaninger Str. 2281675, M\u00fcnchen, Germany. janine.schmid@lrz.tum.de"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Last","ForeName":"Dirk","Initials":"D"},{"@attributes":{"ValidYN":"Y"},"LastName":"Schuster","ForeName":"Tibor","Initials":"T"},{"@attributes":{"ValidYN":"Y"},"LastName":"F\u00f6rstl","ForeName":"Hans","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Schneider-Schelte","ForeName":"Helga","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"}]},"Language":"eng","PublicationTypeList":{"PublicationType":"Journal Article"}},"MedlineJournalInfo":{"Country":"United States","MedlineTA":"Alzheimer Dis Assoc Disord","NlmUniqueID":"8704771","ISSNLinking":"0893-0341"},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Aged, 80 and over"},{"DescriptorName":"Caregivers"},{"DescriptorName":"Delivery of Health Care","QualifierName":"statistics & numerical data"},{"DescriptorName":"Female"},{"DescriptorName":"Frontotemporal Lobar Degeneration","QualifierName":["mortality","nursing"]},{"DescriptorName":"Home Nursing","QualifierName":"statistics & numerical data"},{"DescriptorName":"Homes for the Aged"},{"DescriptorName":"Humans"},{"DescriptorName":"Male"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Nursing Homes"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"entrez"},"Year":"2011","Month":"6","Day":"28","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2011","Month":"6","Day":"28","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2012","Month":"9","Day":"14","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["21705868","10.1097\/WAD.0b013e3182263edc"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"21679929","DateCompleted":{"Year":"2012","Month":"08","Day":"13"},"DateRevised":{"Year":"2016","Month":"11","Day":"25"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1873-2402","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"71","Issue":"9","PubDate":{"Year":"2012","Month":"May","Day":"01"}},"Title":"Biological psychiatry","ISOAbbreviation":"Biol Psychiatry"},"ArticleTitle":"Regional expansion of hypometabolism in Alzheimer's disease follows amyloid deposition with temporal delay.","Pagination":{"MedlinePgn":"792-7"},"ELocationID":"10.1016\/j.biopsych.2011.04.023","Abstract":{"AbstractText":["Cross-sectional imaging studies suggest that patterns of hypometabolism (measured by [(18)F] fluorodeoxyglucose positron emission tomography [FDG-PET]) and amyloid deposition (measured by [(11)C] Pittsburgh Compound B [PiB]- PET) in Alzheimer's disease (AD) show some overlap with each other. This indicates that neuronal dysfunction might spread within the anatomical pattern of amyloid deposition. The aim of this study was to examine longitudinal regional patterns of amyloid deposition and hypometabolism in the same population of mild AD subjects and to establish their regional relationship to each other.","Twenty patients with mild AD underwent baseline (BL) and follow-up (FU) examination with [(18)F] FDG-PET and [(11)C] PiB-PET. Voxel-by-voxel statistical group comparison (SPM5) was performed between patient BL- and FU-PET data as well as between patients and 15 PiB-negative elderly control subjects, who had undergone identical imaging procedures. To obtain objective measures of regional overlap, Dice similarity coefficients (DSC) between the imaging findings were calculated.","Compared with elderly control subjects, AD patients showed typical patterns of BL hypometabolism and BL amyloid deposition, with a similarity of 40% (DSC). Amyloid deposition was more extended than hypometabolism at BL and showed only minor changes over time, whereas significant expansion of hypometabolism was observed, almost exclusively within areas already affected by BL amyloid deposition. Thus, increased similarity of FU hypometabolism with BL amyloid deposition was found (DSC: 47%).","Longitudinal regional expansion of cerebral hypometabolism, as a measure of neuronal dysfunction in AD, seems to follow the anatomical pattern of amyloid deposition with temporal delay. This indicates that amyloid-based disruption of neuronal integrity might contribute to the regional expansion of neuronal dysfunction."],"CopyrightInformation":"Copyright \u00a9 2012 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"F\u00f6rster","ForeName":"Stefan","Initials":"S","AffiliationInfo":{"Affiliation":"Department of Nuclear Medicine, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany. stefan.foerster@lrz.tum.de"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Grimmer","ForeName":"Timo","Initials":"T"},{"@attributes":{"ValidYN":"Y"},"LastName":"Miederer","ForeName":"Isabelle","Initials":"I"},{"@attributes":{"ValidYN":"Y"},"LastName":"Henriksen","ForeName":"Gjermund","Initials":"G"},{"@attributes":{"ValidYN":"Y"},"LastName":"Yousefi","ForeName":"Behrooz Hooshyar","Initials":"BH"},{"@attributes":{"ValidYN":"Y"},"LastName":"Graner","ForeName":"Philipp","Initials":"P"},{"@attributes":{"ValidYN":"Y"},"LastName":"Wester","ForeName":"Hans-J\u00fcrgen","Initials":"HJ"},{"@attributes":{"ValidYN":"Y"},"LastName":"F\u00f6rstl","ForeName":"Hans","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Dickerson","ForeName":"Bradford C","Initials":"BC"},{"@attributes":{"ValidYN":"Y"},"LastName":"Bartenstein","ForeName":"Peter","Initials":"P"},{"@attributes":{"ValidYN":"Y"},"LastName":"Drzezga","ForeName":"Alexander","Initials":"A"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Research Support, Non-U.S. Gov't"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2011","Month":"06","Day":"15"}},"MedlineJournalInfo":{"Country":"United States","MedlineTA":"Biol Psychiatry","NlmUniqueID":"0213264","ISSNLinking":"0006-3223"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole"},{"RegistryNumber":"0","NameOfSubstance":"Amyloid"},{"RegistryNumber":"0","NameOfSubstance":"Aniline Compounds"},{"RegistryNumber":"0","NameOfSubstance":"Biomarkers"},{"RegistryNumber":"0","NameOfSubstance":"Radiopharmaceuticals"},{"RegistryNumber":"0","NameOfSubstance":"Thiazoles"},{"RegistryNumber":"0Z5B2CJX4D","NameOfSubstance":"Fluorodeoxyglucose F18"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Alzheimer Disease","QualifierName":["diagnostic imaging","metabolism"]},{"DescriptorName":"Amyloid","QualifierName":"metabolism"},{"DescriptorName":"Aniline Compounds"},{"DescriptorName":"Biomarkers","QualifierName":"metabolism"},{"DescriptorName":"Brain","QualifierName":["diagnostic imaging","metabolism"]},{"DescriptorName":"Case-Control Studies"},{"DescriptorName":"Female"},{"DescriptorName":"Fluorodeoxyglucose F18"},{"DescriptorName":"Functional Neuroimaging","QualifierName":["methods","psychology"]},{"DescriptorName":"Humans"},{"DescriptorName":"Male"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Neuropsychological Tests"},{"DescriptorName":"Positron-Emission Tomography","QualifierName":["methods","psychology"]},{"DescriptorName":"Radiopharmaceuticals"},{"DescriptorName":"Thiazoles"},{"DescriptorName":"Time Factors"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2010","Month":"11","Day":"06"},{"@attributes":{"PubStatus":"revised"},"Year":"2011","Month":"03","Day":"26"},{"@attributes":{"PubStatus":"accepted"},"Year":"2011","Month":"04","Day":"20"},{"@attributes":{"PubStatus":"entrez"},"Year":"2011","Month":"6","Day":"18","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2011","Month":"6","Day":"18","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2012","Month":"8","Day":"14","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["21679929","S0006-3223(11)00484-7","10.1016\/j.biopsych.2011.04.023"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"21471647","DateCompleted":{"Year":"2011","Month":"11","Day":"15"},"DateRevised":{"Year":"2013","Month":"11","Day":"21"},"Article":{"@attributes":{"PubModel":"Print"},"Journal":{"ISSN":"1875-8908","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"25","Issue":"3","PubDate":{"Year":"2011"}},"Title":"Journal of Alzheimer's disease : JAD","ISOAbbreviation":"J Alzheimers Dis"},"ArticleTitle":"Sustained effects of once-daily memantine treatment on cognition and functional communication skills in patients with moderate to severe Alzheimer's disease: results of a 16-week open-label trial.","Pagination":{"MedlinePgn":"463-75"},"ELocationID":"10.3233\/JAD-2011-101929","Abstract":{"AbstractText":"The present study evaluated the effects of once-daily memantine (20 mg) treatment on cognition and communication in patients with moderate to severe Alzheimer's disease (AD). In a multicenter, single-arm open-label study, outpatients diagnosed with AD (MMSE < 20; n = 97) were titrated from 5 mg to 20 mg once-daily memantine over 4 weeks. Once-daily memantine treatment (20 mg) was then continued for 8 weeks, followed by a 4-week wash-out period. The primary efficacy endpoint was the change from baseline in the Consortium to Establish a Registry for Alzheimer's Disease -Neuropsychological Battery (CERAD-NP) total score. Secondary efficacy endpoints included change from baseline in Functional Communication Language Inventory (FLCI) and ADCS-ADL19 total score, and the response from baseline in Clinical Global Impression of Change (CGI-C). The CERAD-NP total score improved significantly after 12 weeks of once-daily memantine treatment compared with baseline (5.9 \u00b1 8.8; p < 0.0001). The FLCI total score improved significantly after 12 weeks compared with baseline (4.4 \u00b1 6.8; p < 0.0001). These significant improvements were already observed after 4 and 8 weeks of once-daily memantine treatment and persisted after a 4-week wash-out period. ADCS-ADL19 total scores showed only slight increases from baseline, and CGI-C indicated that the majority of patients experienced an improvement or stabilization of the disease after 12 weeks. At least one Treatment-Emergent Adverse Event was reported by 38 (39.2%) patients. In patients with moderate to severe AD, once-daily memantine (20 mg) treatment significantly improved cognition and functional communication and was found to have a favorable safety and tolerability profile."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Schulz","ForeName":"J\u00f6rg B","Initials":"JB","AffiliationInfo":{"Affiliation":"Department of Neurology, University Medical Center, RWTH Aachen, Aachen, Germany. jschulz@ukaachen.de"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Rainer","ForeName":"Michael","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kl\u00fcnemann","ForeName":"Hans-Hermann","Initials":"HH"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Wolf","ForeName":"Stefanie","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"Sternberg","ForeName":"Kati","Initials":"K"},{"@attributes":{"ValidYN":"Y"},"LastName":"Tennigkeit","ForeName":"Frank","Initials":"F"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Clinical Trial","Journal Article","Multicenter Study","Research Support, Non-U.S. Gov't"]}},"MedlineJournalInfo":{"Country":"Netherlands","MedlineTA":"J Alzheimers Dis","NlmUniqueID":"9814863","ISSNLinking":"1387-2877"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"Excitatory Amino Acid Antagonists"},{"RegistryNumber":"W8O17SJF3T","NameOfSubstance":"Memantine"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Activities of Daily Living"},{"DescriptorName":"Aged"},{"DescriptorName":"Aged, 80 and over"},{"DescriptorName":"Alzheimer Disease","QualifierName":["complications","drug therapy"]},{"DescriptorName":"Cognition Disorders","QualifierName":["drug therapy","etiology"]},{"DescriptorName":"Communication"},{"DescriptorName":"Dose-Response Relationship, Drug"},{"DescriptorName":"Drug Administration Schedule"},{"DescriptorName":"Excitatory Amino Acid Antagonists","QualifierName":"therapeutic use"},{"DescriptorName":"Female"},{"DescriptorName":"Follow-Up Studies"},{"DescriptorName":"Humans"},{"DescriptorName":"Male"},{"DescriptorName":"Memantine","QualifierName":"therapeutic use"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Neuropsychological Tests"},{"DescriptorName":"Psychiatric Status Rating Scales"},{"DescriptorName":"Reproducibility of Results"},{"DescriptorName":"Speech Disorders","QualifierName":["drug therapy","etiology"]}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"entrez"},"Year":"2011","Month":"4","Day":"8","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2011","Month":"4","Day":"8","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2011","Month":"11","Day":"16","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["21471647","86UG68625K136376","10.3233\/JAD-2011-101929"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"21422524","DateCompleted":{"Year":"2011","Month":"09","Day":"30"},"DateRevised":{"Year":"2011","Month":"04","Day":"28"},"Article":{"@attributes":{"PubModel":"Print"},"Journal":{"ISSN":"1875-8908","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"24 Suppl 2","PubDate":{"Year":"2011"}},"Title":"Journal of Alzheimer's disease : JAD","ISOAbbreviation":"J Alzheimers Dis"},"ArticleTitle":"Amyloid clearance as a treatment target against Alzheimer's disease.","Pagination":{"MedlinePgn":"61-73"},"ELocationID":"10.3233\/JAD-2011-102139","Abstract":{"AbstractText":"An imbalance between production and clearance of the amyloid-\u03b2 peptide (A\u03b2) is a key momentum of the complex pathological cascade of Alzheimer's disease (AD). It is caused by overproduction of A\u03b2 or, more frequently, by impaired clearance from brain. Clearance can be reduced by increased aggregation, defective degradation, disturbed balance of transport across the blood-brain barrier, or inefficient peripheral removal of the peptide. In recent years these mechanisms have become targets of pharmacological interventions. Although several compounds have been discarded on the grounds of limited clinical efficacy, all major clearance-related approaches still hold promise. Some drug candidates have advanced to Phase III trials including anti-A\u03b2 antibodies, metal complexing agents, ginseng extracts, and intravenous immunoglobulins. Data are currently not available from these studies that might allow an evaluation of efficacy and safety. Phase II trials on active and passive immunization have demonstrated a striking discrepancy between significant neurobiological effects regarding the removal of A\u03b2 deposits and minor clinical outcomes. This does not preclude the possibility that clearance-related strategies have the potential of saving neurons and synapses via reducing the levels of soluble and particularly toxic A\u03b2 species in brain. It may take longer than projected in ongoing trials for such neurobiological effects to translate into measurable changes of clinical progression."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany. alexander.kurz@lrz.tum.de"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Perneczky","ForeName":"Robert","Initials":"R"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Review"]}},"MedlineJournalInfo":{"Country":"Netherlands","MedlineTA":"J Alzheimers Dis","NlmUniqueID":"9814863","ISSNLinking":"1387-2877"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"Amyloid beta-Peptides"},{"RegistryNumber":"0","NameOfSubstance":"Antipsychotic Agents"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Alzheimer Disease","QualifierName":["drug therapy","metabolism","pathology"]},{"DescriptorName":"Amyloid beta-Peptides","QualifierName":["drug effects","metabolism"]},{"DescriptorName":"Animals"},{"DescriptorName":"Antipsychotic Agents","QualifierName":["pharmacology","therapeutic use"]},{"DescriptorName":"Blood-Brain Barrier","QualifierName":"metabolism"},{"DescriptorName":"Humans"},{"DescriptorName":"Models, Biological"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"entrez"},"Year":"2011","Month":"3","Day":"23","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2011","Month":"3","Day":"23","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2011","Month":"10","Day":"1","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["21422524","B75441416776W582","10.3233\/JAD-2011-102139"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"21422523","DateCompleted":{"Year":"2011","Month":"11","Day":"04"},"DateRevised":{"Year":"2013","Month":"11","Day":"21"},"Article":{"@attributes":{"PubModel":"Print"},"Journal":{"ISSN":"1875-8908","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"25","Issue":"2","PubDate":{"Year":"2011"}},"Title":"Journal of Alzheimer's disease : JAD","ISOAbbreviation":"J Alzheimers Dis"},"ArticleTitle":"Disconnection of frontal and parietal areas contributes to impaired attention in very early Alzheimer's disease.","Pagination":{"MedlinePgn":"309-21"},"ELocationID":"10.3233\/JAD-2011-102154","Abstract":{"AbstractText":"In Alzheimer's disease (AD), the loss of cerebral connectivity has been evidenced by numerous studies. There is growing evidence of attention related failures already in prodromal stages of AD; however, connectivity changes within attention networks have been rarely reported. Here we focused on effective connectivity of top-down attention control in patients with prodromal Alzheimer's disease (pAD). We scanned 15 pAD patients and 16 healthy elderly using the Attentional Network Task and determined effective connectivity within a cingulo-fronto-parietal network using Dynamic Causal Modeling. We related connectivity parameters to structural and behavioral parameters (gray matter volume as well as reaction time) to examine the relation between affected domains. Our analyses revealed that effective connectivity from the right middle frontal gyrus to the left superior parietal cortex as well as from the right to the left superior parietal gyrus was reduced in pAD patients. Furthermore, we found that, effective connectivity varied as a function of GM volume in the patient group: right middle frontal gray matter volume significantly correlated with connectivity from the right parietal cortex to the right middle frontal gyrus as well as from the middle frontal gyrus to the anterior cingulate cortex. In addition, inter-parietal connectivity was correlated to right and left parietal gray matter volume. We conclude that, at very early stages of AD, the reduction of effective connectivity in fronto-parietal circuits is related to regional gray matter volume and contributes to impairments in top-down attentional control."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Neufang","ForeName":"Susanne","Initials":"S","AffiliationInfo":{"Affiliation":"Department of Neuroradiology, Klinikum Rechts der Isar, Technical University Munich, Munich, Germany. Neufang@lrz.tumuenchen.de"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Akhrif","ForeName":"Atae","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Riedl","ForeName":"Valentin","Initials":"V"},{"@attributes":{"ValidYN":"Y"},"LastName":"F\u00f6rstl","ForeName":"Hans","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Zimmer","ForeName":"Claus","Initials":"C"},{"@attributes":{"ValidYN":"Y"},"LastName":"Sorg","ForeName":"Christian","Initials":"C"},{"@attributes":{"ValidYN":"Y"},"LastName":"Wohlschl\u00e4ger","ForeName":"Afra M","Initials":"AM"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Research Support, Non-U.S. Gov't"]}},"MedlineJournalInfo":{"Country":"Netherlands","MedlineTA":"J Alzheimers Dis","NlmUniqueID":"9814863","ISSNLinking":"1387-2877"},"ChemicalList":{"Chemical":{"RegistryNumber":"S88TT14065","NameOfSubstance":"Oxygen"}},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Alzheimer Disease","QualifierName":"complications"},{"DescriptorName":"Attention Deficit Disorder with Hyperactivity","QualifierName":["etiology","pathology"]},{"DescriptorName":"Brain Mapping"},{"DescriptorName":"Female"},{"DescriptorName":"Frontal Lobe","QualifierName":["blood supply","pathology"]},{"DescriptorName":"Functional Laterality"},{"DescriptorName":"Humans"},{"DescriptorName":"Image Processing, Computer-Assisted"},{"DescriptorName":"Linear Models"},{"DescriptorName":"Magnetic Resonance Imaging"},{"DescriptorName":"Male"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Neural Pathways","QualifierName":"pathology"},{"DescriptorName":"Neuropsychological Tests"},{"DescriptorName":"Oxygen","QualifierName":"blood"},{"DescriptorName":"Parietal Lobe","QualifierName":["blood supply","pathology"]},{"DescriptorName":"Psychiatric Status Rating Scales"},{"DescriptorName":"Reaction Time"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"entrez"},"Year":"2011","Month":"3","Day":"23","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2011","Month":"3","Day":"23","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2011","Month":"11","Day":"5","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["21422523","UL1136X456M114T0","10.3233\/JAD-2011-102154"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"21422522","DateCompleted":{"Year":"2011","Month":"11","Day":"04"},"DateRevised":{"Year":"2011","Month":"07","Day":"04"},"Article":{"@attributes":{"PubModel":"Print"},"Journal":{"ISSN":"1875-8908","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"25","Issue":"2","PubDate":{"Year":"2011"}},"Title":"Journal of Alzheimer's disease : JAD","ISOAbbreviation":"J Alzheimers Dis"},"ArticleTitle":"Grey-matter atrophy in Alzheimer's disease is asymmetric but not lateralized.","Pagination":{"MedlinePgn":"347-57"},"ELocationID":"10.3233\/JAD-2011-110041","Abstract":{"AbstractText":"In Alzheimer's disease (AD), brain atrophy has been proposed to be left lateralized. Here, we reinvestigated the asymmetry and lateralization (i.e., asymmetry directed toward one hemisphere) of grey-matter (GM) distribution in 35 patients with AD, 24 patients with amnestic mild cognitive impairment (aMCI, a state of increased risk for AD), and 30 age-matched healthy controls (HC). We analyzed GM distribution by applying voxel-based morphometry (VBM) including analyses for asymmetry and lateralization. When comparing MCI with AD patients, VBM revealed GM loss in the entorhinal, temporoparietal, dorsofrontal, and occipital cortices as well as in the precuneus; when comparing HCs with MCI patients, we found similar differences, which were less pronounced especially within the temporoparietal cortex and precuneus. Analyses of regional asymmetry and regional lateralization as well as global lateralization did not yield significant results. However, lobar asymmetry of the temporal, parietal, and occipital lobes increased from HC to AD. Moreover, in aMCI and AD patients, performance of language-based neuropsychological tests correlated with lateralization of GM loss to the left hemisphere. We conclude that, in principle, brain atrophy in AD is asymmetric rather than lateralized. At the individual level however, asymmetry contributes to cognitive deficits."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Derflinger","ForeName":"Sabine","Initials":"S","AffiliationInfo":{"Affiliation":"Department of Neurology, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Sorg","ForeName":"Christian","Initials":"C"},{"@attributes":{"ValidYN":"Y"},"LastName":"Gaser","ForeName":"Christian","Initials":"C"},{"@attributes":{"ValidYN":"Y"},"LastName":"Myers","ForeName":"Nicholas","Initials":"N"},{"@attributes":{"ValidYN":"Y"},"LastName":"Arsic","ForeName":"Milan","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Zimmer","ForeName":"Claus","Initials":"C"},{"@attributes":{"ValidYN":"Y"},"LastName":"Wohlschl\u00e4ger","ForeName":"Afra","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"M\u00fchlau","ForeName":"Mark","Initials":"M"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Research Support, Non-U.S. Gov't"]}},"MedlineJournalInfo":{"Country":"Netherlands","MedlineTA":"J Alzheimers Dis","NlmUniqueID":"9814863","ISSNLinking":"1387-2877"},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Aged, 80 and over"},{"DescriptorName":"Alzheimer Disease","QualifierName":["complications","pathology"]},{"DescriptorName":"Analysis of Variance"},{"DescriptorName":"Atrophy","QualifierName":"etiology"},{"DescriptorName":"Brain","QualifierName":"pathology"},{"DescriptorName":"Brain Mapping"},{"DescriptorName":"Cognition Disorders","QualifierName":["complications","pathology"]},{"DescriptorName":"Female"},{"DescriptorName":"Functional Laterality"},{"DescriptorName":"Humans"},{"DescriptorName":"Image Processing, Computer-Assisted"},{"DescriptorName":"Magnetic Resonance Imaging"},{"DescriptorName":"Male"},{"DescriptorName":"Mental Status Schedule"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Neuropsychological Tests"},{"DescriptorName":"Statistics as Topic"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"entrez"},"Year":"2011","Month":"3","Day":"23","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2011","Month":"3","Day":"23","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2011","Month":"11","Day":"5","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["21422522","VJ2200470Q19153P","10.3233\/JAD-2011-110041"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"21248374","DateCompleted":{"Year":"2011","Month":"06","Day":"13"},"DateRevised":{"Year":"2018","Month":"11","Day":"13"},"Article":{"@attributes":{"PubModel":"Print"},"Journal":{"ISSN":"1945-4589","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"3","Issue":"1","PubDate":{"Year":"2011","Month":"Jan"}},"Title":"Aging","ISOAbbreviation":"Aging (Albany NY)"},"ArticleTitle":"The role of glyoxalases for sugar stress and aging, with relevance for dyskinesia, anxiety, dementia and Parkinson's disease.","Pagination":{"MedlinePgn":"5-9"},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Auburger","ForeName":"Georg","Initials":"G","AffiliationInfo":{"Affiliation":"Exp. Neurology, Department of Neurology, Goethe University Medical School, Frankfurt am Main, Germany. auburger@em.uni\u2010frankfurt.de"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Comment","Journal Article"]}},"MedlineJournalInfo":{"Country":"United States","MedlineTA":"Aging (Albany NY)","NlmUniqueID":"101508617","ISSNLinking":"1945-4589"},"ChemicalList":{"Chemical":{"RegistryNumber":"EC 4.4.1.5","NameOfSubstance":"Lactoylglutathione Lyase"}},"CitationSubset":"IM","CommentsCorrectionsList":{"CommentsCorrections":{"@attributes":{"RefType":"CommentOn"},"RefSource":"Aging (Albany NY). 2010 Dec;2(12):969-80","PMID":"21212464"}},"MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aging","QualifierName":"physiology"},{"DescriptorName":"Animals"},{"DescriptorName":"Anxiety","QualifierName":"physiopathology"},{"DescriptorName":"Carbohydrate Metabolism"},{"DescriptorName":"Dementia","QualifierName":"physiopathology"},{"DescriptorName":"Dyskinesias","QualifierName":"physiopathology"},{"DescriptorName":"Humans"},{"DescriptorName":"Lactoylglutathione Lyase","QualifierName":["genetics","metabolism"]},{"DescriptorName":"Parkinson Disease","QualifierName":"physiopathology"},{"DescriptorName":"Stress, Physiological"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"entrez"},"Year":"2011","Month":"1","Day":"21","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2011","Month":"1","Day":"21","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2011","Month":"6","Day":"15","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["21248374","100258","PMC3047129","10.18632\/aging.100258"]},"ReferenceList":{"Reference":[{"Citation":"Nat Cell Biol. 2009 Jul;11(7):852-8","ArticleIdList":{"ArticleId":"19543272"}},{"Citation":"Metab Eng. 2001 Jul;3(3):218-25","ArticleIdList":{"ArticleId":"11461144"}},{"Citation":"Am J Med Genet A. 2004 Nov 15;131(1):11-7","ArticleIdList":{"ArticleId":"15386471"}},{"Citation":"PLoS One. 2009;4(3):e4649","ArticleIdList":{"ArticleId":"19266052"}},{"Citation":"Aging Cell. 2008 Mar;7(2):260-9","ArticleIdList":{"ArticleId":"18221415"}},{"Citation":"J Exp Bot. 2011 Jan;62(3):1037-47","ArticleIdList":{"ArticleId":"20974739"}},{"Citation":"J Exp Biol. 1997 Jan;200(Pt 2):411-9","ArticleIdList":{"ArticleId":"9050250"}},{"Citation":"Gerontology. 2011;57(5):435-43","ArticleIdList":{"ArticleId":"20962515"}},{"Citation":"Science. 2003 Apr 25;300(5619):636-40","ArticleIdList":{"ArticleId":"12714745"}},{"Citation":"J Biol Chem. 2011 Jan 14;286(2):1374-80","ArticleIdList":{"ArticleId":"21056979"}},{"Citation":"Appl Environ Microbiol. 2002 May;68(5):2382-90","ArticleIdList":{"ArticleId":"11976112"}},{"Citation":"Gen Pharmacol. 1996 Jun;27(4):565-73","ArticleIdList":{"ArticleId":"8853285"}},{"Citation":"Cell Mol Life Sci. 2011 Feb;68(4):721-33","ArticleIdList":{"ArticleId":"20711648"}},{"Citation":"Plant Physiol. 2006 Feb;140(2):613-23","ArticleIdList":{"ArticleId":"16384901"}},{"Citation":"Biochem Soc Trans. 2003 Dec;31(Pt 6):1378-82","ArticleIdList":{"ArticleId":"14641067"}},{"Citation":"Diabetologia. 2001 Nov;44(11):2004-12","ArticleIdList":{"ArticleId":"11719831"}},{"Citation":"Mol Cell Proteomics. 2006 Oct;5(10):1914-20","ArticleIdList":{"ArticleId":"16775081"}},{"Citation":"Nat Genet. 2009 Dec;41(12):1308-12","ArticleIdList":{"ArticleId":"19915575"}},{"Citation":"J Neurosci. 2005 Apr 27;25(17):4375-84","ArticleIdList":{"ArticleId":"15858064"}},{"Citation":"Mol Genet Genomics. 2008 Nov;280(5):365-74","ArticleIdList":{"ArticleId":"18797929"}},{"Citation":"Aging (Albany NY). 2010 Dec;2(12):969-80","ArticleIdList":{"ArticleId":"21212464"}},{"Citation":"J Bacteriol. 2007 Nov;189(21):7586-92","ArticleIdList":{"ArticleId":"17720789"}},{"Citation":"Funct Integr Genomics. 2011 Jun;11(2):293-305","ArticleIdList":{"ArticleId":"21213008"}},{"Citation":"Brain. 2009 May;132(Pt 5):1335-45","ArticleIdList":{"ArticleId":"19251756"}},{"Citation":"Nature. 2005 Dec 1;438(7068):662-6","ArticleIdList":{"ArticleId":"16244648"}},{"Citation":"Biochem Soc Trans. 2008 Oct;36(Pt 5):1045-50","ArticleIdList":{"ArticleId":"18793186"}},{"Citation":"Biochem J. 2001 Feb 1;353(Pt 3):445-52","ArticleIdList":{"ArticleId":"11171039"}},{"Citation":"Exp Neurol. 2004 Jun;187(2):279-88","ArticleIdList":{"ArticleId":"15144854"}},{"Citation":"J Appl Microbiol. 2008 Apr;104(4):1092-102","ArticleIdList":{"ArticleId":"18194258"}},{"Citation":"Mol Pharmacol. 2000 Mar;57(3):619-24","ArticleIdList":{"ArticleId":"10692504"}},{"Citation":"J Chem Neuroanat. 2000 Dec;20(3-4):253-7","ArticleIdList":{"ArticleId":"11207423"}},{"Citation":"J Exp Biol. 2006 Jun;209(Pt 12):2304-11","ArticleIdList":{"ArticleId":"16731806"}},{"Citation":"J Neurochem. 2010 Jun;113(5):1240-51","ArticleIdList":{"ArticleId":"20345757"}},{"Citation":"PLoS One. 2010;5(9):e13007","ArticleIdList":{"ArticleId":"20885985"}},{"Citation":"Free Radic Biol Med. 2006 Apr 1;40(7):1201-9","ArticleIdList":{"ArticleId":"16545688"}},{"Citation":"FASEB J. 2005 Jul;19(9):1143-5","ArticleIdList":{"ArticleId":"15831715"}},{"Citation":"Biogerontology. 2001;2(1):19-34","ArticleIdList":{"ArticleId":"11708614"}},{"Citation":"Plant Cell Physiol. 2011 Feb;52(2):306-16","ArticleIdList":{"ArticleId":"21172955"}},{"Citation":"PLoS One. 2010;5(11):e15062","ArticleIdList":{"ArticleId":"21124777"}},{"Citation":"Biochem J. 1995 Jul 1;309 ( Pt 1):127-31","ArticleIdList":{"ArticleId":"7619046"}},{"Citation":"J Biol Chem. 2005 Jan 7;280(1):253-60","ArticleIdList":{"ArticleId":"15520007"}},{"Citation":"Front Aging Neurosci. 2010 Mar 18;2:10","ArticleIdList":{"ArticleId":"20552048"}},{"Citation":"PLoS One. 2009;4(8):e6805","ArticleIdList":{"ArticleId":"19710909"}},{"Citation":"J Bacteriol. 2007 Jun;189(11):3996-4013","ArticleIdList":{"ArticleId":"17384197"}},{"Citation":"Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):14672-7","ArticleIdList":{"ArticleId":"14638937"}},{"Citation":"Mol Cell Biol. 2001 Jan;21(2):390-9","ArticleIdList":{"ArticleId":"11134328"}},{"Citation":"Nat Cell Biol. 2007 Jan;9(1):99-105","ArticleIdList":{"ArticleId":"17173038"}},{"Citation":"Neurobiol Aging. 2007 Jul;28(7):1044-50","ArticleIdList":{"ArticleId":"16781798"}},{"Citation":"Neurobiol Aging. 2006 Jun;27(6):815-22","ArticleIdList":{"ArticleId":"15950319"}},{"Citation":"J Biol Chem. 2006 Apr 28;281(17):11864-71","ArticleIdList":{"ArticleId":"16505483"}},{"Citation":"Gene. 1999 Nov 15;240(1):149-55","ArticleIdList":{"ArticleId":"10564821"}},{"Citation":"Proc Natl Acad Sci U S A. 2004 May 18;101(20):7687-92","ArticleIdList":{"ArticleId":"15128939"}},{"Citation":"Plant Cell Physiol. 2010 Jun;51(6):997-1006","ArticleIdList":{"ArticleId":"20410049"}},{"Citation":"Adv Clin Chem. 2010;50:123-50","ArticleIdList":{"ArticleId":"20521444"}},{"Citation":"Aging Cell. 2008 Oct;7(5):651-62","ArticleIdList":{"ArticleId":"18616635"}},{"Citation":"Neurobiol Aging. 2007 Jan;28(1):29-41","ArticleIdList":{"ArticleId":"16427160"}},{"Citation":"Hum Mol Genet. 2004 Dec 15;13(24):3161-70","ArticleIdList":{"ArticleId":"15496428"}},{"Citation":"Arch Microbiol. 1998 Oct;170(4):209-18","ArticleIdList":{"ArticleId":"9732434"}},{"Citation":"Arch Gen Psychiatry. 2010 Jun;67(6):589-97","ArticleIdList":{"ArticleId":"20530008"}},{"Citation":"J Clin Invest. 2008 Jun;118(6):2157-68","ArticleIdList":{"ArticleId":"18451999"}},{"Citation":"Aging (Albany NY). 2009 Mar;1(3):328-34","ArticleIdList":{"ArticleId":"20157520"}},{"Citation":"J Biol Chem. 2004 Apr 30;279(18):18614-22","ArticleIdList":{"ArticleId":"14985362"}},{"Citation":"Mol Microbiol. 2010 Dec;78(6):1577-90","ArticleIdList":{"ArticleId":"21143325"}},{"Citation":"J Plant Physiol. 2009 Jan 1;166(1):1-11","ArticleIdList":{"ArticleId":"18433929"}},{"Citation":"Ann Neurol. 1994 Jan;35(1):38-44","ArticleIdList":{"ArticleId":"8285590"}},{"Citation":"Plant J. 1999 Feb;17(4):385-95","ArticleIdList":{"ArticleId":"10205896"}},{"Citation":"Neurosci Lett. 2008 Jun 20;438(2):196-9","ArticleIdList":{"ArticleId":"18455873"}}]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"20836915","DateCompleted":{"Year":"2011","Month":"04","Day":"25"},"DateRevised":{"Year":"2016","Month":"10","Day":"20"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1741-203X","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"23","Issue":"2","PubDate":{"Year":"2011","Month":"Mar"}},"Title":"International psychogeriatrics","ISOAbbreviation":"Int Psychogeriatr"},"ArticleTitle":"Cognitive decline in the behavioral variant of frontotemporal dementia.","Pagination":{"MedlinePgn":"230-7"},"ELocationID":"10.1017\/S104161021000164X","Abstract":{"AbstractText":["Only a small number of studies on the natural disease course in behavioral variant frontotemporal dementia (bvFTD) have been conducted. This is surprising because knowledge about the progression of symptoms is a precondition for the design of clinical drug trials.","The aim of the present study was to examine the cognitive decline of 20 patients with mild bvFTD over one year using the Consortium to Establish a Registry for Alzheimer's Disease - Neuropsychological Assessment Battery (CERAD-NAB).","Within an average follow-up interval of 13 months, patient scores declined significantly in the Mini-mental-State-Examination (MMSE) and the CERAD-NAB subtests of naming, verbal and nonverbal memory. No significant changes were found in the CERAD-NAB subtests of category fluency, recognition, and visuoconstruction. The average annualized decline on the MMSE was 4.0 \u00b1 4.9 points. Ceiling effects were detected in Figures Copy, Word List Recognition and Modified Boston Naming Test. Though the included patient group was rather homogeneous regarding severity of dementia, the cognitive changes were very heterogeneous.","Given the heterogeneity of cognitive decline, the design of a test battery for clinical trials in FTD will be challenging. A cognitive battery should definitely include the MMSE, Word List Learning and Word List Delayed Recall."]},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Diehl-Schmid","ForeName":"Janine","Initials":"J","AffiliationInfo":{"Affiliation":"Department of Psychiatry of Technische Universit\u00e4t M\u00fcnchen, Munich, Germany. anine.schmid@lrz.tu-muenchen.de"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Bornschein","ForeName":"Susanne","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"Pohl","ForeName":"Corina","Initials":"C"},{"@attributes":{"ValidYN":"Y"},"LastName":"F\u00f6rstl","ForeName":"Hans","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Jahn","ForeName":"Thomas","Initials":"T"}]},"Language":"eng","PublicationTypeList":{"PublicationType":"Journal Article"},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2010","Month":"09","Day":"14"}},"MedlineJournalInfo":{"Country":"England","MedlineTA":"Int Psychogeriatr","NlmUniqueID":"9007918","ISSNLinking":"1041-6102"},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Age of Onset"},{"DescriptorName":"Cognition Disorders","QualifierName":["diagnosis","etiology","psychology"]},{"DescriptorName":"Disease Progression"},{"DescriptorName":"Educational Status"},{"DescriptorName":"Frontotemporal Dementia","QualifierName":["complications","psychology"]},{"DescriptorName":"Humans"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Neuropsychological Tests"},{"DescriptorName":"Time Factors"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"entrez"},"Year":"2010","Month":"9","Day":"15","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2010","Month":"9","Day":"15","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2011","Month":"4","Day":"26","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["20836915","S104161021000164X","10.1017\/S104161021000164X"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"20655969","DateCompleted":{"Year":"2011","Month":"11","Day":"22"},"DateRevised":{"Year":"2011","Month":"03","Day":"28"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1878-4216","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"35","Issue":"2","PubDate":{"Year":"2011","Month":"Mar","Day":"30"}},"Title":"Progress in neuro-psychopharmacology & biological psychiatry","ISOAbbreviation":"Prog Neuropsychopharmacol Biol Psychiatry"},"ArticleTitle":"Novel insights for the treatment of Alzheimer's disease.","Pagination":{"MedlinePgn":"373-9"},"ELocationID":"10.1016\/j.pnpbp.2010.07.018","Abstract":{"AbstractText":"The development of treatments for Alzheimer's disease (AD) is currently shifting away from the correction of neurotransmitter abnormalities and from attempts to remove the pathognomonic protein deposits. Drug discovery is heading towards novel types of pharmacological interventions which are aimed at more central and upstream pathophysiological events. The large number of upcoming treatment targets can be grouped into two major categories. The first category consists of antecedents of beta amyloid peptide (A\u03b2) and TAU deposition including A\u03b2 production, degradation and clearance, TAU hyperphosphorylation and aggregation. The second consists of protectors against neuronal dysfunction and premature death such as mitochondrial functioning, nerve growth and regeneration, and neuronal membrane integrity. It is hoped that some of these strategies will not only have larger symptomatic effects than the currently available drugs but also an impact on the underlying neurodegeneration. Since the novel treatments will be typically administered over years they must meet high standards of safety, drug-drug compatibility, and tolerability. Probably the most important target groups for novel treatments are carriers of mutations causing AD, and individuals with minor cognitive impairment representing a pre-dementia stage of the disease. To minimise incorrect case identifications, drug development must be paralleled by improved diagnostic techniques. Novel pharmacological strategies may be cost-effective if disability and need of full-time care can be postponed or prevented without prolonging time lived with dementia or extending survival. We are uncertain whether the advent of novel disease-retarding strategies will revolutionise the management of AD. Symptomatic treatments will continue to be needed, and psychosocial approaches will retain an essential role in supporting affected individuals and their families.","CopyrightInformation":"Copyright \u00a9 2010 Elsevier Inc. All rights reserved."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany. alexander.kurz@lrz.tum.de"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Perneczky","ForeName":"Robert","Initials":"R"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Review"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2010","Month":"07","Day":"23"}},"MedlineJournalInfo":{"Country":"England","MedlineTA":"Prog Neuropsychopharmacol Biol Psychiatry","NlmUniqueID":"8211617","ISSNLinking":"0278-5846"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"APP protein, human"},{"RegistryNumber":"0","NameOfSubstance":"Amyloid beta-Peptides"},{"RegistryNumber":"0","NameOfSubstance":"Amyloid beta-Protein Precursor"},{"RegistryNumber":"0","NameOfSubstance":"Neuroprotective Agents"},{"RegistryNumber":"0","NameOfSubstance":"tau Proteins"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Alzheimer Disease","QualifierName":["drug therapy","physiopathology"]},{"DescriptorName":"Amyloid beta-Peptides","QualifierName":["antagonists & inhibitors","physiology"]},{"DescriptorName":"Amyloid beta-Protein Precursor","QualifierName":["antagonists & inhibitors","physiology"]},{"DescriptorName":"Humans"},{"DescriptorName":"Molecular Targeted Therapy"},{"DescriptorName":"Neuroprotective Agents","QualifierName":["pharmacology","therapeutic use"]},{"DescriptorName":"tau Proteins","QualifierName":"physiology"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2010","Month":"03","Day":"22"},{"@attributes":{"PubStatus":"revised"},"Year":"2010","Month":"07","Day":"02"},{"@attributes":{"PubStatus":"accepted"},"Year":"2010","Month":"07","Day":"15"},{"@attributes":{"PubStatus":"entrez"},"Year":"2010","Month":"7","Day":"27","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2010","Month":"7","Day":"27","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2011","Month":"12","Day":"13","Hour":"0","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["20655969","S0278-5846(10)00281-2","10.1016\/j.pnpbp.2010.07.018"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"20598287","DateCompleted":{"Year":"2011","Month":"03","Day":"01"},"DateRevised":{"Year":"2018","Month":"11","Day":"13"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1873-2402","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"68","Issue":"10","PubDate":{"Year":"2010","Month":"Nov","Day":"15"}},"Title":"Biological psychiatry","ISOAbbreviation":"Biol Psychiatry"},"ArticleTitle":"Progression of cerebral amyloid load is associated with the apolipoprotein E \u03b54 genotype in Alzheimer's disease.","Pagination":{"MedlinePgn":"879-84"},"ELocationID":"10.1016\/j.biopsych.2010.05.013","Abstract":{"AbstractText":["Pittsburgh Compound B ([\u00b9\u00b9C] PiB) is a specific positron emission tomography (PET) marker of cerebral amyloid deposits. Only few data have been published on in vivo longitudinal changes of amyloid load in Alzheimer's disease (AD) patients, with conflicting results. Therefore, little is known about the factors that influence these changes.","A group of 24 patients with probable AD diagnosed by combining established clinical criteria with an AD-typical pattern in [(18)F] fluoro-deoxy-glucose PET underwent [\u00b9\u00b9C] PiB-PET examinations at baseline and after 24 months. The difference of amyloid load between the two examinations and the association with clinical and neurobiological variables was examined with a regions-of-interest approach and voxel-based analyses.","Cerebral [\u00b9\u00b9C] PiB uptake ratio increased significantly by an annual rate of 3.92%. Although the increase occurred in all parts of the neocortex, no increase was detected in the archipallium. The increase was gene-dose-dependent (analysis of variance p = .012) to the number of apolipoprotein E \u03b54 alleles. Progression of dementia symptoms was correlated to the [\u00b9\u00b9C] PiB increase in numerous regions associated with cognition.","The results of this study indicate that a significant increase of amyloid deposition occurs in patients with AD during a relatively short interval of its clinical course. The rate of amyloid aggregation rate is closely associated with the apolipoprotein E genotype, which might be important for the evaluation of antiamyloid drug treatment effects. The present study further emphasizes the value of amyloid-plaque imaging as a marker of disease progression and as a potential surrogate marker to be used in antiamyloid drug trials."],"CopyrightInformation":"Copyright \u00a9 2010 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Grimmer","ForeName":"Timo","Initials":"T","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar der Technischen Universit\u00e4t M\u00fcnchen, Munich, Federal Republic of Germany. t.grimmer@lrz.tum.de"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Tholen","ForeName":"Susanne","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"Yousefi","ForeName":"Behrooz H","Initials":"BH"},{"@attributes":{"ValidYN":"Y"},"LastName":"Alexopoulos","ForeName":"Panagiotis","Initials":"P"},{"@attributes":{"ValidYN":"Y"},"LastName":"F\u00f6rschler","ForeName":"Annette","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"F\u00f6rstl","ForeName":"Hans","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Henriksen","ForeName":"Gjermund","Initials":"G"},{"@attributes":{"ValidYN":"Y"},"LastName":"Klunk","ForeName":"William E","Initials":"WE"},{"@attributes":{"ValidYN":"Y"},"LastName":"Mathis","ForeName":"Chester A","Initials":"CA"},{"@attributes":{"ValidYN":"Y"},"LastName":"Perneczky","ForeName":"Robert","Initials":"R"},{"@attributes":{"ValidYN":"Y"},"LastName":"Sorg","ForeName":"Christian","Initials":"C"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Drzezga","ForeName":"Alexander","Initials":"A"}]},"Language":"eng","GrantList":{"@attributes":{"CompleteYN":"Y"},"Grant":[{"GrantID":"R37 AG025516-02","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"R37 AG025516-06","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"R37 AG025516-01","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"P50 AG005133-28","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"R01 AG018402","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"R37 AG025516-03","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"P01 AG025204-05","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"P01 AG025204-07","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"R37 AG025516-04","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"R37 AG025516","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"R37 AG025516-07","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"P50 AG005133-25","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"P01 AG025204-04","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"P50 AG005133-27","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"P50 AG005133","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"P50 AG005133-26","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"RF1 AG025516","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"R37 AG025516-05","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"P01 AG025204","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"P01 AG025204-04S1","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"P01 AG025204-06","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"R37 AG025516-05S1","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"}]},"PublicationTypeList":{"PublicationType":["Journal Article","Research Support, N.I.H., Extramural","Research Support, Non-U.S. Gov't"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2010","Month":"07","Day":"02"}},"MedlineJournalInfo":{"Country":"United States","MedlineTA":"Biol Psychiatry","NlmUniqueID":"0213264","ISSNLinking":"0006-3223"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole"},{"RegistryNumber":"0","NameOfSubstance":"Aniline Compounds"},{"RegistryNumber":"0","NameOfSubstance":"Apolipoprotein E4"},{"RegistryNumber":"0","NameOfSubstance":"Radiopharmaceuticals"},{"RegistryNumber":"0","NameOfSubstance":"Thiazoles"},{"RegistryNumber":"0Z5B2CJX4D","NameOfSubstance":"Fluorodeoxyglucose F18"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Alzheimer Disease","QualifierName":["diagnostic imaging","genetics","metabolism"]},{"DescriptorName":"Aniline Compounds"},{"DescriptorName":"Apolipoprotein E4","QualifierName":"genetics"},{"DescriptorName":"Brain","QualifierName":["diagnostic imaging","metabolism"]},{"DescriptorName":"Disease Progression"},{"DescriptorName":"Female"},{"DescriptorName":"Fluorodeoxyglucose F18"},{"DescriptorName":"Genotype"},{"DescriptorName":"Humans"},{"DescriptorName":"Male"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Plaque, Amyloid","QualifierName":"metabolism"},{"DescriptorName":"Positron-Emission Tomography","QualifierName":"methods"},{"DescriptorName":"Radiopharmaceuticals"},{"DescriptorName":"Thiazoles"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2010","Month":"01","Day":"28"},{"@attributes":{"PubStatus":"revised"},"Year":"2010","Month":"04","Day":"16"},{"@attributes":{"PubStatus":"accepted"},"Year":"2010","Month":"05","Day":"07"},{"@attributes":{"PubStatus":"entrez"},"Year":"2010","Month":"7","Day":"6","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2010","Month":"7","Day":"6","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2011","Month":"3","Day":"2","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["20598287","S0006-3223(10)00473-7","10.1016\/j.biopsych.2010.05.013","PMC3045041","NIHMS270891"]},"ReferenceList":{"Reference":[{"Citation":"J Cogn Neurosci. 2000 Jan;12(1):1-47","ArticleIdList":{"ArticleId":"10769304"}},{"Citation":"J Nucl Med. 2000 Nov;41(11):1920-8","ArticleIdList":{"ArticleId":"11079505"}},{"Citation":"Stud Health Technol Inform. 2000;77:195-9","ArticleIdList":{"ArticleId":"11187541"}},{"Citation":"J Neuropathol Exp Neurol. 2001 Oct;60(10):946-52","ArticleIdList":{"ArticleId":"11589425"}},{"Citation":"Neuroimage. 2002 Jan;15(1):273-89","ArticleIdList":{"ArticleId":"11771995"}},{"Citation":"Ann Neurol. 2002 Feb;51(2):209-14","ArticleIdList":{"ArticleId":"11835377"}},{"Citation":"Neurology. 2002 Jun 25;58(12):1791-800","ArticleIdList":{"ArticleId":"12084879"}},{"Citation":"Mol Imaging. 2003 Jul;2(3):131-7","ArticleIdList":{"ArticleId":"14649056"}},{"Citation":"Neurobiol Aging. 2009 Dec;30(12):1902-9","ArticleIdList":{"ArticleId":"18346821"}},{"Citation":"Ann Neurol. 2004 Mar;55(3):306-19","ArticleIdList":{"ArticleId":"14991808"}},{"Citation":"Neuroimaging Clin N Am. 2003 Nov;13(4):769-80","ArticleIdList":{"ArticleId":"15024960"}},{"Citation":"J Psychiatr Res. 1975 Nov;12(3):189-98","ArticleIdList":{"ArticleId":"1202204"}},{"Citation":"Neurology. 1984 Jul;34(7):939-44","ArticleIdList":{"ArticleId":"6610841"}},{"Citation":"Neurology. 1989 Sep;39(9):1159-65","ArticleIdList":{"ArticleId":"2771064"}},{"Citation":"Acta Neuropathol. 1991;82(4):239-59","ArticleIdList":{"ArticleId":"1759558"}},{"Citation":"Neurology. 1993 Feb;43(2):250-60","ArticleIdList":{"ArticleId":"8094895"}},{"Citation":"Clin Chem. 1997 Sep;43(9):1657-9","ArticleIdList":{"ArticleId":"9299950"}},{"Citation":"J Neurol Neurosurg Psychiatry. 1998 Jun;64(6):742-6","ArticleIdList":{"ArticleId":"9647302"}},{"Citation":"Neurology. 1998 Jul;51(1):149-53","ArticleIdList":{"ArticleId":"9674794"}},{"Citation":"J Neuropathol Exp Neurol. 2004 Oct;63(10):1028-37","ArticleIdList":{"ArticleId":"15535130"}},{"Citation":"Neurology. 2005 Jan 11;64(1):102-7","ArticleIdList":{"ArticleId":"15642911"}},{"Citation":"Neurology. 2005 Jul 12;65(1):102-6","ArticleIdList":{"ArticleId":"16009893"}},{"Citation":"J Anat. 2005 Jul;207(1):35-66","ArticleIdList":{"ArticleId":"16011544"}},{"Citation":"Neuroscience. 2006 Apr 28;139(1):91-103","ArticleIdList":{"ArticleId":"16324797"}},{"Citation":"Brain. 2006 Nov;129(Pt 11):2856-66","ArticleIdList":{"ArticleId":"16854944"}},{"Citation":"Neurology. 2007 Aug 28;69(9):871-7","ArticleIdList":{"ArticleId":"17724289"}},{"Citation":"Brain. 2007 Oct;130(Pt 10):2607-15","ArticleIdList":{"ArticleId":"17698496"}},{"Citation":"J Neurosci. 2007 Sep 26;27(39):10365-71","ArticleIdList":{"ArticleId":"17898208"}},{"Citation":"J Neurochem. 2008 May;105(4):1428-37","ArticleIdList":{"ArticleId":"18221373"}},{"Citation":"Neurology. 2008 May 6;70(19 Pt 2):1842-9","ArticleIdList":{"ArticleId":"18401023"}},{"Citation":"Brain. 2008 Jun;131(Pt 6):1630-45","ArticleIdList":{"ArticleId":"18339640"}},{"Citation":"Neurology. 2009 Apr 28;72(17):1487-94","ArticleIdList":{"ArticleId":"19339712"}},{"Citation":"Brain. 2009 May;132(Pt 5):1355-65","ArticleIdList":{"ArticleId":"19339253"}},{"Citation":"Biol Psychiatry. 2009 Jun 1;65(11):927-34","ArticleIdList":{"ArticleId":"19268916"}},{"Citation":"Eur J Nucl Med Mol Imaging. 2009 Oct;36(10):1629-38","ArticleIdList":{"ArticleId":"19384547"}},{"Citation":"Eur J Nucl Med Mol Imaging. 2009 Oct;36(10):1651-60","ArticleIdList":{"ArticleId":"19495749"}},{"Citation":"Neurology. 2009 Oct 13;73(15):1186-92","ArticleIdList":{"ArticleId":"19726751"}}]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"20556547","DateCompleted":{"Year":"2010","Month":"10","Day":"28"},"DateRevised":{"Year":"2018","Month":"11","Day":"13"},"Article":{"@attributes":{"PubModel":"Print"},"Journal":{"ISSN":"1534-6293","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"10","Issue":"5","PubDate":{"Year":"2010","Month":"Sep"}},"Title":"Current neurology and neuroscience reports","ISOAbbreviation":"Curr Neurol Neurosci Rep"},"ArticleTitle":"Physical activity and mild cognitive impairment and Alzheimer's disease.","Pagination":{"MedlinePgn":"352-8"},"ELocationID":"10.1007\/s11910-010-0121-7","Abstract":{"AbstractText":"Regular physical activity undoubtedly has many health benefits for all age groups. In the past decade, researchers and clinicians have begun to focus their attention on whether physical activity also can improve health outcomes of older adults who experience mild cognitive impairment (MCI) or dementia. This ongoing question is gaining relevance in light of the aging of the world population and with it the rise of age-related conditions, such as cognitive impairment. Not surprisingly, physical activity is among the potential protective lifestyle factors mentioned when strategies to delay or prevent dementia are discussed. The first large-scale multidomain intervention trials are under way to put this to the test. This review aims to give an overview of recent trials of physical activity in patients with MCI or dementia."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Lautenschlager","ForeName":"Nicola T","Initials":"NT","AffiliationInfo":{"Affiliation":"Academic Unit for Psychiatry of Old Age, St. Vincent's Health, Department of Psychiatry, St. George's Hospital, The University of Melbourne, 283 Cotham Road, Kew, 3103, Victoria, Australia. nicolatl@unimelb.edu.au"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Cox","ForeName":"Kay","Initials":"K"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander F","Initials":"AF"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Research Support, Non-U.S. Gov't","Review"]}},"MedlineJournalInfo":{"Country":"United States","MedlineTA":"Curr Neurol Neurosci Rep","NlmUniqueID":"100931790","ISSNLinking":"1528-4042"},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aging","QualifierName":"physiology"},{"DescriptorName":"Alzheimer Disease","QualifierName":"complications"},{"DescriptorName":"Animals"},{"DescriptorName":"Clinical Trials as Topic"},{"DescriptorName":"Cognition Disorders","QualifierName":"etiology"},{"DescriptorName":"Dementia","QualifierName":"complications"},{"DescriptorName":"Humans"},{"DescriptorName":"Motor Activity","QualifierName":"physiology"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"entrez"},"Year":"2010","Month":"6","Day":"18","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2010","Month":"6","Day":"18","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2010","Month":"10","Day":"29","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["20556547","10.1007\/s11910-010-0121-7"]},"ReferenceList":{"Reference":[{"Citation":"Arch Intern Med. 2010 Jan 25;170(2):179-85","ArticleIdList":{"ArticleId":"20101013"}},{"Citation":"Maturitas. 2009 Aug 20;63(4):319-22","ArticleIdList":{"ArticleId":"19631480"}},{"Citation":"Aging Ment Health. 2008 Jan;12(1):72-80","ArticleIdList":{"ArticleId":"18297481"}},{"Citation":"Stroke. 2010 Jun;41(6):1243-50","ArticleIdList":{"ArticleId":"20371746"}},{"Citation":"J Am Geriatr Soc. 2007 Feb;55(2):158-65","ArticleIdList":{"ArticleId":"17302650"}},{"Citation":"J Gerontol A Biol Sci Med Sci. 2010 Mar;65(3):300-6","ArticleIdList":{"ArticleId":"19789197"}},{"Citation":"Lancet Neurol. 2010 Jan;9(1):4-5","ArticleIdList":{"ArticleId":"20083022"}},{"Citation":"Arch Neurol. 2010 Jan;67(1):80-6","ArticleIdList":{"ArticleId":"20065133"}},{"Citation":"Acta Psychiatr Scand. 2009 Apr;119(4):252-65","ArticleIdList":{"ArticleId":"19236314"}},{"Citation":"JAMA. 2009 Jan 21;301(3):273; author reply 273-4","ArticleIdList":{"ArticleId":"19155451"}},{"Citation":"Arch Neurol. 2009 Oct;66(10):1210-5","ArticleIdList":{"ArticleId":"19822776"}},{"Citation":"Br J Sports Med. 2008 May;42(5):344-51","ArticleIdList":{"ArticleId":"18308888"}},{"Citation":"Clin Geriatr Med. 2010 Feb;26(1):75-87","ArticleIdList":{"ArticleId":"20176294"}},{"Citation":"Arch Neurol. 2010 Jan;67(1):71-9","ArticleIdList":{"ArticleId":"20065132"}},{"Citation":"Cochrane Database Syst Rev. 2008 Jul 16;(3):CD006489","ArticleIdList":{"ArticleId":"18646158"}},{"Citation":"Am J Alzheimers Dis Other Demen. 2007 Feb-Mar;22(1):62-77","ArticleIdList":{"ArticleId":"17534004"}},{"Citation":"Gerontologist. 2009 Jun;49 Suppl 1:S40-9","ArticleIdList":{"ArticleId":"19525216"}},{"Citation":"J Aging Phys Act. 2009 Oct;17(4):398-415","ArticleIdList":{"ArticleId":"19940321"}},{"Citation":"Alzheimers Dement. 2007 Jul;3(3):186-91","ArticleIdList":{"ArticleId":"19595937"}},{"Citation":"PLoS One. 2009;4(5):e5521","ArticleIdList":{"ArticleId":"19436724"}},{"Citation":"Prog Neurobiol. 2009 Dec;89(4):369-82","ArticleIdList":{"ArticleId":"19819293"}},{"Citation":"Arch Intern Med. 2010 Jan 25;170(2):194-201","ArticleIdList":{"ArticleId":"20101015"}},{"Citation":"Arch Neurol. 2010 Jan;67(1):107-11","ArticleIdList":{"ArticleId":"20065137"}},{"Citation":"Arch Intern Med. 2009 Jun 22;169(12):1139-46","ArticleIdList":{"ArticleId":"19546415"}},{"Citation":"Arch Intern Med. 2010 Jan 25;170(2):186-93","ArticleIdList":{"ArticleId":"20101014"}},{"Citation":"Psychol Med. 2009 Jan;39(1):3-11","ArticleIdList":{"ArticleId":"18570697"}},{"Citation":"Am J Alzheimers Dis Other Demen. 2007 Oct-Nov;22(5):389-97","ArticleIdList":{"ArticleId":"17959874"}},{"Citation":"Neuropsychobiology. 2009;59(4):191-8","ArticleIdList":{"ArticleId":"19521110"}},{"Citation":"Alzheimers Dement. 2009 Mar;5(2):114-21","ArticleIdList":{"ArticleId":"19328438"}},{"Citation":"Epidemiol Rev. 2008;30:35-66","ArticleIdList":{"ArticleId":"18779228"}},{"Citation":"Gerontologist. 2009 Jun;49 Suppl 1:S61-71","ArticleIdList":{"ArticleId":"19525218"}},{"Citation":"JAMA. 2009 Aug 12;302(6):627-37","ArticleIdList":{"ArticleId":"19671904"}},{"Citation":"J Intern Med. 2004 Sep;256(3):240-6","ArticleIdList":{"ArticleId":"15324367"}},{"Citation":"Ann Intern Med. 2008 Mar 18;148(6):427-34","ArticleIdList":{"ArticleId":"18347351"}},{"Citation":"Gerontologist. 2009 Jun;49 Suppl 1:S50-60","ArticleIdList":{"ArticleId":"19525217"}},{"Citation":"Int J Clin Pract. 2009 Feb;63(2):303-20","ArticleIdList":{"ArticleId":"19196369"}},{"Citation":"JAMA. 2003 Oct 15;290(15):2015-22","ArticleIdList":{"ArticleId":"14559955"}},{"Citation":"JAMA. 2008 Sep 3;300(9):1027-37","ArticleIdList":{"ArticleId":"18768414"}}]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"20129316","DateCompleted":{"Year":"2010","Month":"04","Day":"16"},"DateRevised":{"Year":"2010","Month":"02","Day":"04"},"Article":{"@attributes":{"PubModel":"Print"},"Journal":{"ISSN":"1552-5279","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"6","Issue":"1","PubDate":{"Year":"2010","Month":"Jan"}},"Title":"Alzheimer's & dementia : the journal of the Alzheimer's Association","ISOAbbreviation":"Alzheimers Dement"},"ArticleTitle":"Efficacy of a medical food in mild Alzheimer's disease: A randomized, controlled trial.","Pagination":{"MedlinePgn":"1-10.e1"},"ELocationID":"10.1016\/j.jalz.2009.10.003","Abstract":{"AbstractText":["To investigate the effect of a medical food on cognitive function in people with mild Alzheimer's disease (AD).","A total of 225 drug-na\u00efve AD patients participated in this randomized, double-blind controlled trial. Patients were randomized to active product, Souvenaid, or a control drink, taken once-daily for 12 weeks. Primary outcome measures were the delayed verbal recall task of the Wechsler Memory Scale-revised, and the 13-item modified Alzheimer's Disease Assessment Scale-cognitive subscale at week 12.","At 12 weeks, significant improvement in the delayed verbal recall task was noted in the active group compared with control (P = .021). Modified Alzheimer's Disease Assessment Scale-cognitive subscale and other outcome scores (e.g., Clinician Interview Based Impression of Change plus Caregiver Input, 12-item Neuropsychiatric Inventory, Alzheimer's disease Co-operative Study-Activities of Daily Living, Quality of Life in Alzheimer's Disease) were unchanged. The control group neither deteriorated nor improved. Compliance was excellent (95%) and the product was well tolerated.","Supplementation with a medical food including phosphatide precursors and cofactors for 12 weeks improved memory (delayed verbal recall) in mild AD patients. This proof-of-concept study justifies further clinical trials."],"CopyrightInformation":"2010 The Alzheimer's Association. All rights reserved."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Scheltens","ForeName":"Philip","Initials":"P","AffiliationInfo":{"Affiliation":"VU University Medical Center, Amsterdam, The Netherlands. p.scheltens@vumc.nl"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Kamphuis","ForeName":"Patrick J G H","Initials":"PJ"},{"@attributes":{"ValidYN":"Y"},"LastName":"Verhey","ForeName":"Frans R J","Initials":"FR"},{"@attributes":{"ValidYN":"Y"},"LastName":"Olde Rikkert","ForeName":"Marcel G M","Initials":"MG"},{"@attributes":{"ValidYN":"Y"},"LastName":"Wurtman","ForeName":"Richard J","Initials":"RJ"},{"@attributes":{"ValidYN":"Y"},"LastName":"Wilkinson","ForeName":"David","Initials":"D"},{"@attributes":{"ValidYN":"Y"},"LastName":"Twisk","ForeName":"Jos W R","Initials":"JW"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Clinical Trial","Journal Article","Multicenter Study","Randomized Controlled Trial","Research Support, Non-U.S. Gov't"]}},"MedlineJournalInfo":{"Country":"United States","MedlineTA":"Alzheimers Dement","NlmUniqueID":"101231978","ISSNLinking":"1552-5260"},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Aged, 80 and over"},{"DescriptorName":"Alzheimer Disease","QualifierName":"complications"},{"DescriptorName":"Case-Control Studies"},{"DescriptorName":"Cognition Disorders","QualifierName":["diet therapy","etiology"]},{"DescriptorName":"Double-Blind Method"},{"DescriptorName":"Drug Administration Schedule"},{"DescriptorName":"Female"},{"DescriptorName":"Follow-Up Studies"},{"DescriptorName":"Functional Food"},{"DescriptorName":"Humans"},{"DescriptorName":"Male"},{"DescriptorName":"Memory","QualifierName":"physiology"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Neuropsychological Tests"},{"DescriptorName":"Psychiatric Status Rating Scales"},{"DescriptorName":"Time Factors"},{"DescriptorName":"Treatment Outcome"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2009","Month":"07","Day":"21"},{"@attributes":{"PubStatus":"revised"},"Year":"2009","Month":"09","Day":"24"},{"@attributes":{"PubStatus":"accepted"},"Year":"2009","Month":"10","Day":"22"},{"@attributes":{"PubStatus":"entrez"},"Year":"2010","Month":"2","Day":"5","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2010","Month":"2","Day":"5","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2010","Month":"4","Day":"17","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["20129316","S1552-5260(09)02329-2","10.1016\/j.jalz.2009.10.003"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"20074912","DateCompleted":{"Year":"2010","Month":"03","Day":"29"},"DateRevised":{"Year":"2016","Month":"11","Day":"25"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"0165-1781","JournalIssue":{"@attributes":{"CitedMedium":"Print"},"Volume":"181","Issue":"2","PubDate":{"Year":"2010","Month":"Feb","Day":"28"}},"Title":"Psychiatry research","ISOAbbreviation":"Psychiatry Res"},"ArticleTitle":"Metabolic alterations associated with impaired clock drawing in Lewy body dementia.","Pagination":{"MedlinePgn":"85-9"},"ELocationID":"10.1016\/j.pscychresns.2009.08.001","Abstract":{"AbstractText":"The clock drawing test (CDT) is a widely used dementia screening instrument that assesses executive and visuospatial abilities; studies in patients with Alzheimer's disease (AD) suggest frontoposterior networks to be involved in clock drawing. Clock drawing errors are also often observed in dementia with Lewy bodies (DLB), but the functional neuroanatomical substrate of impaired clock drawing has not been firmly established in this disorder. The present study was designed to provide initial evidence for brain metabolic alterations associated with CDT performance in DLB. Twenty-one patients with DLB were enrolled. CDT ratings were correlated with the regional cerebral metabolic rate of glucose (rCMRglc) measured by (18)F-fluoro-2-deoxy-glucose positron emission tomography ((18)F-FDG PET) in the statistical parametric mapping software package SPM5, controlling for overall cognitive impairment as measured by the Mini-Mental-State Examination (MMSE) score. There was a significant negative association between test scores and rCMRglc in a left-hemispheric posterofrontal network including the temporoparietal and dorsal pre-motor cortices and the precuneus. The present study provides evidence for a direct association between frontoparietal dysfunction and impaired CDT performance in DLB. These findings also suggest that the CDT is an appropriate screening instrument for this disorder and that metabolic dysfunction, and therefore disease severity, is mirrored by performance on the test.","CopyrightInformation":"Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Perneczky","ForeName":"Robert","Initials":"R","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Technische Ismaninger Str. 22, 81675 M\u00fcnchen, Germany. robert.perneczky@lrz.tum.de"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Drzezga","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Boecker","ForeName":"Henning","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Ceballos-Baumann","ForeName":"Andres O","Initials":"AO"},{"@attributes":{"ValidYN":"Y"},"LastName":"Valet","ForeName":"Michael","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Feurer","ForeName":"Regina","Initials":"R"},{"@attributes":{"ValidYN":"Y"},"LastName":"F\u00f6rstl","ForeName":"Hans","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"H\u00e4ussermann","ForeName":"Peter","Initials":"P"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Research Support, Non-U.S. Gov't"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2010","Month":"01","Day":"13"}},"MedlineJournalInfo":{"Country":"Ireland","MedlineTA":"Psychiatry Res","NlmUniqueID":"7911385","ISSNLinking":"0165-1781"},"ChemicalList":{"Chemical":{"RegistryNumber":"0Z5B2CJX4D","NameOfSubstance":"Fluorodeoxyglucose F18"}},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Analysis of Variance"},{"DescriptorName":"Brain","QualifierName":"diagnostic imaging"},{"DescriptorName":"Brain Mapping"},{"DescriptorName":"Cognition Disorders","QualifierName":["diagnostic imaging","etiology"]},{"DescriptorName":"Executive Function","QualifierName":"physiology"},{"DescriptorName":"Female"},{"DescriptorName":"Fluorodeoxyglucose F18"},{"DescriptorName":"Functional Laterality"},{"DescriptorName":"Humans"},{"DescriptorName":"Lewy Body Disease","QualifierName":["complications","diagnostic imaging","pathology"]},{"DescriptorName":"Male"},{"DescriptorName":"Mental Status Schedule"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Neuropsychological Tests"},{"DescriptorName":"Photic Stimulation","QualifierName":"methods"},{"DescriptorName":"Positron-Emission Tomography","QualifierName":"methods"},{"DescriptorName":"Space Perception","QualifierName":"physiology"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2007","Month":"10","Day":"17"},{"@attributes":{"PubStatus":"revised"},"Year":"2009","Month":"08","Day":"03"},{"@attributes":{"PubStatus":"accepted"},"Year":"2009","Month":"08","Day":"03"},{"@attributes":{"PubStatus":"entrez"},"Year":"2010","Month":"1","Day":"16","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2010","Month":"1","Day":"16","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2010","Month":"3","Day":"30","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["20074912","S0925-4927(09)00177-2","10.1016\/j.pscychresns.2009.08.001"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"19946869","DateCompleted":{"Year":"2011","Month":"03","Day":"15"},"DateRevised":{"Year":"2018","Month":"12","Day":"01"},"Article":{"@attributes":{"PubModel":"Print"},"Journal":{"ISSN":"1099-1166","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"25","Issue":"8","PubDate":{"Year":"2010","Month":"Aug"}},"Title":"International journal of geriatric psychiatry","ISOAbbreviation":"Int J Geriatr Psychiatry"},"ArticleTitle":"Evaluation of a brief educational program for dementia carers: the AENEAS study.","Pagination":{"MedlinePgn":"861-9"},"ELocationID":"10.1002\/gps.2428","Abstract":{"AbstractText":["To evaluate the efficacy of a practical, easily implemented, educational intervention in group format for informal carers of persons with dementia.","Multi-centre, randomised, controlled, single-blind trial involving 292 family caregivers of patients with moderate dementia in Alzheimer's disease.","Participants valued program components which had a practical impact on their caring role. The intervention achieved minor effects on the participants' psychological quality of life and did not reduce carer depression. It was also not associated with a lower rate of patient nursing home admissions. A subgroup analysis suggested that the intervention actually promoted the decision for nursing home placement in caregivers who were over-burdened and not coping well when they entered the study.","To improve dementia carer support, educational components might be intergrated into more comprehensive and individualised interventions which include problem solving and behavioural management strategies, ensure the transfer of newly acquired skills into the everyday context, and adequately deal with the emotional consequences of the caring role."],"CopyrightInformation":"Copyright 2009 John Wiley & Sons, Ltd."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany. alexander.kurz@lrz.tum.de"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Wagenpfeil","ForeName":"Stefan","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"Hallauer","ForeName":"Johannes","Initials":"J"},{"@attributes":{"ValidYN":"Y"},"LastName":"Schneider-Schelte","ForeName":"Helga","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Jansen","ForeName":"Sabine","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"CollectiveName":"AENEAS Study"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Multicenter Study","Randomized Controlled Trial","Research Support, Non-U.S. Gov't"]}},"MedlineJournalInfo":{"Country":"England","MedlineTA":"Int J Geriatr Psychiatry","NlmUniqueID":"8710629","ISSNLinking":"0885-6230"},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Aged, 80 and over"},{"DescriptorName":"Alzheimer Disease","QualifierName":["nursing","psychology"]},{"DescriptorName":"Ambulatory Care Facilities","QualifierName":"statistics & numerical data"},{"DescriptorName":"Caregivers","QualifierName":["education","psychology"]},{"DescriptorName":"Dementia","QualifierName":["nursing","psychology"]},{"DescriptorName":"Depression","QualifierName":"diagnosis"},{"DescriptorName":"Female"},{"DescriptorName":"Health Education","QualifierName":"methods"},{"DescriptorName":"Humans"},{"DescriptorName":"Logistic Models"},{"DescriptorName":"Male"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Nursing Homes","QualifierName":"statistics & numerical data"},{"DescriptorName":"Patient Admission","QualifierName":"statistics & numerical data"},{"DescriptorName":"Program Evaluation"},{"DescriptorName":"Quality of Life"},{"DescriptorName":"Single-Blind Method"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"entrez"},"Year":"2009","Month":"12","Day":"1","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2009","Month":"12","Day":"1","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2011","Month":"3","Day":"16","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["19946869","10.1002\/gps.2428"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"19814839","DateCompleted":{"Year":"2010","Month":"03","Day":"22"},"DateRevised":{"Year":"2016","Month":"10","Day":"20"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1741-203X","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"22","Issue":"1","PubDate":{"Year":"2010","Month":"Feb"}},"Title":"International psychogeriatrics","ISOAbbreviation":"Int Psychogeriatr"},"ArticleTitle":"The concept of dementia: retain, reframe, rename or replace?","Pagination":{"MedlinePgn":"37-42"},"ELocationID":"10.1017\/S1041610209991013","Abstract":{"AbstractText":"From antiquity the term \"dementia\" has denoted a state of severe acquired intellectual deterioration which significantly interferes with the fulfillment of personal, social or occupational roles, and makes the individual dependent on care and supervision by others. The medical concept of dementia refers to a pattern of cognitive and behavioral symptoms which typically arises from chronic and often progressive brain diseases. The quantitative expression of this pattern shows broad variability, and some patients fall within the boundaries of the concept whose intellectual and functional abilities are only mildly impaired. On the other hand, the concept currently has an unduly narrow qualitative bandwidth, because it is modeled after the subtype which occurs in Alzheimer's disease but does not represent a good fit for other important subtypes. In the authors' view, the concept of dementia should be retained despite its limitations, since it has an important role in directing the physician's attention to a certain group of underlying pathologies. This diagnostic role of the concept will remain important in primary care even if biological indicators for one or several etiologies will become part of the diagnostic routine in research units in the future. The medical construct has further value since it entitles patients to medical treatment, social assistance and legal protection. Although in our opinion the concept of dementia does not need to be replaced, upcoming revisions of the psychiatric classification systems will have to reframe it by emphasizing the heterogeneity of the psychopathological symptom pattern. In view of the increasing importance of early diagnosis and treatment, however, the term \"dementia\", which literally means \"absence of mind\", is no longer an appropriate and timely designation for the broad range of cognitive and behavioral limitations covered by the concept. It should be renamed, using a terminology which accommodates scientific advance and meets the requirements of medical communication while preserving the benefits for patients and their families."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander F","Initials":"AF","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Technical University Munich, Germany. alexander.kurz@lrz.tum.de"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Lautenschlager","ForeName":"Nicola T","Initials":"NT"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Review"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2009","Month":"10","Day":"09"}},"MedlineJournalInfo":{"Country":"England","MedlineTA":"Int Psychogeriatr","NlmUniqueID":"9007918","ISSNLinking":"1041-6102"},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Dementia","QualifierName":"classification"},{"DescriptorName":"Humans"},{"DescriptorName":"Terminology as Topic"}]},"NumberOfReferences":"42"},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"entrez"},"Year":"2009","Month":"10","Day":"10","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2009","Month":"10","Day":"10","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2010","Month":"3","Day":"23","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["19814839","S1041610209991013","10.1017\/S1041610209991013"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"19747154","DateCompleted":{"Year":"2010","Month":"01","Day":"05"},"DateRevised":{"Year":"2019","Month":"10","Day":"27"},"Article":{"@attributes":{"PubModel":"Print"},"Journal":{"ISSN":"1875-5828","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"6","Issue":"6","PubDate":{"Year":"2009","Month":"Dec"}},"Title":"Current Alzheimer research","ISOAbbreviation":"Curr Alzheimer Res"},"ArticleTitle":"Impact of Alzheimer's disease on the functional connectivity of spontaneous brain activity.","Pagination":{"MedlinePgn":"541-53"},"Abstract":{"AbstractText":"Alzheimer's disease (AD) prominently affects the structure and function of cerebral networks. Reflecting the complex network structure of the brain, spontaneous brain activity is organized by synchronized activity across distinct temporal and spatial scales. Temporal correlations of the functional MRI (fMRI) signal during rest have been used to characterize the impact of AD on the functional connectivity of spontaneous brain activity. Here we review studies using resting-state fMRI (rs-fMRI) to explore AD-induced changes of synchronized intrinsic activity at three levels of brain organization: the regional, inter-regional and large-scale level. Changes in posterior areas of the default network (DN) and the medial temporal lobes seem to be central to AD. These areas show remarkable disturbances in neuronal communication at all spatial levels and in very early stages of the disease. Finally, rs-fMRI seems to have the potential to produce connectivity-related biomarkers that distinguish AD and healthy aging."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Sorg","ForeName":"Christian","Initials":"C","AffiliationInfo":{"Affiliation":"Department of Psychiatry, Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, Ismaninger Strasse 22, 81675 Munich, Germany. c.sorg@lrz.tum.de"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Riedl","ForeName":"Valentin","Initials":"V"},{"@attributes":{"ValidYN":"Y"},"LastName":"Perneczky","ForeName":"Robert","Initials":"R"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Wohlschl\u00e4ger","ForeName":"Afra M","Initials":"AM"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Research Support, Non-U.S. Gov't","Review"]}},"MedlineJournalInfo":{"Country":"United Arab Emirates","MedlineTA":"Curr Alzheimer Res","NlmUniqueID":"101208441","ISSNLinking":"1567-2050"},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Alzheimer Disease","QualifierName":"physiopathology"},{"DescriptorName":"Brain","QualifierName":"physiopathology"},{"DescriptorName":"Humans"},{"DescriptorName":"Image Processing, Computer-Assisted"},{"DescriptorName":"Magnetic Resonance Imaging"},{"DescriptorName":"Nerve Net","QualifierName":"physiopathology"},{"DescriptorName":"Neural Pathways","QualifierName":"physiopathology"}]},"NumberOfReferences":"91"},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2008","Month":"09","Day":"15"},{"@attributes":{"PubStatus":"accepted"},"Year":"2009","Month":"05","Day":"06"},{"@attributes":{"PubStatus":"entrez"},"Year":"2009","Month":"9","Day":"15","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2009","Month":"9","Day":"15","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2010","Month":"1","Day":"6","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["19747154","CAR-29","10.2174\/156720509790147106"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"19713001","DateCompleted":{"Year":"2012","Month":"05","Day":"07"},"DateRevised":{"Year":"2016","Month":"11","Day":"25"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1558-1497","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"32","Issue":"7","PubDate":{"Year":"2011","Month":"Jul"}},"Title":"Neurobiology of aging","ISOAbbreviation":"Neurobiol Aging"},"ArticleTitle":"Staged decline of visual processing capacity in mild cognitive impairment and Alzheimer's disease.","Pagination":{"MedlinePgn":"1219-30"},"ELocationID":"10.1016\/j.neurobiolaging.2009.07.012","Abstract":{"AbstractText":"Visual information intake was assessed with a whole-report task in patients with probable Alzheimer's disease (AD), mild cognitive impairment (MCI), and healthy elderly control subjects. Based on a theory of visual attention (TVA), four parameters were derived characterising different aspects of visual processing capacity: perceptual threshold, iconic memory, processing speed, and visual short-term memory (VSTM) storage capacity. Results indicated increased perceptual thresholds in MCI, and an additional decline in processing speed and VSTM storage capacity in AD. Cholinomimetic medication had beneficial effects on processing speed in AD patients. Perceptual thresholds were associated with disease duration, but not with cognitive measures, while the reverse was true for speed and VSTM measures. These results reveal a staged pattern of deficits affecting pre-attentive visual processing in MCI, and attentive processing in AD. It is compatible with the amyloid cascade hypothesis and suggests that impaired visual processing is a pathological feature present already at the MCI stage and might represent a distinct marker of upcoming AD independently from memory deficits.","CopyrightInformation":"Copyright \u00a9 2009 Elsevier Inc. All rights reserved."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Bublak","ForeName":"Peter","Initials":"P","AffiliationInfo":{"Affiliation":"Neuropsychology Unit, Klinik f\u00fcr Neurologie, Friedrich-Schiller-Universit\u00e4t Jena, Erlanger Allee 101, Jena, Germany. peter.bublak@med.uni-jena.de"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Redel","ForeName":"Petra","Initials":"P"},{"@attributes":{"ValidYN":"Y"},"LastName":"Sorg","ForeName":"Christian","Initials":"C"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"F\u00f6rstl","ForeName":"Hans","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"M\u00fcller","ForeName":"Hermann J","Initials":"HJ"},{"@attributes":{"ValidYN":"Y"},"LastName":"Schneider","ForeName":"Werner X","Initials":"WX"},{"@attributes":{"ValidYN":"Y"},"LastName":"Finke","ForeName":"Kathrin","Initials":"K"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Clinical Trial","Journal Article","Research Support, Non-U.S. Gov't"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2009","Month":"08","Day":"26"}},"MedlineJournalInfo":{"Country":"United States","MedlineTA":"Neurobiol Aging","NlmUniqueID":"8100437","ISSNLinking":"0197-4580"},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Alzheimer Disease","QualifierName":["diagnosis","drug therapy","physiopathology"]},{"DescriptorName":"Cognition Disorders","QualifierName":["diagnosis","drug therapy","physiopathology"]},{"DescriptorName":"Cognitive Dysfunction","QualifierName":["diagnosis","drug therapy","physiopathology"]},{"DescriptorName":"Female"},{"DescriptorName":"Humans"},{"DescriptorName":"Male"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Perceptual Disorders","QualifierName":["diagnosis","drug therapy","physiopathology"]},{"DescriptorName":"Severity of Illness Index"},{"DescriptorName":"Visual Perception","QualifierName":["drug effects","physiology"]}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2009","Month":"03","Day":"09"},{"@attributes":{"PubStatus":"revised"},"Year":"2009","Month":"06","Day":"14"},{"@attributes":{"PubStatus":"accepted"},"Year":"2009","Month":"07","Day":"27"},{"@attributes":{"PubStatus":"entrez"},"Year":"2009","Month":"8","Day":"29","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2009","Month":"8","Day":"29","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2012","Month":"5","Day":"9","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["19713001","S0197-4580(09)00244-9","10.1016\/j.neurobiolaging.2009.07.012"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"19590201","DateCompleted":{"Year":"2009","Month":"10","Day":"05"},"DateRevised":{"Year":"2009","Month":"07","Day":"24"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1421-9824","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"27","Issue":"6","PubDate":{"Year":"2009"}},"Title":"Dementia and geriatric cognitive disorders","ISOAbbreviation":"Dement Geriatr Cogn Disord"},"ArticleTitle":"Education, occupation, and dementia: the Bavarian school sisters study.","Pagination":{"MedlinePgn":"548-56"},"ELocationID":"10.1159\/000227781","Abstract":{"AbstractText":["An inverse association of educational level with the occurrence of dementia has been repeatedly demonstrated. The mechanism of this relationship is not yet clear. Studies on populations with different educational and occupational levels but uniform living conditions throughout adult life may serve as a natural experiment and may help to rule out lifestyle and environmental factors as possible explanations.","We studied the relationship of education, occupational training, and appointment to a leading position with dementia in a cross-sectional study of older female members of a religious order.","Out of 517 eligible sisters, 442 (85.5%) with an average of 54 years membership in the order participated in the study, among which 104 cases of dementia were identified. We found a strong association of low educational and occupational attainment with dementia. The increased risk of dementia was attributable to sisters being poorly educated (age-adjusted OR = 4.5; 95% CI: 2.0-9.9), not having received any vocational training (OR = 9.1; 95% CI: 3.9-20.9), and never having been appointed to a leading position (OR = 3.7; 95% CI: 2.0-7.0).","In a setting which largely excludes the influence of lifestyle and environmental factors, we observed a strong association between educational variables and dementia. Our findings support the hypothesis of a reserve capacity against the consequences of brain diseases."]},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Bickel","ForeName":"Horst","Initials":"H","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Technische Universit\u00e4t M\u00fcnchen, M\u00fcnchen, Germany. h.bickel@lrz.tum.de"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Research Support, Non-U.S. Gov't"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2009","Month":"07","Day":"08"}},"MedlineJournalInfo":{"Country":"Switzerland","MedlineTA":"Dement Geriatr Cogn Disord","NlmUniqueID":"9705200","ISSNLinking":"1420-8008"},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Aged, 80 and over"},{"DescriptorName":"Alzheimer Disease","QualifierName":["epidemiology","psychology"]},{"DescriptorName":"Cohort Studies"},{"DescriptorName":"Dementia","QualifierName":["epidemiology","psychology"]},{"DescriptorName":"Education"},{"DescriptorName":"Female"},{"DescriptorName":"Germany","QualifierName":"epidemiology"},{"DescriptorName":"Humans"},{"DescriptorName":"Logistic Models"},{"DescriptorName":"Occupations"},{"DescriptorName":"Psychiatric Status Rating Scales"},{"DescriptorName":"Vocational Education"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"accepted"},"Year":"2009","Month":"04","Day":"17"},{"@attributes":{"PubStatus":"entrez"},"Year":"2009","Month":"7","Day":"11","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2009","Month":"7","Day":"11","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2009","Month":"10","Day":"6","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["19590201","000227781","10.1159\/000227781"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"19573486","DateCompleted":{"Year":"2009","Month":"07","Day":"20"},"DateRevised":{"Year":"2013","Month":"11","Day":"21"},"Article":{"@attributes":{"PubModel":"Print"},"Journal":{"ISSN":"1555-2101","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"70","Issue":"6","PubDate":{"Year":"2009","Month":"Jun"}},"Title":"The Journal of clinical psychiatry","ISOAbbreviation":"J Clin Psychiatry"},"ArticleTitle":"Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study.","Pagination":{"MedlinePgn":"922-31"},"Abstract":{"AbstractText":["Lithium, a first-line drug for the treatment of bipolar depression, has recently been shown to regulate glycogen synthase kinase-3 (GSK-3), a kinase that is involved in the phosphorylation of the tau protein. Since hyperphosphorylation of tau is a core pathological feature in Alzheimer's disease, lithium-induced inhibition of GSK-3 activity may have therapeutic effects in Alzheimer's disease. In the current study, we tested the effect of short-term lithium treatment in patients with Alzheimer's disease.","A total of 71 patients with mild Alzheimer's disease (Mini-Mental State Examination score > or = 21 and < or = 26) were successfully randomly assigned to placebo (N = 38) or lithium treatment (N = 33) at 6 academic expert memory clinics. The 10-week treatment included a 6-week titration phase to reach the target serum level of lithium (0.5-0.8 mmol\/L). The primary outcome measures were cerebrospinal fluid (CSF) levels of phosphorylated tau (p-tau) and GSK-3 activity in lymphocytes. Secondary outcome measures were CSF concentration of total tau and beta-amyloid(1-42) (Abeta(1-42)), plasma levels of Abeta(1-42), Alzheimer's Disease Assessment Scale (ADAS)-Cognitive summary scores, MMSE, and Neuropsychiatric Inventory (NPI). Patients were enrolled in the study from November 2004 to July 2005.","No treatment effect on GSK-3 activity or CSF-based biomarker concentrations (P > .05) was observed. Lithium treatment did not lead to change in global cognitive performance as measured by the ADAS-Cog subscale (P = .11) or in depressive symptoms.","The current results do not support the notion that lithium treatment may lead to reduced hyperphosphorylation of tau protein after a short 10-week treatment in the Alzheimer's disease target population.","(Controlled-Trials.com) Identifier: ISRCTN72046462."],"CopyrightInformation":"Copyright 2009 Physicians Postgraduate Press, Inc."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Hampel","ForeName":"Harald","Initials":"H","AffiliationInfo":{"Affiliation":"Trinity Center for Health Sciences, The Adelaide and Meath Hospital Incorporating The National Children's Hospital (AMiNCH), Tallaght, Dublin 24, Ireland. harald.hampel@med.uni-muenchen.de"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Ewers","ForeName":"Michael","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"B\u00fcrger","ForeName":"Katharina","Initials":"K"},{"@attributes":{"ValidYN":"Y"},"LastName":"Annas","ForeName":"Peter","Initials":"P"},{"@attributes":{"ValidYN":"Y"},"LastName":"M\u00f6rtberg","ForeName":"Anette","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Bogstedt","ForeName":"Anna","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Fr\u00f6lich","ForeName":"Lutz","Initials":"L"},{"@attributes":{"ValidYN":"Y"},"LastName":"Schr\u00f6der","ForeName":"Johannes","Initials":"J"},{"@attributes":{"ValidYN":"Y"},"LastName":"Sch\u00f6nknecht","ForeName":"Peter","Initials":"P"},{"@attributes":{"ValidYN":"Y"},"LastName":"Riepe","ForeName":"Matthias W","Initials":"MW"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kraft","ForeName":"Inga","Initials":"I"},{"@attributes":{"ValidYN":"Y"},"LastName":"Gasser","ForeName":"Thomas","Initials":"T"},{"@attributes":{"ValidYN":"Y"},"LastName":"Leyhe","ForeName":"Thomas","Initials":"T"},{"@attributes":{"ValidYN":"Y"},"LastName":"M\u00f6ller","ForeName":"Hans-J\u00fcrgen","Initials":"HJ"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Basun","ForeName":"Hans","Initials":"H"}]},"Language":"eng","DataBankList":{"@attributes":{"CompleteYN":"Y"},"DataBank":{"DataBankName":"ISRCTN","AccessionNumberList":{"AccessionNumber":"ISRCTN72046462"}}},"PublicationTypeList":{"PublicationType":["Journal Article","Multicenter Study","Randomized Controlled Trial","Research Support, Non-U.S. Gov't"]}},"MedlineJournalInfo":{"Country":"United States","MedlineTA":"J Clin Psychiatry","NlmUniqueID":"7801243","ISSNLinking":"0160-6689"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"Amyloid beta-Peptides"},{"RegistryNumber":"0","NameOfSubstance":"Enzyme Inhibitors"},{"RegistryNumber":"0","NameOfSubstance":"MAPT protein, human"},{"RegistryNumber":"0","NameOfSubstance":"Peptide Fragments"},{"RegistryNumber":"0","NameOfSubstance":"amyloid beta-protein (1-42)"},{"RegistryNumber":"0","NameOfSubstance":"tau Proteins"},{"RegistryNumber":"2BMD2GNA4V","NameOfSubstance":"Lithium Carbonate"},{"RegistryNumber":"EC 2.7.11.26","NameOfSubstance":"Glycogen Synthase Kinase 3"}]},"CitationSubset":"IM","CommentsCorrectionsList":{"CommentsCorrections":{"@attributes":{"RefType":"CommentIn"},"RefSource":"J Clin Psychiatry. 2009 Jun;70(6):919-21","PMID":"19573485"}},"MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Aged, 80 and over"},{"DescriptorName":"Alzheimer Disease","QualifierName":["diagnosis","drug therapy","psychology"]},{"DescriptorName":"Amyloid beta-Peptides","QualifierName":"metabolism"},{"DescriptorName":"Enzyme Inhibitors","QualifierName":["adverse effects","therapeutic use"]},{"DescriptorName":"Female"},{"DescriptorName":"Glycogen Synthase Kinase 3","QualifierName":"antagonists & inhibitors"},{"DescriptorName":"Humans"},{"DescriptorName":"Lithium Carbonate","QualifierName":["adverse effects","therapeutic use"]},{"DescriptorName":"Male"},{"DescriptorName":"Mental Status Schedule","QualifierName":"statistics & numerical data"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Neuropsychological Tests","QualifierName":"statistics & numerical data"},{"DescriptorName":"Peptide Fragments","QualifierName":"metabolism"},{"DescriptorName":"Phosphorylation"},{"DescriptorName":"Psychometrics"},{"DescriptorName":"Single-Blind Method"},{"DescriptorName":"tau Proteins","QualifierName":"metabolism"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2008","Month":"08","Day":"08"},{"@attributes":{"PubStatus":"accepted"},"Year":"2008","Month":"11","Day":"13"},{"@attributes":{"PubStatus":"entrez"},"Year":"2009","Month":"7","Day":"4","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2009","Month":"7","Day":"4","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2009","Month":"7","Day":"21","Hour":"9","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["19573486","ej08m04606r"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"19542606","DateCompleted":{"Year":"2010","Month":"09","Day":"22"},"DateRevised":{"Year":"2018","Month":"11","Day":"13"},"Article":{"@attributes":{"PubModel":"Print"},"Journal":{"ISSN":"1875-8908","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"17","Issue":"4","PubDate":{"Year":"2009"}},"Title":"Journal of Alzheimer's disease : JAD","ISOAbbreviation":"J Alzheimers Dis"},"ArticleTitle":"Education attenuates the effect of medial temporal lobe atrophy on cognitive function in Alzheimer's disease: the MIRAGE study.","Pagination":{"MedlinePgn":"855-62"},"ELocationID":"10.3233\/JAD-2009-1117","Abstract":{"AbstractText":"Functional imaging and neuropathological studies suggest that individuals with higher education have better cognitive performance at the same level of brain pathology than less educated subjects. No in vivo studies are available that directly test how education modifies the effect of structural pathology on cognition in Alzheimer's disease (AD). The present study therefore aimed to measure this effect using data from a large multi-center study. 270 patients with AD underwent cognitive testing using the Mini Mental State Examination (MMSE), apolipoprotein E (APOE) genotyping, and cerebral magnetic resonance imaging. A linear regression analysis was used to examine the relation of medial temporal lobe atrophy (MTA), as a proxy of AD pathology, to MMSE score, adjusting for age, gender, APOE, cerebrovascular disease, ethnicity, education, and disease duration. An interaction term for MTA and education was introduced to test the hypothesis that education modifies the effect of MTA on cognition. There was a significant inverse association between MTA and cognition. Most interestingly, the interaction term between education and MTA was significant suggesting that education modifies the relation of MTA to cognition. At any level of pathology, cognition remained higher for better educated individuals."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Perneczky","ForeName":"Robert","Initials":"R","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Technische Universit\u00e4t M\u00fcnchen, M\u00fcnchen, Germany. robert.perneczky@lrz.tum.de"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Wagenpfeil","ForeName":"Stefan","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"Lunetta","ForeName":"Kathryn L","Initials":"KL"},{"@attributes":{"ValidYN":"Y"},"LastName":"Cupples","ForeName":"L Adrienne","Initials":"LA"},{"@attributes":{"ValidYN":"Y"},"LastName":"Green","ForeName":"Robert C","Initials":"RC"},{"@attributes":{"ValidYN":"Y"},"LastName":"DeCarli","ForeName":"Charles","Initials":"C"},{"@attributes":{"ValidYN":"Y"},"LastName":"Farrer","ForeName":"Lindsay A","Initials":"LA"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"}]},"Language":"eng","GrantList":{"@attributes":{"CompleteYN":"Y"},"Grant":[{"GrantID":"K24-AG027841","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"R01-HG\/AG02213","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"R01-AG09029","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"R01 AG009029","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"P30 AG010129-19","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"P30 AG013846","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"K24 AG027841","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"P30 AG010129","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"P30-AG13846","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"}]},"PublicationTypeList":{"PublicationType":["Journal Article","Multicenter Study","Research Support, N.I.H., Extramural"]}},"MedlineJournalInfo":{"Country":"Netherlands","MedlineTA":"J Alzheimers Dis","NlmUniqueID":"9814863","ISSNLinking":"1387-2877"},"ChemicalList":{"Chemical":{"RegistryNumber":"0","NameOfSubstance":"Apolipoproteins E"}},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Age Factors"},{"DescriptorName":"Aged"},{"DescriptorName":"Aged, 80 and over"},{"DescriptorName":"Alzheimer Disease","QualifierName":["diagnosis","pathology","psychology"]},{"DescriptorName":"Apolipoproteins E","QualifierName":"genetics"},{"DescriptorName":"Atrophy"},{"DescriptorName":"Canada"},{"DescriptorName":"Cephalometry","QualifierName":"statistics & numerical data"},{"DescriptorName":"Cerebrovascular Disorders","QualifierName":["pathology","psychology"]},{"DescriptorName":"Cognition"},{"DescriptorName":"Educational Status"},{"DescriptorName":"Female"},{"DescriptorName":"Germany"},{"DescriptorName":"Greece"},{"DescriptorName":"Humans"},{"DescriptorName":"Linear Models"},{"DescriptorName":"Magnetic Resonance Imaging"},{"DescriptorName":"Male"},{"DescriptorName":"Mental Status Schedule"},{"DescriptorName":"Polymerase Chain Reaction"},{"DescriptorName":"Severity of Illness Index"},{"DescriptorName":"Sex Factors"},{"DescriptorName":"Temporal Lobe","QualifierName":"pathology"},{"DescriptorName":"Time Factors"},{"DescriptorName":"United States"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"entrez"},"Year":"2009","Month":"6","Day":"23","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2009","Month":"6","Day":"23","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2010","Month":"9","Day":"24","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["19542606","M3775R2888508626","10.3233\/JAD-2009-1117","PMC2868929","NIHMS197961"]},"ReferenceList":{"Reference":[{"Citation":"Eur J Nucl Med Mol Imaging. 2007 Jul;34(7):1082-7","ArticleIdList":{"ArticleId":"17219132"}},{"Citation":"Dement Geriatr Cogn Disord. 2007;23(6):416-22","ArticleIdList":{"ArticleId":"17457029"}},{"Citation":"J Nucl Med. 2008 Mar;49(3):390-8","ArticleIdList":{"ArticleId":"18287270"}},{"Citation":"Neurology. 2008 May 6;70(19 Pt 2):1732-9","ArticleIdList":{"ArticleId":"18160675"}},{"Citation":"Neurology. 2008 Oct 21;71(17):1342-9","ArticleIdList":{"ArticleId":"18936426"}},{"Citation":"J Neurol. 2008 Sep;255(9):1302-8","ArticleIdList":{"ArticleId":"18825439"}},{"Citation":"Am J Geriatr Psychiatry. 2009 Mar;17(3):188-95","ArticleIdList":{"ArticleId":"19454846"}},{"Citation":"Neuroepidemiology. 2001 May;20(2):105-11","ArticleIdList":{"ArticleId":"11359077"}},{"Citation":"Neurology. 2002 Mar 12;58(5):750-7","ArticleIdList":{"ArticleId":"11889239"}},{"Citation":"J Neurol Neurosurg Psychiatry. 2002 Apr;72(4):491-7","ArticleIdList":{"ArticleId":"11909909"}},{"Citation":"J Int Neuropsychol Soc. 2002 Mar;8(3):448-60","ArticleIdList":{"ArticleId":"11939702"}},{"Citation":"Neurology. 2002 Jun 25;58(12):1791-800","ArticleIdList":{"ArticleId":"12084879"}},{"Citation":"Ann Neurol. 2002 May;51(5):567-77","ArticleIdList":{"ArticleId":"12112102"}},{"Citation":"Neurology. 2002 Aug 13;59(3):383-91","ArticleIdList":{"ArticleId":"12177372"}},{"Citation":"Arch Neurol. 2003 Mar;60(3):359-65","ArticleIdList":{"ArticleId":"12633147"}},{"Citation":"J Clin Exp Neuropsychol. 2003 Aug;25(5):691-701","ArticleIdList":{"ArticleId":"12815506"}},{"Citation":"Neurology. 2003 Jun 24;60(12):1909-15","ArticleIdList":{"ArticleId":"12821732"}},{"Citation":"Psychol Aging. 2003 Jun;18(2):318-31","ArticleIdList":{"ArticleId":"12825779"}},{"Citation":"J Psychiatr Res. 1975 Nov;12(3):189-98","ArticleIdList":{"ArticleId":"1202204"}},{"Citation":"Neurology. 1984 Jul;34(7):939-44","ArticleIdList":{"ArticleId":"6610841"}},{"Citation":"Ann Neurol. 1988 Feb;23(2):138-44","ArticleIdList":{"ArticleId":"2897823"}},{"Citation":"Lancet. 1991 May 11;337(8750):1158-9","ArticleIdList":{"ArticleId":"1674030"}},{"Citation":"Ann Neurol. 1992 Sep;32(3):371-5","ArticleIdList":{"ArticleId":"1416806"}},{"Citation":"J Neurol Neurosurg Psychiatry. 1992 Oct;55(10):967-72","ArticleIdList":{"ArticleId":"1431963"}},{"Citation":"Neurology. 1994 Apr;44(4):652-6","ArticleIdList":{"ArticleId":"8164819"}},{"Citation":"Neurology. 1995 Jan;45(1):55-60","ArticleIdList":{"ArticleId":"7824135"}},{"Citation":"J Neurol. 1995 Sep;242(9):557-60","ArticleIdList":{"ArticleId":"8551316"}},{"Citation":"Neurology. 1996 Mar;46(3):641-50","ArticleIdList":{"ArticleId":"8618660"}},{"Citation":"Acta Neurol Scand Suppl. 1996;165:3-12","ArticleIdList":{"ArticleId":"8740983"}},{"Citation":"Am J Psychiatry. 1997 Feb;154(2):165-72","ArticleIdList":{"ArticleId":"9016263"}},{"Citation":"Neurobiol Aging. 1996 Nov-Dec;17(6):909-19","ArticleIdList":{"ArticleId":"9363803"}},{"Citation":"Neurology. 1997 Dec;49(6):1504-12","ArticleIdList":{"ArticleId":"9409337"}},{"Citation":"Age Ageing. 1999 May;28(3):295-9","ArticleIdList":{"ArticleId":"10475867"}},{"Citation":"Psychiatry Res. 1999 Jun 30;90(3):193-9","ArticleIdList":{"ArticleId":"10466738"}},{"Citation":"Neurobiol Aging. 2005 Apr;26(4):491-510","ArticleIdList":{"ArticleId":"15653178"}},{"Citation":"Neurology. 2005 Sep 27;65(6):953-5","ArticleIdList":{"ArticleId":"16186546"}},{"Citation":"Neurology. 2005 Dec 27;65(12):1888-93","ArticleIdList":{"ArticleId":"16380608"}},{"Citation":"Brain. 2006 Feb;129(Pt 2):386-98","ArticleIdList":{"ArticleId":"16339797"}},{"Citation":"Am J Geriatr Psychiatry. 2006 Feb;14(2):139-44","ArticleIdList":{"ArticleId":"16473978"}},{"Citation":"Lancet Neurol. 2006 May;5(5):406-12","ArticleIdList":{"ArticleId":"16632311"}},{"Citation":"J Neurol Neurosurg Psychiatry. 2006 Sep;77(9):1060-3","ArticleIdList":{"ArticleId":"16709580"}},{"Citation":"Lancet Neurol. 2006 Oct;5(10):828-34","ArticleIdList":{"ArticleId":"16987729"}},{"Citation":"Arch Neurol. 2007 Jan;64(1):108-15","ArticleIdList":{"ArticleId":"17210817"}},{"Citation":"Brain Res. 2007 Feb 16;1133(1):178-85","ArticleIdList":{"ArticleId":"17184752"}},{"Citation":"Acta Neuropathol. 2007 Apr;113(4):349-88","ArticleIdList":{"ArticleId":"17285295"}},{"Citation":"Ann N Y Acad Sci. 2007 Feb;1097:114-45","ArticleIdList":{"ArticleId":"17413016"}},{"Citation":"Alzheimer Dis Assoc Disord. 2007 Apr-Jun;21(2):85-91","ArticleIdList":{"ArticleId":"17545732"}},{"Citation":"Ann Neurol. 2008 Jan;63(1):72-80","ArticleIdList":{"ArticleId":"18157909"}}]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"19454846","DateCompleted":{"Year":"2009","Month":"07","Day":"13"},"DateRevised":{"Year":"2016","Month":"11","Day":"25"},"Article":{"@attributes":{"PubModel":"Print"},"Journal":{"ISSN":"1545-7214","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"17","Issue":"3","PubDate":{"Year":"2009","Month":"Mar"}},"Title":"The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry","ISOAbbreviation":"Am J Geriatr Psychiatry"},"ArticleTitle":"Fluoro-deoxy-glucose positron emission tomography correlates of impaired activities of daily living in dementia with Lewy bodies: implications for cognitive reserve.","Pagination":{"MedlinePgn":"188-95"},"ELocationID":"10.1097\/JGP.0b013e3181961a6f","Abstract":{"AbstractText":["1) To investigate the neural substrate of impaired activities of daily living (ADL) in dementia with Lewy bodies (DLB) and 2) to explore, in the context of cognitive reserve, if hypometabolism was more pronounced in well-educated patients at the same level of everyday impairment.","Twenty-one patients with DLB underwent an extensive clinical evaluation including cerebral positron emission tomography with F-fluoro-2-deoxy-glucose scanning. First, brain areas were identified, where ADL performance and glucose metabolism were significantly correlated, controlling for individual differences in cognitive and motor dysfunction. Second, it was tested if there was a significant negative association between metabolism and years of education in brain regions associated with ADL performance. Again, a correction for cognitive and motor impairment was deployed.","There was a significant association between glucose hypometabolism and impaired ADL performance in an extensive brain cluster located in the right temporoparietal cortex. Furthermore, schooling and metabolic rate were inversely associated in the right Brodmann area 19, controlling for ADL performance.","The study suggests that 1) certain brain metabolic alterations are specifically associated with the loss of everyday competence, even if differences in cognition and motor function are taken into consideration and 2) well-educated patients can offset more brain damage until reaching the same degree of ADL impairment as their less educated counterparts. These results extend the literature on cognitive reserve to a region-specific effect on ADL performance."]},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Perneczky","ForeName":"Robert","Initials":"R","AffiliationInfo":{"Affiliation":"Departments of Psychiatry and Psychotherapy, Technical University Munich, Ismaninger Strasse 22, Munich, Germany. robert.perneczky@lrz.tum.de"}},{"@attributes":{"ValidYN":"Y"},"LastName":"H\u00e4ussermann","ForeName":"Peter","Initials":"P"},{"@attributes":{"ValidYN":"Y"},"LastName":"Drzezga","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Boecker","ForeName":"Henning","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Granert","ForeName":"Oliver","Initials":"O"},{"@attributes":{"ValidYN":"Y"},"LastName":"Feurer","ForeName":"Regina","Initials":"R"},{"@attributes":{"ValidYN":"Y"},"LastName":"F\u00f6rstl","ForeName":"Hans","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Research Support, Non-U.S. Gov't"]}},"MedlineJournalInfo":{"Country":"England","MedlineTA":"Am J Geriatr Psychiatry","NlmUniqueID":"9309609","ISSNLinking":"1064-7481"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"Blood Glucose"},{"RegistryNumber":"0","NameOfSubstance":"Radiopharmaceuticals"},{"RegistryNumber":"0Z5B2CJX4D","NameOfSubstance":"Fluorodeoxyglucose F18"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Activities of Daily Living","QualifierName":"psychology"},{"DescriptorName":"Aged"},{"DescriptorName":"Aged, 80 and over"},{"DescriptorName":"Blood Glucose","QualifierName":"metabolism"},{"DescriptorName":"Brain","QualifierName":["diagnostic imaging","metabolism"]},{"DescriptorName":"Cognition","QualifierName":"physiology"},{"DescriptorName":"Dementia","QualifierName":["diagnostic imaging","metabolism","physiopathology"]},{"DescriptorName":"Educational Status"},{"DescriptorName":"Female"},{"DescriptorName":"Fluorodeoxyglucose F18"},{"DescriptorName":"Humans"},{"DescriptorName":"Image Processing, Computer-Assisted"},{"DescriptorName":"Lewy Body Disease","QualifierName":["diagnostic imaging","metabolism","physiopathology"]},{"DescriptorName":"Male"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Neuropsychological Tests"},{"DescriptorName":"Positron-Emission Tomography","QualifierName":"methods"},{"DescriptorName":"Radiopharmaceuticals"},{"DescriptorName":"Regression Analysis"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"entrez"},"Year":"2009","Month":"5","Day":"21","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2009","Month":"5","Day":"21","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2009","Month":"7","Day":"14","Hour":"9","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["19454846","10.1097\/JGP.0b013e3181961a6f","00019442-200903000-00003"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"19439965","DateCompleted":{"Year":"2009","Month":"08","Day":"12"},"DateRevised":{"Year":"2016","Month":"11","Day":"25"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1421-9824","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"27","Issue":"5","PubDate":{"Year":"2009"}},"Title":"Dementia and geriatric cognitive disorders","ISOAbbreviation":"Dement Geriatr Cogn Disord"},"ArticleTitle":"Brain metabolic correlates of cerebrospinal fluid beta-amyloid 42 and tau in Alzheimer's disease.","Pagination":{"MedlinePgn":"474-80"},"ELocationID":"10.1159\/000218080","Abstract":{"AbstractText":["The cerebrospinal fluid (CSF) proteins beta-amyloid 42 (Abeta42) and Tau are believed to indirectly reflect some core pathological features of Alzheimer's disease (AD). Their topographic origin and their association with synaptic dysfunction are still not well understood.","The present study aimed to explore possible associations between cerebral glucose metabolism and CSF Abeta42 as well as Tau protein levels in AD.","CSF analyses and (18)F-FDG PET scans were conducted on 32 patients with mild-to-moderate AD. Voxel-based statistical parametric correlations were computed for CSF protein levels and cerebral glucose metabolism.","After correction for multiple comparisons, a strong positive association between CSF Abeta42 levels and glucose metabolism was identified for 2 extensive clusters located in the right temporal, prefrontal and anterior cingulate cortices. For CSF Tau protein, no association was observed for any brain region.","These findings point to a significant association between synaptic dysfunction as measured with (18)F-FDG PET and CSF Abeta42 levels, but do not suggest a correlation between synaptic function and CSF Tau levels."]},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Vukovich","ForeName":"Ruth","Initials":"R","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Neurochemistry and Neurogenetics Laboratory, Technische Universit\u00e4t M\u00fcnchen, M\u00fcnchen, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Perneczky","ForeName":"Robert","Initials":"R"},{"@attributes":{"ValidYN":"Y"},"LastName":"Drzezga","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"F\u00f6rstl","ForeName":"Hans","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Riemenschneider","ForeName":"Matthias","Initials":"M"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Research Support, Non-U.S. Gov't"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2009","Month":"05","Day":"12"}},"MedlineJournalInfo":{"Country":"Switzerland","MedlineTA":"Dement Geriatr Cogn Disord","NlmUniqueID":"9705200","ISSNLinking":"1420-8008"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"Amyloid beta-Peptides"},{"RegistryNumber":"0","NameOfSubstance":"Peptide Fragments"},{"RegistryNumber":"0","NameOfSubstance":"Radiopharmaceuticals"},{"RegistryNumber":"0","NameOfSubstance":"amyloid beta-protein (1-42)"},{"RegistryNumber":"0","NameOfSubstance":"tau Proteins"},{"RegistryNumber":"0Z5B2CJX4D","NameOfSubstance":"Fluorodeoxyglucose F18"},{"RegistryNumber":"IY9XDZ35W2","NameOfSubstance":"Glucose"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Alzheimer Disease","QualifierName":["cerebrospinal fluid","diagnostic imaging","psychology"]},{"DescriptorName":"Amyloid beta-Peptides","QualifierName":"cerebrospinal fluid"},{"DescriptorName":"Brain Chemistry","QualifierName":"physiology"},{"DescriptorName":"Female"},{"DescriptorName":"Fluorodeoxyglucose F18"},{"DescriptorName":"Glucose","QualifierName":"metabolism"},{"DescriptorName":"Humans"},{"DescriptorName":"Image Processing, Computer-Assisted"},{"DescriptorName":"Male"},{"DescriptorName":"Neurons","QualifierName":"pathology"},{"DescriptorName":"Neuropsychological Tests"},{"DescriptorName":"Peptide Fragments","QualifierName":"cerebrospinal fluid"},{"DescriptorName":"Positron-Emission Tomography"},{"DescriptorName":"Radiopharmaceuticals"},{"DescriptorName":"tau Proteins","QualifierName":"cerebrospinal fluid"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"accepted"},"Year":"2009","Month":"02","Day":"04"},{"@attributes":{"PubStatus":"entrez"},"Year":"2009","Month":"5","Day":"15","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2009","Month":"5","Day":"15","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2009","Month":"8","Day":"13","Hour":"9","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["19439965","000218080","10.1159\/000218080"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"19405180","DateCompleted":{"Year":"2009","Month":"06","Day":"05"},"DateRevised":{"Year":"2019","Month":"07","Day":"09"},"Article":{"@attributes":{"PubModel":"Print"},"Journal":{"ISSN":"1532-5415","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"57","Issue":"4","PubDate":{"Year":"2009","Month":"Apr"}},"Title":"Journal of the American Geriatrics Society","ISOAbbreviation":"J Am Geriatr Soc"},"ArticleTitle":"Plasma homocysteine and cerebrospinal fluid neurodegeneration biomarkers in mild cognitive impairment and dementia.","Pagination":{"MedlinePgn":"737-9"},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Alexopoulos","ForeName":"Panagiotis","Initials":"P"},{"@attributes":{"ValidYN":"Y"},"LastName":"G\u00fcnther","ForeName":"Florian","Initials":"F"},{"@attributes":{"ValidYN":"Y"},"LastName":"Popp","ForeName":"Julius","Initials":"J"},{"@attributes":{"ValidYN":"Y"},"LastName":"Jessen","ForeName":"Frank","Initials":"F"},{"@attributes":{"ValidYN":"Y"},"LastName":"Peters","ForeName":"Oliver","Initials":"O"},{"@attributes":{"ValidYN":"Y"},"LastName":"Wolf","ForeName":"Stefanie","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kneib","ForeName":"Thomas","Initials":"T"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Richter-Schmidinger","ForeName":"Tanja","Initials":"T"},{"@attributes":{"ValidYN":"Y"},"LastName":"Lewczuk","ForeName":"Piotr","Initials":"P"},{"@attributes":{"ValidYN":"Y"},"LastName":"Bleich","ForeName":"Stefan","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"Wiltfang","ForeName":"Jens","Initials":"J"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kornhuber","ForeName":"Johannes","Initials":"J"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Letter","Multicenter Study","Research Support, Non-U.S. Gov't"]}},"MedlineJournalInfo":{"Country":"United States","MedlineTA":"J Am Geriatr Soc","NlmUniqueID":"7503062","ISSNLinking":"0002-8614"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"Amyloid beta-Peptides"},{"RegistryNumber":"0","NameOfSubstance":"Biomarkers"},{"RegistryNumber":"0","NameOfSubstance":"Peptide Fragments"},{"RegistryNumber":"0","NameOfSubstance":"amyloid beta-protein (1-40)"},{"RegistryNumber":"0","NameOfSubstance":"amyloid beta-protein (1-42)"},{"RegistryNumber":"0","NameOfSubstance":"tau Proteins"},{"RegistryNumber":"0LVT1QZ0BA","NameOfSubstance":"Homocysteine"},{"RegistryNumber":"935E97BOY8","NameOfSubstance":"Folic Acid"},{"RegistryNumber":"AYI8EX34EU","NameOfSubstance":"Creatinine"},{"RegistryNumber":"P6YC3EG204","NameOfSubstance":"Vitamin B 12"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Amyloid beta-Peptides","QualifierName":"cerebrospinal fluid"},{"DescriptorName":"Biomarkers","QualifierName":["blood","cerebrospinal fluid"]},{"DescriptorName":"Chromatography, High Pressure Liquid"},{"DescriptorName":"Creatinine","QualifierName":"cerebrospinal fluid"},{"DescriptorName":"Dementia","QualifierName":["blood","cerebrospinal fluid"]},{"DescriptorName":"Enzyme-Linked Immunosorbent Assay"},{"DescriptorName":"Female"},{"DescriptorName":"Folic Acid","QualifierName":"cerebrospinal fluid"},{"DescriptorName":"Germany"},{"DescriptorName":"Homocysteine","QualifierName":["blood","cerebrospinal fluid"]},{"DescriptorName":"Humans"},{"DescriptorName":"Immunoassay"},{"DescriptorName":"Linear Models"},{"DescriptorName":"Male"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Nephelometry and Turbidimetry"},{"DescriptorName":"Nerve Degeneration","QualifierName":["blood","cerebrospinal fluid"]},{"DescriptorName":"Peptide Fragments","QualifierName":"cerebrospinal fluid"},{"DescriptorName":"Vitamin B 12","QualifierName":"cerebrospinal fluid"},{"DescriptorName":"tau Proteins","QualifierName":"cerebrospinal fluid"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"entrez"},"Year":"2009","Month":"5","Day":"1","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2009","Month":"5","Day":"1","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2009","Month":"6","Day":"6","Hour":"9","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["19405180","10.1111\/j.1532-5415.2009.02212.x"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"19368828","DateCompleted":{"Year":"2009","Month":"11","Day":"17"},"DateRevised":{"Year":"2010","Month":"11","Day":"18"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1872-6240","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"1264","PubDate":{"Year":"2009","Month":"Apr","Day":"06"}},"Title":"Brain research","ISOAbbreviation":"Brain Res"},"ArticleTitle":"Association of SORL1 gene variants with Alzheimer's disease.","Pagination":{"MedlinePgn":"1-6"},"ELocationID":"10.1016\/j.brainres.2009.01.044","Abstract":{"AbstractText":"SORL1 gene variants were described as risk factor of Alzheimer's disease (AD) additionally SORL1 gene variants were associated with altered Abeta(42) CSF levels in AD patients. In the present study we investigated the association of SORL1 gene variants (rs2070045 (SNP19), SORL1-18ex26 (SNP21), rs3824968 (SNP23), rs1010159 (SNP25)) with AD risk by using Cox proportional hazard model and Kaplan-Meier survival analysis in 349 AD patients and 483 controls, recruited from a multicenter study of the German Competence Network Dementias. The SNP21G-allele and a SORL1 haplotype consisting of the SNP19 T-allele, SNP21 G-allele and SNP23 A-allele (T\/G\/A) were associated with increased hazard ratios and an earlier age at onset of AD (SNP21: p=0.002; T\/G\/A haplotype: p=0.007). This effect was most pronounced in carriers of an additional APOE4 allele (SNP21: p=0.003; T\/G\/A haplotype: p=0.005). In conclusion, we found SORL1 gene variants located in the 3' region of the gene to be associated with increased AD risk and an earlier age at onset of AD in our Central-European population. Thus, our data support a role of SORL1 polymorphisms in AD."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"K\u00f6lsch","ForeName":"Heike","Initials":"H","AffiliationInfo":{"Affiliation":"Department of Psychiatry, University of Bonn, Bonn, Germany. heike.koelsch@ukb.uni-bonn.de"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Jessen","ForeName":"Frank","Initials":"F"},{"@attributes":{"ValidYN":"Y"},"LastName":"Wiltfang","ForeName":"Jens","Initials":"J"},{"@attributes":{"ValidYN":"Y"},"LastName":"Lewczuk","ForeName":"Piotr","Initials":"P"},{"@attributes":{"ValidYN":"Y"},"LastName":"Dichgans","ForeName":"Martin","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Teipel","ForeName":"Stefan J","Initials":"SJ"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kornhuber","ForeName":"Johannes","Initials":"J"},{"@attributes":{"ValidYN":"Y"},"LastName":"Fr\u00f6lich","ForeName":"Lutz","Initials":"L"},{"@attributes":{"ValidYN":"Y"},"LastName":"Heuser","ForeName":"Isabella","Initials":"I"},{"@attributes":{"ValidYN":"Y"},"LastName":"Peters","ForeName":"Oliver","Initials":"O"},{"@attributes":{"ValidYN":"Y"},"LastName":"Wiese","ForeName":"Birgitt","Initials":"B"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kaduszkiewicz","ForeName":"Hanna","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"van den Bussche","ForeName":"Hendrik","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"H\u00fcll","ForeName":"Michael","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"R\u00fcther","ForeName":"Eckhart","Initials":"E"},{"@attributes":{"ValidYN":"Y"},"LastName":"Henn","ForeName":"Fritz A","Initials":"FA"},{"@attributes":{"ValidYN":"Y"},"LastName":"Maier","ForeName":"Wolfgang","Initials":"W"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Multicenter Study","Research Support, Non-U.S. Gov't"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2009","Month":"02","Day":"03"}},"MedlineJournalInfo":{"Country":"Netherlands","MedlineTA":"Brain Res","NlmUniqueID":"0045503","ISSNLinking":"0006-8993"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"LDL-Receptor Related Proteins"},{"RegistryNumber":"0","NameOfSubstance":"Membrane Transport Proteins"},{"RegistryNumber":"0","NameOfSubstance":"SORL1 protein, human"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Age of Onset"},{"DescriptorName":"Aged"},{"DescriptorName":"Alleles"},{"DescriptorName":"Alzheimer Disease","QualifierName":"genetics"},{"DescriptorName":"Female"},{"DescriptorName":"Gene Frequency"},{"DescriptorName":"Genetic Predisposition to Disease","QualifierName":"genetics"},{"DescriptorName":"Genetic Variation"},{"DescriptorName":"Haplotypes"},{"DescriptorName":"Humans"},{"DescriptorName":"Kaplan-Meier Estimate"},{"DescriptorName":"LDL-Receptor Related Proteins","QualifierName":"genetics"},{"DescriptorName":"Male"},{"DescriptorName":"Membrane Transport Proteins","QualifierName":"genetics"},{"DescriptorName":"Polymorphism, Genetic","QualifierName":"genetics"},{"DescriptorName":"Regression Analysis"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2008","Month":"05","Day":"28"},{"@attributes":{"PubStatus":"revised"},"Year":"2009","Month":"01","Day":"14"},{"@attributes":{"PubStatus":"accepted"},"Year":"2009","Month":"01","Day":"17"},{"@attributes":{"PubStatus":"entrez"},"Year":"2009","Month":"4","Day":"17","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2009","Month":"4","Day":"17","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2009","Month":"11","Day":"18","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["19368828","S0006-8993(09)00169-3","10.1016\/j.brainres.2009.01.044"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"19268916","DateCompleted":{"Year":"2009","Month":"07","Day":"27"},"DateRevised":{"Year":"2019","Month":"12","Day":"18"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1873-2402","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"65","Issue":"11","PubDate":{"Year":"2009","Month":"Jun","Day":"01"}},"Title":"Biological psychiatry","ISOAbbreviation":"Biol Psychiatry"},"ArticleTitle":"Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid.","Pagination":{"MedlinePgn":"927-34"},"ELocationID":"10.1016\/j.biopsych.2009.01.027","Abstract":{"AbstractText":["A decreased concentration of beta amyloid (1-42) (Abeta42) has consistently been found in the cerebrospinal fluid (CSF) of patients with Alzheimer's disease (AD) and is considered a diagnostic biomarker. However, it is not clear to which extent CSF Abeta42 levels are reflective of cerebral pathology in AD. The aim of the study was to determine the association between cerebral amyloid plaque load, as measured by means of the positron emission tomography (PET) tracer carbon-11-labeled Pittsburgh Compound B ([11C]PiB) and CSF Abeta42 in AD.","A group of 30 patients with probable AD, as defined by established clinical criteria and by an AD-typical pattern of tracer uptake in fluorine-18-labeled fluorodeoxyglucose ([18F]FDG) PET, were included. In all patients, [11C]PiB PET and CSF analysis were performed. The association between amyloid load and CSF Abeta42 levels was examined in three different ways: by linear regression analysis using an overall [11C]PiB value for the entire cerebrum, by correlation analyses using [11C]PiB measurements in anatomically defined regions of interest, and by voxel-based regression analyses.","All patients showed a positive [11C]PiB scan demonstrating amyloid deposition. Linear regression analysis revealed a significant inverse correlation between the overall [11C]PiB uptake and CSF Abeta42 levels. Voxel-based regression and regional correlation analyses did not attain statistical significance after correction for multiple comparisons. Numerically, correlation coefficients were higher in brain regions adjacent to CSF spaces.","The study demonstrates a moderate linear negative association between cerebral amyloid plaque load and CSF Abeta42 levels in AD patients in vivo and suggests possible regional differences of the association."]},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Grimmer","ForeName":"Timo","Initials":"T","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar der Technischen Universit\u00e4t M\u00fcnchen, Munich 81675, Germany. t.grimmer@lrz.tum.de"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Riemenschneider","ForeName":"Matthias","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"F\u00f6rstl","ForeName":"Hans","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Henriksen","ForeName":"Gjermund","Initials":"G"},{"@attributes":{"ValidYN":"Y"},"LastName":"Klunk","ForeName":"William E","Initials":"WE"},{"@attributes":{"ValidYN":"Y"},"LastName":"Mathis","ForeName":"Chester A","Initials":"CA"},{"@attributes":{"ValidYN":"Y"},"LastName":"Shiga","ForeName":"Tohru","Initials":"T"},{"@attributes":{"ValidYN":"Y"},"LastName":"Wester","ForeName":"Hans-J\u00fcrgen","Initials":"HJ"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Drzezga","ForeName":"Alexander","Initials":"A"}]},"Language":"eng","GrantList":{"@attributes":{"CompleteYN":"Y"},"Grant":[{"GrantID":"R01 AG018402","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"R37 AG025516","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"K02 AG001039-05","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"P01 AG025204-050001","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"P50 AG005133","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"RF1 AG025516","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"P50 AG005133-260021","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"R01 AG020226-05","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"R01 AG020226","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"K02 AG001039","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"R37 AG025516-05","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"P01 AG025204","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"}]},"PublicationTypeList":{"PublicationType":["Journal Article","Research Support, N.I.H., Extramural","Research Support, Non-U.S. Gov't"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2009","Month":"03","Day":"06"}},"MedlineJournalInfo":{"Country":"United States","MedlineTA":"Biol Psychiatry","NlmUniqueID":"0213264","ISSNLinking":"0006-3223"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole"},{"RegistryNumber":"0","NameOfSubstance":"Amyloid beta-Peptides"},{"RegistryNumber":"0","NameOfSubstance":"Apolipoproteins E"},{"RegistryNumber":"0","NameOfSubstance":"Benzothiazoles"},{"RegistryNumber":"0","NameOfSubstance":"Carbon Radioisotopes"},{"RegistryNumber":"0","NameOfSubstance":"Peptide Fragments"},{"RegistryNumber":"0","NameOfSubstance":"amyloid beta-protein (1-42)"},{"RegistryNumber":"0Z5B2CJX4D","NameOfSubstance":"Fluorodeoxyglucose F18"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Aged, 80 and over"},{"DescriptorName":"Alzheimer Disease","QualifierName":["cerebrospinal fluid","diagnostic imaging","genetics","pathology"]},{"DescriptorName":"Amyloid beta-Peptides","QualifierName":"metabolism"},{"DescriptorName":"Apolipoproteins E","QualifierName":"genetics"},{"DescriptorName":"Benzothiazoles"},{"DescriptorName":"Brain","QualifierName":["diagnostic imaging","metabolism"]},{"DescriptorName":"Brain Mapping"},{"DescriptorName":"Carbon Radioisotopes"},{"DescriptorName":"Female"},{"DescriptorName":"Fluorodeoxyglucose F18"},{"DescriptorName":"Humans"},{"DescriptorName":"Linear Models"},{"DescriptorName":"Magnetic Resonance Imaging","QualifierName":"methods"},{"DescriptorName":"Male"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Peptide Fragments","QualifierName":"metabolism"},{"DescriptorName":"Positron-Emission Tomography","QualifierName":"methods"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2008","Month":"04","Day":"01"},{"@attributes":{"PubStatus":"revised"},"Year":"2008","Month":"12","Day":"07"},{"@attributes":{"PubStatus":"accepted"},"Year":"2009","Month":"01","Day":"08"},{"@attributes":{"PubStatus":"entrez"},"Year":"2009","Month":"3","Day":"10","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2009","Month":"3","Day":"10","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2009","Month":"7","Day":"28","Hour":"9","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["19268916","S0006-3223(09)00110-3","10.1016\/j.biopsych.2009.01.027","PMC2700302","NIHMS118840"]},"ReferenceList":{"Reference":[{"Citation":"Dement Geriatr Cogn Disord. 2004;18(1):32-6","ArticleIdList":{"ArticleId":"15084791"}},{"Citation":"Neuroimaging Clin N Am. 2003 Nov;13(4):769-80","ArticleIdList":{"ArticleId":"15024960"}},{"Citation":"J Psychiatr Res. 1975 Nov;12(3):189-98","ArticleIdList":{"ArticleId":"1202204"}},{"Citation":"Neurology. 1984 Jul;34(7):939-44","ArticleIdList":{"ArticleId":"6610841"}},{"Citation":"Neurology. 1989 Sep;39(9):1159-65","ArticleIdList":{"ArticleId":"2771064"}},{"Citation":"J Cereb Blood Flow Metab. 1990 Jul;10(4):458-66","ArticleIdList":{"ArticleId":"2347879"}},{"Citation":"Acta Neuropathol. 1991;82(4):239-59","ArticleIdList":{"ArticleId":"1759558"}},{"Citation":"Acta Neuropathol. 1992;83(3):233-9","ArticleIdList":{"ArticleId":"1373020"}},{"Citation":"Neurology. 1993 Feb;43(2):250-60","ArticleIdList":{"ArticleId":"8094895"}},{"Citation":"J Neurochem. 1993 Nov;61(5):1828-34","ArticleIdList":{"ArticleId":"8228996"}},{"Citation":"Neurology. 1996 Nov;47(5):1113-24","ArticleIdList":{"ArticleId":"8909416"}},{"Citation":"Clin Chem. 1997 Sep;43(9):1657-9","ArticleIdList":{"ArticleId":"9299950"}},{"Citation":"J Neuropathol Exp Neurol. 1998 Oct;57(10):885-94","ArticleIdList":{"ArticleId":"9786239"}},{"Citation":"Neurology. 1999 May 12;52(8):1555-62","ArticleIdList":{"ArticleId":"10331678"}},{"Citation":"Neurology. 2005 Jul 26;65(2):323-5","ArticleIdList":{"ArticleId":"16043812"}},{"Citation":"J Nucl Med. 2005 Dec;46(12):1959-72","ArticleIdList":{"ArticleId":"16330558"}},{"Citation":"Ann Neurol. 2006 Mar;59(3):512-9","ArticleIdList":{"ArticleId":"16372280"}},{"Citation":"Sci Aging Knowledge Environ. 2006 Mar 8;2006(6):re1","ArticleIdList":{"ArticleId":"16525193"}},{"Citation":"Neuroimage. 2006 Oct 15;33(1):94-102","ArticleIdList":{"ArticleId":"16905334"}},{"Citation":"Brain. 2006 Nov;129(Pt 11):2856-66","ArticleIdList":{"ArticleId":"16854944"}},{"Citation":"Ann N Y Acad Sci. 2007 Feb;1097:114-45","ArticleIdList":{"ArticleId":"17413016"}},{"Citation":"Can J Neurol Sci. 2007 Mar;34 Suppl 1:S72-6","ArticleIdList":{"ArticleId":"17469687"}},{"Citation":"Brain. 2007 Sep;130(Pt 9):2320-6","ArticleIdList":{"ArticleId":"17586559"}},{"Citation":"Brain. 2008 Jun;131(Pt 6):1630-45","ArticleIdList":{"ArticleId":"18339640"}},{"Citation":"Neurology. 2008 Sep 16;71(12):903-10","ArticleIdList":{"ArticleId":"18794492"}},{"Citation":"J Neurol Neurosurg Psychiatry. 2008 Dec;79(12):1331-8","ArticleIdList":{"ArticleId":"18653550"}},{"Citation":"Neurobiol Aging. 2009 Dec;30(12):1902-9","ArticleIdList":{"ArticleId":"18346821"}},{"Citation":"Neurosci Lett. 2000 Feb 18;280(2):119-22","ArticleIdList":{"ArticleId":"10686392"}},{"Citation":"J Pathol. 2001 May;194(1):1-3","ArticleIdList":{"ArticleId":"11329133"}},{"Citation":"Neuroimage. 2002 Jan;15(1):273-89","ArticleIdList":{"ArticleId":"11771995"}},{"Citation":"Neurobiol Aging. 2002 Mar-Apr;23(2):205-11","ArticleIdList":{"ArticleId":"11804704"}},{"Citation":"Neurology. 2002 Jun 25;58(12):1791-800","ArticleIdList":{"ArticleId":"12084879"}},{"Citation":"Arch Neurol. 2002 Nov;59(11):1729-34","ArticleIdList":{"ArticleId":"12433260"}},{"Citation":"Neurology. 2003 Feb 25;60(4):652-6","ArticleIdList":{"ArticleId":"12601108"}},{"Citation":"JAMA. 2003 Apr 23-30;289(16):2094-103","ArticleIdList":{"ArticleId":"12709467"}},{"Citation":"Lancet Neurol. 2003 Oct;2(10):605-13","ArticleIdList":{"ArticleId":"14505582"}},{"Citation":"Mol Imaging. 2003 Jul;2(3):131-7","ArticleIdList":{"ArticleId":"14649056"}},{"Citation":"Ann Neurol. 2004 Mar;55(3):306-19","ArticleIdList":{"ArticleId":"14991808"}},{"Citation":"Mol Psychiatry. 2004 Jul;9(7):705-10","ArticleIdList":{"ArticleId":"14699432"}},{"Citation":"Brain. 2007 Oct;130(Pt 10):2607-15","ArticleIdList":{"ArticleId":"17698496"}},{"Citation":"J Neurosci. 2007 Sep 26;27(39):10365-71","ArticleIdList":{"ArticleId":"17898208"}},{"Citation":"Clin Chem Lab Med. 2007;45(11):1421-34","ArticleIdList":{"ArticleId":"17970699"}},{"Citation":"Neuroimage. 2008 Jan 15;39(2):619-33","ArticleIdList":{"ArticleId":"17962045"}},{"Citation":"Brain Pathol. 2008 Apr;18(2):253-66","ArticleIdList":{"ArticleId":"18363936"}},{"Citation":"J Neurosci. 2008 Apr 9;28(15):3941-6","ArticleIdList":{"ArticleId":"18400893"}}]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"19255708","DateCompleted":{"Year":"2009","Month":"11","Day":"03"},"DateRevised":{"Year":"2018","Month":"11","Day":"13"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1433-8491","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"259","Issue":"6","PubDate":{"Year":"2009","Month":"Sep"}},"Title":"European archives of psychiatry and clinical neuroscience","ISOAbbreviation":"Eur Arch Psychiatry Clin Neurosci"},"ArticleTitle":"Accelerated clinical decline in well-educated patients with frontotemporal lobar degenerations.","Pagination":{"MedlinePgn":"362-7"},"ELocationID":"10.1007\/s00406-009-0004-6","Abstract":{"AbstractText":"Education seems to protect against symptoms of neurodegeneration, but highly educated individuals experience faster cognitive decline after the onset of dementia. No studies on the effects of education on the clinical course in frontotemporal lobar degenerations (FTLD) exist. The aim of the study was to explore the effect of education on the rate of clinical deterioration in patients with FTLD. Thirty-five patients with FTLD were recruited and followed up for 20 months in average. A correlation was calculated between years of education and monthly rate of change on the clinical dementia rating scale sum of the boxes (CDR-SOB). A linear regression analysis with the CDR-SOB monthly rate of change as dependent, and the educational years and other variables possibly associated with the rate of clinical decline as independent variables was performed. There was a significant positive association between education and CDR-SOB monthly rate of change, indicating a faster decline in the well-educated. Education was the only significant predictor of clinical deterioration."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Perneczky","ForeName":"Robert","Initials":"R","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Technische Universit\u00e4t M\u00fcnchen, 81675 Munich, Germany. robert.perneczky@lrz.tum.de"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Pohl","ForeName":"Corina","Initials":"C"},{"@attributes":{"ValidYN":"Y"},"LastName":"Bornschein","ForeName":"Susanne","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"F\u00f6rstl","ForeName":"Hans","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Diehl-Schmid","ForeName":"Janine","Initials":"J"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Research Support, Non-U.S. Gov't"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2009","Month":"03","Day":"03"}},"MedlineJournalInfo":{"Country":"Germany","MedlineTA":"Eur Arch Psychiatry Clin Neurosci","NlmUniqueID":"9103030","ISSNLinking":"0940-1334"},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Cognition Disorders","QualifierName":["etiology","pathology"]},{"DescriptorName":"Dementia","QualifierName":["pathology","physiopathology"]},{"DescriptorName":"Disease Progression"},{"DescriptorName":"Female"},{"DescriptorName":"Humans"},{"DescriptorName":"Male"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Neuropsychological Tests"},{"DescriptorName":"Psychiatric Status Rating Scales"},{"DescriptorName":"Regression Analysis"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2008","Month":"09","Day":"15"},{"@attributes":{"PubStatus":"accepted"},"Year":"2009","Month":"02","Day":"11"},{"@attributes":{"PubStatus":"entrez"},"Year":"2009","Month":"3","Day":"4","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2009","Month":"3","Day":"4","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2009","Month":"11","Day":"5","Hour":"6","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["19255708","10.1007\/s00406-009-0004-6"]},"ReferenceList":{"Reference":[{"Citation":"Dement Geriatr Cogn Disord. 2006;22(4):352-7","ArticleIdList":{"ArticleId":"16954691"}},{"Citation":"Dement Geriatr Cogn Disord. 1998;9 Suppl 2:20-6","ArticleIdList":{"ArticleId":"9718231"}},{"Citation":"Neurology. 2008 May 27;70(22):2046-52","ArticleIdList":{"ArticleId":"18505978"}},{"Citation":"Am J Geriatr Psychiatry. 2007 Jan;15(1):84-7","ArticleIdList":{"ArticleId":"17194818"}},{"Citation":"Psychopharmacology (Berl). 2004 Apr;172(4):400-8","ArticleIdList":{"ArticleId":"14666399"}},{"Citation":"Neurology. 1994 Dec;44(12):2308-14","ArticleIdList":{"ArticleId":"7991117"}},{"Citation":"Psychol Med. 2006 Aug;36(8):1065-73","ArticleIdList":{"ArticleId":"16650343"}},{"Citation":"Brain Res. 2007 Feb 16;1133(1):178-85","ArticleIdList":{"ArticleId":"17184752"}},{"Citation":"Alzheimer Dis Assoc Disord. 2007 Apr-Jun;21(2):164-6","ArticleIdList":{"ArticleId":"17545743"}},{"Citation":"Neurobiol Aging. 2010 Feb;31(2):270-9","ArticleIdList":{"ArticleId":"18495299"}},{"Citation":"J Gerontol A Biol Sci Med Sci. 1995 Jan;50A(1):M49-55","ArticleIdList":{"ArticleId":"7814789"}},{"Citation":"Neurology. 2000 Dec 12;55(11):1621-6","ArticleIdList":{"ArticleId":"11113214"}},{"Citation":"Neurology. 2003 Jun 24;60(12):1909-15","ArticleIdList":{"ArticleId":"12821732"}},{"Citation":"Am J Alzheimers Dis Other Demen. 2003 Jul-Aug;18(4):205-14","ArticleIdList":{"ArticleId":"12955785"}},{"Citation":"J Clin Exp Neuropsychol. 2003 Aug;25(5):671-9","ArticleIdList":{"ArticleId":"12815504"}},{"Citation":"J Int Neuropsychol Soc. 2002 Mar;8(3):448-60","ArticleIdList":{"ArticleId":"11939702"}},{"Citation":"Alzheimer Dis Assoc Disord. 2004 Oct-Dec;18(4):202-7","ArticleIdList":{"ArticleId":"15592131"}},{"Citation":"Amyotroph Lateral Scler. 2007 Jun;8(3):189-90","ArticleIdList":{"ArticleId":"17538783"}},{"Citation":"J Psychiatr Res. 1975 Nov;12(3):189-98","ArticleIdList":{"ArticleId":"1202204"}},{"Citation":"Eur Arch Psychiatry Clin Neurosci. 2007 Aug;257(5):271-80","ArticleIdList":{"ArticleId":"17401726"}},{"Citation":"Dement Geriatr Cogn Disord. 2004;17(4):355-9","ArticleIdList":{"ArticleId":"15178953"}},{"Citation":"Dement Geriatr Cogn Disord. 2008;25(2):178-85","ArticleIdList":{"ArticleId":"18196898"}},{"Citation":"Neurology. 1999 Dec 10;53(9):1942-7","ArticleIdList":{"ArticleId":"10599762"}},{"Citation":"Neurology. 1998 Dec;51(6):1546-54","ArticleIdList":{"ArticleId":"9855500"}},{"Citation":"Can J Neurol Sci. 1997 Feb;24(1):29-36","ArticleIdList":{"ArticleId":"9043744"}},{"Citation":"J Neurol Neurosurg Psychiatry. 2003 Sep;74(9):1206-9","ArticleIdList":{"ArticleId":"12933919"}},{"Citation":"Alzheimer Dis Assoc Disord. 2006 Apr-Jun;20(2):101-4","ArticleIdList":{"ArticleId":"16772745"}},{"Citation":"Eur J Nucl Med Mol Imaging. 2007 Jul;34(7):1082-7","ArticleIdList":{"ArticleId":"17219132"}},{"Citation":"Am J Alzheimers Dis Other Demen. 2003 Sep-Oct;18(5):265-72","ArticleIdList":{"ArticleId":"14569643"}},{"Citation":"Neurology. 2003 Mar 25;60(6):1005-11","ArticleIdList":{"ArticleId":"12654969"}},{"Citation":"Neurology. 2007 Oct 2;69(14):1442-50","ArticleIdList":{"ArticleId":"17909157"}},{"Citation":"J Geriatr Psychiatry Neurol. 2007 Jun;20(2):84-8","ArticleIdList":{"ArticleId":"17548777"}},{"Citation":"Neurology. 2002 Jun 11;58(11):1615-21","ArticleIdList":{"ArticleId":"12058088"}},{"Citation":"Eur Arch Psychiatry Clin Neurosci. 2007 Aug;257(5):281-9","ArticleIdList":{"ArticleId":"17639447"}},{"Citation":"World J Biol Psychiatry. 2007;8(2):123-6","ArticleIdList":{"ArticleId":"17455105"}},{"Citation":"J Neurol Neurosurg Psychiatry. 2006 Sep;77(9):1060-3","ArticleIdList":{"ArticleId":"16709580"}},{"Citation":"Int J Geriatr Psychiatry. 2008 Jul;23(7):754-9","ArticleIdList":{"ArticleId":"18213609"}},{"Citation":"Am J Geriatr Psychiatry. 2006 Feb;14(2):139-44","ArticleIdList":{"ArticleId":"16473978"}},{"Citation":"Eur Neurol. 2003;49(1):13-9","ArticleIdList":{"ArticleId":"12464713"}},{"Citation":"Arch Neurol. 1999 Jun;56(6):713-8","ArticleIdList":{"ArticleId":"10369312"}}]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"18984958","DateCompleted":{"Year":"2009","Month":"02","Day":"20"},"DateRevised":{"Year":"2013","Month":"11","Day":"21"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1421-9824","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"26","Issue":"5","PubDate":{"Year":"2008"}},"Title":"Dementia and geriatric cognitive disorders","ISOAbbreviation":"Dement Geriatr Cogn Disord"},"ArticleTitle":"Activities of daily living, cerebral glucose metabolism, and cognitive reserve in Lewy body and Parkinson's disease.","Pagination":{"MedlinePgn":"475-81"},"ELocationID":"10.1159\/000167791","Abstract":{"AbstractText":["(1) To investigate the neural substrate of impaired activities of daily living (ADL) in Lewy body-associated disorders, such as dementia with Lewy bodies, classical Parkinson's disease, and Parkinson's disease dementia, and (2) to explore the effect of education on the relationship between cerebral metabolic changes and ADL performance.","Fifty-four patients with Lewy body-associated disorders underwent an extensive clinical evaluation including cerebral positron emission tomography with (18)F-fluoro-2-deoxy-glucose scanning. First, those brain areas were identified where ADL performance and glucose metabolism were significantly correlated. Second, brain regions were detected where the association between metabolic changes and ADL performance differed significantly between patients with a low and a high educational background.","There was a significant association between glucose hypometabolism and impaired ADL performance in the prefrontal, temporoparietal, and occipital association cortices and the precuneus. However, there was a significantly stronger association between hypometabolism and impaired ADL in the low education group compared with the high education group in the right middle occipital gyrus.","The study suggests (1) that brain metabolic alterations are significantly associated with the loss of everyday functioning in Lewy body-associated disorders and (2) that education modifies this association."],"CopyrightInformation":"Copyright 2008 S. Karger AG, Basel."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Perneczky","ForeName":"Robert","Initials":"R","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Technische Universit\u00e4t Munchen, Munich, Germany. robert.perneczky@lrz.tum.de"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Drzezga","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Boecker","ForeName":"Henning","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Ceballos-Baumann","ForeName":"Andres O","Initials":"AO"},{"@attributes":{"ValidYN":"Y"},"LastName":"Granert","ForeName":"Oliver","Initials":"O"},{"@attributes":{"ValidYN":"Y"},"LastName":"F\u00f6rstl","ForeName":"Hans","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"H\u00e4ussermann","ForeName":"Peter","Initials":"P"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Research Support, Non-U.S. Gov't"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2008","Month":"11","Day":"04"}},"MedlineJournalInfo":{"Country":"Switzerland","MedlineTA":"Dement Geriatr Cogn Disord","NlmUniqueID":"9705200","ISSNLinking":"1420-8008"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"Antiparkinson Agents"},{"RegistryNumber":"46627O600J","NameOfSubstance":"Levodopa"},{"RegistryNumber":"IY9XDZ35W2","NameOfSubstance":"Glucose"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Activities of Daily Living"},{"DescriptorName":"Aged"},{"DescriptorName":"Antiparkinson Agents","QualifierName":"therapeutic use"},{"DescriptorName":"Brain Chemistry","QualifierName":"physiology"},{"DescriptorName":"Cognition","QualifierName":"physiology"},{"DescriptorName":"Data Interpretation, Statistical"},{"DescriptorName":"Dementia","QualifierName":["etiology","metabolism","psychology"]},{"DescriptorName":"Education"},{"DescriptorName":"Female"},{"DescriptorName":"Functional Laterality","QualifierName":"physiology"},{"DescriptorName":"Glucose","QualifierName":"metabolism"},{"DescriptorName":"Humans"},{"DescriptorName":"Image Processing, Computer-Assisted"},{"DescriptorName":"Levodopa","QualifierName":"therapeutic use"},{"DescriptorName":"Lewy Body Disease","QualifierName":["metabolism","psychology"]},{"DescriptorName":"Male"},{"DescriptorName":"Neuropsychological Tests"},{"DescriptorName":"Parkinson Disease","QualifierName":["complications","metabolism","psychology"]},{"DescriptorName":"Positron-Emission Tomography"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"accepted"},"Year":"2008","Month":"08","Day":"14"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2008","Month":"11","Day":"6","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2009","Month":"2","Day":"21","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"entrez"},"Year":"2008","Month":"11","Day":"6","Hour":"9","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["18984958","000167791","10.1159\/000167791"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"18790461","DateCompleted":{"Year":"2008","Month":"12","Day":"30"},"DateRevised":{"Year":"2008","Month":"09","Day":"15"},"Article":{"@attributes":{"PubModel":"Print"},"Journal":{"ISSN":"1552-5279","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"4","Issue":"5","PubDate":{"Year":"2008","Month":"Sep"}},"Title":"Alzheimer's & dementia : the journal of the Alzheimer's Association","ISOAbbreviation":"Alzheimers Dement"},"ArticleTitle":"Personal perspectives of persons with Alzheimer's disease and their carers: a global survey.","Pagination":{"MedlinePgn":"345-52"},"ELocationID":"10.1016\/j.jalz.2008.06.002","Abstract":{"AbstractText":["Alzheimer's disease (AD) impacts on persons with AD as well their families. This survey aimed to identify information\/communication gaps, and quality of life and other issues, from both perspectives.","Persons with AD and their families or other carers from Europe, Brazil, and North America completed telephone interviews. Responses were analyzed by country.","Five hundred two persons with AD and 614 carers were included. Issues important to persons with AD were treatment that helps control symptoms; feeling safe and supported at home; and ability to enjoy life. Most felt well-respected by family members. Families\/carers considered a wider range of issues important, including detailed information about AD, regimens that are easier to comply with, and medication in a form that is easier to take. This reflects the fact that carers very often manage medications.","This is the first global survey to include persons with AD themselves. Differences between responses from persons with AD and their caregivers highlight the importance of considering both viewpoints."]},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A","AffiliationInfo":{"Affiliation":"Munich University of Technology and Science, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Schulz","ForeName":"Mary","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Reed","ForeName":"Peter","Initials":"P"},{"@attributes":{"ValidYN":"Y"},"LastName":"Wortmann","ForeName":"Marc","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Rodrigo","ForeName":"Jes\u00fas","Initials":"J"},{"@attributes":{"ValidYN":"Y"},"LastName":"von L\u00fctzau Hohlbein","ForeName":"Heike","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Grossberg","ForeName":"George","Initials":"G"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Research Support, Non-U.S. Gov't"]}},"MedlineJournalInfo":{"Country":"United States","MedlineTA":"Alzheimers Dement","NlmUniqueID":"101231978","ISSNLinking":"1552-5260"},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Alzheimer Disease","QualifierName":["drug therapy","psychology"]},{"DescriptorName":"Caregivers","QualifierName":"psychology"},{"DescriptorName":"Communication"},{"DescriptorName":"Data Collection"},{"DescriptorName":"Female"},{"DescriptorName":"Health Knowledge, Attitudes, Practice"},{"DescriptorName":"Humans"},{"DescriptorName":"Male"},{"DescriptorName":"Patient Compliance"},{"DescriptorName":"Quality of Life"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2008","Month":"03","Day":"31"},{"@attributes":{"PubStatus":"accepted"},"Year":"2008","Month":"06","Day":"27"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2008","Month":"9","Day":"16","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2008","Month":"12","Day":"31","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"entrez"},"Year":"2008","Month":"9","Day":"16","Hour":"9","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["18790461","S1552-5260(08)02836-7","10.1016\/j.jalz.2008.06.002"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"18636436","DateCompleted":{"Year":"2009","Month":"11","Day":"02"},"DateRevised":{"Year":"2018","Month":"12","Day":"01"},"Article":{"@attributes":{"PubModel":"Print"},"Journal":{"ISSN":"1099-1166","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"24","Issue":"2","PubDate":{"Year":"2009","Month":"Feb"}},"Title":"International journal of geriatric psychiatry","ISOAbbreviation":"Int J Geriatr Psychiatry"},"ArticleTitle":"Cognitive rehabilitation in patients with mild cognitive impairment.","Pagination":{"MedlinePgn":"163-8"},"ELocationID":"10.1002\/gps.2086","Abstract":{"AbstractText":["To explore the benefits of a multi-component cognitive rehabilitation programme in patients with mild cognitive impairment (MCI).","Patients with MCI (n = 18) and patients with mild dementia in Alzheimer's disease (n = 10) participated in a 4-week cognitive rehabilitation programme in a day clinic setting. The intervention was provided in group format and included activity planning, self-assertiveness training, relaxation techniques, stress management, use of external memory aids, memory training, and motor exercise.","After 4 weeks, MCI patients showed significant improvements on activities of daily living, mood, verbal and nonverbal episodic memory. In contrast, patients with mild dementia exhibited a non-significant increase in verbal memory but no other changes. MCI subjects allocated to the waiting list control condition (n = 12) showed a significant re-test effect on verbal episodic memory, but no improvement of everyday activities or mood.","The study demonstrates that patients with MCI benefit from a multi-component cognitive rehabilitation programme with regard to activities of daily living, mood, and memory performance."],"CopyrightInformation":"(c) 2008 John Wiley & Sons, Ltd."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technische Universitaet Muenchen, Munich, Germany. alexander.kurz@lrz.tum.de"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Pohl","ForeName":"Corina","Initials":"C"},{"@attributes":{"ValidYN":"Y"},"LastName":"Ramsenthaler","ForeName":"Michaela","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Sorg","ForeName":"Christian","Initials":"C"}]},"Language":"eng","PublicationTypeList":{"PublicationType":"Journal Article"}},"MedlineJournalInfo":{"Country":"England","MedlineTA":"Int J Geriatr Psychiatry","NlmUniqueID":"8710629","ISSNLinking":"0885-6230"},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Activities of Daily Living"},{"DescriptorName":"Affect"},{"DescriptorName":"Aged"},{"DescriptorName":"Cognition Disorders","QualifierName":["psychology","rehabilitation"]},{"DescriptorName":"Cognitive Behavioral Therapy"},{"DescriptorName":"Dementia","QualifierName":["psychology","rehabilitation"]},{"DescriptorName":"Female"},{"DescriptorName":"Humans"},{"DescriptorName":"Male"},{"DescriptorName":"Memory"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Program Evaluation"},{"DescriptorName":"Psychiatric Status Rating Scales"},{"DescriptorName":"Task Performance and Analysis"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"pubmed"},"Year":"2008","Month":"7","Day":"19","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2009","Month":"11","Day":"3","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"entrez"},"Year":"2008","Month":"7","Day":"19","Hour":"9","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["18636436","10.1002\/gps.2086"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"18477846","DateCompleted":{"Year":"2008","Month":"10","Day":"07"},"DateRevised":{"Year":"2016","Month":"11","Day":"24"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1421-9824","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"25","Issue":"6","PubDate":{"Year":"2008"}},"Title":"Dementia and geriatric cognitive disorders","ISOAbbreviation":"Dement Geriatr Cogn Disord"},"ArticleTitle":"Cerebral metabolic dysfunction in patients with dementia with Lewy bodies and visual hallucinations.","Pagination":{"MedlinePgn":"531-8"},"ELocationID":"10.1159\/000132084","Abstract":{"AbstractText":["To identify the pattern of cerebral hypometabolism in patients with dementia with Lewy bodies (DLB) and visual hallucinations (VH).","Fourteen patients with DLB and VH, 7 with DLB without VH and 16 healthy controls underwent clinical and (18)F-FDG PET evaluations. The 2 patient groups did not significantly differ in their clinical characteristics, except in the occurrence of VH. A voxel-wise comparison of (18)F-FDG PET scans was conducted between each of the 2 patient groups and the control group, and the patient groups among each other.","Compared with the control group, hypometabolic regions were more extensive and confluent in the patient group with VH than in the group without VH. The direct comparison between the 2 patient groups revealed a significant metabolic deficit in the group with VH at the right occipito-temporal junction and the right middle frontal gyrus.","These results suggest that hypometabolism in visual association areas rather than the primary visual cortex is involved in VH in DLB."],"CopyrightInformation":"(c) 2008 S. Karger AG, Basel."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Perneczky","ForeName":"Robert","Initials":"R","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Technical University Munich, Munich, Germany. robert.perneczky@lrz.tum.de"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Drzezga","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Boecker","ForeName":"Henning","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"F\u00f6rstl","ForeName":"Hans","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"H\u00e4ussermann","ForeName":"Peter","Initials":"P"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Research Support, Non-U.S. Gov't"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2008","Month":"05","Day":"14"}},"MedlineJournalInfo":{"Country":"Switzerland","MedlineTA":"Dement Geriatr Cogn Disord","NlmUniqueID":"9705200","ISSNLinking":"1420-8008"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"Radiopharmaceuticals"},{"RegistryNumber":"0Z5B2CJX4D","NameOfSubstance":"Fluorodeoxyglucose F18"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Female"},{"DescriptorName":"Fluorodeoxyglucose F18"},{"DescriptorName":"Frontal Lobe","QualifierName":["diagnostic imaging","metabolism"]},{"DescriptorName":"Hallucinations","QualifierName":["diagnostic imaging","etiology","metabolism"]},{"DescriptorName":"Humans"},{"DescriptorName":"Lewy Body Disease","QualifierName":["complications","diagnostic imaging","metabolism"]},{"DescriptorName":"Magnetic Resonance Imaging"},{"DescriptorName":"Male"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Positron-Emission Tomography"},{"DescriptorName":"Radiopharmaceuticals"},{"DescriptorName":"Temporal Lobe","QualifierName":["diagnostic imaging","metabolism"]},{"DescriptorName":"Visual Cortex","QualifierName":["diagnostic imaging","metabolism"]}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"accepted"},"Year":"2008","Month":"03","Day":"23"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2008","Month":"5","Day":"15","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2008","Month":"10","Day":"8","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"entrez"},"Year":"2008","Month":"5","Day":"15","Hour":"9","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["18477846","000132084","10.1159\/000132084"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"18346821","DateCompleted":{"Year":"2010","Month":"01","Day":"11"},"DateRevised":{"Year":"2016","Month":"11","Day":"25"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1558-1497","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"30","Issue":"12","PubDate":{"Year":"2009","Month":"Dec"}},"Title":"Neurobiology of aging","ISOAbbreviation":"Neurobiol Aging"},"ArticleTitle":"Clinical severity of Alzheimer's disease is associated with PIB uptake in PET.","Pagination":{"MedlinePgn":"1902-9"},"ELocationID":"10.1016\/j.neurobiolaging.2008.01.016","Abstract":{"AbstractText":["The positron emission tomography (PET) tracer [11C]-Pittsburgh Compound-B ([11C]PIB) allows the in vivo assessment of amyloid plaque burden in the brain. In a cross-sectional study we examined the association between the severity of dementia assessed using the Clinical Dementia Rating scale sum of boxes (CDR-SOB) and [11C]PIB-PET in patients with Alzheimer's disease (AD).","Patients with probable AD who had an AD-typical [18F]FDG-PET scan were included. Linear regression analysis in anatomically defined regions-of-interest (ROIs) and correlation analysis using statistical parametric mapping (SPM) were used to determine the association between CDR-SOB and [11C]PIB uptake.","The linear regression analyses showed that the CDR-SOB explained approximately 11-22% of the variance of [11C]PIB uptake. The association attained statistical significance in both frontal, in both anterior cingulate cortices, and in both putamina. The SPM analysis showed a significant association in more widespread regions of the brain, with maxima located in similar areas as in the ROI-analysis.","The CDR-SOB score is significantly associated with [11C]PIB uptake in patients with AD. Thus [11C]PIB is a potential surrogate marker of dementia severity."]},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Grimmer","ForeName":"Timo","Initials":"T","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar der Technischen Universit\u00e4t M\u00fcnchen, Ismaninger Str. 22, 81675 Munich, Germany. t.grimmer@lrz.tum.de"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Henriksen","ForeName":"Gjermund","Initials":"G"},{"@attributes":{"ValidYN":"Y"},"LastName":"Wester","ForeName":"Hans-J\u00fcrgen","Initials":"HJ"},{"@attributes":{"ValidYN":"Y"},"LastName":"F\u00f6rstl","ForeName":"Hans","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Klunk","ForeName":"William E","Initials":"WE"},{"@attributes":{"ValidYN":"Y"},"LastName":"Mathis","ForeName":"Chester A","Initials":"CA"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Drzezga","ForeName":"Alexander","Initials":"A"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Research Support, Non-U.S. Gov't"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2008","Month":"03","Day":"17"}},"MedlineJournalInfo":{"Country":"United States","MedlineTA":"Neurobiol Aging","NlmUniqueID":"8100437","ISSNLinking":"0197-4580"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole"},{"RegistryNumber":"0","NameOfSubstance":"Aniline Compounds"},{"RegistryNumber":"0","NameOfSubstance":"Thiazoles"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Aged, 80 and over"},{"DescriptorName":"Alzheimer Disease","QualifierName":"diagnostic imaging"},{"DescriptorName":"Aniline Compounds"},{"DescriptorName":"Brain","QualifierName":"diagnostic imaging"},{"DescriptorName":"Brain Mapping"},{"DescriptorName":"Female"},{"DescriptorName":"Humans"},{"DescriptorName":"Linear Models"},{"DescriptorName":"Male"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Positron-Emission Tomography"},{"DescriptorName":"Severity of Illness Index"},{"DescriptorName":"Signal Processing, Computer-Assisted"},{"DescriptorName":"Thiazoles"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2007","Month":"10","Day":"15"},{"@attributes":{"PubStatus":"revised"},"Year":"2007","Month":"12","Day":"21"},{"@attributes":{"PubStatus":"accepted"},"Year":"2008","Month":"01","Day":"28"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2008","Month":"3","Day":"19","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2010","Month":"1","Day":"12","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"entrez"},"Year":"2008","Month":"3","Day":"19","Hour":"9","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["18346821","S0197-4580(08)00035-3","10.1016\/j.neurobiolaging.2008.01.016"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"18343688","DateCompleted":{"Year":"2008","Month":"06","Day":"23"},"DateRevised":{"Year":"2018","Month":"11","Day":"13"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1053-8119","JournalIssue":{"@attributes":{"CitedMedium":"Print"},"Volume":"40","Issue":"4","PubDate":{"Year":"2008","Month":"May","Day":"01"}},"Title":"NeuroImage","ISOAbbreviation":"Neuroimage"},"ArticleTitle":"Multivariate and univariate neuroimaging biomarkers of Alzheimer's disease.","Pagination":{"MedlinePgn":"1503-15"},"ELocationID":"10.1016\/j.neuroimage.2008.01.056","Abstract":{"AbstractText":"We performed univariate and multivariate discriminant analysis of FDG-PET scans to evaluate their ability to identify Alzheimer's disease (AD). FDG-PET scans came from two sources: 17 AD patients and 33 healthy elderly controls were scanned at the University of Michigan; 102 early AD patients and 20 healthy elderly controls were scanned at the Technical University of Munich, Germany. We selected a derivation sample of 20 AD patients and 20 healthy controls matched on age with the remainder divided into 5 replication samples. The sensitivity and specificity of diagnostic AD-markers and threshold criteria from the derivation sample were determined in the replication samples. Although both univariate and multivariate analyses produced markers with high classification accuracy in the derivation sample, the multivariate marker's diagnostic performance in the replication samples was superior. Further, supplementary analysis showed its performance to be unaffected by the loss of key regions. Multivariate measures of AD utilize the covariance structure of imaging data and provide complementary, clinically relevant information that may be superior to univariate measures."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Habeck","ForeName":"Christian","Initials":"C","AffiliationInfo":{"Affiliation":"Taub Institute, Columbia University Medical Center, New York, NY 10032, USA. ch629@columbia.edu"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Foster","ForeName":"Norman L","Initials":"NL"},{"@attributes":{"ValidYN":"Y"},"LastName":"Perneczky","ForeName":"Robert","Initials":"R"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Alexopoulos","ForeName":"Panagiotis","Initials":"P"},{"@attributes":{"ValidYN":"Y"},"LastName":"Koeppe","ForeName":"Robert A","Initials":"RA"},{"@attributes":{"ValidYN":"Y"},"LastName":"Drzezga","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Stern","ForeName":"Yaakov","Initials":"Y"}]},"Language":"eng","GrantList":{"@attributes":{"CompleteYN":"Y"},"Grant":[{"GrantID":"P50 AG008671","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"R01 AG022394","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"R01 EB006204-02","Acronym":"EB","Agency":"NIBIB NIH HHS","Country":"United States"},{"GrantID":"R01EB006204","Acronym":"EB","Agency":"NIBIB NIH HHS","Country":"United States"},{"GrantID":"R01AG22394","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"R01AG08671","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"R01 EB006204","Acronym":"EB","Agency":"NIBIB NIH HHS","Country":"United States"}]},"PublicationTypeList":{"PublicationType":["Journal Article","Research Support, N.I.H., Extramural"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2008","Month":"02","Day":"14"}},"MedlineJournalInfo":{"Country":"United States","MedlineTA":"Neuroimage","NlmUniqueID":"9215515","ISSNLinking":"1053-8119"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"Biomarkers"},{"RegistryNumber":"0","NameOfSubstance":"Radiopharmaceuticals"},{"RegistryNumber":"0Z5B2CJX4D","NameOfSubstance":"Fluorodeoxyglucose F18"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Algorithms"},{"DescriptorName":"Alzheimer Disease","QualifierName":["diagnostic imaging","metabolism"]},{"DescriptorName":"Analysis of Variance"},{"DescriptorName":"Biomarkers"},{"DescriptorName":"Female"},{"DescriptorName":"Fluorodeoxyglucose F18"},{"DescriptorName":"Humans"},{"DescriptorName":"Image Processing, Computer-Assisted"},{"DescriptorName":"Male"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Multivariate Analysis"},{"DescriptorName":"Positron-Emission Tomography"},{"DescriptorName":"Principal Component Analysis"},{"DescriptorName":"Radiopharmaceuticals"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2007","Month":"08","Day":"02"},{"@attributes":{"PubStatus":"revised"},"Year":"2007","Month":"12","Day":"14"},{"@attributes":{"PubStatus":"accepted"},"Year":"2008","Month":"01","Day":"22"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2008","Month":"3","Day":"18","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2008","Month":"6","Day":"24","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"entrez"},"Year":"2008","Month":"3","Day":"18","Hour":"9","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["18343688","S1053-8119(08)00102-X","10.1016\/j.neuroimage.2008.01.056","PMC2441445","NIHMS48809"]},"ReferenceList":{"Reference":[{"Citation":"Ann N Y Acad Sci. 1999;893:350-2","ArticleIdList":{"ArticleId":"10672264"}},{"Citation":"Brain. 2006 Nov;129(Pt 11):2856-66","ArticleIdList":{"ArticleId":"16854944"}},{"Citation":"Hum Brain Mapp. 2001 Jan;12(1):42-60","ArticleIdList":{"ArticleId":"11198104"}},{"Citation":"Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10966-71","ArticleIdList":{"ArticleId":"11526211"}},{"Citation":"Neurology. 2002 Aug 13;59(3):378-83","ArticleIdList":{"ArticleId":"12177371"}},{"Citation":"Ann Neurol. 2002 Dec;52(6):853-6","ArticleIdList":{"ArticleId":"12447944"}},{"Citation":"Neuroimage. 2002 Sep;17(1):302-16","ArticleIdList":{"ArticleId":"12482085"}},{"Citation":"Neurology. 2003 Apr 22;60(8):1374-7","ArticleIdList":{"ArticleId":"12707450"}},{"Citation":"Brain. 2003 Sep;126(Pt 9):1955-67","ArticleIdList":{"ArticleId":"12821520"}},{"Citation":"Adv Neurol. 2004;94:155-61","ArticleIdList":{"ArticleId":"14509669"}},{"Citation":"Stat Med. 2004 Jan 30;23(2):315-26","ArticleIdList":{"ArticleId":"14716732"}},{"Citation":"Dement Geriatr Cogn Disord. 2004;17(3):207-14","ArticleIdList":{"ArticleId":"14739546"}},{"Citation":"Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4637-42","ArticleIdList":{"ArticleId":"15070770"}},{"Citation":"J Intern Med. 2004 Sep;256(3):240-6","ArticleIdList":{"ArticleId":"15324367"}},{"Citation":"Neuroimage. 2004 Sep;23(1):35-45","ArticleIdList":{"ArticleId":"15325350"}},{"Citation":"J Psychiatr Res. 1975 Nov;12(3):189-98","ArticleIdList":{"ArticleId":"1202204"}},{"Citation":"Neurology. 1984 Jul;34(7):939-44","ArticleIdList":{"ArticleId":"6610841"}},{"Citation":"Am J Psychiatry. 1993 Apr;150(4):639-42","ArticleIdList":{"ArticleId":"8465883"}},{"Citation":"J Cereb Blood Flow Metab. 1996 May;16(3):385-98","ArticleIdList":{"ArticleId":"8621743"}},{"Citation":"Radiology. 1996 Mar;198(3):837-43","ArticleIdList":{"ArticleId":"8628880"}},{"Citation":"Br J Nurs. 1996 Feb 8-21;5(3):162-8","ArticleIdList":{"ArticleId":"8696127"}},{"Citation":"Neurology. 1996 Nov;47(5):1113-24","ArticleIdList":{"ArticleId":"8909416"}},{"Citation":"Neurodegeneration. 1996 Dec;5(4):429-34","ArticleIdList":{"ArticleId":"9117558"}},{"Citation":"Brain. 1997 Aug;120 ( Pt 8):1315-24","ArticleIdList":{"ArticleId":"9278625"}},{"Citation":"J Nucl Med. 1998 Feb;39(2):293-8","ArticleIdList":{"ArticleId":"9476938"}},{"Citation":"J Neural Transm Suppl. 1998;54:97-106","ArticleIdList":{"ArticleId":"9850918"}},{"Citation":"Neurology. 1998 Dec;51(6):1546-54","ArticleIdList":{"ArticleId":"9855500"}},{"Citation":"Brain. 1999 Aug;122 ( Pt 8):1519-31","ArticleIdList":{"ArticleId":"10430835"}},{"Citation":"Neurobiol Aging. 2007 Feb;28(2):284-95","ArticleIdList":{"ArticleId":"16469419"}},{"Citation":"Neurobiol Aging. 2007 Jul;28(7):1062-9","ArticleIdList":{"ArticleId":"16824650"}},{"Citation":"Brain. 2007 Oct;130(Pt 10):2616-35","ArticleIdList":{"ArticleId":"17704526"}},{"Citation":"J Cereb Blood Flow Metab. 1987 Oct;7(5):649-58","ArticleIdList":{"ArticleId":"3498733"}},{"Citation":"Ann Neurol. 1988 May;23(5):477-84","ArticleIdList":{"ArticleId":"3389756"}},{"Citation":"J Neurol Neurosurg Psychiatry. 1991 Oct;54(10):856-62","ArticleIdList":{"ArticleId":"1744638"}},{"Citation":"Neurology. 1992 Jun;42(6):1142-6","ArticleIdList":{"ArticleId":"1603339"}},{"Citation":"Neuroreport. 1999 Jun 23;10(9):1965-71","ArticleIdList":{"ArticleId":"10501542"}},{"Citation":"Neurology. 2005 Jan 11;64(1):102-7","ArticleIdList":{"ArticleId":"15642911"}},{"Citation":"Dement Geriatr Cogn Disord. 2005;19(5-6):266-75","ArticleIdList":{"ArticleId":"15775716"}},{"Citation":"Psychiatry Clin Neurosci. 2005 Jun;59(3):280-90","ArticleIdList":{"ArticleId":"15896221"}},{"Citation":"Neuroimage. 2005 Oct 1;27(4):934-46","ArticleIdList":{"ArticleId":"15979341"}},{"Citation":"Brain. 2005 Nov;128(Pt 11):2626-44","ArticleIdList":{"ArticleId":"16014654"}},{"Citation":"Dement Geriatr Cogn Disord. 2006;21(4):215-20","ArticleIdList":{"ArticleId":"16415572"}},{"Citation":"Biol Psychiatry. 2006 May 15;59(10):940-7","ArticleIdList":{"ArticleId":"16487944"}},{"Citation":"Neuropsychopharmacology. 2006 Jun;31(6):1327-34","ArticleIdList":{"ArticleId":"16292330"}},{"Citation":"Neuroimage. 2006 May 15;31(1):301-7","ArticleIdList":{"ArticleId":"16466936"}},{"Citation":"Neuroreport. 2006 Jul 17;17(10):951-6","ArticleIdList":{"ArticleId":"16791083"}},{"Citation":"Neuroimage. 2006 Aug 1;32(1):301-6","ArticleIdList":{"ArticleId":"16624585"}},{"Citation":"Neurology. 2006 Aug 8;67(3):453-60","ArticleIdList":{"ArticleId":"16894107"}},{"Citation":"J Cereb Blood Flow Metab. 2006 Sep;26(9):1213-21","ArticleIdList":{"ArticleId":"16525414"}},{"Citation":"Neurology. 2000 Sep 12;55(5):673-7","ArticleIdList":{"ArticleId":"10980732"}}]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"18287270","DateCompleted":{"Year":"2008","Month":"05","Day":"16"},"DateRevised":{"Year":"2018","Month":"11","Day":"13"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"0161-5505","JournalIssue":{"@attributes":{"CitedMedium":"Print"},"Volume":"49","Issue":"3","PubDate":{"Year":"2008","Month":"Mar"}},"Title":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","ISOAbbreviation":"J Nucl Med"},"ArticleTitle":"Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias.","Pagination":{"MedlinePgn":"390-8"},"ELocationID":"10.2967\/jnumed.107.045385","Abstract":{"AbstractText":["This multicenter study examined (18)F-FDG PET measures in the differential diagnosis of Alzheimer's disease (AD), frontotemporal dementia (FTD), and dementia with Lewy bodies (DLB) from normal aging and from each other and the relation of disease-specific patterns to mild cognitive impairment (MCI).","We examined the (18)F-FDG PET scans of 548 subjects, including 110 healthy elderly individuals (\"normals\" or NLs), 114 MCI, 199 AD, 98 FTD, and 27 DLB patients, collected at 7 participating centers. Individual PET scans were Z scored using automated voxel-based comparison with generation of disease-specific patterns of cortical and hippocampal (18)F-FDG uptake that were then applied to characterize MCI.","Standardized disease-specific PET patterns were developed that correctly classified 95% AD, 92% DLB, 94% FTD, and 94% NL. MCI patients showed primarily posterior cingulate cortex and hippocampal hypometabolism (81%), whereas neocortical abnormalities varied according to neuropsychological profiles. An AD PET pattern was observed in 79% MCI with deficits in multiple cognitive domains and 31% amnesic MCI. (18)F-FDG PET heterogeneity in MCI with nonmemory deficits ranged from absent hypometabolism to FTD and DLB PET patterns.","Standardized automated analysis of (18)F-FDG PET scans may provide an objective and sensitive support to the clinical diagnosis in early dementia."]},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Mosconi","ForeName":"Lisa","Initials":"L","AffiliationInfo":{"Affiliation":"Center for Brain Health, New York University School of Medicine, New York, New York 10016, USA. lisa.mosconi@med.nyu.edu"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Tsui","ForeName":"Wai H","Initials":"WH"},{"@attributes":{"ValidYN":"Y"},"LastName":"Herholz","ForeName":"Karl","Initials":"K"},{"@attributes":{"ValidYN":"Y"},"LastName":"Pupi","ForeName":"Alberto","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Drzezga","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Lucignani","ForeName":"Giovanni","Initials":"G"},{"@attributes":{"ValidYN":"Y"},"LastName":"Reiman","ForeName":"Eric M","Initials":"EM"},{"@attributes":{"ValidYN":"Y"},"LastName":"Holthoff","ForeName":"Vjera","Initials":"V"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kalbe","ForeName":"Elke","Initials":"E"},{"@attributes":{"ValidYN":"Y"},"LastName":"Sorbi","ForeName":"Sandro","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"Diehl-Schmid","ForeName":"Janine","Initials":"J"},{"@attributes":{"ValidYN":"Y"},"LastName":"Perneczky","ForeName":"Robert","Initials":"R"},{"@attributes":{"ValidYN":"Y"},"LastName":"Clerici","ForeName":"Francesca","Initials":"F"},{"@attributes":{"ValidYN":"Y"},"LastName":"Caselli","ForeName":"Richard","Initials":"R"},{"@attributes":{"ValidYN":"Y"},"LastName":"Beuthien-Baumann","ForeName":"Bettina","Initials":"B"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Minoshima","ForeName":"Satoshi","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"de Leon","ForeName":"Mony J","Initials":"MJ"}]},"Language":"eng","GrantList":{"@attributes":{"CompleteYN":"Y"},"Grant":[{"GrantID":"R01 AG022374","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"M01 RR000096","Acronym":"RR","Agency":"NCRR NIH HHS","Country":"United States"},{"GrantID":"R01 AG013616","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"U01 AG016976","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"P30 AG008051","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"R01 AG012101","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"AG022374","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"AG13616","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"M01RR0096","Acronym":"RR","Agency":"NCRR NIH HHS","Country":"United States"},{"GrantID":"AG08051","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"AG12101","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"}]},"PublicationTypeList":{"PublicationType":["Journal Article","Multicenter Study","Research Support, N.I.H., Extramural","Research Support, Non-U.S. Gov't"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2008","Month":"02","Day":"20"}},"MedlineJournalInfo":{"Country":"United States","MedlineTA":"J Nucl Med","NlmUniqueID":"0217410","ISSNLinking":"0161-5505"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"Radiopharmaceuticals"},{"RegistryNumber":"0Z5B2CJX4D","NameOfSubstance":"Fluorodeoxyglucose F18"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Aged, 80 and over"},{"DescriptorName":"Alzheimer Disease","QualifierName":["diagnostic imaging","epidemiology"]},{"DescriptorName":"Cognition Disorders","QualifierName":["diagnostic imaging","epidemiology"]},{"DescriptorName":"Dementia","QualifierName":["diagnostic imaging","epidemiology"]},{"DescriptorName":"Europe","QualifierName":"epidemiology"},{"DescriptorName":"Female"},{"DescriptorName":"Fluorodeoxyglucose F18"},{"DescriptorName":"Humans"},{"DescriptorName":"Male"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Positron-Emission Tomography","QualifierName":["standards","statistics & numerical data"]},{"DescriptorName":"Prevalence"},{"DescriptorName":"Radiopharmaceuticals"},{"DescriptorName":"Reference Standards"},{"DescriptorName":"Reproducibility of Results"},{"DescriptorName":"Sensitivity and Specificity"},{"DescriptorName":"United States","QualifierName":"epidemiology"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"pubmed"},"Year":"2008","Month":"2","Day":"22","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2008","Month":"5","Day":"17","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"entrez"},"Year":"2008","Month":"2","Day":"22","Hour":"9","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["18287270","jnumed.107.045385","10.2967\/jnumed.107.045385","PMC3703818","NIHMS471249"]},"ReferenceList":{"Reference":[{"Citation":"Dement Geriatr Cogn Disord. 1999 Nov-Dec;10(6):494-504","ArticleIdList":{"ArticleId":"10559566"}},{"Citation":"Neurobiol Aging. 2008 May;29(5):676-92","ArticleIdList":{"ArticleId":"17222480"}},{"Citation":"Hum Brain Mapp. 2000 Jul;10(3):120-31","ArticleIdList":{"ArticleId":"10912591"}},{"Citation":"J Nucl Med. 2001 Apr;42(4):548-57","ArticleIdList":{"ArticleId":"11337540"}},{"Citation":"Neurobiol Aging. 2001 Jul-Aug;22(4):529-39","ArticleIdList":{"ArticleId":"11445252"}},{"Citation":"Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10966-71","ArticleIdList":{"ArticleId":"11526211"}},{"Citation":"Ann Neurol. 2001 Sep;50(3):358-65","ArticleIdList":{"ArticleId":"11558792"}},{"Citation":"Arch Neurol. 2001 Nov;58(11):1803-9","ArticleIdList":{"ArticleId":"11708987"}},{"Citation":"Arch Neurol. 2001 Dec;58(12):1985-92","ArticleIdList":{"ArticleId":"11735772"}},{"Citation":"J Nucl Med. 2002 Feb;43(2):253-66","ArticleIdList":{"ArticleId":"11850493"}},{"Citation":"Neuroimage. 2002 Sep;17(1):302-16","ArticleIdList":{"ArticleId":"12482085"}},{"Citation":"Neuroimage. 2003 Jul;19(3):1137-44","ArticleIdList":{"ArticleId":"12880839"}},{"Citation":"Eur J Nucl Med Mol Imaging. 2003 Aug;30(8):1104-13","ArticleIdList":{"ArticleId":"12764551"}},{"Citation":"Ann Neurol. 2003 Sep;54(3):343-51","ArticleIdList":{"ArticleId":"12953266"}},{"Citation":"Neurology. 1984 Jul;34(7):939-44","ArticleIdList":{"ArticleId":"6610841"}},{"Citation":"Neurology. 1993 Feb;43(2):250-60","ArticleIdList":{"ArticleId":"8094895"}},{"Citation":"Lancet. 1994 Sep 24;344(8926):895","ArticleIdList":{"ArticleId":"7916431"}},{"Citation":"J Nucl Med. 1995 Jul;36(7):1238-48","ArticleIdList":{"ArticleId":"7790950"}},{"Citation":"Neurology. 1996 Aug;47(2):462-6","ArticleIdList":{"ArticleId":"8757021"}},{"Citation":"Neurology. 1996 Nov;47(5):1113-24","ArticleIdList":{"ArticleId":"8909416"}},{"Citation":"Ann Neurol. 1997 Jul;42(1):85-94","ArticleIdList":{"ArticleId":"9225689"}},{"Citation":"J Nucl Med. 1998 Nov;39(11):1875-8","ArticleIdList":{"ArticleId":"9829574"}},{"Citation":"Arch Neurol. 1999 Mar;56(3):303-8","ArticleIdList":{"ArticleId":"10190820"}},{"Citation":"Neurology. 2004 Dec 28;63(12):2332-40","ArticleIdList":{"ArticleId":"15623696"}},{"Citation":"J Nucl Med. 2005 Feb;46(2):233-9","ArticleIdList":{"ArticleId":"15695781"}},{"Citation":"Eur J Nucl Med Mol Imaging. 2005 Apr;32(4):486-510","ArticleIdList":{"ArticleId":"15747152"}},{"Citation":"J Nucl Med. 2005 Jun;46(6):936-44","ArticleIdList":{"ArticleId":"15937303"}},{"Citation":"Neurology. 2005 Jun 14;64(11):1860-7","ArticleIdList":{"ArticleId":"15955934"}},{"Citation":"J Nucl Med. 2005 Oct;46(10):1625-32","ArticleIdList":{"ArticleId":"16204712"}},{"Citation":"Arch Neurol. 2005 Nov;62(11):1728-33","ArticleIdList":{"ArticleId":"16286547"}},{"Citation":"Eur J Nucl Med Mol Imaging. 2006 Feb;33(2):210-21","ArticleIdList":{"ArticleId":"16311757"}},{"Citation":"Lancet. 2006 Apr 15;367(9518):1262-70","ArticleIdList":{"ArticleId":"16631882"}},{"Citation":"J Nucl Med. 2006 Nov;47(11):1778-86","ArticleIdList":{"ArticleId":"17079810"}},{"Citation":"Neurobiol Aging. 2007 Jan;28(1):42-50","ArticleIdList":{"ArticleId":"16448722"}},{"Citation":"Neurology. 2007 May 15;68(20):1718-25","ArticleIdList":{"ArticleId":"17502554"}},{"Citation":"J Nucl Med. 2007 Jul;48(7):1129-34","ArticleIdList":{"ArticleId":"17574982"}},{"Citation":"Exp Neurol. 2000 Apr;162(2):247-56","ArticleIdList":{"ArticleId":"10739631"}}]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"18255191","DateCompleted":{"Year":"2009","Month":"10","Day":"09"},"DateRevised":{"Year":"2016","Month":"11","Day":"25"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1558-1497","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"30","Issue":"9","PubDate":{"Year":"2009","Month":"Sep"}},"Title":"Neurobiology of aging","ISOAbbreviation":"Neurobiol Aging"},"ArticleTitle":"Right prefrontal hypometabolism predicts delusions in dementia with Lewy bodies.","Pagination":{"MedlinePgn":"1420-9"},"ELocationID":"10.1016\/j.neurobiolaging.2007.12.001","Abstract":{"AbstractText":"Delusions (DEL) are frequent in dementia with Lewy bodies (DLB); however, the neural equivalent is poorly understood. The present study therefore aimed to identify the cerebral metabolic pattern of glucose of a DLB group suffering from DEL (DLB+DEL) as compared to a non-delusional group (DLB-DEL) and a control group (NL); and to determine the predictive value of the regional metabolic deficit for DEL symptomatology in comparison to other clinical variables significantly associated with DEL. Voxel-wise comparisons were conducted between the patient and control groups in SPM2. The most significant regional metabolic deficit of the DLB+DEL group was used a predictor for DEL symptomatology in a logistic regression analysis along with other variables significantly associated with DEL, such as visual hallucinations (VH), and overall cognitive impairment. A significant relative hypometabolism of the right prefrontal cortex was found in the DLB+DEL group, which predicted DEL symptomatology in the regression analysis. VH and overall cognitive dysfunction were no significant predictors. These results underline the significance of right prefrontal damage for DEL in DLB."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Perneczky","ForeName":"Robert","Initials":"R","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Technical University Munich, M\u00fcnchen, Germany. robert.perneczky@lrz.tum.de"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Drzezga","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Boecker","ForeName":"Henning","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Wagenpfeil","ForeName":"Stefan","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"F\u00f6rstl","ForeName":"Hans","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"H\u00e4ussermann","ForeName":"Peter","Initials":"P"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Research Support, Non-U.S. Gov't"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2008","Month":"02","Day":"05"}},"MedlineJournalInfo":{"Country":"United States","MedlineTA":"Neurobiol Aging","NlmUniqueID":"8100437","ISSNLinking":"0197-4580"},"ChemicalList":{"Chemical":{"RegistryNumber":"0Z5B2CJX4D","NameOfSubstance":"Fluorodeoxyglucose F18"}},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Cognition Disorders","QualifierName":"etiology"},{"DescriptorName":"Delusions","QualifierName":["diagnostic imaging","etiology","metabolism"]},{"DescriptorName":"Energy Metabolism","QualifierName":"physiology"},{"DescriptorName":"Female"},{"DescriptorName":"Fluorodeoxyglucose F18"},{"DescriptorName":"Functional Laterality","QualifierName":"physiology"},{"DescriptorName":"Hallucinations","QualifierName":"etiology"},{"DescriptorName":"Humans"},{"DescriptorName":"Lewy Body Disease","QualifierName":["complications","diagnostic imaging","metabolism"]},{"DescriptorName":"Male"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Positron-Emission Tomography"},{"DescriptorName":"Predictive Value of Tests"},{"DescriptorName":"Prefrontal Cortex","QualifierName":["diagnostic imaging","metabolism","physiopathology"]},{"DescriptorName":"Regression Analysis"},{"DescriptorName":"Sensitivity and Specificity"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2007","Month":"08","Day":"10"},{"@attributes":{"PubStatus":"revised"},"Year":"2007","Month":"11","Day":"26"},{"@attributes":{"PubStatus":"accepted"},"Year":"2007","Month":"12","Day":"03"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2008","Month":"2","Day":"8","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2009","Month":"10","Day":"10","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"entrez"},"Year":"2008","Month":"2","Day":"8","Hour":"9","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["18255191","S0197-4580(07)00464-2","10.1016\/j.neurobiolaging.2007.12.001"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"18213609","DateCompleted":{"Year":"2008","Month":"12","Day":"29"},"DateRevised":{"Year":"2013","Month":"11","Day":"21"},"Article":{"@attributes":{"PubModel":"Print"},"Journal":{"ISSN":"0885-6230","JournalIssue":{"@attributes":{"CitedMedium":"Print"},"Volume":"23","Issue":"7","PubDate":{"Year":"2008","Month":"Jul"}},"Title":"International journal of geriatric psychiatry","ISOAbbreviation":"Int J Geriatr Psychiatry"},"ArticleTitle":"A 6-month, open-label study of memantine in patients with frontotemporal dementia.","Pagination":{"MedlinePgn":"754-9"},"ELocationID":"10.1002\/gps.1973","Abstract":{"AbstractText":["To evaluate safety and effects on cognition and behavior of memantine 20 mg\/day in the treatment of patients with frontotemporal dementia (FTD).","This was a single-center, 6-month, open, uncontrolled study. Sixteen outpatients with a diagnosis of FTD were enrolled.","On the CIBIC plus 26 weeks after baseline four of the 16 patients were minimally improved, four were unchanged, seven were minimally worse and one patient was moderately worse. Neither the Neuropsychiatric Inventory nor the Frontal Behavioral Inventory demonstrated statistically significant differences in behavior between baseline and final visit. There was an increase in the total Alzheimer's Disease Assessment Scale score, reflecting a decline in cognitive performance. Executive functions as well as activities of daily living and extrapyramidal motor symptoms (EPMS) remained unchanged during the trial.","The number of patients was small, so that the evidence given by statistical tests is limited. Thus, the present study can only show trends regarding drug effects. As memantine is well-tolerated, further randomized and controlled studies should be conducted to evaluate drug efficacy."]},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Diehl-Schmid","ForeName":"Janine","Initials":"J","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany. janine.diehl@lrz.tum.de"}},{"@attributes":{"ValidYN":"Y"},"LastName":"F\u00f6rstl","ForeName":"Hans","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Perneczky","ForeName":"Robert","Initials":"R"},{"@attributes":{"ValidYN":"Y"},"LastName":"Pohl","ForeName":"Corina","Initials":"C"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Clinical Trial","Journal Article"]}},"MedlineJournalInfo":{"Country":"England","MedlineTA":"Int J Geriatr Psychiatry","NlmUniqueID":"8710629","ISSNLinking":"0885-6230"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"Dopamine Agents"},{"RegistryNumber":"0","NameOfSubstance":"Excitatory Amino Acid Antagonists"},{"RegistryNumber":"W8O17SJF3T","NameOfSubstance":"Memantine"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Cognition Disorders","QualifierName":["drug therapy","etiology"]},{"DescriptorName":"Dementia","QualifierName":["drug therapy","psychology"]},{"DescriptorName":"Dopamine Agents","QualifierName":["adverse effects","therapeutic use"]},{"DescriptorName":"Educational Status"},{"DescriptorName":"Excitatory Amino Acid Antagonists","QualifierName":["adverse effects","therapeutic use"]},{"DescriptorName":"Female"},{"DescriptorName":"Humans"},{"DescriptorName":"Male"},{"DescriptorName":"Memantine","QualifierName":["adverse effects","therapeutic use"]},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Neuropsychological Tests"},{"DescriptorName":"Patient Compliance"},{"DescriptorName":"Psychiatric Status Rating Scales"},{"DescriptorName":"Treatment Outcome"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"pubmed"},"Year":"2008","Month":"1","Day":"24","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2008","Month":"12","Day":"30","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"entrez"},"Year":"2008","Month":"1","Day":"24","Hour":"9","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["18213609","10.1002\/gps.1973"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"18204837","DateCompleted":{"Year":"2008","Month":"05","Day":"20"},"DateRevised":{"Year":"2008","Month":"03","Day":"20"},"Article":{"@attributes":{"PubModel":"Print"},"Journal":{"ISSN":"1619-7070","JournalIssue":{"@attributes":{"CitedMedium":"Print"},"Volume":"35 Suppl 1","PubDate":{"Year":"2008","Month":"Mar"}},"Title":"European journal of nuclear medicine and molecular imaging","ISOAbbreviation":"Eur J Nucl Med Mol Imaging"},"ArticleTitle":"Molecular imaging in dementia.","Pagination":{"MedlinePgn":"S1-3"},"ELocationID":"10.1007\/s00259-007-0696-7","AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Drzezga","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"}]},"Language":"eng","PublicationTypeList":{"PublicationType":"Editorial"}},"MedlineJournalInfo":{"Country":"Germany","MedlineTA":"Eur J Nucl Med Mol Imaging","NlmUniqueID":"101140988","ISSNLinking":"1619-7070"},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Dementia","QualifierName":"diagnosis"},{"DescriptorName":"Diagnostic Imaging","QualifierName":"trends"},{"DescriptorName":"Humans"},{"DescriptorName":"Image Enhancement","QualifierName":"methods"},{"DescriptorName":"Molecular Probe Techniques","QualifierName":"trends"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"pubmed"},"Year":"2008","Month":"1","Day":"22","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2008","Month":"5","Day":"21","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"entrez"},"Year":"2008","Month":"1","Day":"22","Hour":"9","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["18204837","10.1007\/s00259-007-0696-7"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"18003904","DateCompleted":{"Year":"2008","Month":"01","Day":"02"},"DateRevised":{"Year":"2018","Month":"11","Day":"13"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1091-6490","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"104","Issue":"47","PubDate":{"Year":"2007","Month":"Nov","Day":"20"}},"Title":"Proceedings of the National Academy of Sciences of the United States of America","ISOAbbreviation":"Proc Natl Acad Sci U S A"},"ArticleTitle":"Selective changes of resting-state networks in individuals at risk for Alzheimer's disease.","Pagination":{"MedlinePgn":"18760-5"},"Abstract":{"AbstractText":"Alzheimer's disease (AD) is a neurodegenerative disorder that prominently affects cerebral connectivity. Assessing the functional connectivity at rest, recent functional MRI (fMRI) studies reported on the existence of resting-state networks (RSNs). RSNs are characterized by spatially coherent, spontaneous fluctuations in the blood oxygen level-dependent signal and are made up of regional patterns commonly involved in functions such as sensory, attention, or default mode processing. In AD, the default mode network (DMN) is affected by reduced functional connectivity and atrophy. In this work, we analyzed functional and structural MRI data from healthy elderly (n = 16) and patients with amnestic mild cognitive impairment (aMCI) (n = 24), a syndrome of high risk for developing AD. Two questions were addressed: (i) Are any RSNs altered in aMCI? (ii) Do changes in functional connectivity relate to possible structural changes? Independent component analysis of resting-state fMRI data identified eight spatially consistent RSNs. Only selected areas of the DMN and the executive attention network demonstrated reduced network-related activity in the patient group. Voxel-based morphometry revealed atrophy in both medial temporal lobes (MTL) of the patients. The functional connectivity between both hippocampi in the MTLs and the posterior cingulate of the DMN was present in healthy controls but absent in patients. We conclude that in individuals at risk for AD, a specific subset of RSNs is altered, likely representing effects of ongoing early neurodegeneration. We interpret our finding as a proof of principle, demonstrating that functional brain disorders can be characterized by functional-disconnectivity profiles of RSNs."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Sorg","ForeName":"Christian","Initials":"C","AffiliationInfo":{"Affiliation":"Department of Psychiatry, Klinikum Rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, Ismaningerstrasse 22, 81675 Munich, Germany. c.sorg@lrz.tum.de"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Riedl","ForeName":"Valentin","Initials":"V"},{"@attributes":{"ValidYN":"Y"},"LastName":"M\u00fchlau","ForeName":"Mark","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Calhoun","ForeName":"Vince D","Initials":"VD"},{"@attributes":{"ValidYN":"Y"},"LastName":"Eichele","ForeName":"Tom","Initials":"T"},{"@attributes":{"ValidYN":"Y"},"LastName":"L\u00e4er","ForeName":"Leonhard","Initials":"L"},{"@attributes":{"ValidYN":"Y"},"LastName":"Drzezga","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"F\u00f6rstl","ForeName":"Hans","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Zimmer","ForeName":"Claus","Initials":"C"},{"@attributes":{"ValidYN":"Y"},"LastName":"Wohlschl\u00e4ger","ForeName":"Afra M","Initials":"AM"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Research Support, Non-U.S. Gov't"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2007","Month":"11","Day":"14"}},"MedlineJournalInfo":{"Country":"United States","MedlineTA":"Proc Natl Acad Sci U S A","NlmUniqueID":"7505876","ISSNLinking":"0027-8424"},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Aged, 80 and over"},{"DescriptorName":"Alzheimer Disease","QualifierName":"pathology"},{"DescriptorName":"Cognition Disorders","QualifierName":"pathology"},{"DescriptorName":"Female"},{"DescriptorName":"Health"},{"DescriptorName":"Hippocampus","QualifierName":"pathology"},{"DescriptorName":"Humans"},{"DescriptorName":"Magnetic Resonance Imaging"},{"DescriptorName":"Male"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Nerve Net","QualifierName":"pathology"},{"DescriptorName":"Risk Factors"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"pubmed"},"Year":"2007","Month":"11","Day":"16","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2008","Month":"1","Day":"3","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"entrez"},"Year":"2007","Month":"11","Day":"16","Hour":"9","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["18003904","0708803104","10.1073\/pnas.0708803104","PMC2141850"]},"ReferenceList":{"Reference":[{"Citation":"Proc Natl Acad Sci U S A. 2006 Jun 27;103(26):10046-51","ArticleIdList":{"ArticleId":"16788060"}},{"Citation":"Hum Brain Mapp. 2007 Nov;28(11):1251-66","ArticleIdList":{"ArticleId":"17274023"}},{"Citation":"IEEE Trans Med Imaging. 2004 Feb;23(2):137-52","ArticleIdList":{"ArticleId":"14964560"}},{"Citation":"Ann Neurol. 2004 Mar;55(3):306-19","ArticleIdList":{"ArticleId":"14991808"}},{"Citation":"J Magn Reson Imaging. 2004 Mar;19(3):365-8","ArticleIdList":{"ArticleId":"14994306"}},{"Citation":"Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4637-42","ArticleIdList":{"ArticleId":"15070770"}},{"Citation":"Science. 2004 Jun 25;304(5679):1926-9","ArticleIdList":{"ArticleId":"15218136"}},{"Citation":"Neurology. 1989 Sep;39(9):1159-65","ArticleIdList":{"ArticleId":"2771064"}},{"Citation":"Acta Neuropathol. 1991;82(4):239-59","ArticleIdList":{"ArticleId":"1759558"}},{"Citation":"Magn Reson Med. 1995 Oct;34(4):537-41","ArticleIdList":{"ArticleId":"8524021"}},{"Citation":"J Neuropsychiatry Clin Neurosci. 1997 Summer;9(3):331-41","ArticleIdList":{"ArticleId":"9276838"}},{"Citation":"Arch Neurol. 1999 Mar;56(3):303-8","ArticleIdList":{"ArticleId":"10190820"}},{"Citation":"Hum Brain Mapp. 1999;8(2-3):151-6","ArticleIdList":{"ArticleId":"10524607"}},{"Citation":"J Neurosci. 2004 Nov 10;24(45):10084-92","ArticleIdList":{"ArticleId":"15537877"}},{"Citation":"Neuroimage. 2005 Mar;25(1):294-311","ArticleIdList":{"ArticleId":"15734364"}},{"Citation":"Brain. 2005 Jun;128(Pt 6):1418-27","ArticleIdList":{"ArticleId":"15705612"}},{"Citation":"Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9673-8","ArticleIdList":{"ArticleId":"15976020"}},{"Citation":"J Anat. 2005 Jul;207(1):3-17","ArticleIdList":{"ArticleId":"16011542"}},{"Citation":"Neurology. 2005 Aug 9;65(3):404-11","ArticleIdList":{"ArticleId":"16087905"}},{"Citation":"Hum Brain Mapp. 2005 Sep;26(1):15-29","ArticleIdList":{"ArticleId":"15852468"}},{"Citation":"J Neurosci. 2005 Aug 24;25(34):7709-17","ArticleIdList":{"ArticleId":"16120771"}},{"Citation":"Hum Brain Mapp. 2005 Dec;26(4):231-9","ArticleIdList":{"ArticleId":"15954139"}},{"Citation":"Neuroreport. 2006 Feb 6;17(2):209-13","ArticleIdList":{"ArticleId":"16407773"}},{"Citation":"Neuroimage. 2006 Feb 15;29(4):1359-67","ArticleIdList":{"ArticleId":"16260155"}},{"Citation":"IEEE Eng Med Biol Mag. 2006 Mar-Apr;25(2):79-90","ArticleIdList":{"ArticleId":"16568940"}},{"Citation":"Lancet. 2006 Apr 15;367(9518):1262-70","ArticleIdList":{"ArticleId":"16631882"}},{"Citation":"Neuroimage. 2006 Jun;31(2):496-504","ArticleIdList":{"ArticleId":"16473024"}},{"Citation":"Annu Rev Neurosci. 2006;29:449-76","ArticleIdList":{"ArticleId":"16776593"}},{"Citation":"Proc Natl Acad Sci U S A. 2006 Jun 27;103(26):10041-5","ArticleIdList":{"ArticleId":"16785436"}},{"Citation":"Nat Rev Neurosci. 2006 Sep;7(9):732-44","ArticleIdList":{"ArticleId":"16924262"}},{"Citation":"Proc Natl Acad Sci U S A. 2006 Sep 12;103(37):13848-53","ArticleIdList":{"ArticleId":"16945915"}},{"Citation":"J Neurosci. 2006 Oct 4;26(40):10222-31","ArticleIdList":{"ArticleId":"17021177"}},{"Citation":"Neuroreport. 2006 Nov 6;17(16):1687-90","ArticleIdList":{"ArticleId":"17047454"}},{"Citation":"J Neurophysiol. 2006 Dec;96(6):3517-31","ArticleIdList":{"ArticleId":"16899645"}},{"Citation":"Neuropsychologia. 2007 Apr 8;45(7):1363-77","ArticleIdList":{"ArticleId":"17126370"}},{"Citation":"Am J Psychiatry. 2007 Mar;164(3):450-7","ArticleIdList":{"ArticleId":"17329470"}},{"Citation":"Neuropsychologia. 2007 Apr 9;45(8):1948-60","ArticleIdList":{"ArticleId":"17275041"}},{"Citation":"Nature. 2007 May 3;447(7140):83-6","ArticleIdList":{"ArticleId":"17476267"}},{"Citation":"Proc Natl Acad Sci U S A. 2007 Aug 7;104(32):13170-5","ArticleIdList":{"ArticleId":"17670949"}},{"Citation":"Arch Neurol. 2007 Aug;64(8):1130-8","ArticleIdList":{"ArticleId":"17698703"}},{"Citation":"Nat Rev Neurosci. 2007 Sep;8(9):700-11","ArticleIdList":{"ArticleId":"17704812"}},{"Citation":"Biol Psychiatry. 2007 Sep 1;62(5):429-37","ArticleIdList":{"ArticleId":"17210143"}},{"Citation":"Proc Natl Acad Sci U S A. 2001 Jan 16;98(2):676-82","ArticleIdList":{"ArticleId":"11209064"}},{"Citation":"J Neurol Neurosurg Psychiatry. 2001 Sep;71(3):315-21","ArticleIdList":{"ArticleId":"11511703"}},{"Citation":"Hum Brain Mapp. 2001 Nov;14(3):140-51","ArticleIdList":{"ArticleId":"11559959"}},{"Citation":"Nat Rev Neurosci. 2001 Oct;2(10):685-94","ArticleIdList":{"ArticleId":"11584306"}},{"Citation":"Hum Brain Mapp. 2002 Apr;15(4):247-62","ArticleIdList":{"ArticleId":"11835612"}},{"Citation":"Nat Rev Neurosci. 2002 Mar;3(3):201-15","ArticleIdList":{"ArticleId":"11994752"}},{"Citation":"J Comp Neurol. 2002 Jun 10;447(4):394-420","ArticleIdList":{"ArticleId":"11992524"}},{"Citation":"J Neurosci. 2002 Nov 1;22(21):9166-70","ArticleIdList":{"ArticleId":"12417640"}},{"Citation":"Neuroimage. 2003 Jul;19(3):674-83","ArticleIdList":{"ArticleId":"12880798"}},{"Citation":"Neuropsychol Rev. 2003 Jun;13(2):79-92","ArticleIdList":{"ArticleId":"12887040"}},{"Citation":"Neuroimage. 2003 Aug;19(4):1463-76","ArticleIdList":{"ArticleId":"12948703"}},{"Citation":"Neuroimage. 2007 Oct 1;37(4):1091-6; discussion 1097-9","ArticleIdList":{"ArticleId":"17368915"}},{"Citation":"Neuroimage. 2007 Oct 1;37(4):1083-90; discussion 1097-9","ArticleIdList":{"ArticleId":"17719799"}},{"Citation":"Hum Brain Mapp. 2007 Oct;28(10):967-78","ArticleIdList":{"ArticleId":"17133390"}},{"Citation":"Lancet. 2006 Jul 29;368(9533):387-403","ArticleIdList":{"ArticleId":"16876668"}}]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"17968544","DateCompleted":{"Year":"2008","Month":"07","Day":"22"},"DateRevised":{"Year":"2018","Month":"11","Day":"13"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1619-7070","JournalIssue":{"@attributes":{"CitedMedium":"Print"},"Volume":"35","Issue":"3","PubDate":{"Year":"2008","Month":"Mar"}},"Title":"European journal of nuclear medicine and molecular imaging","ISOAbbreviation":"Eur J Nucl Med Mol Imaging"},"ArticleTitle":"Urinary incontinence and its functional anatomy in frontotemporal lobar degenerations.","Pagination":{"MedlinePgn":"605-10"},"Abstract":{"AbstractText":["The frontal lobes play a crucial role in micturition control. However, no reports exist on the functional role of distinct frontal brain regions in urinary incontinence (UIC) in patients with a neurodegenerative damage of the frontal lobe. The aim of the present study was therefore to explore if functional brain lesions were associated with UIC in patients suffering from frontotemporal lobar degenerations (FTLD).","Forty-four patients, including eight incontinent subjects, underwent cranial positron emission tomography scanning with (18)F-fluoro-2-deoxy-glucose ((18)F-FDG PET) to assess the relative metabolic rate of glucose (rCMRglc). Group comparisons of rCMRglc were conducted in SPM2 to identify brain regions where the group of incontinent patients (FTLD+UIC) had significant alterations compared with the group without UIC (FTLD-UIC).","At the stringent statistical threshold of p < 0.05, corrected for multiple comparisons according to the family-wise error rate, the statistical analysis revealed two significant right-hemispheric hypometabolic clusters located in the premotor\/anterior cingulate cortex and the putamen\/claustrum\/insula. No hypermetabolic regions were found.","The present study is the first to provide evidence for brain functional alterations involved in the occurrence of UIC in FTLD. These results provide an important piece of evidence to the understanding of a particularly distressing autonomic nervous system symptom of dementia."]},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Perneczky","ForeName":"Robert","Initials":"R","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Technical University Munich Medical School, Munich, Germany. robert.perneczky@lrz.tum.de"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Diehl-Schmid","ForeName":"Janine","Initials":"J"},{"@attributes":{"ValidYN":"Y"},"LastName":"F\u00f6rstl","ForeName":"Hans","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Drzezga","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"May","ForeName":"Florian","Initials":"F"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Research Support, Non-U.S. Gov't"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2007","Month":"10","Day":"30"}},"MedlineJournalInfo":{"Country":"Germany","MedlineTA":"Eur J Nucl Med Mol Imaging","NlmUniqueID":"101140988","ISSNLinking":"1619-7070"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"Radiopharmaceuticals"},{"RegistryNumber":"0Z5B2CJX4D","NameOfSubstance":"Fluorodeoxyglucose F18"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Dementia","QualifierName":["diagnostic imaging","metabolism"]},{"DescriptorName":"Female"},{"DescriptorName":"Fluorodeoxyglucose F18","QualifierName":"pharmacokinetics"},{"DescriptorName":"Frontal Lobe","QualifierName":["diagnostic imaging","metabolism"]},{"DescriptorName":"Humans"},{"DescriptorName":"Male"},{"DescriptorName":"Radionuclide Imaging"},{"DescriptorName":"Radiopharmaceuticals","QualifierName":"pharmacokinetics"},{"DescriptorName":"Tissue Distribution"},{"DescriptorName":"Urinary Incontinence","QualifierName":["diagnostic imaging","metabolism"]}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2007","Month":"06","Day":"29"},{"@attributes":{"PubStatus":"accepted"},"Year":"2007","Month":"09","Day":"28"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2007","Month":"10","Day":"31","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2008","Month":"7","Day":"23","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"entrez"},"Year":"2007","Month":"10","Day":"31","Hour":"9","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["17968544","10.1007\/s00259-007-0626-8"]},"ReferenceList":{"Reference":[{"Citation":"J Comp Neurol. 2005 Dec 5;493(1):27-32","ArticleIdList":{"ArticleId":"16255006"}},{"Citation":"Neuroimage. 2002 Sep;17 (1):302-16","ArticleIdList":{"ArticleId":"12482085"}},{"Citation":"Eur J Nucl Med Mol Imaging. 2007 Sep;34(9):1490-7","ArticleIdList":{"ArticleId":"17318545"}},{"Citation":"Stroke. 2000 Sep;31(9):2182-8","ArticleIdList":{"ArticleId":"10978049"}},{"Citation":"Brain. 1997 Jan;120 ( Pt 1):111-21","ArticleIdList":{"ArticleId":"9055802"}},{"Citation":"Brain Res. 2007 Feb 16;1133(1):178-85","ArticleIdList":{"ArticleId":"17184752"}},{"Citation":"Dementia. 1994 May-Aug;5(3-4):148-52","ArticleIdList":{"ArticleId":"8087170"}},{"Citation":"J Comp Neurol. 1986 Aug 22;250(4):449-61","ArticleIdList":{"ArticleId":"3760249"}},{"Citation":"Ann Neurol. 2004 Mar;55(3):335-46","ArticleIdList":{"ArticleId":"14991811"}},{"Citation":"Ann Neurol. 2001 Sep;50(3):358-65","ArticleIdList":{"ArticleId":"11558792"}},{"Citation":"Neurology. 2000 Dec 12;55(11):1621-6","ArticleIdList":{"ArticleId":"11113214"}},{"Citation":"Brain. 2000 Apr;123 ( Pt 4):781-9","ArticleIdList":{"ArticleId":"10734009"}},{"Citation":"Eur J Neurol. 2004 Oct;11(10 ):705-8","ArticleIdList":{"ArticleId":"15469456"}},{"Citation":"Behav Brain Res. 1998 May;92 (2):151-5","ArticleIdList":{"ArticleId":"9638957"}},{"Citation":"Trends Cogn Sci. 2000 Jun;4(6):215-222","ArticleIdList":{"ArticleId":"10827444"}},{"Citation":"J Urol. 2006 Mar;175(3 Pt 1):994-8","ArticleIdList":{"ArticleId":"16469600"}},{"Citation":"J Neurophysiol. 1949 Nov;12(6):385-92","ArticleIdList":{"ArticleId":"15408005"}},{"Citation":"J Psychiatr Res. 1975 Nov;12(3):189-98","ArticleIdList":{"ArticleId":"1202204"}},{"Citation":"Neurology. 2005 Jan 11;64(1):102-7","ArticleIdList":{"ArticleId":"15642911"}},{"Citation":"Dement Geriatr Cogn Disord. 2006;22(4):346-51","ArticleIdList":{"ArticleId":"16954690"}},{"Citation":"Neurology. 1998 Dec;51(6):1546-54","ArticleIdList":{"ArticleId":"9855500"}},{"Citation":"Can J Neurol Sci. 1997 Feb;24(1):29-36","ArticleIdList":{"ArticleId":"9043744"}},{"Citation":"Nat Neurosci. 2004 Feb;7(2):189-95","ArticleIdList":{"ArticleId":"14730305"}},{"Citation":"Neuroimage. 2007 Aug 1;37(1):1-7","ArticleIdList":{"ArticleId":"17574871"}},{"Citation":"Brain. 1964 Jun;87:233-62","ArticleIdList":{"ArticleId":"14188274"}},{"Citation":"Age Ageing. 2000 Nov;29(6):505-10","ArticleIdList":{"ArticleId":"11191242"}},{"Citation":"J Neurol Neurosurg Psychiatry. 2003 Sep;74(9):1206-9","ArticleIdList":{"ArticleId":"12933919"}},{"Citation":"Neurobiol Aging. 2007 Jan;28(1):42-50","ArticleIdList":{"ArticleId":"16448722"}},{"Citation":"Eur J Nucl Med Mol Imaging. 2003 Aug;30(8):1104-13","ArticleIdList":{"ArticleId":"12764551"}},{"Citation":"Br J Psychiatry. 1982 Jun;140:566-72","ArticleIdList":{"ArticleId":"7104545"}},{"Citation":"Neurology. 2002 Jun 11;58(11):1615-21","ArticleIdList":{"ArticleId":"12058088"}},{"Citation":"Am J Geriatr Psychiatry. 2006 Feb;14(2):139-44","ArticleIdList":{"ArticleId":"16473978"}},{"Citation":"Arch Neurol. 2007 Jul;64(7):984-8","ArticleIdList":{"ArticleId":"17620488"}},{"Citation":"Brain. 2001 Feb;124(Pt 2):369-77","ArticleIdList":{"ArticleId":"11157564"}}]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"17962045","DateCompleted":{"Year":"2008","Month":"02","Day":"25"},"DateRevised":{"Year":"2019","Month":"12","Day":"18"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1053-8119","JournalIssue":{"@attributes":{"CitedMedium":"Print"},"Volume":"39","Issue":"2","PubDate":{"Year":"2008","Month":"Jan","Day":"15"}},"Title":"NeuroImage","ISOAbbreviation":"Neuroimage"},"ArticleTitle":"Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease.","Pagination":{"MedlinePgn":"619-33"},"Abstract":{"AbstractText":"Semantic dementia (SD) is a rare clinical syndrome, assigned to the group of frontotemporal lobar degenerations (FTLD). Histopathological analysis has not revealed the deposition of amyloid plaques in the majority of SD cases, in contrast to dementia of the Alzheimer type (AD). However, based on clinical examination alone a reliable differentiation of the underlying pathology cannot be guaranteed, i.e. AD and SD may be confused in some cases. Our aim was to determine, whether AD and SD can be differentiated in vivo by means of amyloid plaque PET imaging. In groups of AD and SD patients, matched for gender, age and overall degree of cognitive impairment, cerebral glucose metabolism was examined with [(18)F]Fluorodeoxyglucose (FDG)-PET and cerebral amyloid plaque density was assessed using [(11)C]6-OH-BTA-1 (PIB)-PET. A volume-of-interest analysis (VOI), using the cerebellum as a reference region, and voxel-based statistical group comparisons (SPM2) were carried out between the patient groups and matched groups of healthy controls. To control for a potential influence of atrophy on the PET findings, a correction of partial volume effects was performed. Characteristic patterns of hypometabolism could be demonstrated in both clinically defined AD and SD with some regional overlap and subtle differences (AD: bilateral posterior cingulate, temporoparietal and frontal cortex; SD: left>right polar temporal, frontal mesial cortex). Compared with healthy controls, significant [(11)C]PIB amyloid plaque tracer binding was observed only in patients with AD (in bilateral temporoparietal, frontal and posterior cingulate cortex and the precuneus) but not in SD. This difference in amyloid plaque deposition could be reproduced in direct statistical comparison of AD and SD and clearly extended the metabolic differences between the patient groups. These findings support the notion that SD can be diagnosed in vivo as a separate entity from AD using amyloid plaque imaging. In general, amyloid plaque PET may complement neuropsychological assessment regarding reliable differential diagnosis of AD and FTLD dementias based on characterization of underlying pathology and may improve the definition of individual prognosis and the selection of patients for scientific trials."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Drzezga","ForeName":"Alexander","Initials":"A","AffiliationInfo":{"Affiliation":"Department of Nuclear Medicine, Technische Universit\u00e4t, M\u00fcnchen, Ismaninger Str. 22, D-81675 Munich, Germany. a.drzezga@lrz.tu-muenchen.de"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Grimmer","ForeName":"Timo","Initials":"T"},{"@attributes":{"ValidYN":"Y"},"LastName":"Henriksen","ForeName":"Gjermund","Initials":"G"},{"@attributes":{"ValidYN":"Y"},"LastName":"Stangier","ForeName":"Isabelle","Initials":"I"},{"@attributes":{"ValidYN":"Y"},"LastName":"Perneczky","ForeName":"Robert","Initials":"R"},{"@attributes":{"ValidYN":"Y"},"LastName":"Diehl-Schmid","ForeName":"Janine","Initials":"J"},{"@attributes":{"ValidYN":"Y"},"LastName":"Mathis","ForeName":"Chester A","Initials":"CA"},{"@attributes":{"ValidYN":"Y"},"LastName":"Klunk","ForeName":"William E","Initials":"WE"},{"@attributes":{"ValidYN":"Y"},"LastName":"Price","ForeName":"Julie","Initials":"J"},{"@attributes":{"ValidYN":"Y"},"LastName":"DeKosky","ForeName":"Steve","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"Wester","ForeName":"Hans-J\u00fcrgen","Initials":"HJ"},{"@attributes":{"ValidYN":"Y"},"LastName":"Schwaiger","ForeName":"Markus","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Research Support, Non-U.S. Gov't"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2007","Month":"09","Day":"21"}},"MedlineJournalInfo":{"Country":"United States","MedlineTA":"Neuroimage","NlmUniqueID":"9215515","ISSNLinking":"1053-8119"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole"},{"RegistryNumber":"0","NameOfSubstance":"Apolipoproteins E"},{"RegistryNumber":"0","NameOfSubstance":"Benzothiazoles"},{"RegistryNumber":"0","NameOfSubstance":"Radiopharmaceuticals"},{"RegistryNumber":"0Z5B2CJX4D","NameOfSubstance":"Fluorodeoxyglucose F18"},{"RegistryNumber":"IY9XDZ35W2","NameOfSubstance":"Glucose"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Alzheimer Disease","QualifierName":["diagnostic imaging","metabolism","pathology","psychology"]},{"DescriptorName":"Apolipoproteins E","QualifierName":"genetics"},{"DescriptorName":"Benzothiazoles"},{"DescriptorName":"Brain","QualifierName":"diagnostic imaging"},{"DescriptorName":"Brain Chemistry","QualifierName":"physiology"},{"DescriptorName":"Dementia","QualifierName":["diagnostic imaging","metabolism","pathology","psychology"]},{"DescriptorName":"Female"},{"DescriptorName":"Fluorodeoxyglucose F18"},{"DescriptorName":"Functional Laterality","QualifierName":"physiology"},{"DescriptorName":"Genotype"},{"DescriptorName":"Glucose","QualifierName":"metabolism"},{"DescriptorName":"Humans"},{"DescriptorName":"Image Processing, Computer-Assisted"},{"DescriptorName":"Magnetic Resonance Imaging"},{"DescriptorName":"Male"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Neuropsychological Tests"},{"DescriptorName":"Plaque, Amyloid","QualifierName":["diagnostic imaging","pathology"]},{"DescriptorName":"Positron-Emission Tomography"},{"DescriptorName":"Radiopharmaceuticals"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2007","Month":"05","Day":"29"},{"@attributes":{"PubStatus":"revised"},"Year":"2007","Month":"09","Day":"05"},{"@attributes":{"PubStatus":"accepted"},"Year":"2007","Month":"09","Day":"07"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2007","Month":"10","Day":"27","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2008","Month":"2","Day":"26","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"entrez"},"Year":"2007","Month":"10","Day":"27","Hour":"9","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["17962045","S1053-8119(07)00806-3","10.1016\/j.neuroimage.2007.09.020"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"17898350","DateCompleted":{"Year":"2007","Month":"11","Day":"01"},"DateRevised":{"Year":"2016","Month":"11","Day":"24"},"Article":{"@attributes":{"PubModel":"Print"},"Journal":{"ISSN":"0002-953X","JournalIssue":{"@attributes":{"CitedMedium":"Print"},"Volume":"164","Issue":"10","PubDate":{"Year":"2007","Month":"Oct"}},"Title":"The American journal of psychiatry","ISOAbbreviation":"Am J Psychiatry"},"ArticleTitle":"Association of the tau haplotype H2 with age at onset and functional alterations of glucose utilization in frontotemporal dementia.","Pagination":{"MedlinePgn":"1577-84"},"Abstract":{"AbstractText":["The microtubule-associated protein tau gene (MAPT) contains two extended haplotypes, H1 and H2, which have been linked with sporadic tauopathies. However, there is little evidence as to how these haplotypes may influence the clinical features of the disease. The aim of this study was to investigate the MAPT haplotypes in relation to risk for, and functional alterations of glucose metabolism in, patients with frontotemporal dementia (FTD).","The authors investigated MAPT haplotypes in 142 individuals with FTD and 292 comparison subjects. Additionally, in a subset of 41 individuals with FTD and 16 comparison subjects, the authors undertook functional [ (18)F]fluorodeoxyglucose positron emission tomography (PET) imaging.","MAPT haplotype distribution did not differ significantly between individuals with FTD and comparison subjects. However, the H2 haplotype was clinically associated with an earlier age at onset of FTD, which presented in a dose-dependent manner. Correspondingly, PET analysis revealed functional differences in glucose utilization patterns between MAPT haplotypes, with H2 carriers having a more pronounced hypometabolism in frontal brain areas than H1 carriers, which could not be accounted for by differences in duration of illness.","While the extended MAPT H1 and H2 haplotypes do not appear to confer risk for disease development, the H2 haplotype appears to modify age at onset and functionally shows a more severe decline of glucose utilization in frontal brain areas."]},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Laws","ForeName":"Simon M","Initials":"SM","AffiliationInfo":{"Affiliation":"Neurochemistry and Neurogenetics Laboratory, Department of Psychiatry and Psychotherapy, Munich University of Technology, 81675 Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Perneczky","ForeName":"Robert","Initials":"R"},{"@attributes":{"ValidYN":"Y"},"LastName":"Drzezga","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Diehl-Schmid","ForeName":"Janine","Initials":"J"},{"@attributes":{"ValidYN":"Y"},"LastName":"Ibach","ForeName":"Bernd","Initials":"B"},{"@attributes":{"ValidYN":"Y"},"LastName":"B\u00e4uml","ForeName":"Josef","Initials":"J"},{"@attributes":{"ValidYN":"Y"},"LastName":"Eisele","ForeName":"Tamara","Initials":"T"},{"@attributes":{"ValidYN":"Y"},"LastName":"F\u00f6rstl","ForeName":"Hans","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Riemenschneider","ForeName":"Matthias","Initials":"M"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Comparative Study","Journal Article","Research Support, Non-U.S. Gov't"]}},"MedlineJournalInfo":{"Country":"United States","MedlineTA":"Am J Psychiatry","NlmUniqueID":"0370512","ISSNLinking":"0002-953X"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"MAPT protein, human"},{"RegistryNumber":"0","NameOfSubstance":"tau Proteins"},{"RegistryNumber":"0Z5B2CJX4D","NameOfSubstance":"Fluorodeoxyglucose F18"},{"RegistryNumber":"IY9XDZ35W2","NameOfSubstance":"Glucose"}]},"CitationSubset":["AIM","IM"],"MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Age Factors"},{"DescriptorName":"Age of Onset"},{"DescriptorName":"Aged"},{"DescriptorName":"Aged, 80 and over"},{"DescriptorName":"Cerebral Cortex","QualifierName":["diagnostic imaging","metabolism"]},{"DescriptorName":"Dementia","QualifierName":["genetics","metabolism"]},{"DescriptorName":"Fluorodeoxyglucose F18"},{"DescriptorName":"Frontal Lobe","QualifierName":["diagnostic imaging","metabolism"]},{"DescriptorName":"Gene Frequency"},{"DescriptorName":"Genetic Predisposition to Disease","QualifierName":"genetics"},{"DescriptorName":"Genotype"},{"DescriptorName":"Glucose","QualifierName":"metabolism"},{"DescriptorName":"Haplotypes","QualifierName":"genetics"},{"DescriptorName":"Humans"},{"DescriptorName":"Male"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Positron-Emission Tomography"},{"DescriptorName":"Risk Factors"},{"DescriptorName":"Tauopathies","QualifierName":["diagnostic imaging","genetics","metabolism"]},{"DescriptorName":"tau Proteins","QualifierName":"genetics"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"pubmed"},"Year":"2007","Month":"9","Day":"28","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2007","Month":"11","Day":"2","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"entrez"},"Year":"2007","Month":"9","Day":"28","Hour":"9","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["17898350","164\/10\/1577","10.1176\/appi.ajp.2007.06091456"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"17618707","DateCompleted":{"Year":"2009","Month":"02","Day":"19"},"DateRevised":{"Year":"2017","Month":"11","Day":"16"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1558-1497","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"30","Issue":"2","PubDate":{"Year":"2009","Month":"Feb"}},"Title":"Neurobiology of aging","ISOAbbreviation":"Neurobiol Aging"},"ArticleTitle":"No association of common VCP variants with sporadic frontotemporal dementia.","Pagination":{"MedlinePgn":"333-5"},"Abstract":{"AbstractText":"Mutations in the gene for valosin containing protein (VCP) cause autosomal dominant inclusion body myopathy associated with Paget disease and frontotemporal dementia (IBMPFD). To investigate the role of this novel gene in sporadic forms of frontotemporal dementia (FTD), we genotyped 27 single nucleotide polymorphisms covering the entire VCP genomic region in 198 patients with sporadic FTD and 184 matched controls from Germany. No significant association could be demonstrated. There is no evidence, that common variants in VCP confer a strong risk to the development of sporadic FTD."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Schumacher","ForeName":"Axel","Initials":"A","AffiliationInfo":{"Affiliation":"Neurochemistry and Neurogenetics Laboratory, Department of Psychiatry, TU-Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Friedrich","ForeName":"Patricia","Initials":"P"},{"@attributes":{"ValidYN":"Y"},"LastName":"Diehl","ForeName":"Janine","Initials":"J"},{"@attributes":{"ValidYN":"Y"},"LastName":"Ibach","ForeName":"Bernd","Initials":"B"},{"@attributes":{"ValidYN":"Y"},"LastName":"Schoepfer-Wendels","ForeName":"Andreas","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Mueller","ForeName":"Jakob C","Initials":"JC"},{"@attributes":{"ValidYN":"Y"},"LastName":"Konta","ForeName":"Lidija","Initials":"L"},{"@attributes":{"ValidYN":"Y"},"LastName":"Laws","ForeName":"Simon M","Initials":"SM"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Foerstl","ForeName":"Hans","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Riemenschneider","ForeName":"Matthias","Initials":"M"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Research Support, Non-U.S. Gov't"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2007","Month":"07","Day":"05"}},"MedlineJournalInfo":{"Country":"United States","MedlineTA":"Neurobiol Aging","NlmUniqueID":"8100437","ISSNLinking":"0197-4580"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"Cell Cycle Proteins"},{"RegistryNumber":"EC 3.6.1.-","NameOfSubstance":"Adenosine Triphosphatases"},{"RegistryNumber":"EC 3.6.4.6","NameOfSubstance":"VCP protein, human"},{"RegistryNumber":"EC 3.6.4.6","NameOfSubstance":"Valosin Containing Protein"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Adenosine Triphosphatases","QualifierName":"genetics"},{"DescriptorName":"Cell Cycle Proteins","QualifierName":"genetics"},{"DescriptorName":"Dementia","QualifierName":["epidemiology","genetics"]},{"DescriptorName":"Female"},{"DescriptorName":"Genetic Predisposition to Disease","QualifierName":["epidemiology","genetics"]},{"DescriptorName":"Genetic Variation"},{"DescriptorName":"Germany","QualifierName":"epidemiology"},{"DescriptorName":"Humans"},{"DescriptorName":"Incidence"},{"DescriptorName":"Male"},{"DescriptorName":"Polymorphism, Single Nucleotide","QualifierName":"genetics"},{"DescriptorName":"Risk Assessment","QualifierName":"methods"},{"DescriptorName":"Risk Factors"},{"DescriptorName":"Valosin Containing Protein"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2006","Month":"12","Day":"22"},{"@attributes":{"PubStatus":"revised"},"Year":"2007","Month":"03","Day":"20"},{"@attributes":{"PubStatus":"accepted"},"Year":"2007","Month":"05","Day":"27"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2007","Month":"7","Day":"10","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2009","Month":"2","Day":"20","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"entrez"},"Year":"2007","Month":"7","Day":"10","Hour":"9","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["17618707","S0197-4580(07)00236-9","10.1016\/j.neurobiolaging.2007.05.023"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"17548777","DateCompleted":{"Year":"2007","Month":"08","Day":"17"},"DateRevised":{"Year":"2016","Month":"11","Day":"24"},"Article":{"@attributes":{"PubModel":"Print"},"Journal":{"ISSN":"0891-9887","JournalIssue":{"@attributes":{"CitedMedium":"Print"},"Volume":"20","Issue":"2","PubDate":{"Year":"2007","Month":"Jun"}},"Title":"Journal of geriatric psychiatry and neurology","ISOAbbreviation":"J Geriatr Psychiatry Neurol"},"ArticleTitle":"Cerebral metabolic correlates of the clinical dementia rating scale in mild cognitive impairment.","Pagination":{"MedlinePgn":"84-8"},"Abstract":{"AbstractText":"Mild cognitive impairment (MCI) is often a prodromal state of Alzheimer's disease (AD). Imaging studies have shown that metabolic deficits in cerebral regions known to be affected early by AD pathology are predictive of progression to AD. In the present article, the authors examine associations between clinical impairment (Clinical Dementia Rating scale sum of boxes [CDR-SB]) and regional deficits in glucose utilization in a sample of 41 patients with MCI, who underwent cerebral 18F-FDG PET for the measurement of regional glucose metabolism. A linear regression analysis with CDR-SB score as the independent variable and glucose metabolism as the dependent variable, adjusted for age, gender, and years of school education, was conducted in voxel-by-voxel fashion in SPM2. The regression analysis revealed a significant negative association between CDR-SB score and glucose metabolism in the right posterior cingulate gyrus (P < .001, uncorrected for multiple comparisons), which was independent from demographical variables. The authors conclude that clinical severity of impairments is already correlated with deficits in glucose metabolism in the stage of MCI."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Perneczky","ForeName":"Robert","Initials":"R","AffiliationInfo":{"Affiliation":"Department of Psychiatry, Medicine Technische Universit\u00e4t Munchen, Germany. robert.perneczky@lrz.tum.de"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Hartmann","ForeName":"Julia","Initials":"J"},{"@attributes":{"ValidYN":"Y"},"LastName":"Grimmer","ForeName":"Timo","Initials":"T"},{"@attributes":{"ValidYN":"Y"},"LastName":"Drzezga","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Research Support, Non-U.S. Gov't"]}},"MedlineJournalInfo":{"Country":"United States","MedlineTA":"J Geriatr Psychiatry Neurol","NlmUniqueID":"8805645","ISSNLinking":"0891-9887"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"Blood Glucose"},{"RegistryNumber":"0Z5B2CJX4D","NameOfSubstance":"Fluorodeoxyglucose F18"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Aged, 80 and over"},{"DescriptorName":"Alzheimer Disease","QualifierName":"diagnostic imaging"},{"DescriptorName":"Blood Glucose","QualifierName":"metabolism"},{"DescriptorName":"Brain","QualifierName":"diagnostic imaging"},{"DescriptorName":"Cognition Disorders","QualifierName":"diagnostic imaging"},{"DescriptorName":"Disease Progression"},{"DescriptorName":"Dominance, Cerebral","QualifierName":"physiology"},{"DescriptorName":"Female"},{"DescriptorName":"Fluorodeoxyglucose F18"},{"DescriptorName":"Follow-Up Studies"},{"DescriptorName":"Gyrus Cinguli","QualifierName":"diagnostic imaging"},{"DescriptorName":"Humans"},{"DescriptorName":"Male"},{"DescriptorName":"Mental Status Schedule"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Neuropsychological Tests"},{"DescriptorName":"Parietal Lobe","QualifierName":"diagnostic imaging"},{"DescriptorName":"Positron-Emission Tomography"},{"DescriptorName":"Statistics as Topic"},{"DescriptorName":"Temporal Lobe","QualifierName":"diagnostic imaging"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"pubmed"},"Year":"2007","Month":"6","Day":"6","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2007","Month":"8","Day":"19","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"entrez"},"Year":"2007","Month":"6","Day":"6","Hour":"9","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["17548777","20\/2\/84","10.1177\/0891988706297093"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"17479980","DateCompleted":{"Year":"2008","Month":"04","Day":"21"},"DateRevised":{"Year":"2016","Month":"11","Day":"24"},"Article":{"@attributes":{"PubModel":"Print"},"Journal":{"ISSN":"0885-6230","JournalIssue":{"@attributes":{"CitedMedium":"Print"},"Volume":"22","Issue":"11","PubDate":{"Year":"2007","Month":"Nov"}},"Title":"International journal of geriatric psychiatry","ISOAbbreviation":"Int J Geriatr Psychiatry"},"ArticleTitle":"Male gender is associated with greater cerebral hypometabolism in frontotemporal dementia: evidence for sex-related cognitive reserve.","Pagination":{"MedlinePgn":"1135-40"},"Abstract":{"AbstractText":["Neuropathological studies suggest that the association between neurodegenerative brain damage and clinical symptoms may be stronger in women than in men; therefore women are more likely to express neurodegeneration as clinical dementia. Furthermore, a recent 18F-FDG PET study explored gender differences in the regional cerebral metabolic rate of glucose (rCMRglc) in patients with Alzheimer's disease and found that, at the same level of severity of cognitive impairment, men showed a significantly greater hypometabolism than women. This suggests that men can compensate more pathology than women.","To test the hypothesis that cerebral metabolic deficits due to neurodegeneration are more pronounced in men than in women with frontotemporal dementia (FTD), controlling for cognitive impairment.","Twenty-nine patients with FTD (20 men, nine women) underwent an extensive clinical examination and 18F-FDG PET imaging at a university-based outpatient unit for cognitive disorders. An analysis of covariance (with age, total score of the CERAD neuropsychological battery, and years of school education as co-variates) was conducted to identify gender differences in glucose metabolism.","Frontal cortical regions were identified where rCMRglc was significantly reduced in men as compared with women. These regions were located in the left middle, superior, and inferior frontal gyri and the right anterior cingulate, and superior frontal gyri (p < 0.001 uncorrected for multiple comparisons).","The same level of severity of cognitive symptoms is associated with a more pronounced functional brain damage in male than in female patients with FTD, suggesting a greater degree of cognitive reserve in men."],"CopyrightInformation":"Copyright  2007 John Wiley & Sons, Ltd."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Perneczky","ForeName":"Robert","Initials":"R","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Technical University Munich, Munich, Germany. robert.perneczky@lrz.tum.de"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Diehl-Schmid","ForeName":"Janine","Initials":"J"},{"@attributes":{"ValidYN":"Y"},"LastName":"F\u00f6rstl","ForeName":"Hans","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Drzezga","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Research Support, Non-U.S. Gov't"]}},"MedlineJournalInfo":{"Country":"England","MedlineTA":"Int J Geriatr Psychiatry","NlmUniqueID":"8710629","ISSNLinking":"0885-6230"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"Radiopharmaceuticals"},{"RegistryNumber":"0Z5B2CJX4D","NameOfSubstance":"Fluorodeoxyglucose F18"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Brain","QualifierName":["diagnostic imaging","metabolism"]},{"DescriptorName":"Brain Mapping","QualifierName":"methods"},{"DescriptorName":"Cognition Disorders","QualifierName":["diagnostic imaging","etiology","metabolism"]},{"DescriptorName":"Dementia","QualifierName":["diagnostic imaging","metabolism","psychology"]},{"DescriptorName":"Female"},{"DescriptorName":"Fluorodeoxyglucose F18"},{"DescriptorName":"Humans"},{"DescriptorName":"Magnetic Resonance Imaging"},{"DescriptorName":"Male"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Positron-Emission Tomography"},{"DescriptorName":"Prefrontal Cortex","QualifierName":["diagnostic imaging","metabolism"]},{"DescriptorName":"Psychiatric Status Rating Scales"},{"DescriptorName":"Radiopharmaceuticals"},{"DescriptorName":"Sex Characteristics"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"pubmed"},"Year":"2007","Month":"5","Day":"8","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2008","Month":"4","Day":"22","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"entrez"},"Year":"2007","Month":"5","Day":"8","Hour":"9","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["17479980","10.1002\/gps.1803"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"17457029","DateCompleted":{"Year":"2007","Month":"07","Day":"24"},"DateRevised":{"Year":"2016","Month":"11","Day":"24"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1420-8008","JournalIssue":{"@attributes":{"CitedMedium":"Print"},"Volume":"23","Issue":"6","PubDate":{"Year":"2007"}},"Title":"Dementia and geriatric cognitive disorders","ISOAbbreviation":"Dement Geriatr Cogn Disord"},"ArticleTitle":"Metabolic correlates of brain reserve in dementia with Lewy bodies: an FDG PET study.","Pagination":{"MedlinePgn":"416-22"},"Abstract":{"AbstractText":["Studies suggest that brain reserve allows patients with more years of schooling to cope better with brain damage. Research has been mainly focussed on Alzheimer's disease and no studies exist on patients with dementia with Lewy bodies (DLB). The aim of this study was to provide evidence for brain reserve in DLB.","Twenty-one consecutive patients with DLB and 16 age-matched healthy controls were included. The participants underwent cerebral (18)F-FDG PET imaging at rest. A group comparison was conducted in SPM2 between the patient and control groups. A linear regression analysis with glucose metabolism as the dependent and years of schooling as the independent variable was performed. Age, gender and a total score of the Consortium to Establish a Registry for Alzheimer's Disease neuropsychological battery were included as covariates into the analysis.","The patients showed a significant metabolic reduction in the frontal and posterior association cortices, the basal ganglia and the pulvinar of the thalami. Glucose metabolism and education showed an inverse relationship in an extensive cluster in the left temporo-parieto-occipital cortex.","Similar findings were previously reported in Alzheimer's disease and are regarded as evidence for brain reserve. Therefore, we suggest that brain reserve is also present in DLB."]},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Perneczky","ForeName":"Robert","Initials":"R","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Technical University Munich, Munich, Germany. robert.perneczky@lrz.tum.de"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Haussermann","ForeName":"Peter","Initials":"P"},{"@attributes":{"ValidYN":"Y"},"LastName":"Diehl-Schmid","ForeName":"Janine","Initials":"J"},{"@attributes":{"ValidYN":"Y"},"LastName":"Boecker","ForeName":"Henning","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Forstl","ForeName":"Hans","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Drzezga","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Research Support, Non-U.S. Gov't"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2007","Month":"04","Day":"23"}},"MedlineJournalInfo":{"Country":"Switzerland","MedlineTA":"Dement Geriatr Cogn Disord","NlmUniqueID":"9705200","ISSNLinking":"1420-8008"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"Blood Glucose"},{"RegistryNumber":"0","NameOfSubstance":"Radiopharmaceuticals"},{"RegistryNumber":"0Z5B2CJX4D","NameOfSubstance":"Fluorodeoxyglucose F18"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Blood Glucose","QualifierName":"metabolism"},{"DescriptorName":"Brain","QualifierName":["blood supply","diagnostic imaging","physiopathology"]},{"DescriptorName":"Brain Mapping"},{"DescriptorName":"Case-Control Studies"},{"DescriptorName":"Dementia","QualifierName":["complications","diagnostic imaging","metabolism","pathology"]},{"DescriptorName":"Educational Status"},{"DescriptorName":"Energy Metabolism","QualifierName":"physiology"},{"DescriptorName":"Female"},{"DescriptorName":"Fluorodeoxyglucose F18"},{"DescriptorName":"Humans"},{"DescriptorName":"Lewy Body Disease","QualifierName":["complications","diagnostic imaging","metabolism","pathology"]},{"DescriptorName":"Male"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Positron-Emission Tomography"},{"DescriptorName":"Radiopharmaceuticals"},{"DescriptorName":"Recruitment, Neurophysiological","QualifierName":"physiology"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2007","Month":"02","Day":"05"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2007","Month":"4","Day":"26","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2007","Month":"7","Day":"25","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"entrez"},"Year":"2007","Month":"4","Day":"26","Hour":"9","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["17457029","000101956","10.1159\/000101956"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"17360152","DateCompleted":{"Year":"2007","Month":"09","Day":"18"},"DateRevised":{"Year":"2019","Month":"12","Day":"10"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"0887-6177","JournalIssue":{"@attributes":{"CitedMedium":"Print"},"Volume":"22","Issue":"4","PubDate":{"Year":"2007","Month":"May"}},"Title":"Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists","ISOAbbreviation":"Arch Clin Neuropsychol"},"ArticleTitle":"The Ekman 60 Faces Test as a diagnostic instrument in frontotemporal dementia.","Pagination":{"MedlinePgn":"459-64"},"Abstract":{"AbstractText":"Frontotemporal dementia (FTD) is characterized by dramatic changes of personality and behaviour. Impaired ability of emotional processing could contribute to these symptoms, as it may lead to misinterpretation of emotional cues that would normally guide behaviour. The aim of the present study was to investigate if the Ekman 60 Faces Test, an instrument to test the recognition of basic facial emotions, enables the differentiation between patients with mild FTD and cognitively healthy subjects (HC). We found that compared to 33 cognitively healthy subjects, 25 patients with mild FTD were impaired in the recognition of basic emotions. At a cut-off score from 46 out of 60 points, the Ekman 60 Faces Test discriminated between patients with mild FTD and HC with 97% diagnostic accuracy (sensitivity: 94%; specificity: 100%). The results of the present study were consistent with the findings of prior studies on smaller patient samples."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Diehl-Schmid","ForeName":"Janine","Initials":"J","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Technische Universitaet Muenchen, Moehlstrasse 26, D-81675 Munich, Germany. janine.diehl@lrz.tum.de"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Pohl","ForeName":"Corina","Initials":"C"},{"@attributes":{"ValidYN":"Y"},"LastName":"Ruprecht","ForeName":"Carolin","Initials":"C"},{"@attributes":{"ValidYN":"Y"},"LastName":"Wagenpfeil","ForeName":"Stefan","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"Foerstl","ForeName":"Hans","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Randomized Controlled Trial","Research Support, Non-U.S. Gov't"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2007","Month":"03","Day":"13"}},"MedlineJournalInfo":{"Country":"United States","MedlineTA":"Arch Clin Neuropsychol","NlmUniqueID":"9004255","ISSNLinking":"0887-6177"},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Cognition"},{"DescriptorName":"Dementia","QualifierName":["diagnosis","psychology"]},{"DescriptorName":"Emotions"},{"DescriptorName":"Facial Expression"},{"DescriptorName":"Female"},{"DescriptorName":"Humans"},{"DescriptorName":"Male"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Neuropsychological Tests"},{"DescriptorName":"Predictive Value of Tests"},{"DescriptorName":"ROC Curve"},{"DescriptorName":"Recognition, Psychology"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2006","Month":"06","Day":"05"},{"@attributes":{"PubStatus":"revised"},"Year":"2007","Month":"01","Day":"18"},{"@attributes":{"PubStatus":"accepted"},"Year":"2007","Month":"01","Day":"26"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2007","Month":"3","Day":"16","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2007","Month":"9","Day":"19","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"entrez"},"Year":"2007","Month":"3","Day":"16","Hour":"9","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["17360152","S0887-6177(07)00041-8","10.1016\/j.acn.2007.01.024"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"17219132","DateCompleted":{"Year":"2007","Month":"10","Day":"19"},"DateRevised":{"Year":"2018","Month":"11","Day":"13"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1619-7070","JournalIssue":{"@attributes":{"CitedMedium":"Print"},"Volume":"34","Issue":"7","PubDate":{"Year":"2007","Month":"Jul"}},"Title":"European journal of nuclear medicine and molecular imaging","ISOAbbreviation":"Eur J Nucl Med Mol Imaging"},"ArticleTitle":"Brain reserve capacity in frontotemporal dementia: a voxel-based 18F-FDG PET study.","Pagination":{"MedlinePgn":"1082-7"},"Abstract":{"AbstractText":["The association of the regional cerebral metabolic rate of glucose utilisation (rCMRglc) and years of schooling has been extensively studied in Alzheimer's disease (AD). The results suggest that brain reserve capacity (BRC) allows patients with more years of schooling to cope better with AD pathology. The objective of this study was to provide initial evidence for BRC in frontotemporal dementia (FTD).","Twenty-nine patients with FTD and 16 healthy age- and education-matched controls underwent PET imaging of the brain with 18F-fluoro-2-deoxy-glucose. A group comparison of rCMRglc was conducted between patients and controls and the output was saved as region of interest (ROI). A linear regression analysis with education as the independent and rCMRglc as the dependent variable, adjusted for age, gender and total score on the CERAD neuropsychological battery, was conducted in SPM2 over the pre-assigned ROI.","Patients showed a reduced rCMRglc in almost the entire prefrontal cortex and the anterior cingulate cortex as compared with controls (p < 0.05 corrected for multiple comparisons). The regression analysis revealed a significant negative association between years of schooling and rCMRglc in the bilateral inferior frontal cortex (p < 0.001, uncorrected for multiple comparisons), which was independent of demographic variables and cognitive performance level. There was a strong negative correlation of rCMRglc and education (r = -0.45).","The study provides initial evidence for BRC in FTD. The findings suggest that interindividual differences in educational level affect BRC by partially mediating the relationship between neurodegeneration and the clinical manifestation of FTD."]},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Perneczky","ForeName":"Robert","Initials":"R","AffiliationInfo":{"Affiliation":"Klinik und Poliklinik f\u00fcr Psychiatrie und Psychotherapie, Technische Universit\u00e4t M\u00fcnchen, Ismaningerstr. 22, 81675 M\u00fcnchen, Germany. robert.perneczky@lrz.tum.de"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Diehl-Schmid","ForeName":"Janine","Initials":"J"},{"@attributes":{"ValidYN":"Y"},"LastName":"Drzezga","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Research Support, Non-U.S. Gov't"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2007","Month":"01","Day":"12"}},"MedlineJournalInfo":{"Country":"Germany","MedlineTA":"Eur J Nucl Med Mol Imaging","NlmUniqueID":"101140988","ISSNLinking":"1619-7070"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"Radiopharmaceuticals"},{"RegistryNumber":"0Z5B2CJX4D","NameOfSubstance":"Fluorodeoxyglucose F18"},{"RegistryNumber":"IY9XDZ35W2","NameOfSubstance":"Glucose"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Brain","QualifierName":["diagnostic imaging","metabolism"]},{"DescriptorName":"Dementia","QualifierName":["diagnostic imaging","metabolism"]},{"DescriptorName":"Educational Status"},{"DescriptorName":"Female"},{"DescriptorName":"Fluorodeoxyglucose F18","QualifierName":"pharmacokinetics"},{"DescriptorName":"Glucose","QualifierName":"metabolism"},{"DescriptorName":"Humans"},{"DescriptorName":"Male"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Positron-Emission Tomography","QualifierName":"methods"},{"DescriptorName":"Radiopharmaceuticals","QualifierName":"pharmacokinetics"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2006","Month":"05","Day":"04"},{"@attributes":{"PubStatus":"accepted"},"Year":"2006","Month":"10","Day":"25"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2007","Month":"1","Day":"16","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2007","Month":"10","Day":"20","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"entrez"},"Year":"2007","Month":"1","Day":"16","Hour":"9","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["17219132","10.1007\/s00259-006-0323-z"]},"ReferenceList":{"Reference":[{"Citation":"Neuroepidemiology. 1996 Jan-Feb;15(1):20-5","ArticleIdList":{"ArticleId":"8719045"}},{"Citation":"Neurology. 1993 Jan;43(1):13-20","ArticleIdList":{"ArticleId":"8423876"}},{"Citation":"Neurobiol Aging. 2004 Sep;25(8):1051-6","ArticleIdList":{"ArticleId":"15212830"}},{"Citation":"Arch Neurol. 2005 Jun;62(6):925-30","ArticleIdList":{"ArticleId":"15956163"}},{"Citation":"J Neurol Neurosurg Psychiatry. 1994 Apr;57(4):416-8","ArticleIdList":{"ArticleId":"8163988"}},{"Citation":"Neurology. 2005 Jul 12;65(1):102-6","ArticleIdList":{"ArticleId":"16009893"}},{"Citation":"Neurology. 2003 Jun 24;60(12):1909-15","ArticleIdList":{"ArticleId":"12821732"}},{"Citation":"Arch Neurol. 2003 Mar;60(3):359-65","ArticleIdList":{"ArticleId":"12633147"}},{"Citation":"Neurology. 2003 Aug 12;61(3):349-54","ArticleIdList":{"ArticleId":"12913196"}},{"Citation":"Brain Cogn. 2000 Feb;42(1):102-5","ArticleIdList":{"ArticleId":"10739611"}},{"Citation":"Brain. 1997 Jun;120 ( Pt 6):1027-40","ArticleIdList":{"ArticleId":"9217686"}},{"Citation":"J Psychiatr Res. 1975 Nov;12(3):189-98","ArticleIdList":{"ArticleId":"1202204"}},{"Citation":"Chin Med J (Engl). 2003 Aug;116(8):1235-8","ArticleIdList":{"ArticleId":"12935418"}},{"Citation":"Neurology. 2005 Jan 11;64(1):102-7","ArticleIdList":{"ArticleId":"15642911"}},{"Citation":"Psychopharmacol Bull. 1988;24(4):641-52","ArticleIdList":{"ArticleId":"3249766"}},{"Citation":"Ann Neurol. 1992 Sep;32(3):371-5","ArticleIdList":{"ArticleId":"1416806"}},{"Citation":"Neurobiol Aging. 2007 Jan;28(1):42-50","ArticleIdList":{"ArticleId":"16448722"}},{"Citation":"JAMA. 1994 Apr 6;271(13):1004-10","ArticleIdList":{"ArticleId":"8139057"}},{"Citation":"J Neurol Neurosurg Psychiatry. 2006 Sep;77(9):1060-3","ArticleIdList":{"ArticleId":"16709580"}},{"Citation":"Am J Geriatr Psychiatry. 2006 Feb;14(2):139-44","ArticleIdList":{"ArticleId":"16473978"}}]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"17184752","DateCompleted":{"Year":"2007","Month":"04","Day":"05"},"DateRevised":{"Year":"2016","Month":"11","Day":"24"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"0006-8993","JournalIssue":{"@attributes":{"CitedMedium":"Print"},"Volume":"1133","Issue":"1","PubDate":{"Year":"2007","Month":"Feb","Day":"16"}},"Title":"Brain research","ISOAbbreviation":"Brain Res"},"ArticleTitle":"Non-fluent progressive aphasia: cerebral metabolic patterns and brain reserve.","Pagination":{"MedlinePgn":"178-85"},"Abstract":{"AbstractText":"Functional imaging studies suggest that brain reserve allows patients with Alzheimer's disease with more years of schooling to cope better with brain damage. No studies exist on patients with non-fluent progressive aphasia (NFPA). We aimed to explore metabolic patterns of patients with NFPA and to provide evidence for brain reserve in NFPA. 11 right-handed patients with NFPA and 16 age-matched controls underwent (18)F-FDG PET imaging. Scans of patients and controls were compared in SPM2. A linear regression analysis with glucose metabolism as dependent variable and years of schooling as the independent variable, adjusted for age, gender, and a total score of the CERAD neuropsychological battery was conducted. The NFPA group showed a hypometabolism of the left hemisphere including the middle frontal, and inferior temporal and angular gyri, and the bilateral caudate nuclei and thalami (p(corr)<0.05). The regression analysis revealed a significant inverse association between education and glucose metabolism in the left inferior temporal, parahippocampal, and supramarginal gyri (p(corr)<0.05). We conclude that brain reserve is also present in NFPA."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Perneczky","ForeName":"Robert","Initials":"R","AffiliationInfo":{"Affiliation":"Departments of Psychiatry and Psychotherapy, Technische Universit\u00e4t M\u00fcnchen, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Diehl-Schmid","ForeName":"Janine","Initials":"J"},{"@attributes":{"ValidYN":"Y"},"LastName":"Pohl","ForeName":"Corina","Initials":"C"},{"@attributes":{"ValidYN":"Y"},"LastName":"Drzezga","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Research Support, Non-U.S. Gov't"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2006","Month":"12","Day":"20"}},"MedlineJournalInfo":{"Country":"Netherlands","MedlineTA":"Brain Res","NlmUniqueID":"0045503","ISSNLinking":"0006-8993"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0Z5B2CJX4D","NameOfSubstance":"Fluorodeoxyglucose F18"},{"RegistryNumber":"IY9XDZ35W2","NameOfSubstance":"Glucose"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Age Distribution"},{"DescriptorName":"Aged"},{"DescriptorName":"Aged, 80 and over"},{"DescriptorName":"Aphasia, Primary Progressive","QualifierName":["diagnostic imaging","metabolism","physiopathology"]},{"DescriptorName":"Brain","QualifierName":["anatomy & histology","diagnostic imaging","metabolism"]},{"DescriptorName":"Brain Mapping"},{"DescriptorName":"Cognition Disorders","QualifierName":["diagnostic imaging","metabolism","physiopathology"]},{"DescriptorName":"Educational Status"},{"DescriptorName":"Energy Metabolism","QualifierName":"physiology"},{"DescriptorName":"Female"},{"DescriptorName":"Fluorodeoxyglucose F18"},{"DescriptorName":"Frontal Lobe","QualifierName":["diagnostic imaging","metabolism","physiopathology"]},{"DescriptorName":"Functional Laterality","QualifierName":"physiology"},{"DescriptorName":"Glucose","QualifierName":"metabolism"},{"DescriptorName":"Humans"},{"DescriptorName":"Male"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Positron-Emission Tomography"},{"DescriptorName":"Predictive Value of Tests"},{"DescriptorName":"Sex Distribution"},{"DescriptorName":"Temporal Lobe","QualifierName":["diagnostic imaging","metabolism","physiopathology"]}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2006","Month":"10","Day":"06"},{"@attributes":{"PubStatus":"revised"},"Year":"2006","Month":"11","Day":"15"},{"@attributes":{"PubStatus":"accepted"},"Year":"2006","Month":"11","Day":"16"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2006","Month":"12","Day":"23","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2007","Month":"4","Day":"6","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"entrez"},"Year":"2006","Month":"12","Day":"23","Hour":"9","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["17184752","S0006-8993(06)03390-7","10.1016\/j.brainres.2006.11.054"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"17168181","DateCompleted":{"Year":"2007","Month":"02","Day":"01"},"DateRevised":{"Year":"2018","Month":"12","Day":"01"},"Article":{"@attributes":{"PubModel":"Print"},"Journal":{"ISSN":"1438-3276","JournalIssue":{"@attributes":{"CitedMedium":"Print"},"Volume":"148","Issue":"47","PubDate":{"Year":"2006","Month":"Nov","Day":"23"}},"Title":"MMW Fortschritte der Medizin","ISOAbbreviation":"MMW Fortschr Med"},"ArticleTitle":"[Study questions the benefit of the treatment. Aggressive Alzheimer patient -- a (not a) case for atypical neuroleptics?].","Pagination":{"MedlinePgn":"16"},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"}},"Language":"ger","PublicationTypeList":{"PublicationType":"Interview"},"VernacularTitle":"Studie stellt Nutzen der Behandlung infrage. Randalierender Alzheimerpatient-- (k)ein Fall f\u00fcr Atypika?"},"MedlineJournalInfo":{"Country":"Germany","MedlineTA":"MMW Fortschr Med","NlmUniqueID":"100893959","ISSNLinking":"1438-3276"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"Antipsychotic Agents"},{"RegistryNumber":"0","NameOfSubstance":"Dopamine Antagonists"},{"RegistryNumber":"0","NameOfSubstance":"Placebos"},{"RegistryNumber":"0","NameOfSubstance":"Serotonin Antagonists"},{"RegistryNumber":"0","NameOfSubstance":"Serotonin Uptake Inhibitors"},{"RegistryNumber":"12794-10-4","NameOfSubstance":"Benzodiazepines"},{"RegistryNumber":"L6UH7ZF8HC","NameOfSubstance":"Risperidone"},{"RegistryNumber":"N7U69T4SZR","NameOfSubstance":"Olanzapine"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aggression"},{"DescriptorName":"Alzheimer Disease","QualifierName":["drug therapy","psychology"]},{"DescriptorName":"Antipsychotic Agents","QualifierName":["administration & dosage","adverse effects","therapeutic use"]},{"DescriptorName":"Benzodiazepines","QualifierName":["administration & dosage","adverse effects","therapeutic use"]},{"DescriptorName":"Controlled Clinical Trials as Topic"},{"DescriptorName":"Dopamine Antagonists","QualifierName":["administration & dosage","adverse effects","therapeutic use"]},{"DescriptorName":"Humans"},{"DescriptorName":"Olanzapine"},{"DescriptorName":"Placebos"},{"DescriptorName":"Risk Assessment"},{"DescriptorName":"Risperidone","QualifierName":["administration & dosage","adverse effects","therapeutic use"]},{"DescriptorName":"Serotonin Antagonists","QualifierName":["administration & dosage","adverse effects","therapeutic use"]},{"DescriptorName":"Serotonin Uptake Inhibitors","QualifierName":["administration & dosage","adverse effects","therapeutic use"]}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"pubmed"},"Year":"2006","Month":"12","Day":"16","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2007","Month":"2","Day":"3","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"entrez"},"Year":"2006","Month":"12","Day":"16","Hour":"9","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":"17168181"}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"17154660","DateCompleted":{"Year":"2007","Month":"05","Day":"01"},"DateRevised":{"Year":"2018","Month":"12","Day":"01"},"Article":{"@attributes":{"PubModel":"Print"},"Journal":{"ISSN":"1170-229X","JournalIssue":{"@attributes":{"CitedMedium":"Print"},"Volume":"23","Issue":"12","PubDate":{"Year":"2006"}},"Title":"Drugs & aging","ISOAbbreviation":"Drugs Aging"},"ArticleTitle":"Effects of cholinesterase inhibitors on behavioural disturbances in Alzheimer's disease: a systematic review.","Pagination":{"MedlinePgn":"957-67"},"Abstract":{"AbstractText":"Behavioural disturbances, also termed neuropsychiatric symptoms, are a frequent clinical feature of dementia in Alzheimer's disease (AD). Many AD patients receive treatment with cholinesterase inhibitors (ChEIs). This review examines the evidence for behavioural effects of the four ChEIs that have been approved for the treatment of mild to moderate AD. A systematic search of the MEDLINE and EMBASE databases and the Cochrane Library was conducted to identify clinical trials that had a randomised, placebo-controlled design. Studies were included in this review if they enrolled patients who had received a diagnosis of probable AD, involved at least one ChEI, and used an appropriate instrument for the assessment of behavioural disturbances. Fourteen studies that matched the selection criteria were identified in the literature. A statistically significant difference between active treatment and placebo with regard to behavioural symptoms was observed in three of the 14 studies. Treatment effects varied between 2.0 and 6.2 points on the Neuropsychiatric Inventory. ChEIs have moderate effects when used as a blanket treatment for the cluster of behavioural disturbances in AD. With regard to the limitations of the available trials, and in view of the risks that are associated with the use of atypical antipsychotics, the potential of ChEIs for the management of specific neuropsychiatric symptoms in patients with AD should be explored in further studies."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Grimmer","ForeName":"Timo","Initials":"T","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany. t.grimmer@lrz.tum.de"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Review","Systematic Review"]}},"MedlineJournalInfo":{"Country":"New Zealand","MedlineTA":"Drugs Aging","NlmUniqueID":"9102074","ISSNLinking":"1170-229X"},"ChemicalList":{"Chemical":{"RegistryNumber":"0","NameOfSubstance":"Cholinesterase Inhibitors"}},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Alzheimer Disease","QualifierName":"drug therapy"},{"DescriptorName":"Behavioral Symptoms","QualifierName":"chemically induced"},{"DescriptorName":"Cholinesterase Inhibitors","QualifierName":["adverse effects","therapeutic use"]},{"DescriptorName":"Cognition Disorders","QualifierName":"drug therapy"},{"DescriptorName":"Humans"}]},"NumberOfReferences":"44"},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"pubmed"},"Year":"2006","Month":"12","Day":"13","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2007","Month":"5","Day":"2","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"entrez"},"Year":"2006","Month":"12","Day":"13","Hour":"9","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["17154660","23123","10.2165\/00002512-200623120-00003"]},"ReferenceList":{"Reference":[{"Citation":"Int J Geriatr Psychiatry. 1999 Nov;14(11):973-82","ArticleIdList":{"ArticleId":"10556869"}},{"Citation":"Neurology. 2004 Jul 27;63(2):214-9","ArticleIdList":{"ArticleId":"15277611"}},{"Citation":"Neurology. 2000 Jun 27;54(12):2269-76","ArticleIdList":{"ArticleId":"10881251"}},{"Citation":"J Am Geriatr Soc. 2003 Jul;51(7):953-60","ArticleIdList":{"ArticleId":"12834515"}},{"Citation":"Neurology. 2001 Aug 28;57(4):613-20","ArticleIdList":{"ArticleId":"11524468"}},{"Citation":"J Am Geriatr Soc. 2003 Sep;51(9):1305-17","ArticleIdList":{"ArticleId":"12919245"}},{"Citation":"Neurology. 1994 Dec;44(12):2308-14","ArticleIdList":{"ArticleId":"7991117"}},{"Citation":"BMJ. 2005 Apr 16;330(7496):874","ArticleIdList":{"ArticleId":"15722369"}},{"Citation":"Lancet. 2004 Jun 26;363(9427):2105-15","ArticleIdList":{"ArticleId":"15220031"}},{"Citation":"Nervenarzt. 1998 Nov;69(11):999-1006","ArticleIdList":{"ArticleId":"9859122"}},{"Citation":"JAMA. 2005 Oct 19;294(15):1934-43","ArticleIdList":{"ArticleId":"16234500"}},{"Citation":"J Am Geriatr Soc. 2001 Dec;49(12):1590-9","ArticleIdList":{"ArticleId":"11843990"}},{"Citation":"Am J Psychiatry. 1990 Aug;147(8):1049-51","ArticleIdList":{"ArticleId":"2375439"}},{"Citation":"Cochrane Database Syst Rev. 2006 Jan 25;(1):CD003476","ArticleIdList":{"ArticleId":"16437455"}},{"Citation":"J Gen Intern Med. 2003 Dec;18(12):1006-14","ArticleIdList":{"ArticleId":"14687259"}},{"Citation":"Drugs Aging. 2002;19(4):257-76","ArticleIdList":{"ArticleId":"12038878"}},{"Citation":"Int J Geriatr Psychiatry. 2004 Feb;19(2):115-26","ArticleIdList":{"ArticleId":"14758577"}},{"Citation":"Am J Geriatr Psychiatry. 2005 Aug;13(8):722-30","ArticleIdList":{"ArticleId":"16085789"}},{"Citation":"N Engl J Med. 1992 Oct 29;327(18):1253-9","ArticleIdList":{"ArticleId":"1406817"}},{"Citation":"N Engl J Med. 1990 May 3;322(18):1272-6","ArticleIdList":{"ArticleId":"2183056"}},{"Citation":"J Neurol Neurosurg Psychiatry. 2001 Nov;71(5):589-95","ArticleIdList":{"ArticleId":"11606667"}},{"Citation":"Int J Geriatr Psychiatry. 1998 Oct;13(10):682-90","ArticleIdList":{"ArticleId":"9818303"}},{"Citation":"J Clin Psychopharmacol. 2005 Oct;25(5):463-7","ArticleIdList":{"ArticleId":"16160622"}},{"Citation":"Int J Geriatr Psychiatry. 2001 Sep;16(9):900-6","ArticleIdList":{"ArticleId":"11571771"}},{"Citation":"J Clin Psychiatry. 1998 Oct;59(10):550-61; quiz 562-3","ArticleIdList":{"ArticleId":"9818639"}},{"Citation":"JAMA. 1992 Nov 11;268(18):2523-9","ArticleIdList":{"ArticleId":"1404819"}},{"Citation":"J Psychiatr Res. 1975 Nov;12(3):189-98","ArticleIdList":{"ArticleId":"1202204"}},{"Citation":"J Clin Psychiatry. 1987 May;48 Suppl:9-15","ArticleIdList":{"ArticleId":"3553166"}},{"Citation":"JAMA. 1994 Apr 6;271(13):985-91","ArticleIdList":{"ArticleId":"8139083"}},{"Citation":"Eur J Neurol. 1995 Jul;2(3):229-38","ArticleIdList":{"ArticleId":"24283645"}},{"Citation":"J Neuropsychiatry Clin Neurosci. 1992 Spring;4(2):134-9","ArticleIdList":{"ArticleId":"1627973"}},{"Citation":"Neurology. 2001 Aug 14;57(3):489-95","ArticleIdList":{"ArticleId":"11502918"}},{"Citation":"Mech Ageing Dev. 2006 Feb;127(2):158-65","ArticleIdList":{"ArticleId":"16297434"}},{"Citation":"Am J Psychiatry. 2004 Mar;161(3):532-8","ArticleIdList":{"ArticleId":"14992980"}},{"Citation":"Arch Gen Psychiatry. 1997 Mar;54(3):257-63","ArticleIdList":{"ArticleId":"9075466"}},{"Citation":"Arch Neurol. 2004 Dec;61(12):1852-6","ArticleIdList":{"ArticleId":"15596605"}},{"Citation":"Int J Geriatr Psychiatry. 2003 Nov;18(11):1037-42","ArticleIdList":{"ArticleId":"14618556"}},{"Citation":"Neurology. 1984 Jul;34(7):939-44","ArticleIdList":{"ArticleId":"6610841"}},{"Citation":"Am J Psychiatry. 1984 Nov;141(11):1356-64","ArticleIdList":{"ArticleId":"6496779"}},{"Citation":"Int J Geriatr Psychiatry. 1997 Mar;12(3):331-6","ArticleIdList":{"ArticleId":"9152717"}},{"Citation":"JAMA. 2005 Feb 2;293(5):596-608","ArticleIdList":{"ArticleId":"15687315"}},{"Citation":"JAMA. 2003 Jan 8;289(2):210-6","ArticleIdList":{"ArticleId":"12517232"}}]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"16979267","DateCompleted":{"Year":"2007","Month":"11","Day":"30"},"DateRevised":{"Year":"2009","Month":"11","Day":"19"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1558-1497","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"28","Issue":"11","PubDate":{"Year":"2007","Month":"Nov"}},"Title":"Neurobiology of aging","ISOAbbreviation":"Neurobiol Aging"},"ArticleTitle":"No association of chromatin-modifying protein 2B with sporadic frontotemporal dementia.","Pagination":{"MedlinePgn":"1789-90"},"Abstract":{"AbstractText":"Mutations of the chromatin modifying protein 2B gene (CHMP2B) were identified, in a Danish pedigree, to cause familial frontotemporal dementia (FTD). To explore the possible genetic contribution of common CHMP2B variants in sporadic FTD, we analyzed 14 single nucleotide polymorphisms covering the entire genomic region of CHMP2B. After adjustment for multiple testing single marker and haplotype analysis revealed no significant association with sporadic FTD. Thus, we conclude that CHMP2B can be excluded as a susceptibility gene conferring risk to sporadic forms of FTD."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Schumacher","ForeName":"Axel","Initials":"A","AffiliationInfo":{"Affiliation":"Laboratory of Neurochemistry and Neurogenetics, Department of Psychiatry and Psychotherapy, Munich, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Friedrich","ForeName":"Patricia","Initials":"P"},{"@attributes":{"ValidYN":"Y"},"LastName":"Diehl-Schmid","ForeName":"Janine","Initials":"J"},{"@attributes":{"ValidYN":"Y"},"LastName":"Ibach","ForeName":"Bernd","Initials":"B"},{"@attributes":{"ValidYN":"Y"},"LastName":"Eisele","ForeName":"Tamara","Initials":"T"},{"@attributes":{"ValidYN":"Y"},"LastName":"Laws","ForeName":"Simon M","Initials":"SM"},{"@attributes":{"ValidYN":"Y"},"LastName":"F\u00f6rstl","ForeName":"Hans","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Riemenschneider","ForeName":"Matthias","Initials":"M"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Comparative Study","Journal Article"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2006","Month":"09","Day":"18"}},"MedlineJournalInfo":{"Country":"United States","MedlineTA":"Neurobiol Aging","NlmUniqueID":"8100437","ISSNLinking":"0197-4580"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"CHMP2B protein, human"},{"RegistryNumber":"0","NameOfSubstance":"Endosomal Sorting Complexes Required for Transport"},{"RegistryNumber":"0","NameOfSubstance":"Nerve Tissue Proteins"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Dementia","QualifierName":["genetics","metabolism"]},{"DescriptorName":"Endosomal Sorting Complexes Required for Transport"},{"DescriptorName":"Genetic Predisposition to Disease"},{"DescriptorName":"Genetic Variation","QualifierName":"genetics"},{"DescriptorName":"Haplotypes","QualifierName":"genetics"},{"DescriptorName":"Humans"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Nerve Tissue Proteins","QualifierName":"genetics"},{"DescriptorName":"Polymorphism, Single Nucleotide","QualifierName":"genetics"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2006","Month":"06","Day":"16"},{"@attributes":{"PubStatus":"revised"},"Year":"2006","Month":"07","Day":"11"},{"@attributes":{"PubStatus":"accepted"},"Year":"2006","Month":"07","Day":"21"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2006","Month":"9","Day":"19","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2007","Month":"12","Day":"6","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"entrez"},"Year":"2006","Month":"9","Day":"19","Hour":"9","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["16979267","S0197-4580(06)00270-3","10.1016\/j.neurobiolaging.2006.07.016"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"16825285","DateCompleted":{"Year":"2006","Month":"11","Day":"13"},"DateRevised":{"Year":"2010","Month":"11","Day":"18"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"0964-6906","JournalIssue":{"@attributes":{"CitedMedium":"Print"},"Volume":"15","Issue":"16","PubDate":{"Year":"2006","Month":"Aug","Day":"15"}},"Title":"Human molecular genetics","ISOAbbreviation":"Hum Mol Genet"},"ArticleTitle":"A functional polymorphism within plasminogen activator urokinase (PLAU) is associated with Alzheimer's disease.","Pagination":{"MedlinePgn":"2446-56"},"Abstract":{"AbstractText":"A number of susceptibility loci for Alzheimer's disease (AD) have been identified including a region on Chromosome 10q21-q22. Within this region the plasminogen activator urokinase gene (PLAU) was considered as a reasonable candidate from its functional implication in plasmin generation, a serine protease capable of degrading beta-Amyloid (Abeta) protein. We screened 56 single nucleotide polymorphisms (SNPs) around PLAU using 1751 individuals from four independent case-control samples (Munich, N=679; Bonn N=282; Brescia (Italy) N=219; Perth (Australia) N=557 and one discordant sib-pair sample (Munich N=622). In brain tissue samples of neuropathologically confirmed cases with AD (N=33) we analyzed plaque counts according to the risk allele. We identified that one functional exonic SNP (rs2227564) is associated with development of AD using the four independent case-control samples (Munich, P=0.02; Bonn, P=0.005; Brescia (Italy), P=0.001; Perth (Australia), P=0.03) and the discordant sib-pair sample (P=0.001). In brain tissue, from neuropathologically confirmed cases with AD, we identified significantly higher plaque counts in carriers of the risk allele (N=6; 60.3+\/-16.9) compared with non-carriers (N=9; 26.3+\/-8.8; P=0.007). This study provides compelling evidence of a genetic and functional involvement of a common PLAU variant into the pathogenesis of AD. Further functional investigations are warranted to elucidate the specific role of PLAU, respectively, PLAU variants in the metabolism of Abeta proteins."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Riemenschneider","ForeName":"Matthias","Initials":"M","AffiliationInfo":{"Affiliation":"Neurochemistry and Neurogenetics Laboratory, Department of Psychiatry and Psychotherapy, Technische Universitat M\u00fcnchen, Ismaningerstrasse 22, 81675 Munich, Germany. m.riemenschneider@lrz.tu-muenchen.de"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Konta","ForeName":"Lidija","Initials":"L"},{"@attributes":{"ValidYN":"Y"},"LastName":"Friedrich","ForeName":"Patricia","Initials":"P"},{"@attributes":{"ValidYN":"Y"},"LastName":"Schwarz","ForeName":"Sandra","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"Taddei","ForeName":"Kevin","Initials":"K"},{"@attributes":{"ValidYN":"Y"},"LastName":"Neff","ForeName":"Frauke","Initials":"F"},{"@attributes":{"ValidYN":"Y"},"LastName":"Padovani","ForeName":"Alessandro","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"K\u00f6lsch","ForeName":"Heike","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Laws","ForeName":"Simon M","Initials":"SM"},{"@attributes":{"ValidYN":"Y"},"LastName":"Klopp","ForeName":"Norman","Initials":"N"},{"@attributes":{"ValidYN":"Y"},"LastName":"Bickeb\u00f6ller","ForeName":"Heike","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Wagenpfeil","ForeName":"Stefan","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"Mueller","ForeName":"Jakob C","Initials":"JC"},{"@attributes":{"ValidYN":"Y"},"LastName":"Rosenberger","ForeName":"Albert","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Diehl-Schmid","ForeName":"Janine","Initials":"J"},{"@attributes":{"ValidYN":"Y"},"LastName":"Archetti","ForeName":"Silvana","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"Lautenschlager","ForeName":"Nicola","Initials":"N"},{"@attributes":{"ValidYN":"Y"},"LastName":"Borroni","ForeName":"Barbara","Initials":"B"},{"@attributes":{"ValidYN":"Y"},"LastName":"M\u00fcller","ForeName":"Ulrich","Initials":"U"},{"@attributes":{"ValidYN":"Y"},"LastName":"Illig","ForeName":"Thomas","Initials":"T"},{"@attributes":{"ValidYN":"Y"},"LastName":"Heun","ForeName":"Reinhard","Initials":"R"},{"@attributes":{"ValidYN":"Y"},"LastName":"Egensperger","ForeName":"Rupert","Initials":"R"},{"@attributes":{"ValidYN":"Y"},"LastName":"Schlegel","ForeName":"J\u00fcrgen","Initials":"J"},{"@attributes":{"ValidYN":"Y"},"LastName":"F\u00f6rstl","ForeName":"Hans","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Martins","ForeName":"Ralph N","Initials":"RN"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Multicenter Study","Research Support, Non-U.S. Gov't"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2006","Month":"07","Day":"06"}},"MedlineJournalInfo":{"Country":"England","MedlineTA":"Hum Mol Genet","NlmUniqueID":"9208958","ISSNLinking":"0964-6906"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"Apolipoproteins E"},{"RegistryNumber":"EC 3.4.21.73","NameOfSubstance":"Urokinase-Type Plasminogen Activator"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Age of Onset"},{"DescriptorName":"Aged"},{"DescriptorName":"Aged, 80 and over"},{"DescriptorName":"Alzheimer Disease","QualifierName":"genetics"},{"DescriptorName":"Apolipoproteins E","QualifierName":"genetics"},{"DescriptorName":"Brain","QualifierName":"ultrastructure"},{"DescriptorName":"Case-Control Studies"},{"DescriptorName":"Diagnosis"},{"DescriptorName":"Female"},{"DescriptorName":"Gene Frequency"},{"DescriptorName":"Genetic Linkage"},{"DescriptorName":"Genotype"},{"DescriptorName":"Humans"},{"DescriptorName":"Linkage Disequilibrium"},{"DescriptorName":"Male"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Plaque, Amyloid","QualifierName":"ultrastructure"},{"DescriptorName":"Polymorphism, Genetic"},{"DescriptorName":"Reproducibility of Results"},{"DescriptorName":"Sequence Analysis, DNA"},{"DescriptorName":"Urokinase-Type Plasminogen Activator","QualifierName":"genetics"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"pubmed"},"Year":"2006","Month":"7","Day":"11","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2006","Month":"11","Day":"14","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"entrez"},"Year":"2006","Month":"7","Day":"11","Hour":"9","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["16825285","ddl167","10.1093\/hmg\/ddl167"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"16776804","DateCompleted":{"Year":"2006","Month":"07","Day":"20"},"DateRevised":{"Year":"2008","Month":"03","Day":"10"},"Article":{"@attributes":{"PubModel":"Print"},"Journal":{"ISSN":"0002-8614","JournalIssue":{"@attributes":{"CitedMedium":"Print"},"Volume":"54","Issue":"6","PubDate":{"Year":"2006","Month":"Jun"}},"Title":"Journal of the American Geriatrics Society","ISOAbbreviation":"J Am Geriatr Soc"},"ArticleTitle":"Do all patients with mild cognitive impairment progress to dementia?","Pagination":{"MedlinePgn":"1008-10"},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Alexopoulos","ForeName":"Panagiotis","Initials":"P"},{"@attributes":{"ValidYN":"Y"},"LastName":"Grimmer","ForeName":"Timo","Initials":"T"},{"@attributes":{"ValidYN":"Y"},"LastName":"Perneczky","ForeName":"Robert","Initials":"R"},{"@attributes":{"ValidYN":"Y"},"LastName":"Domes","ForeName":"Gregor","Initials":"G"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Comparative Study","Letter","Research Support, Non-U.S. Gov't"]}},"MedlineJournalInfo":{"Country":"United States","MedlineTA":"J Am Geriatr Soc","NlmUniqueID":"7503062","ISSNLinking":"0002-8614"},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Cognition","QualifierName":"physiology"},{"DescriptorName":"Cognition Disorders","QualifierName":"complications"},{"DescriptorName":"Dementia","QualifierName":"etiology"},{"DescriptorName":"Disease Progression"},{"DescriptorName":"Follow-Up Studies"},{"DescriptorName":"Humans"},{"DescriptorName":"Retrospective Studies"},{"DescriptorName":"Severity of Illness Index"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"pubmed"},"Year":"2006","Month":"6","Day":"17","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2006","Month":"7","Day":"21","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"entrez"},"Year":"2006","Month":"6","Day":"17","Hour":"9","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["16776804","JGS752","10.1111\/j.1532-5415.2006.00752.x"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"16675064","DateCompleted":{"Year":"2007","Month":"05","Day":"31"},"DateRevised":{"Year":"2010","Month":"11","Day":"18"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1558-1497","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"28","Issue":"5","PubDate":{"Year":"2007","Month":"May"}},"Title":"Neurobiology of aging","ISOAbbreviation":"Neurobiol Aging"},"ArticleTitle":"Weak independent association signals between IDE polymorphisms, Alzheimer's disease and cognitive measures.","Pagination":{"MedlinePgn":"727-34"},"Abstract":{"AbstractText":"Functional and genetic studies suggest that insulin-degrading enzyme (IDE) may be a strong functional and positional candidate. As there is a lack of consensus in regards to the level and location of IDE association signals we aimed to clarify these discrepancies through genotyping 28 SNPs in a large case-control collective together with quantitative measures of cognitive ability (MMSE). Four SNPs (rs11187007, rs2149632_ide12, rs11187033, rs11187040) were found to be associated with AD (nominal p<0.01). Tests with MMSE scores adjusted for disease duration identified associations, with the most significant result for rs1999763 (nominal p=0.008). Similarly, different reconstructed IDE haplotypes were associated with AD and higher MMSE scores. The association signals are only borderline significant after adjustment for multiple testing, but add further evidence to previous published results on the association between IDE and AD or MMSE. A subgroup analysis indicated more prominent associations with AD in younger, and with MMSE in older patients. There may be two independent effects mediated by IDE variants, risk for AD and modification of disease progression."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Mueller","ForeName":"Jakob C","Initials":"JC","AffiliationInfo":{"Affiliation":"Neurochemistry and Neurogenetics Laboratory, Department of Psychiatry and Psychotherapy, Technical University Munich (TUM), Ismaningerstr. 22, 81675 M\u00fcnchen, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Riemenschneider","ForeName":"Matthias","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Schoepfer-Wendels","ForeName":"Andreas","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Gohlke","ForeName":"Henning","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Konta","ForeName":"Lidija","Initials":"L"},{"@attributes":{"ValidYN":"Y"},"LastName":"Friedrich","ForeName":"Patricia","Initials":"P"},{"@attributes":{"ValidYN":"Y"},"LastName":"Illig","ForeName":"Thomas","Initials":"T"},{"@attributes":{"ValidYN":"Y"},"LastName":"Laws","ForeName":"Simon M","Initials":"SM"},{"@attributes":{"ValidYN":"Y"},"LastName":"F\u00f6rstl","ForeName":"Hans","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Comparative Study","Journal Article","Research Support, Non-U.S. Gov't"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2006","Month":"05","Day":"03"}},"MedlineJournalInfo":{"Country":"United States","MedlineTA":"Neurobiol Aging","NlmUniqueID":"8100437","ISSNLinking":"0197-4580"},"ChemicalList":{"Chemical":{"RegistryNumber":"EC 3.4.24.56","NameOfSubstance":"Insulysin"}},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Alleles"},{"DescriptorName":"Alzheimer Disease","QualifierName":"genetics"},{"DescriptorName":"Case-Control Studies"},{"DescriptorName":"Cognition","QualifierName":"physiology"},{"DescriptorName":"Female"},{"DescriptorName":"Genetic Linkage","QualifierName":"genetics"},{"DescriptorName":"Genetic Variation","QualifierName":"genetics"},{"DescriptorName":"Haplotypes","QualifierName":"genetics"},{"DescriptorName":"Humans"},{"DescriptorName":"Insulysin","QualifierName":"genetics"},{"DescriptorName":"Male"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Polymorphism, Single Nucleotide","QualifierName":"physiology"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2006","Month":"01","Day":"26"},{"@attributes":{"PubStatus":"revised"},"Year":"2006","Month":"02","Day":"21"},{"@attributes":{"PubStatus":"accepted"},"Year":"2006","Month":"03","Day":"20"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2006","Month":"5","Day":"6","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2007","Month":"6","Day":"1","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"entrez"},"Year":"2006","Month":"5","Day":"6","Hour":"9","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["16675064","S0197-4580(06)00106-0","10.1016\/j.neurobiolaging.2006.03.009"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"16652347","DateCompleted":{"Year":"2006","Month":"06","Day":"26"},"DateRevised":{"Year":"2010","Month":"11","Day":"18"},"Article":{"@attributes":{"PubModel":"Print"},"Journal":{"ISSN":"1098-1004","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"27","Issue":"6","PubDate":{"Year":"2006","Month":"Jun"}},"Title":"Human mutation","ISOAbbreviation":"Hum Mutat"},"ArticleTitle":"The cathepsin D rs17571 polymorphism: effects on CSF tau concentrations in Alzheimer disease.","Pagination":{"MedlinePgn":"532-7"},"Abstract":{"AbstractText":"The lysosomal protease cathepsin D (CtsD, EC 3.4.23.5; gene, CTSD) has been associated with Alzheimer disease (AD) due to its cerebral expression being increased early in the course of AD; additionally, a CTSD exon 2 polymorphism (rs17571; NT_009237.17:g.569834T>C) may confer risk to AD. Functionally, it may be implicated in amyloid precursor protein (APP) processing and tau protein degradation. The objective of this study was to determine whether the CTSD exon 2 polymorphism affects cerebrospinal fluid (CSF), concentrations of beta-amyloid (Abeta42) and tau in two independent samples from Germany (n=73) and Sweden (n=66). Patients carrying the CTSD rs17571-T allele had significantly decreased CSF levels of tau (Munich, p=0.003; Swedish, p=0.029; combined sample, p<0.001), whereas no significant effect was observed on Abeta42 concentrations. Likewise, no significant impact was observed on Mini Mental State Examination (MMSE) scores. The data of both independent samples suggest that the CTSD rs17571 polymorphism does not affect APP processing but shows significant effects on tau processing. The result may corroborate the implication of the lysosomal system in the pathogenesis of AD and is of particular importance if CSF tau is used as a diagnostic biomarker.","CopyrightInformation":"Copyright 2006 Wiley-Liss, Inc."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Riemenschneider","ForeName":"Matthias","Initials":"M","AffiliationInfo":{"Affiliation":"Neurochemistry and Neurogenetics Laboratory, Department of Psychiatry and Psychotherapy, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany. m.riemenschneider@lrz.tu-muenchen.de"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Blennow","ForeName":"Kaj","Initials":"K"},{"@attributes":{"ValidYN":"Y"},"LastName":"Wagenpfeil","ForeName":"Stefan","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"Andreasen","ForeName":"Niels","Initials":"N"},{"@attributes":{"ValidYN":"Y"},"LastName":"Prince","ForeName":"Jonathan A","Initials":"JA"},{"@attributes":{"ValidYN":"Y"},"LastName":"Laws","ForeName":"Simon M","Initials":"SM"},{"@attributes":{"ValidYN":"Y"},"LastName":"F\u00f6rstl","ForeName":"Hans","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"}]},"Language":"eng","PublicationTypeList":{"PublicationType":"Journal Article"}},"MedlineJournalInfo":{"Country":"United States","MedlineTA":"Hum Mutat","NlmUniqueID":"9215429","ISSNLinking":"1059-7794"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"Amyloid beta-Peptides"},{"RegistryNumber":"0","NameOfSubstance":"tau Proteins"},{"RegistryNumber":"EC 3.4.23.5","NameOfSubstance":"Cathepsin D"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Alzheimer Disease","QualifierName":["cerebrospinal fluid","genetics"]},{"DescriptorName":"Amyloid beta-Peptides","QualifierName":"cerebrospinal fluid"},{"DescriptorName":"Cathepsin D","QualifierName":"genetics"},{"DescriptorName":"Female"},{"DescriptorName":"Genotype"},{"DescriptorName":"Humans"},{"DescriptorName":"Male"},{"DescriptorName":"Polymorphism, Single Nucleotide"},{"DescriptorName":"tau Proteins","QualifierName":"cerebrospinal fluid"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"pubmed"},"Year":"2006","Month":"5","Day":"3","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2006","Month":"6","Day":"27","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"entrez"},"Year":"2006","Month":"5","Day":"3","Hour":"9","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["16652347","10.1002\/humu.20326"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"16650578","DateCompleted":{"Year":"2006","Month":"08","Day":"18"},"DateRevised":{"Year":"2011","Month":"11","Day":"17"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"0304-3940","JournalIssue":{"@attributes":{"CitedMedium":"Print"},"Volume":"400","Issue":"3","PubDate":{"Year":"2006","Month":"Jun","Day":"12"}},"Title":"Neuroscience letters","ISOAbbreviation":"Neurosci Lett"},"ArticleTitle":"Alpha2-macroglobulin, lipoprotein receptor-related protein and lipoprotein receptor-associated protein and the genetic risk for developing Alzheimer's disease.","Pagination":{"MedlinePgn":"187-90"},"Abstract":{"AbstractText":"Alpha2-macroglobulin (alpha2M) as well as its receptor, the low-density lipoprotein receptor-related (LRP) and the receptor-associated protein (RAP) are involved in the clearance of cerebral A beta. Current evidence suggests that polymorphisms in the genes of alpha2M, LRP and RAP may have functional effects on the proteins. Two independent association samples of 271 AD patients and 280 representative controls were investigated whether the risk for developing AD is altered in carriers of polymorphisms in the alpha2M-gene (Va1000Ile), in the LRP-gene (Ala216Val) and in the RAP-gene (Val311Met). Genotypes were determined by standard PCR and restriction fragment length polymorphism. The results were adjusted for age, gender and apolipoprotein E-epsilon4 (APOE) polymorphism. Inheritance of alpha2M conferred a small increased risk for sporadic AD with an estimated Mantel-Haenszel odds ratio of 1.47. There was no age- or gender-dependent increase in alpha2M Val1000Ile allele frequencies in AD patients compared to controls. There was no significant difference in the allele frequencies among control and AD subjects for the LRP and RAP polymorphisms. We found no evidence of an interaction between the alpha2M and RAP or LRP with regard to conferred risk. Our data suggest that the alpha2M Val1000Ile polymorphism is weakly associated with AD. Although LRP as well as RAP seem to play an essential role in the metabolism of alpha2M and APOE, there is no increase in the genetic risk for AD in patients carrying the investigated polymorphisms."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Depboylu","ForeName":"Candan","Initials":"C","AffiliationInfo":{"Affiliation":"Department of Neurology, Philipps University Marburg, Rudolph-Bultmann-Str. 8, 35039 Marburg, Germany. depboylu@med.uni-marburg.de"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Lohm\u00fcller","ForeName":"Frank","Initials":"F"},{"@attributes":{"ValidYN":"Y"},"LastName":"Du","ForeName":"Yansheng","Initials":"Y"},{"@attributes":{"ValidYN":"Y"},"LastName":"Riemenschneider","ForeName":"Matthias","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Gasser","ForeName":"Thomas","Initials":"T"},{"@attributes":{"ValidYN":"Y"},"LastName":"M\u00fcller","ForeName":"Ulrich","Initials":"U"},{"@attributes":{"ValidYN":"Y"},"LastName":"Dodel","ForeName":"Richard C","Initials":"RC"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Controlled Clinical Trial","Journal Article","Research Support, Non-U.S. Gov't"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2006","Month":"05","Day":"02"}},"MedlineJournalInfo":{"Country":"Ireland","MedlineTA":"Neurosci Lett","NlmUniqueID":"7600130","ISSNLinking":"0304-3940"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"Low Density Lipoprotein Receptor-Related Protein-1"},{"RegistryNumber":"0","NameOfSubstance":"alpha-Macroglobulins"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Aged, 80 and over"},{"DescriptorName":"Alzheimer Disease","QualifierName":["epidemiology","genetics"]},{"DescriptorName":"Cohort Studies"},{"DescriptorName":"Female"},{"DescriptorName":"Genetic Predisposition to Disease","QualifierName":["epidemiology","genetics"]},{"DescriptorName":"Germany","QualifierName":"epidemiology"},{"DescriptorName":"Humans"},{"DescriptorName":"Incidence"},{"DescriptorName":"Low Density Lipoprotein Receptor-Related Protein-1","QualifierName":"genetics"},{"DescriptorName":"Male"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Polymorphism, Genetic"},{"DescriptorName":"Risk Assessment","QualifierName":"methods"},{"DescriptorName":"Risk Factors"},{"DescriptorName":"Sex Distribution"},{"DescriptorName":"alpha-Macroglobulins","QualifierName":"genetics"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2005","Month":"10","Day":"16"},{"@attributes":{"PubStatus":"revised"},"Year":"2005","Month":"12","Day":"30"},{"@attributes":{"PubStatus":"accepted"},"Year":"2006","Month":"01","Day":"16"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2006","Month":"5","Day":"3","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2006","Month":"8","Day":"19","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"entrez"},"Year":"2006","Month":"5","Day":"3","Hour":"9","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["16650578","S0304-3940(06)00067-X","10.1016\/j.neulet.2006.01.040"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"16583352","DateCompleted":{"Year":"2006","Month":"10","Day":"04"},"DateRevised":{"Year":"2007","Month":"11","Day":"15"},"Article":{"@attributes":{"PubModel":"Print"},"Journal":{"ISSN":"0303-4259","JournalIssue":{"@attributes":{"CitedMedium":"Print"},"Volume":"33","Issue":"3","PubDate":{"Year":"2006","Month":"Apr"}},"Title":"Psychiatrische Praxis","ISOAbbreviation":"Psychiatr Prax"},"ArticleTitle":"[Associations between dementia and head circumference as a measure of brain reserve--results from the Bavarian School sisters study].","Pagination":{"MedlinePgn":"138-44"},"Abstract":{"AbstractText":["The aim of the study was to examine the relationship of head circumference as a marker of maximal attained brain size to late-life cognitive impairment and dementia.","Cognitive performance was assessed and the presence of dementia was diagnosed in a cross-sectional study of 442 Catholic sisters aged 65 years and over.","A head circumference below average was significantly associated with the presence of dementia even after adjustment for age, body mass index and presence of one or two apolipoprotein E epsilon4 alleles (OR = 2.0; 95% CI: 1.1-3.6). The combination of small head circumference and apolipoprotein E epsilon4 strongly increased the risk of dementia (OR = 3.59; 95% CI: 1.44-8.97).","The findings support the hypothesis that a larger head size reduces the risk of cognitive decline and dementia in old age."]},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Bickel","ForeName":"Horst","Initials":"H","AffiliationInfo":{"Affiliation":"Klinik und Poliklinik f\u00fcr Psychiatrie und Psychotherapie der Technischen Universit\u00e4t M\u00fcnchen, Klinikum rechts der Isar. h.bickel@lrz.tum.de"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Riemenschneider","ForeName":"Matthias","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"}]},"Language":"ger","PublicationTypeList":{"PublicationType":["English Abstract","Journal Article"]},"VernacularTitle":"Beziehungen zwischen Demenz und dem Kopfumfang als Mass der Reservekapazit\u00e4t: Ergebnisse der Bayerischen Schulschwesternstudie."},"MedlineJournalInfo":{"Country":"Germany","MedlineTA":"Psychiatr Prax","NlmUniqueID":"0423204","ISSNLinking":"0303-4259"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"Apolipoprotein E4"},{"RegistryNumber":"0","NameOfSubstance":"Apolipoproteins E"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Age Factors"},{"DescriptorName":"Aged"},{"DescriptorName":"Alleles"},{"DescriptorName":"Alzheimer Disease","QualifierName":["diagnosis","epidemiology","etiology"]},{"DescriptorName":"Apolipoprotein E4"},{"DescriptorName":"Apolipoproteins E","QualifierName":"genetics"},{"DescriptorName":"Body Mass Index"},{"DescriptorName":"Brain","QualifierName":"pathology"},{"DescriptorName":"Catholicism"},{"DescriptorName":"Cephalometry","QualifierName":"statistics & numerical data"},{"DescriptorName":"Cognition Disorders","QualifierName":["diagnosis","epidemiology","etiology"]},{"DescriptorName":"Cross-Sectional Studies"},{"DescriptorName":"Female"},{"DescriptorName":"Genotype"},{"DescriptorName":"Germany"},{"DescriptorName":"Humans"},{"DescriptorName":"Mental Status Schedule"},{"DescriptorName":"Neuropsychological Tests"},{"DescriptorName":"Religion and Psychology"},{"DescriptorName":"Risk Factors"},{"DescriptorName":"Statistics as Topic"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"pubmed"},"Year":"2006","Month":"4","Day":"4","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2006","Month":"10","Day":"5","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"entrez"},"Year":"2006","Month":"4","Day":"4","Hour":"9","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["16583352","10.1055\/s-2005-915464"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"16473978","DateCompleted":{"Year":"2006","Month":"05","Day":"11"},"DateRevised":{"Year":"2017","Month":"11","Day":"28"},"Article":{"@attributes":{"PubModel":"Print"},"Journal":{"ISSN":"1064-7481","JournalIssue":{"@attributes":{"CitedMedium":"Print"},"Volume":"14","Issue":"2","PubDate":{"Year":"2006","Month":"Feb"}},"Title":"The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry","ISOAbbreviation":"Am J Geriatr Psychiatry"},"ArticleTitle":"Mapping scores onto stages: mini-mental state examination and clinical dementia rating.","Pagination":{"MedlinePgn":"139-44"},"Abstract":{"AbstractText":["Although the clinical course of Alzheimer disease (AD) is gradual, it is useful for a number of reasons to distinguish between different levels of severity. The Clinical Dementia Rating (CDR) has demonstrated high validity and reliability for this purpose, but it requires a considerable amount of data to be collected both from the patient and from an informant. In the present study, the authors mapped Mini-Mental State Examination (MMSE) scores onto CDR categories to determine how well the MMSE performs as a surrogate of the CDR as a timesaving method of staging dementia.","Eight hundred sixty-three probands, including 524 patients with probable AD, 92 patients with questionable dementia, and 247 with memory complaints but no objective cognitive impairment, were included. Cutoff scores were identified on one-half of the sample using a receiver operating characteristic analysis. The cutoff values were then applied to the other half of the sample, and the agreement between MMSE score ranges and CDR stages was determined by calculating Cohen's kappa.","The MMSE discriminated well between CDR stages 0.5, 1, 2, and 3 but performed poorly in the separation between CDR stages zero and 0.5. The MMSE ranges were 30 for no, 26-29 for questionable, 21-25 for mild, 11-20 for moderate, and 0-10 for severe dementia. Substantial agreement between the two instruments was obtained for the categories mild (kappa=0.62, p<0.001, N=115), moderate (kappa=0.69, p<0.001, N=114), and severe dementia (kappa=0.76, p<0.001, N=39), whereas the agreement was moderate for no (kappa=0.44, p<0.001, N=120) and only fair for questionable dementia (kappa=0.28, p<0.001, N=42).","The MMSE can be used as a surrogate measure for the CDR for the staging of dementia in AD."]},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Perneczky","ForeName":"Robert","Initials":"R","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy and the Institute of Medical Statistics and Epidemiology, Technische Universit\u00e4t M\u00fcnchen, Germany. robert.perneczky@lrz.tum.de"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Wagenpfeil","ForeName":"Stefan","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"Komossa","ForeName":"Katja","Initials":"K"},{"@attributes":{"ValidYN":"Y"},"LastName":"Grimmer","ForeName":"Timo","Initials":"T"},{"@attributes":{"ValidYN":"Y"},"LastName":"Diehl","ForeName":"Janine","Initials":"J"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"}]},"Language":"eng","PublicationTypeList":{"PublicationType":"Journal Article"}},"MedlineJournalInfo":{"Country":"England","MedlineTA":"Am J Geriatr Psychiatry","NlmUniqueID":"9309609","ISSNLinking":"1064-7481"},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Alzheimer Disease","QualifierName":"diagnosis"},{"DescriptorName":"Diagnosis, Differential"},{"DescriptorName":"Female"},{"DescriptorName":"Humans"},{"DescriptorName":"Male"},{"DescriptorName":"Neuropsychological Tests"},{"DescriptorName":"Severity of Illness Index"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"pubmed"},"Year":"2006","Month":"2","Day":"14","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2006","Month":"5","Day":"12","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"entrez"},"Year":"2006","Month":"2","Day":"14","Hour":"9","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["16473978","S1064-7481(12)60544-2","10.1097\/01.JGP.0000192478.82189.a8"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"16416470","DateCompleted":{"Year":"2006","Month":"08","Day":"01"},"DateRevised":{"Year":"2009","Month":"07","Day":"23"},"Article":{"@attributes":{"PubModel":"Print"},"Journal":{"ISSN":"0885-6230","JournalIssue":{"@attributes":{"CitedMedium":"Print"},"Volume":"21","Issue":"2","PubDate":{"Year":"2006","Month":"Feb"}},"Title":"International journal of geriatric psychiatry","ISOAbbreviation":"Int J Geriatr Psychiatry"},"ArticleTitle":"Impairment of activities of daily living requiring memory or complex reasoning as part of the MCI syndrome.","Pagination":{"MedlinePgn":"158-62"},"Abstract":{"AbstractText":["Mild Cognitive Impairment (MCI) is a borderline state between age-associated cognitive decline and mild dementia. MCI is separated from mild dementia by an absence of global intellectual deterioration and the preservation of activities of daily living (ADL). However, even mild degrees of cognitive deterioration are known to have negative effects on complex ADL.","To examine whether patients with MCI have impaired ADL as compared to healthy controls, which areas of ADL are particularly involved, and whether limitations on ADL are associated with demographical or clinical data.","Forty-eight patients with MCI diagnosed according to research criteria and 42 cognitively unimpaired controls were enrolled. Cognitive function was inter alia assessed by the MMSE, complex ADL by the ADCS-MCI-ADL scale. Frequency distributions were compared between patients and controls using chi-square tests. Mean values were examined for statistically significant differences using Kruskal-Wallis tests. A Bonferroni correction for multiple comparisons was applied to the comparison of the 18 areas of the ADCS-MCI-ADL scale. Associations between ADL and biographical or clinical data were analysed using non-parametric correlations.","The overall score on the ADCS-MCI-ADL scale was significantly lower in the MCI group. Patients performed significantly worse on 14 out of 18 activities. Activities involving memory or complex reasoning were particularly impaired, whereas more basic activities were unimpaired. There were no statistically significant associations of the ADCS-MCI-ADL overall score with age, years of formal education, gender, or number of cognitive domains affected in the group of MCI patients. However, there was a statistically significant association between the ADCS-MCI-ADL and the MMSE score.","MCI patients may be impaired in complex ADL."],"CopyrightInformation":"Copyright (c) 2006 John Wiley & Sons, Ltd."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Perneczky","ForeName":"Robert","Initials":"R","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany. robert.perneczky@lrz.tum.de"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Pohl","ForeName":"Corina","Initials":"C"},{"@attributes":{"ValidYN":"Y"},"LastName":"Sorg","ForeName":"Christian","Initials":"C"},{"@attributes":{"ValidYN":"Y"},"LastName":"Hartmann","ForeName":"Julia","Initials":"J"},{"@attributes":{"ValidYN":"Y"},"LastName":"Tosic","ForeName":"Natasa","Initials":"N"},{"@attributes":{"ValidYN":"Y"},"LastName":"Grimmer","ForeName":"Timo","Initials":"T"},{"@attributes":{"ValidYN":"Y"},"LastName":"Heitele","ForeName":"Sandra","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Research Support, Non-U.S. Gov't"]}},"MedlineJournalInfo":{"Country":"England","MedlineTA":"Int J Geriatr Psychiatry","NlmUniqueID":"8710629","ISSNLinking":"0885-6230"},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Activities of Daily Living","QualifierName":"psychology"},{"DescriptorName":"Aged"},{"DescriptorName":"Aging","QualifierName":"psychology"},{"DescriptorName":"Alzheimer Disease","QualifierName":"psychology"},{"DescriptorName":"Cognition"},{"DescriptorName":"Cognition Disorders","QualifierName":"psychology"},{"DescriptorName":"Dementia","QualifierName":"psychology"},{"DescriptorName":"Educational Status"},{"DescriptorName":"Female"},{"DescriptorName":"Humans"},{"DescriptorName":"Male"},{"DescriptorName":"Memory"},{"DescriptorName":"Psychiatric Status Rating Scales"},{"DescriptorName":"Severity of Illness Index"},{"DescriptorName":"Sex Factors"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"pubmed"},"Year":"2006","Month":"1","Day":"18","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2006","Month":"8","Day":"2","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"entrez"},"Year":"2006","Month":"1","Day":"18","Hour":"9","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["16416470","10.1002\/gps.1444"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"16240482","DateCompleted":{"Year":"2006","Month":"01","Day":"31"},"DateRevised":{"Year":"2019","Month":"11","Day":"09"},"Article":{"@attributes":{"PubModel":"Print"},"Journal":{"ISSN":"1041-6102","JournalIssue":{"@attributes":{"CitedMedium":"Print"},"Volume":"17 Suppl 1","PubDate":{"Year":"2005"}},"Title":"International psychogeriatrics","ISOAbbreviation":"Int Psychogeriatr"},"ArticleTitle":"Uncommon neurodegenerative causes of dementia.","Pagination":{"MedlinePgn":"S35-49"},"Abstract":{"AbstractText":"A group of neurodegenerative diseases is outlined that affect cortical and subcortical areas of the brain. These diseases give rise to atypical forms of dementia and, unlike Alzheimer's disease (AD), are often associated with neurological symptoms. Clinical symptoms reflect the localization of the degenerative process rather than the nature of the underlying histopathology. Degeneration of the frontal and anterior temporal lobe presents initially with behavioral alterations, but later in the course, impairment of cognition and activities of daily living develops. Posterior cortical atrophy affects the parietal and occipital association cortices and causes complex visual disturbances. In corticobasal degeneration (CBD) the focus of pathology includes the frontoparietal cortex and several subcortical nuclei, causing symmetrical rigidity, bradykinesia, myoclonus and dystonia. Progressive supranuclear palsy (PSP) involves the frontal, temporal and parietal cortex as well as parts of the brain stem. Clinical features include a hypokinetic rigid syndrome with nuchal dystonia and vertical gaze palsy. Huntington's disease is a prototypical autosomal dominant disorder that affects the extrapyramidal system and causes choreatic movements in combination with personality changes and cognitive deterioration. Amyotrophic lateral sclerosis (ALS) with dementia is a neurodegeneration of the frontotemporal cortex and of the anterior horn of the spinal cord. Behavioral change similar to frontotemporal dementia (FTD) is paralleled or followed by the classic features of motor neuron disease."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander F","Initials":"AF","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Technische Universit\u00e4t M\u00fcnchen, Moehlstrasse 26, D-81675 Munich, Germany. alexander.kurz@lrz.tum.de"}}},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Review"]}},"MedlineJournalInfo":{"Country":"England","MedlineTA":"Int Psychogeriatr","NlmUniqueID":"9007918","ISSNLinking":"1041-6102"},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Amyotrophic Lateral Sclerosis","QualifierName":["pathology","physiopathology"]},{"DescriptorName":"Atrophy","QualifierName":["pathology","physiopathology"]},{"DescriptorName":"Basal Ganglia Diseases","QualifierName":["pathology","physiopathology"]},{"DescriptorName":"Cerebral Cortex","QualifierName":["pathology","physiopathology"]},{"DescriptorName":"Dementia","QualifierName":["etiology","pathology","physiopathology"]},{"DescriptorName":"Diagnosis, Differential"},{"DescriptorName":"Frontal Lobe","QualifierName":["pathology","physiopathology"]},{"DescriptorName":"Humans"},{"DescriptorName":"Huntington Disease","QualifierName":["pathology","physiopathology"]},{"DescriptorName":"Nerve Degeneration","QualifierName":["pathology","physiopathology"]},{"DescriptorName":"Perceptual Disorders","QualifierName":"epidemiology"},{"DescriptorName":"Personality Disorders","QualifierName":["diagnosis","epidemiology"]},{"DescriptorName":"Space Perception","QualifierName":"physiology"},{"DescriptorName":"Supranuclear Palsy, Progressive","QualifierName":["pathology","physiopathology"]},{"DescriptorName":"Temporal Lobe","QualifierName":["pathology","physiopathology"]},{"DescriptorName":"Visual Perception","QualifierName":"physiology"}]},"NumberOfReferences":"54"},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"pubmed"},"Year":"2005","Month":"10","Day":"22","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2006","Month":"2","Day":"1","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"entrez"},"Year":"2005","Month":"10","Day":"22","Hour":"9","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["16240482","10.1017\/s1041610205001936"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"16204712","DateCompleted":{"Year":"2006","Month":"01","Day":"10"},"DateRevised":{"Year":"2015","Month":"11","Day":"19"},"Article":{"@attributes":{"PubModel":"Print"},"Journal":{"ISSN":"0161-5505","JournalIssue":{"@attributes":{"CitedMedium":"Print"},"Volume":"46","Issue":"10","PubDate":{"Year":"2005","Month":"Oct"}},"Title":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","ISOAbbreviation":"J Nucl Med"},"ArticleTitle":"Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET.","Pagination":{"MedlinePgn":"1625-32"},"Abstract":{"AbstractText":["Patients with mild cognitive impairment (MCI) represent a risk population for progressing to dementia of the Alzheimer type (DAT). However, clinical criteria do not ensure reliable individual prognosis in these patients. The objective of this longitudinal, prospective study was to examine the value of (18)F-FDG PET of cerebral glucose metabolism and of genetic susceptibility, as defined by an APOEepsilon4-positive genotype, with regard to the early diagnosis of DAT in patients with MCI.","In 30 patients with the diagnosis of MCI (16 female, 14 male; age, 70 +\/- 8 y), baseline and follow-up examinations (mean observation period, 16 mo) were performed. In all patients, the APOE genotype was assessed and cerebral glucose metabolism was evaluated at baseline using cranial (18)F-FDG PET. Individual PET data were screened for findings suggestive of Alzheimer's disease (AD), with the help of an automated computer program. After stereotactical normalization of the PET images, this program performs an observer-independent statistical comparison with an age-matched reference database (n = 22).","In 43% of all MCI subjects, a PET scan suggestive of AD pathology according to our predefined criteria was observed at baseline (PET+); 57% of all MCI patients were carriers of the APOE epsilon4 allele (e4+). In 40% of all patients, progression of symptoms within the observation period justified the clinical diagnosis of probable DAT at the time of follow-up reevaluation. Statistical evaluation revealed the best results for PET with regard to early diagnosis of DAT in MCI patients (sensitivity, 92%; specificity, 89%). Classification according to the APOE genotype was significantly less successful (sensitivity, 75%; specificity, 56%). However, a combination of both diagnostic tests allowed early diagnosis with either very high specificity (PET+ AND e4+: sensitivity, 67%; specificity, 100%) or very high sensitivity (PET+ OR e4+: sensitivity, 100%; specificity, 44%).","(18)F-FDG PET of cerebral glucose metabolism is a valuable diagnostic tool for the prediction of clinical outcome in individual MCI patients. Results are superior to the exclusive assessment of the APOE genotype. A combination of both functional imaging and genotyping may allow an early high-risk or low-risk stratification of patients with either very high sensitivity or very high specificity. This may be valuable, for example, for patient selection in scientific studies."]},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Drzezga","ForeName":"Alexander","Initials":"A","AffiliationInfo":{"Affiliation":"Department of Nuclear Medicine, Technische Universit\u00e4t, M\u00fcnchen, Munich, Germany. a.drzezga@lrz.tu-muenchen.de"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Grimmer","ForeName":"Timo","Initials":"T"},{"@attributes":{"ValidYN":"Y"},"LastName":"Riemenschneider","ForeName":"Matthias","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Lautenschlager","ForeName":"Nicola","Initials":"N"},{"@attributes":{"ValidYN":"Y"},"LastName":"Siebner","ForeName":"Hartwig","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Alexopoulus","ForeName":"Panagiotis","Initials":"P"},{"@attributes":{"ValidYN":"Y"},"LastName":"Minoshima","ForeName":"Satoshi","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"Schwaiger","ForeName":"Markus","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Controlled Clinical Trial","Journal Article"]}},"MedlineJournalInfo":{"Country":"United States","MedlineTA":"J Nucl Med","NlmUniqueID":"0217410","ISSNLinking":"0161-5505"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"Apolipoproteins E"},{"RegistryNumber":"0","NameOfSubstance":"Radiopharmaceuticals"},{"RegistryNumber":"0Z5B2CJX4D","NameOfSubstance":"Fluorodeoxyglucose F18"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Alzheimer Disease","QualifierName":["diagnosis","etiology","genetics"]},{"DescriptorName":"Apolipoproteins E","QualifierName":"genetics"},{"DescriptorName":"Cognition Disorders","QualifierName":["complications","diagnosis","genetics"]},{"DescriptorName":"Female"},{"DescriptorName":"Fluorodeoxyglucose F18"},{"DescriptorName":"Genetic Predisposition to Disease","QualifierName":"genetics"},{"DescriptorName":"Genetic Testing","QualifierName":"methods"},{"DescriptorName":"Humans"},{"DescriptorName":"Male"},{"DescriptorName":"Phenotype"},{"DescriptorName":"Positron-Emission Tomography","QualifierName":"methods"},{"DescriptorName":"Prognosis"},{"DescriptorName":"Radiopharmaceuticals"},{"DescriptorName":"Reproducibility of Results"},{"DescriptorName":"Risk Assessment","QualifierName":"methods"},{"DescriptorName":"Risk Factors"},{"DescriptorName":"Sensitivity and Specificity"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"pubmed"},"Year":"2005","Month":"10","Day":"6","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2006","Month":"1","Day":"13","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"entrez"},"Year":"2005","Month":"10","Day":"6","Hour":"9","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["16204712","46\/10\/1625"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"16191223","DateCompleted":{"Year":"2005","Month":"11","Day":"15"},"DateRevised":{"Year":"2016","Month":"11","Day":"24"},"Article":{"@attributes":{"PubModel":"Print"},"Journal":{"ISSN":"1041-6102","JournalIssue":{"@attributes":{"CitedMedium":"Print"},"Volume":"15 Suppl 1","PubDate":{"Year":"2003"}},"Title":"International psychogeriatrics","ISOAbbreviation":"Int Psychogeriatr"},"ArticleTitle":"Potential biological markers for cerebrovascular disease.","Pagination":{"MedlinePgn":"89-97"},"Abstract":{"AbstractText":"Cerebrovascular diseases can causes cognitive impairment and dementia by loss of neurons and synaptic connections, destruction of axons, and demyelinization. Biological markers including genetic tests, brain imaging techniques, and biochemical assays in the CSF are valuable for the identification and quantification of cerebrovascular diseases. Genetic tests may be used to detect mutations that cause hereditary cerebral amyloid angiopathies or cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). Structural CT and MR imaging is routinely used to visualize and quantify infarcts and white-matter changes. Functional SPET and PET imaging can demonstrate focal and remote effects of vascular lesions on cerebral blood flow and metabolism. Biochemical imaging using proton MRS is a nonspecific marker for neuronal and axonal damage. Among biochemical markers in the CSF, tau protein, phospho-tau, and beta amyloid protein are helpful to differentiate vascular dementia from Alzheimer's disease."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany. alexander.kurz@lrz.tum.de"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Riemenschneider","ForeName":"Matthias","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Wallin","ForeName":"Anders","Initials":"A"}]},"Language":"eng","PublicationTypeList":{"PublicationType":"Journal Article"}},"MedlineJournalInfo":{"Country":"England","MedlineTA":"Int Psychogeriatr","NlmUniqueID":"9007918","ISSNLinking":"1041-6102"},"ChemicalList":{"Chemical":{"RegistryNumber":"0","NameOfSubstance":"Biomarkers"}},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Biomarkers"},{"DescriptorName":"Blood-Brain Barrier","QualifierName":"physiology"},{"DescriptorName":"Brain","QualifierName":["diagnostic imaging","pathology"]},{"DescriptorName":"CADASIL","QualifierName":["complications","diagnosis"]},{"DescriptorName":"Cerebral Amyloid Angiopathy","QualifierName":["complications","diagnosis","genetics"]},{"DescriptorName":"Cerebrovascular Disorders","QualifierName":["complications","diagnosis","physiopathology"]},{"DescriptorName":"Dementia, Vascular","QualifierName":"complications"},{"DescriptorName":"Humans"},{"DescriptorName":"Magnetic Resonance Imaging"},{"DescriptorName":"Myelin Sheath","QualifierName":"pathology"},{"DescriptorName":"Nerve Degeneration","QualifierName":"pathology"},{"DescriptorName":"Positron-Emission Tomography"},{"DescriptorName":"Tomography, Emission-Computed, Single-Photon"},{"DescriptorName":"Tomography, X-Ray Computed"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"pubmed"},"Year":"2005","Month":"9","Day":"30","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2005","Month":"11","Day":"16","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"entrez"},"Year":"2005","Month":"9","Day":"30","Hour":"9","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["16191223","S1041610203009025","10.1017\/S1041610203009025"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"16185378","DateCompleted":{"Year":"2006","Month":"04","Day":"14"},"DateRevised":{"Year":"2016","Month":"10","Day":"20"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1041-6102","JournalIssue":{"@attributes":{"CitedMedium":"Print"},"Volume":"17","Issue":"4","PubDate":{"Year":"2005","Month":"Dec"}},"Title":"International psychogeriatrics","ISOAbbreviation":"Int Psychogeriatr"},"ArticleTitle":"Effects of risperidone on behavioral and psychological symptoms associated with dementia in clinical practice.","Pagination":{"MedlinePgn":"605-16"},"Abstract":{"AbstractText":["Risperidone significantly improves behavioral and psychological symptoms of dementia (BPSD), including aggression, agitation and psychosis, as shown by randomized, placebo-controlled trials.","An 8-week, multicenter, naturalistic, open-label study was carried out to examine whether the benefits of risperidone apply to clinical practice. A total of 4499 patients were treated with risperidone at flexible doses chosen by physicians, and were included in the safety evaluation. Of these, 3909 patients met the intended study criteria (at least 65 years of age, dementia, and the presence of BPSD) and were included in the efficacy analyses.","At the end of the study (after 8 weeks of treatment), risperidone (average final dose 1.6 mg\/day) significantly improved all symptoms studied (agitation, aggressiveness, disturbance of the sleep-wake rhythm, social withdrawal, suspiciousness and delusions) as rated by physicians on a five-point scale of severity. On a four-point scale of global efficacy, more than 90% of patients were rated improved by both physicians and caregivers after 8 weeks of treatment. A significant improvement in sleep-wake cycle disturbances was also noted. A total of 422 adverse events were documented in 346 of the 4499 patients (7.7%); these included insufficient efficacy (2.6%), extrapyramidal symptoms (0.89%), deterioration of psychiatric symptoms (0.73%), sedation (0.56%), gastrointestinal disturbances (0.49%), cardiovascular disorders (0.38%), and cerebrovascular adverse events (0.36%).","Risperidone is an effective and well-tolerated treatment for BPSD in routine clinical practice."]},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A","AffiliationInfo":{"Affiliation":"Technical University Munich, Clinic for Psychiatry, Munich, Germany. alexander.kurz@lrz.tum.de"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Schwalen S","ForeName":"Susanne","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"Schmitt","ForeName":"Andreas","Initials":"A"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Clinical Trial","Journal Article","Multicenter Study"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2005","Month":"09","Day":"27"}},"MedlineJournalInfo":{"Country":"England","MedlineTA":"Int Psychogeriatr","NlmUniqueID":"9007918","ISSNLinking":"1041-6102"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"Antipsychotic Agents"},{"RegistryNumber":"L6UH7ZF8HC","NameOfSubstance":"Risperidone"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Aggression","QualifierName":"psychology"},{"DescriptorName":"Antipsychotic Agents","QualifierName":["adverse effects","therapeutic use"]},{"DescriptorName":"Basal Ganglia Diseases","QualifierName":["chemically induced","epidemiology"]},{"DescriptorName":"Delusions","QualifierName":"epidemiology"},{"DescriptorName":"Dementia","QualifierName":"epidemiology"},{"DescriptorName":"Female"},{"DescriptorName":"Humans"},{"DescriptorName":"Male"},{"DescriptorName":"Prevalence"},{"DescriptorName":"Prospective Studies"},{"DescriptorName":"Psychomotor Agitation","QualifierName":["drug therapy","epidemiology"]},{"DescriptorName":"Psychotic Disorders","QualifierName":["drug therapy","epidemiology"]},{"DescriptorName":"Risperidone","QualifierName":["adverse effects","therapeutic use"]},{"DescriptorName":"Sleep Disorders, Circadian Rhythm","QualifierName":"epidemiology"},{"DescriptorName":"Social Alienation","QualifierName":"psychology"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2004","Month":"10","Day":"19"},{"@attributes":{"PubStatus":"accepted"},"Year":"2005","Month":"04","Day":"13"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2005","Month":"9","Day":"28","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2006","Month":"4","Day":"15","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"entrez"},"Year":"2005","Month":"9","Day":"28","Hour":"9","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["16185378","S1041610205002279","10.1017\/S1041610205002279"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"16159306","DateCompleted":{"Year":"2006","Month":"05","Day":"18"},"DateRevised":{"Year":"2020","Month":"03","Day":"04"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1549-1676","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"2","Issue":"10","PubDate":{"Year":"2005","Month":"Oct"}},"Title":"PLoS medicine","ISOAbbreviation":"PLoS Med"},"ArticleTitle":"Impaired cross-modal inhibition in Alzheimer disease.","Pagination":{"MedlinePgn":"e288"},"Abstract":{"AbstractText":["Successful cognitive performance depends not only on the activation of specific neuronal networks but also on selective suppression of task-irrelevant modalities, i.e., deactivation of non-required cerebral regions. This ability to suppress the activation of specific brain regions has, to our knowledge, never been systematically evaluated in patients with Alzheimer disease (AD). The aim of the current study was to evaluate both cerebral activation and deactivation in (1) healthy volunteers, (2) patients with mild cognitive impairment (MCI) who are at risk for AD, and (3) patients with moderate AD during active navigation, representing a cognitive task typically affected in AD.","Changes in regional cerebral blood flow (rCBF) were assessed with PET imaging during an active navigation task in a 3D virtual-reality environment. The task was based on visual cues exclusively; no auditory cues were provided. Age-matched groups of healthy individuals, patients with MCI, and patients with AD were examined. Specific differences in the activation patterns were observed in the three groups, with stronger activation of cerebellar portions and visual association cortex in controls and stronger activation of primary visual and frontal cortical areas in patients with MCI and AD. Highly significant bilateral decrease of rCBF in task-irrelevant auditory cortical regions was detected in healthy individuals during performance of the task. This rCBF decrease was interpreted as a cross-modal inhibitory effect. It was diminished in patients with MCI and completely absent in patients with AD. A regression analysis across all individuals revealed a clear positive relation between cognitive status (mini mental state examination score) and the extent of auditory cortical deactivation.","During active navigation, a high level of movement automation and an involvement of higher-order cerebral association functions were observed in healthy controls. Conversely, in patients with MCI and AD, increased cognitive effort and attention towards movement planning, as well as stronger involvement of lower-order cerebral systems, was found. Successful cognitive performance in healthy individuals is associated with deactivation of task-irrelevant cerebral regions, whereas the development of AD appears to be characterized by a progressive impairment of cross-modal cerebral deactivation functions. These changes may cause the generally decreased ability of patients with AD to direct attention primarily to the relevant cognitive modality."]},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Drzezga","ForeName":"Alexander","Initials":"A","AffiliationInfo":{"Affiliation":"Department of Nuclear Medicine, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany. a.drzezga@lrz.tum.de"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Grimmer","ForeName":"Timo","Initials":"T"},{"@attributes":{"ValidYN":"Y"},"LastName":"Peller","ForeName":"Martin","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Wermke","ForeName":"Marc","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Siebner","ForeName":"Hartwig","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Rauschecker","ForeName":"Josef P","Initials":"JP"},{"@attributes":{"ValidYN":"Y"},"LastName":"Schwaiger","ForeName":"Markus","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Research Support, Non-U.S. Gov't"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2005","Month":"09","Day":"20"}},"MedlineJournalInfo":{"Country":"United States","MedlineTA":"PLoS Med","NlmUniqueID":"101231360","ISSNLinking":"1549-1277"},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Alzheimer Disease","QualifierName":["diagnostic imaging","physiopathology"]},{"DescriptorName":"Automation"},{"DescriptorName":"Brain","QualifierName":"blood supply"},{"DescriptorName":"Case-Control Studies"},{"DescriptorName":"Cognition","QualifierName":"physiology"},{"DescriptorName":"Female"},{"DescriptorName":"Humans"},{"DescriptorName":"Male"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Nerve Net","QualifierName":"physiology"},{"DescriptorName":"Positron-Emission Tomography"},{"DescriptorName":"Regional Blood Flow"},{"DescriptorName":"Regression Analysis"},{"DescriptorName":"Risk Factors"},{"DescriptorName":"Severity of Illness Index"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2004","Month":"10","Day":"18"},{"@attributes":{"PubStatus":"accepted"},"Year":"2005","Month":"07","Day":"20"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2005","Month":"9","Day":"15","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2006","Month":"5","Day":"19","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"entrez"},"Year":"2005","Month":"9","Day":"15","Hour":"9","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["16159306","04-PLME-RA-0245R3","10.1371\/journal.pmed.0020288","PMC1216331"]},"ReferenceList":{"Reference":[{"Citation":"J Neurosci. 1993 Mar;13(3):1202-26","ArticleIdList":{"ArticleId":"8441008"}},{"Citation":"J Neurosci. 1991 Mar;11(3):641-9","ArticleIdList":{"ArticleId":"2002358"}},{"Citation":"Neuroimage. 2002 Apr;15(4):870-8","ArticleIdList":{"ArticleId":"11906227"}},{"Citation":"Am J Ophthalmol. 2000 Sep;130(3):384-5","ArticleIdList":{"ArticleId":"11020439"}},{"Citation":"Science. 1998 Feb 27;279(5355):1347-51","ArticleIdList":{"ArticleId":"9478894"}},{"Citation":"Nat Neurosci. 2000 Oct;3(10):973-4","ArticleIdList":{"ArticleId":"11017166"}},{"Citation":"Brain. 1999 Feb;122 ( Pt 2):255-63","ArticleIdList":{"ArticleId":"10071054"}},{"Citation":"Brain. 1992 Jun;115 ( Pt 3):711-33","ArticleIdList":{"ArticleId":"1628198"}},{"Citation":"Neuroimage. 2001 Oct;14(4):802-16","ArticleIdList":{"ArticleId":"11554799"}},{"Citation":"Neuron. 2003 Mar 6;37(5):877-88","ArticleIdList":{"ArticleId":"12628177"}},{"Citation":"J Neurophysiol. 1992 Apr;67(4):798-811","ArticleIdList":{"ArticleId":"1316953"}},{"Citation":"Philos Trans R Soc Lond B Biol Sci. 1999 Jul 29;354(1387):1325-46","ArticleIdList":{"ArticleId":"10466154"}},{"Citation":"Cereb Cortex. 1997 Apr-May;7(3):193-206","ArticleIdList":{"ArticleId":"9143441"}},{"Citation":"Neurobiol Aging. 2001 Sep-Oct;22(5):755-63","ArticleIdList":{"ArticleId":"11705635"}},{"Citation":"J Clin Exp Neuropsychol. 1990 Mar;12(2):235-46","ArticleIdList":{"ArticleId":"2341553"}},{"Citation":"Nat Neurosci. 2002 Sep;5(9):905-9","ArticleIdList":{"ArticleId":"12195426"}},{"Citation":"Proc Natl Acad Sci U S A. 1995 Jun 20;92(13):5969-72","ArticleIdList":{"ArticleId":"7597062"}},{"Citation":"Prog Brain Res. 2005;148:199-212","ArticleIdList":{"ArticleId":"15661192"}},{"Citation":"Proc Natl Acad Sci U S A. 2000 Oct 24;97(22):11800-6","ArticleIdList":{"ArticleId":"11050212"}},{"Citation":"Brain. 2003 May;126(Pt 5):1173-81","ArticleIdList":{"ArticleId":"12690056"}},{"Citation":"Arch Neurol. 1999 Mar;56(3):303-8","ArticleIdList":{"ArticleId":"10190820"}},{"Citation":"J Cogn Neurosci. 2002 Apr 1;14(3):420-9","ArticleIdList":{"ArticleId":"11970801"}},{"Citation":"Proc Natl Acad Sci U S A. 2000 Oct 24;97(22):11793-9","ArticleIdList":{"ArticleId":"11050211"}},{"Citation":"J Clin Exp Neuropsychol. 1992 Nov;14(6):871-83","ArticleIdList":{"ArticleId":"1452635"}},{"Citation":"Neurology. 2003 Mar 11;60(5):802-8","ArticleIdList":{"ArticleId":"12629237"}},{"Citation":"J Neurosci. 2004 Apr 7;24(14):3637-42","ArticleIdList":{"ArticleId":"15071112"}},{"Citation":"Acta Neurol Scand Suppl. 2003;179:34-41","ArticleIdList":{"ArticleId":"12603249"}},{"Citation":"J Cereb Blood Flow Metab. 1992 Nov;12(6):900-18","ArticleIdList":{"ArticleId":"1400644"}},{"Citation":"Cereb Cortex. 1996 Sep-Oct;6(5):661-72","ArticleIdList":{"ArticleId":"8921202"}},{"Citation":"J Neurophysiol. 2002 Mar;87(3):1336-47","ArticleIdList":{"ArticleId":"11877508"}},{"Citation":"Neuropsychologia. 2003;41(10):1396-409","ArticleIdList":{"ArticleId":"12757911"}},{"Citation":"J Cereb Blood Flow Metab. 1991 Jul;11(4):690-9","ArticleIdList":{"ArticleId":"2050758"}},{"Citation":"Science. 1998 May 8;280(5365):921-4","ArticleIdList":{"ArticleId":"9572740"}},{"Citation":"Curr Opin Neurobiol. 1999 Apr;9(2):171-7","ArticleIdList":{"ArticleId":"10322179"}},{"Citation":"Neuroimage. 1999 Aug;10(2):209-15","ArticleIdList":{"ArticleId":"10417253"}},{"Citation":"J Nucl Med. 1995 Jul;36(7):1238-48","ArticleIdList":{"ArticleId":"7790950"}},{"Citation":"Philos Trans R Soc Lond B Biol Sci. 1996 Oct 29;351(1346):1445-53","ArticleIdList":{"ArticleId":"8941956"}},{"Citation":"Clin Neurophysiol. 2001 Aug;112(8):1436-41","ArticleIdList":{"ArticleId":"11459683"}},{"Citation":"J Neurosci. 1994 Nov;14(11 Pt 1):6336-53","ArticleIdList":{"ArticleId":"7965040"}},{"Citation":"Am J Psychiatry. 1999 Mar;156(3):470-3","ArticleIdList":{"ArticleId":"10080567"}},{"Citation":"J Cereb Blood Flow Metab. 1990 Jul;10(4):458-66","ArticleIdList":{"ArticleId":"2347879"}},{"Citation":"Annu Rev Neurosci. 1990;13:25-42","ArticleIdList":{"ArticleId":"2183676"}},{"Citation":"Cerebrovasc Brain Metab Rev. 1991 Winter;3(4):297-335","ArticleIdList":{"ArticleId":"1772739"}},{"Citation":"Eur J Nucl Med Mol Imaging. 2003 Aug;30(8):1104-13","ArticleIdList":{"ArticleId":"12764551"}},{"Citation":"Arch Neurol. 1989 Apr;46(4):391-4","ArticleIdList":{"ArticleId":"2705898"}},{"Citation":"Neuropsychologia. 1971 Mar;9(1):97-113","ArticleIdList":{"ArticleId":"5146491"}},{"Citation":"Nat Neurosci. 2001 Dec;4(12):1171-3","ArticleIdList":{"ArticleId":"11704763"}},{"Citation":"Neurology. 1993 Oct;43(10):1893-9","ArticleIdList":{"ArticleId":"8413944"}},{"Citation":"Neuroimage. 2002 Nov;17(3):1325-35","ArticleIdList":{"ArticleId":"12414272"}},{"Citation":"J Comp Neurol. 1985 Aug 15;238(3):263-74","ArticleIdList":{"ArticleId":"4044915"}},{"Citation":"Science. 2001 Apr 13;292(5515):290-3","ArticleIdList":{"ArticleId":"11303104"}},{"Citation":"Brain. 2001 Aug;124(Pt 8):1492-508","ArticleIdList":{"ArticleId":"11459742"}},{"Citation":"N Engl J Med. 2000 Aug 17;343(7):450-6","ArticleIdList":{"ArticleId":"10944562"}},{"Citation":"Eur J Neurosci. 2004 Jul;20(2):566-74","ArticleIdList":{"ArticleId":"15233766"}},{"Citation":"Neuropsychologia. 1996 Jun;34(6):475-83","ArticleIdList":{"ArticleId":"8736560"}},{"Citation":"Science. 1995 Apr 7;268(5207):111-4","ArticleIdList":{"ArticleId":"7701330"}}]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"15956163","DateCompleted":{"Year":"2005","Month":"06","Day":"30"},"DateRevised":{"Year":"2016","Month":"10","Day":"19"},"Article":{"@attributes":{"PubModel":"Print"},"Journal":{"ISSN":"0003-9942","JournalIssue":{"@attributes":{"CitedMedium":"Print"},"Volume":"62","Issue":"6","PubDate":{"Year":"2005","Month":"Jun"}},"Title":"Archives of neurology","ISOAbbreviation":"Arch Neurol"},"ArticleTitle":"Frontotemporal lobar degeneration: demographic characteristics of 353 patients.","Pagination":{"MedlinePgn":"925-30"},"Abstract":{"AbstractText":["Until recently, frontotemporal lobar degeneration (FTLD) was considered a rare neurodegenerative disorder that was difficult to diagnose. The publication of consensus criteria for FTLD, however, prompted systematic studies. The criteria categorize FTLD into 3 subgroups: frontotemporal dementia, semantic dementia, and progressive nonfluent aphasia.","To compare demographic characteristics of patients in the 3 FTLD subgroups.","We compared diagnostic breakdown, age at onset, sex, Mini-Mental State Examination score at first visit, education, and neuropathological diagnoses in a large sample of FTLD patients from 3 different university dementia clinics, including 2 neurologic clinics in the United States and 1 psychiatric clinic in Germany.","The frontotemporal dementia subgroup represented approximately half of all FTLD diagnoses. Patients diagnosed as having frontotemporal dementia (mean age, 57.5 years) and semantic dementia (mean age, 59.3 years) had an earlier age at onset than patients diagnosed as having progressive nonfluent aphasia (mean age, 63.0 years). There were significantly more men diagnosed as having frontotemporal dementia (63.5%) and semantic dementia (66.7%) when compared with progressive nonfluent aphasia (39.1%) (P = .005 for frontotemporal dementia vs progressive nonfluent aphasia and P = .002 for semantic dementia vs progressive nonfluent aphasia). Generally, the demographic features and diagnostic categories of the patient populations across the 3 sites were comparable. There were 68 deaths and 37 autopsies. Frontotemporal lobar degeneration with ubiquitin-positive tau-negative inclusions (48.5%), dementia lacking distinctive histopathological features (18.2%), and Pick disease (15.2%) were the most common neuropathological diagnoses.","These findings show that cohorts of patients can be combined using new research criteria for FTLD and demonstrate striking demographic differences among FTLD subgroups. The sex and age-at-onset differences suggest that there may be biological differences among FTLD subgroups. In this sample, FTLD with ubiquitin-positive inclusions accounted for half of all neuropathological diagnoses."]},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Johnson","ForeName":"Julene K","Initials":"JK","AffiliationInfo":{"Affiliation":"Department of Neurology, Memory and Aging Center, University of California, San Francisco, 94117, USA. jkj@itsa.ucsf.edu"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Diehl","ForeName":"Janine","Initials":"J"},{"@attributes":{"ValidYN":"Y"},"LastName":"Mendez","ForeName":"Mario F","Initials":"MF"},{"@attributes":{"ValidYN":"Y"},"LastName":"Neuhaus","ForeName":"John","Initials":"J"},{"@attributes":{"ValidYN":"Y"},"LastName":"Shapira","ForeName":"Jill S","Initials":"JS"},{"@attributes":{"ValidYN":"Y"},"LastName":"Forman","ForeName":"Mark","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Chute","ForeName":"Dennis J","Initials":"DJ"},{"@attributes":{"ValidYN":"Y"},"LastName":"Roberson","ForeName":"Erik D","Initials":"ED"},{"@attributes":{"ValidYN":"Y"},"LastName":"Pace-Savitsky","ForeName":"Catherine","Initials":"C"},{"@attributes":{"ValidYN":"Y"},"LastName":"Neumann","ForeName":"Manuela","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Chow","ForeName":"Tiffany W","Initials":"TW"},{"@attributes":{"ValidYN":"Y"},"LastName":"Rosen","ForeName":"Howard J","Initials":"HJ"},{"@attributes":{"ValidYN":"Y"},"LastName":"Forstl","ForeName":"Hans","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Miller","ForeName":"Bruce L","Initials":"BL"}]},"Language":"eng","GrantList":{"@attributes":{"CompleteYN":"Y"},"Grant":[{"GrantID":"P50-AG16753","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"K08-AG16753","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"AG10123","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"P01 AG019724","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"},{"GrantID":"P01-AG19724","Acronym":"AG","Agency":"NIA NIH HHS","Country":"United States"}]},"PublicationTypeList":{"PublicationType":["Comparative Study","Journal Article","Multicenter Study","Research Support, N.I.H., Extramural","Research Support, Non-U.S. Gov't","Research Support, U.S. Gov't, P.H.S."]}},"MedlineJournalInfo":{"Country":"United States","MedlineTA":"Arch Neurol","NlmUniqueID":"0372436","ISSNLinking":"0003-9942"},"CitationSubset":["AIM","IM"],"MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Adult"},{"DescriptorName":"Aged"},{"DescriptorName":"Aged, 80 and over"},{"DescriptorName":"Cohort Studies"},{"DescriptorName":"Dementia","QualifierName":["diagnosis","epidemiology","pathology"]},{"DescriptorName":"Demography"},{"DescriptorName":"Female"},{"DescriptorName":"Humans"},{"DescriptorName":"Male"},{"DescriptorName":"Middle Aged"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"pubmed"},"Year":"2005","Month":"6","Day":"16","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2005","Month":"7","Day":"1","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"entrez"},"Year":"2005","Month":"6","Day":"16","Hour":"9","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["15956163","62\/6\/925","10.1001\/archneur.62.6.925"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"15895461","DateCompleted":{"Year":"2006","Month":"09","Day":"13"},"DateRevised":{"Year":"2010","Month":"11","Day":"18"},"Article":{"@attributes":{"PubModel":"Print"},"Journal":{"ISSN":"1098-1004","JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"26","Issue":"1","PubDate":{"Year":"2005","Month":"Jul"}},"Title":"Human mutation","ISOAbbreviation":"Hum Mutat"},"ArticleTitle":"TNF polymorphisms in Alzheimer disease and functional implications on CSF beta-amyloid levels.","Pagination":{"MedlinePgn":"29-35"},"Abstract":{"AbstractText":"Alzheimer disease (AD), vascular dementia, and stroke are all associated with inflammation though their respective initiating factors differ. Recently a polymorphism in the proinflammatory cytokine tumor necrosis factor (TNF), in association with apolipoprotein E (APOE), was reported to increase AD risk. Two SNPs, rs1799724 (-850C>T; NT_007592.14:g.22400733C>T) and rs1800629 (-308G>A; [NT_007592.14:g.22401282G>A]), and the APOE polymorphism were genotyped in 506 patients with sporadic AD and in 277 cognitively healthy controls. In a subset of 90 individuals we also investigated whether these SNPs exerted any functional effects on cerebrospinal fluid (CSF) beta-amyloid (Abeta) levels. The frequency of the rs1799724 genotypes and the rs1799724-T allele were significantly different in AD individuals (P=0.009; odds ratio [OR], 1.63; 95% confidence interval [CI], 1.13-2.34), while the rs1800629 SNP was not associated with AD. Significant interaction was observed between the rs1799724-T and APOE epsilon4 alleles in that the rs1799724-T allele significantly modified risk associated with possession of the epsilon4 allele only (epsilon4 in absence of rs1799724-T: OR, 2.92; 95% CI, 2.00-4.27; epsilon4 in presence of rs1799724-T: OR, 6.65; 95% CI, 3.26-13.55; P=0.03). Haplotyping analysis revealed a significant overrepresentation of an rs1799724-T\/rs1800629-G haplotype in AD (P=0.012; OR, 1.60; 95% CI, 1.11-2.29), although to a lesser degree than rs1799724-T alone. Further, the rs1799724-T allele was found to be associated with lower levels of CSF Abeta42 (P=0.023), thus corroborating the genetic findings. Inheritance of the rs1799724-T allele appears to synergistically increase the risk of AD in APOEepsilon4 carriers and is associated with altered CSF Abeta42 levels. Further investigations are warranted to assess the significance of these novel findings."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Laws","ForeName":"Simon M","Initials":"SM","AffiliationInfo":{"Affiliation":"Alzheimer's and Aging, School of Biomedical and Sports Science, Edith Cowan University, Joondalup, Australia."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Perneczky","ForeName":"Robert","Initials":"R"},{"@attributes":{"ValidYN":"Y"},"LastName":"Wagenpfeil","ForeName":"Stefan","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"M\u00fcller","ForeName":"Ulrich","Initials":"U"},{"@attributes":{"ValidYN":"Y"},"LastName":"F\u00f6rstl","ForeName":"Hans","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Martins","ForeName":"Ralph N","Initials":"RN"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Riemenschneider","ForeName":"Matthias","Initials":"M"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Research Support, Non-U.S. Gov't"]}},"MedlineJournalInfo":{"Country":"United States","MedlineTA":"Hum Mutat","NlmUniqueID":"9215429","ISSNLinking":"1059-7794"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"Amyloid beta-Peptides"},{"RegistryNumber":"0","NameOfSubstance":"Apolipoproteins E"},{"RegistryNumber":"0","NameOfSubstance":"Tumor Necrosis Factor-alpha"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Alzheimer Disease","QualifierName":["cerebrospinal fluid","genetics"]},{"DescriptorName":"Amyloid beta-Peptides","QualifierName":"cerebrospinal fluid"},{"DescriptorName":"Apolipoproteins E","QualifierName":"genetics"},{"DescriptorName":"Female"},{"DescriptorName":"Gene Frequency"},{"DescriptorName":"Genotype"},{"DescriptorName":"Humans"},{"DescriptorName":"Male"},{"DescriptorName":"Polymorphism, Single Nucleotide","QualifierName":"genetics"},{"DescriptorName":"Tumor Necrosis Factor-alpha","QualifierName":"genetics"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"pubmed"},"Year":"2005","Month":"5","Day":"17","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2006","Month":"9","Day":"14","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"entrez"},"Year":"2005","Month":"5","Day":"17","Hour":"9","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["15895461","10.1002\/humu.20180"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"15633073","DateCompleted":{"Year":"2005","Month":"06","Day":"13"},"DateRevised":{"Year":"2015","Month":"11","Day":"19"},"Article":{"@attributes":{"PubModel":"Print"},"Journal":{"ISSN":"0303-4259","JournalIssue":{"@attributes":{"CitedMedium":"Print"},"Volume":"32","Issue":"1","PubDate":{"Year":"2005","Month":"Jan"}},"Title":"Psychiatrische Praxis","ISOAbbreviation":"Psychiatr Prax"},"ArticleTitle":"[State of the art management of BPSD in dementia].","Pagination":{"MedlinePgn":"31-8"},"Abstract":{"AbstractText":["To obtain a cross-sectional overview of therapeutic practice concerning non-cognitive, behavioral signs and symptoms of dementia (BPSD) in Germany, Austria, and Switzerland.","We selected 24 psychiatrists (8 from each country) for a questionnaire-based survey with 28 detailed practical questions.","Attitudes and preferences were in line with the state of the art as documented in the literature, with the exception of the fact that 30 % of the physicians favored a too brief therapeutic trial with selective serotonin re-uptake inhibitors (SSRIs) for agitation. According to the international literature the preferred treatment of psychotic symptoms in Parkinsons's disease is also a little bit different. Modern atypical antipsychotics, and particularly risperidone, were highly favored for agitation, delirium, psychotic symptoms, and rage outbursts; benzodiazepines (oxazepam and lorazepam), and to an extent also low-potency conventional antipsychotics, were favored only for brief ad hoc medication courses. Anxiety and depressive symptoms were preferentially treated with SSRI, with the exception of short-term therapy of generalized anxiety where benzodiazepines were favored. Benzodiazepines and zolpidem were favored for insomnia without pronounced nocturnal agitation.","Psychiatrists at memory clinics in German-speaking Europe have therapeutic attitudes and practices that are consistent with the current state of the art."]},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Rainer","ForeName":"Michael K","Initials":"MK","AffiliationInfo":{"Affiliation":"Memory-Klinik und Psychiatrische Abteilung, Donauspital, Sozialmedizinisches Zentrum Ost, Wien, Osterreich. Michael.Rainer@wienkav.at"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Mucke","ForeName":"Hermann A M","Initials":"HA"},{"@attributes":{"ValidYN":"Y"},"LastName":"Masching","ForeName":"Andreas J","Initials":"AJ"},{"@attributes":{"ValidYN":"Y"},"LastName":"Haushofer","ForeName":"Manfred","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Karger","ForeName":"Martin","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kasper","ForeName":"Siegfried","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"}]},"Language":"ger","PublicationTypeList":{"PublicationType":["English Abstract","Journal Article"]},"VernacularTitle":"Zeitgem\u00e4sses Management von nicht kognitiven Symptomen bei Demenz."},"MedlineJournalInfo":{"Country":"Germany","MedlineTA":"Psychiatr Prax","NlmUniqueID":"0423204","ISSNLinking":"0303-4259"},"ChemicalList":{"Chemical":{"RegistryNumber":"0","NameOfSubstance":"Psychotropic Drugs"}},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Alzheimer Disease","QualifierName":["diagnosis","epidemiology","therapy"]},{"DescriptorName":"Attitude of Health Personnel"},{"DescriptorName":"Austria"},{"DescriptorName":"Comorbidity"},{"DescriptorName":"Cross-Sectional Studies"},{"DescriptorName":"Dementia","QualifierName":["diagnosis","drug therapy","epidemiology","psychology"]},{"DescriptorName":"Germany"},{"DescriptorName":"Health Surveys"},{"DescriptorName":"Humans"},{"DescriptorName":"Mental Disorders","QualifierName":["diagnosis","epidemiology","psychology","therapy"]},{"DescriptorName":"Psychotropic Drugs","QualifierName":"therapeutic use"},{"DescriptorName":"Surveys and Questionnaires"},{"DescriptorName":"Switzerland"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"pubmed"},"Year":"2005","Month":"1","Day":"6","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2005","Month":"6","Day":"14","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"entrez"},"Year":"2005","Month":"1","Day":"6","Hour":"9","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["15633073","10.1055\/s-2003-814885"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"15494617","DateCompleted":{"Year":"2004","Month":"12","Day":"22"},"DateRevised":{"Year":"2019","Month":"11","Day":"09"},"Article":{"@attributes":{"PubModel":"Print"},"Journal":{"ISSN":"0893-0341","JournalIssue":{"@attributes":{"CitedMedium":"Print"},"Volume":"18","Issue":"3","PubDate":{"MedlineDate":"2004 Jul-Sep"}},"Title":"Alzheimer disease and associated disorders","ISOAbbreviation":"Alzheimer Dis Assoc Disord"},"ArticleTitle":"Disease stage in Alzheimer disease and treatment effects of rivastigmine.","Pagination":{"MedlinePgn":"123-8"},"Abstract":{"AbstractText":"The efficacy and tolerability of the cholinesterase inhibitor rivastigmine in the treatment of Alzheimer disease (AD) have been demonstrated in several clinical trials, which included patients with a wide range of dementia severities. To investigate the association between severity of disease and treatment response, the combined data from three large randomized, placebo-controlled trials were analyzed. The pooled patient population was stratified into three cohorts showing moderately severe (Mini-Mental State Examination score [MMSE] < or = 15), moderate (MMSE 16-22), and mild (MMSE > or = 22) dementia. In each cohort, the effects of rivastigmine 6 to 12 mg\/day versus placebo were evaluated using the cognitive subscale of the Alzheimer Disease Assessment Scale (ADAS-cog) and the Progressive Deterioration Scale. Rivastigmine 6 to 12 mg\/day maintained ADAS-cog scores at or above placebo levels in all cohorts, while cognitive deterioration with placebo was progressive and severity dependent. Activities of daily living showed statistically significant benefits with rivastigmine across all severity cohorts."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A","AffiliationInfo":{"Affiliation":"Technische Universit\u00e4t M\u00fcnchen, Munich, Germany. alexander.kurz@lrz.tu.muenchen.de"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Farlow","ForeName":"Martin","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Quarg","ForeName":"Peter","Initials":"P"},{"@attributes":{"ValidYN":"Y"},"LastName":"Spiegel","ForeName":"Ren\u00e9","Initials":"R"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Clinical Trial","Journal Article","Multicenter Study","Randomized Controlled Trial"]}},"MedlineJournalInfo":{"Country":"United States","MedlineTA":"Alzheimer Dis Assoc Disord","NlmUniqueID":"8704771","ISSNLinking":"0893-0341"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"Neuroprotective Agents"},{"RegistryNumber":"0","NameOfSubstance":"Phenylcarbamates"},{"RegistryNumber":"0","NameOfSubstance":"Placebos"},{"RegistryNumber":"PKI06M3IW0","NameOfSubstance":"Rivastigmine"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Activities of Daily Living"},{"DescriptorName":"Aged"},{"DescriptorName":"Aged, 80 and over"},{"DescriptorName":"Alzheimer Disease","QualifierName":["classification","drug therapy"]},{"DescriptorName":"Female"},{"DescriptorName":"Humans"},{"DescriptorName":"Male"},{"DescriptorName":"Mental Status Schedule"},{"DescriptorName":"Neuroprotective Agents","QualifierName":["pharmacology","therapeutic use"]},{"DescriptorName":"Phenylcarbamates","QualifierName":["pharmacology","therapeutic use"]},{"DescriptorName":"Placebos"},{"DescriptorName":"Retrospective Studies"},{"DescriptorName":"Rivastigmine"},{"DescriptorName":"Severity of Illness Index"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"pubmed"},"Year":"2004","Month":"10","Day":"21","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2004","Month":"12","Day":"23","Hour":"9","Minute":"0"},{"@attributes":{"PubStatus":"entrez"},"Year":"2004","Month":"10","Day":"21","Hour":"9","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["15494617","00002093-200407000-00004","10.1097\/01.wad.0000127445.00442.a1"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"14512822","DateCompleted":{"Year":"2003","Month":"11","Day":"21"},"DateRevised":{"Year":"2019","Month":"11","Day":"08"},"Article":{"@attributes":{"PubModel":"Print"},"Journal":{"ISSN":"0893-0341","JournalIssue":{"@attributes":{"CitedMedium":"Print"},"Volume":"17 Suppl 3","PubDate":{"MedlineDate":"2003 Jul-Sep"}},"Title":"Alzheimer disease and associated disorders","ISOAbbreviation":"Alzheimer Dis Assoc Disord"},"ArticleTitle":"Galantamine demonstrates efficacy and safety in elderly patients with Alzheimer disease.","Pagination":{"MedlinePgn":"S86-91"},"Abstract":{"AbstractText":"Alzheimer disease (AD) treatment guidelines state that cholinergic agents are not cost-effective in patients with more severe disease. Because many physicians may deem an older patient unlikely to respond to treatment, older AD patients may remain untreated. Galantamine (Reminyl), a novel cholinergic agent, is effective in mild to moderate AD. This post hoc analysis of pooled phase III galantamine clinical trials was designed to assess whether older (> or =80 years) and younger (< or =79 years) AD patients experience similar benefits with galantamine based on changes in the ADAS-cog and CIBIC-plus. Mean ADAS-cog scores for older patients treated with galantamine 24 mg\/day significantly improved versus baseline and versus placebo at month 3. Cognitive improvement was maintained versus placebo at month 6; the ADAS-cog score for placebo patients dropped below baseline at month 6. Change in CIBIC-plus for galantamine was significantly different from placebo at months 5 to 6. Mean ADAS-cog score in older patients taking galantamine for 12 months remained above baseline. The score for patients taking placebo for 6 months before switching to galantamine did not differ significantly from baseline at 12 months but was lower than in patients receiving galantamine for 12 months. Incidence of adverse events in patients > 80 years was similar to that in the overall study population. Galantamine maintained cognitive and global function in patients > 80 years with mild to moderate AD for at least 5 to 6 months and cognitive efficacy for 12 months. Prescribing approved therapies such as galantamine for older patients with AD is recommended."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Marcusson","ForeName":"Jan","Initials":"J","AffiliationInfo":{"Affiliation":"Department of Geriatric Medicine, Link\u00f6ping University Hospital, Link\u00f6ping, Sweden. jan.marcusson@lio.se"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Bullock","ForeName":"Roger","Initials":"R"},{"@attributes":{"ValidYN":"Y"},"LastName":"Gauthier","ForeName":"Serge","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Schwalen","ForeName":"Susanne","Initials":"S"}]},"Language":"eng","PublicationTypeList":{"PublicationType":"Journal Article"}},"MedlineJournalInfo":{"Country":"United States","MedlineTA":"Alzheimer Dis Assoc Disord","NlmUniqueID":"8704771","ISSNLinking":"0893-0341"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"Cholinesterase Inhibitors"},{"RegistryNumber":"0","NameOfSubstance":"Placebos"},{"RegistryNumber":"0D3Q044KCA","NameOfSubstance":"Galantamine"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Age Factors"},{"DescriptorName":"Aged"},{"DescriptorName":"Aged, 80 and over"},{"DescriptorName":"Alzheimer Disease","QualifierName":"drug therapy"},{"DescriptorName":"Cholinesterase Inhibitors","QualifierName":["adverse effects","pharmacology"]},{"DescriptorName":"Clinical Trials, Phase III as Topic"},{"DescriptorName":"Cognition"},{"DescriptorName":"Female"},{"DescriptorName":"Galantamine","QualifierName":["adverse effects","pharmacology"]},{"DescriptorName":"Humans"},{"DescriptorName":"Male"},{"DescriptorName":"Placebos"},{"DescriptorName":"Quality of Life"},{"DescriptorName":"Randomized Controlled Trials as Topic"},{"DescriptorName":"Severity of Illness Index"},{"DescriptorName":"Treatment Outcome"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"pubmed"},"Year":"2003","Month":"9","Day":"27","Hour":"5","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2003","Month":"12","Day":"3","Hour":"5","Minute":"0"},{"@attributes":{"PubStatus":"entrez"},"Year":"2003","Month":"9","Day":"27","Hour":"5","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["14512822","10.1097\/00002093-200307003-00005"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"12962529","DateCompleted":{"Year":"2003","Month":"11","Day":"07"},"DateRevised":{"Year":"2018","Month":"11","Day":"13"},"Article":{"@attributes":{"PubModel":"Print"},"Journal":{"ISSN":"1172-7047","JournalIssue":{"@attributes":{"CitedMedium":"Print"},"Volume":"17","Issue":"12","PubDate":{"Year":"2003"}},"Title":"CNS drugs","ISOAbbreviation":"CNS Drugs"},"ArticleTitle":"Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer's disease with cerebrovascular disease.","Pagination":{"MedlinePgn":"905-14"},"Abstract":{"AbstractText":["Alzheimer's disease and vascular dementia are the two most common types of dementia, with significant overlap of clinical symptoms and pathology. Previous results from a 6-month, double-blind, placebo-controlled, international, multicentre study of the cholinomimetic galantamine in patients with probable vascular dementia or mixed dementia (Alzheimer's disease with cerebrovascular disease) showed significant cognitive, behavioural and functional benefits in these patients. Furthermore, results of a 6-month, open-label extension of this study confirmed that patients with vascular dementia or Alzheimer's disease with cerebrovascular disease may benefit from galantamine therapy for at least 1 year. The objective of the current analysis was to determine if the long-term cognitive benefits of galantamine seen in the above-mentioned study are influenced by dementia type (probable vascular dementia vs Alzheimer's disease with cerebrovascular disease).","A post hoc sub-analysis of a 6-month, multicentre, randomised, double-blind, placebo-controlled study and a subsequent 6-month, open-label extension.","Patients diagnosed with probable vascular dementia or Alzheimer's disease with cerebrovascular disease were treated with galantamine (Reminyl) 24 mg\/day for 12 months (6 months double-blind and 6 months open-label) or placebo for 6 months (double-blind) followed by galantamine 24 mg\/day for 6 months (open-label). Changes in scores on the 11-item Alzheimer's Disease Assessment Scale cognitive subscale (ADAS-cog\/11) were assessed at months 6, 7.5 and 12. Mean changes from baseline were analysed.","Patients with probable vascular dementia treated with galantamine for 6 or 12 months showed significant improvements in ADAS-cog\/11 scores versus baseline, which were maintained at the end of the 12-month study. Patients who had Alzheimer's disease with cerebrovascular disease continuously treated with galantamine maintained the cognitive abilities seen at baseline for at least 12 months. Additionally, patients who had Alzheimer's disease with cerebrovascular disease who were switched from placebo to open-label galantamine therapy for 6 months demonstrated cognitive benefits, but these benefits were significantly less than those observed in patients treated with galantamine continuously for the 12-month period. Galantamine was well tolerated throughout the entire 12-month study.","These findings suggest that the drug is efficacious for such common forms of dementia as vascular dementia and Alzheimer's disease with cerebrovascular disease. Moreover, some patients benefit from galantamine therapy that is initiated early, soon after diagnosis, and continued for at least 1 year."]},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Small","ForeName":"Gary","Initials":"G","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Biobehavioral Sciences and Neuropsychiatric Institute, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, California 90024, USA. gsmall@mednet.ucla.edu"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Erkinjuntti","ForeName":"Timo","Initials":"T"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Lilienfeld","ForeName":"Sean","Initials":"S"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Clinical Trial","Comparative Study","Journal Article","Multicenter Study","Randomized Controlled Trial","Research Support, Non-U.S. Gov't"]}},"MedlineJournalInfo":{"Country":"New Zealand","MedlineTA":"CNS Drugs","NlmUniqueID":"9431220","ISSNLinking":"1172-7047"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"Cholinesterase Inhibitors"},{"RegistryNumber":"0D3Q044KCA","NameOfSubstance":"Galantamine"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Alzheimer Disease","QualifierName":["drug therapy","psychology"]},{"DescriptorName":"Cerebrovascular Disorders","QualifierName":"complications"},{"DescriptorName":"Cholinesterase Inhibitors","QualifierName":"therapeutic use"},{"DescriptorName":"Cognition","QualifierName":"drug effects"},{"DescriptorName":"Dementia, Vascular","QualifierName":["complications","drug therapy","psychology"]},{"DescriptorName":"Double-Blind Method"},{"DescriptorName":"Female"},{"DescriptorName":"Galantamine","QualifierName":"therapeutic use"},{"DescriptorName":"Humans"},{"DescriptorName":"Male"},{"DescriptorName":"Psychiatric Status Rating Scales"},{"DescriptorName":"Treatment Outcome"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"pubmed"},"Year":"2003","Month":"9","Day":"10","Hour":"5","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2003","Month":"11","Day":"8","Hour":"5","Minute":"0"},{"@attributes":{"PubStatus":"entrez"},"Year":"2003","Month":"9","Day":"10","Hour":"5","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["12962529","17124","10.2165\/00023210-200317120-00004"]},"ReferenceList":{"Reference":[{"Citation":"Neurobiol Aging. 2000 Mar-Apr;21(2):321-30","ArticleIdList":{"ArticleId":"10867217"}},{"Citation":"Am J Psychiatry. 1991 Jan;148(1):102-5","ArticleIdList":{"ArticleId":"1984692"}},{"Citation":"Neurology. 2000 Jan 25;54(2):447-51","ArticleIdList":{"ArticleId":"10668712"}},{"Citation":"Clin Symp. 1996;48(3):2-32","ArticleIdList":{"ArticleId":"8961620"}},{"Citation":"Neurology. 2000 Jun 27;54(12):2269-76","ArticleIdList":{"ArticleId":"10881251"}},{"Citation":"Neurology. 1997 May;48(5 Suppl 6):S10-6","ArticleIdList":{"ArticleId":"9153155"}},{"Citation":"J Neuropsychiatry Clin Neurosci. 1999 Spring;11(2):268-70","ArticleIdList":{"ArticleId":"10333999"}},{"Citation":"J Neurol Sci. 2002 Nov 15;203-204:141-6","ArticleIdList":{"ArticleId":"12417373"}},{"Citation":"Neurology. 2000;54(11 Suppl 5):S4-9","ArticleIdList":{"ArticleId":"10854354"}},{"Citation":"Neurology. 1993 Feb;43(2):250-60","ArticleIdList":{"ArticleId":"8094895"}},{"Citation":"J Neural Transm (Vienna). 1996;103(10):1211-20","ArticleIdList":{"ArticleId":"9013408"}},{"Citation":"Clin Exp Pharmacol Physiol Suppl. 1995 Dec;22(1):S257-9","ArticleIdList":{"ArticleId":"9072380"}},{"Citation":"Dementia. 1994 May-Aug;5(3-4):163-7","ArticleIdList":{"ArticleId":"8087172"}},{"Citation":"Stroke. 1996 Mar;27(3):520-5; discussion 525-6","ArticleIdList":{"ArticleId":"8610323"}},{"Citation":"BMJ. 2000 Dec 9;321(7274):1445-9","ArticleIdList":{"ArticleId":"11110737"}},{"Citation":"Lancet. 1995 Mar 11;345(8950):625-30","ArticleIdList":{"ArticleId":"7534856"}},{"Citation":"Acta Neurol Scand Suppl. 2000;176:68-73","ArticleIdList":{"ArticleId":"11261808"}},{"Citation":"J Neurol Neurosurg Psychiatry. 2001 Nov;71(5):589-95","ArticleIdList":{"ArticleId":"11606667"}},{"Citation":"Toxicology. 2000 Nov 16;153(1-3):167-78","ArticleIdList":{"ArticleId":"11090955"}},{"Citation":"Neurosci Lett. 1994 Jan 17;166(1):117-20","ArticleIdList":{"ArticleId":"7514774"}},{"Citation":"Ann N Y Acad Sci. 2002 Nov;977:513-22","ArticleIdList":{"ArticleId":"12480794"}},{"Citation":"Alzheimer Dis Assoc Disord. 2001 Apr-Jun;15(2):89-95","ArticleIdList":{"ArticleId":"11391090"}},{"Citation":"Biol Psychiatry. 2001 Feb 1;49(3):279-88","ArticleIdList":{"ArticleId":"11230879"}},{"Citation":"Ann N Y Acad Sci. 2002 Nov;977:482-6","ArticleIdList":{"ArticleId":"12480789"}},{"Citation":"Neuroepidemiology. 1995;14(5):240-57","ArticleIdList":{"ArticleId":"7477666"}},{"Citation":"Neurosci Lett. 1999 Dec 31;277(3):169-72","ArticleIdList":{"ArticleId":"10626840"}},{"Citation":"Clin Ther. 2003 Jun;25(6):1765-82","ArticleIdList":{"ArticleId":"12860497"}},{"Citation":"Eur J Neurol. 2000 Mar;7(2):159-69","ArticleIdList":{"ArticleId":"10809936"}},{"Citation":"JAMA. 1997 Mar 12;277(10):813-7","ArticleIdList":{"ArticleId":"9052711"}},{"Citation":"J Neurol Sci. 2002 Nov 15;203-204:57-65","ArticleIdList":{"ArticleId":"12417358"}},{"Citation":"J Neural Transm (Vienna). 2002 May;109(5-6):813-36","ArticleIdList":{"ArticleId":"12111471"}},{"Citation":"J Neural Transm Suppl. 1998;54:117-27","ArticleIdList":{"ArticleId":"9850920"}},{"Citation":"Alzheimer Dis Assoc Disord. 1999 Oct-Dec;13 Suppl 3:S115-23","ArticleIdList":{"ArticleId":"10609690"}},{"Citation":"Alzheimer Dis Assoc Disord. 1997;11 Suppl 2:S22-32","ArticleIdList":{"ArticleId":"9236949"}},{"Citation":"Acta Psychiatr Scand. 1987 Nov;76(5):465-79","ArticleIdList":{"ArticleId":"3324647"}},{"Citation":"Neurology. 2000 Jun 27;54(12):2261-8","ArticleIdList":{"ArticleId":"10881250"}},{"Citation":"Neurology. 1984 Jul;34(7):939-44","ArticleIdList":{"ArticleId":"6610841"}},{"Citation":"Am J Psychiatry. 1984 Nov;141(11):1356-64","ArticleIdList":{"ArticleId":"6496779"}},{"Citation":"Acta Neurol Scand. 1989 May;79(5):397-406","ArticleIdList":{"ArticleId":"2568069"}},{"Citation":"Lancet. 2002 Apr 13;359(9314):1283-90","ArticleIdList":{"ArticleId":"11965273"}}]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"12860497","DateCompleted":{"Year":"2003","Month":"10","Day":"30"},"DateRevised":{"Year":"2019","Month":"09","Day":"22"},"Article":{"@attributes":{"PubModel":"Print"},"Journal":{"ISSN":"0149-2918","JournalIssue":{"@attributes":{"CitedMedium":"Print"},"Volume":"25","Issue":"6","PubDate":{"Year":"2003","Month":"Jun"}},"Title":"Clinical therapeutics","ISOAbbreviation":"Clin Ther"},"ArticleTitle":"An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia.","Pagination":{"MedlinePgn":"1765-82"},"Abstract":{"AbstractText":["Alzheimer's disease (AD) and vascular dementia (VaD) are the most common types of dementia worldwide. Galantamine, an acetylcholinesterase inhibitor and allosteric nicotinic modulator, has shown broad clinical benefits in patients with mild to moderate dementia due to AD, probable VaD, or AD with cerebrovascular disease (CVD)-so-called mixed dementia.","The purpose of this study was to evaluate the efficacy and safety profiles of galantamine 24 mg\/d in patients with VaD or AD with CVD over the longer term (>6 months).","This was an open-label extension of a 6-month double-blind study of galantamine. Patients who had been randomized to receive galantamine 24 mg\/d or placebo in the double-blind phase were eligible to continue open-label treatment with galantamine 24 mg\/d for 6 months. The primary efficacy end point was change in cognition, based on scores on the 11-item Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog\/11). Secondary measures included changes in functional ability (as measured on the Disability Assessment for Dementia [DAD]) and behavior (as measured on the Neuropsychiatric Inventory [NPI]). Safety and tolerability were also monitored.","Four hundred fifty-nine patients (240 men, 219 women; mean [SE] age, 75.2 [0.33] years) entered the open-label phase. Of these patients, 195 (42.5%) had a diagnosis of probable VaD, and 238 (51.9%) had a diagnosis of AD with CVD; the remainder had an inconclusive diagnosis. At month 12 of the study, improvements from baseline (the start of the double-blind phase) in ADAS-cog\/11 scores were observed in both the group that received placebo during the double-blind phase (placebo\/galantamine group: -0.3 point; 95% CI, -1.64 to 1.06) and the group that received galantamine during the double-blind phase (galantamine\/galantamine group: -0.9 point; 95% CI, -1.73 to 0.03). Improvement in functional ability was demonstrated by statistically significant mean (SE) changes from baseline in DAD score in both the placebo\/galantamine group (-7.4 [1.68]; P < or = 0.001) and the galantamine\/galantamine group (-3.6 [1.33]; P < or = 0.01). There was no significant change in mean (SE) NPI scores in either group (0.2 [0.98] and 0.1 [0.70], respectively). Galantamine treatment was well tolerated.","In these patients with VaD and AD with CVD, galantamine treatment produced similar sustained benefits in terms of maintenance of or improvement in cognition (ADAS-cog\/11), functional ability (DAD), and behavior (NPI) after 12 months."]},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Erkinjuntti","ForeName":"Timo","Initials":"T","AffiliationInfo":{"Affiliation":"Department of Clinical Neurosciences, Helsinki University Central Hospital, Helsinki, Finland. timo.erkinjuntti@hus.fi"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Small","ForeName":"Gary W","Initials":"GW"},{"@attributes":{"ValidYN":"Y"},"LastName":"Bullock","ForeName":"Roger","Initials":"R"},{"@attributes":{"ValidYN":"Y"},"LastName":"Lilienfeld","ForeName":"Sean","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"Damaraju","ForeName":"C V","Initials":"CV"},{"@attributes":{"ValidYN":"Y"},"CollectiveName":"GAL-INT-6 Study Group"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Clinical Trial","Journal Article","Randomized Controlled Trial","Research Support, Non-U.S. Gov't"]}},"MedlineJournalInfo":{"Country":"United States","MedlineTA":"Clin Ther","NlmUniqueID":"7706726","ISSNLinking":"0149-2918"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"Cholinesterase Inhibitors"},{"RegistryNumber":"0D3Q044KCA","NameOfSubstance":"Galantamine"}]},"CitationSubset":"IM","CommentsCorrectionsList":{"CommentsCorrections":{"@attributes":{"RefType":"ErratumIn"},"RefSource":"Clin Ther. 2003 Aug;25(8):2336"}},"MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Alzheimer Disease","QualifierName":["complications","drug therapy"]},{"DescriptorName":"Cerebrovascular Disorders","QualifierName":"complications"},{"DescriptorName":"Cholinesterase Inhibitors","QualifierName":["adverse effects","therapeutic use"]},{"DescriptorName":"Cognition","QualifierName":"drug effects"},{"DescriptorName":"Dementia, Vascular","QualifierName":"drug therapy"},{"DescriptorName":"Double-Blind Method"},{"DescriptorName":"Female"},{"DescriptorName":"Galantamine","QualifierName":["adverse effects","therapeutic use"]},{"DescriptorName":"Humans"},{"DescriptorName":"Male"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"pubmed"},"Year":"2003","Month":"7","Day":"16","Hour":"5","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2003","Month":"10","Day":"31","Hour":"5","Minute":"0"},{"@attributes":{"PubStatus":"entrez"},"Year":"2003","Month":"7","Day":"16","Hour":"5","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["12860497","S0149291803801686","10.1016\/s0149-2918(03)80168-6"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"12784034","DateCompleted":{"Year":"2003","Month":"10","Day":"15"},"DateRevised":{"Year":"2017","Month":"11","Day":"01"},"Article":{"@attributes":{"PubModel":"Print"},"Journal":{"ISSN":"1420-8008","JournalIssue":{"@attributes":{"CitedMedium":"Print"},"Volume":"16","Issue":"2","PubDate":{"Year":"2003"}},"Title":"Dementia and geriatric cognitive disorders","ISOAbbreviation":"Dement Geriatr Cogn Disord"},"ArticleTitle":"Dementia accompanying motor neuron disease--7 cases.","Pagination":{"MedlinePgn":"98-102"},"Abstract":{"AbstractText":"Seven typical cases of dementia with motor neuron disease (D-MND) are reported. Among 1,000 dementia cases, D-MND was more frequent than Pick's disease, Lewy body disease or Creutzfeldt-Jakob disease. D-MND accounted for 30.4% of all forms of frontal lobe dementia (FLD) including FLD and Pick's disease. These data support that this combined syndrome may be more frequent than previously reported. As the subcortical neuropathology of D-MND is identical with MND, D-MND is rather the cortical manifestation of MND than a new disease entity.","CopyrightInformation":"Copyright 2003 S. Karger AG, Basel"},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Marquard","ForeName":"Ralf","Initials":"R","AffiliationInfo":{"Affiliation":"Department of Psychiatry, BKH Taufkirchen\/Vils, Taufkirchen, Germany. r.marquard@bkh-taufkirchen.de"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Bergida","ForeName":"Robert","Initials":"R"},{"@attributes":{"ValidYN":"Y"},"LastName":"M\u00fcller","ForeName":"Ruppert","Initials":"R"},{"@attributes":{"ValidYN":"Y"},"LastName":"Becker","ForeName":"Ingrid","Initials":"I"},{"@attributes":{"ValidYN":"Y"},"LastName":"Wada","ForeName":"Makoto","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Case Reports","Journal Article"]}},"MedlineJournalInfo":{"Country":"Switzerland","MedlineTA":"Dement Geriatr Cogn Disord","NlmUniqueID":"9705200","ISSNLinking":"1420-8008"},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Dementia","QualifierName":"complications"},{"DescriptorName":"Female"},{"DescriptorName":"Humans"},{"DescriptorName":"Male"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Motor Neuron Disease","QualifierName":"complications"},{"DescriptorName":"Syndrome"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"accepted"},"Year":"2002","Month":"11","Day":"25"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2003","Month":"6","Day":"5","Hour":"5","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2003","Month":"10","Day":"16","Hour":"5","Minute":"0"},{"@attributes":{"PubStatus":"entrez"},"Year":"2003","Month":"6","Day":"5","Hour":"5","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["12784034","10.1159\/000070682","70682"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"12764551","DateCompleted":{"Year":"2004","Month":"05","Day":"25"},"DateRevised":{"Year":"2018","Month":"11","Day":"13"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":"1619-7070","JournalIssue":{"@attributes":{"CitedMedium":"Print"},"Volume":"30","Issue":"8","PubDate":{"Year":"2003","Month":"Aug"}},"Title":"European journal of nuclear medicine and molecular imaging","ISOAbbreviation":"Eur J Nucl Med Mol Imaging"},"ArticleTitle":"Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study.","Pagination":{"MedlinePgn":"1104-13"},"Abstract":{"AbstractText":"A high percentage of patients with mild cognitive impairment (MCI) develop clinical dementia of the Alzheimer type (AD) within 1 year. The aim of this longitudinal study was to identify characteristic patterns of cerebral metabolism at baseline in patients converting from MCI to AD, and to evaluate the changes in these patterns over time. Baseline and follow-up examinations after 1 year were performed in 22 MCI patients (12 males, 10 females, aged 69.8+\/-5.8 years); these examinations included neuropsychological testing, structural cranial magnetic resonance imaging and fluorine-18 fluorodeoxyglucose positron emission tomography (PET) evaluation of relative cerebral glucose metabolic rate (rCMRglc). Individual PET scans were stereotactically normalised with NEUROSTAT software (Univ. of Michigan, Ann Arbor, USA). Subsequently, statistical comparison of PET data with an age-matched healthy control population and between patient subgroups was performed using SPM 99 (Wellcome Dept. of Neuroimaging Sciences, London, UK). After 1 year, eight patients (36%) had developed probable AD (referred to as MCI(AD)), whereas 12 (55%) were still classified as having stable MCI (referred to as MCI(MCI)). Compared with the healthy control group, a reduced rCMRglc in AD-typical regions, including the temporoparietal and posterior cingulate cortex, was detected at baseline in patients with MCI(AD). Abnormalities in the posterior cingulate cortex reached significance even in comparison with the MCI(MCI) group. After 1 year, MCI(AD) patients demonstrated an additional bilateral reduction of rCMRglc in prefrontal areas, along with a further progression of the abnormalities in the parietal and posterior cingulate cortex. No such changes were observed in the MCI(MCI) group. In patients with MCI, characteristic cerebral metabolic differences can be delineated at the time of initial presentation, which helps to define prognostic subgroups. A newly emerging reduction of rCMRglc in prefrontal cortical areas is associated with the transition from MCI to AD."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Drzezga","ForeName":"Alexander","Initials":"A","AffiliationInfo":{"Affiliation":"Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, Ismaninger Strasse 22, 81675, M\u00fcnchen, Germany, a.drzezga@lrz.tu-muenchen.de"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Lautenschlager","ForeName":"Nicola","Initials":"N"},{"@attributes":{"ValidYN":"Y"},"LastName":"Siebner","ForeName":"Hartwig","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Riemenschneider","ForeName":"Matthias","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Willoch","ForeName":"Frode","Initials":"F"},{"@attributes":{"ValidYN":"Y"},"LastName":"Minoshima","ForeName":"Satoshi","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"Schwaiger","ForeName":"Markus","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Clinical Trial","Comparative Study","Controlled Clinical Trial","Journal Article"]},"ArticleDate":{"@attributes":{"DateType":"Electronic"},"Year":"2003","Month":"05","Day":"23"}},"MedlineJournalInfo":{"Country":"Germany","MedlineTA":"Eur J Nucl Med Mol Imaging","NlmUniqueID":"101140988","ISSNLinking":"1619-7070"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0Z5B2CJX4D","NameOfSubstance":"Fluorodeoxyglucose F18"},{"RegistryNumber":"IY9XDZ35W2","NameOfSubstance":"Glucose"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Alzheimer Disease","QualifierName":["complications","diagnosis","diagnostic imaging","metabolism"]},{"DescriptorName":"Brain Mapping","QualifierName":"methods"},{"DescriptorName":"Cerebral Cortex","QualifierName":["diagnostic imaging","metabolism"]},{"DescriptorName":"Cognition Disorders","QualifierName":["complications","diagnosis","diagnostic imaging","metabolism"]},{"DescriptorName":"Disease Progression"},{"DescriptorName":"Female"},{"DescriptorName":"Fluorodeoxyglucose F18","QualifierName":"pharmacokinetics"},{"DescriptorName":"Follow-Up Studies"},{"DescriptorName":"Glucose","QualifierName":"metabolism"},{"DescriptorName":"Humans"},{"DescriptorName":"Longitudinal Studies"},{"DescriptorName":"Male"},{"DescriptorName":"Neuropsychological Tests"},{"DescriptorName":"Prognosis"},{"DescriptorName":"Reproducibility of Results"},{"DescriptorName":"Risk Assessment","QualifierName":"methods"},{"DescriptorName":"Sensitivity and Specificity"},{"DescriptorName":"Severity of Illness Index"},{"DescriptorName":"Statistics as Topic"},{"DescriptorName":"Tomography, Emission-Computed","QualifierName":"methods"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2003","Month":"01","Day":"13"},{"@attributes":{"PubStatus":"accepted"},"Year":"2003","Month":"03","Day":"14"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2003","Month":"5","Day":"24","Hour":"5","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2004","Month":"5","Day":"27","Hour":"5","Minute":"0"},{"@attributes":{"PubStatus":"entrez"},"Year":"2003","Month":"5","Day":"24","Hour":"5","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["12764551","10.1007\/s00259-003-1194-1"]},"ReferenceList":{"Reference":[{"Citation":"Brain. 1998 Jan;121 ( Pt 1):135-41","ArticleIdList":{"ArticleId":"9549494"}},{"Citation":"J Nucl Med. 1994 Sep;35(9):1528-37","ArticleIdList":{"ArticleId":"8071705"}},{"Citation":"Neurology. 1994 Apr;44(4):609-14","ArticleIdList":{"ArticleId":"8164812"}},{"Citation":"Neurology. 1993 Feb;43(2):250-60","ArticleIdList":{"ArticleId":"8094895"}},{"Citation":"Neurology. 1989 Sep;39(9):1159-65","ArticleIdList":{"ArticleId":"2771064"}},{"Citation":"J Nucl Med. 2001 Apr;42(4):548-57","ArticleIdList":{"ArticleId":"11337540"}},{"Citation":"J Nucl Med. 2000 Jul;41(7):1155-62","ArticleIdList":{"ArticleId":"10914904"}},{"Citation":"Neuroimage. 1999 Jan;9(1):63-80","ArticleIdList":{"ArticleId":"9918728"}},{"Citation":"Arch Neurol. 2001 Sep;58(9):1403-8","ArticleIdList":{"ArticleId":"11559311"}},{"Citation":"J Clin Psychiatry. 1998;59 Suppl 11:4-7","ArticleIdList":{"ArticleId":"9731543"}},{"Citation":"Neuroreport. 2001 Mar 26;12 (4):851-5","ArticleIdList":{"ArticleId":"11277595"}},{"Citation":"Arch Neurol. 1999 Mar;56(3):303-8","ArticleIdList":{"ArticleId":"10190820"}},{"Citation":"Arch Neurol. 1991 Mar;48(3):278-81","ArticleIdList":{"ArticleId":"2001185"}},{"Citation":"J Psychiatr Res. 1996 Mar-Apr;30(2):109-26","ArticleIdList":{"ArticleId":"8816305"}},{"Citation":"J Nucl Med. 1999 May;40(5):737-46","ArticleIdList":{"ArticleId":"10319744"}},{"Citation":"Proc Natl Acad Sci U S A. 2000 May 23;97(11):6037-42","ArticleIdList":{"ArticleId":"10811879"}},{"Citation":"J Nucl Med. 1995 Jul;36(7):1238-48","ArticleIdList":{"ArticleId":"7790950"}},{"Citation":"Int Psychogeriatr. 1997;9 Suppl 1:65-9","ArticleIdList":{"ArticleId":"9447429"}},{"Citation":"Ann Neurol. 1997 Jul;42(1):85-94","ArticleIdList":{"ArticleId":"9225689"}},{"Citation":"Ann Neurol. 2001 Feb;49(2):202-13","ArticleIdList":{"ArticleId":"11220740"}},{"Citation":"J Nucl Med. 1997 Jul;38(7):1095-101","ArticleIdList":{"ArticleId":"9225797"}},{"Citation":"Acta Neurol Scand Suppl. 2003;179:52-76","ArticleIdList":{"ArticleId":"12603252"}},{"Citation":"Neurology. 1998 Dec;51(6):1546-54","ArticleIdList":{"ArticleId":"9855500"}},{"Citation":"Ann Nucl Med. 2002 Dec;16(8):515-25","ArticleIdList":{"ArticleId":"12593416"}},{"Citation":"Neurology. 1993 Dec;43(12):2457-65","ArticleIdList":{"ArticleId":"8255439"}},{"Citation":"J Nucl Med. 1992 Aug;33(8):1579-85","ArticleIdList":{"ArticleId":"1634959"}},{"Citation":"J Neural Transm Suppl. 1998;53:237-50","ArticleIdList":{"ArticleId":"9700661"}},{"Citation":"Neurology. 1984 Jul;34(7):939-44","ArticleIdList":{"ArticleId":"6610841"}},{"Citation":"J Psychiatr Res. 1982-1983;17(1):37-49","ArticleIdList":{"ArticleId":"7183759"}}]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"12727335","DateCompleted":{"Year":"2003","Month":"07","Day":"31"},"DateRevised":{"Year":"2019","Month":"07","Day":"01"},"Article":{"@attributes":{"PubModel":"Print"},"Journal":{"ISSN":"0304-3940","JournalIssue":{"@attributes":{"CitedMedium":"Print"},"Volume":"342","Issue":"1-2","PubDate":{"Year":"2003","Month":"May","Day":"15"}},"Title":"Neuroscience letters","ISOAbbreviation":"Neurosci Lett"},"ArticleTitle":"Lack of association of interleukin-10 promoter region polymorphisms with Alzheimer's disease.","Pagination":{"MedlinePgn":"132-4"},"Abstract":{"AbstractText":"There is increasing evidence that immune mechanisms are involved in the pathogenesis of Alzheimer's disease (AD). Recently, polymorphisms of the interleukin (IL)-1 and IL-6 genes were found to be associated with late-onset AD. The immunoregulatory IL-10 downregulates synthesis of pro-inflammatory cytokines such as IL-1. Current evidence suggests that some polymorphisms in the IL-10 promoter may have functional effects on IL-10 transcription. A total of 406 German AD patients (mean age 70.2+\/-10.0 years, range 50-95 years, 42% female) and 251 unrelated non-demented control subjects (mean age 66.8+\/-10.6 years, range 50-93 years, 38% female) were investigated for the presence of three polymorphisms in the IL-10 promoter region (-1087A\/G, -824C\/T, -597C\/A). No significant differences in the allelic distribution of the analyzed IL-10 polymorphisms have been found between AD patients and controls. We conclude that polymorphisms in the IL-10 promoter region do not increase the risk of developing AD."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Depboylu","ForeName":"Candan","Initials":"C","AffiliationInfo":{"Affiliation":"Department of Neurology, Friedrich-Wilhelms University, Sigmund-Freud-Strasse 25, 53105, Bonn, Germany."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Du","ForeName":"Yansheng","Initials":"Y"},{"@attributes":{"ValidYN":"Y"},"LastName":"M\u00fcller","ForeName":"Ulrich","Initials":"U"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Zimmer","ForeName":"Reinhilde","Initials":"R"},{"@attributes":{"ValidYN":"Y"},"LastName":"Riemenschneider","ForeName":"Matthias","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Gasser","ForeName":"Thomas","Initials":"T"},{"@attributes":{"ValidYN":"Y"},"LastName":"Oertel","ForeName":"Wolfgang H","Initials":"WH"},{"@attributes":{"ValidYN":"Y"},"LastName":"Klockgether","ForeName":"Thomas","Initials":"T"},{"@attributes":{"ValidYN":"Y"},"LastName":"Dodel","ForeName":"Richard C","Initials":"RC"},{"@attributes":{"ValidYN":"N"},"LastName":"Oertelf","ForeName":"Wolfgang H","Initials":"WH"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Research Support, Non-U.S. Gov't"]}},"MedlineJournalInfo":{"Country":"Ireland","MedlineTA":"Neurosci Lett","NlmUniqueID":"7600130","ISSNLinking":"0304-3940"},"ChemicalList":{"Chemical":{"RegistryNumber":"130068-27-8","NameOfSubstance":"Interleukin-10"}},"CitationSubset":"IM","CommentsCorrectionsList":{"CommentsCorrections":{"@attributes":{"RefType":"ErratumIn"},"RefSource":"Neurosci Lett. 2003 Oct 9;349(3):212","Note":"Oertelf Wolfgang H [corrected to Oertel Wolfgang H]"}},"MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Aged, 80 and over"},{"DescriptorName":"Alleles"},{"DescriptorName":"Alzheimer Disease","QualifierName":"genetics"},{"DescriptorName":"Case-Control Studies"},{"DescriptorName":"Down-Regulation"},{"DescriptorName":"Female"},{"DescriptorName":"Genotype"},{"DescriptorName":"Humans"},{"DescriptorName":"Interleukin-10","QualifierName":"genetics"},{"DescriptorName":"Male"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Polymorphism, Genetic"},{"DescriptorName":"Promoter Regions, Genetic"},{"DescriptorName":"Risk Factors"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"pubmed"},"Year":"2003","Month":"5","Day":"3","Hour":"5","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2003","Month":"8","Day":"2","Hour":"5","Minute":"0"},{"@attributes":{"PubStatus":"entrez"},"Year":"2003","Month":"5","Day":"3","Hour":"5","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["12727335","S0304394003002313","10.1016\/s0304-3940(03)00231-3"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"12566596","DateCompleted":{"Year":"2003","Month":"03","Day":"28"},"DateRevised":{"Year":"2017","Month":"11","Day":"01"},"Article":{"@attributes":{"PubModel":"Print"},"Journal":{"ISSN":"1420-8008","JournalIssue":{"@attributes":{"CitedMedium":"Print"},"Volume":"15","Issue":"2","PubDate":{"Year":"2003"}},"Title":"Dementia and geriatric cognitive disorders","ISOAbbreviation":"Dement Geriatr Cogn Disord"},"ArticleTitle":"Galantamine provides sustained benefits in patients with 'advanced moderate' Alzheimer's disease for at least 12 months.","Pagination":{"MedlinePgn":"79-87"},"Abstract":{"AbstractText":"Galantamine (Reminyl), a novel agent with a dual mode of action, modulates nicotinic acetylcholine receptors and inhibits acetylcholinesterase. Galantamine has consistently demonstrated a broad range of beneficial effects and has shown sustained benefits in cognitive and functional abilities for at least 12 months in patients with mild-to-moderate Alzheimer's disease (AD). As pivotal studies demonstrating the efficacy of cholinergic drugs were designed to exclude patients with severer AD, many patients with the advanced stage of this condition are currently not treated due to the lack of demonstrated efficacy in clinical trials. We aimed to investigate whether there was any evidence for the benefits of galantamine in patients with severer disease, by performing a post hoc analysis using data extracted from the population of the two long-term galantamine studies. We evaluated the efficacy of galantamine in patients with 'advanced moderate' AD. 'Advanced moderate' patients were those with baseline Mini Mental State Examination (MMSE) scores <\/=14 or Alzheimer's Disease Assessment Scale - cognitive subscale (ADAS-cog) scores >30. These patients were compared with matched controls who received placebo in a different historical study. Cognitive abilities (assessed using the ADAS-cog scale) of 'advanced moderate' AD patients receiving galantamine for 12 months were maintained at baseline levels after 12 months, and significantly improved over those of placebo patients (p < 0.001). Of the 'advanced moderate' patients receiving galantamine, 51% with baseline ADAS-cog of >30 maintained or improved their ADAS-cog scores over baseline values, compared with 13% receiving placebo (p < 0.001). In the subgroup of 'advanced moderate' patients with baseline MMSE <\/=14, 48% of those receiving galantamine and 4% of those receiving placebo maintained or improved their ADAS-cog scores at 12 months (p = 0.001). In both subgroups, the treatment difference (galantamine vs. historical placebo) amounted to approximately 10 points on the ADAS-cog scale. Functional abilities, as assessed using the Disability Assessment for Dementia scale, remained significantly superior in galantamine-treated patients compared with historical placebo-treated patients at 12 months (p < 0.001). In conclusion, galantamine offered sustained efficacy to patients with 'advanced moderate' AD, confirming the benefits seen in published studies of patients with mild-to-moderate AD. This drug has potential for broader use in clinical practice.","CopyrightInformation":"Copyright 2003 S. Karger AG, Basel"},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Blesa","ForeName":"Rafael","Initials":"R","AffiliationInfo":{"Affiliation":"Hospital Clinic Universitari, Barcelona, Spain. rblesa@clinic.ub.es"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Davidson","ForeName":"Michael","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Reichman","ForeName":"William","Initials":"W"},{"@attributes":{"ValidYN":"Y"},"LastName":"van Baelen","ForeName":"Bart","Initials":"B"},{"@attributes":{"ValidYN":"Y"},"LastName":"Schwalen","ForeName":"Susanne","Initials":"S"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Clinical Trial","Clinical Trial, Phase III","Comparative Study","Journal Article","Multicenter Study","Randomized Controlled Trial"]}},"MedlineJournalInfo":{"Country":"Switzerland","MedlineTA":"Dement Geriatr Cogn Disord","NlmUniqueID":"9705200","ISSNLinking":"1420-8008"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"Cholinesterase Inhibitors"},{"RegistryNumber":"0D3Q044KCA","NameOfSubstance":"Galantamine"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Alzheimer Disease","QualifierName":["diagnosis","drug therapy"]},{"DescriptorName":"Cholinesterase Inhibitors","QualifierName":["adverse effects","therapeutic use"]},{"DescriptorName":"Double-Blind Method"},{"DescriptorName":"Galantamine","QualifierName":["adverse effects","therapeutic use"]},{"DescriptorName":"Humans"},{"DescriptorName":"Psychiatric Status Rating Scales"},{"DescriptorName":"Severity of Illness Index"},{"DescriptorName":"Time Factors"},{"DescriptorName":"Treatment Outcome"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"received"},"Year":"2002","Month":"07","Day":"12"},{"@attributes":{"PubStatus":"pubmed"},"Year":"2003","Month":"2","Day":"5","Hour":"4","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2003","Month":"3","Day":"29","Hour":"5","Minute":"0"},{"@attributes":{"PubStatus":"entrez"},"Year":"2003","Month":"2","Day":"5","Hour":"4","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["12566596","10.1159\/000067974","67974"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"12480788","DateCompleted":{"Year":"2003","Month":"01","Day":"21"},"DateRevised":{"Year":"2019","Month":"06","Day":"16"},"Article":{"@attributes":{"PubModel":"Print"},"Journal":{"ISSN":"0077-8923","JournalIssue":{"@attributes":{"CitedMedium":"Print"},"Volume":"977","PubDate":{"Year":"2002","Month":"Nov"}},"Title":"Annals of the New York Academy of Sciences","ISOAbbreviation":"Ann N Y Acad Sci"},"ArticleTitle":"A novel treatment for patients with Alzheimer's disease and with vascular dementia.","Pagination":{"MedlinePgn":"476-81"},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A","AffiliationInfo":{"Affiliation":"Department of Psychiatry and Psychotherapy, Technische Universit\u00e4t M\u00fcnchen, D-81675 Munich, Germany. alexander.kurz@lrz.tum.de"}}},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Review"]}},"MedlineJournalInfo":{"Country":"United States","MedlineTA":"Ann N Y Acad Sci","NlmUniqueID":"7506858","ISSNLinking":"0077-8923"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"Cholinesterase Inhibitors"},{"RegistryNumber":"0D3Q044KCA","NameOfSubstance":"Galantamine"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Alzheimer Disease","QualifierName":"drug therapy"},{"DescriptorName":"Cholinesterase Inhibitors","QualifierName":"therapeutic use"},{"DescriptorName":"Clinical Trials as Topic"},{"DescriptorName":"Dementia, Vascular","QualifierName":"drug therapy"},{"DescriptorName":"Galantamine","QualifierName":"therapeutic use"},{"DescriptorName":"Humans"},{"DescriptorName":"Phytotherapy"}]},"NumberOfReferences":"18"},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"pubmed"},"Year":"2002","Month":"12","Day":"14","Hour":"4","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2003","Month":"1","Day":"22","Hour":"4","Minute":"0"},{"@attributes":{"PubStatus":"entrez"},"Year":"2002","Month":"12","Day":"14","Hour":"4","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["12480788","10.1111\/j.1749-6632.2002.tb04853.x"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"12242551","DateCompleted":{"Year":"2002","Month":"12","Day":"27"},"DateRevised":{"Year":"2016","Month":"11","Day":"24"},"Article":{"@attributes":{"PubModel":"Print"},"Journal":{"ISSN":"0340-5354","JournalIssue":{"@attributes":{"CitedMedium":"Print"},"Volume":"249","Issue":"9","PubDate":{"Year":"2002","Month":"Sep"}},"Title":"Journal of neurology","ISOAbbreviation":"J Neurol"},"ArticleTitle":"Prominent hypometabolism of the right temporoparietal and frontal cortex in two left-handed patients with primary progressive aphasia.","Pagination":{"MedlinePgn":"1263-7"},"Abstract":{"AbstractText":"Primary progressive aphasia (PPA) is characterized by progressive deterioration of language function with relative preservation of other cognitive functions. Previous studies based on neuroimaging and histology point to predominantly left temporal pathology in PPA patients. Here we report two left-handed subjects with typical symptoms of the nonfluent form of PPA in whom 18F-FDG PET revealed an asymmetric right-hemispheric pattern of reduced glucose metabolism in the frontal and temporoparietal cortex. These findings support the hypothesis that PPA can be considered as a symptom complex rather than a disease entity."},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Drzezga","ForeName":"Alexander","Initials":"A","AffiliationInfo":{"Affiliation":"Nuklearmedizinische Klinik u. Poliklinik, Klinikum rechts der Isar, Ismaninger Strasse 22, 81675 M\u00fcnchen, Germany. a.drzezga@lrz.tu-muenchen.de"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Grimmer","ForeName":"Timo","Initials":"T"},{"@attributes":{"ValidYN":"Y"},"LastName":"Siebner","ForeName":"Hartwig","Initials":"H"},{"@attributes":{"ValidYN":"Y"},"LastName":"Minoshima","ForeName":"Satoshi","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"Schwaiger","ForeName":"Markus","Initials":"M"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Case Reports","Journal Article"]}},"MedlineJournalInfo":{"Country":"Germany","MedlineTA":"J Neurol","NlmUniqueID":"0423161","ISSNLinking":"0340-5354"},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Aphasia, Primary Progressive","QualifierName":["diagnostic imaging","metabolism","physiopathology"]},{"DescriptorName":"Female"},{"DescriptorName":"Frontal Lobe","QualifierName":["metabolism","physiopathology"]},{"DescriptorName":"Functional Laterality","QualifierName":"physiology"},{"DescriptorName":"Humans"},{"DescriptorName":"Male"},{"DescriptorName":"Middle Aged"},{"DescriptorName":"Parietal Lobe","QualifierName":["diagnostic imaging","metabolism","physiopathology"]},{"DescriptorName":"Temporal Lobe","QualifierName":["diagnostic imaging","metabolism","physiopathology"]},{"DescriptorName":"Tomography, Emission-Computed","QualifierName":"methods"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"pubmed"},"Year":"2002","Month":"9","Day":"21","Hour":"10","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2002","Month":"12","Day":"28","Hour":"4","Minute":"0"},{"@attributes":{"PubStatus":"entrez"},"Year":"2002","Month":"9","Day":"21","Hour":"10","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["12242551","10.1007\/s00415-002-0832-z"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"12006732","DateCompleted":{"Year":"2002","Month":"06","Day":"26"},"DateRevised":{"Year":"2017","Month":"11","Day":"01"},"Article":{"@attributes":{"PubModel":"Print"},"Journal":{"ISSN":"1420-8008","JournalIssue":{"@attributes":{"CitedMedium":"Print"},"Volume":"13","Issue":"4","PubDate":{"Year":"2002"}},"Title":"Dementia and geriatric cognitive disorders","ISOAbbreviation":"Dement Geriatr Cogn Disord"},"ArticleTitle":"Clinical efficacy of piracetam in cognitive impairment: a meta-analysis.","Pagination":{"MedlinePgn":"217-24"},"Abstract":{"AbstractText":"A meta-analysis has been performed including nineteen double blind, placebo controlled studies with piracetam in patients suffering from dementia or cognitive impairment in the elderly. These studies had as common outcome measure a clinical global impression of change, a measure of clinically meaningful improvement. The meta-analysis of this global outcome followed the methodology set forward by the Cochrane Collaboration. This article describes the studies, the patient populations and the methods of data extraction. The results of the meta-analysis demonstrate a difference between those individuals treated with piracetam and those given placebo, both as significant odds ratio and as a favourable number needed to treat. While there may be problems in meta-analyses and the interpretation of the statistical results, the results of this analysis provide compelling evidence for the global efficacy of piracetam in a diverse group of older subjects with cognitive impairment.","CopyrightInformation":"Copyright 2002 S. Karger AG, Basel"},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Waegemans","ForeName":"Tony","Initials":"T","AffiliationInfo":{"Affiliation":"Research and Development, UCB SA (Pharma Sector), Braine-l'Alleud, Belgium."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Wilsher","ForeName":"Colin R","Initials":"CR"},{"@attributes":{"ValidYN":"Y"},"LastName":"Danniau","ForeName":"Anne","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Ferris","ForeName":"Steven H","Initials":"SH"},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Winblad","ForeName":"Bengt","Initials":"B"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Journal Article","Meta-Analysis","Research Support, Non-U.S. Gov't"]}},"MedlineJournalInfo":{"Country":"Switzerland","MedlineTA":"Dement Geriatr Cogn Disord","NlmUniqueID":"9705200","ISSNLinking":"1420-8008"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"Neuroprotective Agents"},{"RegistryNumber":"ZH516LNZ10","NameOfSubstance":"Piracetam"}]},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Aged, 80 and over"},{"DescriptorName":"Cognition Disorders","QualifierName":"drug therapy"},{"DescriptorName":"Dementia","QualifierName":"drug therapy"},{"DescriptorName":"Double-Blind Method"},{"DescriptorName":"Humans"},{"DescriptorName":"Neuroprotective Agents","QualifierName":"therapeutic use"},{"DescriptorName":"Piracetam","QualifierName":"therapeutic use"},{"DescriptorName":"Randomized Controlled Trials as Topic"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"pubmed"},"Year":"2002","Month":"5","Day":"15","Hour":"10","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2002","Month":"6","Day":"27","Hour":"10","Minute":"1"},{"@attributes":{"PubStatus":"entrez"},"Year":"2002","Month":"5","Day":"15","Hour":"10","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["12006732","57700","10.1159\/000057700"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"11965273","DateCompleted":{"Year":"2002","Month":"04","Day":"30"},"DateRevised":{"Year":"2015","Month":"06","Day":"16"},"Article":{"@attributes":{"PubModel":"Print"},"Journal":{"ISSN":"0140-6736","JournalIssue":{"@attributes":{"CitedMedium":"Print"},"Volume":"359","Issue":"9314","PubDate":{"Year":"2002","Month":"Apr","Day":"13"}},"Title":"Lancet (London, England)","ISOAbbreviation":"Lancet"},"ArticleTitle":"Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial.","Pagination":{"MedlinePgn":"1283-90"},"Abstract":{"AbstractText":["Vascular dementia is the second commonest form of dementia, and vascular factors contribute to the development of dementia in many patients with Alzheimer's disease. Galantamine amplifies the acetylcholine response by inhibiting acetylcholinesterase and modulating nicotinic receptors. It has shown broad, sustained benefits in patients with Alzheimer's disease. We investigated the effects of galantamine in patients with a diagnosis of probable vascular dementia or Alzheimer's disease combined with cerebrovascular disease.","Eligible patients were randomly assigned galantamine 24 mg\/day (n=396) or placebo (n=196) in a multicentre, double-blind, 6-month trial. Primary endpoints were cognition (Alzheimer's disease assessment scale, cognitive subscale [ADAS-cog]) and global functioning (clinician's interview-based impression of change plus caregiver input [CIBIC-plus]). Secondary endpoints included assessments of activities of daily living and behavioural symptoms. Patients were monitored for adverse events. Analyses were on the basis of observed case or last observation carried forward.","Galantamine showed greater efficacy than placebo on ADAS-cog (galantamine change -1.7 [SE 0.4] vs placebo 1.0 [0.5]; treatment effect 2.7 points; p<0.0001) and CIBIC-plus (213 [74%] vs 95 [59%] patients remained stable or improved, p=0.0001). Activities of daily living and behavioural symptoms were also significantly improved compared with placebo (p=0.002 and p=0.016, respectively). Galantamine was well tolerated.","Galantamine showed a therapeutic effect on all key areas of cognitive and non-cognitive abilities in this group of dementia patients."]},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Erkinjuntti","ForeName":"Timo","Initials":"T","AffiliationInfo":{"Affiliation":"Department of Clinical Neurosciences, Helsinki University Central Hospital, Helsinki, Finland. timo.erkinjuntti@hus.fi"}},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"},{"@attributes":{"ValidYN":"Y"},"LastName":"Gauthier","ForeName":"Serge","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"Bullock","ForeName":"Roger","Initials":"R"},{"@attributes":{"ValidYN":"Y"},"LastName":"Lilienfeld","ForeName":"Sean","Initials":"S"},{"@attributes":{"ValidYN":"Y"},"LastName":"Damaraju","ForeName":"ChandrasekharRao Venkata","Initials":"CV"}]},"Language":"eng","PublicationTypeList":{"PublicationType":["Clinical Trial","Journal Article","Multicenter Study","Randomized Controlled Trial","Research Support, Non-U.S. Gov't"]}},"MedlineJournalInfo":{"Country":"England","MedlineTA":"Lancet","NlmUniqueID":"2985213R","ISSNLinking":"0140-6736"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":"Cholinesterase Inhibitors"},{"RegistryNumber":"0D3Q044KCA","NameOfSubstance":"Galantamine"}]},"CitationSubset":["AIM","IM"],"CommentsCorrectionsList":{"CommentsCorrections":[{"@attributes":{"RefType":"CommentIn"},"RefSource":"Lancet. 2002 Apr 13;359(9314):1265-6","PMID":"11965268"},{"@attributes":{"RefType":"CommentIn"},"RefSource":"ACP J Club. 2002 Nov-Dec;137(3):102","PMID":"12418842"},{"@attributes":{"RefType":"CommentIn"},"RefSource":"Lancet. 2002 Nov 9;360(9344):1512; author reply 1513","PMID":"12433548"},{"@attributes":{"RefType":"CommentIn"},"RefSource":"Lancet. 2002 Nov 9;360(9344):1512-3; author reply 1513","PMID":"12433549"}]},"MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Aged"},{"DescriptorName":"Alzheimer Disease","QualifierName":["complications","drug therapy"]},{"DescriptorName":"Cerebrovascular Disorders","QualifierName":"complications"},{"DescriptorName":"Cholinesterase Inhibitors","QualifierName":["adverse effects","therapeutic use"]},{"DescriptorName":"Cognition","QualifierName":"drug effects"},{"DescriptorName":"Dementia, Vascular","QualifierName":["complications","drug therapy"]},{"DescriptorName":"Double-Blind Method"},{"DescriptorName":"Female"},{"DescriptorName":"Galantamine","QualifierName":["adverse effects","therapeutic use"]},{"DescriptorName":"Humans"},{"DescriptorName":"Male"},{"DescriptorName":"Treatment Outcome"}]}},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"pubmed"},"Year":"2002","Month":"4","Day":"20","Hour":"10","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2002","Month":"5","Day":"1","Hour":"10","Minute":"1"},{"@attributes":{"PubStatus":"entrez"},"Year":"2002","Month":"4","Day":"20","Hour":"10","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":["11965273","S0140-6736(02)08267-3","10.1016\/S0140-6736(02)08267-3"]}}},{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM"},"PMID":"11826666","DateCompleted":{"Year":"2002","Month":"02","Day":"28"},"DateRevised":{"Year":"2005","Month":"11","Day":"16"},"Article":{"@attributes":{"PubModel":"Print"},"Journal":{"ISSN":"0342-9601","JournalIssue":{"@attributes":{"CitedMedium":"Print"},"Volume":"25","Issue":"1","PubDate":{"Year":"2002","Month":"Jan"}},"Title":"Medizinische Monatsschrift fur Pharmazeuten","ISOAbbreviation":"Med Monatsschr Pharm"},"ArticleTitle":"[Treatment of Alzheimer's disease. The status quo].","Pagination":{"MedlinePgn":"8-12"},"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Diehl","ForeName":"Janine","Initials":"J","AffiliationInfo":{"Affiliation":"Klinik f\u00fcr Psychiatrie und Psychotherapie der Technischen Universit\u00e4t M\u00fcnchen, Ismaninger Str. 22, 81675 M\u00fcnchen."}},{"@attributes":{"ValidYN":"Y"},"LastName":"Kurz","ForeName":"Alexander","Initials":"A"}]},"Language":"ger","PublicationTypeList":{"PublicationType":["Journal Article","Review"]},"VernacularTitle":"Therapie der Alzheimer-Krankheit. Status quo."},"MedlineJournalInfo":{"Country":"Germany","MedlineTA":"Med Monatsschr Pharm","NlmUniqueID":"7802665","ISSNLinking":"0342-9601"},"CitationSubset":"IM","MeshHeadingList":{"MeshHeading":[{"DescriptorName":"Alzheimer Disease","QualifierName":["drug therapy","physiopathology","prevention & control"]},{"DescriptorName":"Humans"}]},"NumberOfReferences":"29"},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"pubmed"},"Year":"2002","Month":"2","Day":"6","Hour":"10","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2002","Month":"3","Day":"1","Hour":"10","Minute":"1"},{"@attributes":{"PubStatus":"entrez"},"Year":"2002","Month":"2","Day":"6","Hour":"10","Minute":"0"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":"11826666"}}}]}